Javascript doit fonctionner ! Activez-le et rechargez cette page.
Le Rézo de JeuxDeMots
• Types de relations
• Types de noeuds
• Consolider
le terme
  Options  
             

  Filtrage type relations : +   - (ex: 4, 12, 18, 36, 444, 555, 777)
  Filtrage valeur :          min   max
  Filtrage type noeuds :   +   - (ex: 4, 6, 8, 9, 10, 12, 18, 36, 444, 555, 777)

  Présentation de sortie :   (ex: -rien-, cloud, nicecloud)
 

'en:contraindications aspect'
(id=6798642 ; fe=en:contraindications aspect ; type=1 ; niveau=200 ; luminosité=2 ; somme entrante=326740.3899536133 creation date=2017-06-25 touchdate=2025-09-04 16:50:58.000)
≈ 5779 relations sortantes

  1. en:contraindications aspect -- r_associated #0: 35 / 1 -> en:therapeutic use - qualifier
    n1=en:contraindications aspect | n2=en:therapeutic use - qualifier | rel=r_associated | relid=0 | w=35
  2. en:contraindications aspect -- r_associated #0: 32 / 0.914 -> en:aspects of adverse effects
    n1=en:contraindications aspect | n2=en:aspects of adverse effects | rel=r_associated | relid=0 | w=32
  3. en:contraindications aspect -- r_associated #0: 32 / 0.914 -> en:poisoning aspects
    n1=en:contraindications aspect | n2=en:poisoning aspects | rel=r_associated | relid=0 | w=32
  4. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:1-sarcosine-8-isoleucine angiotensin ii
    n1=en:contraindications aspect | n2=en:1-sarcosine-8-isoleucine angiotensin ii | rel=r_associated | relid=0 | w=30
  5. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:14-alpha demethylase inhibitors
    n1=en:contraindications aspect | n2=en:14-alpha demethylase inhibitors | rel=r_associated | relid=0 | w=30
  6. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:3-oxoacyl-(acyl-carrier-protein) synthase
    n1=en:contraindications aspect | n2=en:3-oxoacyl-(acyl-carrier-protein) synthase | rel=r_associated | relid=0 | w=30
  7. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:3,4-dihydroxyphenylacetic acid
    n1=en:contraindications aspect | n2=en:3,4-dihydroxyphenylacetic acid | rel=r_associated | relid=0 | w=30
  8. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole
    n1=en:contraindications aspect | n2=en:5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole | rel=r_associated | relid=0 | w=30
  9. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:5-methoxytryptamine
    n1=en:contraindications aspect | n2=en:5-methoxytryptamine | rel=r_associated | relid=0 | w=30
  10. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:5,8,11,14-eicosatetraynoic acid
    n1=en:contraindications aspect | n2=en:5,8,11,14-eicosatetraynoic acid | rel=r_associated | relid=0 | w=30
  11. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:aflatoxin m1
    n1=en:contraindications aspect | n2=en:aflatoxin m1 | rel=r_associated | relid=0 | w=30
  12. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:agamous protein, arabidopsis
    n1=en:contraindications aspect | n2=en:agamous protein, arabidopsis | rel=r_associated | relid=0 | w=30
  13. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:agmatine
    n1=en:contraindications aspect | n2=en:agmatine | rel=r_associated | relid=0 | w=30
  14. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:alpha-amanitin
    n1=en:contraindications aspect | n2=en:alpha-amanitin | rel=r_associated | relid=0 | w=30
  15. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:ammotherapy
    n1=en:contraindications aspect | n2=en:ammotherapy | rel=r_associated | relid=0 | w=30
  16. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:androstane-3,17-diol
    n1=en:contraindications aspect | n2=en:androstane-3,17-diol | rel=r_associated | relid=0 | w=30
  17. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:antigens, cd1d
    n1=en:contraindications aspect | n2=en:antigens, cd1d | rel=r_associated | relid=0 | w=30
  18. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:antigens, ly
    n1=en:contraindications aspect | n2=en:antigens, ly | rel=r_associated | relid=0 | w=30
  19. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:aphidicolin
    n1=en:contraindications aspect | n2=en:aphidicolin | rel=r_associated | relid=0 | w=30
  20. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:aurodox
    n1=en:contraindications aspect | n2=en:aurodox | rel=r_associated | relid=0 | w=30
  21. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:auxilins
    n1=en:contraindications aspect | n2=en:auxilins | rel=r_associated | relid=0 | w=30
  22. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:b-cell lymphoma 6 protein
    n1=en:contraindications aspect | n2=en:b-cell lymphoma 6 protein | rel=r_associated | relid=0 | w=30
  23. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:bcl-x protein
    n1=en:contraindications aspect | n2=en:bcl-x protein | rel=r_associated | relid=0 | w=30
  24. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:beta-n-acetyl-galactosaminidase
    n1=en:contraindications aspect | n2=en:beta-n-acetyl-galactosaminidase | rel=r_associated | relid=0 | w=30
  25. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:bornanes
    n1=en:contraindications aspect | n2=en:bornanes | rel=r_associated | relid=0 | w=30
  26. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:brinolase
    n1=en:contraindications aspect | n2=en:brinolase | rel=r_associated | relid=0 | w=30
  27. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:butyrylthiocholine
    n1=en:contraindications aspect | n2=en:butyrylthiocholine | rel=r_associated | relid=0 | w=30
  28. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:carboxyl and carbamoyl transferases
    n1=en:contraindications aspect | n2=en:carboxyl and carbamoyl transferases | rel=r_associated | relid=0 | w=30
  29. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:casein kinase iepsilon
    n1=en:contraindications aspect | n2=en:casein kinase iepsilon | rel=r_associated | relid=0 | w=30
  30. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:complement 3b inactivators
    n1=en:contraindications aspect | n2=en:complement 3b inactivators | rel=r_associated | relid=0 | w=30
  31. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:complement c3c
    n1=en:contraindications aspect | n2=en:complement c3c | rel=r_associated | relid=0 | w=30
  32. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:complement component c1
    n1=en:contraindications aspect | n2=en:complement component c1 | rel=r_associated | relid=0 | w=30
  33. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:complement component c1r
    n1=en:contraindications aspect | n2=en:complement component c1r | rel=r_associated | relid=0 | w=30
  34. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:cortactin
    n1=en:contraindications aspect | n2=en:cortactin | rel=r_associated | relid=0 | w=30
  35. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:cross-linking reagents
    n1=en:contraindications aspect | n2=en:cross-linking reagents | rel=r_associated | relid=0 | w=30
  36. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:cyanoketone
    n1=en:contraindications aspect | n2=en:cyanoketone | rel=r_associated | relid=0 | w=30
  37. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:cyclin g2
    n1=en:contraindications aspect | n2=en:cyclin g2 | rel=r_associated | relid=0 | w=30
  38. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:cyclin-dependent kinase inhibitor p57
    n1=en:contraindications aspect | n2=en:cyclin-dependent kinase inhibitor p57 | rel=r_associated | relid=0 | w=30
  39. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:cytochromes c2
    n1=en:contraindications aspect | n2=en:cytochromes c2 | rel=r_associated | relid=0 | w=30
  40. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:delta chemokine
    n1=en:contraindications aspect | n2=en:delta chemokine | rel=r_associated | relid=0 | w=30
  41. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:deoxyribonuclease hpaii
    n1=en:contraindications aspect | n2=en:deoxyribonuclease hpaii | rel=r_associated | relid=0 | w=30
  42. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:dimethylbenzanthracene
    n1=en:contraindications aspect | n2=en:dimethylbenzanthracene | rel=r_associated | relid=0 | w=30
  43. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:dipeptidyl-peptidases and tripeptidyl-peptidases
    n1=en:contraindications aspect | n2=en:dipeptidyl-peptidases and tripeptidyl-peptidases | rel=r_associated | relid=0 | w=30
  44. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:ectodysplasin a receptor
    n1=en:contraindications aspect | n2=en:ectodysplasin a receptor | rel=r_associated | relid=0 | w=30
  45. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:ectodysplasin a2 receptor
    n1=en:contraindications aspect | n2=en:ectodysplasin a2 receptor | rel=r_associated | relid=0 | w=30
  46. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:ethinyl estradiol-norgestrel combination
    n1=en:contraindications aspect | n2=en:ethinyl estradiol-norgestrel combination | rel=r_associated | relid=0 | w=30
  47. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:ethylenebis(dithiocarbamates)
    n1=en:contraindications aspect | n2=en:ethylenebis(dithiocarbamates) | rel=r_associated | relid=0 | w=30
  48. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:fanft
    n1=en:contraindications aspect | n2=en:fanft | rel=r_associated | relid=0 | w=30
  49. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:felypressin
    n1=en:contraindications aspect | n2=en:felypressin | rel=r_associated | relid=0 | w=30
  50. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:fenbendazole
    n1=en:contraindications aspect | n2=en:fenbendazole | rel=r_associated | relid=0 | w=30
  51. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:fosinopril
    n1=en:contraindications aspect | n2=en:fosinopril | rel=r_associated | relid=0 | w=30
  52. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:galanin-like peptide
    n1=en:contraindications aspect | n2=en:galanin-like peptide | rel=r_associated | relid=0 | w=30
  53. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:gata1 transcription factor
    n1=en:contraindications aspect | n2=en:gata1 transcription factor | rel=r_associated | relid=0 | w=30
  54. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:gentisates
    n1=en:contraindications aspect | n2=en:gentisates | rel=r_associated | relid=0 | w=30
  55. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:glypican
    n1=en:contraindications aspect | n2=en:glypican | rel=r_associated | relid=0 | w=30
  56. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:group v phospholipases a2
    n1=en:contraindications aspect | n2=en:group v phospholipases a2 | rel=r_associated | relid=0 | w=30
  57. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:gtp-binding protein alpha subunits, gi-go
    n1=en:contraindications aspect | n2=en:gtp-binding protein alpha subunits, gi-go | rel=r_associated | relid=0 | w=30
  58. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:haemophilus vaccines
    n1=en:contraindications aspect | n2=en:haemophilus vaccines | rel=r_associated | relid=0 | w=30
  59. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:heymann nephritis antigenic complex
    n1=en:contraindications aspect | n2=en:heymann nephritis antigenic complex | rel=r_associated | relid=0 | w=30
  60. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:hla-dq alpha-chains
    n1=en:contraindications aspect | n2=en:hla-dq alpha-chains | rel=r_associated | relid=0 | w=30
  61. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:hla-dq beta-chains
    n1=en:contraindications aspect | n2=en:hla-dq beta-chains | rel=r_associated | relid=0 | w=30
  62. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:hypoglycemic agents
    n1=en:contraindications aspect | n2=en:hypoglycemic agents | rel=r_associated | relid=0 | w=30
  63. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:ilizarov technique
    n1=en:contraindications aspect | n2=en:ilizarov technique | rel=r_associated | relid=0 | w=30
  64. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:infusions, intralesional
    n1=en:contraindications aspect | n2=en:infusions, intralesional | rel=r_associated | relid=0 | w=30
  65. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:interleukin
    n1=en:contraindications aspect | n2=en:interleukin | rel=r_associated | relid=0 | w=30
  66. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:interleukin-12 subunit p40
    n1=en:contraindications aspect | n2=en:interleukin-12 subunit p40 | rel=r_associated | relid=0 | w=30
  67. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:ion-selective electrodes
    n1=en:contraindications aspect | n2=en:ion-selective electrodes | rel=r_associated | relid=0 | w=30
  68. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:kcnq3 potassium channel
    n1=en:contraindications aspect | n2=en:kcnq3 potassium channel | rel=r_associated | relid=0 | w=30
  69. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:keratin-16
    n1=en:contraindications aspect | n2=en:keratin-16 | rel=r_associated | relid=0 | w=30
  70. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:lipoproteins, hdl2
    n1=en:contraindications aspect | n2=en:lipoproteins, hdl2 | rel=r_associated | relid=0 | w=30
  71. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:lumicolchicines
    n1=en:contraindications aspect | n2=en:lumicolchicines | rel=r_associated | relid=0 | w=30
  72. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:megacins
    n1=en:contraindications aspect | n2=en:megacins | rel=r_associated | relid=0 | w=30
  73. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:metallochaperones
    n1=en:contraindications aspect | n2=en:metallochaperones | rel=r_associated | relid=0 | w=30
  74. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:methylphenazonium methosulfate
    n1=en:contraindications aspect | n2=en:methylphenazonium methosulfate | rel=r_associated | relid=0 | w=30
  75. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:mitogen-activated protein kinase p38
    n1=en:contraindications aspect | n2=en:mitogen-activated protein kinase p38 | rel=r_associated | relid=0 | w=30
  76. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:n-acetylglucosaminyltransferases
    n1=en:contraindications aspect | n2=en:n-acetylglucosaminyltransferases | rel=r_associated | relid=0 | w=30
  77. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:nadh tetrazolium reductase
    n1=en:contraindications aspect | n2=en:nadh tetrazolium reductase | rel=r_associated | relid=0 | w=30
  78. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:nafenopin
    n1=en:contraindications aspect | n2=en:nafenopin | rel=r_associated | relid=0 | w=30
  79. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:nafoxidine
    n1=en:contraindications aspect | n2=en:nafoxidine | rel=r_associated | relid=0 | w=30
  80. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:nitracrine
    n1=en:contraindications aspect | n2=en:nitracrine | rel=r_associated | relid=0 | w=30
  81. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:nitromifene
    n1=en:contraindications aspect | n2=en:nitromifene | rel=r_associated | relid=0 | w=30
  82. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:norgestrienone
    n1=en:contraindications aspect | n2=en:norgestrienone | rel=r_associated | relid=0 | w=30
  83. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:nucleotide deaminases
    n1=en:contraindications aspect | n2=en:nucleotide deaminases | rel=r_associated | relid=0 | w=30
  84. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:octamer transcription factor otf-1
    n1=en:contraindications aspect | n2=en:octamer transcription factor otf-1 | rel=r_associated | relid=0 | w=30
  85. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:omega-conotoxin gvia
    n1=en:contraindications aspect | n2=en:omega-conotoxin gvia | rel=r_associated | relid=0 | w=30
  86. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:oncogene protein v-cbl
    n1=en:contraindications aspect | n2=en:oncogene protein v-cbl | rel=r_associated | relid=0 | w=30
  87. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:oxidoreductases, n-demethylating
    n1=en:contraindications aspect | n2=en:oxidoreductases, n-demethylating | rel=r_associated | relid=0 | w=30
  88. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:oxo-acid-lyases
    n1=en:contraindications aspect | n2=en:oxo-acid-lyases | rel=r_associated | relid=0 | w=30
  89. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:p-azobenzenearsonate
    n1=en:contraindications aspect | n2=en:p-azobenzenearsonate | rel=r_associated | relid=0 | w=30
  90. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:p-hydroxynorephedrine
    n1=en:contraindications aspect | n2=en:p-hydroxynorephedrine | rel=r_associated | relid=0 | w=30
  91. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:papillomavirus e7 proteins
    n1=en:contraindications aspect | n2=en:papillomavirus e7 proteins | rel=r_associated | relid=0 | w=30
  92. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:peptidomimetics
    n1=en:contraindications aspect | n2=en:peptidomimetics | rel=r_associated | relid=0 | w=30
  93. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:phakic intraocular lenses
    n1=en:contraindications aspect | n2=en:phakic intraocular lenses | rel=r_associated | relid=0 | w=30
  94. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:phospholipase a2, group x protein
    n1=en:contraindications aspect | n2=en:phospholipase a2, group x protein | rel=r_associated | relid=0 | w=30
  95. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:phosphoribosylaminoimidazolecarboxamide formyltransferase
    n1=en:contraindications aspect | n2=en:phosphoribosylaminoimidazolecarboxamide formyltransferase | rel=r_associated | relid=0 | w=30
  96. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:prajmaline
    n1=en:contraindications aspect | n2=en:prajmaline | rel=r_associated | relid=0 | w=30
  97. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:prenalterol
    n1=en:contraindications aspect | n2=en:prenalterol | rel=r_associated | relid=0 | w=30
  98. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:pristinamycin
    n1=en:contraindications aspect | n2=en:pristinamycin | rel=r_associated | relid=0 | w=30
  99. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:prostaglandin endoperoxides, synthetic
    n1=en:contraindications aspect | n2=en:prostaglandin endoperoxides, synthetic | rel=r_associated | relid=0 | w=30
  100. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:protein tyrosine phosphatase, non-receptor type 1
    n1=en:contraindications aspect | n2=en:protein tyrosine phosphatase, non-receptor type 1 | rel=r_associated | relid=0 | w=30
  101. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:protein tyrosine phosphatase, non-receptor type 4
    n1=en:contraindications aspect | n2=en:protein tyrosine phosphatase, non-receptor type 4 | rel=r_associated | relid=0 | w=30
  102. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:purinergic p2x receptor antagonists
    n1=en:contraindications aspect | n2=en:purinergic p2x receptor antagonists | rel=r_associated | relid=0 | w=30
  103. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:rab3a gtp-binding protein
    n1=en:contraindications aspect | n2=en:rab3a gtp-binding protein | rel=r_associated | relid=0 | w=30
  104. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:receptor, epha1
    n1=en:contraindications aspect | n2=en:receptor, epha1 | rel=r_associated | relid=0 | w=30
  105. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:receptor, epha4
    n1=en:contraindications aspect | n2=en:receptor, epha4 | rel=r_associated | relid=0 | w=30
  106. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:recombinant fusion proteins
    n1=en:contraindications aspect | n2=en:recombinant fusion proteins | rel=r_associated | relid=0 | w=30
  107. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:resuscitation
    n1=en:contraindications aspect | n2=en:resuscitation | rel=r_associated | relid=0 | w=30
  108. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:s-nitroso-n-acetylpenicillamine
    n1=en:contraindications aspect | n2=en:s-nitroso-n-acetylpenicillamine | rel=r_associated | relid=0 | w=30
  109. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:serotonin 5-ht4 receptor agonists
    n1=en:contraindications aspect | n2=en:serotonin 5-ht4 receptor agonists | rel=r_associated | relid=0 | w=30
  110. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:sh2 domain-containing protein tyrosine phosphatases
    n1=en:contraindications aspect | n2=en:sh2 domain-containing protein tyrosine phosphatases | rel=r_associated | relid=0 | w=30
  111. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:smad proteins, inhibitory
    n1=en:contraindications aspect | n2=en:smad proteins, inhibitory | rel=r_associated | relid=0 | w=30
  112. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:sodium-phosphate cotransporter proteins, type ii
    n1=en:contraindications aspect | n2=en:sodium-phosphate cotransporter proteins, type ii | rel=r_associated | relid=0 | w=30
  113. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:sodium-potassium-chloride symporters
    n1=en:contraindications aspect | n2=en:sodium-potassium-chloride symporters | rel=r_associated | relid=0 | w=30
  114. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:streptogramin group b
    n1=en:contraindications aspect | n2=en:streptogramin group b | rel=r_associated | relid=0 | w=30
  115. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:streptothricins
    n1=en:contraindications aspect | n2=en:streptothricins | rel=r_associated | relid=0 | w=30
  116. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:surgical procedure
    n1=en:contraindications aspect | n2=en:surgical procedure | rel=r_associated | relid=0 | w=30
  117. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:survival of motor neuron 2 protein
    n1=en:contraindications aspect | n2=en:survival of motor neuron 2 protein | rel=r_associated | relid=0 | w=30
  118. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:t-cell protein tyrosine phosphatase
    n1=en:contraindications aspect | n2=en:t-cell protein tyrosine phosphatase | rel=r_associated | relid=0 | w=30
  119. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:tissue inhibitor of metalloproteinase-3
    n1=en:contraindications aspect | n2=en:tissue inhibitor of metalloproteinase-3 | rel=r_associated | relid=0 | w=30
  120. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:total parenteral nutrition
    n1=en:contraindications aspect | n2=en:total parenteral nutrition | rel=r_associated | relid=0 | w=30
  121. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:toyocamycin
    n1=en:contraindications aspect | n2=en:toyocamycin | rel=r_associated | relid=0 | w=30
  122. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:transcription factor brn-3a
    n1=en:contraindications aspect | n2=en:transcription factor brn-3a | rel=r_associated | relid=0 | w=30
  123. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:triethyltin compounds
    n1=en:contraindications aspect | n2=en:triethyltin compounds | rel=r_associated | relid=0 | w=30
  124. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:trihalomethanes
    n1=en:contraindications aspect | n2=en:trihalomethanes | rel=r_associated | relid=0 | w=30
  125. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:trinitrobenzenesulfonic acid
    n1=en:contraindications aspect | n2=en:trinitrobenzenesulfonic acid | rel=r_associated | relid=0 | w=30
  126. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:triparanol
    n1=en:contraindications aspect | n2=en:triparanol | rel=r_associated | relid=0 | w=30
  127. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:trpc cation channels
    n1=en:contraindications aspect | n2=en:trpc cation channels | rel=r_associated | relid=0 | w=30
  128. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:uteroglobin
    n1=en:contraindications aspect | n2=en:uteroglobin | rel=r_associated | relid=0 | w=30
  129. en:contraindications aspect -- r_associated #0: 30 / 0.857 -> en:zeta carotene
    n1=en:contraindications aspect | n2=en:zeta carotene | rel=r_associated | relid=0 | w=30
  130. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> Aedes albopictus
    n1=en:contraindications aspect | n2=Aedes albopictus | rel=r_associated | relid=0 | w=29
  131. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:2-hydroxy-5-nitrobenzyl bromide
    n1=en:contraindications aspect | n2=en:2-hydroxy-5-nitrobenzyl bromide | rel=r_associated | relid=0 | w=29
  132. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:2,3-diphosphoglycerate
    n1=en:contraindications aspect | n2=en:2,3-diphosphoglycerate | rel=r_associated | relid=0 | w=29
  133. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-
    n1=en:contraindications aspect | n2=en:2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- | rel=r_associated | relid=0 | w=29
  134. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:3-methoxy-4-hydroxyphenylethanol
    n1=en:contraindications aspect | n2=en:3-methoxy-4-hydroxyphenylethanol | rel=r_associated | relid=0 | w=29
  135. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:3,3-dichlorobenzidine
    n1=en:contraindications aspect | n2=en:3,3-dichlorobenzidine | rel=r_associated | relid=0 | w=29
  136. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:5-ht3 receptor antagonist
    n1=en:contraindications aspect | n2=en:5-ht3 receptor antagonist | rel=r_associated | relid=0 | w=29
  137. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:acetoxyacetylaminofluorene
    n1=en:contraindications aspect | n2=en:acetoxyacetylaminofluorene | rel=r_associated | relid=0 | w=29
  138. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:adenosine a3 receptor agonists
    n1=en:contraindications aspect | n2=en:adenosine a3 receptor agonists | rel=r_associated | relid=0 | w=29
  139. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:agonists
    n1=en:contraindications aspect | n2=en:agonists | rel=r_associated | relid=0 | w=29
  140. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:alpha-n-acetylgalactosaminidase
    n1=en:contraindications aspect | n2=en:alpha-n-acetylgalactosaminidase | rel=r_associated | relid=0 | w=29
  141. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:alpha-naphthyl acetate esterase
    n1=en:contraindications aspect | n2=en:alpha-naphthyl acetate esterase | rel=r_associated | relid=0 | w=29
  142. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:amino acid transport system x-ag
    n1=en:contraindications aspect | n2=en:amino acid transport system x-ag | rel=r_associated | relid=0 | w=29
  143. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:angiopoietin-1
    n1=en:contraindications aspect | n2=en:angiopoietin-1 | rel=r_associated | relid=0 | w=29
  144. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:apoptosis regulator bax
    n1=en:contraindications aspect | n2=en:apoptosis regulator bax | rel=r_associated | relid=0 | w=29
  145. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:ca(2+) mg(2+)-atpase
    n1=en:contraindications aspect | n2=en:ca(2+) mg(2+)-atpase | rel=r_associated | relid=0 | w=29
  146. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:canrenoic acid
    n1=en:contraindications aspect | n2=en:canrenoic acid | rel=r_associated | relid=0 | w=29
  147. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:cardiac resuscitation
    n1=en:contraindications aspect | n2=en:cardiac resuscitation | rel=r_associated | relid=0 | w=29
  148. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:ccaat enhancer binding protein
    n1=en:contraindications aspect | n2=en:ccaat enhancer binding protein | rel=r_associated | relid=0 | w=29
  149. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:cecropins
    n1=en:contraindications aspect | n2=en:cecropins | rel=r_associated | relid=0 | w=29
  150. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:chemokine cxcl2
    n1=en:contraindications aspect | n2=en:chemokine cxcl2 | rel=r_associated | relid=0 | w=29
  151. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:class iii phosphatidylinositol 3-kinases
    n1=en:contraindications aspect | n2=en:class iii phosphatidylinositol 3-kinases | rel=r_associated | relid=0 | w=29
  152. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:complement c4-a
    n1=en:contraindications aspect | n2=en:complement c4-a | rel=r_associated | relid=0 | w=29
  153. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:complement component 9
    n1=en:contraindications aspect | n2=en:complement component 9 | rel=r_associated | relid=0 | w=29
  154. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:cyclin-dependent kinase 8
    n1=en:contraindications aspect | n2=en:cyclin-dependent kinase 8 | rel=r_associated | relid=0 | w=29
  155. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:cytidine monophosphate n-acetylneuraminic acid
    n1=en:contraindications aspect | n2=en:cytidine monophosphate n-acetylneuraminic acid | rel=r_associated | relid=0 | w=29
  156. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:cytochrome reductases
    n1=en:contraindications aspect | n2=en:cytochrome reductases | rel=r_associated | relid=0 | w=29
  157. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:cytoskeletal protein
    n1=en:contraindications aspect | n2=en:cytoskeletal protein | rel=r_associated | relid=0 | w=29
  158. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:d-alanine transaminase
    n1=en:contraindications aspect | n2=en:d-alanine transaminase | rel=r_associated | relid=0 | w=29
  159. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:deae-cellulose
    n1=en:contraindications aspect | n2=en:deae-cellulose | rel=r_associated | relid=0 | w=29
  160. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:dehydrocholesterols
    n1=en:contraindications aspect | n2=en:dehydrocholesterols | rel=r_associated | relid=0 | w=29
  161. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:dithionitrobenzoic acid
    n1=en:contraindications aspect | n2=en:dithionitrobenzoic acid | rel=r_associated | relid=0 | w=29
  162. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:diynes
    n1=en:contraindications aspect | n2=en:diynes | rel=r_associated | relid=0 | w=29
  163. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:endocrine-gland-derived vascular endothelial growth factor
    n1=en:contraindications aspect | n2=en:endocrine-gland-derived vascular endothelial growth factor | rel=r_associated | relid=0 | w=29
  164. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:enterosorption
    n1=en:contraindications aspect | n2=en:enterosorption | rel=r_associated | relid=0 | w=29
  165. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:ephrin-b1
    n1=en:contraindications aspect | n2=en:ephrin-b1 | rel=r_associated | relid=0 | w=29
  166. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:fenamates
    n1=en:contraindications aspect | n2=en:fenamates | rel=r_associated | relid=0 | w=29
  167. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:fertility agents, female
    n1=en:contraindications aspect | n2=en:fertility agents, female | rel=r_associated | relid=0 | w=29
  168. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:formocresols
    n1=en:contraindications aspect | n2=en:formocresols | rel=r_associated | relid=0 | w=29
  169. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:glucose-1-phosphate adenylyltransferase
    n1=en:contraindications aspect | n2=en:glucose-1-phosphate adenylyltransferase | rel=r_associated | relid=0 | w=29
  170. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:glutathione s-transferase pi
    n1=en:contraindications aspect | n2=en:glutathione s-transferase pi | rel=r_associated | relid=0 | w=29
  171. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:group i chaperonins
    n1=en:contraindications aspect | n2=en:group i chaperonins | rel=r_associated | relid=0 | w=29
  172. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:group ia phospholipases a2
    n1=en:contraindications aspect | n2=en:group ia phospholipases a2 | rel=r_associated | relid=0 | w=29
  173. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:group iii phospholipases a2
    n1=en:contraindications aspect | n2=en:group iii phospholipases a2 | rel=r_associated | relid=0 | w=29
  174. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:gtp-binding protein alpha subunits, g12-g13
    n1=en:contraindications aspect | n2=en:gtp-binding protein alpha subunits, g12-g13 | rel=r_associated | relid=0 | w=29
  175. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:hippocalcin
    n1=en:contraindications aspect | n2=en:hippocalcin | rel=r_associated | relid=0 | w=29
  176. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:hydroxydopamines
    n1=en:contraindications aspect | n2=en:hydroxydopamines | rel=r_associated | relid=0 | w=29
  177. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:hydroxymercuribenzoates
    n1=en:contraindications aspect | n2=en:hydroxymercuribenzoates | rel=r_associated | relid=0 | w=29
  178. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:hydroxymethylglutaryl-coa reductases, nad-dependent
    n1=en:contraindications aspect | n2=en:hydroxymethylglutaryl-coa reductases, nad-dependent | rel=r_associated | relid=0 | w=29
  179. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:hydroxyphenylazouracil
    n1=en:contraindications aspect | n2=en:hydroxyphenylazouracil | rel=r_associated | relid=0 | w=29
  180. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:iodamide
    n1=en:contraindications aspect | n2=en:iodamide | rel=r_associated | relid=0 | w=29
  181. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:kv1.5 potassium channel
    n1=en:contraindications aspect | n2=en:kv1.5 potassium channel | rel=r_associated | relid=0 | w=29
  182. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:leukocyte surface antigen cd47
    n1=en:contraindications aspect | n2=en:leukocyte surface antigen cd47 | rel=r_associated | relid=0 | w=29
  183. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:mannich bases
    n1=en:contraindications aspect | n2=en:mannich bases | rel=r_associated | relid=0 | w=29
  184. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:mechanism of action qualifier
    n1=en:contraindications aspect | n2=en:mechanism of action qualifier | rel=r_associated | relid=0 | w=29
  185. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:methallibure
    n1=en:contraindications aspect | n2=en:methallibure | rel=r_associated | relid=0 | w=29
  186. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:microbubbles
    n1=en:contraindications aspect | n2=en:microbubbles | rel=r_associated | relid=0 | w=29
  187. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:microdialysis
    n1=en:contraindications aspect | n2=en:microdialysis | rel=r_associated | relid=0 | w=29
  188. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:mitogen-activated protein kinase 3
    n1=en:contraindications aspect | n2=en:mitogen-activated protein kinase 3 | rel=r_associated | relid=0 | w=29
  189. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:mucin-6
    n1=en:contraindications aspect | n2=en:mucin-6 | rel=r_associated | relid=0 | w=29
  190. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:myosin subfragments
    n1=en:contraindications aspect | n2=en:myosin subfragments | rel=r_associated | relid=0 | w=29
  191. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:n-butyl-n-(4-hydroxybutyl)nitrosamine
    n1=en:contraindications aspect | n2=en:n-butyl-n-(4-hydroxybutyl)nitrosamine | rel=r_associated | relid=0 | w=29
  192. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:nadp transhydrogenase, ab-specific
    n1=en:contraindications aspect | n2=en:nadp transhydrogenase, ab-specific | rel=r_associated | relid=0 | w=29
  193. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:nf-e2-related factor 1
    n1=en:contraindications aspect | n2=en:nf-e2-related factor 1 | rel=r_associated | relid=0 | w=29
  194. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:nialamide
    n1=en:contraindications aspect | n2=en:nialamide | rel=r_associated | relid=0 | w=29
  195. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:nitroanisole o-demethylase
    n1=en:contraindications aspect | n2=en:nitroanisole o-demethylase | rel=r_associated | relid=0 | w=29
  196. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:nitroquinolines
    n1=en:contraindications aspect | n2=en:nitroquinolines | rel=r_associated | relid=0 | w=29
  197. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:o-acetyl-adp-ribose
    n1=en:contraindications aspect | n2=en:o-acetyl-adp-ribose | rel=r_associated | relid=0 | w=29
  198. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:phenylglyoxal
    n1=en:contraindications aspect | n2=en:phenylglyoxal | rel=r_associated | relid=0 | w=29
  199. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:phenylmethylsulfonyl fluoride
    n1=en:contraindications aspect | n2=en:phenylmethylsulfonyl fluoride | rel=r_associated | relid=0 | w=29
  200. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:phosphatidylinositol 3-kinases
    n1=en:contraindications aspect | n2=en:phosphatidylinositol 3-kinases | rel=r_associated | relid=0 | w=29
  201. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:poly(a)-binding protein i
    n1=en:contraindications aspect | n2=en:poly(a)-binding protein i | rel=r_associated | relid=0 | w=29
  202. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:polyanetholesulfonate
    n1=en:contraindications aspect | n2=en:polyanetholesulfonate | rel=r_associated | relid=0 | w=29
  203. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:potassium ionophores
    n1=en:contraindications aspect | n2=en:potassium ionophores | rel=r_associated | relid=0 | w=29
  204. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:promedol
    n1=en:contraindications aspect | n2=en:promedol | rel=r_associated | relid=0 | w=29
  205. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:protein d-aspartate-l-isoaspartate methyltransferase
    n1=en:contraindications aspect | n2=en:protein d-aspartate-l-isoaspartate methyltransferase | rel=r_associated | relid=0 | w=29
  206. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:protein tyrosine phosphatase, non-receptor type 12
    n1=en:contraindications aspect | n2=en:protein tyrosine phosphatase, non-receptor type 12 | rel=r_associated | relid=0 | w=29
  207. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:proto-oncogene proteins b-raf
    n1=en:contraindications aspect | n2=en:proto-oncogene proteins b-raf | rel=r_associated | relid=0 | w=29
  208. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:proto-oncogene proteins c-hck
    n1=en:contraindications aspect | n2=en:proto-oncogene proteins c-hck | rel=r_associated | relid=0 | w=29
  209. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:proto-oncogene proteins c-maf
    n1=en:contraindications aspect | n2=en:proto-oncogene proteins c-maf | rel=r_associated | relid=0 | w=29
  210. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:proto-oncogene proteins c-pim-1
    n1=en:contraindications aspect | n2=en:proto-oncogene proteins c-pim-1 | rel=r_associated | relid=0 | w=29
  211. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:pyocins
    n1=en:contraindications aspect | n2=en:pyocins | rel=r_associated | relid=0 | w=29
  212. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:pyronine
    n1=en:contraindications aspect | n2=en:pyronine | rel=r_associated | relid=0 | w=29
  213. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:pyruvate dehydrogenase (lipoamide)-phosphatase
    n1=en:contraindications aspect | n2=en:pyruvate dehydrogenase (lipoamide)-phosphatase | rel=r_associated | relid=0 | w=29
  214. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:quinuclidinyl benzilate
    n1=en:contraindications aspect | n2=en:quinuclidinyl benzilate | rel=r_associated | relid=0 | w=29
  215. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:rafoxanide
    n1=en:contraindications aspect | n2=en:rafoxanide | rel=r_associated | relid=0 | w=29
  216. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:ras gtpase-activating proteins
    n1=en:contraindications aspect | n2=en:ras gtpase-activating proteins | rel=r_associated | relid=0 | w=29
  217. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:receptor tyrosine kinase-like orphan receptors
    n1=en:contraindications aspect | n2=en:receptor tyrosine kinase-like orphan receptors | rel=r_associated | relid=0 | w=29
  218. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:receptor, epha2
    n1=en:contraindications aspect | n2=en:receptor, epha2 | rel=r_associated | relid=0 | w=29
  219. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:receptor, trkb
    n1=en:contraindications aspect | n2=en:receptor, trkb | rel=r_associated | relid=0 | w=29
  220. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:rna precursors
    n1=en:contraindications aspect | n2=en:rna precursors | rel=r_associated | relid=0 | w=29
  221. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:rna, ribosomal, 5.8s
    n1=en:contraindications aspect | n2=en:rna, ribosomal, 5.8s | rel=r_associated | relid=0 | w=29
  222. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:secretory phospholipase a2
    n1=en:contraindications aspect | n2=en:secretory phospholipase a2 | rel=r_associated | relid=0 | w=29
  223. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:serine-type d-ala-d-ala carboxypeptidase
    n1=en:contraindications aspect | n2=en:serine-type d-ala-d-ala carboxypeptidase | rel=r_associated | relid=0 | w=29
  224. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:site-specific dna-methyltransferase (cytosine-n4-specific)
    n1=en:contraindications aspect | n2=en:site-specific dna-methyltransferase (cytosine-n4-specific) | rel=r_associated | relid=0 | w=29
  225. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:solute carrier family 12, member 3
    n1=en:contraindications aspect | n2=en:solute carrier family 12, member 3 | rel=r_associated | relid=0 | w=29
  226. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:soxb1 transcription factors
    n1=en:contraindications aspect | n2=en:soxb1 transcription factors | rel=r_associated | relid=0 | w=29
  227. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:spiperone
    n1=en:contraindications aspect | n2=en:spiperone | rel=r_associated | relid=0 | w=29
  228. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:steroid 16-alpha-hydroxylase
    n1=en:contraindications aspect | n2=en:steroid 16-alpha-hydroxylase | rel=r_associated | relid=0 | w=29
  229. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:sulfadimethoxine
    n1=en:contraindications aspect | n2=en:sulfadimethoxine | rel=r_associated | relid=0 | w=29
  230. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:suppressor factors, immunologic
    n1=en:contraindications aspect | n2=en:suppressor factors, immunologic | rel=r_associated | relid=0 | w=29
  231. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:syndecan-3
    n1=en:contraindications aspect | n2=en:syndecan-3 | rel=r_associated | relid=0 | w=29
  232. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:technetium tc-99m pyrophosphate
    n1=en:contraindications aspect | n2=en:technetium tc-99m pyrophosphate | rel=r_associated | relid=0 | w=29
  233. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:thiouracil
    n1=en:contraindications aspect | n2=en:thiouracil | rel=r_associated | relid=0 | w=29
  234. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:threonine-specific trna
    n1=en:contraindications aspect | n2=en:threonine-specific trna | rel=r_associated | relid=0 | w=29
  235. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:thyroid function tests
    n1=en:contraindications aspect | n2=en:thyroid function tests | rel=r_associated | relid=0 | w=29
  236. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:tnf receptor-associated factor 2
    n1=en:contraindications aspect | n2=en:tnf receptor-associated factor 2 | rel=r_associated | relid=0 | w=29
  237. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:transcription factor brn-3
    n1=en:contraindications aspect | n2=en:transcription factor brn-3 | rel=r_associated | relid=0 | w=29
  238. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:transcription factor brn-3b
    n1=en:contraindications aspect | n2=en:transcription factor brn-3b | rel=r_associated | relid=0 | w=29
  239. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:triaziquone
    n1=en:contraindications aspect | n2=en:triaziquone | rel=r_associated | relid=0 | w=29
  240. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:tropocollagen
    n1=en:contraindications aspect | n2=en:tropocollagen | rel=r_associated | relid=0 | w=29
  241. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:trpp cation channels
    n1=en:contraindications aspect | n2=en:trpp cation channels | rel=r_associated | relid=0 | w=29
  242. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:venturicidins
    n1=en:contraindications aspect | n2=en:venturicidins | rel=r_associated | relid=0 | w=29
  243. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:wheat germ agglutinin-horseradish peroxidase conjugate
    n1=en:contraindications aspect | n2=en:wheat germ agglutinin-horseradish peroxidase conjugate | rel=r_associated | relid=0 | w=29
  244. en:contraindications aspect -- r_associated #0: 29 / 0.829 -> en:wnt4 protein
    n1=en:contraindications aspect | n2=en:wnt4 protein | rel=r_associated | relid=0 | w=29
  245. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:1-methyl-4-phenylpyridinium
    n1=en:contraindications aspect | n2=en:1-methyl-4-phenylpyridinium | rel=r_associated | relid=0 | w=28
  246. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt
    n1=en:contraindications aspect | n2=en:1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt | rel=r_associated | relid=0 | w=28
  247. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:1,4-alpha-glucan branching enzyme
    n1=en:contraindications aspect | n2=en:1,4-alpha-glucan branching enzyme | rel=r_associated | relid=0 | w=28
  248. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:2,6-dichloroindophenol
    n1=en:contraindications aspect | n2=en:2,6-dichloroindophenol | rel=r_associated | relid=0 | w=28
  249. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:4-dimensional computed tomography
    n1=en:contraindications aspect | n2=en:4-dimensional computed tomography | rel=r_associated | relid=0 | w=28
  250. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:8-hydroxy-2-(di-n-propylamino)tetralin
    n1=en:contraindications aspect | n2=en:8-hydroxy-2-(di-n-propylamino)tetralin | rel=r_associated | relid=0 | w=28
  251. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:adrenergic beta-3 receptor agonists
    n1=en:contraindications aspect | n2=en:adrenergic beta-3 receptor agonists | rel=r_associated | relid=0 | w=28
  252. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:aequorin
    n1=en:contraindications aspect | n2=en:aequorin | rel=r_associated | relid=0 | w=28
  253. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:agar
    n1=en:contraindications aspect | n2=en:agar | rel=r_associated | relid=0 | w=28
  254. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:alfaxalone alfadolone mixture
    n1=en:contraindications aspect | n2=en:alfaxalone alfadolone mixture | rel=r_associated | relid=0 | w=28
  255. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:antigen ki-67
    n1=en:contraindications aspect | n2=en:antigen ki-67 | rel=r_associated | relid=0 | w=28
  256. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:antigens, cd98 light chains
    n1=en:contraindications aspect | n2=en:antigens, cd98 light chains | rel=r_associated | relid=0 | w=28
  257. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:apoptotic protease-activating factor 1
    n1=en:contraindications aspect | n2=en:apoptotic protease-activating factor 1 | rel=r_associated | relid=0 | w=28
  258. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:azulenes
    n1=en:contraindications aspect | n2=en:azulenes | rel=r_associated | relid=0 | w=28
  259. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:benzophenoneidum
    n1=en:contraindications aspect | n2=en:benzophenoneidum | rel=r_associated | relid=0 | w=28
  260. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:benzoylarginine-2-naphthylamide
    n1=en:contraindications aspect | n2=en:benzoylarginine-2-naphthylamide | rel=r_associated | relid=0 | w=28
  261. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:beta-alanine-pyruvate aminotransferase
    n1=en:contraindications aspect | n2=en:beta-alanine-pyruvate aminotransferase | rel=r_associated | relid=0 | w=28
  262. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:buformin
    n1=en:contraindications aspect | n2=en:buformin | rel=r_associated | relid=0 | w=28
  263. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:carbon-nitrogen ligases with glutamine as amide-n-donor
    n1=en:contraindications aspect | n2=en:carbon-nitrogen ligases with glutamine as amide-n-donor | rel=r_associated | relid=0 | w=28
  264. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:carbonyl cyanide p-trifluoromethoxyphenylhydrazone
    n1=en:contraindications aspect | n2=en:carbonyl cyanide p-trifluoromethoxyphenylhydrazone | rel=r_associated | relid=0 | w=28
  265. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:carboquone
    n1=en:contraindications aspect | n2=en:carboquone | rel=r_associated | relid=0 | w=28
  266. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:cardanolides
    n1=en:contraindications aspect | n2=en:cardanolides | rel=r_associated | relid=0 | w=28
  267. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:cardiac myosins
    n1=en:contraindications aspect | n2=en:cardiac myosins | rel=r_associated | relid=0 | w=28
  268. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:casein kinase ialpha
    n1=en:contraindications aspect | n2=en:casein kinase ialpha | rel=r_associated | relid=0 | w=28
  269. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:catechol 1,2-dioxygenase
    n1=en:contraindications aspect | n2=en:catechol 1,2-dioxygenase | rel=r_associated | relid=0 | w=28
  270. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:cephalosporinase
    n1=en:contraindications aspect | n2=en:cephalosporinase | rel=r_associated | relid=0 | w=28
  271. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:chimerin proteins
    n1=en:contraindications aspect | n2=en:chimerin proteins | rel=r_associated | relid=0 | w=28
  272. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:chlorobenzoates
    n1=en:contraindications aspect | n2=en:chlorobenzoates | rel=r_associated | relid=0 | w=28
  273. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:cholates
    n1=en:contraindications aspect | n2=en:cholates | rel=r_associated | relid=0 | w=28
  274. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:cholestadienes
    n1=en:contraindications aspect | n2=en:cholestadienes | rel=r_associated | relid=0 | w=28
  275. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:cholestanones
    n1=en:contraindications aspect | n2=en:cholestanones | rel=r_associated | relid=0 | w=28
  276. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:co-repressor proteins
    n1=en:contraindications aspect | n2=en:co-repressor proteins | rel=r_associated | relid=0 | w=28
  277. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:complement c3d
    n1=en:contraindications aspect | n2=en:complement c3d | rel=r_associated | relid=0 | w=28
  278. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:complement c5
    n1=en:contraindications aspect | n2=en:complement c5 | rel=r_associated | relid=0 | w=28
  279. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:complement component c1s
    n1=en:contraindications aspect | n2=en:complement component c1s | rel=r_associated | relid=0 | w=28
  280. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:contactin 1
    n1=en:contraindications aspect | n2=en:contactin 1 | rel=r_associated | relid=0 | w=28
  281. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:cytochalasin d
    n1=en:contraindications aspect | n2=en:cytochalasin d | rel=r_associated | relid=0 | w=28
  282. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:cytochrome p-450 cyp1a1
    n1=en:contraindications aspect | n2=en:cytochrome p-450 cyp1a1 | rel=r_associated | relid=0 | w=28
  283. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:cytochrome p-450 cyp1a2
    n1=en:contraindications aspect | n2=en:cytochrome p-450 cyp1a2 | rel=r_associated | relid=0 | w=28
  284. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:d-aspartic acid
    n1=en:contraindications aspect | n2=en:d-aspartic acid | rel=r_associated | relid=0 | w=28
  285. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:dead box protein 20
    n1=en:contraindications aspect | n2=en:dead box protein 20 | rel=r_associated | relid=0 | w=28
  286. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:decoy receptor 3
    n1=en:contraindications aspect | n2=en:decoy receptor 3 | rel=r_associated | relid=0 | w=28
  287. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:dibromothymoquinone
    n1=en:contraindications aspect | n2=en:dibromothymoquinone | rel=r_associated | relid=0 | w=28
  288. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:dichlororibofuranosylbenzimidazole
    n1=en:contraindications aspect | n2=en:dichlororibofuranosylbenzimidazole | rel=r_associated | relid=0 | w=28
  289. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:dimaprit
    n1=en:contraindications aspect | n2=en:dimaprit | rel=r_associated | relid=0 | w=28
  290. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:dithizone
    n1=en:contraindications aspect | n2=en:dithizone | rel=r_associated | relid=0 | w=28
  291. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:dna probes, hla
    n1=en:contraindications aspect | n2=en:dna probes, hla | rel=r_associated | relid=0 | w=28
  292. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:e2f1 transcription factor
    n1=en:contraindications aspect | n2=en:e2f1 transcription factor | rel=r_associated | relid=0 | w=28
  293. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:e2f7 transcription factor
    n1=en:contraindications aspect | n2=en:e2f7 transcription factor | rel=r_associated | relid=0 | w=28
  294. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:electroacupuncture therapy
    n1=en:contraindications aspect | n2=en:electroacupuncture therapy | rel=r_associated | relid=0 | w=28
  295. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:enalaprilat
    n1=en:contraindications aspect | n2=en:enalaprilat | rel=r_associated | relid=0 | w=28
  296. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:endo-1,3-(4)-beta-d-glucanase
    n1=en:contraindications aspect | n2=en:endo-1,3-(4)-beta-d-glucanase | rel=r_associated | relid=0 | w=28
  297. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:endothelin-3
    n1=en:contraindications aspect | n2=en:endothelin-3 | rel=r_associated | relid=0 | w=28
  298. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:epha3 receptor
    n1=en:contraindications aspect | n2=en:epha3 receptor | rel=r_associated | relid=0 | w=28
  299. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:epimestrol
    n1=en:contraindications aspect | n2=en:epimestrol | rel=r_associated | relid=0 | w=28
  300. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:equilin
    n1=en:contraindications aspect | n2=en:equilin | rel=r_associated | relid=0 | w=28
  301. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:ethamoxytriphetol
    n1=en:contraindications aspect | n2=en:ethamoxytriphetol | rel=r_associated | relid=0 | w=28
  302. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:ethylketocyclazocine
    n1=en:contraindications aspect | n2=en:ethylketocyclazocine | rel=r_associated | relid=0 | w=28
  303. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:fanconi anemia complementation group g protein
    n1=en:contraindications aspect | n2=en:fanconi anemia complementation group g protein | rel=r_associated | relid=0 | w=28
  304. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:fenclonine
    n1=en:contraindications aspect | n2=en:fenclonine | rel=r_associated | relid=0 | w=28
  305. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:ferrozine
    n1=en:contraindications aspect | n2=en:ferrozine | rel=r_associated | relid=0 | w=28
  306. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:ficoll
    n1=en:contraindications aspect | n2=en:ficoll | rel=r_associated | relid=0 | w=28
  307. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:furylfuramide
    n1=en:contraindications aspect | n2=en:furylfuramide | rel=r_associated | relid=0 | w=28
  308. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:ga-binding protein transcription factor
    n1=en:contraindications aspect | n2=en:ga-binding protein transcription factor | rel=r_associated | relid=0 | w=28
  309. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:gamma-glutamylcyclotransferase
    n1=en:contraindications aspect | n2=en:gamma-glutamylcyclotransferase | rel=r_associated | relid=0 | w=28
  310. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:hexobendine
    n1=en:contraindications aspect | n2=en:hexobendine | rel=r_associated | relid=0 | w=28
  311. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:hla-b51 antigen
    n1=en:contraindications aspect | n2=en:hla-b51 antigen | rel=r_associated | relid=0 | w=28
  312. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:homoarginine
    n1=en:contraindications aspect | n2=en:homoarginine | rel=r_associated | relid=0 | w=28
  313. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:hsp20 heat-shock proteins
    n1=en:contraindications aspect | n2=en:hsp20 heat-shock proteins | rel=r_associated | relid=0 | w=28
  314. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:imidoesters
    n1=en:contraindications aspect | n2=en:imidoesters | rel=r_associated | relid=0 | w=28
  315. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:indolizidines
    n1=en:contraindications aspect | n2=en:indolizidines | rel=r_associated | relid=0 | w=28
  316. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:integrin beta4
    n1=en:contraindications aspect | n2=en:integrin beta4 | rel=r_associated | relid=0 | w=28
  317. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:interleukin-23 subunit p19
    n1=en:contraindications aspect | n2=en:interleukin-23 subunit p19 | rel=r_associated | relid=0 | w=28
  318. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:jnk mitogen-activated protein kinases
    n1=en:contraindications aspect | n2=en:jnk mitogen-activated protein kinases | rel=r_associated | relid=0 | w=28
  319. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:jumonji domain-containing histone demethylases
    n1=en:contraindications aspect | n2=en:jumonji domain-containing histone demethylases | rel=r_associated | relid=0 | w=28
  320. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:kcnq potassium channels
    n1=en:contraindications aspect | n2=en:kcnq potassium channels | rel=r_associated | relid=0 | w=28
  321. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:keratin-13
    n1=en:contraindications aspect | n2=en:keratin-13 | rel=r_associated | relid=0 | w=28
  322. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:lactase-phlorizin hydrolase
    n1=en:contraindications aspect | n2=en:lactase-phlorizin hydrolase | rel=r_associated | relid=0 | w=28
  323. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:lanosterol 14 alpha-demethylase
    n1=en:contraindications aspect | n2=en:lanosterol 14 alpha-demethylase | rel=r_associated | relid=0 | w=28
  324. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:leucogenenol
    n1=en:contraindications aspect | n2=en:leucogenenol | rel=r_associated | relid=0 | w=28
  325. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:methylglucosides
    n1=en:contraindications aspect | n2=en:methylglucosides | rel=r_associated | relid=0 | w=28
  326. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:mitochondrial proton-translocating atpases
    n1=en:contraindications aspect | n2=en:mitochondrial proton-translocating atpases | rel=r_associated | relid=0 | w=28
  327. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:mitogen-activated protein kinase 14
    n1=en:contraindications aspect | n2=en:mitogen-activated protein kinase 14 | rel=r_associated | relid=0 | w=28
  328. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:mucin-5ac
    n1=en:contraindications aspect | n2=en:mucin-5ac | rel=r_associated | relid=0 | w=28
  329. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:n-acetylhexosaminyltransferases
    n1=en:contraindications aspect | n2=en:n-acetylhexosaminyltransferases | rel=r_associated | relid=0 | w=28
  330. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:niceritrol
    n1=en:contraindications aspect | n2=en:niceritrol | rel=r_associated | relid=0 | w=28
  331. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:nitrohydroxyiodophenylacetate
    n1=en:contraindications aspect | n2=en:nitrohydroxyiodophenylacetate | rel=r_associated | relid=0 | w=28
  332. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:nm23 nucleoside diphosphate kinases
    n1=en:contraindications aspect | n2=en:nm23 nucleoside diphosphate kinases | rel=r_associated | relid=0 | w=28
  333. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:nordefrin
    n1=en:contraindications aspect | n2=en:nordefrin | rel=r_associated | relid=0 | w=28
  334. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:nuclear receptor subfamily 4, group a, member 2
    n1=en:contraindications aspect | n2=en:nuclear receptor subfamily 4, group a, member 2 | rel=r_associated | relid=0 | w=28
  335. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:oncogene protein v-akt
    n1=en:contraindications aspect | n2=en:oncogene protein v-akt | rel=r_associated | relid=0 | w=28
  336. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:organosilicon compounds
    n1=en:contraindications aspect | n2=en:organosilicon compounds | rel=r_associated | relid=0 | w=28
  337. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:oxathiins
    n1=en:contraindications aspect | n2=en:oxathiins | rel=r_associated | relid=0 | w=28
  338. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:p-fluorophenylalanine
    n1=en:contraindications aspect | n2=en:p-fluorophenylalanine | rel=r_associated | relid=0 | w=28
  339. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:phenylthiohydantoin
    n1=en:contraindications aspect | n2=en:phenylthiohydantoin | rel=r_associated | relid=0 | w=28
  340. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:phleomycins
    n1=en:contraindications aspect | n2=en:phleomycins | rel=r_associated | relid=0 | w=28
  341. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:pituitary hormone release inhibiting hormones
    n1=en:contraindications aspect | n2=en:pituitary hormone release inhibiting hormones | rel=r_associated | relid=0 | w=28
  342. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:poly da-dt
    n1=en:contraindications aspect | n2=en:poly da-dt | rel=r_associated | relid=0 | w=28
  343. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:poly(adp-ribose) polymerases
    n1=en:contraindications aspect | n2=en:poly(adp-ribose) polymerases | rel=r_associated | relid=0 | w=28
  344. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:polyglactin 910
    n1=en:contraindications aspect | n2=en:polyglactin 910 | rel=r_associated | relid=0 | w=28
  345. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:proline-specific trna
    n1=en:contraindications aspect | n2=en:proline-specific trna | rel=r_associated | relid=0 | w=28
  346. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:prostaglandin d2
    n1=en:contraindications aspect | n2=en:prostaglandin d2 | rel=r_associated | relid=0 | w=28
  347. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:protein tyrosine phosphatase, non-receptor type 3
    n1=en:contraindications aspect | n2=en:protein tyrosine phosphatase, non-receptor type 3 | rel=r_associated | relid=0 | w=28
  348. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:proton-phosphate symporters
    n1=en:contraindications aspect | n2=en:proton-phosphate symporters | rel=r_associated | relid=0 | w=28
  349. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:purinergic p2x receptor agonists
    n1=en:contraindications aspect | n2=en:purinergic p2x receptor agonists | rel=r_associated | relid=0 | w=28
  350. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:pyrroline carboxylate reductases
    n1=en:contraindications aspect | n2=en:pyrroline carboxylate reductases | rel=r_associated | relid=0 | w=28
  351. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:q beta replicase
    n1=en:contraindications aspect | n2=en:q beta replicase | rel=r_associated | relid=0 | w=28
  352. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:rab2 gtp-binding protein
    n1=en:contraindications aspect | n2=en:rab2 gtp-binding protein | rel=r_associated | relid=0 | w=28
  353. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:rab3 gtp-binding proteins
    n1=en:contraindications aspect | n2=en:rab3 gtp-binding proteins | rel=r_associated | relid=0 | w=28
  354. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:rab5 gtp-binding proteins
    n1=en:contraindications aspect | n2=en:rab5 gtp-binding proteins | rel=r_associated | relid=0 | w=28
  355. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:receptor-like protein tyrosine phosphatases, class 8
    n1=en:contraindications aspect | n2=en:receptor-like protein tyrosine phosphatases, class 8 | rel=r_associated | relid=0 | w=28
  356. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:retinoblastoma-like protein p130
    n1=en:contraindications aspect | n2=en:retinoblastoma-like protein p130 | rel=r_associated | relid=0 | w=28
  357. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:ribosomal protein s6 kinases, 70-kda
    n1=en:contraindications aspect | n2=en:ribosomal protein s6 kinases, 70-kda | rel=r_associated | relid=0 | w=28
  358. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:rna polymerase sigma 54
    n1=en:contraindications aspect | n2=en:rna polymerase sigma 54 | rel=r_associated | relid=0 | w=28
  359. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:rna, small cytoplasmic
    n1=en:contraindications aspect | n2=en:rna, small cytoplasmic | rel=r_associated | relid=0 | w=28
  360. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:sarcoplasmic reticulum calcium-transporting atpases
    n1=en:contraindications aspect | n2=en:sarcoplasmic reticulum calcium-transporting atpases | rel=r_associated | relid=0 | w=28
  361. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:smad proteins, receptor-regulated
    n1=en:contraindications aspect | n2=en:smad proteins, receptor-regulated | rel=r_associated | relid=0 | w=28
  362. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:stat6 transcription factor
    n1=en:contraindications aspect | n2=en:stat6 transcription factor | rel=r_associated | relid=0 | w=28
  363. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:streptogramin group a
    n1=en:contraindications aspect | n2=en:streptogramin group a | rel=r_associated | relid=0 | w=28
  364. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:teprotide
    n1=en:contraindications aspect | n2=en:teprotide | rel=r_associated | relid=0 | w=28
  365. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:thermosomes
    n1=en:contraindications aspect | n2=en:thermosomes | rel=r_associated | relid=0 | w=28
  366. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:topoisomerase iv
    n1=en:contraindications aspect | n2=en:topoisomerase iv | rel=r_associated | relid=0 | w=28
  367. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:tropoelastin
    n1=en:contraindications aspect | n2=en:tropoelastin | rel=r_associated | relid=0 | w=28
  368. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:tubulin
    n1=en:contraindications aspect | n2=en:tubulin | rel=r_associated | relid=0 | w=28
  369. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:v-src protein
    n1=en:contraindications aspect | n2=en:v-src protein | rel=r_associated | relid=0 | w=28
  370. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> en:voltage-gated potassium channel
    n1=en:contraindications aspect | n2=en:voltage-gated potassium channel | rel=r_associated | relid=0 | w=28
  371. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> lipoprotéine
    n1=en:contraindications aspect | n2=lipoprotéine | rel=r_associated | relid=0 | w=28
  372. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> préparation pharmaceutique
    n1=en:contraindications aspect | n2=préparation pharmaceutique | rel=r_associated | relid=0 | w=28
  373. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> protéine du cytosquelette
    n1=en:contraindications aspect | n2=protéine du cytosquelette | rel=r_associated | relid=0 | w=28
  374. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> récepteurs à activité guanylate cyclase
    n1=en:contraindications aspect | n2=récepteurs à activité guanylate cyclase | rel=r_associated | relid=0 | w=28
  375. en:contraindications aspect -- r_associated #0: 28 / 0.8 -> sorbitol
    n1=en:contraindications aspect | n2=sorbitol | rel=r_associated | relid=0 | w=28
  376. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> cystatine B
    n1=en:contraindications aspect | n2=cystatine B | rel=r_associated | relid=0 | w=27
  377. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:1,2-dipalmitoylphosphatidylcholine
    n1=en:contraindications aspect | n2=en:1,2-dipalmitoylphosphatidylcholine | rel=r_associated | relid=0 | w=27
  378. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:2s albumins, plant
    n1=en:contraindications aspect | n2=en:2s albumins, plant | rel=r_associated | relid=0 | w=27
  379. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:4-chloro-7-nitrobenzofurazan
    n1=en:contraindications aspect | n2=en:4-chloro-7-nitrobenzofurazan | rel=r_associated | relid=0 | w=27
  380. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:4-nitroquinoline-1-oxide
    n1=en:contraindications aspect | n2=en:4-nitroquinoline-1-oxide | rel=r_associated | relid=0 | w=27
  381. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:4,5-dihydro-1-(3-(trifluoromethyl)phenyl)-1h-pyrazol-3-amine
    n1=en:contraindications aspect | n2=en:4,5-dihydro-1-(3-(trifluoromethyl)phenyl)-1h-pyrazol-3-amine | rel=r_associated | relid=0 | w=27
  382. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:8-bromo cyclic adenosine monophosphate
    n1=en:contraindications aspect | n2=en:8-bromo cyclic adenosine monophosphate | rel=r_associated | relid=0 | w=27
  383. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:actin-related protein 2-3 complex
    n1=en:contraindications aspect | n2=en:actin-related protein 2-3 complex | rel=r_associated | relid=0 | w=27
  384. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:actin-related protein 3
    n1=en:contraindications aspect | n2=en:actin-related protein 3 | rel=r_associated | relid=0 | w=27
  385. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:adenosine a1 receptor agonists
    n1=en:contraindications aspect | n2=en:adenosine a1 receptor agonists | rel=r_associated | relid=0 | w=27
  386. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:adenosine-5'-(n-ethylcarboxamide)
    n1=en:contraindications aspect | n2=en:adenosine-5'-(n-ethylcarboxamide) | rel=r_associated | relid=0 | w=27
  387. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:aldose-ketose isomerases
    n1=en:contraindications aspect | n2=en:aldose-ketose isomerases | rel=r_associated | relid=0 | w=27
  388. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:alveolar ridge augmentation
    n1=en:contraindications aspect | n2=en:alveolar ridge augmentation | rel=r_associated | relid=0 | w=27
  389. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:aminorex
    n1=en:contraindications aspect | n2=en:aminorex | rel=r_associated | relid=0 | w=27
  390. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:annexin a7
    n1=en:contraindications aspect | n2=en:annexin a7 | rel=r_associated | relid=0 | w=27
  391. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:antigens, cd98 heavy chain
    n1=en:contraindications aspect | n2=en:antigens, cd98 heavy chain | rel=r_associated | relid=0 | w=27
  392. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:arabinofuranosyluracil
    n1=en:contraindications aspect | n2=en:arabinofuranosyluracil | rel=r_associated | relid=0 | w=27
  393. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:arsenite transporting atpases
    n1=en:contraindications aspect | n2=en:arsenite transporting atpases | rel=r_associated | relid=0 | w=27
  394. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:aspartokinase homoserine dehydrogenase
    n1=en:contraindications aspect | n2=en:aspartokinase homoserine dehydrogenase | rel=r_associated | relid=0 | w=27
  395. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:bromodeoxycytidine
    n1=en:contraindications aspect | n2=en:bromodeoxycytidine | rel=r_associated | relid=0 | w=27
  396. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:calcium-independent phospholipase a2
    n1=en:contraindications aspect | n2=en:calcium-independent phospholipase a2 | rel=r_associated | relid=0 | w=27
  397. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:calorimetry, indirect
    n1=en:contraindications aspect | n2=en:calorimetry, indirect | rel=r_associated | relid=0 | w=27
  398. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:caproates
    n1=en:contraindications aspect | n2=en:caproates | rel=r_associated | relid=0 | w=27
  399. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:casein kinase idelta
    n1=en:contraindications aspect | n2=en:casein kinase idelta | rel=r_associated | relid=0 | w=27
  400. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:cellulases
    n1=en:contraindications aspect | n2=en:cellulases | rel=r_associated | relid=0 | w=27
  401. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:class ib phosphatidylinositol 3-kinase
    n1=en:contraindications aspect | n2=en:class ib phosphatidylinositol 3-kinase | rel=r_associated | relid=0 | w=27
  402. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:clofenapate
    n1=en:contraindications aspect | n2=en:clofenapate | rel=r_associated | relid=0 | w=27
  403. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:clopidol
    n1=en:contraindications aspect | n2=en:clopidol | rel=r_associated | relid=0 | w=27
  404. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:complement c2a
    n1=en:contraindications aspect | n2=en:complement c2a | rel=r_associated | relid=0 | w=27
  405. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:cyclic amp-dependent protein kinase rialpha subunit
    n1=en:contraindications aspect | n2=en:cyclic amp-dependent protein kinase rialpha subunit | rel=r_associated | relid=0 | w=27
  406. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:cyclic amp-dependent protein kinase riialpha subunit
    n1=en:contraindications aspect | n2=en:cyclic amp-dependent protein kinase riialpha subunit | rel=r_associated | relid=0 | w=27
  407. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:cyclin d2
    n1=en:contraindications aspect | n2=en:cyclin d2 | rel=r_associated | relid=0 | w=27
  408. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:cystatin b
    n1=en:contraindications aspect | n2=en:cystatin b | rel=r_associated | relid=0 | w=27
  409. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:cytochromes c6
    n1=en:contraindications aspect | n2=en:cytochromes c6 | rel=r_associated | relid=0 | w=27
  410. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:dibenzazepines
    n1=en:contraindications aspect | n2=en:dibenzazepines | rel=r_associated | relid=0 | w=27
  411. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:dibenzylchlorethamine
    n1=en:contraindications aspect | n2=en:dibenzylchlorethamine | rel=r_associated | relid=0 | w=27
  412. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:dicyclohexylcarbodiimide
    n1=en:contraindications aspect | n2=en:dicyclohexylcarbodiimide | rel=r_associated | relid=0 | w=27
  413. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:dinitrogenase reductase
    n1=en:contraindications aspect | n2=en:dinitrogenase reductase | rel=r_associated | relid=0 | w=27
  414. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:diprenorphine
    n1=en:contraindications aspect | n2=en:diprenorphine | rel=r_associated | relid=0 | w=27
  415. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:dna (cytosine-5-)-methyltransferase
    n1=en:contraindications aspect | n2=en:dna (cytosine-5-)-methyltransferase | rel=r_associated | relid=0 | w=27
  416. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:ectodysplasin a protein
    n1=en:contraindications aspect | n2=en:ectodysplasin a protein | rel=r_associated | relid=0 | w=27
  417. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:eledoisin
    n1=en:contraindications aspect | n2=en:eledoisin | rel=r_associated | relid=0 | w=27
  418. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:essential amino acid
    n1=en:contraindications aspect | n2=en:essential amino acid | rel=r_associated | relid=0 | w=27
  419. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:etilefrine
    n1=en:contraindications aspect | n2=en:etilefrine | rel=r_associated | relid=0 | w=27
  420. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:eukaryotic initiation factor-4a
    n1=en:contraindications aspect | n2=en:eukaryotic initiation factor-4a | rel=r_associated | relid=0 | w=27
  421. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:f2-isoprostanes
    n1=en:contraindications aspect | n2=en:f2-isoprostanes | rel=r_associated | relid=0 | w=27
  422. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:fluorouracil
    n1=en:contraindications aspect | n2=en:fluorouracil | rel=r_associated | relid=0 | w=27
  423. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:fura-2
    n1=en:contraindications aspect | n2=en:fura-2 | rel=r_associated | relid=0 | w=27
  424. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:gata3 transcription factor
    n1=en:contraindications aspect | n2=en:gata3 transcription factor | rel=r_associated | relid=0 | w=27
  425. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:gestonorone caproate
    n1=en:contraindications aspect | n2=en:gestonorone caproate | rel=r_associated | relid=0 | w=27
  426. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:ginkgolides
    n1=en:contraindications aspect | n2=en:ginkgolides | rel=r_associated | relid=0 | w=27
  427. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:gtp phosphohydrolase activators
    n1=en:contraindications aspect | n2=en:gtp phosphohydrolase activators | rel=r_associated | relid=0 | w=27
  428. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:gtp phosphohydrolase-linked elongation factors
    n1=en:contraindications aspect | n2=en:gtp phosphohydrolase-linked elongation factors | rel=r_associated | relid=0 | w=27
  429. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:heat shock protein 70
    n1=en:contraindications aspect | n2=en:heat shock protein 70 | rel=r_associated | relid=0 | w=27
  430. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hepatocyte nuclear factor 4
    n1=en:contraindications aspect | n2=en:hepatocyte nuclear factor 4 | rel=r_associated | relid=0 | w=27
  431. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hepatocyte nuclear factor 6
    n1=en:contraindications aspect | n2=en:hepatocyte nuclear factor 6 | rel=r_associated | relid=0 | w=27
  432. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hla-b14 antigen
    n1=en:contraindications aspect | n2=en:hla-b14 antigen | rel=r_associated | relid=0 | w=27
  433. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hla-dp beta-chains
    n1=en:contraindications aspect | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=27
  434. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hla-dr beta ag
    n1=en:contraindications aspect | n2=en:hla-dr beta ag | rel=r_associated | relid=0 | w=27
  435. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hla-dr1 antigen
    n1=en:contraindications aspect | n2=en:hla-dr1 antigen | rel=r_associated | relid=0 | w=27
  436. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hsc70 heat-shock proteins
    n1=en:contraindications aspect | n2=en:hsc70 heat-shock proteins | rel=r_associated | relid=0 | w=27
  437. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hsp30 heat-shock proteins
    n1=en:contraindications aspect | n2=en:hsp30 heat-shock proteins | rel=r_associated | relid=0 | w=27
  438. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hydroxymethyl and formyl transferases
    n1=en:contraindications aspect | n2=en:hydroxymethyl and formyl transferases | rel=r_associated | relid=0 | w=27
  439. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:hydroxytestosterones
    n1=en:contraindications aspect | n2=en:hydroxytestosterones | rel=r_associated | relid=0 | w=27
  440. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:immunophenotyping
    n1=en:contraindications aspect | n2=en:immunophenotyping | rel=r_associated | relid=0 | w=27
  441. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:integrin alpha-v
    n1=en:contraindications aspect | n2=en:integrin alpha-v | rel=r_associated | relid=0 | w=27
  442. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:keratin-6
    n1=en:contraindications aspect | n2=en:keratin-6 | rel=r_associated | relid=0 | w=27
  443. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:lutheran blood-group system
    n1=en:contraindications aspect | n2=en:lutheran blood-group system | rel=r_associated | relid=0 | w=27
  444. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:meptazinol
    n1=en:contraindications aspect | n2=en:meptazinol | rel=r_associated | relid=0 | w=27
  445. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:methacholine compounds
    n1=en:contraindications aspect | n2=en:methacholine compounds | rel=r_associated | relid=0 | w=27
  446. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:methylmannosides
    n1=en:contraindications aspect | n2=en:methylmannosides | rel=r_associated | relid=0 | w=27
  447. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:middle ear ventilation
    n1=en:contraindications aspect | n2=en:middle ear ventilation | rel=r_associated | relid=0 | w=27
  448. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:mitobronitol
    n1=en:contraindications aspect | n2=en:mitobronitol | rel=r_associated | relid=0 | w=27
  449. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:monosaccharide
    n1=en:contraindications aspect | n2=en:monosaccharide | rel=r_associated | relid=0 | w=27
  450. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:n-substituted glycines
    n1=en:contraindications aspect | n2=en:n-substituted glycines | rel=r_associated | relid=0 | w=27
  451. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:neurocalcin
    n1=en:contraindications aspect | n2=en:neurocalcin | rel=r_associated | relid=0 | w=27
  452. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:nitrovin
    n1=en:contraindications aspect | n2=en:nitrovin | rel=r_associated | relid=0 | w=27
  453. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:norwood procedures
    n1=en:contraindications aspect | n2=en:norwood procedures | rel=r_associated | relid=0 | w=27
  454. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:octamer transcription factor-2
    n1=en:contraindications aspect | n2=en:octamer transcription factor-2 | rel=r_associated | relid=0 | w=27
  455. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:oncogene protein v-crk
    n1=en:contraindications aspect | n2=en:oncogene protein v-crk | rel=r_associated | relid=0 | w=27
  456. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:organic anion transport protein 1
    n1=en:contraindications aspect | n2=en:organic anion transport protein 1 | rel=r_associated | relid=0 | w=27
  457. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:oxepins
    n1=en:contraindications aspect | n2=en:oxepins | rel=r_associated | relid=0 | w=27
  458. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:oxytocinase
    n1=en:contraindications aspect | n2=en:oxytocinase | rel=r_associated | relid=0 | w=27
  459. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:pharmacokinetic aspects
    n1=en:contraindications aspect | n2=en:pharmacokinetic aspects | rel=r_associated | relid=0 | w=27
  460. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:phenylthiazolylthiourea
    n1=en:contraindications aspect | n2=en:phenylthiazolylthiourea | rel=r_associated | relid=0 | w=27
  461. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:phex phosphate regulating neutral endopeptidase
    n1=en:contraindications aspect | n2=en:phex phosphate regulating neutral endopeptidase | rel=r_associated | relid=0 | w=27
  462. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:phorbol 12,13-dibutyrate
    n1=en:contraindications aspect | n2=en:phorbol 12,13-dibutyrate | rel=r_associated | relid=0 | w=27
  463. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:picryl chloride
    n1=en:contraindications aspect | n2=en:picryl chloride | rel=r_associated | relid=0 | w=27
  464. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:polyvinylpyridine n-oxide
    n1=en:contraindications aspect | n2=en:polyvinylpyridine n-oxide | rel=r_associated | relid=0 | w=27
  465. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:proadifen
    n1=en:contraindications aspect | n2=en:proadifen | rel=r_associated | relid=0 | w=27
  466. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:propidium
    n1=en:contraindications aspect | n2=en:propidium | rel=r_associated | relid=0 | w=27
  467. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:rab4 gtp-binding proteins
    n1=en:contraindications aspect | n2=en:rab4 gtp-binding proteins | rel=r_associated | relid=0 | w=27
  468. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:ras-related c3 botulinum toxin substrate 1
    n1=en:contraindications aspect | n2=en:ras-related c3 botulinum toxin substrate 1 | rel=r_associated | relid=0 | w=27
  469. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:receptor, epha6
    n1=en:contraindications aspect | n2=en:receptor, epha6 | rel=r_associated | relid=0 | w=27
  470. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:ribonucleoprotein, u7 small nuclear
    n1=en:contraindications aspect | n2=en:ribonucleoprotein, u7 small nuclear | rel=r_associated | relid=0 | w=27
  471. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:salivary alpha-amylases
    n1=en:contraindications aspect | n2=en:salivary alpha-amylases | rel=r_associated | relid=0 | w=27
  472. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:salmine
    n1=en:contraindications aspect | n2=en:salmine | rel=r_associated | relid=0 | w=27
  473. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:sin3 histone deacetylase and corepressor complex
    n1=en:contraindications aspect | n2=en:sin3 histone deacetylase and corepressor complex | rel=r_associated | relid=0 | w=27
  474. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:sphincterotomy, endoscopic
    n1=en:contraindications aspect | n2=en:sphincterotomy, endoscopic | rel=r_associated | relid=0 | w=27
  475. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:stat1 protein
    n1=en:contraindications aspect | n2=en:stat1 protein | rel=r_associated | relid=0 | w=27
  476. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:stilbamidines
    n1=en:contraindications aspect | n2=en:stilbamidines | rel=r_associated | relid=0 | w=27
  477. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:survival of motor neuron 1 protein
    n1=en:contraindications aspect | n2=en:survival of motor neuron 1 protein | rel=r_associated | relid=0 | w=27
  478. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:tacrolimus binding protein 1a
    n1=en:contraindications aspect | n2=en:tacrolimus binding protein 1a | rel=r_associated | relid=0 | w=27
  479. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:talc
    n1=en:contraindications aspect | n2=en:talc | rel=r_associated | relid=0 | w=27
  480. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:technetium tc 99m diethyl-iminodiacetic acid
    n1=en:contraindications aspect | n2=en:technetium tc 99m diethyl-iminodiacetic acid | rel=r_associated | relid=0 | w=27
  481. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:telomeric repeat binding protein 2
    n1=en:contraindications aspect | n2=en:telomeric repeat binding protein 2 | rel=r_associated | relid=0 | w=27
  482. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:thapsigargin
    n1=en:contraindications aspect | n2=en:thapsigargin | rel=r_associated | relid=0 | w=27
  483. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:thioredoxin reductase 1
    n1=en:contraindications aspect | n2=en:thioredoxin reductase 1 | rel=r_associated | relid=0 | w=27
  484. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:tpr/met fusion protein
    n1=en:contraindications aspect | n2=en:tpr/met fusion protein | rel=r_associated | relid=0 | w=27
  485. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride
    n1=en:contraindications aspect | n2=en:trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride | rel=r_associated | relid=0 | w=27
  486. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:transcription factor brn-3c
    n1=en:contraindications aspect | n2=en:transcription factor brn-3c | rel=r_associated | relid=0 | w=27
  487. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:triacetoneamine-n-oxyl
    n1=en:contraindications aspect | n2=en:triacetoneamine-n-oxyl | rel=r_associated | relid=0 | w=27
  488. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:trichodermin
    n1=en:contraindications aspect | n2=en:trichodermin | rel=r_associated | relid=0 | w=27
  489. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:trifluoroethanol
    n1=en:contraindications aspect | n2=en:trifluoroethanol | rel=r_associated | relid=0 | w=27
  490. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:uroplakin ii
    n1=en:contraindications aspect | n2=en:uroplakin ii | rel=r_associated | relid=0 | w=27
  491. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:uroplakin iii
    n1=en:contraindications aspect | n2=en:uroplakin iii | rel=r_associated | relid=0 | w=27
  492. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:valinomycin
    n1=en:contraindications aspect | n2=en:valinomycin | rel=r_associated | relid=0 | w=27
  493. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:viral fusion proteins
    n1=en:contraindications aspect | n2=en:viral fusion proteins | rel=r_associated | relid=0 | w=27
  494. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:visual field study
    n1=en:contraindications aspect | n2=en:visual field study | rel=r_associated | relid=0 | w=27
  495. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:wiskott-aldrich syndrome protein, neuronal
    n1=en:contraindications aspect | n2=en:wiskott-aldrich syndrome protein, neuronal | rel=r_associated | relid=0 | w=27
  496. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> en:wt1 proteins
    n1=en:contraindications aspect | n2=en:wt1 proteins | rel=r_associated | relid=0 | w=27
  497. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> fluorouracile
    n1=en:contraindications aspect | n2=fluorouracile | rel=r_associated | relid=0 | w=27
  498. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> irm
    n1=en:contraindications aspect | n2=irm | rel=r_associated | relid=0 | w=27
  499. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> ose
    n1=en:contraindications aspect | n2=ose | rel=r_associated | relid=0 | w=27
  500. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> protéine
    n1=en:contraindications aspect | n2=protéine | rel=r_associated | relid=0 | w=27
  501. en:contraindications aspect -- r_associated #0: 27 / 0.771 -> traitement médical
    n1=en:contraindications aspect | n2=traitement médical | rel=r_associated | relid=0 | w=27
  502. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:1-(5-isoquinolinesulfonyl)-2-methylpiperazine
    n1=en:contraindications aspect | n2=en:1-(5-isoquinolinesulfonyl)-2-methylpiperazine | rel=r_associated | relid=0 | w=26
  503. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:2',3'-cyclic-nucleotide phosphodiesterases
    n1=en:contraindications aspect | n2=en:2',3'-cyclic-nucleotide phosphodiesterases | rel=r_associated | relid=0 | w=26
  504. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid
    n1=en:contraindications aspect | n2=en:4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid | rel=r_associated | relid=0 | w=26
  505. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:4-chloromercuribenzenesulfonate
    n1=en:contraindications aspect | n2=en:4-chloromercuribenzenesulfonate | rel=r_associated | relid=0 | w=26
  506. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:4,4-methylenebis,2-chloroaniline
    n1=en:contraindications aspect | n2=en:4,4-methylenebis,2-chloroaniline | rel=r_associated | relid=0 | w=26
  507. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:8-azaguanine
    n1=en:contraindications aspect | n2=en:8-azaguanine | rel=r_associated | relid=0 | w=26
  508. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:85 kda calcium-independent phospholipase a2
    n1=en:contraindications aspect | n2=en:85 kda calcium-independent phospholipase a2 | rel=r_associated | relid=0 | w=26
  509. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:aberrometry
    n1=en:contraindications aspect | n2=en:aberrometry | rel=r_associated | relid=0 | w=26
  510. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:acetylthiocholine
    n1=en:contraindications aspect | n2=en:acetylthiocholine | rel=r_associated | relid=0 | w=26
  511. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:activating transcription factor 4
    n1=en:contraindications aspect | n2=en:activating transcription factor 4 | rel=r_associated | relid=0 | w=26
  512. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:adenovirus e4 protein
    n1=en:contraindications aspect | n2=en:adenovirus e4 protein | rel=r_associated | relid=0 | w=26
  513. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:adosterol
    n1=en:contraindications aspect | n2=en:adosterol | rel=r_associated | relid=0 | w=26
  514. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:aminobiphenyl compounds
    n1=en:contraindications aspect | n2=en:aminobiphenyl compounds | rel=r_associated | relid=0 | w=26
  515. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:aminooxyacetic acid
    n1=en:contraindications aspect | n2=en:aminooxyacetic acid | rel=r_associated | relid=0 | w=26
  516. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:androstatrienes
    n1=en:contraindications aspect | n2=en:androstatrienes | rel=r_associated | relid=0 | w=26
  517. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:apolipoprotein e4
    n1=en:contraindications aspect | n2=en:apolipoprotein e4 | rel=r_associated | relid=0 | w=26
  518. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:arabinofuranosylcytosine triphosphate
    n1=en:contraindications aspect | n2=en:arabinofuranosylcytosine triphosphate | rel=r_associated | relid=0 | w=26
  519. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:arabinonucleosides
    n1=en:contraindications aspect | n2=en:arabinonucleosides | rel=r_associated | relid=0 | w=26
  520. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:atp-dependent endopeptidases
    n1=en:contraindications aspect | n2=en:atp-dependent endopeptidases | rel=r_associated | relid=0 | w=26
  521. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:benzo(a)pyrene-7,8-diol 9,10-epoxide
    n1=en:contraindications aspect | n2=en:benzo(a)pyrene-7,8-diol 9,10-epoxide | rel=r_associated | relid=0 | w=26
  522. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:carbamoyl-phosphate synthase (glutamine-hydrolyzing)
    n1=en:contraindications aspect | n2=en:carbamoyl-phosphate synthase (glutamine-hydrolyzing) | rel=r_associated | relid=0 | w=26
  523. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:chaperone
    n1=en:contraindications aspect | n2=en:chaperone | rel=r_associated | relid=0 | w=26
  524. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:chemoradiotherapy, adjuvant
    n1=en:contraindications aspect | n2=en:chemoradiotherapy, adjuvant | rel=r_associated | relid=0 | w=26
  525. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:chloromercuribenzoates
    n1=en:contraindications aspect | n2=en:chloromercuribenzoates | rel=r_associated | relid=0 | w=26
  526. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:chloromercurinitrophenols
    n1=en:contraindications aspect | n2=en:chloromercurinitrophenols | rel=r_associated | relid=0 | w=26
  527. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:cholinesterase
    n1=en:contraindications aspect | n2=en:cholinesterase | rel=r_associated | relid=0 | w=26
  528. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:class i phosphatidylinositol 3-kinases
    n1=en:contraindications aspect | n2=en:class i phosphatidylinositol 3-kinases | rel=r_associated | relid=0 | w=26
  529. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:complement c3-c5 convertases, classical pathway
    n1=en:contraindications aspect | n2=en:complement c3-c5 convertases, classical pathway | rel=r_associated | relid=0 | w=26
  530. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:complement c5a
    n1=en:contraindications aspect | n2=en:complement c5a | rel=r_associated | relid=0 | w=26
  531. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:complement c5b
    n1=en:contraindications aspect | n2=en:complement c5b | rel=r_associated | relid=0 | w=26
  532. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:cyclic amp-dependent protein kinase ribeta subunit
    n1=en:contraindications aspect | n2=en:cyclic amp-dependent protein kinase ribeta subunit | rel=r_associated | relid=0 | w=26
  533. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:cyclic amp-dependent protein kinase riibeta subunit
    n1=en:contraindications aspect | n2=en:cyclic amp-dependent protein kinase riibeta subunit | rel=r_associated | relid=0 | w=26
  534. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:cyclic p-oxides
    n1=en:contraindications aspect | n2=en:cyclic p-oxides | rel=r_associated | relid=0 | w=26
  535. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:deae-dextran
    n1=en:contraindications aspect | n2=en:deae-dextran | rel=r_associated | relid=0 | w=26
  536. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:deoxyribonuclease bamhi
    n1=en:contraindications aspect | n2=en:deoxyribonuclease bamhi | rel=r_associated | relid=0 | w=26
  537. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:diphosphotransferases
    n1=en:contraindications aspect | n2=en:diphosphotransferases | rel=r_associated | relid=0 | w=26
  538. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:dodecenoyl-coa delta-isomerase
    n1=en:contraindications aspect | n2=en:dodecenoyl-coa delta-isomerase | rel=r_associated | relid=0 | w=26
  539. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:e1a-associated p300 protein
    n1=en:contraindications aspect | n2=en:e1a-associated p300 protein | rel=r_associated | relid=0 | w=26
  540. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:echocardiography, doppler, pulsed
    n1=en:contraindications aspect | n2=en:echocardiography, doppler, pulsed | rel=r_associated | relid=0 | w=26
  541. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:emodin
    n1=en:contraindications aspect | n2=en:emodin | rel=r_associated | relid=0 | w=26
  542. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:endotamponade
    n1=en:contraindications aspect | n2=en:endotamponade | rel=r_associated | relid=0 | w=26
  543. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:endothelin-1
    n1=en:contraindications aspect | n2=en:endothelin-1 | rel=r_associated | relid=0 | w=26
  544. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:enkephalin, d-penicillamine (2,5)-
    n1=en:contraindications aspect | n2=en:enkephalin, d-penicillamine (2,5)- | rel=r_associated | relid=0 | w=26
  545. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:enzyme
    n1=en:contraindications aspect | n2=en:enzyme | rel=r_associated | relid=0 | w=26
  546. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:enzyme reactivators
    n1=en:contraindications aspect | n2=en:enzyme reactivators | rel=r_associated | relid=0 | w=26
  547. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:estranes
    n1=en:contraindications aspect | n2=en:estranes | rel=r_associated | relid=0 | w=26
  548. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:ethylnitrosourea
    n1=en:contraindications aspect | n2=en:ethylnitrosourea | rel=r_associated | relid=0 | w=26
  549. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:feprazone
    n1=en:contraindications aspect | n2=en:feprazone | rel=r_associated | relid=0 | w=26
  550. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:fractalkine
    n1=en:contraindications aspect | n2=en:fractalkine | rel=r_associated | relid=0 | w=26
  551. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:furagin
    n1=en:contraindications aspect | n2=en:furagin | rel=r_associated | relid=0 | w=26
  552. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:guanosine 5'-o-(3-thiotriphosphate)
    n1=en:contraindications aspect | n2=en:guanosine 5'-o-(3-thiotriphosphate) | rel=r_associated | relid=0 | w=26
  553. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:hexamethylphosphoramide
    n1=en:contraindications aspect | n2=en:hexamethylphosphoramide | rel=r_associated | relid=0 | w=26
  554. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:hla-dr6 antigen
    n1=en:contraindications aspect | n2=en:hla-dr6 antigen | rel=r_associated | relid=0 | w=26
  555. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:hla-drb1 antigen
    n1=en:contraindications aspect | n2=en:hla-drb1 antigen | rel=r_associated | relid=0 | w=26
  556. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:hmga family protein
    n1=en:contraindications aspect | n2=en:hmga family protein | rel=r_associated | relid=0 | w=26
  557. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:holothurin
    n1=en:contraindications aspect | n2=en:holothurin | rel=r_associated | relid=0 | w=26
  558. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:homoserine o-succinyltransferase
    n1=en:contraindications aspect | n2=en:homoserine o-succinyltransferase | rel=r_associated | relid=0 | w=26
  559. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:hsp72 heat-shock proteins
    n1=en:contraindications aspect | n2=en:hsp72 heat-shock proteins | rel=r_associated | relid=0 | w=26
  560. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:hyalectins
    n1=en:contraindications aspect | n2=en:hyalectins | rel=r_associated | relid=0 | w=26
  561. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:indoleamine 2,3-dioxygenase
    n1=en:contraindications aspect | n2=en:indoleamine 2,3-dioxygenase | rel=r_associated | relid=0 | w=26
  562. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:iodoacetates
    n1=en:contraindications aspect | n2=en:iodoacetates | rel=r_associated | relid=0 | w=26
  563. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:kcnq2 potassium channel
    n1=en:contraindications aspect | n2=en:kcnq2 potassium channel | rel=r_associated | relid=0 | w=26
  564. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:ketocholesterols
    n1=en:contraindications aspect | n2=en:ketocholesterols | rel=r_associated | relid=0 | w=26
  565. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:kv1.6 potassium channel
    n1=en:contraindications aspect | n2=en:kv1.6 potassium channel | rel=r_associated | relid=0 | w=26
  566. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:lipoprotein hdl3
    n1=en:contraindications aspect | n2=en:lipoprotein hdl3 | rel=r_associated | relid=0 | w=26
  567. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:magnetic resonance imaging
    n1=en:contraindications aspect | n2=en:magnetic resonance imaging | rel=r_associated | relid=0 | w=26
  568. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:medigoxin
    n1=en:contraindications aspect | n2=en:medigoxin | rel=r_associated | relid=0 | w=26
  569. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:methylazoxymethanol acetate
    n1=en:contraindications aspect | n2=en:methylazoxymethanol acetate | rel=r_associated | relid=0 | w=26
  570. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:methyldimethylaminoazobenzene
    n1=en:contraindications aspect | n2=en:methyldimethylaminoazobenzene | rel=r_associated | relid=0 | w=26
  571. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:moclobemide
    n1=en:contraindications aspect | n2=en:moclobemide | rel=r_associated | relid=0 | w=26
  572. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:msh release-inhibiting hormone
    n1=en:contraindications aspect | n2=en:msh release-inhibiting hormone | rel=r_associated | relid=0 | w=26
  573. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:naphthylvinylpyridine
    n1=en:contraindications aspect | n2=en:naphthylvinylpyridine | rel=r_associated | relid=0 | w=26
  574. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:ng-nitroarginine methyl ester
    n1=en:contraindications aspect | n2=en:ng-nitroarginine methyl ester | rel=r_associated | relid=0 | w=26
  575. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:nod1 signaling adaptor protein
    n1=en:contraindications aspect | n2=en:nod1 signaling adaptor protein | rel=r_associated | relid=0 | w=26
  576. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:nod2 signaling adaptor protein
    n1=en:contraindications aspect | n2=en:nod2 signaling adaptor protein | rel=r_associated | relid=0 | w=26
  577. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:obidoxime chloride
    n1=en:contraindications aspect | n2=en:obidoxime chloride | rel=r_associated | relid=0 | w=26
  578. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:octamer transcription factor-6
    n1=en:contraindications aspect | n2=en:octamer transcription factor-6 | rel=r_associated | relid=0 | w=26
  579. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:ophthalmodynamometry
    n1=en:contraindications aspect | n2=en:ophthalmodynamometry | rel=r_associated | relid=0 | w=26
  580. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:paired box protein pax-7
    n1=en:contraindications aspect | n2=en:paired box protein pax-7 | rel=r_associated | relid=0 | w=26
  581. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:peptide-n4-(n-acetyl-beta-glucosaminyl)asparagine amidase
    n1=en:contraindications aspect | n2=en:peptide-n4-(n-acetyl-beta-glucosaminyl)asparagine amidase | rel=r_associated | relid=0 | w=26
  582. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:phenylphosphonothioic acid, 2-ethyl 2-(4-nitrophenyl) ester
    n1=en:contraindications aspect | n2=en:phenylphosphonothioic acid, 2-ethyl 2-(4-nitrophenyl) ester | rel=r_associated | relid=0 | w=26
  583. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:phosphotransferases (nitrogenous group acceptor)
    n1=en:contraindications aspect | n2=en:phosphotransferases (nitrogenous group acceptor) | rel=r_associated | relid=0 | w=26
  584. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:photoaffinity labels
    n1=en:contraindications aspect | n2=en:photoaffinity labels | rel=r_associated | relid=0 | w=26
  585. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:plakophilins
    n1=en:contraindications aspect | n2=en:plakophilins | rel=r_associated | relid=0 | w=26
  586. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:platelet glycoprotein gpib-ix complex
    n1=en:contraindications aspect | n2=en:platelet glycoprotein gpib-ix complex | rel=r_associated | relid=0 | w=26
  587. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:polyribonucleotides
    n1=en:contraindications aspect | n2=en:polyribonucleotides | rel=r_associated | relid=0 | w=26
  588. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:proline-directed protein kinases
    n1=en:contraindications aspect | n2=en:proline-directed protein kinases | rel=r_associated | relid=0 | w=26
  589. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:prostaglandin h2
    n1=en:contraindications aspect | n2=en:prostaglandin h2 | rel=r_associated | relid=0 | w=26
  590. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:protease nexins
    n1=en:contraindications aspect | n2=en:protease nexins | rel=r_associated | relid=0 | w=26
  591. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:protein-tyrosine phosphatase lyp
    n1=en:contraindications aspect | n2=en:protein-tyrosine phosphatase lyp | rel=r_associated | relid=0 | w=26
  592. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:proto-oncogene proteins c-fes
    n1=en:contraindications aspect | n2=en:proto-oncogene proteins c-fes | rel=r_associated | relid=0 | w=26
  593. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:pteroylpolyglutamic acids
    n1=en:contraindications aspect | n2=en:pteroylpolyglutamic acids | rel=r_associated | relid=0 | w=26
  594. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:purinergic antagonists
    n1=en:contraindications aspect | n2=en:purinergic antagonists | rel=r_associated | relid=0 | w=26
  595. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:rad52 dna repair and recombination protein
    n1=en:contraindications aspect | n2=en:rad52 dna repair and recombination protein | rel=r_associated | relid=0 | w=26
  596. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:receptor-like protein tyrosine phosphatases, class 7
    n1=en:contraindications aspect | n2=en:receptor-like protein tyrosine phosphatases, class 7 | rel=r_associated | relid=0 | w=26
  597. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:receptor, tie-1
    n1=en:contraindications aspect | n2=en:receptor, tie-1 | rel=r_associated | relid=0 | w=26
  598. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:receptors, guanylate cyclase-coupled
    n1=en:contraindications aspect | n2=en:receptors, guanylate cyclase-coupled | rel=r_associated | relid=0 | w=26
  599. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:ribonuclease h, human immunodeficiency virus
    n1=en:contraindications aspect | n2=en:ribonuclease h, human immunodeficiency virus | rel=r_associated | relid=0 | w=26
  600. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:ribonucleoprotein, u5 small nuclear
    n1=en:contraindications aspect | n2=en:ribonucleoprotein, u5 small nuclear | rel=r_associated | relid=0 | w=26
  601. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:ribosomal protein s6 kinases, 90-kda
    n1=en:contraindications aspect | n2=en:ribosomal protein s6 kinases, 90-kda | rel=r_associated | relid=0 | w=26
  602. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:rna, spliced leader
    n1=en:contraindications aspect | n2=en:rna, spliced leader | rel=r_associated | relid=0 | w=26
  603. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:shaker superfamily of potassium channels
    n1=en:contraindications aspect | n2=en:shaker superfamily of potassium channels | rel=r_associated | relid=0 | w=26
  604. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:skeletal muscle myosins
    n1=en:contraindications aspect | n2=en:skeletal muscle myosins | rel=r_associated | relid=0 | w=26
  605. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:smad5 protein
    n1=en:contraindications aspect | n2=en:smad5 protein | rel=r_associated | relid=0 | w=26
  606. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:sodium chloride symporters
    n1=en:contraindications aspect | n2=en:sodium chloride symporters | rel=r_associated | relid=0 | w=26
  607. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:sydnones
    n1=en:contraindications aspect | n2=en:sydnones | rel=r_associated | relid=0 | w=26
  608. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:thenoyltrifluoroacetone
    n1=en:contraindications aspect | n2=en:thenoyltrifluoroacetone | rel=r_associated | relid=0 | w=26
  609. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:thioredoxin reductase 2
    n1=en:contraindications aspect | n2=en:thioredoxin reductase 2 | rel=r_associated | relid=0 | w=26
  610. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:transcranial doppler ultrasonography
    n1=en:contraindications aspect | n2=en:transcranial doppler ultrasonography | rel=r_associated | relid=0 | w=26
  611. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:transcription factor gata-4
    n1=en:contraindications aspect | n2=en:transcription factor gata-4 | rel=r_associated | relid=0 | w=26
  612. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:transcription factor tfiiia
    n1=en:contraindications aspect | n2=en:transcription factor tfiiia | rel=r_associated | relid=0 | w=26
  613. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:tremorine
    n1=en:contraindications aspect | n2=en:tremorine | rel=r_associated | relid=0 | w=26
  614. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:trimedoxime
    n1=en:contraindications aspect | n2=en:trimedoxime | rel=r_associated | relid=0 | w=26
  615. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:trypsin inhibitor, kunitz soybean
    n1=en:contraindications aspect | n2=en:trypsin inhibitor, kunitz soybean | rel=r_associated | relid=0 | w=26
  616. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:twist transcription factor
    n1=en:contraindications aspect | n2=en:twist transcription factor | rel=r_associated | relid=0 | w=26
  617. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:ultrasonography, interventional
    n1=en:contraindications aspect | n2=en:ultrasonography, interventional | rel=r_associated | relid=0 | w=26
  618. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:uroplakin ib
    n1=en:contraindications aspect | n2=en:uroplakin ib | rel=r_associated | relid=0 | w=26
  619. en:contraindications aspect -- r_associated #0: 26 / 0.743 -> en:vesicle-associated membrane protein 2
    n1=en:contraindications aspect | n2=en:vesicle-associated membrane protein 2 | rel=r_associated | relid=0 | w=26
  620. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:1,2-dimethylhydrazine
    n1=en:contraindications aspect | n2=en:1,2-dimethylhydrazine | rel=r_associated | relid=0 | w=25
  621. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:2-aminopurine
    n1=en:contraindications aspect | n2=en:2-aminopurine | rel=r_associated | relid=0 | w=25
  622. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:24,25-dihydroxycholecalciferol
    n1=en:contraindications aspect | n2=en:24,25-dihydroxycholecalciferol | rel=r_associated | relid=0 | w=25
  623. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:7-alkoxycoumarin o-dealkylase
    n1=en:contraindications aspect | n2=en:7-alkoxycoumarin o-dealkylase | rel=r_associated | relid=0 | w=25
  624. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:adenosine a3 receptor antagonists
    n1=en:contraindications aspect | n2=en:adenosine a3 receptor antagonists | rel=r_associated | relid=0 | w=25
  625. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:anticestodal agents
    n1=en:contraindications aspect | n2=en:anticestodal agents | rel=r_associated | relid=0 | w=25
  626. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:arachidonate lipoxygenases
    n1=en:contraindications aspect | n2=en:arachidonate lipoxygenases | rel=r_associated | relid=0 | w=25
  627. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:benzoylarginine nitroanilide
    n1=en:contraindications aspect | n2=en:benzoylarginine nitroanilide | rel=r_associated | relid=0 | w=25
  628. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:benzylamine oxidase
    n1=en:contraindications aspect | n2=en:benzylamine oxidase | rel=r_associated | relid=0 | w=25
  629. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:benzylammonium compounds
    n1=en:contraindications aspect | n2=en:benzylammonium compounds | rel=r_associated | relid=0 | w=25
  630. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:beta-naphthoflavone
    n1=en:contraindications aspect | n2=en:beta-naphthoflavone | rel=r_associated | relid=0 | w=25
  631. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:bromobenzoates
    n1=en:contraindications aspect | n2=en:bromobenzoates | rel=r_associated | relid=0 | w=25
  632. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cdc42 gtp-binding protein, saccharomyces cerevisiae
    n1=en:contraindications aspect | n2=en:cdc42 gtp-binding protein, saccharomyces cerevisiae | rel=r_associated | relid=0 | w=25
  633. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cephamycins
    n1=en:contraindications aspect | n2=en:cephamycins | rel=r_associated | relid=0 | w=25
  634. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:chloroplast proton-translocating atpases
    n1=en:contraindications aspect | n2=en:chloroplast proton-translocating atpases | rel=r_associated | relid=0 | w=25
  635. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:choledochostomy
    n1=en:contraindications aspect | n2=en:choledochostomy | rel=r_associated | relid=0 | w=25
  636. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cialit
    n1=en:contraindications aspect | n2=en:cialit | rel=r_associated | relid=0 | w=25
  637. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cloacin
    n1=en:contraindications aspect | n2=en:cloacin | rel=r_associated | relid=0 | w=25
  638. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:complement c3 convertase, classical pathway
    n1=en:contraindications aspect | n2=en:complement c3 convertase, classical pathway | rel=r_associated | relid=0 | w=25
  639. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:complement c3-c5 convertases
    n1=en:contraindications aspect | n2=en:complement c3-c5 convertases | rel=r_associated | relid=0 | w=25
  640. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cyclic amp response element modulator
    n1=en:contraindications aspect | n2=en:cyclic amp response element modulator | rel=r_associated | relid=0 | w=25
  641. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cyclin g1
    n1=en:contraindications aspect | n2=en:cyclin g1 | rel=r_associated | relid=0 | w=25
  642. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cyclodecanes
    n1=en:contraindications aspect | n2=en:cyclodecanes | rel=r_associated | relid=0 | w=25
  643. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cystaphos
    n1=en:contraindications aspect | n2=en:cystaphos | rel=r_associated | relid=0 | w=25
  644. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cytochrome p450 cyp11b1, mitochondrial
    n1=en:contraindications aspect | n2=en:cytochrome p450 cyp11b1, mitochondrial | rel=r_associated | relid=0 | w=25
  645. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:cytochromes a1
    n1=en:contraindications aspect | n2=en:cytochromes a1 | rel=r_associated | relid=0 | w=25
  646. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:deoxyribonuclease iv (phage t4-induced)
    n1=en:contraindications aspect | n2=en:deoxyribonuclease iv (phage t4-induced) | rel=r_associated | relid=0 | w=25
  647. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:diabetic diet
    n1=en:contraindications aspect | n2=en:diabetic diet | rel=r_associated | relid=0 | w=25
  648. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:dicarbethoxydihydrocollidine
    n1=en:contraindications aspect | n2=en:dicarbethoxydihydrocollidine | rel=r_associated | relid=0 | w=25
  649. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:dihydroxycholecalciferols
    n1=en:contraindications aspect | n2=en:dihydroxycholecalciferols | rel=r_associated | relid=0 | w=25
  650. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:dihydroxytryptamines
    n1=en:contraindications aspect | n2=en:dihydroxytryptamines | rel=r_associated | relid=0 | w=25
  651. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:dimethyl suberimidate
    n1=en:contraindications aspect | n2=en:dimethyl suberimidate | rel=r_associated | relid=0 | w=25
  652. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:diosgenin
    n1=en:contraindications aspect | n2=en:diosgenin | rel=r_associated | relid=0 | w=25
  653. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:dothiepin
    n1=en:contraindications aspect | n2=en:dothiepin | rel=r_associated | relid=0 | w=25
  654. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:duodenoscopes
    n1=en:contraindications aspect | n2=en:duodenoscopes | rel=r_associated | relid=0 | w=25
  655. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:echocardiography, doppler, color
    n1=en:contraindications aspect | n2=en:echocardiography, doppler, color | rel=r_associated | relid=0 | w=25
  656. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:elav-like protein 3
    n1=en:contraindications aspect | n2=en:elav-like protein 3 | rel=r_associated | relid=0 | w=25
  657. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:enbucrilate
    n1=en:contraindications aspect | n2=en:enbucrilate | rel=r_associated | relid=0 | w=25
  658. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:enprostil
    n1=en:contraindications aspect | n2=en:enprostil | rel=r_associated | relid=0 | w=25
  659. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:epha5 receptor
    n1=en:contraindications aspect | n2=en:epha5 receptor | rel=r_associated | relid=0 | w=25
  660. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:ephrin-b3
    n1=en:contraindications aspect | n2=en:ephrin-b3 | rel=r_associated | relid=0 | w=25
  661. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:estradiol dehydrogenases
    n1=en:contraindications aspect | n2=en:estradiol dehydrogenases | rel=r_associated | relid=0 | w=25
  662. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:fetuin-b
    n1=en:contraindications aspect | n2=en:fetuin-b | rel=r_associated | relid=0 | w=25
  663. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:gelatinases
    n1=en:contraindications aspect | n2=en:gelatinases | rel=r_associated | relid=0 | w=25
  664. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:glucocorticoid receptor-interacting protein 1
    n1=en:contraindications aspect | n2=en:glucocorticoid receptor-interacting protein 1 | rel=r_associated | relid=0 | w=25
  665. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:group ii phospholipases a2
    n1=en:contraindications aspect | n2=en:group ii phospholipases a2 | rel=r_associated | relid=0 | w=25
  666. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:guanine nucleotide-binding protein g(s) subunit alpha isoforms xlas
    n1=en:contraindications aspect | n2=en:guanine nucleotide-binding protein g(s) subunit alpha isoforms xlas | rel=r_associated | relid=0 | w=25
  667. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:guanylthiourea
    n1=en:contraindications aspect | n2=en:guanylthiourea | rel=r_associated | relid=0 | w=25
  668. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:hla-a3 antigen
    n1=en:contraindications aspect | n2=en:hla-a3 antigen | rel=r_associated | relid=0 | w=25
  669. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:hla-b15 antigen
    n1=en:contraindications aspect | n2=en:hla-b15 antigen | rel=r_associated | relid=0 | w=25
  670. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:hla-b18 antigen
    n1=en:contraindications aspect | n2=en:hla-b18 antigen | rel=r_associated | relid=0 | w=25
  671. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:hla-b38 antigen
    n1=en:contraindications aspect | n2=en:hla-b38 antigen | rel=r_associated | relid=0 | w=25
  672. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:hla-b44 antigen
    n1=en:contraindications aspect | n2=en:hla-b44 antigen | rel=r_associated | relid=0 | w=25
  673. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:inflammasomes
    n1=en:contraindications aspect | n2=en:inflammasomes | rel=r_associated | relid=0 | w=25
  674. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:intention to treat analysis
    n1=en:contraindications aspect | n2=en:intention to treat analysis | rel=r_associated | relid=0 | w=25
  675. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:keratin-14
    n1=en:contraindications aspect | n2=en:keratin-14 | rel=r_associated | relid=0 | w=25
  676. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:keratin-15
    n1=en:contraindications aspect | n2=en:keratin-15 | rel=r_associated | relid=0 | w=25
  677. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:keratin, type i cytoskeletal 19
    n1=en:contraindications aspect | n2=en:keratin, type i cytoskeletal 19 | rel=r_associated | relid=0 | w=25
  678. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:lab-on-a-chip devices
    n1=en:contraindications aspect | n2=en:lab-on-a-chip devices | rel=r_associated | relid=0 | w=25
  679. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:leucomycins
    n1=en:contraindications aspect | n2=en:leucomycins | rel=r_associated | relid=0 | w=25
  680. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:levopropoxyphene
    n1=en:contraindications aspect | n2=en:levopropoxyphene | rel=r_associated | relid=0 | w=25
  681. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:marek disease vaccines
    n1=en:contraindications aspect | n2=en:marek disease vaccines | rel=r_associated | relid=0 | w=25
  682. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:meclofenoxate
    n1=en:contraindications aspect | n2=en:meclofenoxate | rel=r_associated | relid=0 | w=25
  683. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:methylnitrosourea
    n1=en:contraindications aspect | n2=en:methylnitrosourea | rel=r_associated | relid=0 | w=25
  684. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:methyltyrosines
    n1=en:contraindications aspect | n2=en:methyltyrosines | rel=r_associated | relid=0 | w=25
  685. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:mikamycin
    n1=en:contraindications aspect | n2=en:mikamycin | rel=r_associated | relid=0 | w=25
  686. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:mitogen-activated protein kinase 13
    n1=en:contraindications aspect | n2=en:mitogen-activated protein kinase 13 | rel=r_associated | relid=0 | w=25
  687. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:molteno implants
    n1=en:contraindications aspect | n2=en:molteno implants | rel=r_associated | relid=0 | w=25
  688. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:multi-ingredient cold, flu, and allergy medications
    n1=en:contraindications aspect | n2=en:multi-ingredient cold, flu, and allergy medications | rel=r_associated | relid=0 | w=25
  689. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:muzolimine
    n1=en:contraindications aspect | n2=en:muzolimine | rel=r_associated | relid=0 | w=25
  690. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:myringoplasty
    n1=en:contraindications aspect | n2=en:myringoplasty | rel=r_associated | relid=0 | w=25
  691. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:n-acylsphingosine galactosyltransferase
    n1=en:contraindications aspect | n2=en:n-acylsphingosine galactosyltransferase | rel=r_associated | relid=0 | w=25
  692. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:nadp transhydrogenase, b-specific
    n1=en:contraindications aspect | n2=en:nadp transhydrogenase, b-specific | rel=r_associated | relid=0 | w=25
  693. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:nf-kappa b p65
    n1=en:contraindications aspect | n2=en:nf-kappa b p65 | rel=r_associated | relid=0 | w=25
  694. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:oligomycins
    n1=en:contraindications aspect | n2=en:oligomycins | rel=r_associated | relid=0 | w=25
  695. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:oncostatin-m
    n1=en:contraindications aspect | n2=en:oncostatin-m | rel=r_associated | relid=0 | w=25
  696. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:oxotremorine
    n1=en:contraindications aspect | n2=en:oxotremorine | rel=r_associated | relid=0 | w=25
  697. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:perazine
    n1=en:contraindications aspect | n2=en:perazine | rel=r_associated | relid=0 | w=25
  698. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:phenetidine
    n1=en:contraindications aspect | n2=en:phenetidine | rel=r_associated | relid=0 | w=25
  699. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:phenylisopropyladenosine
    n1=en:contraindications aspect | n2=en:phenylisopropyladenosine | rel=r_associated | relid=0 | w=25
  700. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:photobioreactors
    n1=en:contraindications aspect | n2=en:photobioreactors | rel=r_associated | relid=0 | w=25
  701. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:physalaemin
    n1=en:contraindications aspect | n2=en:physalaemin | rel=r_associated | relid=0 | w=25
  702. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:pol gene products, human immunodeficiency virus
    n1=en:contraindications aspect | n2=en:pol gene products, human immunodeficiency virus | rel=r_associated | relid=0 | w=25
  703. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:polyisoprenyl phosphate monosaccharides
    n1=en:contraindications aspect | n2=en:polyisoprenyl phosphate monosaccharides | rel=r_associated | relid=0 | w=25
  704. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:polyisoprenyl phosphate sugars
    n1=en:contraindications aspect | n2=en:polyisoprenyl phosphate sugars | rel=r_associated | relid=0 | w=25
  705. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:potassium channels, tandem pore domain
    n1=en:contraindications aspect | n2=en:potassium channels, tandem pore domain | rel=r_associated | relid=0 | w=25
  706. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:pregnenolone carbonitrile
    n1=en:contraindications aspect | n2=en:pregnenolone carbonitrile | rel=r_associated | relid=0 | w=25
  707. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:prodigiosin
    n1=en:contraindications aspect | n2=en:prodigiosin | rel=r_associated | relid=0 | w=25
  708. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:protein kinase c-delta
    n1=en:contraindications aspect | n2=en:protein kinase c-delta | rel=r_associated | relid=0 | w=25
  709. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:protein-arginine n-methyltransferase
    n1=en:contraindications aspect | n2=en:protein-arginine n-methyltransferase | rel=r_associated | relid=0 | w=25
  710. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:proto-oncogene proteins c-raf
    n1=en:contraindications aspect | n2=en:proto-oncogene proteins c-raf | rel=r_associated | relid=0 | w=25
  711. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:qc-snare proteins
    n1=en:contraindications aspect | n2=en:qc-snare proteins | rel=r_associated | relid=0 | w=25
  712. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:receptor-like protein tyrosine phosphatases, class 5
    n1=en:contraindications aspect | n2=en:receptor-like protein tyrosine phosphatases, class 5 | rel=r_associated | relid=0 | w=25
  713. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:receptor, ephb5
    n1=en:contraindications aspect | n2=en:receptor, ephb5 | rel=r_associated | relid=0 | w=25
  714. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:ribonucleoprotein, u2 small nuclear
    n1=en:contraindications aspect | n2=en:ribonucleoprotein, u2 small nuclear | rel=r_associated | relid=0 | w=25
  715. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:ribonucleoprotein, u4-u6 small nuclear
    n1=en:contraindications aspect | n2=en:ribonucleoprotein, u4-u6 small nuclear | rel=r_associated | relid=0 | w=25
  716. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:rotarod performance test
    n1=en:contraindications aspect | n2=en:rotarod performance test | rel=r_associated | relid=0 | w=25
  717. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:shal potassium channels
    n1=en:contraindications aspect | n2=en:shal potassium channels | rel=r_associated | relid=0 | w=25
  718. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:single-strand specific dna and rna endonucleases
    n1=en:contraindications aspect | n2=en:single-strand specific dna and rna endonucleases | rel=r_associated | relid=0 | w=25
  719. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:smad6 protein
    n1=en:contraindications aspect | n2=en:smad6 protein | rel=r_associated | relid=0 | w=25
  720. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:sodium ionophores
    n1=en:contraindications aspect | n2=en:sodium ionophores | rel=r_associated | relid=0 | w=25
  721. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:sodium-coupled vitamin c transporters
    n1=en:contraindications aspect | n2=en:sodium-coupled vitamin c transporters | rel=r_associated | relid=0 | w=25
  722. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:sodium-hydrogen antiporter
    n1=en:contraindications aspect | n2=en:sodium-hydrogen antiporter | rel=r_associated | relid=0 | w=25
  723. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:sorbitol
    n1=en:contraindications aspect | n2=en:sorbitol | rel=r_associated | relid=0 | w=25
  724. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:stat5 transcription factor
    n1=en:contraindications aspect | n2=en:stat5 transcription factor | rel=r_associated | relid=0 | w=25
  725. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:sterol regulatory element binding protein 2
    n1=en:contraindications aspect | n2=en:sterol regulatory element binding protein 2 | rel=r_associated | relid=0 | w=25
  726. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:tetrahydropapaveroline
    n1=en:contraindications aspect | n2=en:tetrahydropapaveroline | rel=r_associated | relid=0 | w=25
  727. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:thoracoscope
    n1=en:contraindications aspect | n2=en:thoracoscope | rel=r_associated | relid=0 | w=25
  728. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:transcription factor mafk
    n1=en:contraindications aspect | n2=en:transcription factor mafk | rel=r_associated | relid=0 | w=25
  729. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:type c phospholipases
    n1=en:contraindications aspect | n2=en:type c phospholipases | rel=r_associated | relid=0 | w=25
  730. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> en:tyrosine phenol-lyase
    n1=en:contraindications aspect | n2=en:tyrosine phenol-lyase | rel=r_associated | relid=0 | w=25
  731. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> lipoproteine
    n1=en:contraindications aspect | n2=lipoproteine | rel=r_associated | relid=0 | w=25
  732. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> tamponnement interne
    n1=en:contraindications aspect | n2=tamponnement interne | rel=r_associated | relid=0 | w=25
  733. en:contraindications aspect -- r_associated #0: 25 / 0.714 -> tubuline
    n1=en:contraindications aspect | n2=tubuline | rel=r_associated | relid=0 | w=25
  734. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:1-methyl-3-isobutylxanthine
    n1=en:contraindications aspect | n2=en:1-methyl-3-isobutylxanthine | rel=r_associated | relid=0 | w=24
  735. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:3-hydroxysteroid dehydrogenases
    n1=en:contraindications aspect | n2=en:3-hydroxysteroid dehydrogenases | rel=r_associated | relid=0 | w=24
  736. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:4-hydroxyaminoquinoline-1-oxide
    n1=en:contraindications aspect | n2=en:4-hydroxyaminoquinoline-1-oxide | rel=r_associated | relid=0 | w=24
  737. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:5,7-dihydroxytryptamine
    n1=en:contraindications aspect | n2=en:5,7-dihydroxytryptamine | rel=r_associated | relid=0 | w=24
  738. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:6-aminonicotinamide
    n1=en:contraindications aspect | n2=en:6-aminonicotinamide | rel=r_associated | relid=0 | w=24
  739. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:acetyldigitoxins
    n1=en:contraindications aspect | n2=en:acetyldigitoxins | rel=r_associated | relid=0 | w=24
  740. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:actihaemyl
    n1=en:contraindications aspect | n2=en:actihaemyl | rel=r_associated | relid=0 | w=24
  741. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:adenine nucleotide translocator 1
    n1=en:contraindications aspect | n2=en:adenine nucleotide translocator 1 | rel=r_associated | relid=0 | w=24
  742. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:adenovirus e3 proteins
    n1=en:contraindications aspect | n2=en:adenovirus e3 proteins | rel=r_associated | relid=0 | w=24
  743. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:adp/atp translocase 3
    n1=en:contraindications aspect | n2=en:adp/atp translocase 3 | rel=r_associated | relid=0 | w=24
  744. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:alpha-2-hs-glycoprotein
    n1=en:contraindications aspect | n2=en:alpha-2-hs-glycoprotein | rel=r_associated | relid=0 | w=24
  745. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:alpha-chlorohydrin
    n1=en:contraindications aspect | n2=en:alpha-chlorohydrin | rel=r_associated | relid=0 | w=24
  746. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:amino acid transport system y+
    n1=en:contraindications aspect | n2=en:amino acid transport system y+ | rel=r_associated | relid=0 | w=24
  747. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:aurovertins
    n1=en:contraindications aspect | n2=en:aurovertins | rel=r_associated | relid=0 | w=24
  748. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide
    n1=en:contraindications aspect | n2=en:benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide | rel=r_associated | relid=0 | w=24
  749. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:benzoxazines
    n1=en:contraindications aspect | n2=en:benzoxazines | rel=r_associated | relid=0 | w=24
  750. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:beta-aminoethyl isothiourea
    n1=en:contraindications aspect | n2=en:beta-aminoethyl isothiourea | rel=r_associated | relid=0 | w=24
  751. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:bromouracil
    n1=en:contraindications aspect | n2=en:bromouracil | rel=r_associated | relid=0 | w=24
  752. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:butoxamine
    n1=en:contraindications aspect | n2=en:butoxamine | rel=r_associated | relid=0 | w=24
  753. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:cd137 antigen
    n1=en:contraindications aspect | n2=en:cd137 antigen | rel=r_associated | relid=0 | w=24
  754. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:cd70 antigen
    n1=en:contraindications aspect | n2=en:cd70 antigen | rel=r_associated | relid=0 | w=24
  755. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:cd82 antigen
    n1=en:contraindications aspect | n2=en:cd82 antigen | rel=r_associated | relid=0 | w=24
  756. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:cdc25 phosphatases
    n1=en:contraindications aspect | n2=en:cdc25 phosphatases | rel=r_associated | relid=0 | w=24
  757. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:chaperonin 10
    n1=en:contraindications aspect | n2=en:chaperonin 10 | rel=r_associated | relid=0 | w=24
  758. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:chlorodiphenyl (54% chlorine)
    n1=en:contraindications aspect | n2=en:chlorodiphenyl (54% chlorine) | rel=r_associated | relid=0 | w=24
  759. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:chondro-4-sulfatase
    n1=en:contraindications aspect | n2=en:chondro-4-sulfatase | rel=r_associated | relid=0 | w=24
  760. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:complement c3 convertase, alternative pathway
    n1=en:contraindications aspect | n2=en:complement c3 convertase, alternative pathway | rel=r_associated | relid=0 | w=24
  761. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:complement c3-c5 convertases, alternative pathway
    n1=en:contraindications aspect | n2=en:complement c3-c5 convertases, alternative pathway | rel=r_associated | relid=0 | w=24
  762. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:complement c3a
    n1=en:contraindications aspect | n2=en:complement c3a | rel=r_associated | relid=0 | w=24
  763. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:complement c5a, des-arginine
    n1=en:contraindications aspect | n2=en:complement c5a, des-arginine | rel=r_associated | relid=0 | w=24
  764. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:contactin
    n1=en:contraindications aspect | n2=en:contactin | rel=r_associated | relid=0 | w=24
  765. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:cuprizone
    n1=en:contraindications aspect | n2=en:cuprizone | rel=r_associated | relid=0 | w=24
  766. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:cyclin-a2
    n1=en:contraindications aspect | n2=en:cyclin-a2 | rel=r_associated | relid=0 | w=24
  767. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:cytochrome b6
    n1=en:contraindications aspect | n2=en:cytochrome b6 | rel=r_associated | relid=0 | w=24
  768. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:cytochrome p450 11b2, mitochondrial
    n1=en:contraindications aspect | n2=en:cytochrome p450 11b2, mitochondrial | rel=r_associated | relid=0 | w=24
  769. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:cytochromes a3
    n1=en:contraindications aspect | n2=en:cytochromes a3 | rel=r_associated | relid=0 | w=24
  770. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:deoxyepinephrine
    n1=en:contraindications aspect | n2=en:deoxyepinephrine | rel=r_associated | relid=0 | w=24
  771. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:deoxyribonuclease ecori
    n1=en:contraindications aspect | n2=en:deoxyribonuclease ecori | rel=r_associated | relid=0 | w=24
  772. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:dibenz(b,f)(1,4)oxazepine-10(11h)-carboxylic acid, 8-chloro-, 2-acetylhydrazide
    n1=en:contraindications aspect | n2=en:dibenz(b,f)(1,4)oxazepine-10(11h)-carboxylic acid, 8-chloro-, 2-acetylhydrazide | rel=r_associated | relid=0 | w=24
  773. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:dibutyryl cyclic gmp
    n1=en:contraindications aspect | n2=en:dibutyryl cyclic gmp | rel=r_associated | relid=0 | w=24
  774. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:dimethoxyphenylethylamine
    n1=en:contraindications aspect | n2=en:dimethoxyphenylethylamine | rel=r_associated | relid=0 | w=24
  775. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:dimyristoyl lecithin
    n1=en:contraindications aspect | n2=en:dimyristoyl lecithin | rel=r_associated | relid=0 | w=24
  776. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:dioctyl sulfosuccinic acid
    n1=en:contraindications aspect | n2=en:dioctyl sulfosuccinic acid | rel=r_associated | relid=0 | w=24
  777. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:dnab helicases
    n1=en:contraindications aspect | n2=en:dnab helicases | rel=r_associated | relid=0 | w=24
  778. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:e2f5 transcription factor
    n1=en:contraindications aspect | n2=en:e2f5 transcription factor | rel=r_associated | relid=0 | w=24
  779. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:eif2b
    n1=en:contraindications aspect | n2=en:eif2b | rel=r_associated | relid=0 | w=24
  780. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:ephrin-a3
    n1=en:contraindications aspect | n2=en:ephrin-a3 | rel=r_associated | relid=0 | w=24
  781. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:ets domain-containing protein elk-1
    n1=en:contraindications aspect | n2=en:ets domain-containing protein elk-1 | rel=r_associated | relid=0 | w=24
  782. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:fertility agents, male
    n1=en:contraindications aspect | n2=en:fertility agents, male | rel=r_associated | relid=0 | w=24
  783. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:gaba-a receptor agonists
    n1=en:contraindications aspect | n2=en:gaba-a receptor agonists | rel=r_associated | relid=0 | w=24
  784. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:gaba-b receptor antagonists
    n1=en:contraindications aspect | n2=en:gaba-b receptor antagonists | rel=r_associated | relid=0 | w=24
  785. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:glycogen synthase kinase 3
    n1=en:contraindications aspect | n2=en:glycogen synthase kinase 3 | rel=r_associated | relid=0 | w=24
  786. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:group ii chaperonins
    n1=en:contraindications aspect | n2=en:group ii chaperonins | rel=r_associated | relid=0 | w=24
  787. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:haemato fu
    n1=en:contraindications aspect | n2=en:haemato fu | rel=r_associated | relid=0 | w=24
  788. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:halcinonide
    n1=en:contraindications aspect | n2=en:halcinonide | rel=r_associated | relid=0 | w=24
  789. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:hepes
    n1=en:contraindications aspect | n2=en:hepes | rel=r_associated | relid=0 | w=24
  790. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:histidinol-phosphatase
    n1=en:contraindications aspect | n2=en:histidinol-phosphatase | rel=r_associated | relid=0 | w=24
  791. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:hla-b13 antigen
    n1=en:contraindications aspect | n2=en:hla-b13 antigen | rel=r_associated | relid=0 | w=24
  792. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:hla-b39 antigen
    n1=en:contraindications aspect | n2=en:hla-b39 antigen | rel=r_associated | relid=0 | w=24
  793. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:hla-dr5 antigen
    n1=en:contraindications aspect | n2=en:hla-dr5 antigen | rel=r_associated | relid=0 | w=24
  794. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:hydroxyacetylaminofluorene
    n1=en:contraindications aspect | n2=en:hydroxyacetylaminofluorene | rel=r_associated | relid=0 | w=24
  795. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:infusions, spinal
    n1=en:contraindications aspect | n2=en:infusions, spinal | rel=r_associated | relid=0 | w=24
  796. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:iodopyridones
    n1=en:contraindications aspect | n2=en:iodopyridones | rel=r_associated | relid=0 | w=24
  797. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:kassinin
    n1=en:contraindications aspect | n2=en:kassinin | rel=r_associated | relid=0 | w=24
  798. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:keratin, type i cytoskeletal 17
    n1=en:contraindications aspect | n2=en:keratin, type i cytoskeletal 17 | rel=r_associated | relid=0 | w=24
  799. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:kynurenine 3-monooxygenase
    n1=en:contraindications aspect | n2=en:kynurenine 3-monooxygenase | rel=r_associated | relid=0 | w=24
  800. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:mesterolone
    n1=en:contraindications aspect | n2=en:mesterolone | rel=r_associated | relid=0 | w=24
  801. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:methoxydimethyltryptamines
    n1=en:contraindications aspect | n2=en:methoxydimethyltryptamines | rel=r_associated | relid=0 | w=24
  802. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:methylthiouracil
    n1=en:contraindications aspect | n2=en:methylthiouracil | rel=r_associated | relid=0 | w=24
  803. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:molybdoferredoxin
    n1=en:contraindications aspect | n2=en:molybdoferredoxin | rel=r_associated | relid=0 | w=24
  804. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:mucin-3
    n1=en:contraindications aspect | n2=en:mucin-3 | rel=r_associated | relid=0 | w=24
  805. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:myelin p2 protein
    n1=en:contraindications aspect | n2=en:myelin p2 protein | rel=r_associated | relid=0 | w=24
  806. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:n-acetylgalactosaminyltransferases
    n1=en:contraindications aspect | n2=en:n-acetylgalactosaminyltransferases | rel=r_associated | relid=0 | w=24
  807. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:n-nitrosodimethylamine
    n1=en:contraindications aspect | n2=en:n-nitrosodimethylamine | rel=r_associated | relid=0 | w=24
  808. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:nf-kappa b p52 subunit
    n1=en:contraindications aspect | n2=en:nf-kappa b p52 subunit | rel=r_associated | relid=0 | w=24
  809. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:nitrosomethylurethane
    n1=en:contraindications aspect | n2=en:nitrosomethylurethane | rel=r_associated | relid=0 | w=24
  810. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:norandrostanes
    n1=en:contraindications aspect | n2=en:norandrostanes | rel=r_associated | relid=0 | w=24
  811. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:norpregnenes
    n1=en:contraindications aspect | n2=en:norpregnenes | rel=r_associated | relid=0 | w=24
  812. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:nuclear respiratory factor 1
    n1=en:contraindications aspect | n2=en:nuclear respiratory factor 1 | rel=r_associated | relid=0 | w=24
  813. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:o-chlorobenzylidenemalonitrile
    n1=en:contraindications aspect | n2=en:o-chlorobenzylidenemalonitrile | rel=r_associated | relid=0 | w=24
  814. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:peridural injection
    n1=en:contraindications aspect | n2=en:peridural injection | rel=r_associated | relid=0 | w=24
  815. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:peroxiredoxin 6
    n1=en:contraindications aspect | n2=en:peroxiredoxin 6 | rel=r_associated | relid=0 | w=24
  816. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:phospholipase a2
    n1=en:contraindications aspect | n2=en:phospholipase a2 | rel=r_associated | relid=0 | w=24
  817. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:phototropins
    n1=en:contraindications aspect | n2=en:phototropins | rel=r_associated | relid=0 | w=24
  818. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:phycobilins
    n1=en:contraindications aspect | n2=en:phycobilins | rel=r_associated | relid=0 | w=24
  819. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:polydioxanone
    n1=en:contraindications aspect | n2=en:polydioxanone | rel=r_associated | relid=0 | w=24
  820. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:polyisoprenyl phosphate oligosaccharides
    n1=en:contraindications aspect | n2=en:polyisoprenyl phosphate oligosaccharides | rel=r_associated | relid=0 | w=24
  821. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:polyubiquitin
    n1=en:contraindications aspect | n2=en:polyubiquitin | rel=r_associated | relid=0 | w=24
  822. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:prostaglandins g
    n1=en:contraindications aspect | n2=en:prostaglandins g | rel=r_associated | relid=0 | w=24
  823. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:protein tyrosine phosphatase, non-receptor type 11
    n1=en:contraindications aspect | n2=en:protein tyrosine phosphatase, non-receptor type 11 | rel=r_associated | relid=0 | w=24
  824. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:proton ionophores
    n1=en:contraindications aspect | n2=en:proton ionophores | rel=r_associated | relid=0 | w=24
  825. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:rap guanine nucleotide exchange factor 1
    n1=en:contraindications aspect | n2=en:rap guanine nucleotide exchange factor 1 | rel=r_associated | relid=0 | w=24
  826. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:rap1 gtp-binding proteins
    n1=en:contraindications aspect | n2=en:rap1 gtp-binding proteins | rel=r_associated | relid=0 | w=24
  827. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:receptor, ephb3
    n1=en:contraindications aspect | n2=en:receptor, ephb3 | rel=r_associated | relid=0 | w=24
  828. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:ribonuclease h
    n1=en:contraindications aspect | n2=en:ribonuclease h | rel=r_associated | relid=0 | w=24
  829. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:ribosome inactivating proteins, type 1
    n1=en:contraindications aspect | n2=en:ribosome inactivating proteins, type 1 | rel=r_associated | relid=0 | w=24
  830. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:rna, transfer, met
    n1=en:contraindications aspect | n2=en:rna, transfer, met | rel=r_associated | relid=0 | w=24
  831. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:runt-related transcription factor 1
    n1=en:contraindications aspect | n2=en:runt-related transcription factor 1 | rel=r_associated | relid=0 | w=24
  832. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:sarcoglycans
    n1=en:contraindications aspect | n2=en:sarcoglycans | rel=r_associated | relid=0 | w=24
  833. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:smad1 protein
    n1=en:contraindications aspect | n2=en:smad1 protein | rel=r_associated | relid=0 | w=24
  834. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:smad2 protein
    n1=en:contraindications aspect | n2=en:smad2 protein | rel=r_associated | relid=0 | w=24
  835. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:smad3 protein
    n1=en:contraindications aspect | n2=en:smad3 protein | rel=r_associated | relid=0 | w=24
  836. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:smad8 protein
    n1=en:contraindications aspect | n2=en:smad8 protein | rel=r_associated | relid=0 | w=24
  837. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:smooth muscle myosins
    n1=en:contraindications aspect | n2=en:smooth muscle myosins | rel=r_associated | relid=0 | w=24
  838. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:sodium-phosphate cotransporter proteins, type iia
    n1=en:contraindications aspect | n2=en:sodium-phosphate cotransporter proteins, type iia | rel=r_associated | relid=0 | w=24
  839. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:sodium-phosphate cotransporter proteins, type iic
    n1=en:contraindications aspect | n2=en:sodium-phosphate cotransporter proteins, type iic | rel=r_associated | relid=0 | w=24
  840. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:sterol regulatory element-binding protein 1
    n1=en:contraindications aspect | n2=en:sterol regulatory element-binding protein 1 | rel=r_associated | relid=0 | w=24
  841. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:sulfur-sulfur bond isomerases
    n1=en:contraindications aspect | n2=en:sulfur-sulfur bond isomerases | rel=r_associated | relid=0 | w=24
  842. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:suloctidil
    n1=en:contraindications aspect | n2=en:suloctidil | rel=r_associated | relid=0 | w=24
  843. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:syntaxin 1
    n1=en:contraindications aspect | n2=en:syntaxin 1 | rel=r_associated | relid=0 | w=24
  844. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:tetraphenylborate
    n1=en:contraindications aspect | n2=en:tetraphenylborate | rel=r_associated | relid=0 | w=24
  845. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:transcription factor pit-1
    n1=en:contraindications aspect | n2=en:transcription factor pit-1 | rel=r_associated | relid=0 | w=24
  846. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:transposon resolvases
    n1=en:contraindications aspect | n2=en:transposon resolvases | rel=r_associated | relid=0 | w=24
  847. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:ultrasonography, doppler, duplex
    n1=en:contraindications aspect | n2=en:ultrasonography, doppler, duplex | rel=r_associated | relid=0 | w=24
  848. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:uroplakins
    n1=en:contraindications aspect | n2=en:uroplakins | rel=r_associated | relid=0 | w=24
  849. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:von hippel-lindau tumor suppressor protein
    n1=en:contraindications aspect | n2=en:von hippel-lindau tumor suppressor protein | rel=r_associated | relid=0 | w=24
  850. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> en:zoxazolamine
    n1=en:contraindications aspect | n2=en:zoxazolamine | rel=r_associated | relid=0 | w=24
  851. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> imagerie par résonance magnétique
    n1=en:contraindications aspect | n2=imagerie par résonance magnétique | rel=r_associated | relid=0 | w=24
  852. en:contraindications aspect -- r_associated #0: 24 / 0.686 -> ressuscitation
    n1=en:contraindications aspect | n2=ressuscitation | rel=r_associated | relid=0 | w=24
  853. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> chaperon moléculaire
    n1=en:contraindications aspect | n2=chaperon moléculaire | rel=r_associated | relid=0 | w=23
  854. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
    n1=en:contraindications aspect | n2=en:15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid | rel=r_associated | relid=0 | w=23
  855. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:2,3-diketogulonic acid
    n1=en:contraindications aspect | n2=en:2,3-diketogulonic acid | rel=r_associated | relid=0 | w=23
  856. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:2,4-dinitrophenol
    n1=en:contraindications aspect | n2=en:2,4-dinitrophenol | rel=r_associated | relid=0 | w=23
  857. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:3,3'-diaminobenzidine
    n1=en:contraindications aspect | n2=en:3,3'-diaminobenzidine | rel=r_associated | relid=0 | w=23
  858. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-isomer
    n1=en:contraindications aspect | n2=en:3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-isomer | rel=r_associated | relid=0 | w=23
  859. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:5,6-dihydroxytryptamine
    n1=en:contraindications aspect | n2=en:5,6-dihydroxytryptamine | rel=r_associated | relid=0 | w=23
  860. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:adenovirus e1 proteins
    n1=en:contraindications aspect | n2=en:adenovirus e1 proteins | rel=r_associated | relid=0 | w=23
  861. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:adp-ribosylation factor 1
    n1=en:contraindications aspect | n2=en:adp-ribosylation factor 1 | rel=r_associated | relid=0 | w=23
  862. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:adp/atp translocase 2
    n1=en:contraindications aspect | n2=en:adp/atp translocase 2 | rel=r_associated | relid=0 | w=23
  863. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:alkylmercury compounds
    n1=en:contraindications aspect | n2=en:alkylmercury compounds | rel=r_associated | relid=0 | w=23
  864. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:amino acid transport system y+l
    n1=en:contraindications aspect | n2=en:amino acid transport system y+l | rel=r_associated | relid=0 | w=23
  865. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:angiopoietin-1 receptor
    n1=en:contraindications aspect | n2=en:angiopoietin-1 receptor | rel=r_associated | relid=0 | w=23
  866. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:armin
    n1=en:contraindications aspect | n2=en:armin | rel=r_associated | relid=0 | w=23
  867. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:benzoylcholine
    n1=en:contraindications aspect | n2=en:benzoylcholine | rel=r_associated | relid=0 | w=23
  868. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:benzyl viologen
    n1=en:contraindications aspect | n2=en:benzyl viologen | rel=r_associated | relid=0 | w=23
  869. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:bephenium compounds
    n1=en:contraindications aspect | n2=en:bephenium compounds | rel=r_associated | relid=0 | w=23
  870. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:catechol 2,3-dioxygenase
    n1=en:contraindications aspect | n2=en:catechol 2,3-dioxygenase | rel=r_associated | relid=0 | w=23
  871. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:ccaat-enhancer-binding protein-delta
    n1=en:contraindications aspect | n2=en:ccaat-enhancer-binding protein-delta | rel=r_associated | relid=0 | w=23
  872. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:cd30 ligand
    n1=en:contraindications aspect | n2=en:cd30 ligand | rel=r_associated | relid=0 | w=23
  873. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:cdc2-cdc28 kinases
    n1=en:contraindications aspect | n2=en:cdc2-cdc28 kinases | rel=r_associated | relid=0 | w=23
  874. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:chloroplast thioredoxins
    n1=en:contraindications aspect | n2=en:chloroplast thioredoxins | rel=r_associated | relid=0 | w=23
  875. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:class ii phosphatidylinositol 3-kinases
    n1=en:contraindications aspect | n2=en:class ii phosphatidylinositol 3-kinases | rel=r_associated | relid=0 | w=23
  876. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:complement c5 convertase, alternative pathway
    n1=en:contraindications aspect | n2=en:complement c5 convertase, alternative pathway | rel=r_associated | relid=0 | w=23
  877. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:complement c5 convertase, classical pathway
    n1=en:contraindications aspect | n2=en:complement c5 convertase, classical pathway | rel=r_associated | relid=0 | w=23
  878. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:complement component c8
    n1=en:contraindications aspect | n2=en:complement component c8 | rel=r_associated | relid=0 | w=23
  879. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:coup transcription factor i
    n1=en:contraindications aspect | n2=en:coup transcription factor i | rel=r_associated | relid=0 | w=23
  880. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:creb-binding protein
    n1=en:contraindications aspect | n2=en:creb-binding protein | rel=r_associated | relid=0 | w=23
  881. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:cxc chemokine ip-10
    n1=en:contraindications aspect | n2=en:cxc chemokine ip-10 | rel=r_associated | relid=0 | w=23
  882. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:cyclic s-oxides
    n1=en:contraindications aspect | n2=en:cyclic s-oxides | rel=r_associated | relid=0 | w=23
  883. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:cyclin-dependent kinase 4 inhibitor c
    n1=en:contraindications aspect | n2=en:cyclin-dependent kinase 4 inhibitor c | rel=r_associated | relid=0 | w=23
  884. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:cyclopenthiazide
    n1=en:contraindications aspect | n2=en:cyclopenthiazide | rel=r_associated | relid=0 | w=23
  885. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:cytosolic phospholipase a2 group iv
    n1=en:contraindications aspect | n2=en:cytosolic phospholipase a2 group iv | rel=r_associated | relid=0 | w=23
  886. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:deoxyribonuclease (pyrimidine dimer)
    n1=en:contraindications aspect | n2=en:deoxyribonuclease (pyrimidine dimer) | rel=r_associated | relid=0 | w=23
  887. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:dihydroxydihydrobenzopyrenes
    n1=en:contraindications aspect | n2=en:dihydroxydihydrobenzopyrenes | rel=r_associated | relid=0 | w=23
  888. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:dimethylphenylpiperazinium iodide
    n1=en:contraindications aspect | n2=en:dimethylphenylpiperazinium iodide | rel=r_associated | relid=0 | w=23
  889. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:dissection
    n1=en:contraindications aspect | n2=en:dissection | rel=r_associated | relid=0 | w=23
  890. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:dydrogesterone
    n1=en:contraindications aspect | n2=en:dydrogesterone | rel=r_associated | relid=0 | w=23
  891. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:ecdysteroids
    n1=en:contraindications aspect | n2=en:ecdysteroids | rel=r_associated | relid=0 | w=23
  892. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:edar-associated death domain protein
    n1=en:contraindications aspect | n2=en:edar-associated death domain protein | rel=r_associated | relid=0 | w=23
  893. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:fanconi anemia complementation group l protein
    n1=en:contraindications aspect | n2=en:fanconi anemia complementation group l protein | rel=r_associated | relid=0 | w=23
  894. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:galactosylgalactosylglucosylceramidase
    n1=en:contraindications aspect | n2=en:galactosylgalactosylglucosylceramidase | rel=r_associated | relid=0 | w=23
  895. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:gamma-cyclodextrins
    n1=en:contraindications aspect | n2=en:gamma-cyclodextrins | rel=r_associated | relid=0 | w=23
  896. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:germine acetates
    n1=en:contraindications aspect | n2=en:germine acetates | rel=r_associated | relid=0 | w=23
  897. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:gtp cyclohydrolase
    n1=en:contraindications aspect | n2=en:gtp cyclohydrolase | rel=r_associated | relid=0 | w=23
  898. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:gtp pyrophosphokinase
    n1=en:contraindications aspect | n2=en:gtp pyrophosphokinase | rel=r_associated | relid=0 | w=23
  899. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:h-2 antigens
    n1=en:contraindications aspect | n2=en:h-2 antigens | rel=r_associated | relid=0 | w=23
  900. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:hematoporphyrin photoradiation
    n1=en:contraindications aspect | n2=en:hematoporphyrin photoradiation | rel=r_associated | relid=0 | w=23
  901. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:herpes simplex virus protein vmw65
    n1=en:contraindications aspect | n2=en:herpes simplex virus protein vmw65 | rel=r_associated | relid=0 | w=23
  902. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:histone demethylases
    n1=en:contraindications aspect | n2=en:histone demethylases | rel=r_associated | relid=0 | w=23
  903. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:hla-a1 antigen
    n1=en:contraindications aspect | n2=en:hla-a1 antigen | rel=r_associated | relid=0 | w=23
  904. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:hla-a11 antigen
    n1=en:contraindications aspect | n2=en:hla-a11 antigen | rel=r_associated | relid=0 | w=23
  905. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:hla-b35 antigen
    n1=en:contraindications aspect | n2=en:hla-b35 antigen | rel=r_associated | relid=0 | w=23
  906. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:hla-b40 antigen, human
    n1=en:contraindications aspect | n2=en:hla-b40 antigen, human | rel=r_associated | relid=0 | w=23
  907. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:hla-dp alpha-chains
    n1=en:contraindications aspect | n2=en:hla-dp alpha-chains | rel=r_associated | relid=0 | w=23
  908. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:hydroxyethylrutoside
    n1=en:contraindications aspect | n2=en:hydroxyethylrutoside | rel=r_associated | relid=0 | w=23
  909. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:hydroxytryptophol
    n1=en:contraindications aspect | n2=en:hydroxytryptophol | rel=r_associated | relid=0 | w=23
  910. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:interferon-stimulated gene factor 3, alpha subunit
    n1=en:contraindications aspect | n2=en:interferon-stimulated gene factor 3, alpha subunit | rel=r_associated | relid=0 | w=23
  911. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:interleukin-1 alpha
    n1=en:contraindications aspect | n2=en:interleukin-1 alpha | rel=r_associated | relid=0 | w=23
  912. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:isopropyl thiogalactoside
    n1=en:contraindications aspect | n2=en:isopropyl thiogalactoside | rel=r_associated | relid=0 | w=23
  913. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:kcnq1 potassium channel
    n1=en:contraindications aspect | n2=en:kcnq1 potassium channel | rel=r_associated | relid=0 | w=23
  914. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:keratin, type i cytoskeletal 20
    n1=en:contraindications aspect | n2=en:keratin, type i cytoskeletal 20 | rel=r_associated | relid=0 | w=23
  915. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:kitasamycin
    n1=en:contraindications aspect | n2=en:kitasamycin | rel=r_associated | relid=0 | w=23
  916. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:kv1.1 potassium channel
    n1=en:contraindications aspect | n2=en:kv1.1 potassium channel | rel=r_associated | relid=0 | w=23
  917. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:kv1.3 potassium channel
    n1=en:contraindications aspect | n2=en:kv1.3 potassium channel | rel=r_associated | relid=0 | w=23
  918. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:maff transcription factor
    n1=en:contraindications aspect | n2=en:maff transcription factor | rel=r_associated | relid=0 | w=23
  919. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:mercaptoethylamines
    n1=en:contraindications aspect | n2=en:mercaptoethylamines | rel=r_associated | relid=0 | w=23
  920. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:metalloproteinase inhibitor 2
    n1=en:contraindications aspect | n2=en:metalloproteinase inhibitor 2 | rel=r_associated | relid=0 | w=23
  921. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:methyl n-butyl ketone
    n1=en:contraindications aspect | n2=en:methyl n-butyl ketone | rel=r_associated | relid=0 | w=23
  922. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:mitogen-activated protein kinase 1
    n1=en:contraindications aspect | n2=en:mitogen-activated protein kinase 1 | rel=r_associated | relid=0 | w=23
  923. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:mnss blood-group system
    n1=en:contraindications aspect | n2=en:mnss blood-group system | rel=r_associated | relid=0 | w=23
  924. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:n-formylmethionine leucyl-phenylalanine
    n1=en:contraindications aspect | n2=en:n-formylmethionine leucyl-phenylalanine | rel=r_associated | relid=0 | w=23
  925. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:n-nitrosodiethylamine
    n1=en:contraindications aspect | n2=en:n-nitrosodiethylamine | rel=r_associated | relid=0 | w=23
  926. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:nadroparin calcium
    n1=en:contraindications aspect | n2=en:nadroparin calcium | rel=r_associated | relid=0 | w=23
  927. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:nebramycin
    n1=en:contraindications aspect | n2=en:nebramycin | rel=r_associated | relid=0 | w=23
  928. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:neuroprostanes
    n1=en:contraindications aspect | n2=en:neuroprostanes | rel=r_associated | relid=0 | w=23
  929. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:norpregnatrienes
    n1=en:contraindications aspect | n2=en:norpregnatrienes | rel=r_associated | relid=0 | w=23
  930. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:nucleoside-phosphate kinase
    n1=en:contraindications aspect | n2=en:nucleoside-phosphate kinase | rel=r_associated | relid=0 | w=23
  931. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:nucleosome assembly protein 1
    n1=en:contraindications aspect | n2=en:nucleosome assembly protein 1 | rel=r_associated | relid=0 | w=23
  932. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:oncogene proteins v-erbb
    n1=en:contraindications aspect | n2=en:oncogene proteins v-erbb | rel=r_associated | relid=0 | w=23
  933. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:oxazolone
    n1=en:contraindications aspect | n2=en:oxazolone | rel=r_associated | relid=0 | w=23
  934. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:oxyphenisatin acetate
    n1=en:contraindications aspect | n2=en:oxyphenisatin acetate | rel=r_associated | relid=0 | w=23
  935. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:p-methoxy-n-methylphenethylamine
    n1=en:contraindications aspect | n2=en:p-methoxy-n-methylphenethylamine | rel=r_associated | relid=0 | w=23
  936. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:pancreatic alpha-amylases
    n1=en:contraindications aspect | n2=en:pancreatic alpha-amylases | rel=r_associated | relid=0 | w=23
  937. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:parachloroamphetamine
    n1=en:contraindications aspect | n2=en:parachloroamphetamine | rel=r_associated | relid=0 | w=23
  938. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:parenteral nutrition, home total
    n1=en:contraindications aspect | n2=en:parenteral nutrition, home total | rel=r_associated | relid=0 | w=23
  939. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:poloxamer
    n1=en:contraindications aspect | n2=en:poloxamer | rel=r_associated | relid=0 | w=23
  940. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:polyubiquitin-c
    n1=en:contraindications aspect | n2=en:polyubiquitin-c | rel=r_associated | relid=0 | w=23
  941. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:propylbenzilylcholine mustard
    n1=en:contraindications aspect | n2=en:propylbenzilylcholine mustard | rel=r_associated | relid=0 | w=23
  942. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:purinergic p2 receptor agonists
    n1=en:contraindications aspect | n2=en:purinergic p2 receptor agonists | rel=r_associated | relid=0 | w=23
  943. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:purinergic p2y receptor antagonists
    n1=en:contraindications aspect | n2=en:purinergic p2y receptor antagonists | rel=r_associated | relid=0 | w=23
  944. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:puromycin aminonucleoside
    n1=en:contraindications aspect | n2=en:puromycin aminonucleoside | rel=r_associated | relid=0 | w=23
  945. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:retinoblastoma binding protein 1
    n1=en:contraindications aspect | n2=en:retinoblastoma binding protein 1 | rel=r_associated | relid=0 | w=23
  946. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:retinoblastoma-binding protein 7
    n1=en:contraindications aspect | n2=en:retinoblastoma-binding protein 7 | rel=r_associated | relid=0 | w=23
  947. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:rhodanine
    n1=en:contraindications aspect | n2=en:rhodanine | rel=r_associated | relid=0 | w=23
  948. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:ribonucleoprotein, u1 small nuclear
    n1=en:contraindications aspect | n2=en:ribonucleoprotein, u1 small nuclear | rel=r_associated | relid=0 | w=23
  949. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:rioprostil
    n1=en:contraindications aspect | n2=en:rioprostil | rel=r_associated | relid=0 | w=23
  950. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:rna, archaeal
    n1=en:contraindications aspect | n2=en:rna, archaeal | rel=r_associated | relid=0 | w=23
  951. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:rutamycin
    n1=en:contraindications aspect | n2=en:rutamycin | rel=r_associated | relid=0 | w=23
  952. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:saccharopine dehydrogenases
    n1=en:contraindications aspect | n2=en:saccharopine dehydrogenases | rel=r_associated | relid=0 | w=23
  953. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:semaphorin-3a
    n1=en:contraindications aspect | n2=en:semaphorin-3a | rel=r_associated | relid=0 | w=23
  954. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:sirtuin 2
    n1=en:contraindications aspect | n2=en:sirtuin 2 | rel=r_associated | relid=0 | w=23
  955. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:soxe transcription factors
    n1=en:contraindications aspect | n2=en:soxe transcription factors | rel=r_associated | relid=0 | w=23
  956. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:sp2 transcription factor
    n1=en:contraindications aspect | n2=en:sp2 transcription factor | rel=r_associated | relid=0 | w=23
  957. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:starch phosphorylase
    n1=en:contraindications aspect | n2=en:starch phosphorylase | rel=r_associated | relid=0 | w=23
  958. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:strophanthidin
    n1=en:contraindications aspect | n2=en:strophanthidin | rel=r_associated | relid=0 | w=23
  959. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:technetium tc-99m mertiatide
    n1=en:contraindications aspect | n2=en:technetium tc-99m mertiatide | rel=r_associated | relid=0 | w=23
  960. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:telomeric repeat binding protein 1
    n1=en:contraindications aspect | n2=en:telomeric repeat binding protein 1 | rel=r_associated | relid=0 | w=23
  961. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:tosyllysine chloromethyl ketone
    n1=en:contraindications aspect | n2=en:tosyllysine chloromethyl ketone | rel=r_associated | relid=0 | w=23
  962. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:tosylphenylalanyl chloromethyl ketone
    n1=en:contraindications aspect | n2=en:tosylphenylalanyl chloromethyl ketone | rel=r_associated | relid=0 | w=23
  963. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:trpm cation channels
    n1=en:contraindications aspect | n2=en:trpm cation channels | rel=r_associated | relid=0 | w=23
  964. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:uridine diphosphate n-acetylmuramic acid
    n1=en:contraindications aspect | n2=en:uridine diphosphate n-acetylmuramic acid | rel=r_associated | relid=0 | w=23
  965. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:veratridine
    n1=en:contraindications aspect | n2=en:veratridine | rel=r_associated | relid=0 | w=23
  966. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:wnt3 protein
    n1=en:contraindications aspect | n2=en:wnt3 protein | rel=r_associated | relid=0 | w=23
  967. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:x-ray microtomography
    n1=en:contraindications aspect | n2=en:x-ray microtomography | rel=r_associated | relid=0 | w=23
  968. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> en:zap-70 kinase
    n1=en:contraindications aspect | n2=en:zap-70 kinase | rel=r_associated | relid=0 | w=23
  969. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> enzyme
    n1=en:contraindications aspect | n2=enzyme | rel=r_associated | relid=0 | w=23
  970. en:contraindications aspect -- r_associated #0: 23 / 0.657 -> prostaglandine
    n1=en:contraindications aspect | n2=prostaglandine | rel=r_associated | relid=0 | w=23
  971. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:1-octanol
    n1=en:contraindications aspect | n2=en:1-octanol | rel=r_associated | relid=0 | w=22
  972. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:12-hydroxy-5,8,10,14-eicosatetraenoic acid
    n1=en:contraindications aspect | n2=en:12-hydroxy-5,8,10,14-eicosatetraenoic acid | rel=r_associated | relid=0 | w=22
  973. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:16,16-dimethylprostaglandin e2
    n1=en:contraindications aspect | n2=en:16,16-dimethylprostaglandin e2 | rel=r_associated | relid=0 | w=22
  974. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:2-chloroadenosine
    n1=en:contraindications aspect | n2=en:2-chloroadenosine | rel=r_associated | relid=0 | w=22
  975. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:3-o-methylglucose
    n1=en:contraindications aspect | n2=en:3-o-methylglucose | rel=r_associated | relid=0 | w=22
  976. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:activating transcription factor 2
    n1=en:contraindications aspect | n2=en:activating transcription factor 2 | rel=r_associated | relid=0 | w=22
  977. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:adenosine a2 receptor antagonists
    n1=en:contraindications aspect | n2=en:adenosine a2 receptor antagonists | rel=r_associated | relid=0 | w=22
  978. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:algestone
    n1=en:contraindications aspect | n2=en:algestone | rel=r_associated | relid=0 | w=22
  979. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:allylestrenol
    n1=en:contraindications aspect | n2=en:allylestrenol | rel=r_associated | relid=0 | w=22
  980. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:amidine-lyases
    n1=en:contraindications aspect | n2=en:amidine-lyases | rel=r_associated | relid=0 | w=22
  981. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:arsenazo iii
    n1=en:contraindications aspect | n2=en:arsenazo iii | rel=r_associated | relid=0 | w=22
  982. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:bcr/abl1 fusion protein
    n1=en:contraindications aspect | n2=en:bcr/abl1 fusion protein | rel=r_associated | relid=0 | w=22
  983. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:butaclamol
    n1=en:contraindications aspect | n2=en:butaclamol | rel=r_associated | relid=0 | w=22
  984. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:calcimimetic agents
    n1=en:contraindications aspect | n2=en:calcimimetic agents | rel=r_associated | relid=0 | w=22
  985. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:canrenone
    n1=en:contraindications aspect | n2=en:canrenone | rel=r_associated | relid=0 | w=22
  986. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:carfecillin
    n1=en:contraindications aspect | n2=en:carfecillin | rel=r_associated | relid=0 | w=22
  987. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:carotid endarterectomy
    n1=en:contraindications aspect | n2=en:carotid endarterectomy | rel=r_associated | relid=0 | w=22
  988. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:casein kinase i
    n1=en:contraindications aspect | n2=en:casein kinase i | rel=r_associated | relid=0 | w=22
  989. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:ccaat/enhancer binding protein beta
    n1=en:contraindications aspect | n2=en:ccaat/enhancer binding protein beta | rel=r_associated | relid=0 | w=22
  990. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:cdc28 protein kinase, s cerevisiae
    n1=en:contraindications aspect | n2=en:cdc28 protein kinase, s cerevisiae | rel=r_associated | relid=0 | w=22
  991. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:cephacetrile
    n1=en:contraindications aspect | n2=en:cephacetrile | rel=r_associated | relid=0 | w=22
  992. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:chaperonin containing tcp-1
    n1=en:contraindications aspect | n2=en:chaperonin containing tcp-1 | rel=r_associated | relid=0 | w=22
  993. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:chemokine ccl4
    n1=en:contraindications aspect | n2=en:chemokine ccl4 | rel=r_associated | relid=0 | w=22
  994. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:chemokine cxcl13
    n1=en:contraindications aspect | n2=en:chemokine cxcl13 | rel=r_associated | relid=0 | w=22
  995. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:chondroitinases and chondroitin lyases
    n1=en:contraindications aspect | n2=en:chondroitinases and chondroitin lyases | rel=r_associated | relid=0 | w=22
  996. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:class ia phosphatidylinositol 3-kinase
    n1=en:contraindications aspect | n2=en:class ia phosphatidylinositol 3-kinase | rel=r_associated | relid=0 | w=22
  997. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:coated materials, biocompatible
    n1=en:contraindications aspect | n2=en:coated materials, biocompatible | rel=r_associated | relid=0 | w=22
  998. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:coformycin
    n1=en:contraindications aspect | n2=en:coformycin | rel=r_associated | relid=0 | w=22
  999. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:complement c2b
    n1=en:contraindications aspect | n2=en:complement c2b | rel=r_associated | relid=0 | w=22
  1000. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:contraindication
    n1=en:contraindications aspect | n2=en:contraindication | rel=r_associated | relid=0 | w=22
  1001. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:corneal topography
    n1=en:contraindications aspect | n2=en:corneal topography | rel=r_associated | relid=0 | w=22
  1002. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:cytosolic phospholipase a2
    n1=en:contraindications aspect | n2=en:cytosolic phospholipase a2 | rel=r_associated | relid=0 | w=22
  1003. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:dalteparin
    n1=en:contraindications aspect | n2=en:dalteparin | rel=r_associated | relid=0 | w=22
  1004. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:dermcidins
    n1=en:contraindications aspect | n2=en:dermcidins | rel=r_associated | relid=0 | w=22
  1005. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:dibenzocycloheptenes
    n1=en:contraindications aspect | n2=en:dibenzocycloheptenes | rel=r_associated | relid=0 | w=22
  1006. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:diphenylcarbazide
    n1=en:contraindications aspect | n2=en:diphenylcarbazide | rel=r_associated | relid=0 | w=22
  1007. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:dithioerythritol
    n1=en:contraindications aspect | n2=en:dithioerythritol | rel=r_associated | relid=0 | w=22
  1008. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:doppler echocardiography
    n1=en:contraindications aspect | n2=en:doppler echocardiography | rel=r_associated | relid=0 | w=22
  1009. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:echocardiography, four-dimensional
    n1=en:contraindications aspect | n2=en:echocardiography, four-dimensional | rel=r_associated | relid=0 | w=22
  1010. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:electronystagmography
    n1=en:contraindications aspect | n2=en:electronystagmography | rel=r_associated | relid=0 | w=22
  1011. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:equol
    n1=en:contraindications aspect | n2=en:equol | rel=r_associated | relid=0 | w=22
  1012. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:ergothioneine
    n1=en:contraindications aspect | n2=en:ergothioneine | rel=r_associated | relid=0 | w=22
  1013. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:ethenoadenosine triphosphate
    n1=en:contraindications aspect | n2=en:ethenoadenosine triphosphate | rel=r_associated | relid=0 | w=22
  1014. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:ether-a-go-go potassium channels
    n1=en:contraindications aspect | n2=en:ether-a-go-go potassium channels | rel=r_associated | relid=0 | w=22
  1015. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:ethisterone
    n1=en:contraindications aspect | n2=en:ethisterone | rel=r_associated | relid=0 | w=22
  1016. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:factor xiiia
    n1=en:contraindications aspect | n2=en:factor xiiia | rel=r_associated | relid=0 | w=22
  1017. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:fanconi anemia group c protein
    n1=en:contraindications aspect | n2=en:fanconi anemia group c protein | rel=r_associated | relid=0 | w=22
  1018. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:gaba-a receptor antagonists
    n1=en:contraindications aspect | n2=en:gaba-a receptor antagonists | rel=r_associated | relid=0 | w=22
  1019. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:glutamate dehydrogenase (nadp+)
    n1=en:contraindications aspect | n2=en:glutamate dehydrogenase (nadp+) | rel=r_associated | relid=0 | w=22
  1020. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:group i phospholipases a2
    n1=en:contraindications aspect | n2=en:group i phospholipases a2 | rel=r_associated | relid=0 | w=22
  1021. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:hepatocyte nuclear factor 1-alpha
    n1=en:contraindications aspect | n2=en:hepatocyte nuclear factor 1-alpha | rel=r_associated | relid=0 | w=22
  1022. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:histamine h3 antagonists
    n1=en:contraindications aspect | n2=en:histamine h3 antagonists | rel=r_associated | relid=0 | w=22
  1023. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:hla-drb5 antigen
    n1=en:contraindications aspect | n2=en:hla-drb5 antigen | rel=r_associated | relid=0 | w=22
  1024. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:htlv-ii antibodies
    n1=en:contraindications aspect | n2=en:htlv-ii antibodies | rel=r_associated | relid=0 | w=22
  1025. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:hydroxypropiophenone
    n1=en:contraindications aspect | n2=en:hydroxypropiophenone | rel=r_associated | relid=0 | w=22
  1026. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:intrauterine cordocentesis
    n1=en:contraindications aspect | n2=en:intrauterine cordocentesis | rel=r_associated | relid=0 | w=22
  1027. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:iodocyanopindolol
    n1=en:contraindications aspect | n2=en:iodocyanopindolol | rel=r_associated | relid=0 | w=22
  1028. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:iodoquinol
    n1=en:contraindications aspect | n2=en:iodoquinol | rel=r_associated | relid=0 | w=22
  1029. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:keratin-2
    n1=en:contraindications aspect | n2=en:keratin-2 | rel=r_associated | relid=0 | w=22
  1030. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:kv1.2 potassium channel
    n1=en:contraindications aspect | n2=en:kv1.2 potassium channel | rel=r_associated | relid=0 | w=22
  1031. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:leptophos
    n1=en:contraindications aspect | n2=en:leptophos | rel=r_associated | relid=0 | w=22
  1032. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:lymphotoxin beta receptor
    n1=en:contraindications aspect | n2=en:lymphotoxin beta receptor | rel=r_associated | relid=0 | w=22
  1033. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:mafg transcription factor
    n1=en:contraindications aspect | n2=en:mafg transcription factor | rel=r_associated | relid=0 | w=22
  1034. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:mediastinoscope
    n1=en:contraindications aspect | n2=en:mediastinoscope | rel=r_associated | relid=0 | w=22
  1035. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:medication
    n1=en:contraindications aspect | n2=en:medication | rel=r_associated | relid=0 | w=22
  1036. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:mercuribenzoates
    n1=en:contraindications aspect | n2=en:mercuribenzoates | rel=r_associated | relid=0 | w=22
  1037. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:methylhistamines
    n1=en:contraindications aspect | n2=en:methylhistamines | rel=r_associated | relid=0 | w=22
  1038. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:metiamide
    n1=en:contraindications aspect | n2=en:metiamide | rel=r_associated | relid=0 | w=22
  1039. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:n-methyl-n-nitro-n-nitrosoguanidine
    n1=en:contraindications aspect | n2=en:n-methyl-n-nitro-n-nitrosoguanidine | rel=r_associated | relid=0 | w=22
  1040. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:n-nitrosopyrrolidine
    n1=en:contraindications aspect | n2=en:n-nitrosopyrrolidine | rel=r_associated | relid=0 | w=22
  1041. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:nf-e2 transcription factor
    n1=en:contraindications aspect | n2=en:nf-e2 transcription factor | rel=r_associated | relid=0 | w=22
  1042. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:nf-e2 transcription factor, p45 subunit
    n1=en:contraindications aspect | n2=en:nf-e2 transcription factor, p45 subunit | rel=r_associated | relid=0 | w=22
  1043. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:nuclear factor 45 protein
    n1=en:contraindications aspect | n2=en:nuclear factor 45 protein | rel=r_associated | relid=0 | w=22
  1044. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:nuclear receptor subfamily 2, group c, member 1
    n1=en:contraindications aspect | n2=en:nuclear receptor subfamily 2, group c, member 1 | rel=r_associated | relid=0 | w=22
  1045. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:nucleoplasmins
    n1=en:contraindications aspect | n2=en:nucleoplasmins | rel=r_associated | relid=0 | w=22
  1046. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:oxyclozanide
    n1=en:contraindications aspect | n2=en:oxyclozanide | rel=r_associated | relid=0 | w=22
  1047. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:p-chloromercuribenzoic acid
    n1=en:contraindications aspect | n2=en:p-chloromercuribenzoic acid | rel=r_associated | relid=0 | w=22
  1048. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:pax9 transcription factor
    n1=en:contraindications aspect | n2=en:pax9 transcription factor | rel=r_associated | relid=0 | w=22
  1049. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:pentoxyl
    n1=en:contraindications aspect | n2=en:pentoxyl | rel=r_associated | relid=0 | w=22
  1050. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:phosphoribosylglycinamide formyltransferase
    n1=en:contraindications aspect | n2=en:phosphoribosylglycinamide formyltransferase | rel=r_associated | relid=0 | w=22
  1051. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:phosphotransferases (paired acceptors)
    n1=en:contraindications aspect | n2=en:phosphotransferases (paired acceptors) | rel=r_associated | relid=0 | w=22
  1052. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:potassium-hydrogen antiporters
    n1=en:contraindications aspect | n2=en:potassium-hydrogen antiporters | rel=r_associated | relid=0 | w=22
  1053. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:prdx3 peroxidase
    n1=en:contraindications aspect | n2=en:prdx3 peroxidase | rel=r_associated | relid=0 | w=22
  1054. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:procaterol
    n1=en:contraindications aspect | n2=en:procaterol | rel=r_associated | relid=0 | w=22
  1055. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:prostaglandin
    n1=en:contraindications aspect | n2=en:prostaglandin | rel=r_associated | relid=0 | w=22
  1056. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:prostaglandins a
    n1=en:contraindications aspect | n2=en:prostaglandins a | rel=r_associated | relid=0 | w=22
  1057. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:protein
    n1=en:contraindications aspect | n2=en:protein | rel=r_associated | relid=0 | w=22
  1058. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:protein tyrosine phosphatase, non-receptor type 6
    n1=en:contraindications aspect | n2=en:protein tyrosine phosphatase, non-receptor type 6 | rel=r_associated | relid=0 | w=22
  1059. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:proto-oncogene int-1 related protein
    n1=en:contraindications aspect | n2=en:proto-oncogene int-1 related protein | rel=r_associated | relid=0 | w=22
  1060. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:protochlorophyllide
    n1=en:contraindications aspect | n2=en:protochlorophyllide | rel=r_associated | relid=0 | w=22
  1061. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:protoveratrines
    n1=en:contraindications aspect | n2=en:protoveratrines | rel=r_associated | relid=0 | w=22
  1062. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:rab1 gtp-binding proteins
    n1=en:contraindications aspect | n2=en:rab1 gtp-binding proteins | rel=r_associated | relid=0 | w=22
  1063. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:receptor, epha7
    n1=en:contraindications aspect | n2=en:receptor, epha7 | rel=r_associated | relid=0 | w=22
  1064. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:retinoblastoma-binding protein 2
    n1=en:contraindications aspect | n2=en:retinoblastoma-binding protein 2 | rel=r_associated | relid=0 | w=22
  1065. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:rev gene products, human immunodeficiency virus
    n1=en:contraindications aspect | n2=en:rev gene products, human immunodeficiency virus | rel=r_associated | relid=0 | w=22
  1066. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:ronidazole
    n1=en:contraindications aspect | n2=en:ronidazole | rel=r_associated | relid=0 | w=22
  1067. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:sigmoidoscope
    n1=en:contraindications aspect | n2=en:sigmoidoscope | rel=r_associated | relid=0 | w=22
  1068. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:sirtuin 1
    n1=en:contraindications aspect | n2=en:sirtuin 1 | rel=r_associated | relid=0 | w=22
  1069. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:sodium cholate
    n1=en:contraindications aspect | n2=en:sodium cholate | rel=r_associated | relid=0 | w=22
  1070. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:sparsomycin
    n1=en:contraindications aspect | n2=en:sparsomycin | rel=r_associated | relid=0 | w=22
  1071. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:sterol 12-alpha-hydroxylase
    n1=en:contraindications aspect | n2=en:sterol 12-alpha-hydroxylase | rel=r_associated | relid=0 | w=22
  1072. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:streptovaricin
    n1=en:contraindications aspect | n2=en:streptovaricin | rel=r_associated | relid=0 | w=22
  1073. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:sulfenic acids
    n1=en:contraindications aspect | n2=en:sulfenic acids | rel=r_associated | relid=0 | w=22
  1074. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:tetraisopropylpyrophosphamide
    n1=en:contraindications aspect | n2=en:tetraisopropylpyrophosphamide | rel=r_associated | relid=0 | w=22
  1075. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:therapeutic procedure
    n1=en:contraindications aspect | n2=en:therapeutic procedure | rel=r_associated | relid=0 | w=22
  1076. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:thiomalates
    n1=en:contraindications aspect | n2=en:thiomalates | rel=r_associated | relid=0 | w=22
  1077. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:thioredoxin h
    n1=en:contraindications aspect | n2=en:thioredoxin h | rel=r_associated | relid=0 | w=22
  1078. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:thiorphan
    n1=en:contraindications aspect | n2=en:thiorphan | rel=r_associated | relid=0 | w=22
  1079. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:tnf receptor-associated factor 1
    n1=en:contraindications aspect | n2=en:tnf receptor-associated factor 1 | rel=r_associated | relid=0 | w=22
  1080. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:triethylenephosphoramide
    n1=en:contraindications aspect | n2=en:triethylenephosphoramide | rel=r_associated | relid=0 | w=22
  1081. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:troponin
    n1=en:contraindications aspect | n2=en:troponin | rel=r_associated | relid=0 | w=22
  1082. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:trypsin inhibitor, bowman-birk soybean
    n1=en:contraindications aspect | n2=en:trypsin inhibitor, bowman-birk soybean | rel=r_associated | relid=0 | w=22
  1083. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:tumor necrosis factor ligand superfamily member 4
    n1=en:contraindications aspect | n2=en:tumor necrosis factor ligand superfamily member 4 | rel=r_associated | relid=0 | w=22
  1084. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:ultrasonography, doppler, pulsed
    n1=en:contraindications aspect | n2=en:ultrasonography, doppler, pulsed | rel=r_associated | relid=0 | w=22
  1085. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:vaccination
    n1=en:contraindications aspect | n2=en:vaccination | rel=r_associated | relid=0 | w=22
  1086. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:valine dehydrogenase (nadp+)
    n1=en:contraindications aspect | n2=en:valine dehydrogenase (nadp+) | rel=r_associated | relid=0 | w=22
  1087. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:vernamycin b
    n1=en:contraindications aspect | n2=en:vernamycin b | rel=r_associated | relid=0 | w=22
  1088. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> en:wnt3a protein
    n1=en:contraindications aspect | n2=en:wnt3a protein | rel=r_associated | relid=0 | w=22
  1089. en:contraindications aspect -- r_associated #0: 22 / 0.629 -> vaccination
    n1=en:contraindications aspect | n2=vaccination | rel=r_associated | relid=0 | w=22
  1090. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:1-naphthylisothiocyanate
    n1=en:contraindications aspect | n2=en:1-naphthylisothiocyanate | rel=r_associated | relid=0 | w=21
  1091. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:2-naphthylamine
    n1=en:contraindications aspect | n2=en:2-naphthylamine | rel=r_associated | relid=0 | w=21
  1092. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1h-3-benzazepine
    n1=en:contraindications aspect | n2=en:2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1h-3-benzazepine | rel=r_associated | relid=0 | w=21
  1093. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:3-mercaptopropionic acid
    n1=en:contraindications aspect | n2=en:3-mercaptopropionic acid | rel=r_associated | relid=0 | w=21
  1094. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:5-alpha-dihydroprogesterone
    n1=en:contraindications aspect | n2=en:5-alpha-dihydroprogesterone | rel=r_associated | relid=0 | w=21
  1095. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:actin-related protein 2
    n1=en:contraindications aspect | n2=en:actin-related protein 2 | rel=r_associated | relid=0 | w=21
  1096. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:antipain
    n1=en:contraindications aspect | n2=en:antipain | rel=r_associated | relid=0 | w=21
  1097. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:aroclors
    n1=en:contraindications aspect | n2=en:aroclors | rel=r_associated | relid=0 | w=21
  1098. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:atp phosphoribosyltransferase
    n1=en:contraindications aspect | n2=en:atp phosphoribosyltransferase | rel=r_associated | relid=0 | w=21
  1099. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:bacterial proton-translocating atpases
    n1=en:contraindications aspect | n2=en:bacterial proton-translocating atpases | rel=r_associated | relid=0 | w=21
  1100. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:bacteriochlorophyll a
    n1=en:contraindications aspect | n2=en:bacteriochlorophyll a | rel=r_associated | relid=0 | w=21
  1101. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:blood patch, epidural
    n1=en:contraindications aspect | n2=en:blood patch, epidural | rel=r_associated | relid=0 | w=21
  1102. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:borohydrides
    n1=en:contraindications aspect | n2=en:borohydrides | rel=r_associated | relid=0 | w=21
  1103. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:bromotrichloromethane
    n1=en:contraindications aspect | n2=en:bromotrichloromethane | rel=r_associated | relid=0 | w=21
  1104. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:butyrate response factor 1
    n1=en:contraindications aspect | n2=en:butyrate response factor 1 | rel=r_associated | relid=0 | w=21
  1105. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:c-c motif chemokine 3
    n1=en:contraindications aspect | n2=en:c-c motif chemokine 3 | rel=r_associated | relid=0 | w=21
  1106. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:calnexin
    n1=en:contraindications aspect | n2=en:calnexin | rel=r_associated | relid=0 | w=21
  1107. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:cd98 antigen
    n1=en:contraindications aspect | n2=en:cd98 antigen | rel=r_associated | relid=0 | w=21
  1108. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:cholenes
    n1=en:contraindications aspect | n2=en:cholenes | rel=r_associated | relid=0 | w=21
  1109. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:complement c1 inactivator proteins
    n1=en:contraindications aspect | n2=en:complement c1 inactivator proteins | rel=r_associated | relid=0 | w=21
  1110. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:complement c4-b
    n1=en:contraindications aspect | n2=en:complement c4-b | rel=r_associated | relid=0 | w=21
  1111. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:crotonates
    n1=en:contraindications aspect | n2=en:crotonates | rel=r_associated | relid=0 | w=21
  1112. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:cyclic amp response element-binding protein a
    n1=en:contraindications aspect | n2=en:cyclic amp response element-binding protein a | rel=r_associated | relid=0 | w=21
  1113. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:cyclic amp-dependent transcription factor atf-1
    n1=en:contraindications aspect | n2=en:cyclic amp-dependent transcription factor atf-1 | rel=r_associated | relid=0 | w=21
  1114. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:cymarine
    n1=en:contraindications aspect | n2=en:cymarine | rel=r_associated | relid=0 | w=21
  1115. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:cytokeratin 8
    n1=en:contraindications aspect | n2=en:cytokeratin 8 | rel=r_associated | relid=0 | w=21
  1116. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:decoquinate
    n1=en:contraindications aspect | n2=en:decoquinate | rel=r_associated | relid=0 | w=21
  1117. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:dehydroascorbatase
    n1=en:contraindications aspect | n2=en:dehydroascorbatase | rel=r_associated | relid=0 | w=21
  1118. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:deoxyribonuclease hindiii
    n1=en:contraindications aspect | n2=en:deoxyribonuclease hindiii | rel=r_associated | relid=0 | w=21
  1119. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:desmocollins
    n1=en:contraindications aspect | n2=en:desmocollins | rel=r_associated | relid=0 | w=21
  1120. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:dihydroergocornine
    n1=en:contraindications aspect | n2=en:dihydroergocornine | rel=r_associated | relid=0 | w=21
  1121. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:dihydromorphine
    n1=en:contraindications aspect | n2=en:dihydromorphine | rel=r_associated | relid=0 | w=21
  1122. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:dimethyl adipimidate
    n1=en:contraindications aspect | n2=en:dimethyl adipimidate | rel=r_associated | relid=0 | w=21
  1123. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:elav-like protein 4
    n1=en:contraindications aspect | n2=en:elav-like protein 4 | rel=r_associated | relid=0 | w=21
  1124. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:enviomycin
    n1=en:contraindications aspect | n2=en:enviomycin | rel=r_associated | relid=0 | w=21
  1125. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:epstein-barr virus nuclear antigens
    n1=en:contraindications aspect | n2=en:epstein-barr virus nuclear antigens | rel=r_associated | relid=0 | w=21
  1126. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:equilenin
    n1=en:contraindications aspect | n2=en:equilenin | rel=r_associated | relid=0 | w=21
  1127. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:ethylmaleimide
    n1=en:contraindications aspect | n2=en:ethylmaleimide | rel=r_associated | relid=0 | w=21
  1128. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:farnesyl-diphosphate farnesyltransferase
    n1=en:contraindications aspect | n2=en:farnesyl-diphosphate farnesyltransferase | rel=r_associated | relid=0 | w=21
  1129. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:ferrichrome
    n1=en:contraindications aspect | n2=en:ferrichrome | rel=r_associated | relid=0 | w=21
  1130. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:fibric acids
    n1=en:contraindications aspect | n2=en:fibric acids | rel=r_associated | relid=0 | w=21
  1131. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:fluorescein-5-isothiocyanate
    n1=en:contraindications aspect | n2=en:fluorescein-5-isothiocyanate | rel=r_associated | relid=0 | w=21
  1132. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:fusion proteins, gag-onc
    n1=en:contraindications aspect | n2=en:fusion proteins, gag-onc | rel=r_associated | relid=0 | w=21
  1133. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:gaba-b receptor agonists
    n1=en:contraindications aspect | n2=en:gaba-b receptor agonists | rel=r_associated | relid=0 | w=21
  1134. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:gi2-alpha protein
    n1=en:contraindications aspect | n2=en:gi2-alpha protein | rel=r_associated | relid=0 | w=21
  1135. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:gtp-binding protein alpha subunits, gq-g11
    n1=en:contraindications aspect | n2=en:gtp-binding protein alpha subunits, gq-g11 | rel=r_associated | relid=0 | w=21
  1136. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:guaiac
    n1=en:contraindications aspect | n2=en:guaiac | rel=r_associated | relid=0 | w=21
  1137. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:heptachlor epoxide
    n1=en:contraindications aspect | n2=en:heptachlor epoxide | rel=r_associated | relid=0 | w=21
  1138. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:hla-c antigens
    n1=en:contraindications aspect | n2=en:hla-c antigens | rel=r_associated | relid=0 | w=21
  1139. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:hsp110 heat-shock proteins
    n1=en:contraindications aspect | n2=en:hsp110 heat-shock proteins | rel=r_associated | relid=0 | w=21
  1140. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:id2 protein
    n1=en:contraindications aspect | n2=en:id2 protein | rel=r_associated | relid=0 | w=21
  1141. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:isothiuronium
    n1=en:contraindications aspect | n2=en:isothiuronium | rel=r_associated | relid=0 | w=21
  1142. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:kinetocardiography
    n1=en:contraindications aspect | n2=en:kinetocardiography | rel=r_associated | relid=0 | w=21
  1143. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:kv1.4 potassium channel
    n1=en:contraindications aspect | n2=en:kv1.4 potassium channel | rel=r_associated | relid=0 | w=21
  1144. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:kynuramine
    n1=en:contraindications aspect | n2=en:kynuramine | rel=r_associated | relid=0 | w=21
  1145. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:laurates
    n1=en:contraindications aspect | n2=en:laurates | rel=r_associated | relid=0 | w=21
  1146. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:levallorphan
    n1=en:contraindications aspect | n2=en:levallorphan | rel=r_associated | relid=0 | w=21
  1147. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:lipoprotein
    n1=en:contraindications aspect | n2=en:lipoprotein | rel=r_associated | relid=0 | w=21
  1148. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:lysine 6-aminotransferase
    n1=en:contraindications aspect | n2=en:lysine 6-aminotransferase | rel=r_associated | relid=0 | w=21
  1149. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:mediator of rna polymerase ii transcription subunit 1
    n1=en:contraindications aspect | n2=en:mediator of rna polymerase ii transcription subunit 1 | rel=r_associated | relid=0 | w=21
  1150. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:melanocortins
    n1=en:contraindications aspect | n2=en:melanocortins | rel=r_associated | relid=0 | w=21
  1151. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:methiothepin
    n1=en:contraindications aspect | n2=en:methiothepin | rel=r_associated | relid=0 | w=21
  1152. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:mi-2 nucleosome remodeling and deacetylase complex
    n1=en:contraindications aspect | n2=en:mi-2 nucleosome remodeling and deacetylase complex | rel=r_associated | relid=0 | w=21
  1153. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:microcystins
    n1=en:contraindications aspect | n2=en:microcystins | rel=r_associated | relid=0 | w=21
  1154. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:mitogen-activated protein kinase 6
    n1=en:contraindications aspect | n2=en:mitogen-activated protein kinase 6 | rel=r_associated | relid=0 | w=21
  1155. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:muramoylpentapeptide carboxypeptidase
    n1=en:contraindications aspect | n2=en:muramoylpentapeptide carboxypeptidase | rel=r_associated | relid=0 | w=21
  1156. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:myeloid differentiation factor 88
    n1=en:contraindications aspect | n2=en:myeloid differentiation factor 88 | rel=r_associated | relid=0 | w=21
  1157. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:nf-kappa b p50 subunit
    n1=en:contraindications aspect | n2=en:nf-kappa b p50 subunit | rel=r_associated | relid=0 | w=21
  1158. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:o-aminoazotoluene
    n1=en:contraindications aspect | n2=en:o-aminoazotoluene | rel=r_associated | relid=0 | w=21
  1159. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:odontometry
    n1=en:contraindications aspect | n2=en:odontometry | rel=r_associated | relid=0 | w=21
  1160. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:pheophytins
    n1=en:contraindications aspect | n2=en:pheophytins | rel=r_associated | relid=0 | w=21
  1161. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:polyglycolic acid
    n1=en:contraindications aspect | n2=en:polyglycolic acid | rel=r_associated | relid=0 | w=21
  1162. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:purinergic p2y receptor agonists
    n1=en:contraindications aspect | n2=en:purinergic p2y receptor agonists | rel=r_associated | relid=0 | w=21
  1163. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:qb-snare proteins
    n1=en:contraindications aspect | n2=en:qb-snare proteins | rel=r_associated | relid=0 | w=21
  1164. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:rad51 recombinase
    n1=en:contraindications aspect | n2=en:rad51 recombinase | rel=r_associated | relid=0 | w=21
  1165. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:sirtuin 3
    n1=en:contraindications aspect | n2=en:sirtuin 3 | rel=r_associated | relid=0 | w=21
  1166. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:skp cullin f-box protein ligases
    n1=en:contraindications aspect | n2=en:skp cullin f-box protein ligases | rel=r_associated | relid=0 | w=21
  1167. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:soxb2 transcription factors
    n1=en:contraindications aspect | n2=en:soxb2 transcription factors | rel=r_associated | relid=0 | w=21
  1168. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:soxf transcription factors
    n1=en:contraindications aspect | n2=en:soxf transcription factors | rel=r_associated | relid=0 | w=21
  1169. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:sp transcription factors
    n1=en:contraindications aspect | n2=en:sp transcription factors | rel=r_associated | relid=0 | w=21
  1170. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:sphincterotomy, transhepatic
    n1=en:contraindications aspect | n2=en:sphincterotomy, transhepatic | rel=r_associated | relid=0 | w=21
  1171. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:stimulants, historical
    n1=en:contraindications aspect | n2=en:stimulants, historical | rel=r_associated | relid=0 | w=21
  1172. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:succinyldiaminopimelate aminotransferase
    n1=en:contraindications aspect | n2=en:succinyldiaminopimelate aminotransferase | rel=r_associated | relid=0 | w=21
  1173. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:synaptosomal-associated protein 25
    n1=en:contraindications aspect | n2=en:synaptosomal-associated protein 25 | rel=r_associated | relid=0 | w=21
  1174. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:syndecan-4
    n1=en:contraindications aspect | n2=en:syndecan-4 | rel=r_associated | relid=0 | w=21
  1175. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:thiocholine
    n1=en:contraindications aspect | n2=en:thiocholine | rel=r_associated | relid=0 | w=21
  1176. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:tolloid-like metalloproteinases
    n1=en:contraindications aspect | n2=en:tolloid-like metalloproteinases | rel=r_associated | relid=0 | w=21
  1177. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:tumor necrosis factor ligand superfamily member 14
    n1=en:contraindications aspect | n2=en:tumor necrosis factor ligand superfamily member 14 | rel=r_associated | relid=0 | w=21
  1178. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:ultrasonography, doppler, color
    n1=en:contraindications aspect | n2=en:ultrasonography, doppler, color | rel=r_associated | relid=0 | w=21
  1179. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:v-set domain-containing t-cell activation inhibitor 1
    n1=en:contraindications aspect | n2=en:v-set domain-containing t-cell activation inhibitor 1 | rel=r_associated | relid=0 | w=21
  1180. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> en:vif gene products, human immunodeficiency virus
    n1=en:contraindications aspect | n2=en:vif gene products, human immunodeficiency virus | rel=r_associated | relid=0 | w=21
  1181. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> interleukine
    n1=en:contraindications aspect | n2=interleukine | rel=r_associated | relid=0 | w=21
  1182. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> procédure thérapeutique
    n1=en:contraindications aspect | n2=procédure thérapeutique | rel=r_associated | relid=0 | w=21
  1183. en:contraindications aspect -- r_associated #0: 21 / 0.6 -> troponine
    n1=en:contraindications aspect | n2=troponine | rel=r_associated | relid=0 | w=21
  1184. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> 1-acylglycérol-3-phosphate O-acyltransférase
    n1=en:contraindications aspect | n2=1-acylglycérol-3-phosphate O-acyltransférase | rel=r_associated | relid=0 | w=20
  1185. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> 1-méthyl-4-phényl-1,2,3,6-tétrahydropyridine
    n1=en:contraindications aspect | n2=1-méthyl-4-phényl-1,2,3,6-tétrahydropyridine | rel=r_associated | relid=0 | w=20
  1186. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> 2-aminopurine
    n1=en:contraindications aspect | n2=2-aminopurine | rel=r_associated | relid=0 | w=20
  1187. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> 2-isopropylmalate synthase
    n1=en:contraindications aspect | n2=2-isopropylmalate synthase | rel=r_associated | relid=0 | w=20
  1188. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> 3,4-dihydroxyphénylalanine
    n1=en:contraindications aspect | n2=3,4-dihydroxyphénylalanine | rel=r_associated | relid=0 | w=20
  1189. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> 3TC
    n1=en:contraindications aspect | n2=3TC | rel=r_associated | relid=0 | w=20
  1190. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> 5 fluoro-uracile
    n1=en:contraindications aspect | n2=5 fluoro-uracile | rel=r_associated | relid=0 | w=20
  1191. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> 5 FU
    n1=en:contraindications aspect | n2=5 FU | rel=r_associated | relid=0 | w=20
  1192. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> 5'-nucléotidase
    n1=en:contraindications aspect | n2=5'-nucléotidase | rel=r_associated | relid=0 | w=20
  1193. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> abatacept
    n1=en:contraindications aspect | n2=abatacept | rel=r_associated | relid=0 | w=20
  1194. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acarbose
    n1=en:contraindications aspect | n2=acarbose | rel=r_associated | relid=0 | w=20
  1195. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acénocoumarol
    n1=en:contraindications aspect | n2=acénocoumarol | rel=r_associated | relid=0 | w=20
  1196. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acétaminophène
    n1=en:contraindications aspect | n2=acétaminophène | rel=r_associated | relid=0 | w=20
  1197. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acétate de glatiramère
    n1=en:contraindications aspect | n2=acétate de glatiramère | rel=r_associated | relid=0 | w=20
  1198. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acétate de potassium
    n1=en:contraindications aspect | n2=acétate de potassium | rel=r_associated | relid=0 | w=20
  1199. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acétoïne
    n1=en:contraindications aspect | n2=acétoïne | rel=r_associated | relid=0 | w=20
  1200. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acétolactate synthase
    n1=en:contraindications aspect | n2=acétolactate synthase | rel=r_associated | relid=0 | w=20
  1201. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acétyl-CoA C-acétyltransférase
    n1=en:contraindications aspect | n2=acétyl-CoA C-acétyltransférase | rel=r_associated | relid=0 | w=20
  1202. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acétylcystéine
    n1=en:contraindications aspect | n2=acétylcystéine | rel=r_associated | relid=0 | w=20
  1203. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide 3-hydroxy-3-méthylglutarique
    n1=en:contraindications aspect | n2=acide 3-hydroxy-3-méthylglutarique | rel=r_associated | relid=0 | w=20
  1204. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide 3-hydroxyanthranilique
    n1=en:contraindications aspect | n2=acide 3-hydroxyanthranilique | rel=r_associated | relid=0 | w=20
  1205. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide abscissique
    n1=en:contraindications aspect | n2=acide abscissique | rel=r_associated | relid=0 | w=20
  1206. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide aspartique
    n1=en:contraindications aspect | n2=acide aspartique | rel=r_associated | relid=0 | w=20
  1207. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide citrique
    n1=en:contraindications aspect | n2=acide citrique | rel=r_associated | relid=0 | w=20
  1208. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide cystéique
    n1=en:contraindications aspect | n2=acide cystéique | rel=r_associated | relid=0 | w=20
  1209. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide dicarboxylique
    n1=en:contraindications aspect | n2=acide dicarboxylique | rel=r_associated | relid=0 | w=20
  1210. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide gallique
    n1=en:contraindications aspect | n2=acide gallique | rel=r_associated | relid=0 | w=20
  1211. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Acide gallique
    n1=en:contraindications aspect | n2=Acide gallique | rel=r_associated | relid=0 | w=20
  1212. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide glucarique
    n1=en:contraindications aspect | n2=acide glucarique | rel=r_associated | relid=0 | w=20
  1213. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide gras libre
    n1=en:contraindications aspect | n2=acide gras libre | rel=r_associated | relid=0 | w=20
  1214. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide iduronique
    n1=en:contraindications aspect | n2=acide iduronique | rel=r_associated | relid=0 | w=20
  1215. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide kaïnique
    n1=en:contraindications aspect | n2=acide kaïnique | rel=r_associated | relid=0 | w=20
  1216. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide kainique
    n1=en:contraindications aspect | n2=acide kainique | rel=r_associated | relid=0 | w=20
  1217. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Acide lactique
    n1=en:contraindications aspect | n2=Acide lactique | rel=r_associated | relid=0 | w=20
  1218. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide lactique
    n1=en:contraindications aspect | n2=acide lactique | rel=r_associated | relid=0 | w=20
  1219. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide lysergique
    n1=en:contraindications aspect | n2=acide lysergique | rel=r_associated | relid=0 | w=20
  1220. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide nucléique peptidique
    n1=en:contraindications aspect | n2=acide nucléique peptidique | rel=r_associated | relid=0 | w=20
  1221. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide okadaïque
    n1=en:contraindications aspect | n2=acide okadaïque | rel=r_associated | relid=0 | w=20
  1222. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide ophtalmique
    n1=en:contraindications aspect | n2=acide ophtalmique | rel=r_associated | relid=0 | w=20
  1223. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide orotique
    n1=en:contraindications aspect | n2=acide orotique | rel=r_associated | relid=0 | w=20
  1224. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide oxalique
    n1=en:contraindications aspect | n2=acide oxalique | rel=r_associated | relid=0 | w=20
  1225. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Acide oxalique
    n1=en:contraindications aspect | n2=Acide oxalique | rel=r_associated | relid=0 | w=20
  1226. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide pantothénique
    n1=en:contraindications aspect | n2=acide pantothénique | rel=r_associated | relid=0 | w=20
  1227. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide phytique
    n1=en:contraindications aspect | n2=acide phytique | rel=r_associated | relid=0 | w=20
  1228. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide pidolique
    n1=en:contraindications aspect | n2=acide pidolique | rel=r_associated | relid=0 | w=20
  1229. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide pyroglutamique
    n1=en:contraindications aspect | n2=acide pyroglutamique | rel=r_associated | relid=0 | w=20
  1230. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide pyruvique
    n1=en:contraindications aspect | n2=acide pyruvique | rel=r_associated | relid=0 | w=20
  1231. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide ribonucléique
    n1=en:contraindications aspect | n2=acide ribonucléique | rel=r_associated | relid=0 | w=20
  1232. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide shikimique
    n1=en:contraindications aspect | n2=acide shikimique | rel=r_associated | relid=0 | w=20
  1233. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide succinique
    n1=en:contraindications aspect | n2=acide succinique | rel=r_associated | relid=0 | w=20
  1234. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acide tranexamique
    n1=en:contraindications aspect | n2=acide tranexamique | rel=r_associated | relid=0 | w=20
  1235. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acides glutiminiques
    n1=en:contraindications aspect | n2=acides glutiminiques | rel=r_associated | relid=0 | w=20
  1236. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acides gras libres
    n1=en:contraindications aspect | n2=acides gras libres | rel=r_associated | relid=0 | w=20
  1237. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acides gras non estérifiés
    n1=en:contraindications aspect | n2=acides gras non estérifiés | rel=r_associated | relid=0 | w=20
  1238. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acides muramiques
    n1=en:contraindications aspect | n2=acides muramiques | rel=r_associated | relid=0 | w=20
  1239. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acides nicotiniques
    n1=en:contraindications aspect | n2=acides nicotiniques | rel=r_associated | relid=0 | w=20
  1240. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acides phénylpyruviques
    n1=en:contraindications aspect | n2=acides phénylpyruviques | rel=r_associated | relid=0 | w=20
  1241. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acitrétine
    n1=en:contraindications aspect | n2=acitrétine | rel=r_associated | relid=0 | w=20
  1242. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acquaintance
    n1=en:contraindications aspect | n2=acquaintance | rel=r_associated | relid=0 | w=20
  1243. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acridine
    n1=en:contraindications aspect | n2=acridine | rel=r_associated | relid=0 | w=20
  1244. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acrylates
    n1=en:contraindications aspect | n2=acrylates | rel=r_associated | relid=0 | w=20
  1245. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acte médical
    n1=en:contraindications aspect | n2=acte médical | rel=r_associated | relid=0 | w=20
  1246. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Acte médical
    n1=en:contraindications aspect | n2=Acte médical | rel=r_associated | relid=0 | w=20
  1247. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> activateur du plasminogène
    n1=en:contraindications aspect | n2=activateur du plasminogène | rel=r_associated | relid=0 | w=20
  1248. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acupuncture auriculaire
    n1=en:contraindications aspect | n2=acupuncture auriculaire | rel=r_associated | relid=0 | w=20
  1249. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> acyltransférase
    n1=en:contraindications aspect | n2=acyltransférase | rel=r_associated | relid=0 | w=20
  1250. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> adénosylméthionine décarboxylase
    n1=en:contraindications aspect | n2=adénosylméthionine décarboxylase | rel=r_associated | relid=0 | w=20
  1251. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> adénylate cyclase
    n1=en:contraindications aspect | n2=adénylate cyclase | rel=r_associated | relid=0 | w=20
  1252. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Adénylate cyclase
    n1=en:contraindications aspect | n2=Adénylate cyclase | rel=r_associated | relid=0 | w=20
  1253. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> adénylate-cyclase
    n1=en:contraindications aspect | n2=adénylate-cyclase | rel=r_associated | relid=0 | w=20
  1254. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> adiponectine
    n1=en:contraindications aspect | n2=adiponectine | rel=r_associated | relid=0 | w=20
  1255. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> adjuvant immunologique
    n1=en:contraindications aspect | n2=adjuvant immunologique | rel=r_associated | relid=0 | w=20
  1256. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Adjuvant immunologique
    n1=en:contraindications aspect | n2=Adjuvant immunologique | rel=r_associated | relid=0 | w=20
  1257. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ADN bactérien
    n1=en:contraindications aspect | n2=ADN bactérien | rel=r_associated | relid=0 | w=20
  1258. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> adonitol
    n1=en:contraindications aspect | n2=adonitol | rel=r_associated | relid=0 | w=20
  1259. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> adrénodoxine
    n1=en:contraindications aspect | n2=adrénodoxine | rel=r_associated | relid=0 | w=20
  1260. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aedes albopictus
    n1=en:contraindications aspect | n2=aedes albopictus | rel=r_associated | relid=0 | w=20
  1261. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agar
    n1=en:contraindications aspect | n2=agar | rel=r_associated | relid=0 | w=20
  1262. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agar-agar
    n1=en:contraindications aspect | n2=agar-agar | rel=r_associated | relid=0 | w=20
  1263. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agent antidiarrhéique
    n1=en:contraindications aspect | n2=agent antidiarrhéique | rel=r_associated | relid=0 | w=20
  1264. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agent antinéoplasique
    n1=en:contraindications aspect | n2=agent antinéoplasique | rel=r_associated | relid=0 | w=20
  1265. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agent antiviral
    n1=en:contraindications aspect | n2=agent antiviral | rel=r_associated | relid=0 | w=20
  1266. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agent biologique
    n1=en:contraindications aspect | n2=agent biologique | rel=r_associated | relid=0 | w=20
  1267. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agent de contraste
    n1=en:contraindications aspect | n2=agent de contraste | rel=r_associated | relid=0 | w=20
  1268. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agent intercalant
    n1=en:contraindications aspect | n2=agent intercalant | rel=r_associated | relid=0 | w=20
  1269. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agent laxatif
    n1=en:contraindications aspect | n2=agent laxatif | rel=r_associated | relid=0 | w=20
  1270. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agent vasodilatateur
    n1=en:contraindications aspect | n2=agent vasodilatateur | rel=r_associated | relid=0 | w=20
  1271. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agents cariogènes
    n1=en:contraindications aspect | n2=agents cariogènes | rel=r_associated | relid=0 | w=20
  1272. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agents déodorants
    n1=en:contraindications aspect | n2=agents déodorants | rel=r_associated | relid=0 | w=20
  1273. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agents désodorisants
    n1=en:contraindications aspect | n2=agents désodorisants | rel=r_associated | relid=0 | w=20
  1274. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agglutinine
    n1=en:contraindications aspect | n2=agglutinine | rel=r_associated | relid=0 | w=20
  1275. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agoniste dopaminergique
    n1=en:contraindications aspect | n2=agoniste dopaminergique | rel=r_associated | relid=0 | w=20
  1276. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agoniste myelo ablatif
    n1=en:contraindications aspect | n2=agoniste myelo ablatif | rel=r_associated | relid=0 | w=20
  1277. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agonistes myelo ablatifs
    n1=en:contraindications aspect | n2=agonistes myelo ablatifs | rel=r_associated | relid=0 | w=20
  1278. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agonistes myelo-ablatifs
    n1=en:contraindications aspect | n2=agonistes myelo-ablatifs | rel=r_associated | relid=0 | w=20
  1279. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agonistes myélo-ablatifs
    n1=en:contraindications aspect | n2=agonistes myélo-ablatifs | rel=r_associated | relid=0 | w=20
  1280. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agonistes myéloablatifs
    n1=en:contraindications aspect | n2=agonistes myéloablatifs | rel=r_associated | relid=0 | w=20
  1281. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> agonistes purinergiques
    n1=en:contraindications aspect | n2=agonistes purinergiques | rel=r_associated | relid=0 | w=20
  1282. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Air comprimé
    n1=en:contraindications aspect | n2=Air comprimé | rel=r_associated | relid=0 | w=20
  1283. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> air comprimé
    n1=en:contraindications aspect | n2=air comprimé | rel=r_associated | relid=0 | w=20
  1284. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> alanine racémase
    n1=en:contraindications aspect | n2=alanine racémase | rel=r_associated | relid=0 | w=20
  1285. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> albumine bovine sérique
    n1=en:contraindications aspect | n2=albumine bovine sérique | rel=r_associated | relid=0 | w=20
  1286. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> albumine de sérum bovin
    n1=en:contraindications aspect | n2=albumine de sérum bovin | rel=r_associated | relid=0 | w=20
  1287. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> albumine de sérum de boeuf
    n1=en:contraindications aspect | n2=albumine de sérum de boeuf | rel=r_associated | relid=0 | w=20
  1288. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> albumine sérique bovine
    n1=en:contraindications aspect | n2=albumine sérique bovine | rel=r_associated | relid=0 | w=20
  1289. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> albumine sérique radio-iodée
    n1=en:contraindications aspect | n2=albumine sérique radio-iodée | rel=r_associated | relid=0 | w=20
  1290. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> albumine sérique radioiodée
    n1=en:contraindications aspect | n2=albumine sérique radioiodée | rel=r_associated | relid=0 | w=20
  1291. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> alcoylant
    n1=en:contraindications aspect | n2=alcoylant | rel=r_associated | relid=0 | w=20
  1292. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aldicarbe
    n1=en:contraindications aspect | n2=aldicarbe | rel=r_associated | relid=0 | w=20
  1293. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> alginates
    n1=en:contraindications aspect | n2=alginates | rel=r_associated | relid=0 | w=20
  1294. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> alimentation parentérale exclusive
    n1=en:contraindications aspect | n2=alimentation parentérale exclusive | rel=r_associated | relid=0 | w=20
  1295. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> alimentation parentérale totale
    n1=en:contraindications aspect | n2=alimentation parentérale totale | rel=r_associated | relid=0 | w=20
  1296. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aller ensemble
    n1=en:contraindications aspect | n2=aller ensemble | rel=r_associated | relid=0 | w=20
  1297. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> allongement d'un nerf
    n1=en:contraindications aspect | n2=allongement d'un nerf | rel=r_associated | relid=0 | w=20
  1298. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> allongement du nerf
    n1=en:contraindications aspect | n2=allongement du nerf | rel=r_associated | relid=0 | w=20
  1299. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> alpha-amylase
    n1=en:contraindications aspect | n2=alpha-amylase | rel=r_associated | relid=0 | w=20
  1300. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> alvéolectomie
    n1=en:contraindications aspect | n2=alvéolectomie | rel=r_associated | relid=0 | w=20
  1301. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> amifostine
    n1=en:contraindications aspect | n2=amifostine | rel=r_associated | relid=0 | w=20
  1302. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> amino-transférase
    n1=en:contraindications aspect | n2=amino-transférase | rel=r_associated | relid=0 | w=20
  1303. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aminophénols
    n1=en:contraindications aspect | n2=aminophénols | rel=r_associated | relid=0 | w=20
  1304. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aminotransférase
    n1=en:contraindications aspect | n2=aminotransférase | rel=r_associated | relid=0 | w=20
  1305. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> amitriptyline
    n1=en:contraindications aspect | n2=amitriptyline | rel=r_associated | relid=0 | w=20
  1306. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> amitryptyline
    n1=en:contraindications aspect | n2=amitryptyline | rel=r_associated | relid=0 | w=20
  1307. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> amniocentèse
    n1=en:contraindications aspect | n2=amniocentèse | rel=r_associated | relid=0 | w=20
  1308. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> amorces d'adn
    n1=en:contraindications aspect | n2=amorces d'adn | rel=r_associated | relid=0 | w=20
  1309. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> amorceurs d'adn
    n1=en:contraindications aspect | n2=amorceurs d'adn | rel=r_associated | relid=0 | w=20
  1310. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> amputation
    n1=en:contraindications aspect | n2=amputation | rel=r_associated | relid=0 | w=20
  1311. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> analyse en intention de traiter
    n1=en:contraindications aspect | n2=analyse en intention de traiter | rel=r_associated | relid=0 | w=20
  1312. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anaphylatoxines
    n1=en:contraindications aspect | n2=anaphylatoxines | rel=r_associated | relid=0 | w=20
  1313. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anæsthésique
    n1=en:contraindications aspect | n2=anæsthésique | rel=r_associated | relid=0 | w=20
  1314. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> androstanes
    n1=en:contraindications aspect | n2=androstanes | rel=r_associated | relid=0 | w=20
  1315. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anesthésique
    n1=en:contraindications aspect | n2=anesthésique | rel=r_associated | relid=0 | w=20
  1316. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> angéiographie
    n1=en:contraindications aspect | n2=angéiographie | rel=r_associated | relid=0 | w=20
  1317. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> angiocardiographie
    n1=en:contraindications aspect | n2=angiocardiographie | rel=r_associated | relid=0 | w=20
  1318. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> angiocholécystographie
    n1=en:contraindications aspect | n2=angiocholécystographie | rel=r_associated | relid=0 | w=20
  1319. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> angiocholégraphie
    n1=en:contraindications aspect | n2=angiocholégraphie | rel=r_associated | relid=0 | w=20
  1320. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> angiogramme
    n1=en:contraindications aspect | n2=angiogramme | rel=r_associated | relid=0 | w=20
  1321. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> angioscopie
    n1=en:contraindications aspect | n2=angioscopie | rel=r_associated | relid=0 | w=20
  1322. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> angiostatine
    n1=en:contraindications aspect | n2=angiostatine | rel=r_associated | relid=0 | w=20
  1323. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antagoniste adrénergique
    n1=en:contraindications aspect | n2=antagoniste adrénergique | rel=r_associated | relid=0 | w=20
  1324. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antagoniste des morphiniques
    n1=en:contraindications aspect | n2=antagoniste des morphiniques | rel=r_associated | relid=0 | w=20
  1325. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anthracènes
    n1=en:contraindications aspect | n2=anthracènes | rel=r_associated | relid=0 | w=20
  1326. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anthranilate synthase
    n1=en:contraindications aspect | n2=anthranilate synthase | rel=r_associated | relid=0 | w=20
  1327. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anti-coagulant
    n1=en:contraindications aspect | n2=anti-coagulant | rel=r_associated | relid=0 | w=20
  1328. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anti-diarrhéique
    n1=en:contraindications aspect | n2=anti-diarrhéique | rel=r_associated | relid=0 | w=20
  1329. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anti-fongiques
    n1=en:contraindications aspect | n2=anti-fongiques | rel=r_associated | relid=0 | w=20
  1330. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anti-parasitaire
    n1=en:contraindications aspect | n2=anti-parasitaire | rel=r_associated | relid=0 | w=20
  1331. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anti-perspirants
    n1=en:contraindications aspect | n2=anti-perspirants | rel=r_associated | relid=0 | w=20
  1332. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anti-streptolysine
    n1=en:contraindications aspect | n2=anti-streptolysine | rel=r_associated | relid=0 | w=20
  1333. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anti-transpirants
    n1=en:contraindications aspect | n2=anti-transpirants | rel=r_associated | relid=0 | w=20
  1334. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antibiotique antineoplasique
    n1=en:contraindications aspect | n2=antibiotique antineoplasique | rel=r_associated | relid=0 | w=20
  1335. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antibiotique antinéoplasique
    n1=en:contraindications aspect | n2=antibiotique antinéoplasique | rel=r_associated | relid=0 | w=20
  1336. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antibody
    n1=en:contraindications aspect | n2=antibody | rel=r_associated | relid=0 | w=20
  1337. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anticoagulant
    n1=en:contraindications aspect | n2=anticoagulant | rel=r_associated | relid=0 | w=20
  1338. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anticoagulant (médicament)
    n1=en:contraindications aspect | n2=anticoagulant (médicament) | rel=r_associated | relid=0 | w=20
  1339. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anticoagulants oraux directs
    n1=en:contraindications aspect | n2=anticoagulants oraux directs | rel=r_associated | relid=0 | w=20
  1340. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anticodon
    n1=en:contraindications aspect | n2=anticodon | rel=r_associated | relid=0 | w=20
  1341. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anticorps
    n1=en:contraindications aspect | n2=anticorps | rel=r_associated | relid=0 | w=20
  1342. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anticorps monoclonal
    n1=en:contraindications aspect | n2=anticorps monoclonal | rel=r_associated | relid=0 | w=20
  1343. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Anticorps monoclonal
    n1=en:contraindications aspect | n2=Anticorps monoclonal | rel=r_associated | relid=0 | w=20
  1344. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antidiarrhéique
    n1=en:contraindications aspect | n2=antidiarrhéique | rel=r_associated | relid=0 | w=20
  1345. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antienzyme
    n1=en:contraindications aspect | n2=antienzyme | rel=r_associated | relid=0 | w=20
  1346. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antifongique
    n1=en:contraindications aspect | n2=antifongique | rel=r_associated | relid=0 | w=20
  1347. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antifongiques
    n1=en:contraindications aspect | n2=antifongiques | rel=r_associated | relid=0 | w=20
  1348. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antigène
    n1=en:contraindications aspect | n2=antigène | rel=r_associated | relid=0 | w=20
  1349. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antigène de Forssman
    n1=en:contraindications aspect | n2=antigène de Forssman | rel=r_associated | relid=0 | w=20
  1350. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antigène de forssman
    n1=en:contraindications aspect | n2=antigène de forssman | rel=r_associated | relid=0 | w=20
  1351. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antigènes plaquettaires humains
    n1=en:contraindications aspect | n2=antigènes plaquettaires humains | rel=r_associated | relid=0 | w=20
  1352. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antihormone
    n1=en:contraindications aspect | n2=antihormone | rel=r_associated | relid=0 | w=20
  1353. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antimétabolite
    n1=en:contraindications aspect | n2=antimétabolite | rel=r_associated | relid=0 | w=20
  1354. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antiparasitaire
    n1=en:contraindications aspect | n2=antiparasitaire | rel=r_associated | relid=0 | w=20
  1355. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antiperspirants
    n1=en:contraindications aspect | n2=antiperspirants | rel=r_associated | relid=0 | w=20
  1356. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antistreptolysine
    n1=en:contraindications aspect | n2=antistreptolysine | rel=r_associated | relid=0 | w=20
  1357. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> antitranspirants
    n1=en:contraindications aspect | n2=antitranspirants | rel=r_associated | relid=0 | w=20
  1358. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> anus artificiel
    n1=en:contraindications aspect | n2=anus artificiel | rel=r_associated | relid=0 | w=20
  1359. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> AOD et NAOC
    n1=en:contraindications aspect | n2=AOD et NAOC | rel=r_associated | relid=0 | w=20
  1360. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aortographie
    n1=en:contraindications aspect | n2=aortographie | rel=r_associated | relid=0 | w=20
  1361. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> apatites
    n1=en:contraindications aspect | n2=apatites | rel=r_associated | relid=0 | w=20
  1362. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> apexification
    n1=en:contraindications aspect | n2=apexification | rel=r_associated | relid=0 | w=20
  1363. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> apolipoprotéines
    n1=en:contraindications aspect | n2=apolipoprotéines | rel=r_associated | relid=0 | w=20
  1364. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> apoprotéines
    n1=en:contraindications aspect | n2=apoprotéines | rel=r_associated | relid=0 | w=20
  1365. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> appareil dentaire
    n1=en:contraindications aspect | n2=appareil dentaire | rel=r_associated | relid=0 | w=20
  1366. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aquaporine de type 4
    n1=en:contraindications aspect | n2=aquaporine de type 4 | rel=r_associated | relid=0 | w=20
  1367. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> arabinose
    n1=en:contraindications aspect | n2=arabinose | rel=r_associated | relid=0 | w=20
  1368. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> arbutine
    n1=en:contraindications aspect | n2=arbutine | rel=r_associated | relid=0 | w=20
  1369. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ARN ribosomal
    n1=en:contraindications aspect | n2=ARN ribosomal | rel=r_associated | relid=0 | w=20
  1370. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> arn ribosomique
    n1=en:contraindications aspect | n2=arn ribosomique | rel=r_associated | relid=0 | w=20
  1371. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ARN ribosomique
    n1=en:contraindications aspect | n2=ARN ribosomique | rel=r_associated | relid=0 | w=20
  1372. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> arséniates
    n1=en:contraindications aspect | n2=arséniates | rel=r_associated | relid=0 | w=20
  1373. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> arthroplastie
    n1=en:contraindications aspect | n2=arthroplastie | rel=r_associated | relid=0 | w=20
  1374. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aryl sulfonates
    n1=en:contraindications aspect | n2=aryl sulfonates | rel=r_associated | relid=0 | w=20
  1375. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aryl sulfotransférase
    n1=en:contraindications aspect | n2=aryl sulfotransférase | rel=r_associated | relid=0 | w=20
  1376. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> arylsulfatases
    n1=en:contraindications aspect | n2=arylsulfatases | rel=r_associated | relid=0 | w=20
  1377. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> asparaginase
    n1=en:contraindications aspect | n2=asparaginase | rel=r_associated | relid=0 | w=20
  1378. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> astringente
    n1=en:contraindications aspect | n2=astringente | rel=r_associated | relid=0 | w=20
  1379. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aténolol
    n1=en:contraindications aspect | n2=aténolol | rel=r_associated | relid=0 | w=20
  1380. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> atrazine
    n1=en:contraindications aspect | n2=atrazine | rel=r_associated | relid=0 | w=20
  1381. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> auranofine
    n1=en:contraindications aspect | n2=auranofine | rel=r_associated | relid=0 | w=20
  1382. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> auriculothérapie
    n1=en:contraindications aspect | n2=auriculothérapie | rel=r_associated | relid=0 | w=20
  1383. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> aurothioglucose
    n1=en:contraindications aspect | n2=aurothioglucose | rel=r_associated | relid=0 | w=20
  1384. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> auscultation cardiaque
    n1=en:contraindications aspect | n2=auscultation cardiaque | rel=r_associated | relid=0 | w=20
  1385. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> auto-épissage de l'arn ribosomique
    n1=en:contraindications aspect | n2=auto-épissage de l'arn ribosomique | rel=r_associated | relid=0 | w=20
  1386. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> autoépissage de l'arn ribosomal
    n1=en:contraindications aspect | n2=autoépissage de l'arn ribosomal | rel=r_associated | relid=0 | w=20
  1387. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> autoépissage de l'arn ribosomique
    n1=en:contraindications aspect | n2=autoépissage de l'arn ribosomique | rel=r_associated | relid=0 | w=20
  1388. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> axotomie
    n1=en:contraindications aspect | n2=axotomie | rel=r_associated | relid=0 | w=20
  1389. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> azolidines
    n1=en:contraindications aspect | n2=azolidines | rel=r_associated | relid=0 | w=20
  1390. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> æquorine
    n1=en:contraindications aspect | n2=æquorine | rel=r_associated | relid=0 | w=20
  1391. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> baclofen
    n1=en:contraindications aspect | n2=baclofen | rel=r_associated | relid=0 | w=20
  1392. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> baclofène
    n1=en:contraindications aspect | n2=baclofène | rel=r_associated | relid=0 | w=20
  1393. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bactériocine
    n1=en:contraindications aspect | n2=bactériocine | rel=r_associated | relid=0 | w=20
  1394. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bagues
    n1=en:contraindications aspect | n2=bagues | rel=r_associated | relid=0 | w=20
  1395. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bain de dialyse
    n1=en:contraindications aspect | n2=bain de dialyse | rel=r_associated | relid=0 | w=20
  1396. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> balistocardiographie
    n1=en:contraindications aspect | n2=balistocardiographie | rel=r_associated | relid=0 | w=20
  1397. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bandage compressif
    n1=en:contraindications aspect | n2=bandage compressif | rel=r_associated | relid=0 | w=20
  1398. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bande adhésive élastique ace
    n1=en:contraindications aspect | n2=bande adhésive élastique ace | rel=r_associated | relid=0 | w=20
  1399. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bande élastique
    n1=en:contraindications aspect | n2=bande élastique | rel=r_associated | relid=0 | w=20
  1400. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bande Velpeau
    n1=en:contraindications aspect | n2=bande Velpeau | rel=r_associated | relid=0 | w=20
  1401. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bandelettes réactives
    n1=en:contraindications aspect | n2=bandelettes réactives | rel=r_associated | relid=0 | w=20
  1402. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bas de compression
    n1=en:contraindications aspect | n2=bas de compression | rel=r_associated | relid=0 | w=20
  1403. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bas de contention
    n1=en:contraindications aspect | n2=bas de contention | rel=r_associated | relid=0 | w=20
  1404. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Batken (virus)
    n1=en:contraindications aspect | n2=Batken (virus) | rel=r_associated | relid=0 | w=20
  1405. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> batroxobine
    n1=en:contraindications aspect | n2=batroxobine | rel=r_associated | relid=0 | w=20
  1406. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> baumes
    n1=en:contraindications aspect | n2=baumes | rel=r_associated | relid=0 | w=20
  1407. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bed
    n1=en:contraindications aspect | n2=bed | rel=r_associated | relid=0 | w=20
  1408. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> benzaldéhyde
    n1=en:contraindications aspect | n2=benzaldéhyde | rel=r_associated | relid=0 | w=20
  1409. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> benzaldéhydes
    n1=en:contraindications aspect | n2=benzaldéhydes | rel=r_associated | relid=0 | w=20
  1410. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> benzidines
    n1=en:contraindications aspect | n2=benzidines | rel=r_associated | relid=0 | w=20
  1411. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> benzilates
    n1=en:contraindications aspect | n2=benzilates | rel=r_associated | relid=0 | w=20
  1412. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> berbérine
    n1=en:contraindications aspect | n2=berbérine | rel=r_associated | relid=0 | w=20
  1413. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bêta-amylase
    n1=en:contraindications aspect | n2=bêta-amylase | rel=r_associated | relid=0 | w=20
  1414. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bêta-lipoprotéine
    n1=en:contraindications aspect | n2=bêta-lipoprotéine | rel=r_associated | relid=0 | w=20
  1415. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bêtalipoprotéine
    n1=en:contraindications aspect | n2=bêtalipoprotéine | rel=r_associated | relid=0 | w=20
  1416. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> béthanéchol
    n1=en:contraindications aspect | n2=béthanéchol | rel=r_associated | relid=0 | w=20
  1417. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bevacizumab
    n1=en:contraindications aspect | n2=bevacizumab | rel=r_associated | relid=0 | w=20
  1418. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> biguanides
    n1=en:contraindications aspect | n2=biguanides | rel=r_associated | relid=0 | w=20
  1419. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> biligraphie
    n1=en:contraindications aspect | n2=biligraphie | rel=r_associated | relid=0 | w=20
  1420. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bioprothèse
    n1=en:contraindications aspect | n2=bioprothèse | rel=r_associated | relid=0 | w=20
  1421. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> biopsie
    n1=en:contraindications aspect | n2=biopsie | rel=r_associated | relid=0 | w=20
  1422. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> biphosphonate
    n1=en:contraindications aspect | n2=biphosphonate | rel=r_associated | relid=0 | w=20
  1423. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bisphosphoglycérate mutase
    n1=en:contraindications aspect | n2=bisphosphoglycérate mutase | rel=r_associated | relid=0 | w=20
  1424. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> biuret
    n1=en:contraindications aspect | n2=biuret | rel=r_associated | relid=0 | w=20
  1425. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> BKNV
    n1=en:contraindications aspect | n2=BKNV | rel=r_associated | relid=0 | w=20
  1426. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bleu de méthylène
    n1=en:contraindications aspect | n2=bleu de méthylène | rel=r_associated | relid=0 | w=20
  1427. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bleu méthylène
    n1=en:contraindications aspect | n2=bleu méthylène | rel=r_associated | relid=0 | w=20
  1428. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bloquant adrénergique
    n1=en:contraindications aspect | n2=bloquant adrénergique | rel=r_associated | relid=0 | w=20
  1429. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> braces
    n1=en:contraindications aspect | n2=braces | rel=r_associated | relid=0 | w=20
  1430. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bretelles
    n1=en:contraindications aspect | n2=bretelles | rel=r_associated | relid=0 | w=20
  1431. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bronchogramme
    n1=en:contraindications aspect | n2=bronchogramme | rel=r_associated | relid=0 | w=20
  1432. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bronchogramme de contraste
    n1=en:contraindications aspect | n2=bronchogramme de contraste | rel=r_associated | relid=0 | w=20
  1433. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bronchographie
    n1=en:contraindications aspect | n2=bronchographie | rel=r_associated | relid=0 | w=20
  1434. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bronchographies
    n1=en:contraindications aspect | n2=bronchographies | rel=r_associated | relid=0 | w=20
  1435. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bronchoscope
    n1=en:contraindications aspect | n2=bronchoscope | rel=r_associated | relid=0 | w=20
  1436. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bronchoscopie
    n1=en:contraindications aspect | n2=bronchoscopie | rel=r_associated | relid=0 | w=20
  1437. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bronchospirométrie
    n1=en:contraindications aspect | n2=bronchospirométrie | rel=r_associated | relid=0 | w=20
  1438. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> bufoténine
    n1=en:contraindications aspect | n2=bufoténine | rel=r_associated | relid=0 | w=20
  1439. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> busulfan
    n1=en:contraindications aspect | n2=busulfan | rel=r_associated | relid=0 | w=20
  1440. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> butanes
    n1=en:contraindications aspect | n2=butanes | rel=r_associated | relid=0 | w=20
  1441. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> câblage électrique
    n1=en:contraindications aspect | n2=câblage électrique | rel=r_associated | relid=0 | w=20
  1442. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cadhérine
    n1=en:contraindications aspect | n2=cadhérine | rel=r_associated | relid=0 | w=20
  1443. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cadres de marche
    n1=en:contraindications aspect | n2=cadres de marche | rel=r_associated | relid=0 | w=20
  1444. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> caecostomie
    n1=en:contraindications aspect | n2=caecostomie | rel=r_associated | relid=0 | w=20
  1445. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cancer colloïde
    n1=en:contraindications aspect | n2=cancer colloïde | rel=r_associated | relid=0 | w=20
  1446. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cancérigène
    n1=en:contraindications aspect | n2=cancérigène | rel=r_associated | relid=0 | w=20
  1447. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cannabidiol
    n1=en:contraindications aspect | n2=cannabidiol | rel=r_associated | relid=0 | w=20
  1448. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cannabinol
    n1=en:contraindications aspect | n2=cannabinol | rel=r_associated | relid=0 | w=20
  1449. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> canthaxanthine
    n1=en:contraindications aspect | n2=canthaxanthine | rel=r_associated | relid=0 | w=20
  1450. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> caoutchouc naturel
    n1=en:contraindications aspect | n2=caoutchouc naturel | rel=r_associated | relid=0 | w=20
  1451. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> capécitabine
    n1=en:contraindications aspect | n2=capécitabine | rel=r_associated | relid=0 | w=20
  1452. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> capnographie
    n1=en:contraindications aspect | n2=capnographie | rel=r_associated | relid=0 | w=20
  1453. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> capote anglaise
    n1=en:contraindications aspect | n2=capote anglaise | rel=r_associated | relid=0 | w=20
  1454. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> caprolactame
    n1=en:contraindications aspect | n2=caprolactame | rel=r_associated | relid=0 | w=20
  1455. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> capsaïcine
    n1=en:contraindications aspect | n2=capsaïcine | rel=r_associated | relid=0 | w=20
  1456. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> capsaïsine
    n1=en:contraindications aspect | n2=capsaïsine | rel=r_associated | relid=0 | w=20
  1457. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> carbachol
    n1=en:contraindications aspect | n2=carbachol | rel=r_associated | relid=0 | w=20
  1458. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> carbapénèmes
    n1=en:contraindications aspect | n2=carbapénèmes | rel=r_associated | relid=0 | w=20
  1459. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> carbofuran
    n1=en:contraindications aspect | n2=carbofuran | rel=r_associated | relid=0 | w=20
  1460. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> carbohydrate
    n1=en:contraindications aspect | n2=carbohydrate | rel=r_associated | relid=0 | w=20
  1461. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> carbonate de lithium
    n1=en:contraindications aspect | n2=carbonate de lithium | rel=r_associated | relid=0 | w=20
  1462. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> carbonate lithium
    n1=en:contraindications aspect | n2=carbonate lithium | rel=r_associated | relid=0 | w=20
  1463. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> carcinogène
    n1=en:contraindications aspect | n2=carcinogène | rel=r_associated | relid=0 | w=20
  1464. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cardiomyoplastie
    n1=en:contraindications aspect | n2=cardiomyoplastie | rel=r_associated | relid=0 | w=20
  1465. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> carmustine
    n1=en:contraindications aspect | n2=carmustine | rel=r_associated | relid=0 | w=20
  1466. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cartographie
    n1=en:contraindications aspect | n2=cartographie | rel=r_associated | relid=0 | w=20
  1467. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cartographie isotopique
    n1=en:contraindications aspect | n2=cartographie isotopique | rel=r_associated | relid=0 | w=20
  1468. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> caspase 10
    n1=en:contraindications aspect | n2=caspase 10 | rel=r_associated | relid=0 | w=20
  1469. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> caspase 14
    n1=en:contraindications aspect | n2=caspase 14 | rel=r_associated | relid=0 | w=20
  1470. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> CAT-scan
    n1=en:contraindications aspect | n2=CAT-scan | rel=r_associated | relid=0 | w=20
  1471. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> catalase
    n1=en:contraindications aspect | n2=catalase | rel=r_associated | relid=0 | w=20
  1472. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> catgut
    n1=en:contraindications aspect | n2=catgut | rel=r_associated | relid=0 | w=20
  1473. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cathétérisation
    n1=en:contraindications aspect | n2=cathétérisation | rel=r_associated | relid=0 | w=20
  1474. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cathétérisation veineuse centrale
    n1=en:contraindications aspect | n2=cathétérisation veineuse centrale | rel=r_associated | relid=0 | w=20
  1475. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cathétérisme veineux central
    n1=en:contraindications aspect | n2=cathétérisme veineux central | rel=r_associated | relid=0 | w=20
  1476. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cefotiam
    n1=en:contraindications aspect | n2=cefotiam | rel=r_associated | relid=0 | w=20
  1477. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cémentation
    n1=en:contraindications aspect | n2=cémentation | rel=r_associated | relid=0 | w=20
  1478. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> centrifugation
    n1=en:contraindications aspect | n2=centrifugation | rel=r_associated | relid=0 | w=20
  1479. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> céphalométrie
    n1=en:contraindications aspect | n2=céphalométrie | rel=r_associated | relid=0 | w=20
  1480. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> céphalosporinase
    n1=en:contraindications aspect | n2=céphalosporinase | rel=r_associated | relid=0 | w=20
  1481. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> certolizumab pegol
    n1=en:contraindications aspect | n2=certolizumab pegol | rel=r_associated | relid=0 | w=20
  1482. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cervicectomie
    n1=en:contraindications aspect | n2=cervicectomie | rel=r_associated | relid=0 | w=20
  1483. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cétirizine
    n1=en:contraindications aspect | n2=cétirizine | rel=r_associated | relid=0 | w=20
  1484. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cetuximab
    n1=en:contraindications aspect | n2=cetuximab | rel=r_associated | relid=0 | w=20
  1485. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chaîne légère d'immunoglobuline
    n1=en:contraindications aspect | n2=chaîne légère d'immunoglobuline | rel=r_associated | relid=0 | w=20
  1486. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chalcone
    n1=en:contraindications aspect | n2=chalcone | rel=r_associated | relid=0 | w=20
  1487. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chartographie
    n1=en:contraindications aspect | n2=chartographie | rel=r_associated | relid=0 | w=20
  1488. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chélateur
    n1=en:contraindications aspect | n2=chélateur | rel=r_associated | relid=0 | w=20
  1489. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chimique organique
    n1=en:contraindications aspect | n2=chimique organique | rel=r_associated | relid=0 | w=20
  1490. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chirurgie articulaire reconstructrice
    n1=en:contraindications aspect | n2=chirurgie articulaire reconstructrice | rel=r_associated | relid=0 | w=20
  1491. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chirurgie bucco-dentaire et maxillaire
    n1=en:contraindications aspect | n2=chirurgie bucco-dentaire et maxillaire | rel=r_associated | relid=0 | w=20
  1492. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chloramines
    n1=en:contraindications aspect | n2=chloramines | rel=r_associated | relid=0 | w=20
  1493. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlorates
    n1=en:contraindications aspect | n2=chlorates | rel=r_associated | relid=0 | w=20
  1494. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlordécone
    n1=en:contraindications aspect | n2=chlordécone | rel=r_associated | relid=0 | w=20
  1495. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlore
    n1=en:contraindications aspect | n2=chlore | rel=r_associated | relid=0 | w=20
  1496. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlorfenvinphos
    n1=en:contraindications aspect | n2=chlorfenvinphos | rel=r_associated | relid=0 | w=20
  1497. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlorhydrate de péthidine
    n1=en:contraindications aspect | n2=chlorhydrate de péthidine | rel=r_associated | relid=0 | w=20
  1498. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlorine
    n1=en:contraindications aspect | n2=chlorine | rel=r_associated | relid=0 | w=20
  1499. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlorobenzènes
    n1=en:contraindications aspect | n2=chlorobenzènes | rel=r_associated | relid=0 | w=20
  1500. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chloroéthène
    n1=en:contraindications aspect | n2=chloroéthène | rel=r_associated | relid=0 | w=20
  1501. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chloroprène
    n1=en:contraindications aspect | n2=chloroprène | rel=r_associated | relid=0 | w=20
  1502. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlorpyrifos
    n1=en:contraindications aspect | n2=chlorpyrifos | rel=r_associated | relid=0 | w=20
  1503. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlortétracycline
    n1=en:contraindications aspect | n2=chlortétracycline | rel=r_associated | relid=0 | w=20
  1504. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlorure de magnésium
    n1=en:contraindications aspect | n2=chlorure de magnésium | rel=r_associated | relid=0 | w=20
  1505. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Chlorure de potassium
    n1=en:contraindications aspect | n2=Chlorure de potassium | rel=r_associated | relid=0 | w=20
  1506. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chlorure de potassium
    n1=en:contraindications aspect | n2=chlorure de potassium | rel=r_associated | relid=0 | w=20
  1507. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Chola
    n1=en:contraindications aspect | n2=Chola | rel=r_associated | relid=0 | w=20
  1508. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cholangio
    n1=en:contraindications aspect | n2=cholangio | rel=r_associated | relid=0 | w=20
  1509. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cholangiographie
    n1=en:contraindications aspect | n2=cholangiographie | rel=r_associated | relid=0 | w=20
  1510. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cholangiographies
    n1=en:contraindications aspect | n2=cholangiographies | rel=r_associated | relid=0 | w=20
  1511. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cholangiopancréatographie rétrograde
    n1=en:contraindications aspect | n2=cholangiopancréatographie rétrograde | rel=r_associated | relid=0 | w=20
  1512. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cholangiopancréatographie rétrograde endoscopique
    n1=en:contraindications aspect | n2=cholangiopancréatographie rétrograde endoscopique | rel=r_associated | relid=0 | w=20
  1513. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cholécystectomie
    n1=en:contraindications aspect | n2=cholécystectomie | rel=r_associated | relid=0 | w=20
  1514. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cholécystographie
    n1=en:contraindications aspect | n2=cholécystographie | rel=r_associated | relid=0 | w=20
  1515. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cholécystostomie
    n1=en:contraindications aspect | n2=cholécystostomie | rel=r_associated | relid=0 | w=20
  1516. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cholécystotomie
    n1=en:contraindications aspect | n2=cholécystotomie | rel=r_associated | relid=0 | w=20
  1517. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chondro-4-sulfatase
    n1=en:contraindications aspect | n2=chondro-4-sulfatase | rel=r_associated | relid=0 | w=20
  1518. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chordotomie
    n1=en:contraindications aspect | n2=chordotomie | rel=r_associated | relid=0 | w=20
  1519. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chordotomie spinale
    n1=en:contraindications aspect | n2=chordotomie spinale | rel=r_associated | relid=0 | w=20
  1520. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chromogranine
    n1=en:contraindications aspect | n2=chromogranine | rel=r_associated | relid=0 | w=20
  1521. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> chymotrypsine
    n1=en:contraindications aspect | n2=chymotrypsine | rel=r_associated | relid=0 | w=20
  1522. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cimentation
    n1=en:contraindications aspect | n2=cimentation | rel=r_associated | relid=0 | w=20
  1523. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cimentoplastie
    n1=en:contraindications aspect | n2=cimentoplastie | rel=r_associated | relid=0 | w=20
  1524. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cimétidine
    n1=en:contraindications aspect | n2=cimétidine | rel=r_associated | relid=0 | w=20
  1525. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cinéangiographie
    n1=en:contraindications aspect | n2=cinéangiographie | rel=r_associated | relid=0 | w=20
  1526. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cis-diaminedichloroplatine
    n1=en:contraindications aspect | n2=cis-diaminedichloroplatine | rel=r_associated | relid=0 | w=20
  1527. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cisplatine
    n1=en:contraindications aspect | n2=cisplatine | rel=r_associated | relid=0 | w=20
  1528. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> citrulline
    n1=en:contraindications aspect | n2=citrulline | rel=r_associated | relid=0 | w=20
  1529. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clarithromycine
    n1=en:contraindications aspect | n2=clarithromycine | rel=r_associated | relid=0 | w=20
  1530. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clé à fourche
    n1=en:contraindications aspect | n2=clé à fourche | rel=r_associated | relid=0 | w=20
  1531. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clé à fourches
    n1=en:contraindications aspect | n2=clé à fourches | rel=r_associated | relid=0 | w=20
  1532. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clé ouverte
    n1=en:contraindications aspect | n2=clé ouverte | rel=r_associated | relid=0 | w=20
  1533. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clef
    n1=en:contraindications aspect | n2=clef | rel=r_associated | relid=0 | w=20
  1534. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clef à fourche
    n1=en:contraindications aspect | n2=clef à fourche | rel=r_associated | relid=0 | w=20
  1535. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clef à fourches
    n1=en:contraindications aspect | n2=clef à fourches | rel=r_associated | relid=0 | w=20
  1536. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clef ouverte
    n1=en:contraindications aspect | n2=clef ouverte | rel=r_associated | relid=0 | w=20
  1537. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clofazimine
    n1=en:contraindications aspect | n2=clofazimine | rel=r_associated | relid=0 | w=20
  1538. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> clopidol
    n1=en:contraindications aspect | n2=clopidol | rel=r_associated | relid=0 | w=20
  1539. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cobalamine
    n1=en:contraindications aspect | n2=cobalamine | rel=r_associated | relid=0 | w=20
  1540. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> codéine
    n1=en:contraindications aspect | n2=codéine | rel=r_associated | relid=0 | w=20
  1541. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> codéïne
    n1=en:contraindications aspect | n2=codéïne | rel=r_associated | relid=0 | w=20
  1542. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> codon
    n1=en:contraindications aspect | n2=codon | rel=r_associated | relid=0 | w=20
  1543. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> colectomie
    n1=en:contraindications aspect | n2=colectomie | rel=r_associated | relid=0 | w=20
  1544. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> collagénase
    n1=en:contraindications aspect | n2=collagénase | rel=r_associated | relid=0 | w=20
  1545. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> colloid
    n1=en:contraindications aspect | n2=colloid | rel=r_associated | relid=0 | w=20
  1546. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> colloïdal
    n1=en:contraindications aspect | n2=colloïdal | rel=r_associated | relid=0 | w=20
  1547. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> colonoscope
    n1=en:contraindications aspect | n2=colonoscope | rel=r_associated | relid=0 | w=20
  1548. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> colostomie
    n1=en:contraindications aspect | n2=colostomie | rel=r_associated | relid=0 | w=20
  1549. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> colposcope
    n1=en:contraindications aspect | n2=colposcope | rel=r_associated | relid=0 | w=20
  1550. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> colposcopie
    n1=en:contraindications aspect | n2=colposcopie | rel=r_associated | relid=0 | w=20
  1551. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> colpotomie
    n1=en:contraindications aspect | n2=colpotomie | rel=r_associated | relid=0 | w=20
  1552. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> composé chimique organique
    n1=en:contraindications aspect | n2=composé chimique organique | rel=r_associated | relid=0 | w=20
  1553. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> composé de cadmium
    n1=en:contraindications aspect | n2=composé de cadmium | rel=r_associated | relid=0 | w=20
  1554. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> composés d'ammonium quaternaire
    n1=en:contraindications aspect | n2=composés d'ammonium quaternaire | rel=r_associated | relid=0 | w=20
  1555. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> composés de l'aniline
    n1=en:contraindications aspect | n2=composés de l'aniline | rel=r_associated | relid=0 | w=20
  1556. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> computed tomography
    n1=en:contraindications aspect | n2=computed tomography | rel=r_associated | relid=0 | w=20
  1557. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> condom
    n1=en:contraindications aspect | n2=condom | rel=r_associated | relid=0 | w=20
  1558. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> conisation
    n1=en:contraindications aspect | n2=conisation | rel=r_associated | relid=0 | w=20
  1559. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> connexions
    n1=en:contraindications aspect | n2=connexions | rel=r_associated | relid=0 | w=20
  1560. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> contraceptif oral
    n1=en:contraindications aspect | n2=contraceptif oral | rel=r_associated | relid=0 | w=20
  1561. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> contraception orale
    n1=en:contraindications aspect | n2=contraception orale | rel=r_associated | relid=0 | w=20
  1562. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> contre-argument
    n1=en:contraindications aspect | n2=contre-argument | rel=r_associated | relid=0 | w=20
  1563. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> contre-indication
    n1=en:contraindications aspect | n2=contre-indication | rel=r_associated | relid=0 | w=20
  1564. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> contrepulsion diastolique intra-aortique
    n1=en:contraindications aspect | n2=contrepulsion diastolique intra-aortique | rel=r_associated | relid=0 | w=20
  1565. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> contrepulsion diastolique intraaortique
    n1=en:contraindications aspect | n2=contrepulsion diastolique intraaortique | rel=r_associated | relid=0 | w=20
  1566. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> contrindication
    n1=en:contraindications aspect | n2=contrindication | rel=r_associated | relid=0 | w=20
  1567. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cordotomie
    n1=en:contraindications aspect | n2=cordotomie | rel=r_associated | relid=0 | w=20
  1568. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cordotomie spinale
    n1=en:contraindications aspect | n2=cordotomie spinale | rel=r_associated | relid=0 | w=20
  1569. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> corticostérone
    n1=en:contraindications aspect | n2=corticostérone | rel=r_associated | relid=0 | w=20
  1570. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cortisol
    n1=en:contraindications aspect | n2=cortisol | rel=r_associated | relid=0 | w=20
  1571. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> couches pour adulte incontinent
    n1=en:contraindications aspect | n2=couches pour adulte incontinent | rel=r_associated | relid=0 | w=20
  1572. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> couches pour incontinents
    n1=en:contraindications aspect | n2=couches pour incontinents | rel=r_associated | relid=0 | w=20
  1573. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> coumaphène
    n1=en:contraindications aspect | n2=coumaphène | rel=r_associated | relid=0 | w=20
  1574. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cow-pox
    n1=en:contraindications aspect | n2=cow-pox | rel=r_associated | relid=0 | w=20
  1575. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cowpox
    n1=en:contraindications aspect | n2=cowpox | rel=r_associated | relid=0 | w=20
  1576. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> craniométrie
    n1=en:contraindications aspect | n2=craniométrie | rel=r_associated | relid=0 | w=20
  1577. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cryoanesthésie
    n1=en:contraindications aspect | n2=cryoanesthésie | rel=r_associated | relid=0 | w=20
  1578. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cryochirurgie
    n1=en:contraindications aspect | n2=cryochirurgie | rel=r_associated | relid=0 | w=20
  1579. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cryoglobuline
    n1=en:contraindications aspect | n2=cryoglobuline | rel=r_associated | relid=0 | w=20
  1580. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> CT
    n1=en:contraindications aspect | n2=CT | rel=r_associated | relid=0 | w=20
  1581. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> CT scan
    n1=en:contraindications aspect | n2=CT scan | rel=r_associated | relid=0 | w=20
  1582. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> CT-scan
    n1=en:contraindications aspect | n2=CT-scan | rel=r_associated | relid=0 | w=20
  1583. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> culdoscopie
    n1=en:contraindications aspect | n2=culdoscopie | rel=r_associated | relid=0 | w=20
  1584. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> curcumine
    n1=en:contraindications aspect | n2=curcumine | rel=r_associated | relid=0 | w=20
  1585. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cure thermale
    n1=en:contraindications aspect | n2=cure thermale | rel=r_associated | relid=0 | w=20
  1586. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cuti
    n1=en:contraindications aspect | n2=cuti | rel=r_associated | relid=0 | w=20
  1587. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cuti-réaction
    n1=en:contraindications aspect | n2=cuti-réaction | rel=r_associated | relid=0 | w=20
  1588. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> CVC
    n1=en:contraindications aspect | n2=CVC | rel=r_associated | relid=0 | w=20
  1589. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cyclitols
    n1=en:contraindications aspect | n2=cyclitols | rel=r_associated | relid=0 | w=20
  1590. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cyclobutanes
    n1=en:contraindications aspect | n2=cyclobutanes | rel=r_associated | relid=0 | w=20
  1591. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cycloleucine
    n1=en:contraindications aspect | n2=cycloleucine | rel=r_associated | relid=0 | w=20
  1592. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cyclooxygenase 2
    n1=en:contraindications aspect | n2=cyclooxygenase 2 | rel=r_associated | relid=0 | w=20
  1593. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cyclophosphamide
    n1=en:contraindications aspect | n2=cyclophosphamide | rel=r_associated | relid=0 | w=20
  1594. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cymarine
    n1=en:contraindications aspect | n2=cymarine | rel=r_associated | relid=0 | w=20
  1595. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cyprotérone
    n1=en:contraindications aspect | n2=cyprotérone | rel=r_associated | relid=0 | w=20
  1596. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cystathionine bêta-synthase
    n1=en:contraindications aspect | n2=cystathionine bêta-synthase | rel=r_associated | relid=0 | w=20
  1597. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cystectomie
    n1=en:contraindications aspect | n2=cystectomie | rel=r_associated | relid=0 | w=20
  1598. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cystéine synthase
    n1=en:contraindications aspect | n2=cystéine synthase | rel=r_associated | relid=0 | w=20
  1599. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cystoscope
    n1=en:contraindications aspect | n2=cystoscope | rel=r_associated | relid=0 | w=20
  1600. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cystostomie
    n1=en:contraindications aspect | n2=cystostomie | rel=r_associated | relid=0 | w=20
  1601. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cystotomie
    n1=en:contraindications aspect | n2=cystotomie | rel=r_associated | relid=0 | w=20
  1602. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cytidine triphosphate
    n1=en:contraindications aspect | n2=cytidine triphosphate | rel=r_associated | relid=0 | w=20
  1603. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cytochrome a
    n1=en:contraindications aspect | n2=cytochrome a | rel=r_associated | relid=0 | w=20
  1604. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cytochrome a et a3
    n1=en:contraindications aspect | n2=cytochrome a et a3 | rel=r_associated | relid=0 | w=20
  1605. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cytochrome b6f
    n1=en:contraindications aspect | n2=cytochrome b6f | rel=r_associated | relid=0 | w=20
  1606. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cytochrome c1
    n1=en:contraindications aspect | n2=cytochrome c1 | rel=r_associated | relid=0 | w=20
  1607. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cytochromes b
    n1=en:contraindications aspect | n2=cytochromes b | rel=r_associated | relid=0 | w=20
  1608. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cytochromes b5
    n1=en:contraindications aspect | n2=cytochromes b5 | rel=r_associated | relid=0 | w=20
  1609. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cytochromes c'
    n1=en:contraindications aspect | n2=cytochromes c' | rel=r_associated | relid=0 | w=20
  1610. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> cytochromes de type d
    n1=en:contraindications aspect | n2=cytochromes de type d | rel=r_associated | relid=0 | w=20
  1611. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dacryocysto-rhinostomie
    n1=en:contraindications aspect | n2=dacryocysto-rhinostomie | rel=r_associated | relid=0 | w=20
  1612. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dacryocystorhinostomie
    n1=en:contraindications aspect | n2=dacryocystorhinostomie | rel=r_associated | relid=0 | w=20
  1613. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dactinomycine
    n1=en:contraindications aspect | n2=dactinomycine | rel=r_associated | relid=0 | w=20
  1614. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dapsone
    n1=en:contraindications aspect | n2=dapsone | rel=r_associated | relid=0 | w=20
  1615. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dasatinib
    n1=en:contraindications aspect | n2=dasatinib | rel=r_associated | relid=0 | w=20
  1616. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> daunorubicine
    n1=en:contraindications aspect | n2=daunorubicine | rel=r_associated | relid=0 | w=20
  1617. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> de mercure
    n1=en:contraindications aspect | n2=de mercure | rel=r_associated | relid=0 | w=20
  1618. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> débridement
    n1=en:contraindications aspect | n2=débridement | rel=r_associated | relid=0 | w=20
  1619. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> défécographie
    n1=en:contraindications aspect | n2=défécographie | rel=r_associated | relid=0 | w=20
  1620. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> défibrillateurs
    n1=en:contraindications aspect | n2=défibrillateurs | rel=r_associated | relid=0 | w=20
  1621. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> delavirdine
    n1=en:contraindications aspect | n2=delavirdine | rel=r_associated | relid=0 | w=20
  1622. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> déméclocycline
    n1=en:contraindications aspect | n2=déméclocycline | rel=r_associated | relid=0 | w=20
  1623. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dentier
    n1=en:contraindications aspect | n2=dentier | rel=r_associated | relid=0 | w=20
  1624. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dentifrice
    n1=en:contraindications aspect | n2=dentifrice | rel=r_associated | relid=0 | w=20
  1625. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dentifrices
    n1=en:contraindications aspect | n2=dentifrices | rel=r_associated | relid=0 | w=20
  1626. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dentures
    n1=en:contraindications aspect | n2=dentures | rel=r_associated | relid=0 | w=20
  1627. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> déodorants
    n1=en:contraindications aspect | n2=déodorants | rel=r_associated | relid=0 | w=20
  1628. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dérivés de l'aniline
    n1=en:contraindications aspect | n2=dérivés de l'aniline | rel=r_associated | relid=0 | w=20
  1629. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dermoscopie
    n1=en:contraindications aspect | n2=dermoscopie | rel=r_associated | relid=0 | w=20
  1630. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> déroulase
    n1=en:contraindications aspect | n2=déroulase | rel=r_associated | relid=0 | w=20
  1631. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> desmogléine II
    n1=en:contraindications aspect | n2=desmogléine II | rel=r_associated | relid=0 | w=20
  1632. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> desmostérol
    n1=en:contraindications aspect | n2=desmostérol | rel=r_associated | relid=0 | w=20
  1633. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> désodorisants
    n1=en:contraindications aspect | n2=désodorisants | rel=r_associated | relid=0 | w=20
  1634. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> désoximétasone
    n1=en:contraindications aspect | n2=désoximétasone | rel=r_associated | relid=0 | w=20
  1635. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> désoxyribonucléase
    n1=en:contraindications aspect | n2=désoxyribonucléase | rel=r_associated | relid=0 | w=20
  1636. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> désoxyribonucléoprotéines
    n1=en:contraindications aspect | n2=désoxyribonucléoprotéines | rel=r_associated | relid=0 | w=20
  1637. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> désoxyribose
    n1=en:contraindications aspect | n2=désoxyribose | rel=r_associated | relid=0 | w=20
  1638. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> détermination de la pression artérielle
    n1=en:contraindications aspect | n2=détermination de la pression artérielle | rel=r_associated | relid=0 | w=20
  1639. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> détersion
    n1=en:contraindications aspect | n2=détersion | rel=r_associated | relid=0 | w=20
  1640. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dextrométhorphane
    n1=en:contraindications aspect | n2=dextrométhorphane | rel=r_associated | relid=0 | w=20
  1641. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dextrorphane
    n1=en:contraindications aspect | n2=dextrorphane | rel=r_associated | relid=0 | w=20
  1642. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diacylglycérol O-acyltransférase
    n1=en:contraindications aspect | n2=diacylglycérol O-acyltransférase | rel=r_associated | relid=0 | w=20
  1643. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diagnostic pré-implantatoire
    n1=en:contraindications aspect | n2=diagnostic pré-implantatoire | rel=r_associated | relid=0 | w=20
  1644. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diagnostic préimplantatoire
    n1=en:contraindications aspect | n2=diagnostic préimplantatoire | rel=r_associated | relid=0 | w=20
  1645. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diamanté
    n1=en:contraindications aspect | n2=diamanté | rel=r_associated | relid=0 | w=20
  1646. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diamond
    n1=en:contraindications aspect | n2=diamond | rel=r_associated | relid=0 | w=20
  1647. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diathermie
    n1=en:contraindications aspect | n2=diathermie | rel=r_associated | relid=0 | w=20
  1648. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diazinon
    n1=en:contraindications aspect | n2=diazinon | rel=r_associated | relid=0 | w=20
  1649. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diazométhane
    n1=en:contraindications aspect | n2=diazométhane | rel=r_associated | relid=0 | w=20
  1650. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dichlorodiphényldichloroéthane
    n1=en:contraindications aspect | n2=dichlorodiphényldichloroéthane | rel=r_associated | relid=0 | w=20
  1651. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diclofénac
    n1=en:contraindications aspect | n2=diclofénac | rel=r_associated | relid=0 | w=20
  1652. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dicofol
    n1=en:contraindications aspect | n2=dicofol | rel=r_associated | relid=0 | w=20
  1653. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dicumarol
    n1=en:contraindications aspect | n2=dicumarol | rel=r_associated | relid=0 | w=20
  1654. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diénestrol
    n1=en:contraindications aspect | n2=diénestrol | rel=r_associated | relid=0 | w=20
  1655. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diéthylstilbestrol
    n1=en:contraindications aspect | n2=diéthylstilbestrol | rel=r_associated | relid=0 | w=20
  1656. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diéthylstilboestrol
    n1=en:contraindications aspect | n2=diéthylstilboestrol | rel=r_associated | relid=0 | w=20
  1657. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diflubenzuron
    n1=en:contraindications aspect | n2=diflubenzuron | rel=r_associated | relid=0 | w=20
  1658. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> digitoxine
    n1=en:contraindications aspect | n2=digitoxine | rel=r_associated | relid=0 | w=20
  1659. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diglycérides
    n1=en:contraindications aspect | n2=diglycérides | rel=r_associated | relid=0 | w=20
  1660. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> digoxigénine
    n1=en:contraindications aspect | n2=digoxigénine | rel=r_associated | relid=0 | w=20
  1661. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Digue dentaire
    n1=en:contraindications aspect | n2=Digue dentaire | rel=r_associated | relid=0 | w=20
  1662. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> digue dentaire
    n1=en:contraindications aspect | n2=digue dentaire | rel=r_associated | relid=0 | w=20
  1663. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dihydroergocornine
    n1=en:contraindications aspect | n2=dihydroergocornine | rel=r_associated | relid=0 | w=20
  1664. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diméthoate
    n1=en:contraindications aspect | n2=diméthoate | rel=r_associated | relid=0 | w=20
  1665. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dinoprostone
    n1=en:contraindications aspect | n2=dinoprostone | rel=r_associated | relid=0 | w=20
  1666. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dioxanes
    n1=en:contraindications aspect | n2=dioxanes | rel=r_associated | relid=0 | w=20
  1667. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dipeptidases
    n1=en:contraindications aspect | n2=dipeptidases | rel=r_associated | relid=0 | w=20
  1668. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diphenhydramine
    n1=en:contraindications aspect | n2=diphenhydramine | rel=r_associated | relid=0 | w=20
  1669. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diphénhydramine
    n1=en:contraindications aspect | n2=diphénhydramine | rel=r_associated | relid=0 | w=20
  1670. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diphénoxylate
    n1=en:contraindications aspect | n2=diphénoxylate | rel=r_associated | relid=0 | w=20
  1671. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diphosphoglycérate-mutase
    n1=en:contraindications aspect | n2=diphosphoglycérate-mutase | rel=r_associated | relid=0 | w=20
  1672. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diphosphonate
    n1=en:contraindications aspect | n2=diphosphonate | rel=r_associated | relid=0 | w=20
  1673. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diquat
    n1=en:contraindications aspect | n2=diquat | rel=r_associated | relid=0 | w=20
  1674. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> disopyramide
    n1=en:contraindications aspect | n2=disopyramide | rel=r_associated | relid=0 | w=20
  1675. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> disopyramide n. m
    n1=en:contraindications aspect | n2=disopyramide n. m | rel=r_associated | relid=0 | w=20
  1676. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dispositif intra-utérin
    n1=en:contraindications aspect | n2=dispositif intra-utérin | rel=r_associated | relid=0 | w=20
  1677. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> disulfoton
    n1=en:contraindications aspect | n2=disulfoton | rel=r_associated | relid=0 | w=20
  1678. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dithionite
    n1=en:contraindications aspect | n2=dithionite | rel=r_associated | relid=0 | w=20
  1679. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> DIU
    (dispositif intra-utérin)
    n1=en:contraindications aspect | n2=DIU
    (dispositif intra-utérin)
    | rel=r_associated | relid=0 | w=20
  1680. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diurétique osmotique
    n1=en:contraindications aspect | n2=diurétique osmotique | rel=r_associated | relid=0 | w=20
  1681. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> diuron
    n1=en:contraindications aspect | n2=diuron | rel=r_associated | relid=0 | w=20
  1682. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dna glycosylase
    n1=en:contraindications aspect | n2=dna glycosylase | rel=r_associated | relid=0 | w=20
  1683. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dna polymerase ii
    n1=en:contraindications aspect | n2=dna polymerase ii | rel=r_associated | relid=0 | w=20
  1684. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dobutamine
    n1=en:contraindications aspect | n2=dobutamine | rel=r_associated | relid=0 | w=20
  1685. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dolichol monophosphate mannose
    n1=en:contraindications aspect | n2=dolichol monophosphate mannose | rel=r_associated | relid=0 | w=20
  1686. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dopa-décarboxylase
    n1=en:contraindications aspect | n2=dopa-décarboxylase | rel=r_associated | relid=0 | w=20
  1687. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dopathérapie
    n1=en:contraindications aspect | n2=dopathérapie | rel=r_associated | relid=0 | w=20
  1688. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> doppler transcrânien
    n1=en:contraindications aspect | n2=doppler transcrânien | rel=r_associated | relid=0 | w=20
  1689. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> douche nasale
    n1=en:contraindications aspect | n2=douche nasale | rel=r_associated | relid=0 | w=20
  1690. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> dpi
    n1=en:contraindications aspect | n2=dpi | rel=r_associated | relid=0 | w=20
  1691. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> duodénojéjunal (angle)
    n1=en:contraindications aspect | n2=duodénojéjunal (angle) | rel=r_associated | relid=0 | w=20
  1692. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> duodénoscopie
    n1=en:contraindications aspect | n2=duodénoscopie | rel=r_associated | relid=0 | w=20
  1693. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> duodénostomie
    n1=en:contraindications aspect | n2=duodénostomie | rel=r_associated | relid=0 | w=20
  1694. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E100
    n1=en:contraindications aspect | n2=E100 | rel=r_associated | relid=0 | w=20
  1695. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E100(i)
    n1=en:contraindications aspect | n2=E100(i) | rel=r_associated | relid=0 | w=20
  1696. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E1521
    n1=en:contraindications aspect | n2=E1521 | rel=r_associated | relid=0 | w=20
  1697. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E161g
    n1=en:contraindications aspect | n2=E161g | rel=r_associated | relid=0 | w=20
  1698. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E240
    n1=en:contraindications aspect | n2=E240 | rel=r_associated | relid=0 | w=20
  1699. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E261
    n1=en:contraindications aspect | n2=E261 | rel=r_associated | relid=0 | w=20
  1700. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E261(i)
    n1=en:contraindications aspect | n2=E261(i) | rel=r_associated | relid=0 | w=20
  1701. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E270
    n1=en:contraindications aspect | n2=E270 | rel=r_associated | relid=0 | w=20
  1702. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E330
    n1=en:contraindications aspect | n2=E330 | rel=r_associated | relid=0 | w=20
  1703. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E391
    n1=en:contraindications aspect | n2=E391 | rel=r_associated | relid=0 | w=20
  1704. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E406
    n1=en:contraindications aspect | n2=E406 | rel=r_associated | relid=0 | w=20
  1705. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E420(i)
    n1=en:contraindications aspect | n2=E420(i) | rel=r_associated | relid=0 | w=20
  1706. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E452
    n1=en:contraindications aspect | n2=E452 | rel=r_associated | relid=0 | w=20
  1707. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E508
    n1=en:contraindications aspect | n2=E508 | rel=r_associated | relid=0 | w=20
  1708. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E553(iii)
    n1=en:contraindications aspect | n2=E553(iii) | rel=r_associated | relid=0 | w=20
  1709. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E621
    n1=en:contraindications aspect | n2=E621 | rel=r_associated | relid=0 | w=20
  1710. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> E954(i)
    n1=en:contraindications aspect | n2=E954(i) | rel=r_associated | relid=0 | w=20
  1711. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ECC
    n1=en:contraindications aspect | n2=ECC | rel=r_associated | relid=0 | w=20
  1712. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> échinomycine
    n1=en:contraindications aspect | n2=échinomycine | rel=r_associated | relid=0 | w=20
  1713. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> échocardiographie
    n1=en:contraindications aspect | n2=échocardiographie | rel=r_associated | relid=0 | w=20
  1714. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> échocardiographie par voie transoesophagienne
    n1=en:contraindications aspect | n2=échocardiographie par voie transoesophagienne | rel=r_associated | relid=0 | w=20
  1715. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> échodoppler cardiaque
    n1=en:contraindications aspect | n2=échodoppler cardiaque | rel=r_associated | relid=0 | w=20
  1716. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> échographie cardiaque
    n1=en:contraindications aspect | n2=échographie cardiaque | rel=r_associated | relid=0 | w=20
  1717. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ECLS
    n1=en:contraindications aspect | n2=ECLS | rel=r_associated | relid=0 | w=20
  1718. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Électrode
    n1=en:contraindications aspect | n2=Électrode | rel=r_associated | relid=0 | w=20
  1719. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> électrode
    n1=en:contraindications aspect | n2=électrode | rel=r_associated | relid=0 | w=20
  1720. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> électronarcose
    n1=en:contraindications aspect | n2=électronarcose | rel=r_associated | relid=0 | w=20
  1721. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> électronystagmographie
    n1=en:contraindications aspect | n2=électronystagmographie | rel=r_associated | relid=0 | w=20
  1722. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> embolisation thérapeutique
    n1=en:contraindications aspect | n2=embolisation thérapeutique | rel=r_associated | relid=0 | w=20
  1723. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> émétine
    n1=en:contraindications aspect | n2=émétine | rel=r_associated | relid=0 | w=20
  1724. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> emtricitabine
    n1=en:contraindications aspect | n2=emtricitabine | rel=r_associated | relid=0 | w=20
  1725. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en diamant
    n1=en:contraindications aspect | n2=en diamant | rel=r_associated | relid=0 | w=20
  1726. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:1-acylglycerol-3-phosphate o-acyltransferase
    n1=en:contraindications aspect | n2=en:1-acylglycerol-3-phosphate o-acyltransferase | rel=r_associated | relid=0 | w=20
  1727. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:1-acylglycerophosphocholine o-acyltransferase
    n1=en:contraindications aspect | n2=en:1-acylglycerophosphocholine o-acyltransferase | rel=r_associated | relid=0 | w=20
  1728. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:1-carboxyglutamic acid
    n1=en:contraindications aspect | n2=en:1-carboxyglutamic acid | rel=r_associated | relid=0 | w=20
  1729. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
    n1=en:contraindications aspect | n2=en:1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | rel=r_associated | relid=0 | w=20
  1730. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:1-naphthylamine
    n1=en:contraindications aspect | n2=en:1-naphthylamine | rel=r_associated | relid=0 | w=20
  1731. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:1-propanol
    n1=en:contraindications aspect | n2=en:1-propanol | rel=r_associated | relid=0 | w=20
  1732. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:1,25-dihydroxyvitamin d(3) 24-hydroxylase, mitochondrial
    n1=en:contraindications aspect | n2=en:1,25-dihydroxyvitamin d(3) 24-hydroxylase, mitochondrial | rel=r_associated | relid=0 | w=20
  1733. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:11 epicortisol
    n1=en:contraindications aspect | n2=en:11 epicortisol | rel=r_associated | relid=0 | w=20
  1734. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:11-beta-hydroxysteroid dehydrogenase type 1
    n1=en:contraindications aspect | n2=en:11-beta-hydroxysteroid dehydrogenase type 1 | rel=r_associated | relid=0 | w=20
  1735. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:11-beta-hydroxysteroid dehydrogenase type 2
    n1=en:contraindications aspect | n2=en:11-beta-hydroxysteroid dehydrogenase type 2 | rel=r_associated | relid=0 | w=20
  1736. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:11-hydroxycorticosteroids
    n1=en:contraindications aspect | n2=en:11-hydroxycorticosteroids | rel=r_associated | relid=0 | w=20
  1737. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:17-hydroxycorticosteroids
    n1=en:contraindications aspect | n2=en:17-hydroxycorticosteroids | rel=r_associated | relid=0 | w=20
  1738. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:17-hydroxycorticosterone
    n1=en:contraindications aspect | n2=en:17-hydroxycorticosterone | rel=r_associated | relid=0 | w=20
  1739. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:17-hydroxysteroid dehydrogenases
    n1=en:contraindications aspect | n2=en:17-hydroxysteroid dehydrogenases | rel=r_associated | relid=0 | w=20
  1740. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:17-ketosteroids
    n1=en:contraindications aspect | n2=en:17-ketosteroids | rel=r_associated | relid=0 | w=20
  1741. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:18-hydroxycorticosterone
    n1=en:contraindications aspect | n2=en:18-hydroxycorticosterone | rel=r_associated | relid=0 | w=20
  1742. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:18-hydroxydesoxycorticosterone
    n1=en:contraindications aspect | n2=en:18-hydroxydesoxycorticosterone | rel=r_associated | relid=0 | w=20
  1743. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:19-iodocholesterol
    n1=en:contraindications aspect | n2=en:19-iodocholesterol | rel=r_associated | relid=0 | w=20
  1744. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2-5a synthetase
    n1=en:contraindications aspect | n2=en:2-5a synthetase | rel=r_associated | relid=0 | w=20
  1745. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2-acetolactate mutase
    n1=en:contraindications aspect | n2=en:2-acetolactate mutase | rel=r_associated | relid=0 | w=20
  1746. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2-acetylaminofluorene
    n1=en:contraindications aspect | n2=en:2-acetylaminofluorene | rel=r_associated | relid=0 | w=20
  1747. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2-amino-5-phosphonovalerate
    n1=en:contraindications aspect | n2=en:2-amino-5-phosphonovalerate | rel=r_associated | relid=0 | w=20
  1748. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2-hydroxyphenethylamine
    n1=en:contraindications aspect | n2=en:2-hydroxyphenethylamine | rel=r_associated | relid=0 | w=20
  1749. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2-hydroxypropanoic acid
    n1=en:contraindications aspect | n2=en:2-hydroxypropanoic acid | rel=r_associated | relid=0 | w=20
  1750. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2-isopropylmalate synthase
    n1=en:contraindications aspect | n2=en:2-isopropylmalate synthase | rel=r_associated | relid=0 | w=20
  1751. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2-methyl-4-chlorophenoxyacetic acid
    n1=en:contraindications aspect | n2=en:2-methyl-4-chlorophenoxyacetic acid | rel=r_associated | relid=0 | w=20
  1752. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2,2'-dipyridyl
    n1=en:contraindications aspect | n2=en:2,2'-dipyridyl | rel=r_associated | relid=0 | w=20
  1753. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2,4-dichlorophenoxyacetic acid
    n1=en:contraindications aspect | n2=en:2,4-dichlorophenoxyacetic acid | rel=r_associated | relid=0 | w=20
  1754. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:2,4,5-trichlorophenoxyacetic acid
    n1=en:contraindications aspect | n2=en:2,4,5-trichlorophenoxyacetic acid | rel=r_associated | relid=0 | w=20
  1755. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:20-hydroxysteroid dehydrogenases
    n1=en:contraindications aspect | n2=en:20-hydroxysteroid dehydrogenases | rel=r_associated | relid=0 | w=20
  1756. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:20-methylcholanthrene
    n1=en:contraindications aspect | n2=en:20-methylcholanthrene | rel=r_associated | relid=0 | w=20
  1757. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:25-hydroxyvitamin d 2
    n1=en:contraindications aspect | n2=en:25-hydroxyvitamin d 2 | rel=r_associated | relid=0 | w=20
  1758. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:25-hydroxyvitamin d-1 alpha-hydroxylase, mitochondrial
    n1=en:contraindications aspect | n2=en:25-hydroxyvitamin d-1 alpha-hydroxylase, mitochondrial | rel=r_associated | relid=0 | w=20
  1759. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:3-deazauridine
    n1=en:contraindications aspect | n2=en:3-deazauridine | rel=r_associated | relid=0 | w=20
  1760. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:3-hydroxyacyl coa dehydrogenases
    n1=en:contraindications aspect | n2=en:3-hydroxyacyl coa dehydrogenases | rel=r_associated | relid=0 | w=20
  1761. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:3-hydroxyanthranilic acid
    n1=en:contraindications aspect | n2=en:3-hydroxyanthranilic acid | rel=r_associated | relid=0 | w=20
  1762. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:3-hydroxybutyric acid
    n1=en:contraindications aspect | n2=en:3-hydroxybutyric acid | rel=r_associated | relid=0 | w=20
  1763. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:3-iodotyrosine
    n1=en:contraindications aspect | n2=en:3-iodotyrosine | rel=r_associated | relid=0 | w=20
  1764. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:3',5'-cyclic-gmp phosphodiesterases
    n1=en:contraindications aspect | n2=en:3',5'-cyclic-gmp phosphodiesterases | rel=r_associated | relid=0 | w=20
  1765. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:3',5'-cyclic-nucleotide phosphodiesterase
    n1=en:contraindications aspect | n2=en:3',5'-cyclic-nucleotide phosphodiesterase | rel=r_associated | relid=0 | w=20
  1766. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone
    n1=en:contraindications aspect | n2=en:4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | rel=r_associated | relid=0 | w=20
  1767. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:4-aminobenzoic acid
    n1=en:contraindications aspect | n2=en:4-aminobenzoic acid | rel=r_associated | relid=0 | w=20
  1768. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:4-butyrolactone
    n1=en:contraindications aspect | n2=en:4-butyrolactone | rel=r_associated | relid=0 | w=20
  1769. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:4-hydroxybenzoate 3-monooxygenase
    n1=en:contraindications aspect | n2=en:4-hydroxybenzoate 3-monooxygenase | rel=r_associated | relid=0 | w=20
  1770. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:4-hydroxycoumarins
    n1=en:contraindications aspect | n2=en:4-hydroxycoumarins | rel=r_associated | relid=0 | w=20
  1771. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:4-hydroxyphenylpyruvate dioxygenase
    n1=en:contraindications aspect | n2=en:4-hydroxyphenylpyruvate dioxygenase | rel=r_associated | relid=0 | w=20
  1772. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:4-nitrophenylphosphatase
    n1=en:contraindications aspect | n2=en:4-nitrophenylphosphatase | rel=r_associated | relid=0 | w=20
  1773. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:4-quinolones
    n1=en:contraindications aspect | n2=en:4-quinolones | rel=r_associated | relid=0 | w=20
  1774. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:5-hydroxyindoleacetic acid
    n1=en:contraindications aspect | n2=en:5-hydroxyindoleacetic acid | rel=r_associated | relid=0 | w=20
  1775. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:5-lipoxygenase-activating protein inhibitors
    n1=en:contraindications aspect | n2=en:5-lipoxygenase-activating protein inhibitors | rel=r_associated | relid=0 | w=20
  1776. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:5'-nucléotidase
    n1=en:contraindications aspect | n2=en:5'-nucléotidase | rel=r_associated | relid=0 | w=20
  1777. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:5'-nucleotidase
    n1=en:contraindications aspect | n2=en:5'-nucleotidase | rel=r_associated | relid=0 | w=20
  1778. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:6-ketoprostaglandin f1 alpha
    n1=en:contraindications aspect | n2=en:6-ketoprostaglandin f1 alpha | rel=r_associated | relid=0 | w=20
  1779. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:a set of false teeth
    n1=en:contraindications aspect | n2=en:a set of false teeth | rel=r_associated | relid=0 | w=20
  1780. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:abatacept
    n1=en:contraindications aspect | n2=en:abatacept | rel=r_associated | relid=0 | w=20
  1781. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:abdominal radiography
    n1=en:contraindications aspect | n2=en:abdominal radiography | rel=r_associated | relid=0 | w=20
  1782. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:abdominal wound closure techniques
    n1=en:contraindications aspect | n2=en:abdominal wound closure techniques | rel=r_associated | relid=0 | w=20
  1783. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:abiraterone acetate
    n1=en:contraindications aspect | n2=en:abiraterone acetate | rel=r_associated | relid=0 | w=20
  1784. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:abo blood group
    n1=en:contraindications aspect | n2=en:abo blood group | rel=r_associated | relid=0 | w=20
  1785. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:abortifacient agents
    n1=en:contraindications aspect | n2=en:abortifacient agents | rel=r_associated | relid=0 | w=20
  1786. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:abortifacient agents, steroidal
    n1=en:contraindications aspect | n2=en:abortifacient agents, steroidal | rel=r_associated | relid=0 | w=20
  1787. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:abscisic acid
    n1=en:contraindications aspect | n2=en:abscisic acid | rel=r_associated | relid=0 | w=20
  1788. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:absorbable gelatin sponge
    n1=en:contraindications aspect | n2=en:absorbable gelatin sponge | rel=r_associated | relid=0 | w=20
  1789. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:absorbable implants
    n1=en:contraindications aspect | n2=en:absorbable implants | rel=r_associated | relid=0 | w=20
  1790. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:absorbent pads
    n1=en:contraindications aspect | n2=en:absorbent pads | rel=r_associated | relid=0 | w=20
  1791. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acarbose
    n1=en:contraindications aspect | n2=en:acarbose | rel=r_associated | relid=0 | w=20
  1792. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acenocoumarol
    n1=en:contraindications aspect | n2=en:acenocoumarol | rel=r_associated | relid=0 | w=20
  1793. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acetaldehyde dehydrogenase inhibitors
    n1=en:contraindications aspect | n2=en:acetaldehyde dehydrogenase inhibitors | rel=r_associated | relid=0 | w=20
  1794. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acetaminophen
    n1=en:contraindications aspect | n2=en:acetaminophen | rel=r_associated | relid=0 | w=20
  1795. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acetic anhydrides
    n1=en:contraindications aspect | n2=en:acetic anhydrides | rel=r_associated | relid=0 | w=20
  1796. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acetoin
    n1=en:contraindications aspect | n2=en:acetoin | rel=r_associated | relid=0 | w=20
  1797. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acetolactate synthase
    n1=en:contraindications aspect | n2=en:acetolactate synthase | rel=r_associated | relid=0 | w=20
  1798. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acetyl-coa c-acetyltransferase
    n1=en:contraindications aspect | n2=en:acetyl-coa c-acetyltransferase | rel=r_associated | relid=0 | w=20
  1799. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acetylcysteine
    n1=en:contraindications aspect | n2=en:acetylcysteine | rel=r_associated | relid=0 | w=20
  1800. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acetylesterase
    n1=en:contraindications aspect | n2=en:acetylesterase | rel=r_associated | relid=0 | w=20
  1801. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acetylgalactosamine
    n1=en:contraindications aspect | n2=en:acetylgalactosamine | rel=r_associated | relid=0 | w=20
  1802. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acid etching, dental
    n1=en:contraindications aspect | n2=en:acid etching, dental | rel=r_associated | relid=0 | w=20
  1803. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acids, carbocyclic
    n1=en:contraindications aspect | n2=en:acids, carbocyclic | rel=r_associated | relid=0 | w=20
  1804. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acitretin
    n1=en:contraindications aspect | n2=en:acitretin | rel=r_associated | relid=0 | w=20
  1805. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aconitic acid
    n1=en:contraindications aspect | n2=en:aconitic acid | rel=r_associated | relid=0 | w=20
  1806. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acoustic impedance tests
    n1=en:contraindications aspect | n2=en:acoustic impedance tests | rel=r_associated | relid=0 | w=20
  1807. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acquaintance
    n1=en:contraindications aspect | n2=en:acquaintance | rel=r_associated | relid=0 | w=20
  1808. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acquaintances
    n1=en:contraindications aspect | n2=en:acquaintances | rel=r_associated | relid=0 | w=20
  1809. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acridine
    n1=en:contraindications aspect | n2=en:acridine | rel=r_associated | relid=0 | w=20
  1810. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acridine orange
    n1=en:contraindications aspect | n2=en:acridine orange | rel=r_associated | relid=0 | w=20
  1811. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acrylates
    n1=en:contraindications aspect | n2=en:acrylates | rel=r_associated | relid=0 | w=20
  1812. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acrylic resins
    n1=en:contraindications aspect | n2=en:acrylic resins | rel=r_associated | relid=0 | w=20
  1813. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:actin depolymerizing factors
    n1=en:contraindications aspect | n2=en:actin depolymerizing factors | rel=r_associated | relid=0 | w=20
  1814. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:actinoid series elements
    n1=en:contraindications aspect | n2=en:actinoid series elements | rel=r_associated | relid=0 | w=20
  1815. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:actinoscopy
    n1=en:contraindications aspect | n2=en:actinoscopy | rel=r_associated | relid=0 | w=20
  1816. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:activator appliances
    n1=en:contraindications aspect | n2=en:activator appliances | rel=r_associated | relid=0 | w=20
  1817. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:activin receptors, type i
    n1=en:contraindications aspect | n2=en:activin receptors, type i | rel=r_associated | relid=0 | w=20
  1818. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:activin receptors, type ii
    n1=en:contraindications aspect | n2=en:activin receptors, type ii | rel=r_associated | relid=0 | w=20
  1819. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:actuarial analysis
    n1=en:contraindications aspect | n2=en:actuarial analysis | rel=r_associated | relid=0 | w=20
  1820. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acupuncture therapy
    n1=en:contraindications aspect | n2=en:acupuncture therapy | rel=r_associated | relid=0 | w=20
  1821. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acupuncture, ear
    n1=en:contraindications aspect | n2=en:acupuncture, ear | rel=r_associated | relid=0 | w=20
  1822. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acyl-carrier protein s-malonyltransferase
    n1=en:contraindications aspect | n2=en:acyl-carrier protein s-malonyltransferase | rel=r_associated | relid=0 | w=20
  1823. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acylneuraminate cytidylyltransferase
    n1=en:contraindications aspect | n2=en:acylneuraminate cytidylyltransferase | rel=r_associated | relid=0 | w=20
  1824. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:acyltransferase
    n1=en:contraindications aspect | n2=en:acyltransferase | rel=r_associated | relid=0 | w=20
  1825. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adam10 protein
    n1=en:contraindications aspect | n2=en:adam10 protein | rel=r_associated | relid=0 | w=20
  1826. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adam12 protein
    n1=en:contraindications aspect | n2=en:adam12 protein | rel=r_associated | relid=0 | w=20
  1827. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adamts proteins
    n1=en:contraindications aspect | n2=en:adamts proteins | rel=r_associated | relid=0 | w=20
  1828. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adamts1 protein
    n1=en:contraindications aspect | n2=en:adamts1 protein | rel=r_associated | relid=0 | w=20
  1829. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adamts13 protein
    n1=en:contraindications aspect | n2=en:adamts13 protein | rel=r_associated | relid=0 | w=20
  1830. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adamts4 protein
    n1=en:contraindications aspect | n2=en:adamts4 protein | rel=r_associated | relid=0 | w=20
  1831. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adamts5 protein
    n1=en:contraindications aspect | n2=en:adamts5 protein | rel=r_associated | relid=0 | w=20
  1832. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adamts7 protein
    n1=en:contraindications aspect | n2=en:adamts7 protein | rel=r_associated | relid=0 | w=20
  1833. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adamts9 protein
    n1=en:contraindications aspect | n2=en:adamts9 protein | rel=r_associated | relid=0 | w=20
  1834. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adaptor protein complex alpha subunits
    n1=en:contraindications aspect | n2=en:adaptor protein complex alpha subunits | rel=r_associated | relid=0 | w=20
  1835. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adaptor protein complex delta subunits
    n1=en:contraindications aspect | n2=en:adaptor protein complex delta subunits | rel=r_associated | relid=0 | w=20
  1836. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adaptor protein complex sigma subunits
    n1=en:contraindications aspect | n2=en:adaptor protein complex sigma subunits | rel=r_associated | relid=0 | w=20
  1837. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adaptor proteins, vesicular transport
    n1=en:contraindications aspect | n2=en:adaptor proteins, vesicular transport | rel=r_associated | relid=0 | w=20
  1838. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenosine a1 receptor antagonists
    n1=en:contraindications aspect | n2=en:adenosine a1 receptor antagonists | rel=r_associated | relid=0 | w=20
  1839. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenosine deaminase inhibitor
    n1=en:contraindications aspect | n2=en:adenosine deaminase inhibitor | rel=r_associated | relid=0 | w=20
  1840. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenosine diphosphate glucose
    n1=en:contraindications aspect | n2=en:adenosine diphosphate glucose | rel=r_associated | relid=0 | w=20
  1841. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenosine diphosphate sugars
    n1=en:contraindications aspect | n2=en:adenosine diphosphate sugars | rel=r_associated | relid=0 | w=20
  1842. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenosine phosphosulfate
    n1=en:contraindications aspect | n2=en:adenosine phosphosulfate | rel=r_associated | relid=0 | w=20
  1843. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenosylmethionine decarboxylase
    n1=en:contraindications aspect | n2=en:adenosylmethionine decarboxylase | rel=r_associated | relid=0 | w=20
  1844. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenovirus vaccine
    n1=en:contraindications aspect | n2=en:adenovirus vaccine | rel=r_associated | relid=0 | w=20
  1845. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenylate cyclase
    n1=en:contraindications aspect | n2=en:adenylate cyclase | rel=r_associated | relid=0 | w=20
  1846. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenylate cyclase toxin
    n1=en:contraindications aspect | n2=en:adenylate cyclase toxin | rel=r_associated | relid=0 | w=20
  1847. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenylyl cyclase inhibitors
    n1=en:contraindications aspect | n2=en:adenylyl cyclase inhibitors | rel=r_associated | relid=0 | w=20
  1848. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adenylylcyclase
    n1=en:contraindications aspect | n2=en:adenylylcyclase | rel=r_associated | relid=0 | w=20
  1849. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adipates
    n1=en:contraindications aspect | n2=en:adipates | rel=r_associated | relid=0 | w=20
  1850. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adiponectin
    n1=en:contraindications aspect | n2=en:adiponectin | rel=r_associated | relid=0 | w=20
  1851. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adjuvant
    n1=en:contraindications aspect | n2=en:adjuvant | rel=r_associated | relid=0 | w=20
  1852. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adp-ribosyl cyclase
    n1=en:contraindications aspect | n2=en:adp-ribosyl cyclase | rel=r_associated | relid=0 | w=20
  1853. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adrenal cortex function tests
    n1=en:contraindications aspect | n2=en:adrenal cortex function tests | rel=r_associated | relid=0 | w=20
  1854. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adrenergic alpha-1 receptor agonists
    n1=en:contraindications aspect | n2=en:adrenergic alpha-1 receptor agonists | rel=r_associated | relid=0 | w=20
  1855. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adrenergic alpha-1 receptor antagonists
    n1=en:contraindications aspect | n2=en:adrenergic alpha-1 receptor antagonists | rel=r_associated | relid=0 | w=20
  1856. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adrenergic antagonist
    n1=en:contraindications aspect | n2=en:adrenergic antagonist | rel=r_associated | relid=0 | w=20
  1857. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adrenergic beta-3 receptor antagonists
    n1=en:contraindications aspect | n2=en:adrenergic beta-3 receptor antagonists | rel=r_associated | relid=0 | w=20
  1858. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:adrenodoxin
    n1=en:contraindications aspect | n2=en:adrenodoxin | rel=r_associated | relid=0 | w=20
  1859. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:advanced cardiac life support
    n1=en:contraindications aspect | n2=en:advanced cardiac life support | rel=r_associated | relid=0 | w=20
  1860. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:advanced glycation end product
    n1=en:contraindications aspect | n2=en:advanced glycation end product | rel=r_associated | relid=0 | w=20
  1861. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aedes albopictus
    n1=en:contraindications aspect | n2=en:aedes albopictus | rel=r_associated | relid=0 | w=20
  1862. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aerosol propellants
    n1=en:contraindications aspect | n2=en:aerosol propellants | rel=r_associated | relid=0 | w=20
  1863. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:agglutination tests
    n1=en:contraindications aspect | n2=en:agglutination tests | rel=r_associated | relid=0 | w=20
  1864. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:agglutinin
    n1=en:contraindications aspect | n2=en:agglutinin | rel=r_associated | relid=0 | w=20
  1865. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:air bags
    n1=en:contraindications aspect | n2=en:air bags | rel=r_associated | relid=0 | w=20
  1866. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:air filters
    n1=en:contraindications aspect | n2=en:air filters | rel=r_associated | relid=0 | w=20
  1867. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:airway management
    n1=en:contraindications aspect | n2=en:airway management | rel=r_associated | relid=0 | w=20
  1868. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alamethicin
    n1=en:contraindications aspect | n2=en:alamethicin | rel=r_associated | relid=0 | w=20
  1869. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alanine aminotransferase 1
    n1=en:contraindications aspect | n2=en:alanine aminotransferase 1 | rel=r_associated | relid=0 | w=20
  1870. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alanine racemase
    n1=en:contraindications aspect | n2=en:alanine racemase | rel=r_associated | relid=0 | w=20
  1871. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alcian blue
    n1=en:contraindications aspect | n2=en:alcian blue | rel=r_associated | relid=0 | w=20
  1872. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aldicarb
    n1=en:contraindications aspect | n2=en:aldicarb | rel=r_associated | relid=0 | w=20
  1873. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alginates
    n1=en:contraindications aspect | n2=en:alginates | rel=r_associated | relid=0 | w=20
  1874. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alkylating agent
    n1=en:contraindications aspect | n2=en:alkylating agent | rel=r_associated | relid=0 | w=20
  1875. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:allografting
    n1=en:contraindications aspect | n2=en:allografting | rel=r_associated | relid=0 | w=20
  1876. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:allyl compounds
    n1=en:contraindications aspect | n2=en:allyl compounds | rel=r_associated | relid=0 | w=20
  1877. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:allylisopropylacetamide
    n1=en:contraindications aspect | n2=en:allylisopropylacetamide | rel=r_associated | relid=0 | w=20
  1878. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha chemokine
    n1=en:contraindications aspect | n2=en:alpha chemokine | rel=r_associated | relid=0 | w=20
  1879. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha karyopherins
    n1=en:contraindications aspect | n2=en:alpha karyopherins | rel=r_associated | relid=0 | w=20
  1880. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha-adrenergic agonist
    n1=en:contraindications aspect | n2=en:alpha-adrenergic agonist | rel=r_associated | relid=0 | w=20
  1881. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha-adrenergic antagonist
    n1=en:contraindications aspect | n2=en:alpha-adrenergic antagonist | rel=r_associated | relid=0 | w=20
  1882. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
    n1=en:contraindications aspect | n2=en:alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | rel=r_associated | relid=0 | w=20
  1883. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha-aminoadipic acid
    n1=en:contraindications aspect | n2=en:alpha-aminoadipic acid | rel=r_associated | relid=0 | w=20
  1884. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha-amylase
    n1=en:contraindications aspect | n2=en:alpha-amylase | rel=r_associated | relid=0 | w=20
  1885. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha-crystallin a chain
    n1=en:contraindications aspect | n2=en:alpha-crystallin a chain | rel=r_associated | relid=0 | w=20
  1886. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha-crystallins
    n1=en:contraindications aspect | n2=en:alpha-crystallins | rel=r_associated | relid=0 | w=20
  1887. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha-cyclodextrins
    n1=en:contraindications aspect | n2=en:alpha-cyclodextrins | rel=r_associated | relid=0 | w=20
  1888. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alpha-hypophamine
    n1=en:contraindications aspect | n2=en:alpha-hypophamine | rel=r_associated | relid=0 | w=20
  1889. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alum compounds
    n1=en:contraindications aspect | n2=en:alum compounds | rel=r_associated | relid=0 | w=20
  1890. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aluminum compounds
    n1=en:contraindications aspect | n2=en:aluminum compounds | rel=r_associated | relid=0 | w=20
  1891. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aluminum hydroxide
    n1=en:contraindications aspect | n2=en:aluminum hydroxide | rel=r_associated | relid=0 | w=20
  1892. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aluminum silicate
    n1=en:contraindications aspect | n2=en:aluminum silicate | rel=r_associated | relid=0 | w=20
  1893. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alveolar bone grafting
    n1=en:contraindications aspect | n2=en:alveolar bone grafting | rel=r_associated | relid=0 | w=20
  1894. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alveolectomy
    n1=en:contraindications aspect | n2=en:alveolectomy | rel=r_associated | relid=0 | w=20
  1895. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:alveoloplasty
    n1=en:contraindications aspect | n2=en:alveoloplasty | rel=r_associated | relid=0 | w=20
  1896. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ambergris
    n1=en:contraindications aspect | n2=en:ambergris | rel=r_associated | relid=0 | w=20
  1897. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ambulatory surgical procedure
    n1=en:contraindications aspect | n2=en:ambulatory surgical procedure | rel=r_associated | relid=0 | w=20
  1898. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amido black
    n1=en:contraindications aspect | n2=en:amido black | rel=r_associated | relid=0 | w=20
  1899. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amifostine
    n1=en:contraindications aspect | n2=en:amifostine | rel=r_associated | relid=0 | w=20
  1900. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino acid isomerases
    n1=en:contraindications aspect | n2=en:amino acid isomerases | rel=r_associated | relid=0 | w=20
  1901. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino acid n-acetyltransferase
    n1=en:contraindications aspect | n2=en:amino acid n-acetyltransferase | rel=r_associated | relid=0 | w=20
  1902. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino acid transport system a
    n1=en:contraindications aspect | n2=en:amino acid transport system a | rel=r_associated | relid=0 | w=20
  1903. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino acid transport system l
    n1=en:contraindications aspect | n2=en:amino acid transport system l | rel=r_associated | relid=0 | w=20
  1904. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino acid transport systems, acidic
    n1=en:contraindications aspect | n2=en:amino acid transport systems, acidic | rel=r_associated | relid=0 | w=20
  1905. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino acids, branched-chain
    n1=en:contraindications aspect | n2=en:amino acids, branched-chain | rel=r_associated | relid=0 | w=20
  1906. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino acids, diamino
    n1=en:contraindications aspect | n2=en:amino acids, diamino | rel=r_associated | relid=0 | w=20
  1907. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino acids, dicarboxylic
    n1=en:contraindications aspect | n2=en:amino acids, dicarboxylic | rel=r_associated | relid=0 | w=20
  1908. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino alcohols
    n1=en:contraindications aspect | n2=en:amino alcohols | rel=r_associated | relid=0 | w=20
  1909. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amino-transferase
    n1=en:contraindications aspect | n2=en:amino-transferase | rel=r_associated | relid=0 | w=20
  1910. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aminocaproic acid
    n1=en:contraindications aspect | n2=en:aminocaproic acid | rel=r_associated | relid=0 | w=20
  1911. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aminoethylphosphonic acid
    n1=en:contraindications aspect | n2=en:aminoethylphosphonic acid | rel=r_associated | relid=0 | w=20
  1912. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aminoglycoside antibiotic
    n1=en:contraindications aspect | n2=en:aminoglycoside antibiotic | rel=r_associated | relid=0 | w=20
  1913. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aminohippuric acid
    n1=en:contraindications aspect | n2=en:aminohippuric acid | rel=r_associated | relid=0 | w=20
  1914. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aminophenols
    n1=en:contraindications aspect | n2=en:aminophenols | rel=r_associated | relid=0 | w=20
  1915. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aminopyrine n-demethylase
    n1=en:contraindications aspect | n2=en:aminopyrine n-demethylase | rel=r_associated | relid=0 | w=20
  1916. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aminosalicylic acids
    n1=en:contraindications aspect | n2=en:aminosalicylic acids | rel=r_associated | relid=0 | w=20
  1917. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amitriptyline
    n1=en:contraindications aspect | n2=en:amitriptyline | rel=r_associated | relid=0 | w=20
  1918. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ammonia-lyases
    n1=en:contraindications aspect | n2=en:ammonia-lyases | rel=r_associated | relid=0 | w=20
  1919. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amniocentesis
    n1=en:contraindications aspect | n2=en:amniocentesis | rel=r_associated | relid=0 | w=20
  1920. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ampholyte mixtures
    n1=en:contraindications aspect | n2=en:ampholyte mixtures | rel=r_associated | relid=0 | w=20
  1921. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:amputation
    n1=en:contraindications aspect | n2=en:amputation | rel=r_associated | relid=0 | w=20
  1922. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ampyrone
    n1=en:contraindications aspect | n2=en:ampyrone | rel=r_associated | relid=0 | w=20
  1923. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anacardic acids
    n1=en:contraindications aspect | n2=en:anacardic acids | rel=r_associated | relid=0 | w=20
  1924. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:analgesia, obstetrical
    n1=en:contraindications aspect | n2=en:analgesia, obstetrical | rel=r_associated | relid=0 | w=20
  1925. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:analgesic agent
    n1=en:contraindications aspect | n2=en:analgesic agent | rel=r_associated | relid=0 | w=20
  1926. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:analgesics, short-acting
    n1=en:contraindications aspect | n2=en:analgesics, short-acting | rel=r_associated | relid=0 | w=20
  1927. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anaphylatoxins
    n1=en:contraindications aspect | n2=en:anaphylatoxins | rel=r_associated | relid=0 | w=20
  1928. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:androgen receptor antagonists
    n1=en:contraindications aspect | n2=en:androgen receptor antagonists | rel=r_associated | relid=0 | w=20
  1929. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:androstanes
    n1=en:contraindications aspect | n2=en:androstanes | rel=r_associated | relid=0 | w=20
  1930. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:androstenes
    n1=en:contraindications aspect | n2=en:androstenes | rel=r_associated | relid=0 | w=20
  1931. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anesthesia, caudal
    n1=en:contraindications aspect | n2=en:anesthesia, caudal | rel=r_associated | relid=0 | w=20
  1932. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anesthesia, closed-circuit
    n1=en:contraindications aspect | n2=en:anesthesia, closed-circuit | rel=r_associated | relid=0 | w=20
  1933. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anesthesia, dental
    n1=en:contraindications aspect | n2=en:anesthesia, dental | rel=r_associated | relid=0 | w=20
  1934. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anesthesia, inhalation
    n1=en:contraindications aspect | n2=en:anesthesia, inhalation | rel=r_associated | relid=0 | w=20
  1935. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anesthetic agent
    n1=en:contraindications aspect | n2=en:anesthetic agent | rel=r_associated | relid=0 | w=20
  1936. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anesthetics, intravenous
    n1=en:contraindications aspect | n2=en:anesthetics, intravenous | rel=r_associated | relid=0 | w=20
  1937. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aneugens
    n1=en:contraindications aspect | n2=en:aneugens | rel=r_associated | relid=0 | w=20
  1938. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiocardiography
    n1=en:contraindications aspect | n2=en:angiocardiography | rel=r_associated | relid=0 | w=20
  1939. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiocholecystography
    n1=en:contraindications aspect | n2=en:angiocholecystography | rel=r_associated | relid=0 | w=20
  1940. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiocholegraphy
    n1=en:contraindications aspect | n2=en:angiocholegraphy | rel=r_associated | relid=0 | w=20
  1941. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiogenesis inducing agents
    n1=en:contraindications aspect | n2=en:angiogenesis inducing agents | rel=r_associated | relid=0 | w=20
  1942. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiogram
    n1=en:contraindications aspect | n2=en:angiogram | rel=r_associated | relid=0 | w=20
  1943. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiography
    n1=en:contraindications aspect | n2=en:angiography | rel=r_associated | relid=0 | w=20
  1944. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angioplasty, balloon, laser-assisted
    n1=en:contraindications aspect | n2=en:angioplasty, balloon, laser-assisted | rel=r_associated | relid=0 | w=20
  1945. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angioscopes
    n1=en:contraindications aspect | n2=en:angioscopes | rel=r_associated | relid=0 | w=20
  1946. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angioscopy
    n1=en:contraindications aspect | n2=en:angioscopy | rel=r_associated | relid=0 | w=20
  1947. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiostatin
    n1=en:contraindications aspect | n2=en:angiostatin | rel=r_associated | relid=0 | w=20
  1948. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiotensin amide
    n1=en:contraindications aspect | n2=en:angiotensin amide | rel=r_associated | relid=0 | w=20
  1949. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiotensin ii type 1 receptor blockers
    n1=en:contraindications aspect | n2=en:angiotensin ii type 1 receptor blockers | rel=r_associated | relid=0 | w=20
  1950. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiotensin ii type 2 receptor blockers
    n1=en:contraindications aspect | n2=en:angiotensin ii type 2 receptor blockers | rel=r_associated | relid=0 | w=20
  1951. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiotensin receptor antagonists
    n1=en:contraindications aspect | n2=en:angiotensin receptor antagonists | rel=r_associated | relid=0 | w=20
  1952. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:angiotensin-2
    n1=en:contraindications aspect | n2=en:angiotensin-2 | rel=r_associated | relid=0 | w=20
  1953. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aniline compounds
    n1=en:contraindications aspect | n2=en:aniline compounds | rel=r_associated | relid=0 | w=20
  1954. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aniline mustard
    n1=en:contraindications aspect | n2=en:aniline mustard | rel=r_associated | relid=0 | w=20
  1955. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anisoles
    n1=en:contraindications aspect | n2=en:anisoles | rel=r_associated | relid=0 | w=20
  1956. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:annexin a1
    n1=en:contraindications aspect | n2=en:annexin a1 | rel=r_associated | relid=0 | w=20
  1957. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:annexin a3
    n1=en:contraindications aspect | n2=en:annexin a3 | rel=r_associated | relid=0 | w=20
  1958. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anonymous testing
    n1=en:contraindications aspect | n2=en:anonymous testing | rel=r_associated | relid=0 | w=20
  1959. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:answer
    n1=en:contraindications aspect | n2=en:answer | rel=r_associated | relid=0 | w=20
  1960. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:answer sb back
    n1=en:contraindications aspect | n2=en:answer sb back | rel=r_associated | relid=0 | w=20
  1961. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:answer somebody back
    n1=en:contraindications aspect | n2=en:answer somebody back | rel=r_associated | relid=0 | w=20
  1962. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ant venoms
    n1=en:contraindications aspect | n2=en:ant venoms | rel=r_associated | relid=0 | w=20
  1963. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antacid preparation
    n1=en:contraindications aspect | n2=en:antacid preparation | rel=r_associated | relid=0 | w=20
  1964. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anthracenes
    n1=en:contraindications aspect | n2=en:anthracenes | rel=r_associated | relid=0 | w=20
  1965. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anthranilate synthase
    n1=en:contraindications aspect | n2=en:anthranilate synthase | rel=r_associated | relid=0 | w=20
  1966. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anti-allergic agents
    n1=en:contraindications aspect | n2=en:anti-allergic agents | rel=r_associated | relid=0 | w=20
  1967. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anti-asthmatic agent
    n1=en:contraindications aspect | n2=en:anti-asthmatic agent | rel=r_associated | relid=0 | w=20
  1968. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anti-immune body
    n1=en:contraindications aspect | n2=en:anti-immune body | rel=r_associated | relid=0 | w=20
  1969. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anti-immune substance
    n1=en:contraindications aspect | n2=en:anti-immune substance | rel=r_associated | relid=0 | w=20
  1970. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anti-inflammatory agents
    n1=en:contraindications aspect | n2=en:anti-inflammatory agents | rel=r_associated | relid=0 | w=20
  1971. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anti-intermediary body
    n1=en:contraindications aspect | n2=en:anti-intermediary body | rel=r_associated | relid=0 | w=20
  1972. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anti-obesity agents
    n1=en:contraindications aspect | n2=en:anti-obesity agents | rel=r_associated | relid=0 | w=20
  1973. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anti-retroviral agents
    n1=en:contraindications aspect | n2=en:anti-retroviral agents | rel=r_associated | relid=0 | w=20
  1974. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anti-ulcer agent
    n1=en:contraindications aspect | n2=en:anti-ulcer agent | rel=r_associated | relid=0 | w=20
  1975. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antianxiety agent
    n1=en:contraindications aspect | n2=en:antianxiety agent | rel=r_associated | relid=0 | w=20
  1976. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antibiotics, antitubercular
    n1=en:contraindications aspect | n2=en:antibiotics, antitubercular | rel=r_associated | relid=0 | w=20
  1977. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antibodies, archaeal
    n1=en:contraindications aspect | n2=en:antibodies, archaeal | rel=r_associated | relid=0 | w=20
  1978. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antibodies, monoclonal, murine-derived
    n1=en:contraindications aspect | n2=en:antibodies, monoclonal, murine-derived | rel=r_associated | relid=0 | w=20
  1979. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antibody
    n1=en:contraindications aspect | n2=en:antibody | rel=r_associated | relid=0 | w=20
  1980. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anticardiolipin antibody
    n1=en:contraindications aspect | n2=en:anticardiolipin antibody | rel=r_associated | relid=0 | w=20
  1981. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anticoagulant agent
    n1=en:contraindications aspect | n2=en:anticoagulant agent | rel=r_associated | relid=0 | w=20
  1982. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:anticodon
    n1=en:contraindications aspect | n2=en:anticodon | rel=r_associated | relid=0 | w=20
  1983. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antidepressive agents, second-generation
    n1=en:contraindications aspect | n2=en:antidepressive agents, second-generation | rel=r_associated | relid=0 | w=20
  1984. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antidiarrheal agent
    n1=en:contraindications aspect | n2=en:antidiarrheal agent | rel=r_associated | relid=0 | w=20
  1985. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antidiphtheric serum
    n1=en:contraindications aspect | n2=en:antidiphtheric serum | rel=r_associated | relid=0 | w=20
  1986. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antienzyme
    n1=en:contraindications aspect | n2=en:antienzyme | rel=r_associated | relid=0 | w=20
  1987. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antienzyme.
    n1=en:contraindications aspect | n2=en:antienzyme. | rel=r_associated | relid=0 | w=20
  1988. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antifibrinolytic agents
    n1=en:contraindications aspect | n2=en:antifibrinolytic agents | rel=r_associated | relid=0 | w=20
  1989. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antifoaming agents
    n1=en:contraindications aspect | n2=en:antifoaming agents | rel=r_associated | relid=0 | w=20
  1990. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antifreeze proteins, type i
    n1=en:contraindications aspect | n2=en:antifreeze proteins, type i | rel=r_associated | relid=0 | w=20
  1991. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antifreeze proteins, type iii
    n1=en:contraindications aspect | n2=en:antifreeze proteins, type iii | rel=r_associated | relid=0 | w=20
  1992. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antifreeze proteins, type iv
    n1=en:contraindications aspect | n2=en:antifreeze proteins, type iv | rel=r_associated | relid=0 | w=20
  1993. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antifungal agent
    n1=en:contraindications aspect | n2=en:antifungal agent | rel=r_associated | relid=0 | w=20
  1994. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antigen
    n1=en:contraindications aspect | n2=en:antigen | rel=r_associated | relid=0 | w=20
  1995. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antigens, cd79
    n1=en:contraindications aspect | n2=en:antigens, cd79 | rel=r_associated | relid=0 | w=20
  1996. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antigens, differentiation, t-lymphocyte
    n1=en:contraindications aspect | n2=en:antigens, differentiation, t-lymphocyte | rel=r_associated | relid=0 | w=20
  1997. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antigens, neoplasm
    n1=en:contraindications aspect | n2=en:antigens, neoplasm | rel=r_associated | relid=0 | w=20
  1998. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antihormone
    n1=en:contraindications aspect | n2=en:antihormone | rel=r_associated | relid=0 | w=20
  1999. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antihyperkalemic agents
    n1=en:contraindications aspect | n2=en:antihyperkalemic agents | rel=r_associated | relid=0 | w=20
  2000. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antihypertensive agent
    n1=en:contraindications aspect | n2=en:antihypertensive agent | rel=r_associated | relid=0 | w=20
  2001. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antilymphocyte serum
    n1=en:contraindications aspect | n2=en:antilymphocyte serum | rel=r_associated | relid=0 | w=20
  2002. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antimetabolite
    n1=en:contraindications aspect | n2=en:antimetabolite | rel=r_associated | relid=0 | w=20
  2003. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antimuscarinic agent
    n1=en:contraindications aspect | n2=en:antimuscarinic agent | rel=r_associated | relid=0 | w=20
  2004. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antimutagenic agents
    n1=en:contraindications aspect | n2=en:antimutagenic agents | rel=r_associated | relid=0 | w=20
  2005. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antinematodal agents
    n1=en:contraindications aspect | n2=en:antinematodal agents | rel=r_associated | relid=0 | w=20
  2006. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antineoplastic agent
    n1=en:contraindications aspect | n2=en:antineoplastic agent | rel=r_associated | relid=0 | w=20
  2007. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antineoplastic antibiotic
    n1=en:contraindications aspect | n2=en:antineoplastic antibiotic | rel=r_associated | relid=0 | w=20
  2008. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antineutrophil cytoplasmic antibody
    n1=en:contraindications aspect | n2=en:antineutrophil cytoplasmic antibody | rel=r_associated | relid=0 | w=20
  2009. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antinuclear antibody
    n1=en:contraindications aspect | n2=en:antinuclear antibody | rel=r_associated | relid=0 | w=20
  2010. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antiparasitic agent
    n1=en:contraindications aspect | n2=en:antiparasitic agent | rel=r_associated | relid=0 | w=20
  2011. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antiperspirants
    n1=en:contraindications aspect | n2=en:antiperspirants | rel=r_associated | relid=0 | w=20
  2012. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antiphospholipid antibody
    n1=en:contraindications aspect | n2=en:antiphospholipid antibody | rel=r_associated | relid=0 | w=20
  2013. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antirheumatic agents
    n1=en:contraindications aspect | n2=en:antirheumatic agents | rel=r_associated | relid=0 | w=20
  2014. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antistreptolysin
    n1=en:contraindications aspect | n2=en:antistreptolysin | rel=r_associated | relid=0 | w=20
  2015. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antitetanic serum
    n1=en:contraindications aspect | n2=en:antitetanic serum | rel=r_associated | relid=0 | w=20
  2016. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antithrombin proteins
    n1=en:contraindications aspect | n2=en:antithrombin proteins | rel=r_associated | relid=0 | w=20
  2017. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antithyroid agent
    n1=en:contraindications aspect | n2=en:antithyroid agent | rel=r_associated | relid=0 | w=20
  2018. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antitreponemal agents
    n1=en:contraindications aspect | n2=en:antitreponemal agents | rel=r_associated | relid=0 | w=20
  2019. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:antiviral agent
    n1=en:contraindications aspect | n2=en:antiviral agent | rel=r_associated | relid=0 | w=20
  2020. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aortography
    n1=en:contraindications aspect | n2=en:aortography | rel=r_associated | relid=0 | w=20
  2021. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apatites
    n1=en:contraindications aspect | n2=en:apatites | rel=r_associated | relid=0 | w=20
  2022. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apc2 subunit, anaphase-promoting complex-cyclosome
    n1=en:contraindications aspect | n2=en:apc2 subunit, anaphase-promoting complex-cyclosome | rel=r_associated | relid=0 | w=20
  2023. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apc5 subunit, anaphase-promoting complex-cyclosome
    n1=en:contraindications aspect | n2=en:apc5 subunit, anaphase-promoting complex-cyclosome | rel=r_associated | relid=0 | w=20
  2024. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apexification
    n1=en:contraindications aspect | n2=en:apexification | rel=r_associated | relid=0 | w=20
  2025. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aphrodisiacs
    n1=en:contraindications aspect | n2=en:aphrodisiacs | rel=r_associated | relid=0 | w=20
  2026. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apicoectomy
    n1=en:contraindications aspect | n2=en:apicoectomy | rel=r_associated | relid=0 | w=20
  2027. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apoferritins
    n1=en:contraindications aspect | n2=en:apoferritins | rel=r_associated | relid=0 | w=20
  2028. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apolipoprotein B-100
    n1=en:contraindications aspect | n2=en:apolipoprotein B-100 | rel=r_associated | relid=0 | w=20
  2029. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apolipoprotein b-100
    n1=en:contraindications aspect | n2=en:apolipoprotein b-100 | rel=r_associated | relid=0 | w=20
  2030. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apolipoprotein b-48
    n1=en:contraindications aspect | n2=en:apolipoprotein b-48 | rel=r_associated | relid=0 | w=20
  2031. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apolipoprotein C-I
    n1=en:contraindications aspect | n2=en:apolipoprotein C-I | rel=r_associated | relid=0 | w=20
  2032. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apolipoprotein c-i
    n1=en:contraindications aspect | n2=en:apolipoprotein c-i | rel=r_associated | relid=0 | w=20
  2033. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apolipoprotein e2
    n1=en:contraindications aspect | n2=en:apolipoprotein e2 | rel=r_associated | relid=0 | w=20
  2034. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apolipoproteins
    n1=en:contraindications aspect | n2=en:apolipoproteins | rel=r_associated | relid=0 | w=20
  2035. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apoproteins
    n1=en:contraindications aspect | n2=en:apoproteins | rel=r_associated | relid=0 | w=20
  2036. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aprindine
    n1=en:contraindications aspect | n2=en:aprindine | rel=r_associated | relid=0 | w=20
  2037. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:apurinic acid
    n1=en:contraindications aspect | n2=en:apurinic acid | rel=r_associated | relid=0 | w=20
  2038. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aquaporin 4
    n1=en:contraindications aspect | n2=en:aquaporin 4 | rel=r_associated | relid=0 | w=20
  2039. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aquaporin 6
    n1=en:contraindications aspect | n2=en:aquaporin 6 | rel=r_associated | relid=0 | w=20
  2040. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arabinose
    n1=en:contraindications aspect | n2=en:arabinose | rel=r_associated | relid=0 | w=20
  2041. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arac transcription factor
    n1=en:contraindications aspect | n2=en:arac transcription factor | rel=r_associated | relid=0 | w=20
  2042. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arbutin
    n1=en:contraindications aspect | n2=en:arbutin | rel=r_associated | relid=0 | w=20
  2043. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arecoline
    n1=en:contraindications aspect | n2=en:arecoline | rel=r_associated | relid=0 | w=20
  2044. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arginine specific trna
    n1=en:contraindications aspect | n2=en:arginine specific trna | rel=r_associated | relid=0 | w=20
  2045. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:argininosuccinic acid
    n1=en:contraindications aspect | n2=en:argininosuccinic acid | rel=r_associated | relid=0 | w=20
  2046. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aromatase inhibitor
    n1=en:contraindications aspect | n2=en:aromatase inhibitor | rel=r_associated | relid=0 | w=20
  2047. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aromatherapy and essential oils
    n1=en:contraindications aspect | n2=en:aromatherapy and essential oils | rel=r_associated | relid=0 | w=20
  2048. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aromatic-l-amino-acid decarboxylases
    n1=en:contraindications aspect | n2=en:aromatic-l-amino-acid decarboxylases | rel=r_associated | relid=0 | w=20
  2049. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arsenates
    n1=en:contraindications aspect | n2=en:arsenates | rel=r_associated | relid=0 | w=20
  2050. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:artemisinins
    n1=en:contraindications aspect | n2=en:artemisinins | rel=r_associated | relid=0 | w=20
  2051. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arterial pressure
    n1=en:contraindications aspect | n2=en:arterial pressure | rel=r_associated | relid=0 | w=20
  2052. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arterial tension
    n1=en:contraindications aspect | n2=en:arterial tension | rel=r_associated | relid=0 | w=20
  2053. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arteriovenous shunt procedure
    n1=en:contraindications aspect | n2=en:arteriovenous shunt procedure | rel=r_associated | relid=0 | w=20
  2054. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arthrodesis
    n1=en:contraindications aspect | n2=en:arthrodesis | rel=r_associated | relid=0 | w=20
  2055. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arthrogram
    n1=en:contraindications aspect | n2=en:arthrogram | rel=r_associated | relid=0 | w=20
  2056. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arthroplasty
    n1=en:contraindications aspect | n2=en:arthroplasty | rel=r_associated | relid=0 | w=20
  2057. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arthroplasty of the knee
    n1=en:contraindications aspect | n2=en:arthroplasty of the knee | rel=r_associated | relid=0 | w=20
  2058. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arthroplasty, replacement, finger
    n1=en:contraindications aspect | n2=en:arthroplasty, replacement, finger | rel=r_associated | relid=0 | w=20
  2059. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arthroscopes
    n1=en:contraindications aspect | n2=en:arthroscopes | rel=r_associated | relid=0 | w=20
  2060. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:artificial anus
    n1=en:contraindications aspect | n2=en:artificial anus | rel=r_associated | relid=0 | w=20
  2061. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:artificial breast
    n1=en:contraindications aspect | n2=en:artificial breast | rel=r_associated | relid=0 | w=20
  2062. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:artificial organs
    n1=en:contraindications aspect | n2=en:artificial organs | rel=r_associated | relid=0 | w=20
  2063. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:artificial saliva
    n1=en:contraindications aspect | n2=en:artificial saliva | rel=r_associated | relid=0 | w=20
  2064. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:artificial skin
    n1=en:contraindications aspect | n2=en:artificial skin | rel=r_associated | relid=0 | w=20
  2065. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:artificial teeth
    n1=en:contraindications aspect | n2=en:artificial teeth | rel=r_associated | relid=0 | w=20
  2066. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aryl sulfotransferase
    n1=en:contraindications aspect | n2=en:aryl sulfotransferase | rel=r_associated | relid=0 | w=20
  2067. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arylsulfatases
    n1=en:contraindications aspect | n2=en:arylsulfatases | rel=r_associated | relid=0 | w=20
  2068. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arylsulfonates
    n1=en:contraindications aspect | n2=en:arylsulfonates | rel=r_associated | relid=0 | w=20
  2069. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:arylsulfonic acids
    n1=en:contraindications aspect | n2=en:arylsulfonic acids | rel=r_associated | relid=0 | w=20
  2070. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:asbestos, serpentine
    n1=en:contraindications aspect | n2=en:asbestos, serpentine | rel=r_associated | relid=0 | w=20
  2071. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:asparaginase
    n1=en:contraindications aspect | n2=en:asparaginase | rel=r_associated | relid=0 | w=20
  2072. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:asparagine-specific trna
    n1=en:contraindications aspect | n2=en:asparagine-specific trna | rel=r_associated | relid=0 | w=20
  2073. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aspartate aminotransferase, cytoplasmic
    n1=en:contraindications aspect | n2=en:aspartate aminotransferase, cytoplasmic | rel=r_associated | relid=0 | w=20
  2074. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aspartate aminotransferase, mitochondrial
    n1=en:contraindications aspect | n2=en:aspartate aminotransferase, mitochondrial | rel=r_associated | relid=0 | w=20
  2075. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aspartate carbamoyltransferase
    n1=en:contraindications aspect | n2=en:aspartate carbamoyltransferase | rel=r_associated | relid=0 | w=20
  2076. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aspartic acid
    n1=en:contraindications aspect | n2=en:aspartic acid | rel=r_associated | relid=0 | w=20
  2077. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aspartic acid endopeptidases
    n1=en:contraindications aspect | n2=en:aspartic acid endopeptidases | rel=r_associated | relid=0 | w=20
  2078. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aspartyl peptidase
    n1=en:contraindications aspect | n2=en:aspartyl peptidase | rel=r_associated | relid=0 | w=20
  2079. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:astringent
    n1=en:contraindications aspect | n2=en:astringent | rel=r_associated | relid=0 | w=20
  2080. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ataxin-3
    n1=en:contraindications aspect | n2=en:ataxin-3 | rel=r_associated | relid=0 | w=20
  2081. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atazanavir sulfate
    n1=en:contraindications aspect | n2=en:atazanavir sulfate | rel=r_associated | relid=0 | w=20
  2082. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atenolol
    n1=en:contraindications aspect | n2=en:atenolol | rel=r_associated | relid=0 | w=20
  2083. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:athletic tape
    n1=en:contraindications aspect | n2=en:athletic tape | rel=r_associated | relid=0 | w=20
  2084. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atmosphere exposure chambers
    n1=en:contraindications aspect | n2=en:atmosphere exposure chambers | rel=r_associated | relid=0 | w=20
  2085. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atomoxetine hydrochloride
    n1=en:contraindications aspect | n2=en:atomoxetine hydrochloride | rel=r_associated | relid=0 | w=20
  2086. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atorvastatin calcium
    n1=en:contraindications aspect | n2=en:atorvastatin calcium | rel=r_associated | relid=0 | w=20
  2087. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atosil
    n1=en:contraindications aspect | n2=en:atosil | rel=r_associated | relid=0 | w=20
  2088. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atp binding cassette transporter, sub-family g, member 1
    n1=en:contraindications aspect | n2=en:atp binding cassette transporter, sub-family g, member 1 | rel=r_associated | relid=0 | w=20
  2089. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atp binding cassette transporter, sub-family g, member 2
    n1=en:contraindications aspect | n2=en:atp binding cassette transporter, sub-family g, member 2 | rel=r_associated | relid=0 | w=20
  2090. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atp binding cassette transporter, sub-family g, member 5
    n1=en:contraindications aspect | n2=en:atp binding cassette transporter, sub-family g, member 5 | rel=r_associated | relid=0 | w=20
  2091. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atp binding cassette transporter, sub-family g, member 8
    n1=en:contraindications aspect | n2=en:atp binding cassette transporter, sub-family g, member 8 | rel=r_associated | relid=0 | w=20
  2092. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atp synthetase complexes
    n1=en:contraindications aspect | n2=en:atp synthetase complexes | rel=r_associated | relid=0 | w=20
  2093. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atp-citrate synthase
    n1=en:contraindications aspect | n2=en:atp-citrate synthase | rel=r_associated | relid=0 | w=20
  2094. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atpase
    n1=en:contraindications aspect | n2=en:atpase | rel=r_associated | relid=0 | w=20
  2095. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atrazine
    n1=en:contraindications aspect | n2=en:atrazine | rel=r_associated | relid=0 | w=20
  2096. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atrial myosins
    n1=en:contraindications aspect | n2=en:atrial myosins | rel=r_associated | relid=0 | w=20
  2097. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:atropine derivatives
    n1=en:contraindications aspect | n2=en:atropine derivatives | rel=r_associated | relid=0 | w=20
  2098. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:auditory brain stem implants
    n1=en:contraindications aspect | n2=en:auditory brain stem implants | rel=r_associated | relid=0 | w=20
  2099. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:auranofin
    n1=en:contraindications aspect | n2=en:auranofin | rel=r_associated | relid=0 | w=20
  2100. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:auriculotherapy
    n1=en:contraindications aspect | n2=en:auriculotherapy | rel=r_associated | relid=0 | w=20
  2101. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aurintricarboxylic acid
    n1=en:contraindications aspect | n2=en:aurintricarboxylic acid | rel=r_associated | relid=0 | w=20
  2102. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aurkc protein, human
    n1=en:contraindications aspect | n2=en:aurkc protein, human | rel=r_associated | relid=0 | w=20
  2103. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:aurothioglucose
    n1=en:contraindications aspect | n2=en:aurothioglucose | rel=r_associated | relid=0 | w=20
  2104. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:autoanalysis procedure
    n1=en:contraindications aspect | n2=en:autoanalysis procedure | rel=r_associated | relid=0 | w=20
  2105. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:autonomic denervation
    n1=en:contraindications aspect | n2=en:autonomic denervation | rel=r_associated | relid=0 | w=20
  2106. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:autophagy-related protein 5
    n1=en:contraindications aspect | n2=en:autophagy-related protein 5 | rel=r_associated | relid=0 | w=20
  2107. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:autophagy-related protein 7
    n1=en:contraindications aspect | n2=en:autophagy-related protein 7 | rel=r_associated | relid=0 | w=20
  2108. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:autophagy-related protein-1 homolog
    n1=en:contraindications aspect | n2=en:autophagy-related protein-1 homolog | rel=r_associated | relid=0 | w=20
  2109. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:autovaccines
    n1=en:contraindications aspect | n2=en:autovaccines | rel=r_associated | relid=0 | w=20
  2110. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:axial computerized tomography
    n1=en:contraindications aspect | n2=en:axial computerized tomography | rel=r_associated | relid=0 | w=20
  2111. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:axin protein
    n1=en:contraindications aspect | n2=en:axin protein | rel=r_associated | relid=0 | w=20
  2112. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:axonemal dyneins
    n1=en:contraindications aspect | n2=en:axonemal dyneins | rel=r_associated | relid=0 | w=20
  2113. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:axotomy
    n1=en:contraindications aspect | n2=en:axotomy | rel=r_associated | relid=0 | w=20
  2114. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:azetidinecarboxylic acid
    n1=en:contraindications aspect | n2=en:azetidinecarboxylic acid | rel=r_associated | relid=0 | w=20
  2115. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:azetines
    n1=en:contraindications aspect | n2=en:azetines | rel=r_associated | relid=0 | w=20
  2116. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:b-dna
    n1=en:contraindications aspect | n2=en:b-dna | rel=r_associated | relid=0 | w=20
  2117. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:b3 antigen
    n1=en:contraindications aspect | n2=en:b3 antigen | rel=r_associated | relid=0 | w=20
  2118. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:baclofen
    n1=en:contraindications aspect | n2=en:baclofen | rel=r_associated | relid=0 | w=20
  2119. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bacterial secretion systems
    n1=en:contraindications aspect | n2=en:bacterial secretion systems | rel=r_associated | relid=0 | w=20
  2120. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bacterial vaccine
    n1=en:contraindications aspect | n2=en:bacterial vaccine | rel=r_associated | relid=0 | w=20
  2121. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bacteriochlorophylls
    n1=en:contraindications aspect | n2=en:bacteriochlorophylls | rel=r_associated | relid=0 | w=20
  2122. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bacteriocin
    n1=en:contraindications aspect | n2=en:bacteriocin | rel=r_associated | relid=0 | w=20
  2123. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:baculoviral iap repeat-containing protein 1
    n1=en:contraindications aspect | n2=en:baculoviral iap repeat-containing protein 1 | rel=r_associated | relid=0 | w=20
  2124. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ballistocardiography
    n1=en:contraindications aspect | n2=en:ballistocardiography | rel=r_associated | relid=0 | w=20
  2125. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:balloon angioplasty
    n1=en:contraindications aspect | n2=en:balloon angioplasty | rel=r_associated | relid=0 | w=20
  2126. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:balloon embolectomy
    n1=en:contraindications aspect | n2=en:balloon embolectomy | rel=r_associated | relid=0 | w=20
  2127. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:balloon valvuloplasty
    n1=en:contraindications aspect | n2=en:balloon valvuloplasty | rel=r_associated | relid=0 | w=20
  2128. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:balsams
    n1=en:contraindications aspect | n2=en:balsams | rel=r_associated | relid=0 | w=20
  2129. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:barium radioisotopes
    n1=en:contraindications aspect | n2=en:barium radioisotopes | rel=r_associated | relid=0 | w=20
  2130. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bathing
    n1=en:contraindications aspect | n2=en:bathing | rel=r_associated | relid=0 | w=20
  2131. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:batroxobin
    n1=en:contraindications aspect | n2=en:batroxobin | rel=r_associated | relid=0 | w=20
  2132. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bcl2 antagonist of cell death
    n1=en:contraindications aspect | n2=en:bcl2 antagonist of cell death | rel=r_associated | relid=0 | w=20
  2133. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:be a counterpart to something
    n1=en:contraindications aspect | n2=en:be a counterpart to something | rel=r_associated | relid=0 | w=20
  2134. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:be the counterpart of
    n1=en:contraindications aspect | n2=en:be the counterpart of | rel=r_associated | relid=0 | w=20
  2135. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beam radiation therapy
    n1=en:contraindications aspect | n2=en:beam radiation therapy | rel=r_associated | relid=0 | w=20
  2136. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bed
    n1=en:contraindications aspect | n2=en:bed | rel=r_associated | relid=0 | w=20
  2137. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bedding and linens
    n1=en:contraindications aspect | n2=en:bedding and linens | rel=r_associated | relid=0 | w=20
  2138. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:behind-the-counter drugs
    n1=en:contraindications aspect | n2=en:behind-the-counter drugs | rel=r_associated | relid=0 | w=20
  2139. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bendamustine hydrochloride
    n1=en:contraindications aspect | n2=en:bendamustine hydrochloride | rel=r_associated | relid=0 | w=20
  2140. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzaldehyde
    n1=en:contraindications aspect | n2=en:benzaldehyde | rel=r_associated | relid=0 | w=20
  2141. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzaldehydes
    n1=en:contraindications aspect | n2=en:benzaldehydes | rel=r_associated | relid=0 | w=20
  2142. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzbromarone
    n1=en:contraindications aspect | n2=en:benzbromarone | rel=r_associated | relid=0 | w=20
  2143. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzidines
    n1=en:contraindications aspect | n2=en:benzidines | rel=r_associated | relid=0 | w=20
  2144. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzilates
    n1=en:contraindications aspect | n2=en:benzilates | rel=r_associated | relid=0 | w=20
  2145. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzophenones
    n1=en:contraindications aspect | n2=en:benzophenones | rel=r_associated | relid=0 | w=20
  2146. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzopyrene hydroxylase
    n1=en:contraindications aspect | n2=en:benzopyrene hydroxylase | rel=r_associated | relid=0 | w=20
  2147. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzoxepins
    n1=en:contraindications aspect | n2=en:benzoxepins | rel=r_associated | relid=0 | w=20
  2148. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzyl alcohols
    n1=en:contraindications aspect | n2=en:benzyl alcohols | rel=r_associated | relid=0 | w=20
  2149. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:benzyl compounds
    n1=en:contraindications aspect | n2=en:benzyl compounds | rel=r_associated | relid=0 | w=20
  2150. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:berberine
    n1=en:contraindications aspect | n2=en:berberine | rel=r_associated | relid=0 | w=20
  2151. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:berberine alkaloids
    n1=en:contraindications aspect | n2=en:berberine alkaloids | rel=r_associated | relid=0 | w=20
  2152. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta chemokine
    n1=en:contraindications aspect | n2=en:beta chemokine | rel=r_associated | relid=0 | w=20
  2153. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta karyopherins
    n1=en:contraindications aspect | n2=en:beta karyopherins | rel=r_associated | relid=0 | w=20
  2154. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-2-microglobulin protein
    n1=en:contraindications aspect | n2=en:beta-2-microglobulin protein | rel=r_associated | relid=0 | w=20
  2155. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-adrenergic agonist
    n1=en:contraindications aspect | n2=en:beta-adrenergic agonist | rel=r_associated | relid=0 | w=20
  2156. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-adrenergic antagonist
    n1=en:contraindications aspect | n2=en:beta-adrenergic antagonist | rel=r_associated | relid=0 | w=20
  2157. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-adrenergic receptor kinase 2
    n1=en:contraindications aspect | n2=en:beta-adrenergic receptor kinase 2 | rel=r_associated | relid=0 | w=20
  2158. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-alanine
    n1=en:contraindications aspect | n2=en:beta-alanine | rel=r_associated | relid=0 | w=20
  2159. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-amylase
    n1=en:contraindications aspect | n2=en:beta-amylase | rel=r_associated | relid=0 | w=20
  2160. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-crystallin a chain
    n1=en:contraindications aspect | n2=en:beta-crystallin a chain | rel=r_associated | relid=0 | w=20
  2161. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-crystallins
    n1=en:contraindications aspect | n2=en:beta-crystallins | rel=r_associated | relid=0 | w=20
  2162. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-hexosaminidase alpha chain
    n1=en:contraindications aspect | n2=en:beta-hexosaminidase alpha chain | rel=r_associated | relid=0 | w=20
  2163. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-hexosaminidase beta chain
    n1=en:contraindications aspect | n2=en:beta-hexosaminidase beta chain | rel=r_associated | relid=0 | w=20
  2164. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-lipotropin
    n1=en:contraindications aspect | n2=en:beta-lipotropin | rel=r_associated | relid=0 | w=20
  2165. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-synuclein
    n1=en:contraindications aspect | n2=en:beta-synuclein | rel=r_associated | relid=0 | w=20
  2166. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:beta-transducin repeat-containing proteins
    n1=en:contraindications aspect | n2=en:beta-transducin repeat-containing proteins | rel=r_associated | relid=0 | w=20
  2167. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:betacellulin
    n1=en:contraindications aspect | n2=en:betacellulin | rel=r_associated | relid=0 | w=20
  2168. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:betacyanins
    n1=en:contraindications aspect | n2=en:betacyanins | rel=r_associated | relid=0 | w=20
  2169. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:betaxanthins
    n1=en:contraindications aspect | n2=en:betaxanthins | rel=r_associated | relid=0 | w=20
  2170. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bethanechol
    n1=en:contraindications aspect | n2=en:bethanechol | rel=r_associated | relid=0 | w=20
  2171. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bevacizumab
    n1=en:contraindications aspect | n2=en:bevacizumab | rel=r_associated | relid=0 | w=20
  2172. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bh3-interacting domain death agonist
    n1=en:contraindications aspect | n2=en:bh3-interacting domain death agonist | rel=r_associated | relid=0 | w=20
  2173. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bicyclo compounds
    n1=en:contraindications aspect | n2=en:bicyclo compounds | rel=r_associated | relid=0 | w=20
  2174. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biflavonoids
    n1=en:contraindications aspect | n2=en:biflavonoids | rel=r_associated | relid=0 | w=20
  2175. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biguanides
    n1=en:contraindications aspect | n2=en:biguanides | rel=r_associated | relid=0 | w=20
  2176. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bilobalides
    n1=en:contraindications aspect | n2=en:bilobalides | rel=r_associated | relid=0 | w=20
  2177. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bioartificial organs
    n1=en:contraindications aspect | n2=en:bioartificial organs | rel=r_associated | relid=0 | w=20
  2178. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bioassay
    n1=en:contraindications aspect | n2=en:bioassay | rel=r_associated | relid=0 | w=20
  2179. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bioelectric energy sources
    n1=en:contraindications aspect | n2=en:bioelectric energy sources | rel=r_associated | relid=0 | w=20
  2180. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biogenic amines
    n1=en:contraindications aspect | n2=en:biogenic amines | rel=r_associated | relid=0 | w=20
  2181. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biogenic monoamines
    n1=en:contraindications aspect | n2=en:biogenic monoamines | rel=r_associated | relid=0 | w=20
  2182. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biolistics
    n1=en:contraindications aspect | n2=en:biolistics | rel=r_associated | relid=0 | w=20
  2183. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biological agent
    n1=en:contraindications aspect | n2=en:biological agent | rel=r_associated | relid=0 | w=20
  2184. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biological dressings
    n1=en:contraindications aspect | n2=en:biological dressings | rel=r_associated | relid=0 | w=20
  2185. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biological factors
    n1=en:contraindications aspect | n2=en:biological factors | rel=r_associated | relid=0 | w=20
  2186. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biological therapy
    n1=en:contraindications aspect | n2=en:biological therapy | rel=r_associated | relid=0 | w=20
  2187. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biomimetic materials
    n1=en:contraindications aspect | n2=en:biomimetic materials | rel=r_associated | relid=0 | w=20
  2188. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bioprosthesis device
    n1=en:contraindications aspect | n2=en:bioprosthesis device | rel=r_associated | relid=0 | w=20
  2189. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biopsy
    n1=en:contraindications aspect | n2=en:biopsy | rel=r_associated | relid=0 | w=20
  2190. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bioresonance therapy
    n1=en:contraindications aspect | n2=en:bioresonance therapy | rel=r_associated | relid=0 | w=20
  2191. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biphosphonate
    n1=en:contraindications aspect | n2=en:biphosphonate | rel=r_associated | relid=0 | w=20
  2192. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bis(chloromethyl) ether
    n1=en:contraindications aspect | n2=en:bis(chloromethyl) ether | rel=r_associated | relid=0 | w=20
  2193. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bispecific antibody
    n1=en:contraindications aspect | n2=en:bispecific antibody | rel=r_associated | relid=0 | w=20
  2194. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bisphosphoglycerate mutase
    n1=en:contraindications aspect | n2=en:bisphosphoglycerate mutase | rel=r_associated | relid=0 | w=20
  2195. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:biuret
    n1=en:contraindications aspect | n2=en:biuret | rel=r_associated | relid=0 | w=20
  2196. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blade implantation
    n1=en:contraindications aspect | n2=en:blade implantation | rel=r_associated | relid=0 | w=20
  2197. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bleaching agents
    n1=en:contraindications aspect | n2=en:bleaching agents | rel=r_associated | relid=0 | w=20
  2198. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood coagulation factor inhibitors
    n1=en:contraindications aspect | n2=en:blood coagulation factor inhibitors | rel=r_associated | relid=0 | w=20
  2199. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood glucose self-monitoring
    n1=en:contraindications aspect | n2=en:blood glucose self-monitoring | rel=r_associated | relid=0 | w=20
  2200. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood grouping and crossmatching
    n1=en:contraindications aspect | n2=en:blood grouping and crossmatching | rel=r_associated | relid=0 | w=20
  2201. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood preservation
    n1=en:contraindications aspect | n2=en:blood preservation | rel=r_associated | relid=0 | w=20
  2202. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood pressure
    n1=en:contraindications aspect | n2=en:blood pressure | rel=r_associated | relid=0 | w=20
  2203. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood pressure determination
    n1=en:contraindications aspect | n2=en:blood pressure determination | rel=r_associated | relid=0 | w=20
  2204. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood substitute
    n1=en:contraindications aspect | n2=en:blood substitute | rel=r_associated | relid=0 | w=20
  2205. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood transfusion
    n1=en:contraindications aspect | n2=en:blood transfusion | rel=r_associated | relid=0 | w=20
  2206. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood vessel prosthesis
    n1=en:contraindications aspect | n2=en:blood vessel prosthesis | rel=r_associated | relid=0 | w=20
  2207. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:blood volume determination
    n1=en:contraindications aspect | n2=en:blood volume determination | rel=r_associated | relid=0 | w=20
  2208. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bloodletting
    n1=en:contraindications aspect | n2=en:bloodletting | rel=r_associated | relid=0 | w=20
  2209. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:body surface potential mapping
    n1=en:contraindications aspect | n2=en:body surface potential mapping | rel=r_associated | relid=0 | w=20
  2210. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bone graft
    n1=en:contraindications aspect | n2=en:bone graft | rel=r_associated | relid=0 | w=20
  2211. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bone morphogenetic protein
    n1=en:contraindications aspect | n2=en:bone morphogenetic protein | rel=r_associated | relid=0 | w=20
  2212. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bone morphogenetic protein 4
    n1=en:contraindications aspect | n2=en:bone morphogenetic protein 4 | rel=r_associated | relid=0 | w=20
  2213. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bone plates
    n1=en:contraindications aspect | n2=en:bone plates | rel=r_associated | relid=0 | w=20
  2214. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bone screws
    n1=en:contraindications aspect | n2=en:bone screws | rel=r_associated | relid=0 | w=20
  2215. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bone substitutes
    n1=en:contraindications aspect | n2=en:bone substitutes | rel=r_associated | relid=0 | w=20
  2216. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bone wires
    n1=en:contraindications aspect | n2=en:bone wires | rel=r_associated | relid=0 | w=20
  2217. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bone-patellar tendon-bone grafting
    n1=en:contraindications aspect | n2=en:bone-patellar tendon-bone grafting | rel=r_associated | relid=0 | w=20
  2218. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bortezomib
    n1=en:contraindications aspect | n2=en:bortezomib | rel=r_associated | relid=0 | w=20
  2219. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:botulinum toxin type a
    n1=en:contraindications aspect | n2=en:botulinum toxin type a | rel=r_associated | relid=0 | w=20
  2220. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bovine serum albumin
    n1=en:contraindications aspect | n2=en:bovine serum albumin | rel=r_associated | relid=0 | w=20
  2221. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:braces
    n1=en:contraindications aspect | n2=en:braces | rel=r_associated | relid=0 | w=20
  2222. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:brain-computer interfaces
    n1=en:contraindications aspect | n2=en:brain-computer interfaces | rel=r_associated | relid=0 | w=20
  2223. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:brassinosteroids
    n1=en:contraindications aspect | n2=en:brassinosteroids | rel=r_associated | relid=0 | w=20
  2224. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:breast cancer type 1 susceptibility protein
    n1=en:contraindications aspect | n2=en:breast cancer type 1 susceptibility protein | rel=r_associated | relid=0 | w=20
  2225. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:breast cancer type 2 susceptibility protein
    n1=en:contraindications aspect | n2=en:breast cancer type 2 susceptibility protein | rel=r_associated | relid=0 | w=20
  2226. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:breast implant
    n1=en:contraindications aspect | n2=en:breast implant | rel=r_associated | relid=0 | w=20
  2227. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:breast prosthesis, internal
    n1=en:contraindications aspect | n2=en:breast prosthesis, internal | rel=r_associated | relid=0 | w=20
  2228. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:breast self-examination
    n1=en:contraindications aspect | n2=en:breast self-examination | rel=r_associated | relid=0 | w=20
  2229. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bretylol
    n1=en:contraindications aspect | n2=en:bretylol | rel=r_associated | relid=0 | w=20
  2230. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:brocresine
    n1=en:contraindications aspect | n2=en:brocresine | rel=r_associated | relid=0 | w=20
  2231. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bromelains
    n1=en:contraindications aspect | n2=en:bromelains | rel=r_associated | relid=0 | w=20
  2232. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bromosuccinimide
    n1=en:contraindications aspect | n2=en:bromosuccinimide | rel=r_associated | relid=0 | w=20
  2233. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bronchoalveolar lavage
    n1=en:contraindications aspect | n2=en:bronchoalveolar lavage | rel=r_associated | relid=0 | w=20
  2234. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bronchography
    n1=en:contraindications aspect | n2=en:bronchography | rel=r_associated | relid=0 | w=20
  2235. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bronchoscope
    n1=en:contraindications aspect | n2=en:bronchoscope | rel=r_associated | relid=0 | w=20
  2236. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bronchoscopy
    n1=en:contraindications aspect | n2=en:bronchoscopy | rel=r_associated | relid=0 | w=20
  2237. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bronchospirometry
    n1=en:contraindications aspect | n2=en:bronchospirometry | rel=r_associated | relid=0 | w=20
  2238. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bucrylate
    n1=en:contraindications aspect | n2=en:bucrylate | rel=r_associated | relid=0 | w=20
  2239. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bufotenin
    n1=en:contraindications aspect | n2=en:bufotenin | rel=r_associated | relid=0 | w=20
  2240. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:bungarotoxins
    n1=en:contraindications aspect | n2=en:bungarotoxins | rel=r_associated | relid=0 | w=20
  2241. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:burimamide
    n1=en:contraindications aspect | n2=en:burimamide | rel=r_associated | relid=0 | w=20
  2242. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:burr hole procedure
    n1=en:contraindications aspect | n2=en:burr hole procedure | rel=r_associated | relid=0 | w=20
  2243. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:busulfan
    n1=en:contraindications aspect | n2=en:busulfan | rel=r_associated | relid=0 | w=20
  2244. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:butanes
    n1=en:contraindications aspect | n2=en:butanes | rel=r_associated | relid=0 | w=20
  2245. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:butirosin sulfate
    n1=en:contraindications aspect | n2=en:butirosin sulfate | rel=r_associated | relid=0 | w=20
  2246. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:c-x-c motif chemokine 6
    n1=en:contraindications aspect | n2=en:c-x-c motif chemokine 6 | rel=r_associated | relid=0 | w=20
  2247. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ca19-9 antigen
    n1=en:contraindications aspect | n2=en:ca19-9 antigen | rel=r_associated | relid=0 | w=20
  2248. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cadherin
    n1=en:contraindications aspect | n2=en:cadherin | rel=r_associated | relid=0 | w=20
  2249. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cadherin related proteins
    n1=en:contraindications aspect | n2=en:cadherin related proteins | rel=r_associated | relid=0 | w=20
  2250. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cadmium chloride
    n1=en:contraindications aspect | n2=en:cadmium chloride | rel=r_associated | relid=0 | w=20
  2251. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cadmium compound
    n1=en:contraindications aspect | n2=en:cadmium compound | rel=r_associated | relid=0 | w=20
  2252. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caffeic acids
    n1=en:contraindications aspect | n2=en:caffeic acids | rel=r_associated | relid=0 | w=20
  2253. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium channel blocker
    n1=en:contraindications aspect | n2=en:calcium channel blocker | rel=r_associated | relid=0 | w=20
  2254. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium channel inhibitor
    n1=en:contraindications aspect | n2=en:calcium channel inhibitor | rel=r_associated | relid=0 | w=20
  2255. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium channels, q-type
    n1=en:contraindications aspect | n2=en:calcium channels, q-type | rel=r_associated | relid=0 | w=20
  2256. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium channels, r-type
    n1=en:contraindications aspect | n2=en:calcium channels, r-type | rel=r_associated | relid=0 | w=20
  2257. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium citrate
    n1=en:contraindications aspect | n2=en:calcium citrate | rel=r_associated | relid=0 | w=20
  2258. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium ionophores
    n1=en:contraindications aspect | n2=en:calcium ionophores | rel=r_associated | relid=0 | w=20
  2259. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium isotopes
    n1=en:contraindications aspect | n2=en:calcium isotopes | rel=r_associated | relid=0 | w=20
  2260. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium-activated potassium channel
    n1=en:contraindications aspect | n2=en:calcium-activated potassium channel | rel=r_associated | relid=0 | w=20
  2261. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium-calmodulin-dependent protein kinase type 1
    n1=en:contraindications aspect | n2=en:calcium-calmodulin-dependent protein kinase type 1 | rel=r_associated | relid=0 | w=20
  2262. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calcium-calmodulin-dependent protein kinase type 4
    n1=en:contraindications aspect | n2=en:calcium-calmodulin-dependent protein kinase type 4 | rel=r_associated | relid=0 | w=20
  2263. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calmodulin-dependent protein kinase ii
    n1=en:contraindications aspect | n2=en:calmodulin-dependent protein kinase ii | rel=r_associated | relid=0 | w=20
  2264. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:calretinin
    n1=en:contraindications aspect | n2=en:calretinin | rel=r_associated | relid=0 | w=20
  2265. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cam exercise therapy
    n1=en:contraindications aspect | n2=en:cam exercise therapy | rel=r_associated | relid=0 | w=20
  2266. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cane, includes canes of all materials, adjustable or fixed, with tip
    n1=en:contraindications aspect | n2=en:cane, includes canes of all materials, adjustable or fixed, with tip | rel=r_associated | relid=0 | w=20
  2267. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cannabidiol
    n1=en:contraindications aspect | n2=en:cannabidiol | rel=r_associated | relid=0 | w=20
  2268. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cannabinoid receptor antagonists
    n1=en:contraindications aspect | n2=en:cannabinoid receptor antagonists | rel=r_associated | relid=0 | w=20
  2269. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cannabinol
    n1=en:contraindications aspect | n2=en:cannabinol | rel=r_associated | relid=0 | w=20
  2270. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:canthaxanthin
    n1=en:contraindications aspect | n2=en:canthaxanthin | rel=r_associated | relid=0 | w=20
  2271. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:capecitabine
    n1=en:contraindications aspect | n2=en:capecitabine | rel=r_associated | relid=0 | w=20
  2272. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:capillary tubing
    n1=en:contraindications aspect | n2=en:capillary tubing | rel=r_associated | relid=0 | w=20
  2273. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:capnography
    n1=en:contraindications aspect | n2=en:capnography | rel=r_associated | relid=0 | w=20
  2274. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caprolactam
    n1=en:contraindications aspect | n2=en:caprolactam | rel=r_associated | relid=0 | w=20
  2275. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:capsaicin
    n1=en:contraindications aspect | n2=en:capsaicin | rel=r_associated | relid=0 | w=20
  2276. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:capsule endoscope
    n1=en:contraindications aspect | n2=en:capsule endoscope | rel=r_associated | relid=0 | w=20
  2277. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:capsulorhexis
    n1=en:contraindications aspect | n2=en:capsulorhexis | rel=r_associated | relid=0 | w=20
  2278. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbachol
    n1=en:contraindications aspect | n2=en:carbachol | rel=r_associated | relid=0 | w=20
  2279. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbachol chloride
    n1=en:contraindications aspect | n2=en:carbachol chloride | rel=r_associated | relid=0 | w=20
  2280. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbamoyl phosphate synthetase i activators
    n1=en:contraindications aspect | n2=en:carbamoyl phosphate synthetase i activators | rel=r_associated | relid=0 | w=20
  2281. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbapenems
    n1=en:contraindications aspect | n2=en:carbapenems | rel=r_associated | relid=0 | w=20
  2282. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbenoxolone
    n1=en:contraindications aspect | n2=en:carbenoxolone | rel=r_associated | relid=0 | w=20
  2283. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbofuran
    n1=en:contraindications aspect | n2=en:carbofuran | rel=r_associated | relid=0 | w=20
  2284. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbohydrate
    n1=en:contraindications aspect | n2=en:carbohydrate | rel=r_associated | relid=0 | w=20
  2285. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbohydrate epimerases
    n1=en:contraindications aspect | n2=en:carbohydrate epimerases | rel=r_associated | relid=0 | w=20
  2286. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbon-nitrogen lyases
    n1=en:contraindications aspect | n2=en:carbon-nitrogen lyases | rel=r_associated | relid=0 | w=20
  2287. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbon-oxygen lyases
    n1=en:contraindications aspect | n2=en:carbon-oxygen lyases | rel=r_associated | relid=0 | w=20
  2288. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbonate dehydratase
    n1=en:contraindications aspect | n2=en:carbonate dehydratase | rel=r_associated | relid=0 | w=20
  2289. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbonate ion
    n1=en:contraindications aspect | n2=en:carbonate ion | rel=r_associated | relid=0 | w=20
  2290. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbonic anhydrase iii
    n1=en:contraindications aspect | n2=en:carbonic anhydrase iii | rel=r_associated | relid=0 | w=20
  2291. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbonic anhydrase ix
    n1=en:contraindications aspect | n2=en:carbonic anhydrase ix | rel=r_associated | relid=0 | w=20
  2292. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carbonyl cyanide m-chlorophenyl hydrazone
    n1=en:contraindications aspect | n2=en:carbonyl cyanide m-chlorophenyl hydrazone | rel=r_associated | relid=0 | w=20
  2293. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carboxymethylcellulose sodium
    n1=en:contraindications aspect | n2=en:carboxymethylcellulose sodium | rel=r_associated | relid=0 | w=20
  2294. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carcinoembryonic antigen
    n1=en:contraindications aspect | n2=en:carcinoembryonic antigen | rel=r_associated | relid=0 | w=20
  2295. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carcinogen
    n1=en:contraindications aspect | n2=en:carcinogen | rel=r_associated | relid=0 | w=20
  2296. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carcinogenicity test
    n1=en:contraindications aspect | n2=en:carcinogenicity test | rel=r_associated | relid=0 | w=20
  2297. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cardiac catheterization
    n1=en:contraindications aspect | n2=en:cardiac catheterization | rel=r_associated | relid=0 | w=20
  2298. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cardiac catheters
    n1=en:contraindications aspect | n2=en:cardiac catheters | rel=r_associated | relid=0 | w=20
  2299. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cardiac resynchronization therapy
    n1=en:contraindications aspect | n2=en:cardiac resynchronization therapy | rel=r_associated | relid=0 | w=20
  2300. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cardiac resynchronization therapy devices
    n1=en:contraindications aspect | n2=en:cardiac resynchronization therapy devices | rel=r_associated | relid=0 | w=20
  2301. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cardiac-gated imaging techniques
    n1=en:contraindications aspect | n2=en:cardiac-gated imaging techniques | rel=r_associated | relid=0 | w=20
  2302. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cardioangiography
    n1=en:contraindications aspect | n2=en:cardioangiography | rel=r_associated | relid=0 | w=20
  2303. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cardiomyoplasty
    n1=en:contraindications aspect | n2=en:cardiomyoplasty | rel=r_associated | relid=0 | w=20
  2304. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cardiopulmonary bypass
    n1=en:contraindications aspect | n2=en:cardiopulmonary bypass | rel=r_associated | relid=0 | w=20
  2305. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cardiotonic agent
    n1=en:contraindications aspect | n2=en:cardiotonic agent | rel=r_associated | relid=0 | w=20
  2306. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cariogenic agents
    n1=en:contraindications aspect | n2=en:cariogenic agents | rel=r_associated | relid=0 | w=20
  2307. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:carmustine
    n1=en:contraindications aspect | n2=en:carmustine | rel=r_associated | relid=0 | w=20
  2308. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cartography
    n1=en:contraindications aspect | n2=en:cartography | rel=r_associated | relid=0 | w=20
  2309. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:casein kinase 2
    n1=en:contraindications aspect | n2=en:casein kinase 2 | rel=r_associated | relid=0 | w=20
  2310. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caspase 14
    n1=en:contraindications aspect | n2=en:caspase 14 | rel=r_associated | relid=0 | w=20
  2311. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caspase inhibitor
    n1=en:contraindications aspect | n2=en:caspase inhibitor | rel=r_associated | relid=0 | w=20
  2312. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caspase-10
    n1=en:contraindications aspect | n2=en:caspase-10 | rel=r_associated | relid=0 | w=20
  2313. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caspase-3
    n1=en:contraindications aspect | n2=en:caspase-3 | rel=r_associated | relid=0 | w=20
  2314. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caspase-9
    n1=en:contraindications aspect | n2=en:caspase-9 | rel=r_associated | relid=0 | w=20
  2315. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caspases, effector
    n1=en:contraindications aspect | n2=en:caspases, effector | rel=r_associated | relid=0 | w=20
  2316. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caspases, initiator
    n1=en:contraindications aspect | n2=en:caspases, initiator | rel=r_associated | relid=0 | w=20
  2317. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:casts, surgical
    n1=en:contraindications aspect | n2=en:casts, surgical | rel=r_associated | relid=0 | w=20
  2318. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:catalase
    n1=en:contraindications aspect | n2=en:catalase | rel=r_associated | relid=0 | w=20
  2319. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:catgut
    n1=en:contraindications aspect | n2=en:catgut | rel=r_associated | relid=0 | w=20
  2320. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cathepsin f
    n1=en:contraindications aspect | n2=en:cathepsin f | rel=r_associated | relid=0 | w=20
  2321. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cathepsin l1
    n1=en:contraindications aspect | n2=en:cathepsin l1 | rel=r_associated | relid=0 | w=20
  2322. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cathepsin w
    n1=en:contraindications aspect | n2=en:cathepsin w | rel=r_associated | relid=0 | w=20
  2323. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:catheterization
    n1=en:contraindications aspect | n2=en:catheterization | rel=r_associated | relid=0 | w=20
  2324. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:catheterization, central venous
    n1=en:contraindications aspect | n2=en:catheterization, central venous | rel=r_associated | relid=0 | w=20
  2325. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:catheterization, peripheral
    n1=en:contraindications aspect | n2=en:catheterization, peripheral | rel=r_associated | relid=0 | w=20
  2326. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cathode ray tubes
    n1=en:contraindications aspect | n2=en:cathode ray tubes | rel=r_associated | relid=0 | w=20
  2327. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cation exchange resins
    n1=en:contraindications aspect | n2=en:cation exchange resins | rel=r_associated | relid=0 | w=20
  2328. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cation transport proteins
    n1=en:contraindications aspect | n2=en:cation transport proteins | rel=r_associated | relid=0 | w=20
  2329. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cationic amino acid transporter 1
    n1=en:contraindications aspect | n2=en:cationic amino acid transporter 1 | rel=r_associated | relid=0 | w=20
  2330. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cations, monovalent
    n1=en:contraindications aspect | n2=en:cations, monovalent | rel=r_associated | relid=0 | w=20
  2331. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:caveolin 2
    n1=en:contraindications aspect | n2=en:caveolin 2 | rel=r_associated | relid=0 | w=20
  2332. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cd1 glycoprotein
    n1=en:contraindications aspect | n2=en:cd1 glycoprotein | rel=r_associated | relid=0 | w=20
  2333. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cd15 antigen
    n1=en:contraindications aspect | n2=en:cd15 antigen | rel=r_associated | relid=0 | w=20
  2334. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cd151 antigen
    n1=en:contraindications aspect | n2=en:cd151 antigen | rel=r_associated | relid=0 | w=20
  2335. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cd3 complex
    n1=en:contraindications aspect | n2=en:cd3 complex | rel=r_associated | relid=0 | w=20
  2336. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cd40 ligand
    n1=en:contraindications aspect | n2=en:cd40 ligand | rel=r_associated | relid=0 | w=20
  2337. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cd44 antigen
    n1=en:contraindications aspect | n2=en:cd44 antigen | rel=r_associated | relid=0 | w=20
  2338. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cd8 antigens
    n1=en:contraindications aspect | n2=en:cd8 antigens | rel=r_associated | relid=0 | w=20
  2339. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cdx2 transcription factor
    n1=en:contraindications aspect | n2=en:cdx2 transcription factor | rel=r_associated | relid=0 | w=20
  2340. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cecostomy
    n1=en:contraindications aspect | n2=en:cecostomy | rel=r_associated | relid=0 | w=20
  2341. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cefotiam
    n1=en:contraindications aspect | n2=en:cefotiam | rel=r_associated | relid=0 | w=20
  2342. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:celf proteins
    n1=en:contraindications aspect | n2=en:celf proteins | rel=r_associated | relid=0 | w=20
  2343. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:celf1 protein
    n1=en:contraindications aspect | n2=en:celf1 protein | rel=r_associated | relid=0 | w=20
  2344. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cell adhesion molecules, neuron-glia
    n1=en:contraindications aspect | n2=en:cell adhesion molecules, neuron-glia | rel=r_associated | relid=0 | w=20
  2345. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cell extracts
    n1=en:contraindications aspect | n2=en:cell extracts | rel=r_associated | relid=0 | w=20
  2346. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cell surface antigen
    n1=en:contraindications aspect | n2=en:cell surface antigen | rel=r_associated | relid=0 | w=20
  2347. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cementation
    n1=en:contraindications aspect | n2=en:cementation | rel=r_associated | relid=0 | w=20
  2348. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cementoplasty
    n1=en:contraindications aspect | n2=en:cementoplasty | rel=r_associated | relid=0 | w=20
  2349. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:central nervous system agents
    n1=en:contraindications aspect | n2=en:central nervous system agents | rel=r_associated | relid=0 | w=20
  2350. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:central venous access catheter
    n1=en:contraindications aspect | n2=en:central venous access catheter | rel=r_associated | relid=0 | w=20
  2351. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:centrifugation
    n1=en:contraindications aspect | n2=en:centrifugation | rel=r_associated | relid=0 | w=20
  2352. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cephalometry
    n1=en:contraindications aspect | n2=en:cephalometry | rel=r_associated | relid=0 | w=20
  2353. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cerebral computerized tomography
    n1=en:contraindications aspect | n2=en:cerebral computerized tomography | rel=r_associated | relid=0 | w=20
  2354. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cerebrospinal fluid proteins
    n1=en:contraindications aspect | n2=en:cerebrospinal fluid proteins | rel=r_associated | relid=0 | w=20
  2355. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cerebrospinal fluid shunts procedure
    n1=en:contraindications aspect | n2=en:cerebrospinal fluid shunts procedure | rel=r_associated | relid=0 | w=20
  2356. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cermet cements
    n1=en:contraindications aspect | n2=en:cermet cements | rel=r_associated | relid=0 | w=20
  2357. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:certolizumab pegol
    n1=en:contraindications aspect | n2=en:certolizumab pegol | rel=r_associated | relid=0 | w=20
  2358. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cervical length measurement
    n1=en:contraindications aspect | n2=en:cervical length measurement | rel=r_associated | relid=0 | w=20
  2359. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cervicectomy
    n1=en:contraindications aspect | n2=en:cervicectomy | rel=r_associated | relid=0 | w=20
  2360. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cetirizine
    n1=en:contraindications aspect | n2=en:cetirizine | rel=r_associated | relid=0 | w=20
  2361. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cetuximab
    n1=en:contraindications aspect | n2=en:cetuximab | rel=r_associated | relid=0 | w=20
  2362. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cgmp phosphodiesterase inhibitor
    n1=en:contraindications aspect | n2=en:cgmp phosphodiesterase inhibitor | rel=r_associated | relid=0 | w=20
  2363. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chalcone
    n1=en:contraindications aspect | n2=en:chalcone | rel=r_associated | relid=0 | w=20
  2364. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chelating agent
    n1=en:contraindications aspect | n2=en:chelating agent | rel=r_associated | relid=0 | w=20
  2365. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chemoembolization, therapeutic
    n1=en:contraindications aspect | n2=en:chemoembolization, therapeutic | rel=r_associated | relid=0 | w=20
  2366. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chemokine ccl20
    n1=en:contraindications aspect | n2=en:chemokine ccl20 | rel=r_associated | relid=0 | w=20
  2367. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chemosterilants
    n1=en:contraindications aspect | n2=en:chemosterilants | rel=r_associated | relid=0 | w=20
  2368. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chemotherapeutic perfusion
    n1=en:contraindications aspect | n2=en:chemotherapeutic perfusion | rel=r_associated | relid=0 | w=20
  2369. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chenodiol
    n1=en:contraindications aspect | n2=en:chenodiol | rel=r_associated | relid=0 | w=20
  2370. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:child restraint systems
    n1=en:contraindications aspect | n2=en:child restraint systems | rel=r_associated | relid=0 | w=20
  2371. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chiropractic manipulation
    n1=en:contraindications aspect | n2=en:chiropractic manipulation | rel=r_associated | relid=0 | w=20
  2372. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chitin synthase
    n1=en:contraindications aspect | n2=en:chitin synthase | rel=r_associated | relid=0 | w=20
  2373. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chloramines
    n1=en:contraindications aspect | n2=en:chloramines | rel=r_associated | relid=0 | w=20
  2374. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chloramphenicol o-acetyltransferase
    n1=en:contraindications aspect | n2=en:chloramphenicol o-acetyltransferase | rel=r_associated | relid=0 | w=20
  2375. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chlorates
    n1=en:contraindications aspect | n2=en:chlorates | rel=r_associated | relid=0 | w=20
  2376. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chlordecone
    n1=en:contraindications aspect | n2=en:chlordecone | rel=r_associated | relid=0 | w=20
  2377. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chlorfenvinphos
    n1=en:contraindications aspect | n2=en:chlorfenvinphos | rel=r_associated | relid=0 | w=20
  2378. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chloride channel agonists
    n1=en:contraindications aspect | n2=en:chloride channel agonists | rel=r_associated | relid=0 | w=20
  2379. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chlorine
    n1=en:contraindications aspect | n2=en:chlorine | rel=r_associated | relid=0 | w=20
  2380. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chlormadinone acetate
    n1=en:contraindications aspect | n2=en:chlormadinone acetate | rel=r_associated | relid=0 | w=20
  2381. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chlorobenzenes
    n1=en:contraindications aspect | n2=en:chlorobenzenes | rel=r_associated | relid=0 | w=20
  2382. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chlorophyll binding proteins
    n1=en:contraindications aspect | n2=en:chlorophyll binding proteins | rel=r_associated | relid=0 | w=20
  2383. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chloroplast dna
    n1=en:contraindications aspect | n2=en:chloroplast dna | rel=r_associated | relid=0 | w=20
  2384. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chloroplast proteins
    n1=en:contraindications aspect | n2=en:chloroplast proteins | rel=r_associated | relid=0 | w=20
  2385. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chloroprene
    n1=en:contraindications aspect | n2=en:chloroprene | rel=r_associated | relid=0 | w=20
  2386. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chloroquinolinols
    n1=en:contraindications aspect | n2=en:chloroquinolinols | rel=r_associated | relid=0 | w=20
  2387. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chlorpyrifos
    n1=en:contraindications aspect | n2=en:chlorpyrifos | rel=r_associated | relid=0 | w=20
  2388. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chlortetracycline
    n1=en:contraindications aspect | n2=en:chlortetracycline | rel=r_associated | relid=0 | w=20
  2389. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholangiogram
    n1=en:contraindications aspect | n2=en:cholangiogram | rel=r_associated | relid=0 | w=20
  2390. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholangiography
    n1=en:contraindications aspect | n2=en:cholangiography | rel=r_associated | relid=0 | w=20
  2391. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholecystectomy
    n1=en:contraindications aspect | n2=en:cholecystectomy | rel=r_associated | relid=0 | w=20
  2392. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholecystography
    n1=en:contraindications aspect | n2=en:cholecystography | rel=r_associated | relid=0 | w=20
  2393. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholecystostomy
    n1=en:contraindications aspect | n2=en:cholecystostomy | rel=r_associated | relid=0 | w=20
  2394. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholestadienols
    n1=en:contraindications aspect | n2=en:cholestadienols | rel=r_associated | relid=0 | w=20
  2395. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholestanes
    n1=en:contraindications aspect | n2=en:cholestanes | rel=r_associated | relid=0 | w=20
  2396. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholestenone 5 alpha-reductase
    n1=en:contraindications aspect | n2=en:cholestenone 5 alpha-reductase | rel=r_associated | relid=0 | w=20
  2397. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholestenones
    n1=en:contraindications aspect | n2=en:cholestenones | rel=r_associated | relid=0 | w=20
  2398. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholesterol esters
    n1=en:contraindications aspect | n2=en:cholesterol esters | rel=r_associated | relid=0 | w=20
  2399. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:choline o-acetyltransferase
    n1=en:contraindications aspect | n2=en:choline o-acetyltransferase | rel=r_associated | relid=0 | w=20
  2400. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:choline-phosphate cytidylyltransferase
    n1=en:contraindications aspect | n2=en:choline-phosphate cytidylyltransferase | rel=r_associated | relid=0 | w=20
  2401. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cholinergic antagonists
    n1=en:contraindications aspect | n2=en:cholinergic antagonists | rel=r_associated | relid=0 | w=20
  2402. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chondroitin abc lyase
    n1=en:contraindications aspect | n2=en:chondroitin abc lyase | rel=r_associated | relid=0 | w=20
  2403. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chondroitin lyases
    n1=en:contraindications aspect | n2=en:chondroitin lyases | rel=r_associated | relid=0 | w=20
  2404. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chondroitinsulfatases
    n1=en:contraindications aspect | n2=en:chondroitinsulfatases | rel=r_associated | relid=0 | w=20
  2405. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chromium compounds
    n1=en:contraindications aspect | n2=en:chromium compounds | rel=r_associated | relid=0 | w=20
  2406. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chromium radioisotopes
    n1=en:contraindications aspect | n2=en:chromium radioisotopes | rel=r_associated | relid=0 | w=20
  2407. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chromogranin
    n1=en:contraindications aspect | n2=en:chromogranin | rel=r_associated | relid=0 | w=20
  2408. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chromosmon
    n1=en:contraindications aspect | n2=en:chromosmon | rel=r_associated | relid=0 | w=20
  2409. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chylomicron remnants
    n1=en:contraindications aspect | n2=en:chylomicron remnants | rel=r_associated | relid=0 | w=20
  2410. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:chymotrypsin
    n1=en:contraindications aspect | n2=en:chymotrypsin | rel=r_associated | relid=0 | w=20
  2411. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ciliary neurotrophic factor
    n1=en:contraindications aspect | n2=en:ciliary neurotrophic factor | rel=r_associated | relid=0 | w=20
  2412. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cimetidine
    n1=en:contraindications aspect | n2=en:cimetidine | rel=r_associated | relid=0 | w=20
  2413. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cinacalcet hydrochloride
    n1=en:contraindications aspect | n2=en:cinacalcet hydrochloride | rel=r_associated | relid=0 | w=20
  2414. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cineangiography
    n1=en:contraindications aspect | n2=en:cineangiography | rel=r_associated | relid=0 | w=20
  2415. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:circulatory arrest, deep hypothermia induced
    n1=en:contraindications aspect | n2=en:circulatory arrest, deep hypothermia induced | rel=r_associated | relid=0 | w=20
  2416. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cisplatin
    n1=en:contraindications aspect | n2=en:cisplatin | rel=r_associated | relid=0 | w=20
  2417. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cisplatinum
    n1=en:contraindications aspect | n2=en:cisplatinum | rel=r_associated | relid=0 | w=20
  2418. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:citraconic anhydrides
    n1=en:contraindications aspect | n2=en:citraconic anhydrides | rel=r_associated | relid=0 | w=20
  2419. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:citrate (si)-synthase
    n1=en:contraindications aspect | n2=en:citrate (si)-synthase | rel=r_associated | relid=0 | w=20
  2420. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:citric acid
    n1=en:contraindications aspect | n2=en:citric acid | rel=r_associated | relid=0 | w=20
  2421. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:citrulline
    n1=en:contraindications aspect | n2=en:citrulline | rel=r_associated | relid=0 | w=20
  2422. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:clarithromycin
    n1=en:contraindications aspect | n2=en:clarithromycin | rel=r_associated | relid=0 | w=20
  2423. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:clathrin heavy chains
    n1=en:contraindications aspect | n2=en:clathrin heavy chains | rel=r_associated | relid=0 | w=20
  2424. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:clathrin light chains
    n1=en:contraindications aspect | n2=en:clathrin light chains | rel=r_associated | relid=0 | w=20
  2425. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:claudin 4
    n1=en:contraindications aspect | n2=en:claudin 4 | rel=r_associated | relid=0 | w=20
  2426. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:claudins
    n1=en:contraindications aspect | n2=en:claudins | rel=r_associated | relid=0 | w=20
  2427. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cleavage and polyadenylation specificity factor
    n1=en:contraindications aspect | n2=en:cleavage and polyadenylation specificity factor | rel=r_associated | relid=0 | w=20
  2428. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:clinical alarms
    n1=en:contraindications aspect | n2=en:clinical alarms | rel=r_associated | relid=0 | w=20
  2429. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:clinical chemistry tests
    n1=en:contraindications aspect | n2=en:clinical chemistry tests | rel=r_associated | relid=0 | w=20
  2430. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:clofazimine
    n1=en:contraindications aspect | n2=en:clofazimine | rel=r_associated | relid=0 | w=20
  2431. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cloprostenol
    n1=en:contraindications aspect | n2=en:cloprostenol | rel=r_associated | relid=0 | w=20
  2432. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cnidarian venoms
    n1=en:contraindications aspect | n2=en:cnidarian venoms | rel=r_associated | relid=0 | w=20
  2433. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:coagulation study
    n1=en:contraindications aspect | n2=en:coagulation study | rel=r_associated | relid=0 | w=20
  2434. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:coatomer protein
    n1=en:contraindications aspect | n2=en:coatomer protein | rel=r_associated | relid=0 | w=20
  2435. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cobalamin
    n1=en:contraindications aspect | n2=en:cobalamin | rel=r_associated | relid=0 | w=20
  2436. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cobamides
    n1=en:contraindications aspect | n2=en:cobamides | rel=r_associated | relid=0 | w=20
  2437. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cobicistat
    n1=en:contraindications aspect | n2=en:cobicistat | rel=r_associated | relid=0 | w=20
  2438. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cobra venoms
    n1=en:contraindications aspect | n2=en:cobra venoms | rel=r_associated | relid=0 | w=20
  2439. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cochlear implant procedure
    n1=en:contraindications aspect | n2=en:cochlear implant procedure | rel=r_associated | relid=0 | w=20
  2440. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cochlear implants
    n1=en:contraindications aspect | n2=en:cochlear implants | rel=r_associated | relid=0 | w=20
  2441. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:code
    n1=en:contraindications aspect | n2=en:code | rel=r_associated | relid=0 | w=20
  2442. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:codeine
    n1=en:contraindications aspect | n2=en:codeine | rel=r_associated | relid=0 | w=20
  2443. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:codon
    n1=en:contraindications aspect | n2=en:codon | rel=r_associated | relid=0 | w=20
  2444. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:codon, terminator
    n1=en:contraindications aspect | n2=en:codon, terminator | rel=r_associated | relid=0 | w=20
  2445. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cofilin-1
    n1=en:contraindications aspect | n2=en:cofilin-1 | rel=r_associated | relid=0 | w=20
  2446. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:coitus
    n1=en:contraindications aspect | n2=en:coitus | rel=r_associated | relid=0 | w=20
  2447. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:colectomy
    n1=en:contraindications aspect | n2=en:colectomy | rel=r_associated | relid=0 | w=20
  2448. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:collagen iv
    n1=en:contraindications aspect | n2=en:collagen iv | rel=r_associated | relid=0 | w=20
  2449. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:collagen type ix
    n1=en:contraindications aspect | n2=en:collagen type ix | rel=r_associated | relid=0 | w=20
  2450. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:collagen type vii
    n1=en:contraindications aspect | n2=en:collagen type vii | rel=r_associated | relid=0 | w=20
  2451. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:collagen type viii
    n1=en:contraindications aspect | n2=en:collagen type viii | rel=r_associated | relid=0 | w=20
  2452. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:collagen type xi
    n1=en:contraindications aspect | n2=en:collagen type xi | rel=r_associated | relid=0 | w=20
  2453. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:collagen type xviii
    n1=en:contraindications aspect | n2=en:collagen type xviii | rel=r_associated | relid=0 | w=20
  2454. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:collagenase
    n1=en:contraindications aspect | n2=en:collagenase | rel=r_associated | relid=0 | w=20
  2455. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:collapse therapy
    n1=en:contraindications aspect | n2=en:collapse therapy | rel=r_associated | relid=0 | w=20
  2456. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:collection of blood specimen for laboratory procedure
    n1=en:contraindications aspect | n2=en:collection of blood specimen for laboratory procedure | rel=r_associated | relid=0 | w=20
  2457. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:colloid
    n1=en:contraindications aspect | n2=en:colloid | rel=r_associated | relid=0 | w=20
  2458. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:colonic pouches
    n1=en:contraindications aspect | n2=en:colonic pouches | rel=r_associated | relid=0 | w=20
  2459. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:colonoscope
    n1=en:contraindications aspect | n2=en:colonoscope | rel=r_associated | relid=0 | w=20
  2460. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:colony stimulating factor
    n1=en:contraindications aspect | n2=en:colony stimulating factor | rel=r_associated | relid=0 | w=20
  2461. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:color perception tests
    n1=en:contraindications aspect | n2=en:color perception tests | rel=r_associated | relid=0 | w=20
  2462. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:colostomy
    n1=en:contraindications aspect | n2=en:colostomy | rel=r_associated | relid=0 | w=20
  2463. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:colposcope
    n1=en:contraindications aspect | n2=en:colposcope | rel=r_associated | relid=0 | w=20
  2464. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:colposcopy
    n1=en:contraindications aspect | n2=en:colposcopy | rel=r_associated | relid=0 | w=20
  2465. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:colpotomy
    n1=en:contraindications aspect | n2=en:colpotomy | rel=r_associated | relid=0 | w=20
  2466. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:communication aids for disabled
    n1=en:contraindications aspect | n2=en:communication aids for disabled | rel=r_associated | relid=0 | w=20
  2467. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:complement c3b
    n1=en:contraindications aspect | n2=en:complement c3b | rel=r_associated | relid=0 | w=20
  2468. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:complement component c7
    n1=en:contraindications aspect | n2=en:complement component c7 | rel=r_associated | relid=0 | w=20
  2469. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:complement factor h, human
    n1=en:contraindications aspect | n2=en:complement factor h, human | rel=r_associated | relid=0 | w=20
  2470. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:complete upper denture
    n1=en:contraindications aspect | n2=en:complete upper denture | rel=r_associated | relid=0 | w=20
  2471. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:compound q
    n1=en:contraindications aspect | n2=en:compound q | rel=r_associated | relid=0 | w=20
  2472. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:compressed air
    n1=en:contraindications aspect | n2=en:compressed air | rel=r_associated | relid=0 | w=20
  2473. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:compression bandage
    n1=en:contraindications aspect | n2=en:compression bandage | rel=r_associated | relid=0 | w=20
  2474. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:compression stockings
    n1=en:contraindications aspect | n2=en:compression stockings | rel=r_associated | relid=0 | w=20
  2475. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:computed tomography
    n1=en:contraindications aspect | n2=en:computed tomography | rel=r_associated | relid=0 | w=20
  2476. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:computed tomography colonography
    n1=en:contraindications aspect | n2=en:computed tomography colonography | rel=r_associated | relid=0 | w=20
  2477. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:computer language
    n1=en:contraindications aspect | n2=en:computer language | rel=r_associated | relid=0 | w=20
  2478. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:computer-assisted tomography
    n1=en:contraindications aspect | n2=en:computer-assisted tomography | rel=r_associated | relid=0 | w=20
  2479. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:concanavalin a
    n1=en:contraindications aspect | n2=en:concanavalin a | rel=r_associated | relid=0 | w=20
  2480. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:condom
    n1=en:contraindications aspect | n2=en:condom | rel=r_associated | relid=0 | w=20
  2481. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cone opsins
    n1=en:contraindications aspect | n2=en:cone opsins | rel=r_associated | relid=0 | w=20
  2482. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cone-beam computed tomography
    n1=en:contraindications aspect | n2=en:cone-beam computed tomography | rel=r_associated | relid=0 | w=20
  2483. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:conization
    n1=en:contraindications aspect | n2=en:conization | rel=r_associated | relid=0 | w=20
  2484. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:conjugate vaccine
    n1=en:contraindications aspect | n2=en:conjugate vaccine | rel=r_associated | relid=0 | w=20
  2485. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:connections
    n1=en:contraindications aspect | n2=en:connections | rel=r_associated | relid=0 | w=20
  2486. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:consciousness monitors
    n1=en:contraindications aspect | n2=en:consciousness monitors | rel=r_associated | relid=0 | w=20
  2487. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:conserved helix-loop-helix ubiquitous kinase
    n1=en:contraindications aspect | n2=en:conserved helix-loop-helix ubiquitous kinase | rel=r_associated | relid=0 | w=20
  2488. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contact lens solutions
    n1=en:contraindications aspect | n2=en:contact lens solutions | rel=r_associated | relid=0 | w=20
  2489. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contact lenses
    n1=en:contraindications aspect | n2=en:contact lenses | rel=r_associated | relid=0 | w=20
  2490. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contact lenses, extended-wear
    n1=en:contraindications aspect | n2=en:contact lenses, extended-wear | rel=r_associated | relid=0 | w=20
  2491. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contact lenses, hydrophilic
    n1=en:contraindications aspect | n2=en:contact lenses, hydrophilic | rel=r_associated | relid=0 | w=20
  2492. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contactin 2
    n1=en:contraindications aspect | n2=en:contactin 2 | rel=r_associated | relid=0 | w=20
  2493. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contacts
    n1=en:contraindications aspect | n2=en:contacts | rel=r_associated | relid=0 | w=20
  2494. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:continent urinary reservoir
    n1=en:contraindications aspect | n2=en:continent urinary reservoir | rel=r_associated | relid=0 | w=20
  2495. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:continuous sphygmomanometers
    n1=en:contraindications aspect | n2=en:continuous sphygmomanometers | rel=r_associated | relid=0 | w=20
  2496. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contra-indication
    n1=en:contraindications aspect | n2=en:contra-indication | rel=r_associated | relid=0 | w=20
  2497. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contraceptive device
    n1=en:contraindications aspect | n2=en:contraceptive device | rel=r_associated | relid=0 | w=20
  2498. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contraceptive devices, female
    n1=en:contraindications aspect | n2=en:contraceptive devices, female | rel=r_associated | relid=0 | w=20
  2499. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contraceptive devices, male
    n1=en:contraindications aspect | n2=en:contraceptive devices, male | rel=r_associated | relid=0 | w=20
  2500. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contraceptives, oral, hormonal
    n1=en:contraindications aspect | n2=en:contraceptives, oral, hormonal | rel=r_associated | relid=0 | w=20
  2501. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contraceptives, oral, synthetic
    n1=en:contraindications aspect | n2=en:contraceptives, oral, synthetic | rel=r_associated | relid=0 | w=20
  2502. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contraceptives, postcoital, hormonal
    n1=en:contraindications aspect | n2=en:contraceptives, postcoital, hormonal | rel=r_associated | relid=0 | w=20
  2503. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contraceptives, postcoital, synthetic
    n1=en:contraindications aspect | n2=en:contraceptives, postcoital, synthetic | rel=r_associated | relid=0 | w=20
  2504. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contrast agent
    n1=en:contraindications aspect | n2=en:contrast agent | rel=r_associated | relid=0 | w=20
  2505. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contrast bronchogram
    n1=en:contraindications aspect | n2=en:contrast bronchogram | rel=r_associated | relid=0 | w=20
  2506. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contrast media
    n1=en:contraindications aspect | n2=en:contrast media | rel=r_associated | relid=0 | w=20
  2507. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:contrast medium
    n1=en:contraindications aspect | n2=en:contrast medium | rel=r_associated | relid=0 | w=20
  2508. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:controlled substance
    n1=en:contraindications aspect | n2=en:controlled substance | rel=r_associated | relid=0 | w=20
  2509. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:convulsants
    n1=en:contraindications aspect | n2=en:convulsants | rel=r_associated | relid=0 | w=20
  2510. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:convulsive therapy
    n1=en:contraindications aspect | n2=en:convulsive therapy | rel=r_associated | relid=0 | w=20
  2511. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:copper-containing intrauterine device [epc]
    n1=en:contraindications aspect | n2=en:copper-containing intrauterine device [epc] | rel=r_associated | relid=0 | w=20
  2512. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:coproporphyrinogens
    n1=en:contraindications aspect | n2=en:coproporphyrinogens | rel=r_associated | relid=0 | w=20
  2513. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cordotomy
    n1=en:contraindications aspect | n2=en:cordotomy | rel=r_associated | relid=0 | w=20
  2514. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:core binding factor alpha subunits
    n1=en:contraindications aspect | n2=en:core binding factor alpha subunits | rel=r_associated | relid=0 | w=20
  2515. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:core binding factor beta subunit
    n1=en:contraindications aspect | n2=en:core binding factor beta subunit | rel=r_associated | relid=0 | w=20
  2516. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:corneal pachymetry
    n1=en:contraindications aspect | n2=en:corneal pachymetry | rel=r_associated | relid=0 | w=20
  2517. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:corneal transplant
    n1=en:contraindications aspect | n2=en:corneal transplant | rel=r_associated | relid=0 | w=20
  2518. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:correspond to
    n1=en:contraindications aspect | n2=en:correspond to | rel=r_associated | relid=0 | w=20
  2519. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:corrinoids
    n1=en:contraindications aspect | n2=en:corrinoids | rel=r_associated | relid=0 | w=20
  2520. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:corticosterone
    n1=en:contraindications aspect | n2=en:corticosterone | rel=r_associated | relid=0 | w=20
  2521. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:corticotropin-like intermediate lobe peptide
    n1=en:contraindications aspect | n2=en:corticotropin-like intermediate lobe peptide | rel=r_associated | relid=0 | w=20
  2522. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cortifair
    n1=en:contraindications aspect | n2=en:cortifair | rel=r_associated | relid=0 | w=20
  2523. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cortisol
    n1=en:contraindications aspect | n2=en:cortisol | rel=r_associated | relid=0 | w=20
  2524. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cosmetic
    n1=en:contraindications aspect | n2=en:cosmetic | rel=r_associated | relid=0 | w=20
  2525. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:coumaric acids
    n1=en:contraindications aspect | n2=en:coumaric acids | rel=r_associated | relid=0 | w=20
  2526. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:counter-argument
    n1=en:contraindications aspect | n2=en:counter-argument | rel=r_associated | relid=0 | w=20
  2527. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:counterindication
    n1=en:contraindications aspect | n2=en:counterindication | rel=r_associated | relid=0 | w=20
  2528. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:counterpulsation
    n1=en:contraindications aspect | n2=en:counterpulsation | rel=r_associated | relid=0 | w=20
  2529. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:coup transcription factor 2
    n1=en:contraindications aspect | n2=en:coup transcription factor 2 | rel=r_associated | relid=0 | w=20
  2530. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cowpox
    n1=en:contraindications aspect | n2=en:cowpox | rel=r_associated | relid=0 | w=20
  2531. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:craniometry
    n1=en:contraindications aspect | n2=en:craniometry | rel=r_associated | relid=0 | w=20
  2532. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:creatine kinase, mitochondrial form
    n1=en:contraindications aspect | n2=en:creatine kinase, mitochondrial form | rel=r_associated | relid=0 | w=20
  2533. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:creatine kinase, mm form
    n1=en:contraindications aspect | n2=en:creatine kinase, mm form | rel=r_associated | relid=0 | w=20
  2534. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:creation of peritoneovascular shunt
    n1=en:contraindications aspect | n2=en:creation of peritoneovascular shunt | rel=r_associated | relid=0 | w=20
  2535. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:crêpe bandage
    n1=en:contraindications aspect | n2=en:crêpe bandage | rel=r_associated | relid=0 | w=20
  2536. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:crocidolite asbestos
    n1=en:contraindications aspect | n2=en:crocidolite asbestos | rel=r_associated | relid=0 | w=20
  2537. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cross circulation
    n1=en:contraindications aspect | n2=en:cross circulation | rel=r_associated | relid=0 | w=20
  2538. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:croton oil
    n1=en:contraindications aspect | n2=en:croton oil | rel=r_associated | relid=0 | w=20
  2539. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:crown compounds
    n1=en:contraindications aspect | n2=en:crown compounds | rel=r_associated | relid=0 | w=20
  2540. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:crown lengthening
    n1=en:contraindications aspect | n2=en:crown lengthening | rel=r_associated | relid=0 | w=20
  2541. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:crowns
    n1=en:contraindications aspect | n2=en:crowns | rel=r_associated | relid=0 | w=20
  2542. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cryoanesthesia
    n1=en:contraindications aspect | n2=en:cryoanesthesia | rel=r_associated | relid=0 | w=20
  2543. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cryogels
    n1=en:contraindications aspect | n2=en:cryogels | rel=r_associated | relid=0 | w=20
  2544. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cryoglobulin
    n1=en:contraindications aspect | n2=en:cryoglobulin | rel=r_associated | relid=0 | w=20
  2545. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cryoprotective agent
    n1=en:contraindications aspect | n2=en:cryoprotective agent | rel=r_associated | relid=0 | w=20
  2546. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cryosurgery
    n1=en:contraindications aspect | n2=en:cryosurgery | rel=r_associated | relid=0 | w=20
  2547. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cryptoxanthins
    n1=en:contraindications aspect | n2=en:cryptoxanthins | rel=r_associated | relid=0 | w=20
  2548. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:crystalline silica quartz
    n1=en:contraindications aspect | n2=en:crystalline silica quartz | rel=r_associated | relid=0 | w=20
  2549. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:CT scanner
    n1=en:contraindications aspect | n2=en:CT scanner | rel=r_associated | relid=0 | w=20
  2550. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ct scanner
    n1=en:contraindications aspect | n2=en:ct scanner | rel=r_associated | relid=0 | w=20
  2551. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:CT-scan
    n1=en:contraindications aspect | n2=en:CT-scan | rel=r_associated | relid=0 | w=20
  2552. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cucumber mosaic virus satellite
    n1=en:contraindications aspect | n2=en:cucumber mosaic virus satellite | rel=r_associated | relid=0 | w=20
  2553. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:culdoscopy
    n1=en:contraindications aspect | n2=en:culdoscopy | rel=r_associated | relid=0 | w=20
  2554. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:culture media, serum-free
    n1=en:contraindications aspect | n2=en:culture media, serum-free | rel=r_associated | relid=0 | w=20
  2555. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:curcumin
    n1=en:contraindications aspect | n2=en:curcumin | rel=r_associated | relid=0 | w=20
  2556. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:curing lights, dental
    n1=en:contraindications aspect | n2=en:curing lights, dental | rel=r_associated | relid=0 | w=20
  2557. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cutaneous radiotherapy
    n1=en:contraindications aspect | n2=en:cutaneous radiotherapy | rel=r_associated | relid=0 | w=20
  2558. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cycasin
    n1=en:contraindications aspect | n2=en:cycasin | rel=r_associated | relid=0 | w=20
  2559. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclic adp-ribose
    n1=en:contraindications aspect | n2=en:cyclic adp-ribose | rel=r_associated | relid=0 | w=20
  2560. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclic amp-dependent protein kinase type i
    n1=en:contraindications aspect | n2=en:cyclic amp-dependent protein kinase type i | rel=r_associated | relid=0 | w=20
  2561. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclic amp-dependent protein kinase type ii
    n1=en:contraindications aspect | n2=en:cyclic amp-dependent protein kinase type ii | rel=r_associated | relid=0 | w=20
  2562. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclic amp-dependent transcription factor atf-3
    n1=en:contraindications aspect | n2=en:cyclic amp-dependent transcription factor atf-3 | rel=r_associated | relid=0 | w=20
  2563. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclic imp
    n1=en:contraindications aspect | n2=en:cyclic imp | rel=r_associated | relid=0 | w=20
  2564. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclic nucleotide phosphodiesterases, type 2
    n1=en:contraindications aspect | n2=en:cyclic nucleotide phosphodiesterases, type 2 | rel=r_associated | relid=0 | w=20
  2565. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclic nucleotide phosphodiesterases, type 5
    n1=en:contraindications aspect | n2=en:cyclic nucleotide phosphodiesterases, type 5 | rel=r_associated | relid=0 | w=20
  2566. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclin b1
    n1=en:contraindications aspect | n2=en:cyclin b1 | rel=r_associated | relid=0 | w=20
  2567. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclin g
    n1=en:contraindications aspect | n2=en:cyclin g | rel=r_associated | relid=0 | w=20
  2568. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclin i
    n1=en:contraindications aspect | n2=en:cyclin i | rel=r_associated | relid=0 | w=20
  2569. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclin t
    n1=en:contraindications aspect | n2=en:cyclin t | rel=r_associated | relid=0 | w=20
  2570. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclin-a1
    n1=en:contraindications aspect | n2=en:cyclin-a1 | rel=r_associated | relid=0 | w=20
  2571. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclin-dependent kinase 1
    n1=en:contraindications aspect | n2=en:cyclin-dependent kinase 1 | rel=r_associated | relid=0 | w=20
  2572. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclin-dependent kinase 6
    n1=en:contraindications aspect | n2=en:cyclin-dependent kinase 6 | rel=r_associated | relid=0 | w=20
  2573. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclin-h
    n1=en:contraindications aspect | n2=en:cyclin-h | rel=r_associated | relid=0 | w=20
  2574. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclitols
    n1=en:contraindications aspect | n2=en:cyclitols | rel=r_associated | relid=0 | w=20
  2575. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclobutanes
    n1=en:contraindications aspect | n2=en:cyclobutanes | rel=r_associated | relid=0 | w=20
  2576. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclohexanecarboxylic acids
    n1=en:contraindications aspect | n2=en:cyclohexanecarboxylic acids | rel=r_associated | relid=0 | w=20
  2577. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cycloleucine
    n1=en:contraindications aspect | n2=en:cycloleucine | rel=r_associated | relid=0 | w=20
  2578. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclooxygenase 2
    n1=en:contraindications aspect | n2=en:cyclooxygenase 2 | rel=r_associated | relid=0 | w=20
  2579. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclooxygenase inhibitor
    n1=en:contraindications aspect | n2=en:cyclooxygenase inhibitor | rel=r_associated | relid=0 | w=20
  2580. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclophilin a
    n1=en:contraindications aspect | n2=en:cyclophilin a | rel=r_associated | relid=0 | w=20
  2581. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclophosphamide
    n1=en:contraindications aspect | n2=en:cyclophosphamide | rel=r_associated | relid=0 | w=20
  2582. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyclopropanes
    n1=en:contraindications aspect | n2=en:cyclopropanes | rel=r_associated | relid=0 | w=20
  2583. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cyproterone
    n1=en:contraindications aspect | n2=en:cyproterone | rel=r_associated | relid=0 | w=20
  2584. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cystathionine beta-synthase
    n1=en:contraindications aspect | n2=en:cystathionine beta-synthase | rel=r_associated | relid=0 | w=20
  2585. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cystectomy
    n1=en:contraindications aspect | n2=en:cystectomy | rel=r_associated | relid=0 | w=20
  2586. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cysteic acid
    n1=en:contraindications aspect | n2=en:cysteic acid | rel=r_associated | relid=0 | w=20
  2587. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cysteine synthase
    n1=en:contraindications aspect | n2=en:cysteine synthase | rel=r_associated | relid=0 | w=20
  2588. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cysteine-rich protein 61
    n1=en:contraindications aspect | n2=en:cysteine-rich protein 61 | rel=r_associated | relid=0 | w=20
  2589. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cystine depleting agents
    n1=en:contraindications aspect | n2=en:cystine depleting agents | rel=r_associated | relid=0 | w=20
  2590. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cystoscope
    n1=en:contraindications aspect | n2=en:cystoscope | rel=r_associated | relid=0 | w=20
  2591. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cystostomy
    n1=en:contraindications aspect | n2=en:cystostomy | rel=r_associated | relid=0 | w=20
  2592. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cystotomy
    n1=en:contraindications aspect | n2=en:cystotomy | rel=r_associated | relid=0 | w=20
  2593. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytidine diphosphate diglycerides
    n1=en:contraindications aspect | n2=en:cytidine diphosphate diglycerides | rel=r_associated | relid=0 | w=20
  2594. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytidine triphosphate
    n1=en:contraindications aspect | n2=en:cytidine triphosphate | rel=r_associated | relid=0 | w=20
  2595. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochalasin b
    n1=en:contraindications aspect | n2=en:cytochalasin b | rel=r_associated | relid=0 | w=20
  2596. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome a
    n1=en:contraindications aspect | n2=en:cytochrome a | rel=r_associated | relid=0 | w=20
  2597. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome b6f
    n1=en:contraindications aspect | n2=en:cytochrome b6f | rel=r_associated | relid=0 | w=20
  2598. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome c1
    n1=en:contraindications aspect | n2=en:cytochrome c1 | rel=r_associated | relid=0 | w=20
  2599. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p-450 cyp1a2 inducers
    n1=en:contraindications aspect | n2=en:cytochrome p-450 cyp1a2 inducers | rel=r_associated | relid=0 | w=20
  2600. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p-450 cyp2b6 inhibitors
    n1=en:contraindications aspect | n2=en:cytochrome p-450 cyp2b6 inhibitors | rel=r_associated | relid=0 | w=20
  2601. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p-450 cyp2d6 inducers
    n1=en:contraindications aspect | n2=en:cytochrome p-450 cyp2d6 inducers | rel=r_associated | relid=0 | w=20
  2602. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p-450 cyp2d6 inhibitors
    n1=en:contraindications aspect | n2=en:cytochrome p-450 cyp2d6 inhibitors | rel=r_associated | relid=0 | w=20
  2603. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p-450 cyp2e1 inhibitors
    n1=en:contraindications aspect | n2=en:cytochrome p-450 cyp2e1 inhibitors | rel=r_associated | relid=0 | w=20
  2604. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p-450 cyp3a inducers
    n1=en:contraindications aspect | n2=en:cytochrome p-450 cyp3a inducers | rel=r_associated | relid=0 | w=20
  2605. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p-450 enzyme inhibitors
    n1=en:contraindications aspect | n2=en:cytochrome p-450 enzyme inhibitors | rel=r_associated | relid=0 | w=20
  2606. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p450 cyp2c9 enzyme
    n1=en:contraindications aspect | n2=en:cytochrome p450 cyp2c9 enzyme | rel=r_associated | relid=0 | w=20
  2607. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p450 family 19
    n1=en:contraindications aspect | n2=en:cytochrome p450 family 19 | rel=r_associated | relid=0 | w=20
  2608. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p450 family 24
    n1=en:contraindications aspect | n2=en:cytochrome p450 family 24 | rel=r_associated | relid=0 | w=20
  2609. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p450 family 3
    n1=en:contraindications aspect | n2=en:cytochrome p450 family 3 | rel=r_associated | relid=0 | w=20
  2610. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p450 family 46
    n1=en:contraindications aspect | n2=en:cytochrome p450 family 46 | rel=r_associated | relid=0 | w=20
  2611. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochrome p450 family 6
    n1=en:contraindications aspect | n2=en:cytochrome p450 family 6 | rel=r_associated | relid=0 | w=20
  2612. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochromes b
    n1=en:contraindications aspect | n2=en:cytochromes b | rel=r_associated | relid=0 | w=20
  2613. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochromes b5
    n1=en:contraindications aspect | n2=en:cytochromes b5 | rel=r_associated | relid=0 | w=20
  2614. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochromes c'
    n1=en:contraindications aspect | n2=en:cytochromes c' | rel=r_associated | relid=0 | w=20
  2615. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytochromes d
    n1=en:contraindications aspect | n2=en:cytochromes d | rel=r_associated | relid=0 | w=20
  2616. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:cytologic test
    n1=en:contraindications aspect | n2=en:cytologic test | rel=r_associated | relid=0 | w=20
  2617. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:d-ala(2),mephe(4),met(0)-ol-enkephalin
    n1=en:contraindications aspect | n2=en:d-ala(2),mephe(4),met(0)-ol-enkephalin | rel=r_associated | relid=0 | w=20
  2618. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dacryocystorhinostomy
    n1=en:contraindications aspect | n2=en:dacryocystorhinostomy | rel=r_associated | relid=0 | w=20
  2619. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dactinomycin
    n1=en:contraindications aspect | n2=en:dactinomycin | rel=r_associated | relid=0 | w=20
  2620. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dalfampridine
    n1=en:contraindications aspect | n2=en:dalfampridine | rel=r_associated | relid=0 | w=20
  2621. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dapsone
    n1=en:contraindications aspect | n2=en:dapsone | rel=r_associated | relid=0 | w=20
  2622. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:darbepoetin alfa
    n1=en:contraindications aspect | n2=en:darbepoetin alfa | rel=r_associated | relid=0 | w=20
  2623. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dasatinib
    n1=en:contraindications aspect | n2=en:dasatinib | rel=r_associated | relid=0 | w=20
  2624. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:daunorubicin
    n1=en:contraindications aspect | n2=en:daunorubicin | rel=r_associated | relid=0 | w=20
  2625. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:deafferentation
    n1=en:contraindications aspect | n2=en:deafferentation | rel=r_associated | relid=0 | w=20
  2626. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:debridement
    n1=en:contraindications aspect | n2=en:debridement | rel=r_associated | relid=0 | w=20
  2627. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:decamethonium compounds
    n1=en:contraindications aspect | n2=en:decamethonium compounds | rel=r_associated | relid=0 | w=20
  2628. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:decanoates
    n1=en:contraindications aspect | n2=en:decanoates | rel=r_associated | relid=0 | w=20
  2629. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:decortication
    n1=en:contraindications aspect | n2=en:decortication | rel=r_associated | relid=0 | w=20
  2630. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:deep sedation
    n1=en:contraindications aspect | n2=en:deep sedation | rel=r_associated | relid=0 | w=20
  2631. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:defecography
    n1=en:contraindications aspect | n2=en:defecography | rel=r_associated | relid=0 | w=20
  2632. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:defibrillators
    n1=en:contraindications aspect | n2=en:defibrillators | rel=r_associated | relid=0 | w=20
  2633. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dehydroepiandrosterone sulfate
    n1=en:contraindications aspect | n2=en:dehydroepiandrosterone sulfate | rel=r_associated | relid=0 | w=20
  2634. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:delavirdine
    n1=en:contraindications aspect | n2=en:delavirdine | rel=r_associated | relid=0 | w=20
  2635. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:delayed rectifier potassium channel
    n1=en:contraindications aspect | n2=en:delayed rectifier potassium channel | rel=r_associated | relid=0 | w=20
  2636. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:demeclocycline
    n1=en:contraindications aspect | n2=en:demeclocycline | rel=r_associated | relid=0 | w=20
  2637. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:demecolcine
    n1=en:contraindications aspect | n2=en:demecolcine | rel=r_associated | relid=0 | w=20
  2638. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denosumab
    n1=en:contraindications aspect | n2=en:denosumab | rel=r_associated | relid=0 | w=20
  2639. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental abutments
    n1=en:contraindications aspect | n2=en:dental abutments | rel=r_associated | relid=0 | w=20
  2640. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental alloys
    n1=en:contraindications aspect | n2=en:dental alloys | rel=r_associated | relid=0 | w=20
  2641. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental amalgam
    n1=en:contraindications aspect | n2=en:dental amalgam | rel=r_associated | relid=0 | w=20
  2642. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental articulators
    n1=en:contraindications aspect | n2=en:dental articulators | rel=r_associated | relid=0 | w=20
  2643. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental atraumatic restorative treatment
    n1=en:contraindications aspect | n2=en:dental atraumatic restorative treatment | rel=r_associated | relid=0 | w=20
  2644. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental brace
    n1=en:contraindications aspect | n2=en:dental brace | rel=r_associated | relid=0 | w=20
  2645. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental care for children
    n1=en:contraindications aspect | n2=en:dental care for children | rel=r_associated | relid=0 | w=20
  2646. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental caries activity tests
    n1=en:contraindications aspect | n2=en:dental caries activity tests | rel=r_associated | relid=0 | w=20
  2647. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental cavity lining
    n1=en:contraindications aspect | n2=en:dental cavity lining | rel=r_associated | relid=0 | w=20
  2648. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental clasps
    n1=en:contraindications aspect | n2=en:dental clasps | rel=r_associated | relid=0 | w=20
  2649. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental dam
    n1=en:contraindications aspect | n2=en:dental dam | rel=r_associated | relid=0 | w=20
  2650. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental devices, home care
    n1=en:contraindications aspect | n2=en:dental devices, home care | rel=r_associated | relid=0 | w=20
  2651. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental enamel proteins
    n1=en:contraindications aspect | n2=en:dental enamel proteins | rel=r_associated | relid=0 | w=20
  2652. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental endosseous implant insertion
    n1=en:contraindications aspect | n2=en:dental endosseous implant insertion | rel=r_associated | relid=0 | w=20
  2653. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental equipment
    n1=en:contraindications aspect | n2=en:dental equipment | rel=r_associated | relid=0 | w=20
  2654. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental etching
    n1=en:contraindications aspect | n2=en:dental etching | rel=r_associated | relid=0 | w=20
  2655. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental high-speed equipment
    n1=en:contraindications aspect | n2=en:dental high-speed equipment | rel=r_associated | relid=0 | w=20
  2656. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental high-speed technique
    n1=en:contraindications aspect | n2=en:dental high-speed technique | rel=r_associated | relid=0 | w=20
  2657. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental implant
    n1=en:contraindications aspect | n2=en:dental implant | rel=r_associated | relid=0 | w=20
  2658. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental implant-abutment design
    n1=en:contraindications aspect | n2=en:dental implant-abutment design | rel=r_associated | relid=0 | w=20
  2659. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental implantation, endosseous, endodontic
    n1=en:contraindications aspect | n2=en:dental implantation, endosseous, endodontic | rel=r_associated | relid=0 | w=20
  2660. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental implantation, subperiosteal
    n1=en:contraindications aspect | n2=en:dental implantation, subperiosteal | rel=r_associated | relid=0 | w=20
  2661. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental implants, single-tooth
    n1=en:contraindications aspect | n2=en:dental implants, single-tooth | rel=r_associated | relid=0 | w=20
  2662. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental impression materials
    n1=en:contraindications aspect | n2=en:dental impression materials | rel=r_associated | relid=0 | w=20
  2663. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental inlays
    n1=en:contraindications aspect | n2=en:dental inlays | rel=r_associated | relid=0 | w=20
  2664. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental instruments
    n1=en:contraindications aspect | n2=en:dental instruments | rel=r_associated | relid=0 | w=20
  2665. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental models
    n1=en:contraindications aspect | n2=en:dental models | rel=r_associated | relid=0 | w=20
  2666. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental pins
    n1=en:contraindications aspect | n2=en:dental pins | rel=r_associated | relid=0 | w=20
  2667. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental plate
    n1=en:contraindications aspect | n2=en:dental plate | rel=r_associated | relid=0 | w=20
  2668. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental polishes
    n1=en:contraindications aspect | n2=en:dental polishes | rel=r_associated | relid=0 | w=20
  2669. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental procedure
    n1=en:contraindications aspect | n2=en:dental procedure | rel=r_associated | relid=0 | w=20
  2670. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental prosthesis
    n1=en:contraindications aspect | n2=en:dental prosthesis | rel=r_associated | relid=0 | w=20
  2671. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental prosthesis, implant-supported
    n1=en:contraindications aspect | n2=en:dental prosthesis, implant-supported | rel=r_associated | relid=0 | w=20
  2672. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental pulp devitalization
    n1=en:contraindications aspect | n2=en:dental pulp devitalization | rel=r_associated | relid=0 | w=20
  2673. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental pulp test
    n1=en:contraindications aspect | n2=en:dental pulp test | rel=r_associated | relid=0 | w=20
  2674. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental restoration repair
    n1=en:contraindications aspect | n2=en:dental restoration repair | rel=r_associated | relid=0 | w=20
  2675. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental scaling
    n1=en:contraindications aspect | n2=en:dental scaling | rel=r_associated | relid=0 | w=20
  2676. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental soldering
    n1=en:contraindications aspect | n2=en:dental soldering | rel=r_associated | relid=0 | w=20
  2677. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dental veneer application
    n1=en:contraindications aspect | n2=en:dental veneer application | rel=r_associated | relid=0 | w=20
  2678. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dentifrice
    n1=en:contraindications aspect | n2=en:dentifrice | rel=r_associated | relid=0 | w=20
  2679. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dentifrices
    n1=en:contraindications aspect | n2=en:dentifrices | rel=r_associated | relid=0 | w=20
  2680. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dentin desensitizing agents
    n1=en:contraindications aspect | n2=en:dentin desensitizing agents | rel=r_associated | relid=0 | w=20
  2681. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture
    n1=en:contraindications aspect | n2=en:denture | rel=r_associated | relid=0 | w=20
  2682. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture bases
    n1=en:contraindications aspect | n2=en:denture bases | rel=r_associated | relid=0 | w=20
  2683. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture identification marking
    n1=en:contraindications aspect | n2=en:denture identification marking | rel=r_associated | relid=0 | w=20
  2684. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture liners
    n1=en:contraindications aspect | n2=en:denture liners | rel=r_associated | relid=0 | w=20
  2685. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture precision attachment device
    n1=en:contraindications aspect | n2=en:denture precision attachment device | rel=r_associated | relid=0 | w=20
  2686. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture retention
    n1=en:contraindications aspect | n2=en:denture retention | rel=r_associated | relid=0 | w=20
  2687. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture, complete
    n1=en:contraindications aspect | n2=en:denture, complete | rel=r_associated | relid=0 | w=20
  2688. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture, complete, immediate
    n1=en:contraindications aspect | n2=en:denture, complete, immediate | rel=r_associated | relid=0 | w=20
  2689. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture, partial
    n1=en:contraindications aspect | n2=en:denture, partial | rel=r_associated | relid=0 | w=20
  2690. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture, partial, fixed
    n1=en:contraindications aspect | n2=en:denture, partial, fixed | rel=r_associated | relid=0 | w=20
  2691. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture, partial, fixed, resin-bonded
    n1=en:contraindications aspect | n2=en:denture, partial, fixed, resin-bonded | rel=r_associated | relid=0 | w=20
  2692. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture, partial, immediate
    n1=en:contraindications aspect | n2=en:denture, partial, immediate | rel=r_associated | relid=0 | w=20
  2693. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:denture, partial, temporary
    n1=en:contraindications aspect | n2=en:denture, partial, temporary | rel=r_associated | relid=0 | w=20
  2694. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dentures
    n1=en:contraindications aspect | n2=en:dentures | rel=r_associated | relid=0 | w=20
  2695. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:deodorants
    n1=en:contraindications aspect | n2=en:deodorants | rel=r_associated | relid=0 | w=20
  2696. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:deoxycholic acid
    n1=en:contraindications aspect | n2=en:deoxycholic acid | rel=r_associated | relid=0 | w=20
  2697. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:deoxyribonuclease
    n1=en:contraindications aspect | n2=en:deoxyribonuclease | rel=r_associated | relid=0 | w=20
  2698. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:deoxyribonucleoproteins
    n1=en:contraindications aspect | n2=en:deoxyribonucleoproteins | rel=r_associated | relid=0 | w=20
  2699. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:deoxyribose
    n1=en:contraindications aspect | n2=en:deoxyribose | rel=r_associated | relid=0 | w=20
  2700. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:deoxyuracil nucleotides
    n1=en:contraindications aspect | n2=en:deoxyuracil nucleotides | rel=r_associated | relid=0 | w=20
  2701. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:deoxyuridine
    n1=en:contraindications aspect | n2=en:deoxyuridine | rel=r_associated | relid=0 | w=20
  2702. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dermoscopy
    n1=en:contraindications aspect | n2=en:dermoscopy | rel=r_associated | relid=0 | w=20
  2703. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:desmoglein 1
    n1=en:contraindications aspect | n2=en:desmoglein 1 | rel=r_associated | relid=0 | w=20
  2704. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:desmoglein 2
    n1=en:contraindications aspect | n2=en:desmoglein 2 | rel=r_associated | relid=0 | w=20
  2705. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:desmosterol
    n1=en:contraindications aspect | n2=en:desmosterol | rel=r_associated | relid=0 | w=20
  2706. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:desoximetasone
    n1=en:contraindications aspect | n2=en:desoximetasone | rel=r_associated | relid=0 | w=20
  2707. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:desoxycorticosterone acetate
    n1=en:contraindications aspect | n2=en:desoxycorticosterone acetate | rel=r_associated | relid=0 | w=20
  2708. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:destrin
    n1=en:contraindications aspect | n2=en:destrin | rel=r_associated | relid=0 | w=20
  2709. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:detergent
    n1=en:contraindications aspect | n2=en:detergent | rel=r_associated | relid=0 | w=20
  2710. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:device removal
    n1=en:contraindications aspect | n2=en:device removal | rel=r_associated | relid=0 | w=20
  2711. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dextran sulfate
    n1=en:contraindications aspect | n2=en:dextran sulfate | rel=r_associated | relid=0 | w=20
  2712. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dextromethorphan
    n1=en:contraindications aspect | n2=en:dextromethorphan | rel=r_associated | relid=0 | w=20
  2713. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dextrorphan
    n1=en:contraindications aspect | n2=en:dextrorphan | rel=r_associated | relid=0 | w=20
  2714. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diacylglycerol o-acyltransferase
    n1=en:contraindications aspect | n2=en:diacylglycerol o-acyltransferase | rel=r_associated | relid=0 | w=20
  2715. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diagnostic equipment
    n1=en:contraindications aspect | n2=en:diagnostic equipment | rel=r_associated | relid=0 | w=20
  2716. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diagnostic imaging
    n1=en:contraindications aspect | n2=en:diagnostic imaging | rel=r_associated | relid=0 | w=20
  2717. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diagnostic techniques, surgical
    n1=en:contraindications aspect | n2=en:diagnostic techniques, surgical | rel=r_associated | relid=0 | w=20
  2718. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dialysis
    n1=en:contraindications aspect | n2=en:dialysis | rel=r_associated | relid=0 | w=20
  2719. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dialysis fluid
    n1=en:contraindications aspect | n2=en:dialysis fluid | rel=r_associated | relid=0 | w=20
  2720. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diaminopimelic acid
    n1=en:contraindications aspect | n2=en:diaminopimelic acid | rel=r_associated | relid=0 | w=20
  2721. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diamond
    n1=en:contraindications aspect | n2=en:diamond | rel=r_associated | relid=0 | w=20
  2722. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dianhydrogalactitol
    n1=en:contraindications aspect | n2=en:dianhydrogalactitol | rel=r_associated | relid=0 | w=20
  2723. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diapers, adult
    n1=en:contraindications aspect | n2=en:diapers, adult | rel=r_associated | relid=0 | w=20
  2724. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diathermy
    n1=en:contraindications aspect | n2=en:diathermy | rel=r_associated | relid=0 | w=20
  2725. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diazinon
    n1=en:contraindications aspect | n2=en:diazinon | rel=r_associated | relid=0 | w=20
  2726. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diazomethane
    n1=en:contraindications aspect | n2=en:diazomethane | rel=r_associated | relid=0 | w=20
  2727. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dibenzofurans
    n1=en:contraindications aspect | n2=en:dibenzofurans | rel=r_associated | relid=0 | w=20
  2728. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dibenzofurans, polychlorinated
    n1=en:contraindications aspect | n2=en:dibenzofurans, polychlorinated | rel=r_associated | relid=0 | w=20
  2729. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dibenzothiazepines
    n1=en:contraindications aspect | n2=en:dibenzothiazepines | rel=r_associated | relid=0 | w=20
  2730. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dicarboxylate-binding protein
    n1=en:contraindications aspect | n2=en:dicarboxylate-binding protein | rel=r_associated | relid=0 | w=20
  2731. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dicarboxylic acid
    n1=en:contraindications aspect | n2=en:dicarboxylic acid | rel=r_associated | relid=0 | w=20
  2732. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dichlorodiphenyldichloroethane
    n1=en:contraindications aspect | n2=en:dichlorodiphenyldichloroethane | rel=r_associated | relid=0 | w=20
  2733. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dichotic listening tests
    n1=en:contraindications aspect | n2=en:dichotic listening tests | rel=r_associated | relid=0 | w=20
  2734. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diclofenac
    n1=en:contraindications aspect | n2=en:diclofenac | rel=r_associated | relid=0 | w=20
  2735. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dicofol
    n1=en:contraindications aspect | n2=en:dicofol | rel=r_associated | relid=0 | w=20
  2736. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dicumarol
    n1=en:contraindications aspect | n2=en:dicumarol | rel=r_associated | relid=0 | w=20
  2737. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dienestrol
    n1=en:contraindications aspect | n2=en:dienestrol | rel=r_associated | relid=0 | w=20
  2738. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diet, protein-restricted
    n1=en:contraindications aspect | n2=en:diet, protein-restricted | rel=r_associated | relid=0 | w=20
  2739. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dietary calcium
    n1=en:contraindications aspect | n2=en:dietary calcium | rel=r_associated | relid=0 | w=20
  2740. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dietary lipid
    n1=en:contraindications aspect | n2=en:dietary lipid | rel=r_associated | relid=0 | w=20
  2741. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dietary phosphorus
    n1=en:contraindications aspect | n2=en:dietary phosphorus | rel=r_associated | relid=0 | w=20
  2742. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dietary sodium
    n1=en:contraindications aspect | n2=en:dietary sodium | rel=r_associated | relid=0 | w=20
  2743. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diethyl pyrocarbonate
    n1=en:contraindications aspect | n2=en:diethyl pyrocarbonate | rel=r_associated | relid=0 | w=20
  2744. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diethylstilbestrol
    n1=en:contraindications aspect | n2=en:diethylstilbestrol | rel=r_associated | relid=0 | w=20
  2745. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diffusion magnetic resonance imaging
    n1=en:contraindications aspect | n2=en:diffusion magnetic resonance imaging | rel=r_associated | relid=0 | w=20
  2746. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diffusion mri
    n1=en:contraindications aspect | n2=en:diffusion mri | rel=r_associated | relid=0 | w=20
  2747. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diflubenzuron
    n1=en:contraindications aspect | n2=en:diflubenzuron | rel=r_associated | relid=0 | w=20
  2748. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:digalactolipids
    n1=en:contraindications aspect | n2=en:digalactolipids | rel=r_associated | relid=0 | w=20
  2749. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:digital subtraction angiography
    n1=en:contraindications aspect | n2=en:digital subtraction angiography | rel=r_associated | relid=0 | w=20
  2750. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:digitoxin
    n1=en:contraindications aspect | n2=en:digitoxin | rel=r_associated | relid=0 | w=20
  2751. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diglycerides
    n1=en:contraindications aspect | n2=en:diglycerides | rel=r_associated | relid=0 | w=20
  2752. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diglycine
    n1=en:contraindications aspect | n2=en:diglycine | rel=r_associated | relid=0 | w=20
  2753. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:digoxigenin
    n1=en:contraindications aspect | n2=en:digoxigenin | rel=r_associated | relid=0 | w=20
  2754. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:digoxigénine
    n1=en:contraindications aspect | n2=en:digoxigénine | rel=r_associated | relid=0 | w=20
  2755. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dihydroalprenolol
    n1=en:contraindications aspect | n2=en:dihydroalprenolol | rel=r_associated | relid=0 | w=20
  2756. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dimethoate
    n1=en:contraindications aspect | n2=en:dimethoate | rel=r_associated | relid=0 | w=20
  2757. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dimethyl sulfoxide
    n1=en:contraindications aspect | n2=en:dimethyl sulfoxide | rel=r_associated | relid=0 | w=20
  2758. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dimethyldithiocarbamate
    n1=en:contraindications aspect | n2=en:dimethyldithiocarbamate | rel=r_associated | relid=0 | w=20
  2759. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diminazene
    n1=en:contraindications aspect | n2=en:diminazene | rel=r_associated | relid=0 | w=20
  2760. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dinoprostone
    n1=en:contraindications aspect | n2=en:dinoprostone | rel=r_associated | relid=0 | w=20
  2761. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dioxanes
    n1=en:contraindications aspect | n2=en:dioxanes | rel=r_associated | relid=0 | w=20
  2762. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dioxin compound
    n1=en:contraindications aspect | n2=en:dioxin compound | rel=r_associated | relid=0 | w=20
  2763. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dioxins and dioxin-like compounds
    n1=en:contraindications aspect | n2=en:dioxins and dioxin-like compounds | rel=r_associated | relid=0 | w=20
  2764. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dioxolanes
    n1=en:contraindications aspect | n2=en:dioxolanes | rel=r_associated | relid=0 | w=20
  2765. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dipeptidases
    n1=en:contraindications aspect | n2=en:dipeptidases | rel=r_associated | relid=0 | w=20
  2766. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diphenhydramine
    n1=en:contraindications aspect | n2=en:diphenhydramine | rel=r_associated | relid=0 | w=20
  2767. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diphenoxylate
    n1=en:contraindications aspect | n2=en:diphenoxylate | rel=r_associated | relid=0 | w=20
  2768. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diphenylacetic acids
    n1=en:contraindications aspect | n2=en:diphenylacetic acids | rel=r_associated | relid=0 | w=20
  2769. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diphtheria antitoxin
    n1=en:contraindications aspect | n2=en:diphtheria antitoxin | rel=r_associated | relid=0 | w=20
  2770. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diprazin
    n1=en:contraindications aspect | n2=en:diprazin | rel=r_associated | relid=0 | w=20
  2771. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diquat
    n1=en:contraindications aspect | n2=en:diquat | rel=r_associated | relid=0 | w=20
  2772. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dishevelled proteins
    n1=en:contraindications aspect | n2=en:dishevelled proteins | rel=r_associated | relid=0 | w=20
  2773. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:disinfectant
    n1=en:contraindications aspect | n2=en:disinfectant | rel=r_associated | relid=0 | w=20
  2774. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:disopyramide
    n1=en:contraindications aspect | n2=en:disopyramide | rel=r_associated | relid=0 | w=20
  2775. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:disulfides
    n1=en:contraindications aspect | n2=en:disulfides | rel=r_associated | relid=0 | w=20
  2776. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:disulfoton
    n1=en:contraindications aspect | n2=en:disulfoton | rel=r_associated | relid=0 | w=20
  2777. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diterpenes, abietane
    n1=en:contraindications aspect | n2=en:diterpenes, abietane | rel=r_associated | relid=0 | w=20
  2778. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dithionite
    n1=en:contraindications aspect | n2=en:dithionite | rel=r_associated | relid=0 | w=20
  2779. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:diuron
    n1=en:contraindications aspect | n2=en:diuron | rel=r_associated | relid=0 | w=20
  2780. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna glycosylase
    n1=en:contraindications aspect | n2=en:dna glycosylase | rel=r_associated | relid=0 | w=20
  2781. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna helicase
    n1=en:contraindications aspect | n2=en:dna helicase | rel=r_associated | relid=0 | w=20
  2782. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna intercalating agent
    n1=en:contraindications aspect | n2=en:dna intercalating agent | rel=r_associated | relid=0 | w=20
  2783. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna mutational analysis
    n1=en:contraindications aspect | n2=en:dna mutational analysis | rel=r_associated | relid=0 | w=20
  2784. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna nucleotidylexotransferase
    n1=en:contraindications aspect | n2=en:dna nucleotidylexotransferase | rel=r_associated | relid=0 | w=20
  2785. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna nucleotidyltransferases
    n1=en:contraindications aspect | n2=en:dna nucleotidyltransferases | rel=r_associated | relid=0 | w=20
  2786. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna photolyase
    n1=en:contraindications aspect | n2=en:dna photolyase | rel=r_associated | relid=0 | w=20
  2787. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna polymerase ii
    n1=en:contraindications aspect | n2=en:dna polymerase ii | rel=r_associated | relid=0 | w=20
  2788. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna primers
    n1=en:contraindications aspect | n2=en:dna primers | rel=r_associated | relid=0 | w=20
  2789. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna restriction-modification enzymes
    n1=en:contraindications aspect | n2=en:dna restriction-modification enzymes | rel=r_associated | relid=0 | w=20
  2790. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna topoisomerases
    n1=en:contraindications aspect | n2=en:dna topoisomerases | rel=r_associated | relid=0 | w=20
  2791. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna vaccine
    n1=en:contraindications aspect | n2=en:dna vaccine | rel=r_associated | relid=0 | w=20
  2792. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:DNA vaccine
    n1=en:contraindications aspect | n2=en:DNA vaccine | rel=r_associated | relid=0 | w=20
  2793. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna-(apurinic or apyrimidinic site) lyase
    n1=en:contraindications aspect | n2=en:dna-(apurinic or apyrimidinic site) lyase | rel=r_associated | relid=0 | w=20
  2794. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna-directed dna polymerase
    n1=en:contraindications aspect | n2=en:dna-directed dna polymerase | rel=r_associated | relid=0 | w=20
  2795. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna-directed rna polymerase
    n1=en:contraindications aspect | n2=en:dna-directed rna polymerase | rel=r_associated | relid=0 | w=20
  2796. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna, bacterial
    n1=en:contraindications aspect | n2=en:dna, bacterial | rel=r_associated | relid=0 | w=20
  2797. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna, kinetoplast
    n1=en:contraindications aspect | n2=en:dna, kinetoplast | rel=r_associated | relid=0 | w=20
  2798. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna, ribosomal spacer
    n1=en:contraindications aspect | n2=en:dna, ribosomal spacer | rel=r_associated | relid=0 | w=20
  2799. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dna, superhelical
    n1=en:contraindications aspect | n2=en:dna, superhelical | rel=r_associated | relid=0 | w=20
  2800. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dobutamine
    n1=en:contraindications aspect | n2=en:dobutamine | rel=r_associated | relid=0 | w=20
  2801. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dolantin
    n1=en:contraindications aspect | n2=en:dolantin | rel=r_associated | relid=0 | w=20
  2802. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dolargan
    n1=en:contraindications aspect | n2=en:dolargan | rel=r_associated | relid=0 | w=20
  2803. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dolcontral
    n1=en:contraindications aspect | n2=en:dolcontral | rel=r_associated | relid=0 | w=20
  2804. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dolichol monophosphate mannose
    n1=en:contraindications aspect | n2=en:dolichol monophosphate mannose | rel=r_associated | relid=0 | w=20
  2805. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dolin
    n1=en:contraindications aspect | n2=en:dolin | rel=r_associated | relid=0 | w=20
  2806. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dolosal
    n1=en:contraindications aspect | n2=en:dolosal | rel=r_associated | relid=0 | w=20
  2807. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dolsin
    n1=en:contraindications aspect | n2=en:dolsin | rel=r_associated | relid=0 | w=20
  2808. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dopa
    n1=en:contraindications aspect | n2=en:dopa | rel=r_associated | relid=0 | w=20
  2809. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dopa decarboxylase
    n1=en:contraindications aspect | n2=en:dopa decarboxylase | rel=r_associated | relid=0 | w=20
  2810. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dopamine agonist
    n1=en:contraindications aspect | n2=en:dopamine agonist | rel=r_associated | relid=0 | w=20
  2811. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dopamine and camp-regulated phosphoprotein 32
    n1=en:contraindications aspect | n2=en:dopamine and camp-regulated phosphoprotein 32 | rel=r_associated | relid=0 | w=20
  2812. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dopamine antagonist
    n1=en:contraindications aspect | n2=en:dopamine antagonist | rel=r_associated | relid=0 | w=20
  2813. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dopamine d2 receptor antagonists
    n1=en:contraindications aspect | n2=en:dopamine d2 receptor antagonists | rel=r_associated | relid=0 | w=20
  2814. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dopamine transporter
    n1=en:contraindications aspect | n2=en:dopamine transporter | rel=r_associated | relid=0 | w=20
  2815. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dopaminergic agents
    n1=en:contraindications aspect | n2=en:dopaminergic agents | rel=r_associated | relid=0 | w=20
  2816. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dpi
    n1=en:contraindications aspect | n2=en:dpi | rel=r_associated | relid=0 | w=20
  2817. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:droxidopa
    n1=en:contraindications aspect | n2=en:droxidopa | rel=r_associated | relid=0 | w=20
  2818. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:drug delivery system
    n1=en:contraindications aspect | n2=en:drug delivery system | rel=r_associated | relid=0 | w=20
  2819. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:drug eluting stent
    n1=en:contraindications aspect | n2=en:drug eluting stent | rel=r_associated | relid=0 | w=20
  2820. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:drug monitoring
    n1=en:contraindications aspect | n2=en:drug monitoring | rel=r_associated | relid=0 | w=20
  2821. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:drug residues
    n1=en:contraindications aspect | n2=en:drug residues | rel=r_associated | relid=0 | w=20
  2822. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:drug substitution
    n1=en:contraindications aspect | n2=en:drug substitution | rel=r_associated | relid=0 | w=20
  2823. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:drugs, chinese herbal
    n1=en:contraindications aspect | n2=en:drugs, chinese herbal | rel=r_associated | relid=0 | w=20
  2824. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dry powder inhaler (device)
    n1=en:contraindications aspect | n2=en:dry powder inhaler (device) | rel=r_associated | relid=0 | w=20
  2825. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dual specificity mitogen-activated protein kinase kinase 4
    n1=en:contraindications aspect | n2=en:dual specificity mitogen-activated protein kinase kinase 4 | rel=r_associated | relid=0 | w=20
  2826. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dual specificity phosphatase 1
    n1=en:contraindications aspect | n2=en:dual specificity phosphatase 1 | rel=r_associated | relid=0 | w=20
  2827. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dual specificity protein phosphatase 6
    n1=en:contraindications aspect | n2=en:dual specificity protein phosphatase 6 | rel=r_associated | relid=0 | w=20
  2828. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:duffy blood group system
    n1=en:contraindications aspect | n2=en:duffy blood group system | rel=r_associated | relid=0 | w=20
  2829. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dulanermin
    n1=en:contraindications aspect | n2=en:dulanermin | rel=r_associated | relid=0 | w=20
  2830. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:duodenofibrescopy
    n1=en:contraindications aspect | n2=en:duodenofibrescopy | rel=r_associated | relid=0 | w=20
  2831. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:duodenoscopy
    n1=en:contraindications aspect | n2=en:duodenoscopy | rel=r_associated | relid=0 | w=20
  2832. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:duodenostomy
    n1=en:contraindications aspect | n2=en:duodenostomy | rel=r_associated | relid=0 | w=20
  2833. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dutasteride
    n1=en:contraindications aspect | n2=en:dutasteride | rel=r_associated | relid=0 | w=20
  2834. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dye
    n1=en:contraindications aspect | n2=en:dye | rel=r_associated | relid=0 | w=20
  2835. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dye dilution technique
    n1=en:contraindications aspect | n2=en:dye dilution technique | rel=r_associated | relid=0 | w=20
  2836. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dynamin i
    n1=en:contraindications aspect | n2=en:dynamin i | rel=r_associated | relid=0 | w=20
  2837. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dynamin iii
    n1=en:contraindications aspect | n2=en:dynamin iii | rel=r_associated | relid=0 | w=20
  2838. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dystroglycans
    n1=en:contraindications aspect | n2=en:dystroglycans | rel=r_associated | relid=0 | w=20
  2839. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:dystrophin-associated protein complex
    n1=en:contraindications aspect | n2=en:dystrophin-associated protein complex | rel=r_associated | relid=0 | w=20
  2840. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:e-z scrub
    n1=en:contraindications aspect | n2=en:e-z scrub | rel=r_associated | relid=0 | w=20
  2841. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ear protective devices
    n1=en:contraindications aspect | n2=en:ear protective devices | rel=r_associated | relid=0 | w=20
  2842. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:early termination of clinical trials
    n1=en:contraindications aspect | n2=en:early termination of clinical trials | rel=r_associated | relid=0 | w=20
  2843. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ebola vaccines
    n1=en:contraindications aspect | n2=en:ebola vaccines | rel=r_associated | relid=0 | w=20
  2844. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:echinomycin
    n1=en:contraindications aspect | n2=en:echinomycin | rel=r_associated | relid=0 | w=20
  2845. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:echocardiography
    n1=en:contraindications aspect | n2=en:echocardiography | rel=r_associated | relid=0 | w=20
  2846. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:echocardiography, three-dimensional
    n1=en:contraindications aspect | n2=en:echocardiography, three-dimensional | rel=r_associated | relid=0 | w=20
  2847. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:echocardiography, transesophageal
    n1=en:contraindications aspect | n2=en:echocardiography, transesophageal | rel=r_associated | relid=0 | w=20
  2848. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination
    n1=en:contraindications aspect | n2=en:efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination | rel=r_associated | relid=0 | w=20
  2849. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:egf family of proteins
    n1=en:contraindications aspect | n2=en:egf family of proteins | rel=r_associated | relid=0 | w=20
  2850. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:egg proteins, dietary
    n1=en:contraindications aspect | n2=en:egg proteins, dietary | rel=r_associated | relid=0 | w=20
  2851. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eicosanoic acids
    n1=en:contraindications aspect | n2=en:eicosanoic acids | rel=r_associated | relid=0 | w=20
  2852. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eicosapentaenoic acid
    n1=en:contraindications aspect | n2=en:eicosapentaenoic acid | rel=r_associated | relid=0 | w=20
  2853. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:elastic bandage
    n1=en:contraindications aspect | n2=en:elastic bandage | rel=r_associated | relid=0 | w=20
  2854. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:elastography
    n1=en:contraindications aspect | n2=en:elastography | rel=r_associated | relid=0 | w=20
  2855. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:elav-like protein 1
    n1=en:contraindications aspect | n2=en:elav-like protein 1 | rel=r_associated | relid=0 | w=20
  2856. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:elav-like protein 2
    n1=en:contraindications aspect | n2=en:elav-like protein 2 | rel=r_associated | relid=0 | w=20
  2857. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:elbow prostheses (device)
    n1=en:contraindications aspect | n2=en:elbow prostheses (device) | rel=r_associated | relid=0 | w=20
  2858. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:elective surgical procedure
    n1=en:contraindications aspect | n2=en:elective surgical procedure | rel=r_associated | relid=0 | w=20
  2859. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electric cardioversion
    n1=en:contraindications aspect | n2=en:electric cardioversion | rel=r_associated | relid=0 | w=20
  2860. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electric power supplies
    n1=en:contraindications aspect | n2=en:electric power supplies | rel=r_associated | relid=0 | w=20
  2861. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electric wiring
    n1=en:contraindications aspect | n2=en:electric wiring | rel=r_associated | relid=0 | w=20
  2862. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electrical equipment and supplies
    n1=en:contraindications aspect | n2=en:electrical equipment and supplies | rel=r_associated | relid=0 | w=20
  2863. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electroconvulsive shock
    n1=en:contraindications aspect | n2=en:electroconvulsive shock | rel=r_associated | relid=0 | w=20
  2864. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electrode
    n1=en:contraindications aspect | n2=en:electrode | rel=r_associated | relid=0 | w=20
  2865. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electron transport chain complex proteins
    n1=en:contraindications aspect | n2=en:electron transport chain complex proteins | rel=r_associated | relid=0 | w=20
  2866. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electron transport complex i
    n1=en:contraindications aspect | n2=en:electron transport complex i | rel=r_associated | relid=0 | w=20
  2867. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electronarcosis
    n1=en:contraindications aspect | n2=en:electronarcosis | rel=r_associated | relid=0 | w=20
  2868. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electronic amplifiers
    n1=en:contraindications aspect | n2=en:electronic amplifiers | rel=r_associated | relid=0 | w=20
  2869. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electronic nose
    n1=en:contraindications aspect | n2=en:electronic nose | rel=r_associated | relid=0 | w=20
  2870. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:electrosurgery
    n1=en:contraindications aspect | n2=en:electrosurgery | rel=r_associated | relid=0 | w=20
  2871. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ellagic acid
    n1=en:contraindications aspect | n2=en:ellagic acid | rel=r_associated | relid=0 | w=20
  2872. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ellipticines
    n1=en:contraindications aspect | n2=en:ellipticines | rel=r_associated | relid=0 | w=20
  2873. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate drug combination
    n1=en:contraindications aspect | n2=en:elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate drug combination | rel=r_associated | relid=0 | w=20
  2874. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:embolic protection devices
    n1=en:contraindications aspect | n2=en:embolic protection devices | rel=r_associated | relid=0 | w=20
  2875. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:embolization therapy
    n1=en:contraindications aspect | n2=en:embolization therapy | rel=r_associated | relid=0 | w=20
  2876. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:emergency care
    n1=en:contraindications aspect | n2=en:emergency care | rel=r_associated | relid=0 | w=20
  2877. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:emergency medical tags
    n1=en:contraindications aspect | n2=en:emergency medical tags | rel=r_associated | relid=0 | w=20
  2878. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:emetic
    n1=en:contraindications aspect | n2=en:emetic | rel=r_associated | relid=0 | w=20
  2879. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:emetine
    n1=en:contraindications aspect | n2=en:emetine | rel=r_associated | relid=0 | w=20
  2880. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:emtricitabine
    n1=en:contraindications aspect | n2=en:emtricitabine | rel=r_associated | relid=0 | w=20
  2881. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:emtricitabine, rilpivirine, tenofovir drug combination
    n1=en:contraindications aspect | n2=en:emtricitabine, rilpivirine, tenofovir drug combination | rel=r_associated | relid=0 | w=20
  2882. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:emtricitabine, tenofovir disoproxil fumarate drug combination
    n1=en:contraindications aspect | n2=en:emtricitabine, tenofovir disoproxil fumarate drug combination | rel=r_associated | relid=0 | w=20
  2883. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enamel microabrasion
    n1=en:contraindications aspect | n2=en:enamel microabrasion | rel=r_associated | relid=0 | w=20
  2884. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enclomiphene
    n1=en:contraindications aspect | n2=en:enclomiphene | rel=r_associated | relid=0 | w=20
  2885. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:endoscopes, gastrointestinal
    n1=en:contraindications aspect | n2=en:endoscopes, gastrointestinal | rel=r_associated | relid=0 | w=20
  2886. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:endoscopic retrograde cholangiopancreatography
    n1=en:contraindications aspect | n2=en:endoscopic retrograde cholangiopancreatography | rel=r_associated | relid=0 | w=20
  2887. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:endoscopy, gastrointestinal
    n1=en:contraindications aspect | n2=en:endoscopy, gastrointestinal | rel=r_associated | relid=0 | w=20
  2888. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:endostatin
    n1=en:contraindications aspect | n2=en:endostatin | rel=r_associated | relid=0 | w=20
  2889. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:endothelin receptor type a antagonist
    n1=en:contraindications aspect | n2=en:endothelin receptor type a antagonist | rel=r_associated | relid=0 | w=20
  2890. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:endpoint determination
    n1=en:contraindications aspect | n2=en:endpoint determination | rel=r_associated | relid=0 | w=20
  2891. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enema administration
    n1=en:contraindications aspect | n2=en:enema administration | rel=r_associated | relid=0 | w=20
  2892. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enhancer of zeste homolog 2 protein
    n1=en:contraindications aspect | n2=en:enhancer of zeste homolog 2 protein | rel=r_associated | relid=0 | w=20
  2893. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enkephalin, leucine-2-alanine
    n1=en:contraindications aspect | n2=en:enkephalin, leucine-2-alanine | rel=r_associated | relid=0 | w=20
  2894. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enoyl-coa hydratase
    n1=en:contraindications aspect | n2=en:enoyl-coa hydratase | rel=r_associated | relid=0 | w=20
  2895. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enoyl-coa hydratase 2
    n1=en:contraindications aspect | n2=en:enoyl-coa hydratase 2 | rel=r_associated | relid=0 | w=20
  2896. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enteric coated tablet dosage form
    n1=en:contraindications aspect | n2=en:enteric coated tablet dosage form | rel=r_associated | relid=0 | w=20
  2897. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enteroproctia
    n1=en:contraindications aspect | n2=en:enteroproctia | rel=r_associated | relid=0 | w=20
  2898. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:env gene products, human immunodeficiency virus
    n1=en:contraindications aspect | n2=en:env gene products, human immunodeficiency virus | rel=r_associated | relid=0 | w=20
  2899. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:enzyme inhibitor
    n1=en:contraindications aspect | n2=en:enzyme inhibitor | rel=r_associated | relid=0 | w=20
  2900. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eosinophil granule proteins
    n1=en:contraindications aspect | n2=en:eosinophil granule proteins | rel=r_associated | relid=0 | w=20
  2901. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eosinophil major basic protein
    n1=en:contraindications aspect | n2=en:eosinophil major basic protein | rel=r_associated | relid=0 | w=20
  2902. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eotaxin
    n1=en:contraindications aspect | n2=en:eotaxin | rel=r_associated | relid=0 | w=20
  2903. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ephrin type-a receptor 8
    n1=en:contraindications aspect | n2=en:ephrin type-a receptor 8 | rel=r_associated | relid=0 | w=20
  2904. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ephrin type-b receptor 1
    n1=en:contraindications aspect | n2=en:ephrin type-b receptor 1 | rel=r_associated | relid=0 | w=20
  2905. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ephrins
    n1=en:contraindications aspect | n2=en:ephrins | rel=r_associated | relid=0 | w=20
  2906. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:epigen
    n1=en:contraindications aspect | n2=en:epigen | rel=r_associated | relid=0 | w=20
  2907. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:epiregulin
    n1=en:contraindications aspect | n2=en:epiregulin | rel=r_associated | relid=0 | w=20
  2908. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:epitope
    n1=en:contraindications aspect | n2=en:epitope | rel=r_associated | relid=0 | w=20
  2909. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:epitopes, b-lymphocyte
    n1=en:contraindications aspect | n2=en:epitopes, b-lymphocyte | rel=r_associated | relid=0 | w=20
  2910. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:epoetin alfa
    n1=en:contraindications aspect | n2=en:epoetin alfa | rel=r_associated | relid=0 | w=20
  2911. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:epoxide compound
    n1=en:contraindications aspect | n2=en:epoxide compound | rel=r_associated | relid=0 | w=20
  2912. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:epsilon-crystallins
    n1=en:contraindications aspect | n2=en:epsilon-crystallins | rel=r_associated | relid=0 | w=20
  2913. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:epsilon-globins
    n1=en:contraindications aspect | n2=en:epsilon-globins | rel=r_associated | relid=0 | w=20
  2914. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:Epsom salt
    n1=en:contraindications aspect | n2=en:Epsom salt | rel=r_associated | relid=0 | w=20
  2915. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:epsom salt
    n1=en:contraindications aspect | n2=en:epsom salt | rel=r_associated | relid=0 | w=20
  2916. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:equilibrative nucleoside transport proteins
    n1=en:contraindications aspect | n2=en:equilibrative nucleoside transport proteins | rel=r_associated | relid=0 | w=20
  2917. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:equilibrative nucleoside transporter 2
    n1=en:contraindications aspect | n2=en:equilibrative nucleoside transporter 2 | rel=r_associated | relid=0 | w=20
  2918. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:equipment and supplies
    n1=en:contraindications aspect | n2=en:equipment and supplies | rel=r_associated | relid=0 | w=20
  2919. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:equipment and supplies, hospital
    n1=en:contraindications aspect | n2=en:equipment and supplies, hospital | rel=r_associated | relid=0 | w=20
  2920. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ergocalciferols
    n1=en:contraindications aspect | n2=en:ergocalciferols | rel=r_associated | relid=0 | w=20
  2921. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ergometry
    n1=en:contraindications aspect | n2=en:ergometry | rel=r_associated | relid=0 | w=20
  2922. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:esomeprazole
    n1=en:contraindications aspect | n2=en:esomeprazole | rel=r_associated | relid=0 | w=20
  2923. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:esophagoscopes
    n1=en:contraindications aspect | n2=en:esophagoscopes | rel=r_associated | relid=0 | w=20
  2924. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:estetrol
    n1=en:contraindications aspect | n2=en:estetrol | rel=r_associated | relid=0 | w=20
  2925. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:estrogen receptor antagonists
    n1=en:contraindications aspect | n2=en:estrogen receptor antagonists | rel=r_associated | relid=0 | w=20
  2926. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:estrogenic steroids, alkylated
    n1=en:contraindications aspect | n2=en:estrogenic steroids, alkylated | rel=r_associated | relid=0 | w=20
  2927. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:estrus detection
    n1=en:contraindications aspect | n2=en:estrus detection | rel=r_associated | relid=0 | w=20
  2928. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eszopiclone
    n1=en:contraindications aspect | n2=en:eszopiclone | rel=r_associated | relid=0 | w=20
  2929. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ethan-1,2-diol
    n1=en:contraindications aspect | n2=en:ethan-1,2-diol | rel=r_associated | relid=0 | w=20
  2930. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ethanediol
    n1=en:contraindications aspect | n2=en:ethanediol | rel=r_associated | relid=0 | w=20
  2931. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ethanolaminephosphotransferase
    n1=en:contraindications aspect | n2=en:ethanolaminephosphotransferase | rel=r_associated | relid=0 | w=20
  2932. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ether
    n1=en:contraindications aspect | n2=en:ether | rel=r_associated | relid=0 | w=20
  2933. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ethinyl estradiol
    n1=en:contraindications aspect | n2=en:ethinyl estradiol | rel=r_associated | relid=0 | w=20
  2934. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ethosuximide
    n1=en:contraindications aspect | n2=en:ethosuximide | rel=r_associated | relid=0 | w=20
  2935. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ethylene glycol
    n1=en:contraindications aspect | n2=en:ethylene glycol | rel=r_associated | relid=0 | w=20
  2936. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ethylene glycols
    n1=en:contraindications aspect | n2=en:ethylene glycols | rel=r_associated | relid=0 | w=20
  2937. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ethylmercuric chloride
    n1=en:contraindications aspect | n2=en:ethylmercuric chloride | rel=r_associated | relid=0 | w=20
  2938. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ethylmorphine-n-demethylase
    n1=en:contraindications aspect | n2=en:ethylmorphine-n-demethylase | rel=r_associated | relid=0 | w=20
  2939. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eukaryotic translation initiation factor 4e
    n1=en:contraindications aspect | n2=en:eukaryotic translation initiation factor 4e | rel=r_associated | relid=0 | w=20
  2940. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eukaryotic translation initiation factor 4f
    n1=en:contraindications aspect | n2=en:eukaryotic translation initiation factor 4f | rel=r_associated | relid=0 | w=20
  2941. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eukaryotic translation initiation factor 5
    n1=en:contraindications aspect | n2=en:eukaryotic translation initiation factor 5 | rel=r_associated | relid=0 | w=20
  2942. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:everolimus
    n1=en:contraindications aspect | n2=en:everolimus | rel=r_associated | relid=0 | w=20
  2943. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:examination tables
    n1=en:contraindications aspect | n2=en:examination tables | rel=r_associated | relid=0 | w=20
  2944. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:excitatory amino acid agents
    n1=en:contraindications aspect | n2=en:excitatory amino acid agents | rel=r_associated | relid=0 | w=20
  2945. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:excitatory amino acid antagonists
    n1=en:contraindications aspect | n2=en:excitatory amino acid antagonists | rel=r_associated | relid=0 | w=20
  2946. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:excitatory amino acid transporter 1
    n1=en:contraindications aspect | n2=en:excitatory amino acid transporter 1 | rel=r_associated | relid=0 | w=20
  2947. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:excitatory amino acid transporter 3
    n1=en:contraindications aspect | n2=en:excitatory amino acid transporter 3 | rel=r_associated | relid=0 | w=20
  2948. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:exopeptidase
    n1=en:contraindications aspect | n2=en:exopeptidase | rel=r_associated | relid=0 | w=20
  2949. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:exoskeleton device
    n1=en:contraindications aspect | n2=en:exoskeleton device | rel=r_associated | relid=0 | w=20
  2950. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:external fixation devices
    n1=en:contraindications aspect | n2=en:external fixation devices | rel=r_associated | relid=0 | w=20
  2951. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:extracellular matrix protein
    n1=en:contraindications aspect | n2=en:extracellular matrix protein | rel=r_associated | relid=0 | w=20
  2952. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:extracorporeal life support
    n1=en:contraindications aspect | n2=en:extracorporeal life support | rel=r_associated | relid=0 | w=20
  2953. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:extracorporeal membrane oxygenation
    n1=en:contraindications aspect | n2=en:extracorporeal membrane oxygenation | rel=r_associated | relid=0 | w=20
  2954. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:extracorporeal photopheresis
    n1=en:contraindications aspect | n2=en:extracorporeal photopheresis | rel=r_associated | relid=0 | w=20
  2955. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:extraction of tooth
    n1=en:contraindications aspect | n2=en:extraction of tooth | rel=r_associated | relid=0 | w=20
  2956. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:extraoral traction appliances
    n1=en:contraindications aspect | n2=en:extraoral traction appliances | rel=r_associated | relid=0 | w=20
  2957. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eye protective devices
    n1=en:contraindications aspect | n2=en:eye protective devices | rel=r_associated | relid=0 | w=20
  2958. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:eyeglasses
    n1=en:contraindications aspect | n2=en:eyeglasses | rel=r_associated | relid=0 | w=20
  2959. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ezetimibe
    n1=en:contraindications aspect | n2=en:ezetimibe | rel=r_associated | relid=0 | w=20
  2960. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ezetimibe/simvastatin
    n1=en:contraindications aspect | n2=en:ezetimibe/simvastatin | rel=r_associated | relid=0 | w=20
  2961. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:F agent
    n1=en:contraindications aspect | n2=en:F agent | rel=r_associated | relid=0 | w=20
  2962. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:F episome
    n1=en:contraindications aspect | n2=en:F episome | rel=r_associated | relid=0 | w=20
  2963. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:f factor
    n1=en:contraindications aspect | n2=en:f factor | rel=r_associated | relid=0 | w=20
  2964. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fab fragment
    n1=en:contraindications aspect | n2=en:fab fragment | rel=r_associated | relid=0 | w=20
  2965. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:facial transplantation
    n1=en:contraindications aspect | n2=en:facial transplantation | rel=r_associated | relid=0 | w=20
  2966. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:factor va
    n1=en:contraindications aspect | n2=en:factor va | rel=r_associated | relid=0 | w=20
  2967. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:false teeth
    n1=en:contraindications aspect | n2=en:false teeth | rel=r_associated | relid=0 | w=20
  2968. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:false tooth
    n1=en:contraindications aspect | n2=en:false tooth | rel=r_associated | relid=0 | w=20
  2969. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fanconi anemia group a protein
    n1=en:contraindications aspect | n2=en:fanconi anemia group a protein | rel=r_associated | relid=0 | w=20
  2970. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fanconi anemia group d2 protein
    n1=en:contraindications aspect | n2=en:fanconi anemia group d2 protein | rel=r_associated | relid=0 | w=20
  2971. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fanconi anemia group e protein
    n1=en:contraindications aspect | n2=en:fanconi anemia group e protein | rel=r_associated | relid=0 | w=20
  2972. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:farnesyltranstransferase
    n1=en:contraindications aspect | n2=en:farnesyltranstransferase | rel=r_associated | relid=0 | w=20
  2973. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fat emulsion
    n1=en:contraindications aspect | n2=en:fat emulsion | rel=r_associated | relid=0 | w=20
  2974. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fat substitutes
    n1=en:contraindications aspect | n2=en:fat substitutes | rel=r_associated | relid=0 | w=20
  2975. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fat-restricted diet
    n1=en:contraindications aspect | n2=en:fat-restricted diet | rel=r_associated | relid=0 | w=20
  2976. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fatty acid
    n1=en:contraindications aspect | n2=en:fatty acid | rel=r_associated | relid=0 | w=20
  2977. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fatty acid synthesis inhibitors
    n1=en:contraindications aspect | n2=en:fatty acid synthesis inhibitors | rel=r_associated | relid=0 | w=20
  2978. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fatty acid transport proteins
    n1=en:contraindications aspect | n2=en:fatty acid transport proteins | rel=r_associated | relid=0 | w=20
  2979. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fatty acid-binding protein 7
    n1=en:contraindications aspect | n2=en:fatty acid-binding protein 7 | rel=r_associated | relid=0 | w=20
  2980. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fatty alcohols
    n1=en:contraindications aspect | n2=en:fatty alcohols | rel=r_associated | relid=0 | w=20
  2981. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:female condoms
    n1=en:contraindications aspect | n2=en:female condoms | rel=r_associated | relid=0 | w=20
  2982. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:feminine hygiene products
    n1=en:contraindications aspect | n2=en:feminine hygiene products | rel=r_associated | relid=0 | w=20
  2983. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fenitrothion
    n1=en:contraindications aspect | n2=en:fenitrothion | rel=r_associated | relid=0 | w=20
  2984. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ferrocyanides
    n1=en:contraindications aspect | n2=en:ferrocyanides | rel=r_associated | relid=0 | w=20
  2985. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ferrous compounds
    n1=en:contraindications aspect | n2=en:ferrous compounds | rel=r_associated | relid=0 | w=20
  2986. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fertilins
    n1=en:contraindications aspect | n2=en:fertilins | rel=r_associated | relid=0 | w=20
  2987. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fetal globulins
    n1=en:contraindications aspect | n2=en:fetal globulins | rel=r_associated | relid=0 | w=20
  2988. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fetal proteins
    n1=en:contraindications aspect | n2=en:fetal proteins | rel=r_associated | relid=0 | w=20
  2989. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fetal tissue transplantation
    n1=en:contraindications aspect | n2=en:fetal tissue transplantation | rel=r_associated | relid=0 | w=20
  2990. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fgfr4 protein, human
    n1=en:contraindications aspect | n2=en:fgfr4 protein, human | rel=r_associated | relid=0 | w=20
  2991. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fiber optic cables
    n1=en:contraindications aspect | n2=en:fiber optic cables | rel=r_associated | relid=0 | w=20
  2992. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fibrillins
    n1=en:contraindications aspect | n2=en:fibrillins | rel=r_associated | relid=0 | w=20
  2993. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fibrin foam
    n1=en:contraindications aspect | n2=en:fibrin foam | rel=r_associated | relid=0 | w=20
  2994. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fibrinogens, abnormal
    n1=en:contraindications aspect | n2=en:fibrinogens, abnormal | rel=r_associated | relid=0 | w=20
  2995. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fibroblast growth factor 9
    n1=en:contraindications aspect | n2=en:fibroblast growth factor 9 | rel=r_associated | relid=0 | w=20
  2996. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fibroblast growth factor receptor 3
    n1=en:contraindications aspect | n2=en:fibroblast growth factor receptor 3 | rel=r_associated | relid=0 | w=20
  2997. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fiducial marker
    n1=en:contraindications aspect | n2=en:fiducial marker | rel=r_associated | relid=0 | w=20
  2998. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:filaricides
    n1=en:contraindications aspect | n2=en:filaricides | rel=r_associated | relid=0 | w=20
  2999. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:filgrastim
    n1=en:contraindications aspect | n2=en:filgrastim | rel=r_associated | relid=0 | w=20
  3000. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:film dosimetry
    n1=en:contraindications aspect | n2=en:film dosimetry | rel=r_associated | relid=0 | w=20
  3001. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fimbriae proteins
    n1=en:contraindications aspect | n2=en:fimbriae proteins | rel=r_associated | relid=0 | w=20
  3002. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:finasteride
    n1=en:contraindications aspect | n2=en:finasteride | rel=r_associated | relid=0 | w=20
  3003. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fingolimod hydrochloride
    n1=en:contraindications aspect | n2=en:fingolimod hydrochloride | rel=r_associated | relid=0 | w=20
  3004. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:first aid
    n1=en:contraindications aspect | n2=en:first aid | rel=r_associated | relid=0 | w=20
  3005. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:first-aid
    n1=en:contraindications aspect | n2=en:first-aid | rel=r_associated | relid=0 | w=20
  3006. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fixative
    n1=en:contraindications aspect | n2=en:fixative | rel=r_associated | relid=0 | w=20
  3007. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:flavor excipient
    n1=en:contraindications aspect | n2=en:flavor excipient | rel=r_associated | relid=0 | w=20
  3008. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:flowmeters
    n1=en:contraindications aspect | n2=en:flowmeters | rel=r_associated | relid=0 | w=20
  3009. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:flucytosine
    n1=en:contraindications aspect | n2=en:flucytosine | rel=r_associated | relid=0 | w=20
  3010. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:flufenamic acid
    n1=en:contraindications aspect | n2=en:flufenamic acid | rel=r_associated | relid=0 | w=20
  3011. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fluorenes
    n1=en:contraindications aspect | n2=en:fluorenes | rel=r_associated | relid=0 | w=20
  3012. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fluorescamine
    n1=en:contraindications aspect | n2=en:fluorescamine | rel=r_associated | relid=0 | w=20
  3013. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fluorescence angiography
    n1=en:contraindications aspect | n2=en:fluorescence angiography | rel=r_associated | relid=0 | w=20
  3014. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fluorescent treponemal antibody-absorption test
    n1=en:contraindications aspect | n2=en:fluorescent treponemal antibody-absorption test | rel=r_associated | relid=0 | w=20
  3015. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fluorine radioisotopes
    n1=en:contraindications aspect | n2=en:fluorine radioisotopes | rel=r_associated | relid=0 | w=20
  3016. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fluoro-uracile
    n1=en:contraindications aspect | n2=en:fluoro-uracile | rel=r_associated | relid=0 | w=20
  3017. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fluorodeoxyuridylate
    n1=en:contraindications aspect | n2=en:fluorodeoxyuridylate | rel=r_associated | relid=0 | w=20
  3018. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fluoroscopy
    n1=en:contraindications aspect | n2=en:fluoroscopy | rel=r_associated | relid=0 | w=20
  3019. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:folate receptor beta
    n1=en:contraindications aspect | n2=en:folate receptor beta | rel=r_associated | relid=0 | w=20
  3020. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:folate transporter 1
    n1=en:contraindications aspect | n2=en:folate transporter 1 | rel=r_associated | relid=0 | w=20
  3021. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:follitropin
    n1=en:contraindications aspect | n2=en:follitropin | rel=r_associated | relid=0 | w=20
  3022. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fontan procedure
    n1=en:contraindications aspect | n2=en:fontan procedure | rel=r_associated | relid=0 | w=20
  3023. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:foot orthoses
    n1=en:contraindications aspect | n2=en:foot orthoses | rel=r_associated | relid=0 | w=20
  3024. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fork wrench
    n1=en:contraindications aspect | n2=en:fork wrench | rel=r_associated | relid=0 | w=20
  3025. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:forkhead transcription factors
    n1=en:contraindications aspect | n2=en:forkhead transcription factors | rel=r_associated | relid=0 | w=20
  3026. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:form a pair with something
    n1=en:contraindications aspect | n2=en:form a pair with something | rel=r_associated | relid=0 | w=20
  3027. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:formaldehyde
    n1=en:contraindications aspect | n2=en:formaldehyde | rel=r_associated | relid=0 | w=20
  3028. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:formalin
    n1=en:contraindications aspect | n2=en:formalin | rel=r_associated | relid=0 | w=20
  3029. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:formamides
    n1=en:contraindications aspect | n2=en:formamides | rel=r_associated | relid=0 | w=20
  3030. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:formoterol fumarate
    n1=en:contraindications aspect | n2=en:formoterol fumarate | rel=r_associated | relid=0 | w=20
  3031. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:Forssman antigen
    n1=en:contraindications aspect | n2=en:Forssman antigen | rel=r_associated | relid=0 | w=20
  3032. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:forssman antigen
    n1=en:contraindications aspect | n2=en:forssman antigen | rel=r_associated | relid=0 | w=20
  3033. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fos oncoprotein
    n1=en:contraindications aspect | n2=en:fos oncoprotein | rel=r_associated | relid=0 | w=20
  3034. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fracture fixation
    n1=en:contraindications aspect | n2=en:fracture fixation | rel=r_associated | relid=0 | w=20
  3035. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fracture fixation, internal
    n1=en:contraindications aspect | n2=en:fracture fixation, internal | rel=r_associated | relid=0 | w=20
  3036. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fracture fixation, intramedullary
    n1=en:contraindications aspect | n2=en:fracture fixation, intramedullary | rel=r_associated | relid=0 | w=20
  3037. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fragile x mental retardation protein 1
    n1=en:contraindications aspect | n2=en:fragile x mental retardation protein 1 | rel=r_associated | relid=0 | w=20
  3038. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:frankincense
    n1=en:contraindications aspect | n2=en:frankincense | rel=r_associated | relid=0 | w=20
  3039. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:free fatty acid
    n1=en:contraindications aspect | n2=en:free fatty acid | rel=r_associated | relid=0 | w=20
  3040. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:free flap
    n1=en:contraindications aspect | n2=en:free flap | rel=r_associated | relid=0 | w=20
  3041. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:free radical scavengers
    n1=en:contraindications aspect | n2=en:free radical scavengers | rel=r_associated | relid=0 | w=20
  3042. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:French letter
    n1=en:contraindications aspect | n2=en:French letter | rel=r_associated | relid=0 | w=20
  3043. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:French rubber
    n1=en:contraindications aspect | n2=en:French rubber | rel=r_associated | relid=0 | w=20
  3044. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fructokinases
    n1=en:contraindications aspect | n2=en:fructokinases | rel=r_associated | relid=0 | w=20
  3045. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fructose-1,6-bisphosphatase 1
    n1=en:contraindications aspect | n2=en:fructose-1,6-bisphosphatase 1 | rel=r_associated | relid=0 | w=20
  3046. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fructosediphosphates
    n1=en:contraindications aspect | n2=en:fructosediphosphates | rel=r_associated | relid=0 | w=20
  3047. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fructosephosphates
    n1=en:contraindications aspect | n2=en:fructosephosphates | rel=r_associated | relid=0 | w=20
  3048. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fucosidase
    n1=en:contraindications aspect | n2=en:fucosidase | rel=r_associated | relid=0 | w=20
  3049. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:functional neuroimaging
    n1=en:contraindications aspect | n2=en:functional neuroimaging | rel=r_associated | relid=0 | w=20
  3050. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fundoplication
    n1=en:contraindications aspect | n2=en:fundoplication | rel=r_associated | relid=0 | w=20
  3051. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fundoscopic examination
    n1=en:contraindications aspect | n2=en:fundoscopic examination | rel=r_associated | relid=0 | w=20
  3052. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fundoscopy
    n1=en:contraindications aspect | n2=en:fundoscopy | rel=r_associated | relid=0 | w=20
  3053. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:fusaric acid
    n1=en:contraindications aspect | n2=en:fusaric acid | rel=r_associated | relid=0 | w=20
  3054. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:g(m2) activator protein
    n1=en:contraindications aspect | n2=en:g(m2) activator protein | rel=r_associated | relid=0 | w=20
  3055. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:g/t mismatch-specific thymine dna glycosylase
    n1=en:contraindications aspect | n2=en:g/t mismatch-specific thymine dna glycosylase | rel=r_associated | relid=0 | w=20
  3056. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:g1/s-specific cyclin-d3
    n1=en:contraindications aspect | n2=en:g1/s-specific cyclin-d3 | rel=r_associated | relid=0 | w=20
  3057. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:g2/mitotic-specific cyclin-b2
    n1=en:contraindications aspect | n2=en:g2/mitotic-specific cyclin-b2 | rel=r_associated | relid=0 | w=20
  3058. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gaba agents
    n1=en:contraindications aspect | n2=en:gaba agents | rel=r_associated | relid=0 | w=20
  3059. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gaba agonists
    n1=en:contraindications aspect | n2=en:gaba agonists | rel=r_associated | relid=0 | w=20
  3060. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gaba transporter
    n1=en:contraindications aspect | n2=en:gaba transporter | rel=r_associated | relid=0 | w=20
  3061. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:galactogogues
    n1=en:contraindications aspect | n2=en:galactogogues | rel=r_associated | relid=0 | w=20
  3062. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:galactolipids
    n1=en:contraindications aspect | n2=en:galactolipids | rel=r_associated | relid=0 | w=20
  3063. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:galactose dehydrogenases
    n1=en:contraindications aspect | n2=en:galactose dehydrogenases | rel=r_associated | relid=0 | w=20
  3064. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:galactosephosphates
    n1=en:contraindications aspect | n2=en:galactosephosphates | rel=r_associated | relid=0 | w=20
  3065. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:galectin 2
    n1=en:contraindications aspect | n2=en:galectin 2 | rel=r_associated | relid=0 | w=20
  3066. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:galectin-1
    n1=en:contraindications aspect | n2=en:galectin-1 | rel=r_associated | relid=0 | w=20
  3067. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gallic acid
    n1=en:contraindications aspect | n2=en:gallic acid | rel=r_associated | relid=0 | w=20
  3068. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gamma chemokine
    n1=en:contraindications aspect | n2=en:gamma chemokine | rel=r_associated | relid=0 | w=20
  3069. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gamma-crystallins
    n1=en:contraindications aspect | n2=en:gamma-crystallins | rel=r_associated | relid=0 | w=20
  3070. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gamma-globins
    n1=en:contraindications aspect | n2=en:gamma-globins | rel=r_associated | relid=0 | w=20
  3071. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gamma-glutamyl transpeptidase
    n1=en:contraindications aspect | n2=en:gamma-glutamyl transpeptidase | rel=r_associated | relid=0 | w=20
  3072. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gamma-glutamylcysteine synthetase
    n1=en:contraindications aspect | n2=en:gamma-glutamylcysteine synthetase | rel=r_associated | relid=0 | w=20
  3073. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gamma-lipotropin
    n1=en:contraindications aspect | n2=en:gamma-lipotropin | rel=r_associated | relid=0 | w=20
  3074. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gamma-tocopherol
    n1=en:contraindications aspect | n2=en:gamma-tocopherol | rel=r_associated | relid=0 | w=20
  3075. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gammagraphy
    n1=en:contraindications aspect | n2=en:gammagraphy | rel=r_associated | relid=0 | w=20
  3076. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gas
    n1=en:contraindications aspect | n2=en:gas | rel=r_associated | relid=0 | w=20
  3077. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gastric balloon
    n1=en:contraindications aspect | n2=en:gastric balloon | rel=r_associated | relid=0 | w=20
  3078. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gastrin-releasing peptide
    n1=en:contraindications aspect | n2=en:gastrin-releasing peptide | rel=r_associated | relid=0 | w=20
  3079. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gastrointestinal endoscopy
    n1=en:contraindications aspect | n2=en:gastrointestinal endoscopy | rel=r_associated | relid=0 | w=20
  3080. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gastroscope
    n1=en:contraindications aspect | n2=en:gastroscope | rel=r_associated | relid=0 | w=20
  3081. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gastroscopy
    n1=en:contraindications aspect | n2=en:gastroscopy | rel=r_associated | relid=0 | w=20
  3082. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gated blood-pool imaging
    n1=en:contraindications aspect | n2=en:gated blood-pool imaging | rel=r_associated | relid=0 | w=20
  3083. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gdp
    n1=en:contraindications aspect | n2=en:gdp | rel=r_associated | relid=0 | w=20
  3084. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gelatin sponge, absorbable
    n1=en:contraindications aspect | n2=en:gelatin sponge, absorbable | rel=r_associated | relid=0 | w=20
  3085. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gene knock-in techniques
    n1=en:contraindications aspect | n2=en:gene knock-in techniques | rel=r_associated | relid=0 | w=20
  3086. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gene products, rex
    n1=en:contraindications aspect | n2=en:gene products, rex | rel=r_associated | relid=0 | w=20
  3087. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gene products, vif
    n1=en:contraindications aspect | n2=en:gene products, vif | rel=r_associated | relid=0 | w=20
  3088. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:general anesthesia procedure
    n1=en:contraindications aspect | n2=en:general anesthesia procedure | rel=r_associated | relid=0 | w=20
  3089. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:general hair removal - epilation
    n1=en:contraindications aspect | n2=en:general hair removal - epilation | rel=r_associated | relid=0 | w=20
  3090. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:genetic complementation test
    n1=en:contraindications aspect | n2=en:genetic complementation test | rel=r_associated | relid=0 | w=20
  3091. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:genetic vectors
    n1=en:contraindications aspect | n2=en:genetic vectors | rel=r_associated | relid=0 | w=20
  3092. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:genistein
    n1=en:contraindications aspect | n2=en:genistein | rel=r_associated | relid=0 | w=20
  3093. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gentian violet
    n1=en:contraindications aspect | n2=en:gentian violet | rel=r_associated | relid=0 | w=20
  3094. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:geranylgeranyl-diphosphate geranylgeranyltransferase
    n1=en:contraindications aspect | n2=en:geranylgeranyl-diphosphate geranylgeranyltransferase | rel=r_associated | relid=0 | w=20
  3095. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:get acquainted with somebody
    n1=en:contraindications aspect | n2=en:get acquainted with somebody | rel=r_associated | relid=0 | w=20
  3096. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:get to know somebody
    n1=en:contraindications aspect | n2=en:get to know somebody | rel=r_associated | relid=0 | w=20
  3097. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gibberellins
    n1=en:contraindications aspect | n2=en:gibberellins | rel=r_associated | relid=0 | w=20
  3098. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gingival retraction techniques
    n1=en:contraindications aspect | n2=en:gingival retraction techniques | rel=r_associated | relid=0 | w=20
  3099. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gingivectomy
    n1=en:contraindications aspect | n2=en:gingivectomy | rel=r_associated | relid=0 | w=20
  3100. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glasses
    n1=en:contraindications aspect | n2=en:glasses | rel=r_associated | relid=0 | w=20
  3101. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glatiramer acetate
    n1=en:contraindications aspect | n2=en:glatiramer acetate | rel=r_associated | relid=0 | w=20
  3102. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glaucoma drainage implants
    n1=en:contraindications aspect | n2=en:glaucoma drainage implants | rel=r_associated | relid=0 | w=20
  3103. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glia maturation factor
    n1=en:contraindications aspect | n2=en:glia maturation factor | rel=r_associated | relid=0 | w=20
  3104. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glial cell line-derived neurotrophic factor
    n1=en:contraindications aspect | n2=en:glial cell line-derived neurotrophic factor | rel=r_associated | relid=0 | w=20
  3105. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glial cell line-derived neurotrophic factors
    n1=en:contraindications aspect | n2=en:glial cell line-derived neurotrophic factors | rel=r_associated | relid=0 | w=20
  3106. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glicentin
    n1=en:contraindications aspect | n2=en:glicentin | rel=r_associated | relid=0 | w=20
  3107. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gloves, surgical
    n1=en:contraindications aspect | n2=en:gloves, surgical | rel=r_associated | relid=0 | w=20
  3108. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucan 1,4-alpha-glucosidase
    n1=en:contraindications aspect | n2=en:glucan 1,4-alpha-glucosidase | rel=r_associated | relid=0 | w=20
  3109. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucaric acid
    n1=en:contraindications aspect | n2=en:glucaric acid | rel=r_associated | relid=0 | w=20
  3110. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucid
    n1=en:contraindications aspect | n2=en:glucid | rel=r_associated | relid=0 | w=20
  3111. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucocorticoid
    n1=en:contraindications aspect | n2=en:glucocorticoid | rel=r_associated | relid=0 | w=20
  3112. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucosamine
    n1=en:contraindications aspect | n2=en:glucosamine | rel=r_associated | relid=0 | w=20
  3113. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucose dehydrogenases
    n1=en:contraindications aspect | n2=en:glucose dehydrogenases | rel=r_associated | relid=0 | w=20
  3114. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucose oxidase
    n1=en:contraindications aspect | n2=en:glucose oxidase | rel=r_associated | relid=0 | w=20
  3115. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucose solution, hypertonic
    n1=en:contraindications aspect | n2=en:glucose solution, hypertonic | rel=r_associated | relid=0 | w=20
  3116. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucose transporter type 2
    n1=en:contraindications aspect | n2=en:glucose transporter type 2 | rel=r_associated | relid=0 | w=20
  3117. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucosephosphate isomerase
    n1=en:contraindications aspect | n2=en:glucosephosphate isomerase | rel=r_associated | relid=0 | w=20
  3118. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucosephosphates
    n1=en:contraindications aspect | n2=en:glucosephosphates | rel=r_associated | relid=0 | w=20
  3119. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucosinolate
    n1=en:contraindications aspect | n2=en:glucosinolate | rel=r_associated | relid=0 | w=20
  3120. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glucuronide
    n1=en:contraindications aspect | n2=en:glucuronide | rel=r_associated | relid=0 | w=20
  3121. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glut-1 protein
    n1=en:contraindications aspect | n2=en:glut-1 protein | rel=r_associated | relid=0 | w=20
  3122. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glutamate decarboxylase
    n1=en:contraindications aspect | n2=en:glutamate decarboxylase | rel=r_associated | relid=0 | w=20
  3123. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glutamate formiminotransferase
    n1=en:contraindications aspect | n2=en:glutamate formiminotransferase | rel=r_associated | relid=0 | w=20
  3124. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glutamate plasma membrane transport proteins
    n1=en:contraindications aspect | n2=en:glutamate plasma membrane transport proteins | rel=r_associated | relid=0 | w=20
  3125. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glutamic acid-specific trna
    n1=en:contraindications aspect | n2=en:glutamic acid-specific trna | rel=r_associated | relid=0 | w=20
  3126. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glutamyl aminopeptidase
    n1=en:contraindications aspect | n2=en:glutamyl aminopeptidase | rel=r_associated | relid=0 | w=20
  3127. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glutaral
    n1=en:contraindications aspect | n2=en:glutaral | rel=r_associated | relid=0 | w=20
  3128. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glutathione
    n1=en:contraindications aspect | n2=en:glutathione | rel=r_associated | relid=0 | w=20
  3129. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glutens
    n1=en:contraindications aspect | n2=en:glutens | rel=r_associated | relid=0 | w=20
  3130. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glyceraldehyde
    n1=en:contraindications aspect | n2=en:glyceraldehyde | rel=r_associated | relid=0 | w=20
  3131. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)
    n1=en:contraindications aspect | n2=en:glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) | rel=r_associated | relid=0 | w=20
  3132. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycerophosphoinositol inositolphosphodiesterase
    n1=en:contraindications aspect | n2=en:glycerophosphoinositol inositolphosphodiesterase | rel=r_associated | relid=0 | w=20
  3133. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycerophospholipids
    n1=en:contraindications aspect | n2=en:glycerophospholipids | rel=r_associated | relid=0 | w=20
  3134. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycerylphosphorylcholine
    n1=en:contraindications aspect | n2=en:glycerylphosphorylcholine | rel=r_associated | relid=0 | w=20
  3135. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycine
    n1=en:contraindications aspect | n2=en:glycine | rel=r_associated | relid=0 | w=20
  3136. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycine agents
    n1=en:contraindications aspect | n2=en:glycine agents | rel=r_associated | relid=0 | w=20
  3137. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycine decarboxylase complex h-protein
    n1=en:contraindications aspect | n2=en:glycine decarboxylase complex h-protein | rel=r_associated | relid=0 | w=20
  3138. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycine n-methyltransferase
    n1=en:contraindications aspect | n2=en:glycine n-methyltransferase | rel=r_associated | relid=0 | w=20
  3139. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycochenodeoxycholic acid
    n1=en:contraindications aspect | n2=en:glycochenodeoxycholic acid | rel=r_associated | relid=0 | w=20
  3140. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycodelin
    n1=en:contraindications aspect | n2=en:glycodelin | rel=r_associated | relid=0 | w=20
  3141. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycogen (starch) synthase
    n1=en:contraindications aspect | n2=en:glycogen (starch) synthase | rel=r_associated | relid=0 | w=20
  3142. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycogen debranching enzyme system
    n1=en:contraindications aspect | n2=en:glycogen debranching enzyme system | rel=r_associated | relid=0 | w=20
  3143. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycogen phosphorylase
    n1=en:contraindications aspect | n2=en:glycogen phosphorylase | rel=r_associated | relid=0 | w=20
  3144. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycogen phosphorylase, brain form
    n1=en:contraindications aspect | n2=en:glycogen phosphorylase, brain form | rel=r_associated | relid=0 | w=20
  3145. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycogen phosphorylase, liver form
    n1=en:contraindications aspect | n2=en:glycogen phosphorylase, liver form | rel=r_associated | relid=0 | w=20
  3146. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycophorin
    n1=en:contraindications aspect | n2=en:glycophorin | rel=r_associated | relid=0 | w=20
  3147. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycosaminoglycan
    n1=en:contraindications aspect | n2=en:glycosaminoglycan | rel=r_associated | relid=0 | w=20
  3148. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycoside hydrolase inhibitors
    n1=en:contraindications aspect | n2=en:glycoside hydrolase inhibitors | rel=r_associated | relid=0 | w=20
  3149. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glycosylphosphatidylinositol diacylglycerol-lyase
    n1=en:contraindications aspect | n2=en:glycosylphosphatidylinositol diacylglycerol-lyase | rel=r_associated | relid=0 | w=20
  3150. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glyoxal
    n1=en:contraindications aspect | n2=en:glyoxal | rel=r_associated | relid=0 | w=20
  3151. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:glyoxylates
    n1=en:contraindications aspect | n2=en:glyoxylates | rel=r_associated | relid=0 | w=20
  3152. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:go well together
    n1=en:contraindications aspect | n2=en:go well together | rel=r_associated | relid=0 | w=20
  3153. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:go with something
    n1=en:contraindications aspect | n2=en:go with something | rel=r_associated | relid=0 | w=20
  3154. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gold compounds
    n1=en:contraindications aspect | n2=en:gold compounds | rel=r_associated | relid=0 | w=20
  3155. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gold isotopes
    n1=en:contraindications aspect | n2=en:gold isotopes | rel=r_associated | relid=0 | w=20
  3156. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gold sodium thiomalate
    n1=en:contraindications aspect | n2=en:gold sodium thiomalate | rel=r_associated | relid=0 | w=20
  3157. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gonadostimulin
    n1=en:contraindications aspect | n2=en:gonadostimulin | rel=r_associated | relid=0 | w=20
  3158. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gonadotropin
    n1=en:contraindications aspect | n2=en:gonadotropin | rel=r_associated | relid=0 | w=20
  3159. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:goserelin
    n1=en:contraindications aspect | n2=en:goserelin | rel=r_associated | relid=0 | w=20
  3160. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:graft enhancement, immunologic
    n1=en:contraindications aspect | n2=en:graft enhancement, immunologic | rel=r_associated | relid=0 | w=20
  3161. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:granulocyte colony-stimulating factor
    n1=en:contraindications aspect | n2=en:granulocyte colony-stimulating factor | rel=r_associated | relid=0 | w=20
  3162. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:granzyme
    n1=en:contraindications aspect | n2=en:granzyme | rel=r_associated | relid=0 | w=20
  3163. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:grape seed extract
    n1=en:contraindications aspect | n2=en:grape seed extract | rel=r_associated | relid=0 | w=20
  3164. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gravity suits
    n1=en:contraindications aspect | n2=en:gravity suits | rel=r_associated | relid=0 | w=20
  3165. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:green fluorescent proteins
    n1=en:contraindications aspect | n2=en:green fluorescent proteins | rel=r_associated | relid=0 | w=20
  3166. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:growth differentiation factor 1
    n1=en:contraindications aspect | n2=en:growth differentiation factor 1 | rel=r_associated | relid=0 | w=20
  3167. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:growth differentiation factor 2
    n1=en:contraindications aspect | n2=en:growth differentiation factor 2 | rel=r_associated | relid=0 | w=20
  3168. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:growth differentiation factor 5
    n1=en:contraindications aspect | n2=en:growth differentiation factor 5 | rel=r_associated | relid=0 | w=20
  3169. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:growth differentiation factor 6
    n1=en:contraindications aspect | n2=en:growth differentiation factor 6 | rel=r_associated | relid=0 | w=20
  3170. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:growth hormone releasing hormone
    n1=en:contraindications aspect | n2=en:growth hormone releasing hormone | rel=r_associated | relid=0 | w=20
  3171. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:growth/differentiation factor 3
    n1=en:contraindications aspect | n2=en:growth/differentiation factor 3 | rel=r_associated | relid=0 | w=20
  3172. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gtp
    n1=en:contraindications aspect | n2=en:gtp | rel=r_associated | relid=0 | w=20
  3173. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:gtp-binding protein gamma subunits
    n1=en:contraindications aspect | n2=en:gtp-binding protein gamma subunits | rel=r_associated | relid=0 | w=20
  3174. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:guanine deaminase
    n1=en:contraindications aspect | n2=en:guanine deaminase | rel=r_associated | relid=0 | w=20
  3175. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:guanine nucleotide dissociation inhibitors
    n1=en:contraindications aspect | n2=en:guanine nucleotide dissociation inhibitors | rel=r_associated | relid=0 | w=20
  3176. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:guanosine diphosphate fucose
    n1=en:contraindications aspect | n2=en:guanosine diphosphate fucose | rel=r_associated | relid=0 | w=20
  3177. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:guanosine pentaphosphate
    n1=en:contraindications aspect | n2=en:guanosine pentaphosphate | rel=r_associated | relid=0 | w=20
  3178. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:guanosine tetraphosphate
    n1=en:contraindications aspect | n2=en:guanosine tetraphosphate | rel=r_associated | relid=0 | w=20
  3179. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:guanylyl imidodiphosphate
    n1=en:contraindications aspect | n2=en:guanylyl imidodiphosphate | rel=r_associated | relid=0 | w=20
  3180. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:guided tissue regeneration, periodontal
    n1=en:contraindications aspect | n2=en:guided tissue regeneration, periodontal | rel=r_associated | relid=0 | w=20
  3181. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:h-y antigen
    n1=en:contraindications aspect | n2=en:h-y antigen | rel=r_associated | relid=0 | w=20
  3182. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:halogenated diphenyl ethers
    n1=en:contraindications aspect | n2=en:halogenated diphenyl ethers | rel=r_associated | relid=0 | w=20
  3183. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:halorhodopsins
    n1=en:contraindications aspect | n2=en:halorhodopsins | rel=r_associated | relid=0 | w=20
  3184. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:halothane
    n1=en:contraindications aspect | n2=en:halothane | rel=r_associated | relid=0 | w=20
  3185. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hand assisted laparoscopy
    n1=en:contraindications aspect | n2=en:hand assisted laparoscopy | rel=r_associated | relid=0 | w=20
  3186. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hazardous substances
    n1=en:contraindications aspect | n2=en:hazardous substances | rel=r_associated | relid=0 | w=20
  3187. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heart auscultation
    n1=en:contraindications aspect | n2=en:heart auscultation | rel=r_associated | relid=0 | w=20
  3188. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heart bypass, left
    n1=en:contraindications aspect | n2=en:heart bypass, left | rel=r_associated | relid=0 | w=20
  3189. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heat shock protein 90
    n1=en:contraindications aspect | n2=en:heat shock protein 90 | rel=r_associated | relid=0 | w=20
  3190. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heimlich maneuver
    n1=en:contraindications aspect | n2=en:heimlich maneuver | rel=r_associated | relid=0 | w=20
  3191. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heliation
    n1=en:contraindications aspect | n2=en:heliation | rel=r_associated | relid=0 | w=20
  3192. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heliotherapy
    n1=en:contraindications aspect | n2=en:heliotherapy | rel=r_associated | relid=0 | w=20
  3193. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:helium
    n1=en:contraindications aspect | n2=en:helium | rel=r_associated | relid=0 | w=20
  3194. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemagglutination inhibition assay
    n1=en:contraindications aspect | n2=en:hemagglutination inhibition assay | rel=r_associated | relid=0 | w=20
  3195. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemagglutinin
    n1=en:contraindications aspect | n2=en:hemagglutinin | rel=r_associated | relid=0 | w=20
  3196. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemagglutinin glycoproteins, influenza virus
    n1=en:contraindications aspect | n2=en:hemagglutinin glycoproteins, influenza virus | rel=r_associated | relid=0 | w=20
  3197. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hematocrit measurement
    n1=en:contraindications aspect | n2=en:hematocrit measurement | rel=r_associated | relid=0 | w=20
  3198. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hematologic tests
    n1=en:contraindications aspect | n2=en:hematologic tests | rel=r_associated | relid=0 | w=20
  3199. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hematometachysis
    n1=en:contraindications aspect | n2=en:hematometachysis | rel=r_associated | relid=0 | w=20
  3200. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemodialysis solutions
    n1=en:contraindications aspect | n2=en:hemodialysis solutions | rel=r_associated | relid=0 | w=20
  3201. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemoglobin
    n1=en:contraindications aspect | n2=en:hemoglobin | rel=r_associated | relid=0 | w=20
  3202. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemoglobin subunit delta
    n1=en:contraindications aspect | n2=en:hemoglobin subunit delta | rel=r_associated | relid=0 | w=20
  3203. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemoglobin subunits
    n1=en:contraindications aspect | n2=en:hemoglobin subunits | rel=r_associated | relid=0 | w=20
  3204. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemoglobinometry
    n1=en:contraindications aspect | n2=en:hemoglobinometry | rel=r_associated | relid=0 | w=20
  3205. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemolytic agents
    n1=en:contraindications aspect | n2=en:hemolytic agents | rel=r_associated | relid=0 | w=20
  3206. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemoperfusion
    n1=en:contraindications aspect | n2=en:hemoperfusion | rel=r_associated | relid=0 | w=20
  3207. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemostasis, endoscopic
    n1=en:contraindications aspect | n2=en:hemostasis, endoscopic | rel=r_associated | relid=0 | w=20
  3208. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hemostatic agent
    n1=en:contraindications aspect | n2=en:hemostatic agent | rel=r_associated | relid=0 | w=20
  3209. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heparan sulfate proteoglycan
    n1=en:contraindications aspect | n2=en:heparan sulfate proteoglycan | rel=r_associated | relid=0 | w=20
  3210. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heparin cofactor 2
    n1=en:contraindications aspect | n2=en:heparin cofactor 2 | rel=r_associated | relid=0 | w=20
  3211. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hepatitis a vaccine
    n1=en:contraindications aspect | n2=en:hepatitis a vaccine | rel=r_associated | relid=0 | w=20
  3212. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hepatitis A vaccine
    n1=en:contraindications aspect | n2=en:hepatitis A vaccine | rel=r_associated | relid=0 | w=20
  3213. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hepatitis b e antigens
    n1=en:contraindications aspect | n2=en:hepatitis b e antigens | rel=r_associated | relid=0 | w=20
  3214. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hepatitis b vaccines
    n1=en:contraindications aspect | n2=en:hepatitis b vaccines | rel=r_associated | relid=0 | w=20
  3215. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hepatitis b virus hbsag surface protein antigen
    n1=en:contraindications aspect | n2=en:hepatitis b virus hbsag surface protein antigen | rel=r_associated | relid=0 | w=20
  3216. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hepcidin
    n1=en:contraindications aspect | n2=en:hepcidin | rel=r_associated | relid=0 | w=20
  3217. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heptanoates
    n1=en:contraindications aspect | n2=en:heptanoates | rel=r_associated | relid=0 | w=20
  3218. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heptanol
    n1=en:contraindications aspect | n2=en:heptanol | rel=r_associated | relid=0 | w=20
  3219. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heptavalent pneumococcal conjugate vaccine
    n1=en:contraindications aspect | n2=en:heptavalent pneumococcal conjugate vaccine | rel=r_associated | relid=0 | w=20
  3220. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heptoses
    n1=en:contraindications aspect | n2=en:heptoses | rel=r_associated | relid=0 | w=20
  3221. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:herpes simplex virus vaccines
    n1=en:contraindications aspect | n2=en:herpes simplex virus vaccines | rel=r_associated | relid=0 | w=20
  3222. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:herpesvirus vaccines
    n1=en:contraindications aspect | n2=en:herpesvirus vaccines | rel=r_associated | relid=0 | w=20
  3223. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heterogeneous nuclear ribonucleoprotein m
    n1=en:contraindications aspect | n2=en:heterogeneous nuclear ribonucleoprotein m | rel=r_associated | relid=0 | w=20
  3224. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heterogeneous-nuclear ribonucleoprotein d
    n1=en:contraindications aspect | n2=en:heterogeneous-nuclear ribonucleoprotein d | rel=r_associated | relid=0 | w=20
  3225. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heterogeneous-nuclear ribonucleoprotein group c
    n1=en:contraindications aspect | n2=en:heterogeneous-nuclear ribonucleoprotein group c | rel=r_associated | relid=0 | w=20
  3226. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heterogeneous-nuclear ribonucleoprotein l
    n1=en:contraindications aspect | n2=en:heterogeneous-nuclear ribonucleoprotein l | rel=r_associated | relid=0 | w=20
  3227. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:heterotrimeric g protein
    n1=en:contraindications aspect | n2=en:heterotrimeric g protein | rel=r_associated | relid=0 | w=20
  3228. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hexetidine
    n1=en:contraindications aspect | n2=en:hexetidine | rel=r_associated | relid=0 | w=20
  3229. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hexosediphosphates
    n1=en:contraindications aspect | n2=en:hexosediphosphates | rel=r_associated | relid=0 | w=20
  3230. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hexosyltransferase
    n1=en:contraindications aspect | n2=en:hexosyltransferase | rel=r_associated | relid=0 | w=20
  3231. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hexylresorcinol
    n1=en:contraindications aspect | n2=en:hexylresorcinol | rel=r_associated | relid=0 | w=20
  3232. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:high affinity nerve growth factor receptor
    n1=en:contraindications aspect | n2=en:high affinity nerve growth factor receptor | rel=r_associated | relid=0 | w=20
  3233. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:high density lipoprotein
    n1=en:contraindications aspect | n2=en:high density lipoprotein | rel=r_associated | relid=0 | w=20
  3234. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:high density lipoprotein cholesterol
    n1=en:contraindications aspect | n2=en:high density lipoprotein cholesterol | rel=r_associated | relid=0 | w=20
  3235. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:high mobility group protein hmg-y
    n1=en:contraindications aspect | n2=en:high mobility group protein hmg-y | rel=r_associated | relid=0 | w=20
  3236. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:high-frequency jet ventilation
    n1=en:contraindications aspect | n2=en:high-frequency jet ventilation | rel=r_associated | relid=0 | w=20
  3237. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:high-intensity focused ultrasound ablation
    n1=en:contraindications aspect | n2=en:high-intensity focused ultrasound ablation | rel=r_associated | relid=0 | w=20
  3238. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hip joint implantable prostheses (device)
    n1=en:contraindications aspect | n2=en:hip joint implantable prostheses (device) | rel=r_associated | relid=0 | w=20
  3239. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hip replacement arthroplasty (procedure)
    n1=en:contraindications aspect | n2=en:hip replacement arthroplasty (procedure) | rel=r_associated | relid=0 | w=20
  3240. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hirudin therapy
    n1=en:contraindications aspect | n2=en:hirudin therapy | rel=r_associated | relid=0 | w=20
  3241. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hirudins
    n1=en:contraindications aspect | n2=en:hirudins | rel=r_associated | relid=0 | w=20
  3242. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:histamine agents
    n1=en:contraindications aspect | n2=en:histamine agents | rel=r_associated | relid=0 | w=20
  3243. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:histamine n-methyltransferase
    n1=en:contraindications aspect | n2=en:histamine n-methyltransferase | rel=r_associated | relid=0 | w=20
  3244. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:histamine-1 receptor antagonist
    n1=en:contraindications aspect | n2=en:histamine-1 receptor antagonist | rel=r_associated | relid=0 | w=20
  3245. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:histamine-2 receptor antagonist
    n1=en:contraindications aspect | n2=en:histamine-2 receptor antagonist | rel=r_associated | relid=0 | w=20
  3246. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:histidine decarboxylase
    n1=en:contraindications aspect | n2=en:histidine decarboxylase | rel=r_associated | relid=0 | w=20
  3247. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:histidine kinase
    n1=en:contraindications aspect | n2=en:histidine kinase | rel=r_associated | relid=0 | w=20
  3248. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:histone deacetylase 1
    n1=en:contraindications aspect | n2=en:histone deacetylase 1 | rel=r_associated | relid=0 | w=20
  3249. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hiv antibody
    n1=en:contraindications aspect | n2=en:hiv antibody | rel=r_associated | relid=0 | w=20
  3250. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hiv envelope protein gp120
    n1=en:contraindications aspect | n2=en:hiv envelope protein gp120 | rel=r_associated | relid=0 | w=20
  3251. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hiv envelope protein gp41
    n1=en:contraindications aspect | n2=en:hiv envelope protein gp41 | rel=r_associated | relid=0 | w=20
  3252. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hiv integrase
    n1=en:contraindications aspect | n2=en:hiv integrase | rel=r_associated | relid=0 | w=20
  3253. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hiv protease inhibitor
    n1=en:contraindications aspect | n2=en:hiv protease inhibitor | rel=r_associated | relid=0 | w=20
  3254. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hiv reverse transcriptase
    n1=en:contraindications aspect | n2=en:hiv reverse transcriptase | rel=r_associated | relid=0 | w=20
  3255. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hla class i histocompatibility antigen, a-24 alpha chain
    n1=en:contraindications aspect | n2=en:hla class i histocompatibility antigen, a-24 alpha chain | rel=r_associated | relid=0 | w=20
  3256. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hla class i histocompatibility antigen, alpha chain g
    n1=en:contraindications aspect | n2=en:hla class i histocompatibility antigen, alpha chain g | rel=r_associated | relid=0 | w=20
  3257. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hla-dq antigen
    n1=en:contraindications aspect | n2=en:hla-dq antigen | rel=r_associated | relid=0 | w=20
  3258. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hmg-coa reductase inhibitor
    n1=en:contraindications aspect | n2=en:hmg-coa reductase inhibitor | rel=r_associated | relid=0 | w=20
  3259. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hmgb family protein
    n1=en:contraindications aspect | n2=en:hmgb family protein | rel=r_associated | relid=0 | w=20
  3260. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hn protein
    n1=en:contraindications aspect | n2=en:hn protein | rel=r_associated | relid=0 | w=20
  3261. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:home childbirth
    n1=en:contraindications aspect | n2=en:home childbirth | rel=r_associated | relid=0 | w=20
  3262. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hormone antagonist
    n1=en:contraindications aspect | n2=en:hormone antagonist | rel=r_associated | relid=0 | w=20
  3263. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:host-derived cellular factors
    n1=en:contraindications aspect | n2=en:host-derived cellular factors | rel=r_associated | relid=0 | w=20
  3264. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hpv dna probes
    n1=en:contraindications aspect | n2=en:hpv dna probes | rel=r_associated | relid=0 | w=20
  3265. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:htlv-i antigens
    n1=en:contraindications aspect | n2=en:htlv-i antigens | rel=r_associated | relid=0 | w=20
  3266. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:human glandular kallikrein
    n1=en:contraindications aspect | n2=en:human glandular kallikrein | rel=r_associated | relid=0 | w=20
  3267. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:human immunodeficiency virus proteins
    n1=en:contraindications aspect | n2=en:human immunodeficiency virus proteins | rel=r_associated | relid=0 | w=20
  3268. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:human menopausal gonadotrophin
    n1=en:contraindications aspect | n2=en:human menopausal gonadotrophin | rel=r_associated | relid=0 | w=20
  3269. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:human menopausal gonadotropin
    n1=en:contraindications aspect | n2=en:human menopausal gonadotropin | rel=r_associated | relid=0 | w=20
  3270. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:human platelet antigens
    n1=en:contraindications aspect | n2=en:human platelet antigens | rel=r_associated | relid=0 | w=20
  3271. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:human rho(d) immune globulin
    n1=en:contraindications aspect | n2=en:human rho(d) immune globulin | rel=r_associated | relid=0 | w=20
  3272. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydro-lyases
    n1=en:contraindications aspect | n2=en:hydro-lyases | rel=r_associated | relid=0 | w=20
  3273. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydrobromic acid
    n1=en:contraindications aspect | n2=en:hydrobromic acid | rel=r_associated | relid=0 | w=20
  3274. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydrocarbon
    n1=en:contraindications aspect | n2=en:hydrocarbon | rel=r_associated | relid=0 | w=20
  3275. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydrocarbons, alicyclic
    n1=en:contraindications aspect | n2=en:hydrocarbons, alicyclic | rel=r_associated | relid=0 | w=20
  3276. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydrochlorothiazide
    n1=en:contraindications aspect | n2=en:hydrochlorothiazide | rel=r_associated | relid=0 | w=20
  3277. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydrocortisone
    n1=en:contraindications aspect | n2=en:hydrocortisone | rel=r_associated | relid=0 | w=20
  3278. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydrotherapy
    n1=en:contraindications aspect | n2=en:hydrotherapy | rel=r_associated | relid=0 | w=20
  3279. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydroxy acids
    n1=en:contraindications aspect | n2=en:hydroxy acids | rel=r_associated | relid=0 | w=20
  3280. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydroxycholecalciferols
    n1=en:contraindications aspect | n2=en:hydroxycholecalciferols | rel=r_associated | relid=0 | w=20
  3281. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydroxycholesterols
    n1=en:contraindications aspect | n2=en:hydroxycholesterols | rel=r_associated | relid=0 | w=20
  3282. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydroxymethylglutaryl-coa synthase
    n1=en:contraindications aspect | n2=en:hydroxymethylglutaryl-coa synthase | rel=r_associated | relid=0 | w=20
  3283. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hydroxysteroid dehydrogenases
    n1=en:contraindications aspect | n2=en:hydroxysteroid dehydrogenases | rel=r_associated | relid=0 | w=20
  3284. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hygromycin b
    n1=en:contraindications aspect | n2=en:hygromycin b | rel=r_associated | relid=0 | w=20
  3285. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hyperpolarization-activated cyclic nucleotide-gated channels
    n1=en:contraindications aspect | n2=en:hyperpolarization-activated cyclic nucleotide-gated channels | rel=r_associated | relid=0 | w=20
  3286. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypnosis, dental
    n1=en:contraindications aspect | n2=en:hypnosis, dental | rel=r_associated | relid=0 | w=20
  3287. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypodicarbonous acid
    n1=en:contraindications aspect | n2=en:hypodicarbonous acid | rel=r_associated | relid=0 | w=20
  3288. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypoglycins
    n1=en:contraindications aspect | n2=en:hypoglycins | rel=r_associated | relid=0 | w=20
  3289. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypolipidemic agents
    n1=en:contraindications aspect | n2=en:hypolipidemic agents | rel=r_associated | relid=0 | w=20
  3290. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypophysectomy
    n1=en:contraindications aspect | n2=en:hypophysectomy | rel=r_associated | relid=0 | w=20
  3291. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypophysectomy, chemical
    n1=en:contraindications aspect | n2=en:hypophysectomy, chemical | rel=r_associated | relid=0 | w=20
  3292. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypotension, controlled
    n1=en:contraindications aspect | n2=en:hypotension, controlled | rel=r_associated | relid=0 | w=20
  3293. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypothermia, induced
    n1=en:contraindications aspect | n2=en:hypothermia, induced | rel=r_associated | relid=0 | w=20
  3294. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypoxanthine
    n1=en:contraindications aspect | n2=en:hypoxanthine | rel=r_associated | relid=0 | w=20
  3295. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypoxanthines
    n1=en:contraindications aspect | n2=en:hypoxanthines | rel=r_associated | relid=0 | w=20
  3296. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypoxia-inducible factor 1-alpha
    n1=en:contraindications aspect | n2=en:hypoxia-inducible factor 1-alpha | rel=r_associated | relid=0 | w=20
  3297. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypoxia-inducible factor-1
    n1=en:contraindications aspect | n2=en:hypoxia-inducible factor-1 | rel=r_associated | relid=0 | w=20
  3298. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hypoxia-inducible factor-proline dioxygenases
    n1=en:contraindications aspect | n2=en:hypoxia-inducible factor-proline dioxygenases | rel=r_associated | relid=0 | w=20
  3299. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hysteroscopes
    n1=en:contraindications aspect | n2=en:hysteroscopes | rel=r_associated | relid=0 | w=20
  3300. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hysteroscopy
    n1=en:contraindications aspect | n2=en:hysteroscopy | rel=r_associated | relid=0 | w=20
  3301. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:hysterotomy
    n1=en:contraindications aspect | n2=en:hysterotomy | rel=r_associated | relid=0 | w=20
  3302. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:i blood-group system
    n1=en:contraindications aspect | n2=en:i blood-group system | rel=r_associated | relid=0 | w=20
  3303. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:i kappa b
    n1=en:contraindications aspect | n2=en:i kappa b | rel=r_associated | relid=0 | w=20
  3304. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iduronic acid
    n1=en:contraindications aspect | n2=en:iduronic acid | rel=r_associated | relid=0 | w=20
  3305. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ikaros transcription factor
    n1=en:contraindications aspect | n2=en:ikaros transcription factor | rel=r_associated | relid=0 | w=20
  3306. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ileostomy
    n1=en:contraindications aspect | n2=en:ileostomy | rel=r_associated | relid=0 | w=20
  3307. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:imatinib mesylate
    n1=en:contraindications aspect | n2=en:imatinib mesylate | rel=r_associated | relid=0 | w=20
  3308. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immediate dental implant loading
    n1=en:contraindications aspect | n2=en:immediate dental implant loading | rel=r_associated | relid=0 | w=20
  3309. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immune body
    n1=en:contraindications aspect | n2=en:immune body | rel=r_associated | relid=0 | w=20
  3310. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunization
    n1=en:contraindications aspect | n2=en:immunization | rel=r_associated | relid=0 | w=20
  3311. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoadjuvant
    n1=en:contraindications aspect | n2=en:immunoadjuvant | rel=r_associated | relid=0 | w=20
  3312. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoconglutinins
    n1=en:contraindications aspect | n2=en:immunoconglutinins | rel=r_associated | relid=0 | w=20
  3313. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunodominant epitopes
    n1=en:contraindications aspect | n2=en:immunodominant epitopes | rel=r_associated | relid=0 | w=20
  3314. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoenzyme procedure
    n1=en:contraindications aspect | n2=en:immunoenzyme procedure | rel=r_associated | relid=0 | w=20
  3315. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoglobin
    n1=en:contraindications aspect | n2=en:immunoglobin | rel=r_associated | relid=0 | w=20
  3316. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoglobulin
    n1=en:contraindications aspect | n2=en:immunoglobulin | rel=r_associated | relid=0 | w=20
  3317. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoglobulin alpha-chains
    n1=en:contraindications aspect | n2=en:immunoglobulin alpha-chains | rel=r_associated | relid=0 | w=20
  3318. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoglobulin delta-chains
    n1=en:contraindications aspect | n2=en:immunoglobulin delta-chains | rel=r_associated | relid=0 | w=20
  3319. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoglobulin fragments
    n1=en:contraindications aspect | n2=en:immunoglobulin fragments | rel=r_associated | relid=0 | w=20
  3320. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoglobulin light chain
    n1=en:contraindications aspect | n2=en:immunoglobulin light chain | rel=r_associated | relid=0 | w=20
  3321. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunology test
    n1=en:contraindications aspect | n2=en:immunology test | rel=r_associated | relid=0 | w=20
  3322. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunoprecipitation
    n1=en:contraindications aspect | n2=en:immunoprecipitation | rel=r_associated | relid=0 | w=20
  3323. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunosorbent techniques
    n1=en:contraindications aspect | n2=en:immunosorbent techniques | rel=r_associated | relid=0 | w=20
  3324. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunosorbents
    n1=en:contraindications aspect | n2=en:immunosorbents | rel=r_associated | relid=0 | w=20
  3325. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:immunotoxin
    n1=en:contraindications aspect | n2=en:immunotoxin | rel=r_associated | relid=0 | w=20
  3326. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:implantable neurostimulators
    n1=en:contraindications aspect | n2=en:implantable neurostimulators | rel=r_associated | relid=0 | w=20
  3327. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:implantable pump
    n1=en:contraindications aspect | n2=en:implantable pump | rel=r_associated | relid=0 | w=20
  3328. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:in vitro fertilisation
    n1=en:contraindications aspect | n2=en:in vitro fertilisation | rel=r_associated | relid=0 | w=20
  3329. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:in vitro fertilization
    n1=en:contraindications aspect | n2=en:in vitro fertilization | rel=r_associated | relid=0 | w=20
  3330. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:incontinence pads
    n1=en:contraindications aspect | n2=en:incontinence pads | rel=r_associated | relid=0 | w=20
  3331. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:incubators, infant
    n1=en:contraindications aspect | n2=en:incubators, infant | rel=r_associated | relid=0 | w=20
  3332. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:indican
    n1=en:contraindications aspect | n2=en:indican | rel=r_associated | relid=0 | w=20
  3333. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:indicators and reagents
    n1=en:contraindications aspect | n2=en:indicators and reagents | rel=r_associated | relid=0 | w=20
  3334. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:indigotindisulfonate sodium
    n1=en:contraindications aspect | n2=en:indigotindisulfonate sodium | rel=r_associated | relid=0 | w=20
  3335. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:indocyanine green
    n1=en:contraindications aspect | n2=en:indocyanine green | rel=r_associated | relid=0 | w=20
  3336. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:indolequinones
    n1=en:contraindications aspect | n2=en:indolequinones | rel=r_associated | relid=0 | w=20
  3337. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:indomethacin
    n1=en:contraindications aspect | n2=en:indomethacin | rel=r_associated | relid=0 | w=20
  3338. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:induced hypotension
    n1=en:contraindications aspect | n2=en:induced hypotension | rel=r_associated | relid=0 | w=20
  3339. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inducible t-cell co-stimulator ligand
    n1=en:contraindications aspect | n2=en:inducible t-cell co-stimulator ligand | rel=r_associated | relid=0 | w=20
  3340. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:induction of labor
    n1=en:contraindications aspect | n2=en:induction of labor | rel=r_associated | relid=0 | w=20
  3341. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:induction of neuromuscular blockade
    n1=en:contraindications aspect | n2=en:induction of neuromuscular blockade | rel=r_associated | relid=0 | w=20
  3342. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:infant diaper
    n1=en:contraindications aspect | n2=en:infant diaper | rel=r_associated | relid=0 | w=20
  3343. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:influenza virus vaccine
    n1=en:contraindications aspect | n2=en:influenza virus vaccine | rel=r_associated | relid=0 | w=20
  3344. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inhalation spacers
    n1=en:contraindications aspect | n2=en:inhalation spacers | rel=r_associated | relid=0 | w=20
  3345. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inhibitor of differentiation protein 1
    n1=en:contraindications aspect | n2=en:inhibitor of differentiation protein 1 | rel=r_associated | relid=0 | w=20
  3346. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:injections, intraventricular
    n1=en:contraindications aspect | n2=en:injections, intraventricular | rel=r_associated | relid=0 | w=20
  3347. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:injections, jet
    n1=en:contraindications aspect | n2=en:injections, jet | rel=r_associated | relid=0 | w=20
  3348. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inlay casting wax
    n1=en:contraindications aspect | n2=en:inlay casting wax | rel=r_associated | relid=0 | w=20
  3349. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inoculation
    n1=en:contraindications aspect | n2=en:inoculation | rel=r_associated | relid=0 | w=20
  3350. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inosine
    n1=en:contraindications aspect | n2=en:inosine | rel=r_associated | relid=0 | w=20
  3351. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inosine diphosphate
    n1=en:contraindications aspect | n2=en:inosine diphosphate | rel=r_associated | relid=0 | w=20
  3352. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inosine monophosphate dehydrogenase
    n1=en:contraindications aspect | n2=en:inosine monophosphate dehydrogenase | rel=r_associated | relid=0 | w=20
  3353. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inosine triphosphate
    n1=en:contraindications aspect | n2=en:inosine triphosphate | rel=r_associated | relid=0 | w=20
  3354. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inositol
    n1=en:contraindications aspect | n2=en:inositol | rel=r_associated | relid=0 | w=20
  3355. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inositol phosphates
    n1=en:contraindications aspect | n2=en:inositol phosphates | rel=r_associated | relid=0 | w=20
  3356. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insect repellents
    n1=en:contraindications aspect | n2=en:insect repellents | rel=r_associated | relid=0 | w=20
  3357. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insecticide-treated bednets
    n1=en:contraindications aspect | n2=en:insecticide-treated bednets | rel=r_associated | relid=0 | w=20
  3358. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insecticides
    n1=en:contraindications aspect | n2=en:insecticides | rel=r_associated | relid=0 | w=20
  3359. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insemination, artificial, homologous
    n1=en:contraindications aspect | n2=en:insemination, artificial, homologous | rel=r_associated | relid=0 | w=20
  3360. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin glargine
    n1=en:contraindications aspect | n2=en:insulin glargine | rel=r_associated | relid=0 | w=20
  3361. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin-like growth factor
    n1=en:contraindications aspect | n2=en:insulin-like growth factor | rel=r_associated | relid=0 | w=20
  3362. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin-like growth factor-binding protein
    n1=en:contraindications aspect | n2=en:insulin-like growth factor-binding protein | rel=r_associated | relid=0 | w=20
  3363. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin-like growth factor-binding protein 2
    n1=en:contraindications aspect | n2=en:insulin-like growth factor-binding protein 2 | rel=r_associated | relid=0 | w=20
  3364. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin-like growth factor-binding protein 3
    n1=en:contraindications aspect | n2=en:insulin-like growth factor-binding protein 3 | rel=r_associated | relid=0 | w=20
  3365. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin-like growth factor-binding protein 4
    n1=en:contraindications aspect | n2=en:insulin-like growth factor-binding protein 4 | rel=r_associated | relid=0 | w=20
  3366. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin-like growth factor-binding protein 5
    n1=en:contraindications aspect | n2=en:insulin-like growth factor-binding protein 5 | rel=r_associated | relid=0 | w=20
  3367. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin-like growth factor-binding protein 6
    n1=en:contraindications aspect | n2=en:insulin-like growth factor-binding protein 6 | rel=r_associated | relid=0 | w=20
  3368. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin, regular
    n1=en:contraindications aspect | n2=en:insulin, regular | rel=r_associated | relid=0 | w=20
  3369. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:insulin, ultralente
    n1=en:contraindications aspect | n2=en:insulin, ultralente | rel=r_associated | relid=0 | w=20
  3370. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:integrin alpha-4
    n1=en:contraindications aspect | n2=en:integrin alpha-4 | rel=r_associated | relid=0 | w=20
  3371. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:integrin alpha-6
    n1=en:contraindications aspect | n2=en:integrin alpha-6 | rel=r_associated | relid=0 | w=20
  3372. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:integrin alpha4
    n1=en:contraindications aspect | n2=en:integrin alpha4 | rel=r_associated | relid=0 | w=20
  3373. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:integrin alpha6
    n1=en:contraindications aspect | n2=en:integrin alpha6 | rel=r_associated | relid=0 | w=20
  3374. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:integrin alphav
    n1=en:contraindications aspect | n2=en:integrin alphav | rel=r_associated | relid=0 | w=20
  3375. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intercalating agent
    n1=en:contraindications aspect | n2=en:intercalating agent | rel=r_associated | relid=0 | w=20
  3376. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intercourse
    n1=en:contraindications aspect | n2=en:intercourse | rel=r_associated | relid=0 | w=20
  3377. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:interferometry
    n1=en:contraindications aspect | n2=en:interferometry | rel=r_associated | relid=0 | w=20
  3378. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:interferon treatment
    n1=en:contraindications aspect | n2=en:interferon treatment | rel=r_associated | relid=0 | w=20
  3379. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:interleukin-1 receptor-associated kinases
    n1=en:contraindications aspect | n2=en:interleukin-1 receptor-associated kinases | rel=r_associated | relid=0 | w=20
  3380. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:interleukin-15
    n1=en:contraindications aspect | n2=en:interleukin-15 | rel=r_associated | relid=0 | w=20
  3381. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:interleukin-18
    n1=en:contraindications aspect | n2=en:interleukin-18 | rel=r_associated | relid=0 | w=20
  3382. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:interleukin-2
    n1=en:contraindications aspect | n2=en:interleukin-2 | rel=r_associated | relid=0 | w=20
  3383. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:interleukin-2 receptor beta
    n1=en:contraindications aspect | n2=en:interleukin-2 receptor beta | rel=r_associated | relid=0 | w=20
  3384. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:interleukin-4
    n1=en:contraindications aspect | n2=en:interleukin-4 | rel=r_associated | relid=0 | w=20
  3385. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:internal fixators
    n1=en:contraindications aspect | n2=en:internal fixators | rel=r_associated | relid=0 | w=20
  3386. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:interpleural analgesia
    n1=en:contraindications aspect | n2=en:interpleural analgesia | rel=r_associated | relid=0 | w=20
  3387. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intervertebral disc chemolysis
    n1=en:contraindications aspect | n2=en:intervertebral disc chemolysis | rel=r_associated | relid=0 | w=20
  3388. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intra uterine device
    n1=en:contraindications aspect | n2=en:intra uterine device | rel=r_associated | relid=0 | w=20
  3389. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intra-aortic balloon pumping
    n1=en:contraindications aspect | n2=en:intra-aortic balloon pumping | rel=r_associated | relid=0 | w=20
  3390. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intradermal tests
    n1=en:contraindications aspect | n2=en:intradermal tests | rel=r_associated | relid=0 | w=20
  3391. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intramolecular lyases
    n1=en:contraindications aspect | n2=en:intramolecular lyases | rel=r_associated | relid=0 | w=20
  3392. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intramolecular oxidoreductases
    n1=en:contraindications aspect | n2=en:intramolecular oxidoreductases | rel=r_associated | relid=0 | w=20
  3393. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intraocular lens implant device
    n1=en:contraindications aspect | n2=en:intraocular lens implant device | rel=r_associated | relid=0 | w=20
  3394. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intraocular lens implantation procedure
    n1=en:contraindications aspect | n2=en:intraocular lens implantation procedure | rel=r_associated | relid=0 | w=20
  3395. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intraocular tamponade
    n1=en:contraindications aspect | n2=en:intraocular tamponade | rel=r_associated | relid=0 | w=20
  3396. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intrapartum cardiotocography
    n1=en:contraindications aspect | n2=en:intrapartum cardiotocography | rel=r_associated | relid=0 | w=20
  3397. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intrauterine device
    n1=en:contraindications aspect | n2=en:intrauterine device | rel=r_associated | relid=0 | w=20
  3398. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intrauterine devices, medicated
    n1=en:contraindications aspect | n2=en:intrauterine devices, medicated | rel=r_associated | relid=0 | w=20
  3399. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intravenous infusion
    n1=en:contraindications aspect | n2=en:intravenous infusion | rel=r_associated | relid=0 | w=20
  3400. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:intubation procedure
    n1=en:contraindications aspect | n2=en:intubation procedure | rel=r_associated | relid=0 | w=20
  3401. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inulin
    n1=en:contraindications aspect | n2=en:inulin | rel=r_associated | relid=0 | w=20
  3402. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:inward rectifier potassium channel
    n1=en:contraindications aspect | n2=en:inward rectifier potassium channel | rel=r_associated | relid=0 | w=20
  3403. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iodates
    n1=en:contraindications aspect | n2=en:iodates | rel=r_associated | relid=0 | w=20
  3404. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iodides
    n1=en:contraindications aspect | n2=en:iodides | rel=r_associated | relid=0 | w=20
  3405. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iodine
    n1=en:contraindications aspect | n2=en:iodine | rel=r_associated | relid=0 | w=20
  3406. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iodoacetic acid
    n1=en:contraindications aspect | n2=en:iodoacetic acid | rel=r_associated | relid=0 | w=20
  3407. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iodohippuric acid
    n1=en:contraindications aspect | n2=en:iodohippuric acid | rel=r_associated | relid=0 | w=20
  3408. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iofetamine
    n1=en:contraindications aspect | n2=en:iofetamine | rel=r_associated | relid=0 | w=20
  3409. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ionic liquids
    n1=en:contraindications aspect | n2=en:ionic liquids | rel=r_associated | relid=0 | w=20
  3410. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ionomycin
    n1=en:contraindications aspect | n2=en:ionomycin | rel=r_associated | relid=0 | w=20
  3411. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iron carbonyl compounds
    n1=en:contraindications aspect | n2=en:iron carbonyl compounds | rel=r_associated | relid=0 | w=20
  3412. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iron compounds, organic
    n1=en:contraindications aspect | n2=en:iron compounds, organic | rel=r_associated | relid=0 | w=20
  3413. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:iron dextran complex
    n1=en:contraindications aspect | n2=en:iron dextran complex | rel=r_associated | relid=0 | w=20
  3414. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ischemic preconditioning, myocardial
    n1=en:contraindications aspect | n2=en:ischemic preconditioning, myocardial | rel=r_associated | relid=0 | w=20
  3415. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isochores
    n1=en:contraindications aspect | n2=en:isochores | rel=r_associated | relid=0 | w=20
  3416. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isocitrates
    n1=en:contraindications aspect | n2=en:isocitrates | rel=r_associated | relid=0 | w=20
  3417. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isocoumarins
    n1=en:contraindications aspect | n2=en:isocoumarins | rel=r_associated | relid=0 | w=20
  3418. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isodesmosin
    n1=en:contraindications aspect | n2=en:isodesmosin | rel=r_associated | relid=0 | w=20
  3419. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isodesmosine
    n1=en:contraindications aspect | n2=en:isodesmosine | rel=r_associated | relid=0 | w=20
  3420. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isoflurane
    n1=en:contraindications aspect | n2=en:isoflurane | rel=r_associated | relid=0 | w=20
  3421. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isoindoles
    n1=en:contraindications aspect | n2=en:isoindoles | rel=r_associated | relid=0 | w=20
  3422. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isomaltose
    n1=en:contraindications aspect | n2=en:isomaltose | rel=r_associated | relid=0 | w=20
  3423. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isoniazid
    n1=en:contraindications aspect | n2=en:isoniazid | rel=r_associated | relid=0 | w=20
  3424. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isonicotinic acids
    n1=en:contraindications aspect | n2=en:isonicotinic acids | rel=r_associated | relid=0 | w=20
  3425. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isopréniques
    n1=en:contraindications aspect | n2=en:isopréniques | rel=r_associated | relid=0 | w=20
  3426. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isopromethazine
    n1=en:contraindications aspect | n2=en:isopromethazine | rel=r_associated | relid=0 | w=20
  3427. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isotretinoin
    n1=en:contraindications aspect | n2=en:isotretinoin | rel=r_associated | relid=0 | w=20
  3428. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:isozyme
    n1=en:contraindications aspect | n2=en:isozyme | rel=r_associated | relid=0 | w=20
  3429. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:IUD
    n1=en:contraindications aspect | n2=en:IUD | rel=r_associated | relid=0 | w=20
  3430. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:IVF
    n1=en:contraindications aspect | n2=en:IVF | rel=r_associated | relid=0 | w=20
  3431. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:jagged-1 protein
    n1=en:contraindications aspect | n2=en:jagged-1 protein | rel=r_associated | relid=0 | w=20
  3432. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:janus kinase 3
    n1=en:contraindications aspect | n2=en:janus kinase 3 | rel=r_associated | relid=0 | w=20
  3433. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:janus kinase family
    n1=en:contraindications aspect | n2=en:janus kinase family | rel=r_associated | relid=0 | w=20
  3434. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:jejunoileal bypass
    n1=en:contraindications aspect | n2=en:jejunoileal bypass | rel=r_associated | relid=0 | w=20
  3435. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:jejunostomy
    n1=en:contraindications aspect | n2=en:jejunostomy | rel=r_associated | relid=0 | w=20
  3436. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:junctional adhesion molecule c
    n1=en:contraindications aspect | n2=en:junctional adhesion molecule c | rel=r_associated | relid=0 | w=20
  3437. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:juvenile hormones
    n1=en:contraindications aspect | n2=en:juvenile hormones | rel=r_associated | relid=0 | w=20
  3438. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:kaempferols
    n1=en:contraindications aspect | n2=en:kaempferols | rel=r_associated | relid=0 | w=20
  3439. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:kainic acid
    n1=en:contraindications aspect | n2=en:kainic acid | rel=r_associated | relid=0 | w=20
  3440. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:karaya gum
    n1=en:contraindications aspect | n2=en:karaya gum | rel=r_associated | relid=0 | w=20
  3441. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:katp channels
    n1=en:contraindications aspect | n2=en:katp channels | rel=r_associated | relid=0 | w=20
  3442. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:keratectomy, subepithelial, laser-assisted
    n1=en:contraindications aspect | n2=en:keratectomy, subepithelial, laser-assisted | rel=r_associated | relid=0 | w=20
  3443. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:keratin 18
    n1=en:contraindications aspect | n2=en:keratin 18 | rel=r_associated | relid=0 | w=20
  3444. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:keratin, type ii cytoskeletal 5
    n1=en:contraindications aspect | n2=en:keratin, type ii cytoskeletal 5 | rel=r_associated | relid=0 | w=20
  3445. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:keratin, type ii cytoskeletal 7
    n1=en:contraindications aspect | n2=en:keratin, type ii cytoskeletal 7 | rel=r_associated | relid=0 | w=20
  3446. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:keratins, hair-specific
    n1=en:contraindications aspect | n2=en:keratins, hair-specific | rel=r_associated | relid=0 | w=20
  3447. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:keratomileusis, laser in situ
    n1=en:contraindications aspect | n2=en:keratomileusis, laser in situ | rel=r_associated | relid=0 | w=20
  3448. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:keratoplasty
    n1=en:contraindications aspect | n2=en:keratoplasty | rel=r_associated | relid=0 | w=20
  3449. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:keratoscopy
    n1=en:contraindications aspect | n2=en:keratoscopy | rel=r_associated | relid=0 | w=20
  3450. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:keto acids
    n1=en:contraindications aspect | n2=en:keto acids | rel=r_associated | relid=0 | w=20
  3451. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ketogenic diet
    n1=en:contraindications aspect | n2=en:ketogenic diet | rel=r_associated | relid=0 | w=20
  3452. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ketoglutaric acids
    n1=en:contraindications aspect | n2=en:ketoglutaric acids | rel=r_associated | relid=0 | w=20
  3453. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:key moment
    n1=en:contraindications aspect | n2=en:key moment | rel=r_associated | relid=0 | w=20
  3454. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:kidd blood-group system
    n1=en:contraindications aspect | n2=en:kidd blood-group system | rel=r_associated | relid=0 | w=20
  3455. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:kinetin
    n1=en:contraindications aspect | n2=en:kinetin | rel=r_associated | relid=0 | w=20
  3456. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:kininogen, low-molecular-weight protein
    n1=en:contraindications aspect | n2=en:kininogen, low-molecular-weight protein | rel=r_associated | relid=0 | w=20
  3457. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:kininogens
    n1=en:contraindications aspect | n2=en:kininogens | rel=r_associated | relid=0 | w=20
  3458. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:kv channel-interacting proteins
    n1=en:contraindications aspect | n2=en:kv channel-interacting proteins | rel=r_associated | relid=0 | w=20
  3459. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:kyphoplasty
    n1=en:contraindications aspect | n2=en:kyphoplasty | rel=r_associated | relid=0 | w=20
  3460. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:l-ascorbate oxidase
    n1=en:contraindications aspect | n2=en:l-ascorbate oxidase | rel=r_associated | relid=0 | w=20
  3461. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:L-dopa
    n1=en:contraindications aspect | n2=en:L-dopa | rel=r_associated | relid=0 | w=20
  3462. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:l-serine dehydratase
    n1=en:contraindications aspect | n2=en:l-serine dehydratase | rel=r_associated | relid=0 | w=20
  3463. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:l-type calcium channels
    n1=en:contraindications aspect | n2=en:l-type calcium channels | rel=r_associated | relid=0 | w=20
  3464. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:l-tyrosine
    n1=en:contraindications aspect | n2=en:l-tyrosine | rel=r_associated | relid=0 | w=20
  3465. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lacryglobin
    n1=en:contraindications aspect | n2=en:lacryglobin | rel=r_associated | relid=0 | w=20
  3466. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lactams, macrocyclic
    n1=en:contraindications aspect | n2=en:lactams, macrocyclic | rel=r_associated | relid=0 | w=20
  3467. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lactase
    n1=en:contraindications aspect | n2=en:lactase | rel=r_associated | relid=0 | w=20
  3468. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lactate dehydrogenases
    n1=en:contraindications aspect | n2=en:lactate dehydrogenases | rel=r_associated | relid=0 | w=20
  3469. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lactic acid
    n1=en:contraindications aspect | n2=en:lactic acid | rel=r_associated | relid=0 | w=20
  3470. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lactosylceramides
    n1=en:contraindications aspect | n2=en:lactosylceramides | rel=r_associated | relid=0 | w=20
  3471. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lactotransferrin
    n1=en:contraindications aspect | n2=en:lactotransferrin | rel=r_associated | relid=0 | w=20
  3472. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lamin b
    n1=en:contraindications aspect | n2=en:lamin b | rel=r_associated | relid=0 | w=20
  3473. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:laminectomy
    n1=en:contraindications aspect | n2=en:laminectomy | rel=r_associated | relid=0 | w=20
  3474. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lamivudine
    n1=en:contraindications aspect | n2=en:lamivudine | rel=r_associated | relid=0 | w=20
  3475. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lanthanoid series elements
    n1=en:contraindications aspect | n2=en:lanthanoid series elements | rel=r_associated | relid=0 | w=20
  3476. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:laparoscope
    n1=en:contraindications aspect | n2=en:laparoscope | rel=r_associated | relid=0 | w=20
  3477. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:laparoscopic cholecystectomy
    n1=en:contraindications aspect | n2=en:laparoscopic cholecystectomy | rel=r_associated | relid=0 | w=20
  3478. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:large neutral amino acids transporter small subunit 1
    n1=en:contraindications aspect | n2=en:large neutral amino acids transporter small subunit 1 | rel=r_associated | relid=0 | w=20
  3479. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:large-conductance calcium-activated potassium channel alpha subunits
    n1=en:contraindications aspect | n2=en:large-conductance calcium-activated potassium channel alpha subunits | rel=r_associated | relid=0 | w=20
  3480. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:large-conductance calcium-activated potassium channel beta subunits
    n1=en:contraindications aspect | n2=en:large-conductance calcium-activated potassium channel beta subunits | rel=r_associated | relid=0 | w=20
  3481. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:laroxyl
    n1=en:contraindications aspect | n2=en:laroxyl | rel=r_associated | relid=0 | w=20
  3482. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:laryngeal masks
    n1=en:contraindications aspect | n2=en:laryngeal masks | rel=r_associated | relid=0 | w=20
  3483. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:laryngoscopy
    n1=en:contraindications aspect | n2=en:laryngoscopy | rel=r_associated | relid=0 | w=20
  3484. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:laser lithotripsy
    n1=en:contraindications aspect | n2=en:laser lithotripsy | rel=r_associated | relid=0 | w=20
  3485. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:latent tgf-beta binding proteins
    n1=en:contraindications aspect | n2=en:latent tgf-beta binding proteins | rel=r_associated | relid=0 | w=20
  3486. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:latex fixation tests
    n1=en:contraindications aspect | n2=en:latex fixation tests | rel=r_associated | relid=0 | w=20
  3487. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:laxative
    n1=en:contraindications aspect | n2=en:laxative | rel=r_associated | relid=0 | w=20
  3488. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ldl cholesterol lipoproteins
    n1=en:contraindications aspect | n2=en:ldl cholesterol lipoproteins | rel=r_associated | relid=0 | w=20
  3489. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:left-right determination factors
    n1=en:contraindications aspect | n2=en:left-right determination factors | rel=r_associated | relid=0 | w=20
  3490. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:leptin
    n1=en:contraindications aspect | n2=en:leptin | rel=r_associated | relid=0 | w=20
  3491. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:leu-enkephalin
    n1=en:contraindications aspect | n2=en:leu-enkephalin | rel=r_associated | relid=0 | w=20
  3492. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:leucine transaminase
    n1=en:contraindications aspect | n2=en:leucine transaminase | rel=r_associated | relid=0 | w=20
  3493. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:leukocidins
    n1=en:contraindications aspect | n2=en:leukocidins | rel=r_associated | relid=0 | w=20
  3494. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:leukotriene c4
    n1=en:contraindications aspect | n2=en:leukotriene c4 | rel=r_associated | relid=0 | w=20
  3495. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:leukotriene d4
    n1=en:contraindications aspect | n2=en:leukotriene d4 | rel=r_associated | relid=0 | w=20
  3496. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:levodopa
    n1=en:contraindications aspect | n2=en:levodopa | rel=r_associated | relid=0 | w=20
  3497. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:levofloxacin
    n1=en:contraindications aspect | n2=en:levofloxacin | rel=r_associated | relid=0 | w=20
  3498. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:levomepromazine
    n1=en:contraindications aspect | n2=en:levomepromazine | rel=r_associated | relid=0 | w=20
  3499. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:levulinic acids
    n1=en:contraindications aspect | n2=en:levulinic acids | rel=r_associated | relid=0 | w=20
  3500. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lewis blood-group system
    n1=en:contraindications aspect | n2=en:lewis blood-group system | rel=r_associated | relid=0 | w=20
  3501. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ligand-gated ion channels
    n1=en:contraindications aspect | n2=en:ligand-gated ion channels | rel=r_associated | relid=0 | w=20
  3502. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:light-curing of dental adhesives
    n1=en:contraindications aspect | n2=en:light-curing of dental adhesives | rel=r_associated | relid=0 | w=20
  3503. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lim kinases
    n1=en:contraindications aspect | n2=en:lim kinases | rel=r_associated | relid=0 | w=20
  3504. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:linagliptin
    n1=en:contraindications aspect | n2=en:linagliptin | rel=r_associated | relid=0 | w=20
  3505. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:linolenic acids
    n1=en:contraindications aspect | n2=en:linolenic acids | rel=r_associated | relid=0 | w=20
  3506. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:linuron
    n1=en:contraindications aspect | n2=en:linuron | rel=r_associated | relid=0 | w=20
  3507. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lipase
    n1=en:contraindications aspect | n2=en:lipase | rel=r_associated | relid=0 | w=20
  3508. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lipectomy
    n1=en:contraindications aspect | n2=en:lipectomy | rel=r_associated | relid=0 | w=20
  3509. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lipid a
    n1=en:contraindications aspect | n2=en:lipid a | rel=r_associated | relid=0 | w=20
  3510. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lipid droplet associated proteins
    n1=en:contraindications aspect | n2=en:lipid droplet associated proteins | rel=r_associated | relid=0 | w=20
  3511. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lipid regulating agents
    n1=en:contraindications aspect | n2=en:lipid regulating agents | rel=r_associated | relid=0 | w=20
  3512. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lipocalin-2
    n1=en:contraindications aspect | n2=en:lipocalin-2 | rel=r_associated | relid=0 | w=20
  3513. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lipofuscin
    n1=en:contraindications aspect | n2=en:lipofuscin | rel=r_associated | relid=0 | w=20
  3514. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lipoprotein lipase
    n1=en:contraindications aspect | n2=en:lipoprotein lipase | rel=r_associated | relid=0 | w=20
  3515. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:liposoma
    n1=en:contraindications aspect | n2=en:liposoma | rel=r_associated | relid=0 | w=20
  3516. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:liposome
    n1=en:contraindications aspect | n2=en:liposome | rel=r_associated | relid=0 | w=20
  3517. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:liposuccion
    n1=en:contraindications aspect | n2=en:liposuccion | rel=r_associated | relid=0 | w=20
  3518. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:liposuction
    n1=en:contraindications aspect | n2=en:liposuction | rel=r_associated | relid=0 | w=20
  3519. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lipotropic agents
    n1=en:contraindications aspect | n2=en:lipotropic agents | rel=r_associated | relid=0 | w=20
  3520. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:liraglutide
    n1=en:contraindications aspect | n2=en:liraglutide | rel=r_associated | relid=0 | w=20
  3521. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lisdexamfetamine dimesylate
    n1=en:contraindications aspect | n2=en:lisdexamfetamine dimesylate | rel=r_associated | relid=0 | w=20
  3522. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lisinopril
    n1=en:contraindications aspect | n2=en:lisinopril | rel=r_associated | relid=0 | w=20
  3523. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lithium carbonate
    n1=en:contraindications aspect | n2=en:lithium carbonate | rel=r_associated | relid=0 | w=20
  3524. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lithium compounds
    n1=en:contraindications aspect | n2=en:lithium compounds | rel=r_associated | relid=0 | w=20
  3525. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:liver filtrate factor
    n1=en:contraindications aspect | n2=en:liver filtrate factor | rel=r_associated | relid=0 | w=20
  3526. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:liver glycogen
    n1=en:contraindications aspect | n2=en:liver glycogen | rel=r_associated | relid=0 | w=20
  3527. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:liver, artificial
    n1=en:contraindications aspect | n2=en:liver, artificial | rel=r_associated | relid=0 | w=20
  3528. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:local anesthesia procedure
    n1=en:contraindications aspect | n2=en:local anesthesia procedure | rel=r_associated | relid=0 | w=20
  3529. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lorajmine
    n1=en:contraindications aspect | n2=en:lorajmine | rel=r_associated | relid=0 | w=20
  3530. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lovastatin
    n1=en:contraindications aspect | n2=en:lovastatin | rel=r_associated | relid=0 | w=20
  3531. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:low density lipoprotein
    n1=en:contraindications aspect | n2=en:low density lipoprotein | rel=r_associated | relid=0 | w=20
  3532. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:low molecular weight heparin
    n1=en:contraindications aspect | n2=en:low molecular weight heparin | rel=r_associated | relid=0 | w=20
  3533. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lubricant
    n1=en:contraindications aspect | n2=en:lubricant | rel=r_associated | relid=0 | w=20
  3534. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:luciferases, renilla
    n1=en:contraindications aspect | n2=en:luciferases, renilla | rel=r_associated | relid=0 | w=20
  3535. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:luminescent proteins
    n1=en:contraindications aspect | n2=en:luminescent proteins | rel=r_associated | relid=0 | w=20
  3536. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lung transplantation
    n1=en:contraindications aspect | n2=en:lung transplantation | rel=r_associated | relid=0 | w=20
  3537. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lupus coagulation inhibitor
    n1=en:contraindications aspect | n2=en:lupus coagulation inhibitor | rel=r_associated | relid=0 | w=20
  3538. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lurasidone hydrochloride
    n1=en:contraindications aspect | n2=en:lurasidone hydrochloride | rel=r_associated | relid=0 | w=20
  3539. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:luteolin
    n1=en:contraindications aspect | n2=en:luteolin | rel=r_associated | relid=0 | w=20
  3540. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lye
    n1=en:contraindications aspect | n2=en:lye | rel=r_associated | relid=0 | w=20
  3541. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lymecycline
    n1=en:contraindications aspect | n2=en:lymecycline | rel=r_associated | relid=0 | w=20
  3542. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lymphangiography
    n1=en:contraindications aspect | n2=en:lymphangiography | rel=r_associated | relid=0 | w=20
  3543. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lymphocyte function-associated antigen 3
    n1=en:contraindications aspect | n2=en:lymphocyte function-associated antigen 3 | rel=r_associated | relid=0 | w=20
  3544. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lymphocyte transfusion
    n1=en:contraindications aspect | n2=en:lymphocyte transfusion | rel=r_associated | relid=0 | w=20
  3545. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lymphotoxin alpha1, beta2 heterotrimer
    n1=en:contraindications aspect | n2=en:lymphotoxin alpha1, beta2 heterotrimer | rel=r_associated | relid=0 | w=20
  3546. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lymphotoxin beta
    n1=en:contraindications aspect | n2=en:lymphotoxin beta | rel=r_associated | relid=0 | w=20
  3547. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lymphotoxin-alpha
    n1=en:contraindications aspect | n2=en:lymphotoxin-alpha | rel=r_associated | relid=0 | w=20
  3548. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lynestrenol
    n1=en:contraindications aspect | n2=en:lynestrenol | rel=r_associated | relid=0 | w=20
  3549. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lysergic acid
    n1=en:contraindications aspect | n2=en:lysergic acid | rel=r_associated | relid=0 | w=20
  3550. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lysinoalanine
    n1=en:contraindications aspect | n2=en:lysinoalanine | rel=r_associated | relid=0 | w=20
  3551. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lysophosphatidylcholines
    n1=en:contraindications aspect | n2=en:lysophosphatidylcholines | rel=r_associated | relid=0 | w=20
  3552. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:lysosome-associated membrane glycoprotein 1
    n1=en:contraindications aspect | n2=en:lysosome-associated membrane glycoprotein 1 | rel=r_associated | relid=0 | w=20
  3553. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:machine-teeth
    n1=en:contraindications aspect | n2=en:machine-teeth | rel=r_associated | relid=0 | w=20
  3554. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:macrophage-1 antigen
    n1=en:contraindications aspect | n2=en:macrophage-1 antigen | rel=r_associated | relid=0 | w=20
  3555. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:macrophage-activating factors
    n1=en:contraindications aspect | n2=en:macrophage-activating factors | rel=r_associated | relid=0 | w=20
  3556. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:macular pigment
    n1=en:contraindications aspect | n2=en:macular pigment | rel=r_associated | relid=0 | w=20
  3557. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:maf transcription factors, large
    n1=en:contraindications aspect | n2=en:maf transcription factors, large | rel=r_associated | relid=0 | w=20
  3558. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:maf transcription factors, small
    n1=en:contraindications aspect | n2=en:maf transcription factors, small | rel=r_associated | relid=0 | w=20
  3559. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:magainins
    n1=en:contraindications aspect | n2=en:magainins | rel=r_associated | relid=0 | w=20
  3560. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:magnesium chloride
    n1=en:contraindications aspect | n2=en:magnesium chloride | rel=r_associated | relid=0 | w=20
  3561. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:magnesium oxide
    n1=en:contraindications aspect | n2=en:magnesium oxide | rel=r_associated | relid=0 | w=20
  3562. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:magnesium sulfate
    n1=en:contraindications aspect | n2=en:magnesium sulfate | rel=r_associated | relid=0 | w=20
  3563. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:magnesium sulphate
    n1=en:contraindications aspect | n2=en:magnesium sulphate | rel=r_associated | relid=0 | w=20
  3564. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:magnetic resonance cholangiopancreatography
    n1=en:contraindications aspect | n2=en:magnetic resonance cholangiopancreatography | rel=r_associated | relid=0 | w=20
  3565. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:magnetic resonance imaging, interventional
    n1=en:contraindications aspect | n2=en:magnetic resonance imaging, interventional | rel=r_associated | relid=0 | w=20
  3566. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:magnetocardiography
    n1=en:contraindications aspect | n2=en:magnetocardiography | rel=r_associated | relid=0 | w=20
  3567. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:maintenance chemotherapy
    n1=en:contraindications aspect | n2=en:maintenance chemotherapy | rel=r_associated | relid=0 | w=20
  3568. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:make a counterpart to something
    n1=en:contraindications aspect | n2=en:make a counterpart to something | rel=r_associated | relid=0 | w=20
  3569. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:make a pair with something
    n1=en:contraindications aspect | n2=en:make a pair with something | rel=r_associated | relid=0 | w=20
  3570. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:make somebody 's acquaintance
    n1=en:contraindications aspect | n2=en:make somebody 's acquaintance | rel=r_associated | relid=0 | w=20
  3571. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:make somebody's acquaintance
    n1=en:contraindications aspect | n2=en:make somebody's acquaintance | rel=r_associated | relid=0 | w=20
  3572. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:malaria vaccines
    n1=en:contraindications aspect | n2=en:malaria vaccines | rel=r_associated | relid=0 | w=20
  3573. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:maltose-binding proteins
    n1=en:contraindications aspect | n2=en:maltose-binding proteins | rel=r_associated | relid=0 | w=20
  3574. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mammaglobin-a
    n1=en:contraindications aspect | n2=en:mammaglobin-a | rel=r_associated | relid=0 | w=20
  3575. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mammary prosthesis
    n1=en:contraindications aspect | n2=en:mammary prosthesis | rel=r_associated | relid=0 | w=20
  3576. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mammiplasty
    n1=en:contraindications aspect | n2=en:mammiplasty | rel=r_associated | relid=0 | w=20
  3577. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mammography
    n1=en:contraindications aspect | n2=en:mammography | rel=r_associated | relid=0 | w=20
  3578. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mammoplasty
    n1=en:contraindications aspect | n2=en:mammoplasty | rel=r_associated | relid=0 | w=20
  3579. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mandibular advancement
    n1=en:contraindications aspect | n2=en:mandibular advancement | rel=r_associated | relid=0 | w=20
  3580. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mandibular prosthesis
    n1=en:contraindications aspect | n2=en:mandibular prosthesis | rel=r_associated | relid=0 | w=20
  3581. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mandibular reconstruction
    n1=en:contraindications aspect | n2=en:mandibular reconstruction | rel=r_associated | relid=0 | w=20
  3582. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:manipulation of spine
    n1=en:contraindications aspect | n2=en:manipulation of spine | rel=r_associated | relid=0 | w=20
  3583. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mannomustine
    n1=en:contraindications aspect | n2=en:mannomustine | rel=r_associated | relid=0 | w=20
  3584. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mannose-6-phosphate isomerase
    n1=en:contraindications aspect | n2=en:mannose-6-phosphate isomerase | rel=r_associated | relid=0 | w=20
  3585. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mannosyl-glycoprotein endo-beta-n-acetylglucosaminidase
    n1=en:contraindications aspect | n2=en:mannosyl-glycoprotein endo-beta-n-acetylglucosaminidase | rel=r_associated | relid=0 | w=20
  3586. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:manometry
    n1=en:contraindications aspect | n2=en:manometry | rel=r_associated | relid=0 | w=20
  3587. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:map kinase kinase 5
    n1=en:contraindications aspect | n2=en:map kinase kinase 5 | rel=r_associated | relid=0 | w=20
  3588. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:map kinase kinase 7
    n1=en:contraindications aspect | n2=en:map kinase kinase 7 | rel=r_associated | relid=0 | w=20
  3589. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:map kinase kinase kinase 1
    n1=en:contraindications aspect | n2=en:map kinase kinase kinase 1 | rel=r_associated | relid=0 | w=20
  3590. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:maping
    n1=en:contraindications aspect | n2=en:maping | rel=r_associated | relid=0 | w=20
  3591. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mapping
    n1=en:contraindications aspect | n2=en:mapping | rel=r_associated | relid=0 | w=20
  3592. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:marine toxins
    n1=en:contraindications aspect | n2=en:marine toxins | rel=r_associated | relid=0 | w=20
  3593. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:masoprocol
    n1=en:contraindications aspect | n2=en:masoprocol | rel=r_associated | relid=0 | w=20
  3594. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mast/stem cell growth factor receptor kit
    n1=en:contraindications aspect | n2=en:mast/stem cell growth factor receptor kit | rel=r_associated | relid=0 | w=20
  3595. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:match
    n1=en:contraindications aspect | n2=en:match | rel=r_associated | relid=0 | w=20
  3596. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:matrix bands
    n1=en:contraindications aspect | n2=en:matrix bands | rel=r_associated | relid=0 | w=20
  3597. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:matrix metalloproteinase
    n1=en:contraindications aspect | n2=en:matrix metalloproteinase | rel=r_associated | relid=0 | w=20
  3598. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:matrix metalloproteinase 20
    n1=en:contraindications aspect | n2=en:matrix metalloproteinase 20 | rel=r_associated | relid=0 | w=20
  3599. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:matrix metalloproteinase-16
    n1=en:contraindications aspect | n2=en:matrix metalloproteinase-16 | rel=r_associated | relid=0 | w=20
  3600. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:maxillofacial prosthesis implantation
    n1=en:contraindications aspect | n2=en:maxillofacial prosthesis implantation | rel=r_associated | relid=0 | w=20
  3601. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:maximal respiratory pressures
    n1=en:contraindications aspect | n2=en:maximal respiratory pressures | rel=r_associated | relid=0 | w=20
  3602. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mean platelet volume measurement
    n1=en:contraindications aspect | n2=en:mean platelet volume measurement | rel=r_associated | relid=0 | w=20
  3603. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:measles/mumps/rubella vaccine
    n1=en:contraindications aspect | n2=en:measles/mumps/rubella vaccine | rel=r_associated | relid=0 | w=20
  3604. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:measure of the blood pressure
    n1=en:contraindications aspect | n2=en:measure of the blood pressure | rel=r_associated | relid=0 | w=20
  3605. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:measurement of blood pressure
    n1=en:contraindications aspect | n2=en:measurement of blood pressure | rel=r_associated | relid=0 | w=20
  3606. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mechanical ventilator
    n1=en:contraindications aspect | n2=en:mechanical ventilator | rel=r_associated | relid=0 | w=20
  3607. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:medazepam
    n1=en:contraindications aspect | n2=en:medazepam | rel=r_associated | relid=0 | w=20
  3608. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:medical marijuana
    n1=en:contraindications aspect | n2=en:medical marijuana | rel=r_associated | relid=0 | w=20
  3609. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:medical pins
    n1=en:contraindications aspect | n2=en:medical pins | rel=r_associated | relid=0 | w=20
  3610. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:medical procedure
    n1=en:contraindications aspect | n2=en:medical procedure | rel=r_associated | relid=0 | w=20
  3611. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:medical treatment
    n1=en:contraindications aspect | n2=en:medical treatment | rel=r_associated | relid=0 | w=20
  3612. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:medicine chests
    n1=en:contraindications aspect | n2=en:medicine chests | rel=r_associated | relid=0 | w=20
  3613. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:meet
    n1=en:contraindications aspect | n2=en:meet | rel=r_associated | relid=0 | w=20
  3614. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:meglutol
    n1=en:contraindications aspect | n2=en:meglutol | rel=r_associated | relid=0 | w=20
  3615. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:melanocyte stimulating hormone
    n1=en:contraindications aspect | n2=en:melanocyte stimulating hormone | rel=r_associated | relid=0 | w=20
  3616. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:membrane-type 1 matrix metalloproteinase
    n1=en:contraindications aspect | n2=en:membrane-type 1 matrix metalloproteinase | rel=r_associated | relid=0 | w=20
  3617. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:menadione
    n1=en:contraindications aspect | n2=en:menadione | rel=r_associated | relid=0 | w=20
  3618. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:menstrual hygiene products
    n1=en:contraindications aspect | n2=en:menstrual hygiene products | rel=r_associated | relid=0 | w=20
  3619. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:menstruation-inducing agents
    n1=en:contraindications aspect | n2=en:menstruation-inducing agents | rel=r_associated | relid=0 | w=20
  3620. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:meperidine
    n1=en:contraindications aspect | n2=en:meperidine | rel=r_associated | relid=0 | w=20
  3621. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:meperidine hydrochloride
    n1=en:contraindications aspect | n2=en:meperidine hydrochloride | rel=r_associated | relid=0 | w=20
  3622. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mercury
    n1=en:contraindications aspect | n2=en:mercury | rel=r_associated | relid=0 | w=20
  3623. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:Mercury
    n1=en:contraindications aspect | n2=en:Mercury | rel=r_associated | relid=0 | w=20
  3624. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:merozoite surface protein 1
    n1=en:contraindications aspect | n2=en:merozoite surface protein 1 | rel=r_associated | relid=0 | w=20
  3625. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mescaline
    n1=en:contraindications aspect | n2=en:mescaline | rel=r_associated | relid=0 | w=20
  3626. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mesna
    n1=en:contraindications aspect | n2=en:mesna | rel=r_associated | relid=0 | w=20
  3627. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mesoporphyrins
    n1=en:contraindications aspect | n2=en:mesoporphyrins | rel=r_associated | relid=0 | w=20
  3628. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:metalloexopeptidases
    n1=en:contraindications aspect | n2=en:metalloexopeptidases | rel=r_associated | relid=0 | w=20
  3629. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:metalloids
    n1=en:contraindications aspect | n2=en:metalloids | rel=r_associated | relid=0 | w=20
  3630. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:metallothionein
    n1=en:contraindications aspect | n2=en:metallothionein | rel=r_associated | relid=0 | w=20
  3631. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methacycline
    n1=en:contraindications aspect | n2=en:methacycline | rel=r_associated | relid=0 | w=20
  3632. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methadone
    n1=en:contraindications aspect | n2=en:methadone | rel=r_associated | relid=0 | w=20
  3633. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methiocarb
    n1=en:contraindications aspect | n2=en:methiocarb | rel=r_associated | relid=0 | w=20
  3634. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methionine adenosyltransferase
    n1=en:contraindications aspect | n2=en:methionine adenosyltransferase | rel=r_associated | relid=0 | w=20
  3635. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methionine synthase
    n1=en:contraindications aspect | n2=en:methionine synthase | rel=r_associated | relid=0 | w=20
  3636. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methoxsalen
    n1=en:contraindications aspect | n2=en:methoxsalen | rel=r_associated | relid=0 | w=20
  3637. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methyl benzene
    n1=en:contraindications aspect | n2=en:methyl benzene | rel=r_associated | relid=0 | w=20
  3638. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methyl green
    n1=en:contraindications aspect | n2=en:methyl green | rel=r_associated | relid=0 | w=20
  3639. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methyl methanesulfonate
    n1=en:contraindications aspect | n2=en:methyl methanesulfonate | rel=r_associated | relid=0 | w=20
  3640. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methyl-gag
    n1=en:contraindications aspect | n2=en:methyl-gag | rel=r_associated | relid=0 | w=20
  3641. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methylene blue
    n1=en:contraindications aspect | n2=en:methylene blue | rel=r_associated | relid=0 | w=20
  3642. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methylhistidines
    n1=en:contraindications aspect | n2=en:methylhistidines | rel=r_associated | relid=0 | w=20
  3643. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methylhydrazines
    n1=en:contraindications aspect | n2=en:methylhydrazines | rel=r_associated | relid=0 | w=20
  3644. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methylmalonyl-coa mutase
    n1=en:contraindications aspect | n2=en:methylmalonyl-coa mutase | rel=r_associated | relid=0 | w=20
  3645. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methylmorphine
    n1=en:contraindications aspect | n2=en:methylmorphine | rel=r_associated | relid=0 | w=20
  3646. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methylprednisolone hemisuccinate
    n1=en:contraindications aspect | n2=en:methylprednisolone hemisuccinate | rel=r_associated | relid=0 | w=20
  3647. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:methylthionine chloride
    n1=en:contraindications aspect | n2=en:methylthionine chloride | rel=r_associated | relid=0 | w=20
  3648. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:metribolone
    n1=en:contraindications aspect | n2=en:metribolone | rel=r_associated | relid=0 | w=20
  3649. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mevalonic acid
    n1=en:contraindications aspect | n2=en:mevalonic acid | rel=r_associated | relid=0 | w=20
  3650. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mhc class ii protein
    n1=en:contraindications aspect | n2=en:mhc class ii protein | rel=r_associated | relid=0 | w=20
  3651. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:microdissection
    n1=en:contraindications aspect | n2=en:microdissection | rel=r_associated | relid=0 | w=20
  3652. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:microinjections
    n1=en:contraindications aspect | n2=en:microinjections | rel=r_associated | relid=0 | w=20
  3653. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:micromanipulation
    n1=en:contraindications aspect | n2=en:micromanipulation | rel=r_associated | relid=0 | w=20
  3654. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:micronucleus tests
    n1=en:contraindications aspect | n2=en:micronucleus tests | rel=r_associated | relid=0 | w=20
  3655. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:micronutrients
    n1=en:contraindications aspect | n2=en:micronutrients | rel=r_associated | relid=0 | w=20
  3656. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:microscopy, fluorescence, multiphoton
    n1=en:contraindications aspect | n2=en:microscopy, fluorescence, multiphoton | rel=r_associated | relid=0 | w=20
  3657. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:microscopy, interference
    n1=en:contraindications aspect | n2=en:microscopy, interference | rel=r_associated | relid=0 | w=20
  3658. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:microtubule associated protein
    n1=en:contraindications aspect | n2=en:microtubule associated protein | rel=r_associated | relid=0 | w=20
  3659. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:microtubule proteins
    n1=en:contraindications aspect | n2=en:microtubule proteins | rel=r_associated | relid=0 | w=20
  3660. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:milk acid
    n1=en:contraindications aspect | n2=en:milk acid | rel=r_associated | relid=0 | w=20
  3661. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:milk proteins
    n1=en:contraindications aspect | n2=en:milk proteins | rel=r_associated | relid=0 | w=20
  3662. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mimosine
    n1=en:contraindications aspect | n2=en:mimosine | rel=r_associated | relid=0 | w=20
  3663. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mind-body therapies
    n1=en:contraindications aspect | n2=en:mind-body therapies | rel=r_associated | relid=0 | w=20
  3664. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:minichromosome maintenance complex component 5
    n1=en:contraindications aspect | n2=en:minichromosome maintenance complex component 5 | rel=r_associated | relid=0 | w=20
  3665. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:minichromosome maintenance complex component 6
    n1=en:contraindications aspect | n2=en:minichromosome maintenance complex component 6 | rel=r_associated | relid=0 | w=20
  3666. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:minocycline
    n1=en:contraindications aspect | n2=en:minocycline | rel=r_associated | relid=0 | w=20
  3667. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:minor lymphocyte stimulatory antigens
    n1=en:contraindications aspect | n2=en:minor lymphocyte stimulatory antigens | rel=r_associated | relid=0 | w=20
  3668. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mitochondrial trifunctional protein, alpha subunit
    n1=en:contraindications aspect | n2=en:mitochondrial trifunctional protein, alpha subunit | rel=r_associated | relid=0 | w=20
  3669. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mitochondrial trifunctional protein, beta subunit
    n1=en:contraindications aspect | n2=en:mitochondrial trifunctional protein, beta subunit | rel=r_associated | relid=0 | w=20
  3670. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mitogen
    n1=en:contraindications aspect | n2=en:mitogen | rel=r_associated | relid=0 | w=20
  3671. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mitogen-activated protein kinase
    n1=en:contraindications aspect | n2=en:mitogen-activated protein kinase | rel=r_associated | relid=0 | w=20
  3672. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mitogen-activated protein kinase 10
    n1=en:contraindications aspect | n2=en:mitogen-activated protein kinase 10 | rel=r_associated | relid=0 | w=20
  3673. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mitoguazone
    n1=en:contraindications aspect | n2=en:mitoguazone | rel=r_associated | relid=0 | w=20
  3674. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mitomycin antineoplastic antibiotic
    n1=en:contraindications aspect | n2=en:mitomycin antineoplastic antibiotic | rel=r_associated | relid=0 | w=20
  3675. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mitosis modulators
    n1=en:contraindications aspect | n2=en:mitosis modulators | rel=r_associated | relid=0 | w=20
  3676. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mixed function oxidase
    n1=en:contraindications aspect | n2=en:mixed function oxidase | rel=r_associated | relid=0 | w=20
  3677. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:moire topography
    n1=en:contraindications aspect | n2=en:moire topography | rel=r_associated | relid=0 | w=20
  3678. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mollusk venoms
    n1=en:contraindications aspect | n2=en:mollusk venoms | rel=r_associated | relid=0 | w=20
  3679. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:monitoring, ambulatory
    n1=en:contraindications aspect | n2=en:monitoring, ambulatory | rel=r_associated | relid=0 | w=20
  3680. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:monoamine oxidase inhibitor
    n1=en:contraindications aspect | n2=en:monoamine oxidase inhibitor | rel=r_associated | relid=0 | w=20
  3681. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:monocarboxylic acid transporters
    n1=en:contraindications aspect | n2=en:monocarboxylic acid transporters | rel=r_associated | relid=0 | w=20
  3682. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:monoclonal ab
    n1=en:contraindications aspect | n2=en:monoclonal ab | rel=r_associated | relid=0 | w=20
  3683. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:monoclonal antibody
    n1=en:contraindications aspect | n2=en:monoclonal antibody | rel=r_associated | relid=0 | w=20
  3684. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:monocrotophos
    n1=en:contraindications aspect | n2=en:monocrotophos | rel=r_associated | relid=0 | w=20
  3685. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:monocyte chemoattractant protein-2
    n1=en:contraindications aspect | n2=en:monocyte chemoattractant protein-2 | rel=r_associated | relid=0 | w=20
  3686. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:monomeric clathrin assembly proteins
    n1=en:contraindications aspect | n2=en:monomeric clathrin assembly proteins | rel=r_associated | relid=0 | w=20
  3687. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:monosodium glutamate
    n1=en:contraindications aspect | n2=en:monosodium glutamate | rel=r_associated | relid=0 | w=20
  3688. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mosquito nets
    n1=en:contraindications aspect | n2=en:mosquito nets | rel=r_associated | relid=0 | w=20
  3689. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mouth off to [sb]
    n1=en:contraindications aspect | n2=en:mouth off to [sb] | rel=r_associated | relid=0 | w=20
  3690. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:MRI
    n1=en:contraindications aspect | n2=en:MRI | rel=r_associated | relid=0 | w=20
  3691. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mri-based angiogram
    n1=en:contraindications aspect | n2=en:mri-based angiogram | rel=r_associated | relid=0 | w=20
  3692. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mucin-2
    n1=en:contraindications aspect | n2=en:mucin-2 | rel=r_associated | relid=0 | w=20
  3693. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:muellerian-inhibiting factor
    n1=en:contraindications aspect | n2=en:muellerian-inhibiting factor | rel=r_associated | relid=0 | w=20
  3694. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:multidetector computed tomography
    n1=en:contraindications aspect | n2=en:multidetector computed tomography | rel=r_associated | relid=0 | w=20
  3695. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:multimodality therapy
    n1=en:contraindications aspect | n2=en:multimodality therapy | rel=r_associated | relid=0 | w=20
  3696. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:muramic acids
    n1=en:contraindications aspect | n2=en:muramic acids | rel=r_associated | relid=0 | w=20
  3697. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:murexide
    n1=en:contraindications aspect | n2=en:murexide | rel=r_associated | relid=0 | w=20
  3698. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:muscle denervation procedure
    n1=en:contraindications aspect | n2=en:muscle denervation procedure | rel=r_associated | relid=0 | w=20
  3699. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:muscle strength dynamometer
    n1=en:contraindications aspect | n2=en:muscle strength dynamometer | rel=r_associated | relid=0 | w=20
  3700. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mustard compounds
    n1=en:contraindications aspect | n2=en:mustard compounds | rel=r_associated | relid=0 | w=20
  3701. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mutagen
    n1=en:contraindications aspect | n2=en:mutagen | rel=r_associated | relid=0 | w=20
  3702. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mutant chimeric proteins
    n1=en:contraindications aspect | n2=en:mutant chimeric proteins | rel=r_associated | relid=0 | w=20
  3703. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mycophenolic acid
    n1=en:contraindications aspect | n2=en:mycophenolic acid | rel=r_associated | relid=0 | w=20
  3704. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:mycotoxin
    n1=en:contraindications aspect | n2=en:mycotoxin | rel=r_associated | relid=0 | w=20
  3705. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myeloablative agonist
    n1=en:contraindications aspect | n2=en:myeloablative agonist | rel=r_associated | relid=0 | w=20
  3706. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myelography
    n1=en:contraindications aspect | n2=en:myelography | rel=r_associated | relid=0 | w=20
  3707. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myocardial depressant factor
    n1=en:contraindications aspect | n2=en:myocardial depressant factor | rel=r_associated | relid=0 | w=20
  3708. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myocardial revascularization
    n1=en:contraindications aspect | n2=en:myocardial revascularization | rel=r_associated | relid=0 | w=20
  3709. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myod protein
    n1=en:contraindications aspect | n2=en:myod protein | rel=r_associated | relid=0 | w=20
  3710. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myogenic regulatory factor 5
    n1=en:contraindications aspect | n2=en:myogenic regulatory factor 5 | rel=r_associated | relid=0 | w=20
  3711. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myosin iv
    n1=en:contraindications aspect | n2=en:myosin iv | rel=r_associated | relid=0 | w=20
  3712. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myosin light chain kinase, smooth muscle
    n1=en:contraindications aspect | n2=en:myosin light chain kinase, smooth muscle | rel=r_associated | relid=0 | w=20
  3713. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myosin type i
    n1=en:contraindications aspect | n2=en:myosin type i | rel=r_associated | relid=0 | w=20
  3714. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:myristates
    n1=en:contraindications aspect | n2=en:myristates | rel=r_associated | relid=0 | w=20
  3715. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:n-chimaerin
    n1=en:contraindications aspect | n2=en:n-chimaerin | rel=r_associated | relid=0 | w=20
  3716. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:n-formylmethionine
    n1=en:contraindications aspect | n2=en:n-formylmethionine | rel=r_associated | relid=0 | w=20
  3717. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:n-glycosyl hydrolases
    n1=en:contraindications aspect | n2=en:n-glycosyl hydrolases | rel=r_associated | relid=0 | w=20
  3718. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:n-terminal acetyltransferase a
    n1=en:contraindications aspect | n2=en:n-terminal acetyltransferase a | rel=r_associated | relid=0 | w=20
  3719. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:n,n-dimethylformamide
    n1=en:contraindications aspect | n2=en:n,n-dimethylformamide | rel=r_associated | relid=0 | w=20
  3720. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nacre
    n1=en:contraindications aspect | n2=en:nacre | rel=r_associated | relid=0 | w=20
  3721. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nadolol
    n1=en:contraindications aspect | n2=en:nadolol | rel=r_associated | relid=0 | w=20
  3722. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:NADPH oxidase
    n1=en:contraindications aspect | n2=en:NADPH oxidase | rel=r_associated | relid=0 | w=20
  3723. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nadph oxidase
    n1=en:contraindications aspect | n2=en:nadph oxidase | rel=r_associated | relid=0 | w=20
  3724. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nalorphine
    n1=en:contraindications aspect | n2=en:nalorphine | rel=r_associated | relid=0 | w=20
  3725. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nanog homeobox protein
    n1=en:contraindications aspect | n2=en:nanog homeobox protein | rel=r_associated | relid=0 | w=20
  3726. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:naphthacenes
    n1=en:contraindications aspect | n2=en:naphthacenes | rel=r_associated | relid=0 | w=20
  3727. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:naphthaleneacetic acids
    n1=en:contraindications aspect | n2=en:naphthaleneacetic acids | rel=r_associated | relid=0 | w=20
  3728. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:naproxen
    n1=en:contraindications aspect | n2=en:naproxen | rel=r_associated | relid=0 | w=20
  3729. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nasal decongestants
    n1=en:contraindications aspect | n2=en:nasal decongestants | rel=r_associated | relid=0 | w=20
  3730. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nasal lavage
    n1=en:contraindications aspect | n2=en:nasal lavage | rel=r_associated | relid=0 | w=20
  3731. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nasal wash
    n1=en:contraindications aspect | n2=en:nasal wash | rel=r_associated | relid=0 | w=20
  3732. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:natalizumab
    n1=en:contraindications aspect | n2=en:natalizumab | rel=r_associated | relid=0 | w=20
  3733. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:natriuretic agents
    n1=en:contraindications aspect | n2=en:natriuretic agents | rel=r_associated | relid=0 | w=20
  3734. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:natriuretic peptide, c-type
    n1=en:contraindications aspect | n2=en:natriuretic peptide, c-type | rel=r_associated | relid=0 | w=20
  3735. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:natural childbirth assistance
    n1=en:contraindications aspect | n2=en:natural childbirth assistance | rel=r_associated | relid=0 | w=20
  3736. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:natural rubber
    n1=en:contraindications aspect | n2=en:natural rubber | rel=r_associated | relid=0 | w=20
  3737. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nav1.2 voltage-gated sodium channel
    n1=en:contraindications aspect | n2=en:nav1.2 voltage-gated sodium channel | rel=r_associated | relid=0 | w=20
  3738. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:needle biopsy
    n1=en:contraindications aspect | n2=en:needle biopsy | rel=r_associated | relid=0 | w=20
  3739. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nef gene products, human immunodeficiency virus
    n1=en:contraindications aspect | n2=en:nef gene products, human immunodeficiency virus | rel=r_associated | relid=0 | w=20
  3740. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:negative-pressure ventilators
    n1=en:contraindications aspect | n2=en:negative-pressure ventilators | rel=r_associated | relid=0 | w=20
  3741. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nelfinavir
    n1=en:contraindications aspect | n2=en:nelfinavir | rel=r_associated | relid=0 | w=20
  3742. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neoplasm grading
    n1=en:contraindications aspect | n2=en:neoplasm grading | rel=r_associated | relid=0 | w=20
  3743. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neoplasm proteins
    n1=en:contraindications aspect | n2=en:neoplasm proteins | rel=r_associated | relid=0 | w=20
  3744. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neostigmine
    n1=en:contraindications aspect | n2=en:neostigmine | rel=r_associated | relid=0 | w=20
  3745. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nerve expansion
    n1=en:contraindications aspect | n2=en:nerve expansion | rel=r_associated | relid=0 | w=20
  3746. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nestin
    n1=en:contraindications aspect | n2=en:nestin | rel=r_associated | relid=0 | w=20
  3747. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuraminic acids
    n1=en:contraindications aspect | n2=en:neuraminic acids | rel=r_associated | relid=0 | w=20
  3748. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuregulin
    n1=en:contraindications aspect | n2=en:neuregulin | rel=r_associated | relid=0 | w=20
  3749. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuroendoscopes
    n1=en:contraindications aspect | n2=en:neuroendoscopes | rel=r_associated | relid=0 | w=20
  3750. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuroimaging
    n1=en:contraindications aspect | n2=en:neuroimaging | rel=r_associated | relid=0 | w=20
  3751. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neurokinin a
    n1=en:contraindications aspect | n2=en:neurokinin a | rel=r_associated | relid=0 | w=20
  3752. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuromuscular blocking agents
    n1=en:contraindications aspect | n2=en:neuromuscular blocking agents | rel=r_associated | relid=0 | w=20
  3753. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuromuscular depolarizing agents
    n1=en:contraindications aspect | n2=en:neuromuscular depolarizing agents | rel=r_associated | relid=0 | w=20
  3754. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuromuscular nondepolarizing agents
    n1=en:contraindications aspect | n2=en:neuromuscular nondepolarizing agents | rel=r_associated | relid=0 | w=20
  3755. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuronal calcium-sensor proteins
    n1=en:contraindications aspect | n2=en:neuronal calcium-sensor proteins | rel=r_associated | relid=0 | w=20
  3756. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuronal tract-tracers
    n1=en:contraindications aspect | n2=en:neuronal tract-tracers | rel=r_associated | relid=0 | w=20
  3757. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuropeptide
    n1=en:contraindications aspect | n2=en:neuropeptide | rel=r_associated | relid=0 | w=20
  3758. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neurophysiological monitoring
    n1=en:contraindications aspect | n2=en:neurophysiological monitoring | rel=r_associated | relid=0 | w=20
  3759. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neuroprotective agent
    n1=en:contraindications aspect | n2=en:neuroprotective agent | rel=r_associated | relid=0 | w=20
  3760. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neurosurgical procedure
    n1=en:contraindications aspect | n2=en:neurosurgical procedure | rel=r_associated | relid=0 | w=20
  3761. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neurotensin
    n1=en:contraindications aspect | n2=en:neurotensin | rel=r_associated | relid=0 | w=20
  3762. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neutron capture therapy
    n1=en:contraindications aspect | n2=en:neutron capture therapy | rel=r_associated | relid=0 | w=20
  3763. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:neutrophil collagenase
    n1=en:contraindications aspect | n2=en:neutrophil collagenase | rel=r_associated | relid=0 | w=20
  3764. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:niacinamide
    n1=en:contraindications aspect | n2=en:niacinamide | rel=r_associated | relid=0 | w=20
  3765. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nicotinamide phosphoribosyltransferase
    n1=en:contraindications aspect | n2=en:nicotinamide phosphoribosyltransferase | rel=r_associated | relid=0 | w=20
  3766. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nicotinamide-nucleotide adenylyltransferase
    n1=en:contraindications aspect | n2=en:nicotinamide-nucleotide adenylyltransferase | rel=r_associated | relid=0 | w=20
  3767. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nicotine
    n1=en:contraindications aspect | n2=en:nicotine | rel=r_associated | relid=0 | w=20
  3768. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nicotinic acids
    n1=en:contraindications aspect | n2=en:nicotinic acids | rel=r_associated | relid=0 | w=20
  3769. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nicotinic agonist
    n1=en:contraindications aspect | n2=en:nicotinic agonist | rel=r_associated | relid=0 | w=20
  3770. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nicotinic antagonist
    n1=en:contraindications aspect | n2=en:nicotinic antagonist | rel=r_associated | relid=0 | w=20
  3771. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nicotinyl alcohol
    n1=en:contraindications aspect | n2=en:nicotinyl alcohol | rel=r_associated | relid=0 | w=20
  3772. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nima-interacting peptidylprolyl isomerase
    n1=en:contraindications aspect | n2=en:nima-interacting peptidylprolyl isomerase | rel=r_associated | relid=0 | w=20
  3773. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nisoldipine
    n1=en:contraindications aspect | n2=en:nisoldipine | rel=r_associated | relid=0 | w=20
  3774. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nitrate reductases
    n1=en:contraindications aspect | n2=en:nitrate reductases | rel=r_associated | relid=0 | w=20
  3775. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nitric oxide synthase type i
    n1=en:contraindications aspect | n2=en:nitric oxide synthase type i | rel=r_associated | relid=0 | w=20
  3776. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nitric oxide synthase type ii
    n1=en:contraindications aspect | n2=en:nitric oxide synthase type ii | rel=r_associated | relid=0 | w=20
  3777. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nitric oxide synthetase
    n1=en:contraindications aspect | n2=en:nitric oxide synthetase | rel=r_associated | relid=0 | w=20
  3778. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nitroblue tetrazolium
    n1=en:contraindications aspect | n2=en:nitroblue tetrazolium | rel=r_associated | relid=0 | w=20
  3779. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nitrogen mustard compound
    n1=en:contraindications aspect | n2=en:nitrogen mustard compound | rel=r_associated | relid=0 | w=20
  3780. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nitrophenylgalactosides
    n1=en:contraindications aspect | n2=en:nitrophenylgalactosides | rel=r_associated | relid=0 | w=20
  3781. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nlr proteins
    n1=en:contraindications aspect | n2=en:nlr proteins | rel=r_associated | relid=0 | w=20
  3782. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:NMR imaging
    n1=en:contraindications aspect | n2=en:NMR imaging | rel=r_associated | relid=0 | w=20
  3783. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nodal protein
    n1=en:contraindications aspect | n2=en:nodal protein | rel=r_associated | relid=0 | w=20
  3784. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:non-histone chromosomal protein hmg-17
    n1=en:contraindications aspect | n2=en:non-histone chromosomal protein hmg-17 | rel=r_associated | relid=0 | w=20
  3785. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:non-steroidal estrogen
    n1=en:contraindications aspect | n2=en:non-steroidal estrogen | rel=r_associated | relid=0 | w=20
  3786. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nonesterified fatty acids
    n1=en:contraindications aspect | n2=en:nonesterified fatty acids | rel=r_associated | relid=0 | w=20
  3787. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nonheme iron proteins
    n1=en:contraindications aspect | n2=en:nonheme iron proteins | rel=r_associated | relid=0 | w=20
  3788. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nonmuscle myosin type iib
    n1=en:contraindications aspect | n2=en:nonmuscle myosin type iib | rel=r_associated | relid=0 | w=20
  3789. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nonrandomized clinical trial
    n1=en:contraindications aspect | n2=en:nonrandomized clinical trial | rel=r_associated | relid=0 | w=20
  3790. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nonsuppressible insulin-like activity
    n1=en:contraindications aspect | n2=en:nonsuppressible insulin-like activity | rel=r_associated | relid=0 | w=20
  3791. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:norepinephrine plasma membrane transport proteins
    n1=en:contraindications aspect | n2=en:norepinephrine plasma membrane transport proteins | rel=r_associated | relid=0 | w=20
  3792. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:norepinephrine, dl-
    n1=en:contraindications aspect | n2=en:norepinephrine, dl- | rel=r_associated | relid=0 | w=20
  3793. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:norethandrolone
    n1=en:contraindications aspect | n2=en:norethandrolone | rel=r_associated | relid=0 | w=20
  3794. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:norfloxacin
    n1=en:contraindications aspect | n2=en:norfloxacin | rel=r_associated | relid=0 | w=20
  3795. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:novobiocin
    n1=en:contraindications aspect | n2=en:novobiocin | rel=r_associated | relid=0 | w=20
  3796. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:noxae
    n1=en:contraindications aspect | n2=en:noxae | rel=r_associated | relid=0 | w=20
  3797. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuchal translucency screen
    n1=en:contraindications aspect | n2=en:nuchal translucency screen | rel=r_associated | relid=0 | w=20
  3798. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear cap-binding protein complex
    n1=en:contraindications aspect | n2=en:nuclear cap-binding protein complex | rel=r_associated | relid=0 | w=20
  3799. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear factor erythroid 2-related factor 2
    n1=en:contraindications aspect | n2=en:nuclear factor erythroid 2-related factor 2 | rel=r_associated | relid=0 | w=20
  3800. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear factor-i
    n1=en:contraindications aspect | n2=en:nuclear factor-i | rel=r_associated | relid=0 | w=20
  3801. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear localization signal
    n1=en:contraindications aspect | n2=en:nuclear localization signal | rel=r_associated | relid=0 | w=20
  3802. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear magnetic resonance imaging
    n1=en:contraindications aspect | n2=en:nuclear magnetic resonance imaging | rel=r_associated | relid=0 | w=20
  3803. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear receptor co-repressor 1
    n1=en:contraindications aspect | n2=en:nuclear receptor co-repressor 1 | rel=r_associated | relid=0 | w=20
  3804. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear receptor corepressor 1
    n1=en:contraindications aspect | n2=en:nuclear receptor corepressor 1 | rel=r_associated | relid=0 | w=20
  3805. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear receptor corepressor 2
    n1=en:contraindications aspect | n2=en:nuclear receptor corepressor 2 | rel=r_associated | relid=0 | w=20
  3806. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear receptor subfamily 1 group d member 1
    n1=en:contraindications aspect | n2=en:nuclear receptor subfamily 1 group d member 1 | rel=r_associated | relid=0 | w=20
  3807. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nuclear receptor subfamily 4 group a member 1
    n1=en:contraindications aspect | n2=en:nuclear receptor subfamily 4 group a member 1 | rel=r_associated | relid=0 | w=20
  3808. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nucleic acid heteroduplexes
    n1=en:contraindications aspect | n2=en:nucleic acid heteroduplexes | rel=r_associated | relid=0 | w=20
  3809. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nucleic acid precursors
    n1=en:contraindications aspect | n2=en:nucleic acid precursors | rel=r_associated | relid=0 | w=20
  3810. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nucleobase transport proteins
    n1=en:contraindications aspect | n2=en:nucleobase transport proteins | rel=r_associated | relid=0 | w=20
  3811. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nucleobase, nucleoside, nucleotide, and nucleic acid transport proteins
    n1=en:contraindications aspect | n2=en:nucleobase, nucleoside, nucleotide, and nucleic acid transport proteins | rel=r_associated | relid=0 | w=20
  3812. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nucleoside diphosphate kinase d
    n1=en:contraindications aspect | n2=en:nucleoside diphosphate kinase d | rel=r_associated | relid=0 | w=20
  3813. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nucleoside q
    n1=en:contraindications aspect | n2=en:nucleoside q | rel=r_associated | relid=0 | w=20
  3814. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nutrition, cholesterol
    n1=en:contraindications aspect | n2=en:nutrition, cholesterol | rel=r_associated | relid=0 | w=20
  3815. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nutritional therapy
    n1=en:contraindications aspect | n2=en:nutritional therapy | rel=r_associated | relid=0 | w=20
  3816. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:nutritive sweeteners
    n1=en:contraindications aspect | n2=en:nutritive sweeteners | rel=r_associated | relid=0 | w=20
  3817. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:o antigens
    n1=en:contraindications aspect | n2=en:o antigens | rel=r_associated | relid=0 | w=20
  3818. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:occludin
    n1=en:contraindications aspect | n2=en:occludin | rel=r_associated | relid=0 | w=20
  3819. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:occlusive dressings
    n1=en:contraindications aspect | n2=en:occlusive dressings | rel=r_associated | relid=0 | w=20
  3820. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:octanols
    n1=en:contraindications aspect | n2=en:octanols | rel=r_associated | relid=0 | w=20
  3821. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oil
    n1=en:contraindications aspect | n2=en:oil | rel=r_associated | relid=0 | w=20
  3822. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ointment dosage form
    n1=en:contraindications aspect | n2=en:ointment dosage form | rel=r_associated | relid=0 | w=20
  3823. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:olfactometry
    n1=en:contraindications aspect | n2=en:olfactometry | rel=r_associated | relid=0 | w=20
  3824. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oligo-1,6-glucosidase
    n1=en:contraindications aspect | n2=en:oligo-1,6-glucosidase | rel=r_associated | relid=0 | w=20
  3825. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oligodeoxyribonucleotides, antisense
    n1=en:contraindications aspect | n2=en:oligodeoxyribonucleotides, antisense | rel=r_associated | relid=0 | w=20
  3826. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oligonucleotide
    n1=en:contraindications aspect | n2=en:oligonucleotide | rel=r_associated | relid=0 | w=20
  3827. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oligonucleotide probes
    n1=en:contraindications aspect | n2=en:oligonucleotide probes | rel=r_associated | relid=0 | w=20
  3828. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oligosaccharides, branched-chain
    n1=en:contraindications aspect | n2=en:oligosaccharides, branched-chain | rel=r_associated | relid=0 | w=20
  3829. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:omalizumab
    n1=en:contraindications aspect | n2=en:omalizumab | rel=r_associated | relid=0 | w=20
  3830. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:omega-conotoxins
    n1=en:contraindications aspect | n2=en:omega-conotoxins | rel=r_associated | relid=0 | w=20
  3831. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:omeprazole
    n1=en:contraindications aspect | n2=en:omeprazole | rel=r_associated | relid=0 | w=20
  3832. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oncogene protein p65(gag-jun)
    n1=en:contraindications aspect | n2=en:oncogene protein p65(gag-jun) | rel=r_associated | relid=0 | w=20
  3833. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oncogene proteins v-abl
    n1=en:contraindications aspect | n2=en:oncogene proteins v-abl | rel=r_associated | relid=0 | w=20
  3834. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oncogene proteins v-erba
    n1=en:contraindications aspect | n2=en:oncogene proteins v-erba | rel=r_associated | relid=0 | w=20
  3835. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:one-stage prothrombin time test
    n1=en:contraindications aspect | n2=en:one-stage prothrombin time test | rel=r_associated | relid=0 | w=20
  3836. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:open end wrench
    n1=en:contraindications aspect | n2=en:open end wrench | rel=r_associated | relid=0 | w=20
  3837. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:open-end wrench
    n1=en:contraindications aspect | n2=en:open-end wrench | rel=r_associated | relid=0 | w=20
  3838. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:open-ended spanner
    n1=en:contraindications aspect | n2=en:open-ended spanner | rel=r_associated | relid=0 | w=20
  3839. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:operating tables
    n1=en:contraindications aspect | n2=en:operating tables | rel=r_associated | relid=0 | w=20
  3840. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:operative blood salvage (procedure)
    n1=en:contraindications aspect | n2=en:operative blood salvage (procedure) | rel=r_associated | relid=0 | w=20
  3841. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:operative treatment
    n1=en:contraindications aspect | n2=en:operative treatment | rel=r_associated | relid=0 | w=20
  3842. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:operidine epj i
    n1=en:contraindications aspect | n2=en:operidine epj i | rel=r_associated | relid=0 | w=20
  3843. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ophthalmic solution
    n1=en:contraindications aspect | n2=en:ophthalmic solution | rel=r_associated | relid=0 | w=20
  3844. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ophthalmologic surgical procedure
    n1=en:contraindications aspect | n2=en:ophthalmologic surgical procedure | rel=r_associated | relid=0 | w=20
  3845. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ophthalmoscopy
    n1=en:contraindications aspect | n2=en:ophthalmoscopy | rel=r_associated | relid=0 | w=20
  3846. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:opiate antagonist
    n1=en:contraindications aspect | n2=en:opiate antagonist | rel=r_associated | relid=0 | w=20
  3847. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:opium
    n1=en:contraindications aspect | n2=en:opium | rel=r_associated | relid=0 | w=20
  3848. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:optical coherence tomography
    n1=en:contraindications aspect | n2=en:optical coherence tomography | rel=r_associated | relid=0 | w=20
  3849. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oral contraception
    n1=en:contraindications aspect | n2=en:oral contraception | rel=r_associated | relid=0 | w=20
  3850. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oral contraceptive
    n1=en:contraindications aspect | n2=en:oral contraceptive | rel=r_associated | relid=0 | w=20
  3851. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oral surgery
    n1=en:contraindications aspect | n2=en:oral surgery | rel=r_associated | relid=0 | w=20
  3852. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orbit evisceration
    n1=en:contraindications aspect | n2=en:orbit evisceration | rel=r_associated | relid=0 | w=20
  3853. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orexin receptor antagonists
    n1=en:contraindications aspect | n2=en:orexin receptor antagonists | rel=r_associated | relid=0 | w=20
  3854. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orexins
    n1=en:contraindications aspect | n2=en:orexins | rel=r_associated | relid=0 | w=20
  3855. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:organ preservation
    n1=en:contraindications aspect | n2=en:organ preservation | rel=r_associated | relid=0 | w=20
  3856. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:organic anion transport polypeptide c
    n1=en:contraindications aspect | n2=en:organic anion transport polypeptide c | rel=r_associated | relid=0 | w=20
  3857. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:organic anion transporters, atp-dependent
    n1=en:contraindications aspect | n2=en:organic anion transporters, atp-dependent | rel=r_associated | relid=0 | w=20
  3858. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:organic anion transporters, sodium-dependent
    n1=en:contraindications aspect | n2=en:organic anion transporters, sodium-dependent | rel=r_associated | relid=0 | w=20
  3859. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:organic chemical
    n1=en:contraindications aspect | n2=en:organic chemical | rel=r_associated | relid=0 | w=20
  3860. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:organic ester
    n1=en:contraindications aspect | n2=en:organic ester | rel=r_associated | relid=0 | w=20
  3861. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:organogold compounds
    n1=en:contraindications aspect | n2=en:organogold compounds | rel=r_associated | relid=0 | w=20
  3862. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:organothiophosphonates
    n1=en:contraindications aspect | n2=en:organothiophosphonates | rel=r_associated | relid=0 | w=20
  3863. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ornithine decarboxylase
    n1=en:contraindications aspect | n2=en:ornithine decarboxylase | rel=r_associated | relid=0 | w=20
  3864. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ornithine decarboxylase inhibitor
    n1=en:contraindications aspect | n2=en:ornithine decarboxylase inhibitor | rel=r_associated | relid=0 | w=20
  3865. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orotic acid
    n1=en:contraindications aspect | n2=en:orotic acid | rel=r_associated | relid=0 | w=20
  3866. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orotidine-5'-phosphate decarboxylase
    n1=en:contraindications aspect | n2=en:orotidine-5'-phosphate decarboxylase | rel=r_associated | relid=0 | w=20
  3867. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orthodontic appliances
    n1=en:contraindications aspect | n2=en:orthodontic appliances | rel=r_associated | relid=0 | w=20
  3868. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orthodontic retainer (physical object)
    n1=en:contraindications aspect | n2=en:orthodontic retainer (physical object) | rel=r_associated | relid=0 | w=20
  3869. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orthodontic space closure
    n1=en:contraindications aspect | n2=en:orthodontic space closure | rel=r_associated | relid=0 | w=20
  3870. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orthodontic wires
    n1=en:contraindications aspect | n2=en:orthodontic wires | rel=r_associated | relid=0 | w=20
  3871. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orthopedic procedures
    n1=en:contraindications aspect | n2=en:orthopedic procedures | rel=r_associated | relid=0 | w=20
  3872. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:orthotic devices
    n1=en:contraindications aspect | n2=en:orthotic devices | rel=r_associated | relid=0 | w=20
  3873. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oscillometry
    n1=en:contraindications aspect | n2=en:oscillometry | rel=r_associated | relid=0 | w=20
  3874. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:osmium tetroxide
    n1=en:contraindications aspect | n2=en:osmium tetroxide | rel=r_associated | relid=0 | w=20
  3875. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:osmotic diuretic
    n1=en:contraindications aspect | n2=en:osmotic diuretic | rel=r_associated | relid=0 | w=20
  3876. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ossicular replacement prosthesis
    n1=en:contraindications aspect | n2=en:ossicular replacement prosthesis | rel=r_associated | relid=0 | w=20
  3877. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:osteopontin
    n1=en:contraindications aspect | n2=en:osteopontin | rel=r_associated | relid=0 | w=20
  3878. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ovarian function tests
    n1=en:contraindications aspect | n2=en:ovarian function tests | rel=r_associated | relid=0 | w=20
  3879. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:over the counter product
    n1=en:contraindications aspect | n2=en:over the counter product | rel=r_associated | relid=0 | w=20
  3880. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ovulation prediction
    n1=en:contraindications aspect | n2=en:ovulation prediction | rel=r_associated | relid=0 | w=20
  3881. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxalic acid
    n1=en:contraindications aspect | n2=en:oxalic acid | rel=r_associated | relid=0 | w=20
  3882. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxamic acid
    n1=en:contraindications aspect | n2=en:oxamic acid | rel=r_associated | relid=0 | w=20
  3883. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxazepines
    n1=en:contraindications aspect | n2=en:oxazepines | rel=r_associated | relid=0 | w=20
  3884. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxazocines
    n1=en:contraindications aspect | n2=en:oxazocines | rel=r_associated | relid=0 | w=20
  3885. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxidants, photochemical
    n1=en:contraindications aspect | n2=en:oxidants, photochemical | rel=r_associated | relid=0 | w=20
  3886. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxitriptan
    n1=en:contraindications aspect | n2=en:oxitriptan | rel=r_associated | relid=0 | w=20
  3887. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxygen radical
    n1=en:contraindications aspect | n2=en:oxygen radical | rel=r_associated | relid=0 | w=20
  3888. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxygenated hemoglobin
    n1=en:contraindications aspect | n2=en:oxygenated hemoglobin | rel=r_associated | relid=0 | w=20
  3889. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxygenators, membrane
    n1=en:contraindications aspect | n2=en:oxygenators, membrane | rel=r_associated | relid=0 | w=20
  3890. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxyhemoglobin
    n1=en:contraindications aspect | n2=en:oxyhemoglobin | rel=r_associated | relid=0 | w=20
  3891. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxymetholone
    n1=en:contraindications aspect | n2=en:oxymetholone | rel=r_associated | relid=0 | w=20
  3892. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxyntomodulin
    n1=en:contraindications aspect | n2=en:oxyntomodulin | rel=r_associated | relid=0 | w=20
  3893. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxyphenbutazone
    n1=en:contraindications aspect | n2=en:oxyphenbutazone | rel=r_associated | relid=0 | w=20
  3894. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxytetracycline
    n1=en:contraindications aspect | n2=en:oxytetracycline | rel=r_associated | relid=0 | w=20
  3895. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxytocic hormone
    n1=en:contraindications aspect | n2=en:oxytocic hormone | rel=r_associated | relid=0 | w=20
  3896. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:oxytocin
    n1=en:contraindications aspect | n2=en:oxytocin | rel=r_associated | relid=0 | w=20
  3897. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:p120 gtpase activating protein
    n1=en:contraindications aspect | n2=en:p120 gtpase activating protein | rel=r_associated | relid=0 | w=20
  3898. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:p21 ras protein
    n1=en:contraindications aspect | n2=en:p21 ras protein | rel=r_associated | relid=0 | w=20
  3899. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pactamycin
    n1=en:contraindications aspect | n2=en:pactamycin | rel=r_associated | relid=0 | w=20
  3900. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pain assessment
    n1=en:contraindications aspect | n2=en:pain assessment | rel=r_associated | relid=0 | w=20
  3901. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pair of specs
    n1=en:contraindications aspect | n2=en:pair of specs | rel=r_associated | relid=0 | w=20
  3902. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pair of spectacles
    n1=en:contraindications aspect | n2=en:pair of spectacles | rel=r_associated | relid=0 | w=20
  3903. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:palatal obturators
    n1=en:contraindications aspect | n2=en:palatal obturators | rel=r_associated | relid=0 | w=20
  3904. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:paliperidone palmitate
    n1=en:contraindications aspect | n2=en:paliperidone palmitate | rel=r_associated | relid=0 | w=20
  3905. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:palivizumab
    n1=en:contraindications aspect | n2=en:palivizumab | rel=r_associated | relid=0 | w=20
  3906. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:palmitoyl coenzyme a
    n1=en:contraindications aspect | n2=en:palmitoyl coenzyme a | rel=r_associated | relid=0 | w=20
  3907. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pancreas transplantation
    n1=en:contraindications aspect | n2=en:pancreas transplantation | rel=r_associated | relid=0 | w=20
  3908. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pancreas, artificial
    n1=en:contraindications aspect | n2=en:pancreas, artificial | rel=r_associated | relid=0 | w=20
  3909. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:panoramic radiography
    n1=en:contraindications aspect | n2=en:panoramic radiography | rel=r_associated | relid=0 | w=20
  3910. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pantetheine
    n1=en:contraindications aspect | n2=en:pantetheine | rel=r_associated | relid=0 | w=20
  3911. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pantothenic acid
    n1=en:contraindications aspect | n2=en:pantothenic acid | rel=r_associated | relid=0 | w=20
  3912. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parabiosis
    n1=en:contraindications aspect | n2=en:parabiosis | rel=r_associated | relid=0 | w=20
  3913. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:paracetamol
    n1=en:contraindications aspect | n2=en:paracetamol | rel=r_associated | relid=0 | w=20
  3914. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:paraldehyde
    n1=en:contraindications aspect | n2=en:paraldehyde | rel=r_associated | relid=0 | w=20
  3915. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parasite egg count
    n1=en:contraindications aspect | n2=en:parasite egg count | rel=r_associated | relid=0 | w=20
  3916. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parasympathectomy
    n1=en:contraindications aspect | n2=en:parasympathectomy | rel=r_associated | relid=0 | w=20
  3917. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parasympatholytics
    n1=en:contraindications aspect | n2=en:parasympatholytics | rel=r_associated | relid=0 | w=20
  3918. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parathormone
    n1=en:contraindications aspect | n2=en:parathormone | rel=r_associated | relid=0 | w=20
  3919. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parathyrin
    n1=en:contraindications aspect | n2=en:parathyrin | rel=r_associated | relid=0 | w=20
  3920. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parathyroïd hormone
    n1=en:contraindications aspect | n2=en:parathyroïd hormone | rel=r_associated | relid=0 | w=20
  3921. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parathyroid hormone
    n1=en:contraindications aspect | n2=en:parathyroid hormone | rel=r_associated | relid=0 | w=20
  3922. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parathyroid hormone-related protein
    n1=en:contraindications aspect | n2=en:parathyroid hormone-related protein | rel=r_associated | relid=0 | w=20
  3923. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parenteral infusion procedure
    n1=en:contraindications aspect | n2=en:parenteral infusion procedure | rel=r_associated | relid=0 | w=20
  3924. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parenteral nutrition solutions
    n1=en:contraindications aspect | n2=en:parenteral nutrition solutions | rel=r_associated | relid=0 | w=20
  3925. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:parietal cell vagotomy
    n1=en:contraindications aspect | n2=en:parietal cell vagotomy | rel=r_associated | relid=0 | w=20
  3926. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:particulate matter
    n1=en:contraindications aspect | n2=en:particulate matter | rel=r_associated | relid=0 | w=20
  3927. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:passive immunization
    n1=en:contraindications aspect | n2=en:passive immunization | rel=r_associated | relid=0 | w=20
  3928. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peanut agglutinin
    n1=en:contraindications aspect | n2=en:peanut agglutinin | rel=r_associated | relid=0 | w=20
  3929. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pemoline
    n1=en:contraindications aspect | n2=en:pemoline | rel=r_associated | relid=0 | w=20
  3930. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:penicillamine
    n1=en:contraindications aspect | n2=en:penicillamine | rel=r_associated | relid=0 | w=20
  3931. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:penicillin g benzathine
    n1=en:contraindications aspect | n2=en:penicillin g benzathine | rel=r_associated | relid=0 | w=20
  3932. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pentachlorophenol
    n1=en:contraindications aspect | n2=en:pentachlorophenol | rel=r_associated | relid=0 | w=20
  3933. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pentacyclic triterpenes
    n1=en:contraindications aspect | n2=en:pentacyclic triterpenes | rel=r_associated | relid=0 | w=20
  3934. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pentamidine
    n1=en:contraindications aspect | n2=en:pentamidine | rel=r_associated | relid=0 | w=20
  3935. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pentetic acid
    n1=en:contraindications aspect | n2=en:pentetic acid | rel=r_associated | relid=0 | w=20
  3936. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pentoxifylline
    n1=en:contraindications aspect | n2=en:pentoxifylline | rel=r_associated | relid=0 | w=20
  3937. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:people that you know
    n1=en:contraindications aspect | n2=en:people that you know | rel=r_associated | relid=0 | w=20
  3938. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:people you know
    n1=en:contraindications aspect | n2=en:people you know | rel=r_associated | relid=0 | w=20
  3939. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pepsinogen c
    n1=en:contraindications aspect | n2=en:pepsinogen c | rel=r_associated | relid=0 | w=20
  3940. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peptide elongation factor g
    n1=en:contraindications aspect | n2=en:peptide elongation factor g | rel=r_associated | relid=0 | w=20
  3941. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peptide hydrolases
    n1=en:contraindications aspect | n2=en:peptide hydrolases | rel=r_associated | relid=0 | w=20
  3942. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peptide synthase
    n1=en:contraindications aspect | n2=en:peptide synthase | rel=r_associated | relid=0 | w=20
  3943. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peptides hydrolases
    n1=en:contraindications aspect | n2=en:peptides hydrolases | rel=r_associated | relid=0 | w=20
  3944. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peptidyl-prolyl cis-trans isomerase nima-interacting 4
    n1=en:contraindications aspect | n2=en:peptidyl-prolyl cis-trans isomerase nima-interacting 4 | rel=r_associated | relid=0 | w=20
  3945. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peptidyltransferase
    n1=en:contraindications aspect | n2=en:peptidyltransferase | rel=r_associated | relid=0 | w=20
  3946. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:perchlorates
    n1=en:contraindications aspect | n2=en:perchlorates | rel=r_associated | relid=0 | w=20
  3947. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:percutaneous transluminal coronary angioplasty
    n1=en:contraindications aspect | n2=en:percutaneous transluminal coronary angioplasty | rel=r_associated | relid=0 | w=20
  3948. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:perforin
    n1=en:contraindications aspect | n2=en:perforin | rel=r_associated | relid=0 | w=20
  3949. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pericardiectomy
    n1=en:contraindications aspect | n2=en:pericardiectomy | rel=r_associated | relid=0 | w=20
  3950. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:perilipin 2
    n1=en:contraindications aspect | n2=en:perilipin 2 | rel=r_associated | relid=0 | w=20
  3951. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:perilipin-4
    n1=en:contraindications aspect | n2=en:perilipin-4 | rel=r_associated | relid=0 | w=20
  3952. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:perilipin-5
    n1=en:contraindications aspect | n2=en:perilipin-5 | rel=r_associated | relid=0 | w=20
  3953. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:perindopril
    n1=en:contraindications aspect | n2=en:perindopril | rel=r_associated | relid=0 | w=20
  3954. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:period circadian proteins
    n1=en:contraindications aspect | n2=en:period circadian proteins | rel=r_associated | relid=0 | w=20
  3955. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:periodontal splints
    n1=en:contraindications aspect | n2=en:periodontal splints | rel=r_associated | relid=0 | w=20
  3956. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peripherins
    n1=en:contraindications aspect | n2=en:peripherins | rel=r_associated | relid=0 | w=20
  3957. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peritoneal dialysis, continuous ambulatory
    n1=en:contraindications aspect | n2=en:peritoneal dialysis, continuous ambulatory | rel=r_associated | relid=0 | w=20
  3958. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:permanent dental restoration
    n1=en:contraindications aspect | n2=en:permanent dental restoration | rel=r_associated | relid=0 | w=20
  3959. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peroxisomal bifunctional enzyme
    n1=en:contraindications aspect | n2=en:peroxisomal bifunctional enzyme | rel=r_associated | relid=0 | w=20
  3960. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peroxisomal multifunctional protein-2
    n1=en:contraindications aspect | n2=en:peroxisomal multifunctional protein-2 | rel=r_associated | relid=0 | w=20
  3961. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peroxisome proliferator-activated receptor gamma
    n1=en:contraindications aspect | n2=en:peroxisome proliferator-activated receptor gamma | rel=r_associated | relid=0 | w=20
  3962. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peroxisome proliferators
    n1=en:contraindications aspect | n2=en:peroxisome proliferators | rel=r_associated | relid=0 | w=20
  3963. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:peroxynitrous acid
    n1=en:contraindications aspect | n2=en:peroxynitrous acid | rel=r_associated | relid=0 | w=20
  3964. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:perphenazine
    n1=en:contraindications aspect | n2=en:perphenazine | rel=r_associated | relid=0 | w=20
  3965. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pertussis toxin
    n1=en:contraindications aspect | n2=en:pertussis toxin | rel=r_associated | relid=0 | w=20
  3966. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:perylene
    n1=en:contraindications aspect | n2=en:perylene | rel=r_associated | relid=0 | w=20
  3967. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:PET scan
    n1=en:contraindications aspect | n2=en:PET scan | rel=r_associated | relid=0 | w=20
  3968. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pethidin
    n1=en:contraindications aspect | n2=en:pethidin | rel=r_associated | relid=0 | w=20
  3969. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pethidine hydrochloride
    n1=en:contraindications aspect | n2=en:pethidine hydrochloride | rel=r_associated | relid=0 | w=20
  3970. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:petrosal sinus sampling
    n1=en:contraindications aspect | n2=en:petrosal sinus sampling | rel=r_associated | relid=0 | w=20
  3971. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pharmaceutic aids
    n1=en:contraindications aspect | n2=en:pharmaceutic aids | rel=r_associated | relid=0 | w=20
  3972. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pharmaceutical excipient
    n1=en:contraindications aspect | n2=en:pharmaceutical excipient | rel=r_associated | relid=0 | w=20
  3973. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phenindione
    n1=en:contraindications aspect | n2=en:phenindione | rel=r_associated | relid=0 | w=20
  3974. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phenobarbital
    n1=en:contraindications aspect | n2=en:phenobarbital | rel=r_associated | relid=0 | w=20
  3975. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phenothiazine
    n1=en:contraindications aspect | n2=en:phenothiazine | rel=r_associated | relid=0 | w=20
  3976. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phenoxyacetates
    n1=en:contraindications aspect | n2=en:phenoxyacetates | rel=r_associated | relid=0 | w=20
  3977. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phenoxypropanolamines
    n1=en:contraindications aspect | n2=en:phenoxypropanolamines | rel=r_associated | relid=0 | w=20
  3978. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phensedyl
    n1=en:contraindications aspect | n2=en:phensedyl | rel=r_associated | relid=0 | w=20
  3979. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phenylpyruvic acids
    n1=en:contraindications aspect | n2=en:phenylpyruvic acids | rel=r_associated | relid=0 | w=20
  3980. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pheromones, human
    n1=en:contraindications aspect | n2=en:pheromones, human | rel=r_associated | relid=0 | w=20
  3981. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phlebotomy
    n1=en:contraindications aspect | n2=en:phlebotomy | rel=r_associated | relid=0 | w=20
  3982. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phonocardiography
    n1=en:contraindications aspect | n2=en:phonocardiography | rel=r_associated | relid=0 | w=20
  3983. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphate-binding proteins
    n1=en:contraindications aspect | n2=en:phosphate-binding proteins | rel=r_associated | relid=0 | w=20
  3984. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphatidylcholine-sterol o-acyltransferase
    n1=en:contraindications aspect | n2=en:phosphatidylcholine-sterol o-acyltransferase | rel=r_associated | relid=0 | w=20
  3985. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphatidylinositol
    n1=en:contraindications aspect | n2=en:phosphatidylinositol | rel=r_associated | relid=0 | w=20
  3986. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphatidylinositol 3 kinase
    n1=en:contraindications aspect | n2=en:phosphatidylinositol 3 kinase | rel=r_associated | relid=0 | w=20
  3987. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphatidylinositol 4,5-bisphosphate
    n1=en:contraindications aspect | n2=en:phosphatidylinositol 4,5-bisphosphate | rel=r_associated | relid=0 | w=20
  3988. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphatidylinositol-3,4,5-trisphosphate 5-phosphatases
    n1=en:contraindications aspect | n2=en:phosphatidylinositol-3,4,5-trisphosphate 5-phosphatases | rel=r_associated | relid=0 | w=20
  3989. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphites
    n1=en:contraindications aspect | n2=en:phosphites | rel=r_associated | relid=0 | w=20
  3990. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphoadenosine phosphosulfate
    n1=en:contraindications aspect | n2=en:phosphoadenosine phosphosulfate | rel=r_associated | relid=0 | w=20
  3991. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphoamino acids
    n1=en:contraindications aspect | n2=en:phosphoamino acids | rel=r_associated | relid=0 | w=20
  3992. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphodiesterase 4 inhibitors
    n1=en:contraindications aspect | n2=en:phosphodiesterase 4 inhibitors | rel=r_associated | relid=0 | w=20
  3993. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphoenolpyruvate carboxylase
    n1=en:contraindications aspect | n2=en:phosphoenolpyruvate carboxylase | rel=r_associated | relid=0 | w=20
  3994. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphofructokinase
    n1=en:contraindications aspect | n2=en:phosphofructokinase | rel=r_associated | relid=0 | w=20
  3995. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphofructokinase-1, liver type
    n1=en:contraindications aspect | n2=en:phosphofructokinase-1, liver type | rel=r_associated | relid=0 | w=20
  3996. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphoglycerate mutase
    n1=en:contraindications aspect | n2=en:phosphoglycerate mutase | rel=r_associated | relid=0 | w=20
  3997. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphoinositide phosphatases
    n1=en:contraindications aspect | n2=en:phosphoinositide phosphatases | rel=r_associated | relid=0 | w=20
  3998. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phospholipase A1
    n1=en:contraindications aspect | n2=en:phospholipase A1 | rel=r_associated | relid=0 | w=20
  3999. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phospholipase a1
    n1=en:contraindications aspect | n2=en:phospholipase a1 | rel=r_associated | relid=0 | w=20
  4000. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phospholipase a2 enzyme family
    n1=en:contraindications aspect | n2=en:phospholipase a2 enzyme family | rel=r_associated | relid=0 | w=20
  4001. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phospholipase c delta
    n1=en:contraindications aspect | n2=en:phospholipase c delta | rel=r_associated | relid=0 | w=20
  4002. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phospholipases a
    n1=en:contraindications aspect | n2=en:phospholipases a | rel=r_associated | relid=0 | w=20
  4003. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphoprotein phosphatase
    n1=en:contraindications aspect | n2=en:phosphoprotein phosphatase | rel=r_associated | relid=0 | w=20
  4004. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphoramide mustards
    n1=en:contraindications aspect | n2=en:phosphoramide mustards | rel=r_associated | relid=0 | w=20
  4005. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphorous acids
    n1=en:contraindications aspect | n2=en:phosphorous acids | rel=r_associated | relid=0 | w=20
  4006. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphorylases
    n1=en:contraindications aspect | n2=en:phosphorylases | rel=r_associated | relid=0 | w=20
  4007. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosphotungstic acid
    n1=en:contraindications aspect | n2=en:phosphotungstic acid | rel=r_associated | relid=0 | w=20
  4008. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phosvitin
    n1=en:contraindications aspect | n2=en:phosvitin | rel=r_associated | relid=0 | w=20
  4009. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:photodynamic therapy
    n1=en:contraindications aspect | n2=en:photodynamic therapy | rel=r_associated | relid=0 | w=20
  4010. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:photogrammetry
    n1=en:contraindications aspect | n2=en:photogrammetry | rel=r_associated | relid=0 | w=20
  4011. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phthalazines
    n1=en:contraindications aspect | n2=en:phthalazines | rel=r_associated | relid=0 | w=20
  4012. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phycobiliproteins
    n1=en:contraindications aspect | n2=en:phycobiliproteins | rel=r_associated | relid=0 | w=20
  4013. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phycoerythrin
    n1=en:contraindications aspect | n2=en:phycoerythrin | rel=r_associated | relid=0 | w=20
  4014. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:physical conditioning, animal
    n1=en:contraindications aspect | n2=en:physical conditioning, animal | rel=r_associated | relid=0 | w=20
  4015. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:physical conditioning, human
    n1=en:contraindications aspect | n2=en:physical conditioning, human | rel=r_associated | relid=0 | w=20
  4016. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:physical therapy exercises
    n1=en:contraindications aspect | n2=en:physical therapy exercises | rel=r_associated | relid=0 | w=20
  4017. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:physostigmine
    n1=en:contraindications aspect | n2=en:physostigmine | rel=r_associated | relid=0 | w=20
  4018. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phytase
    n1=en:contraindications aspect | n2=en:phytase | rel=r_associated | relid=0 | w=20
  4019. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phytic acid
    n1=en:contraindications aspect | n2=en:phytic acid | rel=r_associated | relid=0 | w=20
  4020. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phytochelatins
    n1=en:contraindications aspect | n2=en:phytochelatins | rel=r_associated | relid=0 | w=20
  4021. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phytochrome b
    n1=en:contraindications aspect | n2=en:phytochrome b | rel=r_associated | relid=0 | w=20
  4022. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phytomenadione
    n1=en:contraindications aspect | n2=en:phytomenadione | rel=r_associated | relid=0 | w=20
  4023. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:phytonadione
    n1=en:contraindications aspect | n2=en:phytonadione | rel=r_associated | relid=0 | w=20
  4024. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:picloram
    n1=en:contraindications aspect | n2=en:picloram | rel=r_associated | relid=0 | w=20
  4025. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:picoline compound
    n1=en:contraindications aspect | n2=en:picoline compound | rel=r_associated | relid=0 | w=20
  4026. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:picolinic acids
    n1=en:contraindications aspect | n2=en:picolinic acids | rel=r_associated | relid=0 | w=20
  4027. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pidolic acid
    n1=en:contraindications aspect | n2=en:pidolic acid | rel=r_associated | relid=0 | w=20
  4028. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:piezosurgery
    n1=en:contraindications aspect | n2=en:piezosurgery | rel=r_associated | relid=0 | w=20
  4029. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pimelic acids
    n1=en:contraindications aspect | n2=en:pimelic acids | rel=r_associated | relid=0 | w=20
  4030. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pipobroman
    n1=en:contraindications aspect | n2=en:pipobroman | rel=r_associated | relid=0 | w=20
  4031. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:piroxicam
    n1=en:contraindications aspect | n2=en:piroxicam | rel=r_associated | relid=0 | w=20
  4032. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pitocin
    n1=en:contraindications aspect | n2=en:pitocin | rel=r_associated | relid=0 | w=20
  4033. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pituitary adenylate cyclase activating polypeptide
    n1=en:contraindications aspect | n2=en:pituitary adenylate cyclase activating polypeptide | rel=r_associated | relid=0 | w=20
  4034. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pituitary function tests
    n1=en:contraindications aspect | n2=en:pituitary function tests | rel=r_associated | relid=0 | w=20
  4035. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pituitary hormone-releasing hormones
    n1=en:contraindications aspect | n2=en:pituitary hormone-releasing hormones | rel=r_associated | relid=0 | w=20
  4036. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pituitary irradiation
    n1=en:contraindications aspect | n2=en:pituitary irradiation | rel=r_associated | relid=0 | w=20
  4037. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pituitary-adrenal function tests
    n1=en:contraindications aspect | n2=en:pituitary-adrenal function tests | rel=r_associated | relid=0 | w=20
  4038. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pivotal moment
    n1=en:contraindications aspect | n2=en:pivotal moment | rel=r_associated | relid=0 | w=20
  4039. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:placental extracts
    n1=en:contraindications aspect | n2=en:placental extracts | rel=r_associated | relid=0 | w=20
  4040. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:placental growth factor
    n1=en:contraindications aspect | n2=en:placental growth factor | rel=r_associated | relid=0 | w=20
  4041. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plant oil
    n1=en:contraindications aspect | n2=en:plant oil | rel=r_associated | relid=0 | w=20
  4042. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plant viral movement proteins
    n1=en:contraindications aspect | n2=en:plant viral movement proteins | rel=r_associated | relid=0 | w=20
  4043. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plasma serine protease inhibitor
    n1=en:contraindications aspect | n2=en:plasma serine protease inhibitor | rel=r_associated | relid=0 | w=20
  4044. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plasma skin regeneration
    n1=en:contraindications aspect | n2=en:plasma skin regeneration | rel=r_associated | relid=0 | w=20
  4045. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plasmapheresis
    n1=en:contraindications aspect | n2=en:plasmapheresis | rel=r_associated | relid=0 | w=20
  4046. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plasminogen activator
    n1=en:contraindications aspect | n2=en:plasminogen activator | rel=r_associated | relid=0 | w=20
  4047. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plasminogen activator inhibitor
    n1=en:contraindications aspect | n2=en:plasminogen activator inhibitor | rel=r_associated | relid=0 | w=20
  4048. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plastic surgery, neck
    n1=en:contraindications aspect | n2=en:plastic surgery, neck | rel=r_associated | relid=0 | w=20
  4049. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:platelet endothelial cell adhesion molecule
    n1=en:contraindications aspect | n2=en:platelet endothelial cell adhesion molecule | rel=r_associated | relid=0 | w=20
  4050. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:platelet transfusion
    n1=en:contraindications aspect | n2=en:platelet transfusion | rel=r_associated | relid=0 | w=20
  4051. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:platelet-derived growth factor receptor beta
    n1=en:contraindications aspect | n2=en:platelet-derived growth factor receptor beta | rel=r_associated | relid=0 | w=20
  4052. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:platelet-derived growth factor subunit b
    n1=en:contraindications aspect | n2=en:platelet-derived growth factor subunit b | rel=r_associated | relid=0 | w=20
  4053. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:platinum compound
    n1=en:contraindications aspect | n2=en:platinum compound | rel=r_associated | relid=0 | w=20
  4054. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plethysmography
    n1=en:contraindications aspect | n2=en:plethysmography | rel=r_associated | relid=0 | w=20
  4055. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plethysmography, impedance
    n1=en:contraindications aspect | n2=en:plethysmography, impedance | rel=r_associated | relid=0 | w=20
  4056. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:plethysmography, whole body
    n1=en:contraindications aspect | n2=en:plethysmography, whole body | rel=r_associated | relid=0 | w=20
  4057. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pneumoperitoneum, artificial
    n1=en:contraindications aspect | n2=en:pneumoperitoneum, artificial | rel=r_associated | relid=0 | w=20
  4058. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:poisons
    n1=en:contraindications aspect | n2=en:poisons | rel=r_associated | relid=0 | w=20
  4059. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pokeweed mitogen
    n1=en:contraindications aspect | n2=en:pokeweed mitogen | rel=r_associated | relid=0 | w=20
  4060. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pol1 transcription initiation complex proteins
    n1=en:contraindications aspect | n2=en:pol1 transcription initiation complex proteins | rel=r_associated | relid=0 | w=20
  4061. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:poloxalene
    n1=en:contraindications aspect | n2=en:poloxalene | rel=r_associated | relid=0 | w=20
  4062. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:poly (adp-ribose) polymerase inhibitor
    n1=en:contraindications aspect | n2=en:poly (adp-ribose) polymerase inhibitor | rel=r_associated | relid=0 | w=20
  4063. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:poly adenosine diphosphate ribose
    n1=en:contraindications aspect | n2=en:poly adenosine diphosphate ribose | rel=r_associated | relid=0 | w=20
  4064. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:poly c
    n1=en:contraindications aspect | n2=en:poly c | rel=r_associated | relid=0 | w=20
  4065. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:poly g
    n1=en:contraindications aspect | n2=en:poly g | rel=r_associated | relid=0 | w=20
  4066. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:poly t
    n1=en:contraindications aspect | n2=en:poly t | rel=r_associated | relid=0 | w=20
  4067. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polyamine compound
    n1=en:contraindications aspect | n2=en:polyamine compound | rel=r_associated | relid=0 | w=20
  4068. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polychlorinated biphenyl
    n1=en:contraindications aspect | n2=en:polychlorinated biphenyl | rel=r_associated | relid=0 | w=20
  4069. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polychlorinated dibenzodioxins
    n1=en:contraindications aspect | n2=en:polychlorinated dibenzodioxins | rel=r_associated | relid=0 | w=20
  4070. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polycomb-group protein
    n1=en:contraindications aspect | n2=en:polycomb-group protein | rel=r_associated | relid=0 | w=20
  4071. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polycyclic aromatic hydrocarbons
    n1=en:contraindications aspect | n2=en:polycyclic aromatic hydrocarbons | rel=r_associated | relid=0 | w=20
  4072. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polyesters
    n1=en:contraindications aspect | n2=en:polyesters | rel=r_associated | relid=0 | w=20
  4073. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polyethylene glycol
    n1=en:contraindications aspect | n2=en:polyethylene glycol | rel=r_associated | relid=0 | w=20
  4074. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polyéthylène glycol
    n1=en:contraindications aspect | n2=en:polyéthylène glycol | rel=r_associated | relid=0 | w=20
  4075. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polygeline
    n1=en:contraindications aspect | n2=en:polygeline | rel=r_associated | relid=0 | w=20
  4076. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polyglutamic acid
    n1=en:contraindications aspect | n2=en:polyglutamic acid | rel=r_associated | relid=0 | w=20
  4077. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polymer
    n1=en:contraindications aspect | n2=en:polymer | rel=r_associated | relid=0 | w=20
  4078. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polyphosphates
    n1=en:contraindications aspect | n2=en:polyphosphates | rel=r_associated | relid=0 | w=20
  4079. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polyribonucleotide nucleotidyltransferase
    n1=en:contraindications aspect | n2=en:polyribonucleotide nucleotidyltransferase | rel=r_associated | relid=0 | w=20
  4080. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polytetrafluoroethylene
    n1=en:contraindications aspect | n2=en:polytetrafluoroethylene | rel=r_associated | relid=0 | w=20
  4081. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:polyvinyls
    n1=en:contraindications aspect | n2=en:polyvinyls | rel=r_associated | relid=0 | w=20
  4082. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:porphyrin
    n1=en:contraindications aspect | n2=en:porphyrin | rel=r_associated | relid=0 | w=20
  4083. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:porphyrosine
    n1=en:contraindications aspect | n2=en:porphyrosine | rel=r_associated | relid=0 | w=20
  4084. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:portography
    n1=en:contraindications aspect | n2=en:portography | rel=r_associated | relid=0 | w=20
  4085. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:positron emission tomography
    n1=en:contraindications aspect | n2=en:positron emission tomography | rel=r_associated | relid=0 | w=20
  4086. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:posterior cruciate ligament reconstruction
    n1=en:contraindications aspect | n2=en:posterior cruciate ligament reconstruction | rel=r_associated | relid=0 | w=20
  4087. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:potassium acetate
    n1=en:contraindications aspect | n2=en:potassium acetate | rel=r_associated | relid=0 | w=20
  4088. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:potassium chloride
    n1=en:contraindications aspect | n2=en:potassium chloride | rel=r_associated | relid=0 | w=20
  4089. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:potassium citrate
    n1=en:contraindications aspect | n2=en:potassium citrate | rel=r_associated | relid=0 | w=20
  4090. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:potassium iodide
    n1=en:contraindications aspect | n2=en:potassium iodide | rel=r_associated | relid=0 | w=20
  4091. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:potassium magnesium aspartate
    n1=en:contraindications aspect | n2=en:potassium magnesium aspartate | rel=r_associated | relid=0 | w=20
  4092. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ppar-beta
    n1=en:contraindications aspect | n2=en:ppar-beta | rel=r_associated | relid=0 | w=20
  4093. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pralidoxime compounds
    n1=en:contraindications aspect | n2=en:pralidoxime compounds | rel=r_associated | relid=0 | w=20
  4094. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prasterone
    n1=en:contraindications aspect | n2=en:prasterone | rel=r_associated | relid=0 | w=20
  4095. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pre-implantation diagnosis
    n1=en:contraindications aspect | n2=en:pre-implantation diagnosis | rel=r_associated | relid=0 | w=20
  4096. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pregabalin
    n1=en:contraindications aspect | n2=en:pregabalin | rel=r_associated | relid=0 | w=20
  4097. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pregnancy-associated alpha 2-macroglobulins
    n1=en:contraindications aspect | n2=en:pregnancy-associated alpha 2-macroglobulins | rel=r_associated | relid=0 | w=20
  4098. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pregnancy-specific beta 1-glycoproteins
    n1=en:contraindications aspect | n2=en:pregnancy-specific beta 1-glycoproteins | rel=r_associated | relid=0 | w=20
  4099. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pregnant mare serum gonadotropin
    n1=en:contraindications aspect | n2=en:pregnant mare serum gonadotropin | rel=r_associated | relid=0 | w=20
  4100. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pregnenes
    n1=en:contraindications aspect | n2=en:pregnenes | rel=r_associated | relid=0 | w=20
  4101. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:preimplantation diagnosis
    n1=en:contraindications aspect | n2=en:preimplantation diagnosis | rel=r_associated | relid=0 | w=20
  4102. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:preimplantation screenings
    n1=en:contraindications aspect | n2=en:preimplantation screenings | rel=r_associated | relid=0 | w=20
  4103. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prescription drugs
    n1=en:contraindications aspect | n2=en:prescription drugs | rel=r_associated | relid=0 | w=20
  4104. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prescription glasses
    n1=en:contraindications aspect | n2=en:prescription glasses | rel=r_associated | relid=0 | w=20
  4105. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:presenilins
    n1=en:contraindications aspect | n2=en:presenilins | rel=r_associated | relid=0 | w=20
  4106. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:preservative excipient
    n1=en:contraindications aspect | n2=en:preservative excipient | rel=r_associated | relid=0 | w=20
  4107. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:primary care nursing
    n1=en:contraindications aspect | n2=en:primary care nursing | rel=r_associated | relid=0 | w=20
  4108. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prion proteins
    n1=en:contraindications aspect | n2=en:prion proteins | rel=r_associated | relid=0 | w=20
  4109. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prions
    n1=en:contraindications aspect | n2=en:prions | rel=r_associated | relid=0 | w=20
  4110. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:procarbazine
    n1=en:contraindications aspect | n2=en:procarbazine | rel=r_associated | relid=0 | w=20
  4111. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prochlorperazine
    n1=en:contraindications aspect | n2=en:prochlorperazine | rel=r_associated | relid=0 | w=20
  4112. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prodigiozan
    n1=en:contraindications aspect | n2=en:prodigiozan | rel=r_associated | relid=0 | w=20
  4113. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:proflavine
    n1=en:contraindications aspect | n2=en:proflavine | rel=r_associated | relid=0 | w=20
  4114. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:progestin
    n1=en:contraindications aspect | n2=en:progestin | rel=r_associated | relid=0 | w=20
  4115. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:proglucagon
    n1=en:contraindications aspect | n2=en:proglucagon | rel=r_associated | relid=0 | w=20
  4116. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:proguanil
    n1=en:contraindications aspect | n2=en:proguanil | rel=r_associated | relid=0 | w=20
  4117. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:proinsulin
    n1=en:contraindications aspect | n2=en:proinsulin | rel=r_associated | relid=0 | w=20
  4118. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prokaryotic initiation factor-1
    n1=en:contraindications aspect | n2=en:prokaryotic initiation factor-1 | rel=r_associated | relid=0 | w=20
  4119. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prokaryotic initiation factors
    n1=en:contraindications aspect | n2=en:prokaryotic initiation factors | rel=r_associated | relid=0 | w=20
  4120. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:promazine
    n1=en:contraindications aspect | n2=en:promazine | rel=r_associated | relid=0 | w=20
  4121. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:promet
    n1=en:contraindications aspect | n2=en:promet | rel=r_associated | relid=0 | w=20
  4122. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:promethazine
    n1=en:contraindications aspect | n2=en:promethazine | rel=r_associated | relid=0 | w=20
  4123. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:promethium
    n1=en:contraindications aspect | n2=en:promethium | rel=r_associated | relid=0 | w=20
  4124. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:propanediol dehydratase
    n1=en:contraindications aspect | n2=en:propanediol dehydratase | rel=r_associated | relid=0 | w=20
  4125. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:propanil
    n1=en:contraindications aspect | n2=en:propanil | rel=r_associated | relid=0 | w=20
  4126. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:propanolamines
    n1=en:contraindications aspect | n2=en:propanolamines | rel=r_associated | relid=0 | w=20
  4127. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:proscillaridin
    n1=en:contraindications aspect | n2=en:proscillaridin | rel=r_associated | relid=0 | w=20
  4128. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prostaglandin antagonists
    n1=en:contraindications aspect | n2=en:prostaglandin antagonists | rel=r_associated | relid=0 | w=20
  4129. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prostaglandin g/h synthase 1
    n1=en:contraindications aspect | n2=en:prostaglandin g/h synthase 1 | rel=r_associated | relid=0 | w=20
  4130. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prostaglandin-e synthases
    n1=en:contraindications aspect | n2=en:prostaglandin-e synthases | rel=r_associated | relid=0 | w=20
  4131. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prostaglandine
    n1=en:contraindications aspect | n2=en:prostaglandine | rel=r_associated | relid=0 | w=20
  4132. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prostaglandins e, synthetic
    n1=en:contraindications aspect | n2=en:prostaglandins e, synthetic | rel=r_associated | relid=0 | w=20
  4133. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prostaglandins h
    n1=en:contraindications aspect | n2=en:prostaglandins h | rel=r_associated | relid=0 | w=20
  4134. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prostatectomy
    n1=en:contraindications aspect | n2=en:prostatectomy | rel=r_associated | relid=0 | w=20
  4135. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prostatic secretory proteins
    n1=en:contraindications aspect | n2=en:prostatic secretory proteins | rel=r_associated | relid=0 | w=20
  4136. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prosthesis retention
    n1=en:contraindications aspect | n2=en:prosthesis retention | rel=r_associated | relid=0 | w=20
  4137. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protease inhibitor
    n1=en:contraindications aspect | n2=en:protease inhibitor | rel=r_associated | relid=0 | w=20
  4138. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:proteasome inhibitor
    n1=en:contraindications aspect | n2=en:proteasome inhibitor | rel=r_associated | relid=0 | w=20
  4139. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protective clothing
    n1=en:contraindications aspect | n2=en:protective clothing | rel=r_associated | relid=0 | w=20
  4140. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protein footprinting
    n1=en:contraindications aspect | n2=en:protein footprinting | rel=r_associated | relid=0 | w=20
  4141. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protein inhibitors of activated stat
    n1=en:contraindications aspect | n2=en:protein inhibitors of activated stat | rel=r_associated | relid=0 | w=20
  4142. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protein kinase
    n1=en:contraindications aspect | n2=en:protein kinase | rel=r_associated | relid=0 | w=20
  4143. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protein kinase c beta type
    n1=en:contraindications aspect | n2=en:protein kinase c beta type | rel=r_associated | relid=0 | w=20
  4144. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protein kinase c-epsilon
    n1=en:contraindications aspect | n2=en:protein kinase c-epsilon | rel=r_associated | relid=0 | w=20
  4145. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protein replacement therapy
    n1=en:contraindications aspect | n2=en:protein replacement therapy | rel=r_associated | relid=0 | w=20
  4146. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protein s100-a9
    n1=en:contraindications aspect | n2=en:protein s100-a9 | rel=r_associated | relid=0 | w=20
  4147. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protein tyrosine kinase
    n1=en:contraindications aspect | n2=en:protein tyrosine kinase | rel=r_associated | relid=0 | w=20
  4148. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:protein tyrosine kinase pyk2
    n1=en:contraindications aspect | n2=en:protein tyrosine kinase pyk2 | rel=r_associated | relid=0 | w=20
  4149. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:proteinase inhibitory proteins, secretory
    n1=en:contraindications aspect | n2=en:proteinase inhibitory proteins, secretory | rel=r_associated | relid=0 | w=20
  4150. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prothazin
    n1=en:contraindications aspect | n2=en:prothazin | rel=r_associated | relid=0 | w=20
  4151. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prothrombin
    n1=en:contraindications aspect | n2=en:prothrombin | rel=r_associated | relid=0 | w=20
  4152. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prothrombin time
    n1=en:contraindications aspect | n2=en:prothrombin time | rel=r_associated | relid=0 | w=20
  4153. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:proto-oncogene protein c-ets-1
    n1=en:contraindications aspect | n2=en:proto-oncogene protein c-ets-1 | rel=r_associated | relid=0 | w=20
  4154. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prp 27-30 protein
    n1=en:contraindications aspect | n2=en:prp 27-30 protein | rel=r_associated | relid=0 | w=20
  4155. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prpc proteins
    n1=en:contraindications aspect | n2=en:prpc proteins | rel=r_associated | relid=0 | w=20
  4156. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:prpsc proteins
    n1=en:contraindications aspect | n2=en:prpsc proteins | rel=r_associated | relid=0 | w=20
  4157. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pseudocholinesterase
    n1=en:contraindications aspect | n2=en:pseudocholinesterase | rel=r_associated | relid=0 | w=20
  4158. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pseudorabies vaccines
    n1=en:contraindications aspect | n2=en:pseudorabies vaccines | rel=r_associated | relid=0 | w=20
  4159. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pseudouridine
    n1=en:contraindications aspect | n2=en:pseudouridine | rel=r_associated | relid=0 | w=20
  4160. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:psychosine
    n1=en:contraindications aspect | n2=en:psychosine | rel=r_associated | relid=0 | w=20
  4161. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:psychotropic agent
    n1=en:contraindications aspect | n2=en:psychotropic agent | rel=r_associated | relid=0 | w=20
  4162. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:psyllium husk
    n1=en:contraindications aspect | n2=en:psyllium husk | rel=r_associated | relid=0 | w=20
  4163. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pulmonary surfactant-associated protein a
    n1=en:contraindications aspect | n2=en:pulmonary surfactant-associated protein a | rel=r_associated | relid=0 | w=20
  4164. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pulmonary surfactant-associated protein d
    n1=en:contraindications aspect | n2=en:pulmonary surfactant-associated protein d | rel=r_associated | relid=0 | w=20
  4165. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pulpectomy
    n1=en:contraindications aspect | n2=en:pulpectomy | rel=r_associated | relid=0 | w=20
  4166. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pulse radiolysis
    n1=en:contraindications aspect | n2=en:pulse radiolysis | rel=r_associated | relid=0 | w=20
  4167. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pulsed radiofrequency treatment
    n1=en:contraindications aspect | n2=en:pulsed radiofrequency treatment | rel=r_associated | relid=0 | w=20
  4168. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:punch-biopsy
    n1=en:contraindications aspect | n2=en:punch-biopsy | rel=r_associated | relid=0 | w=20
  4169. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:punctal plugs
    n1=en:contraindications aspect | n2=en:punctal plugs | rel=r_associated | relid=0 | w=20
  4170. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pupilloscopy
    n1=en:contraindications aspect | n2=en:pupilloscopy | rel=r_associated | relid=0 | w=20
  4171. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:purine nucleosides
    n1=en:contraindications aspect | n2=en:purine nucleosides | rel=r_associated | relid=0 | w=20
  4172. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:purine nucleotides
    n1=en:contraindications aspect | n2=en:purine nucleotides | rel=r_associated | relid=0 | w=20
  4173. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:purinergic agonists
    n1=en:contraindications aspect | n2=en:purinergic agonists | rel=r_associated | relid=0 | w=20
  4174. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:purinergic p1 receptor agonists
    n1=en:contraindications aspect | n2=en:purinergic p1 receptor agonists | rel=r_associated | relid=0 | w=20
  4175. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:put powder on something
    n1=en:contraindications aspect | n2=en:put powder on something | rel=r_associated | relid=0 | w=20
  4176. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:put talc on something
    n1=en:contraindications aspect | n2=en:put talc on something | rel=r_associated | relid=0 | w=20
  4177. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:putrescin
    n1=en:contraindications aspect | n2=en:putrescin | rel=r_associated | relid=0 | w=20
  4178. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:putrescine
    n1=en:contraindications aspect | n2=en:putrescine | rel=r_associated | relid=0 | w=20
  4179. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyrazolones
    n1=en:contraindications aspect | n2=en:pyrazolones | rel=r_associated | relid=0 | w=20
  4180. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyrethia
    n1=en:contraindications aspect | n2=en:pyrethia | rel=r_associated | relid=0 | w=20
  4181. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyridinium compounds
    n1=en:contraindications aspect | n2=en:pyridinium compounds | rel=r_associated | relid=0 | w=20
  4182. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyridostigmine bromide
    n1=en:contraindications aspect | n2=en:pyridostigmine bromide | rel=r_associated | relid=0 | w=20
  4183. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyridoxic acid
    n1=en:contraindications aspect | n2=en:pyridoxic acid | rel=r_associated | relid=0 | w=20
  4184. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyrrolidines
    n1=en:contraindications aspect | n2=en:pyrrolidines | rel=r_associated | relid=0 | w=20
  4185. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyrrolidinones
    n1=en:contraindications aspect | n2=en:pyrrolidinones | rel=r_associated | relid=0 | w=20
  4186. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyrroloiminoquinones
    n1=en:contraindications aspect | n2=en:pyrroloiminoquinones | rel=r_associated | relid=0 | w=20
  4187. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyruvaldehyde
    n1=en:contraindications aspect | n2=en:pyruvaldehyde | rel=r_associated | relid=0 | w=20
  4188. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyruvate dehydrogenase complex
    n1=en:contraindications aspect | n2=en:pyruvate dehydrogenase complex | rel=r_associated | relid=0 | w=20
  4189. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyruvate oxidase
    n1=en:contraindications aspect | n2=en:pyruvate oxidase | rel=r_associated | relid=0 | w=20
  4190. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyruvic acid
    n1=en:contraindications aspect | n2=en:pyruvic acid | rel=r_associated | relid=0 | w=20
  4191. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:pyrvinium compounds
    n1=en:contraindications aspect | n2=en:pyrvinium compounds | rel=r_associated | relid=0 | w=20
  4192. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:q-snare proteins
    n1=en:contraindications aspect | n2=en:q-snare proteins | rel=r_associated | relid=0 | w=20
  4193. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:qigong
    n1=en:contraindications aspect | n2=en:qigong | rel=r_associated | relid=0 | w=20
  4194. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:quantitative computerized tomography
    n1=en:contraindications aspect | n2=en:quantitative computerized tomography | rel=r_associated | relid=0 | w=20
  4195. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:quaternary ammonium compounds
    n1=en:contraindications aspect | n2=en:quaternary ammonium compounds | rel=r_associated | relid=0 | w=20
  4196. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:quillaja saponins
    n1=en:contraindications aspect | n2=en:quillaja saponins | rel=r_associated | relid=0 | w=20
  4197. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:quinolinic acid
    n1=en:contraindications aspect | n2=en:quinolinic acid | rel=r_associated | relid=0 | w=20
  4198. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:quinolinic acids
    n1=en:contraindications aspect | n2=en:quinolinic acids | rel=r_associated | relid=0 | w=20
  4199. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:quinolizidines
    n1=en:contraindications aspect | n2=en:quinolizidines | rel=r_associated | relid=0 | w=20
  4200. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiation dosimetry
    n1=en:contraindications aspect | n2=en:radiation dosimetry | rel=r_associated | relid=0 | w=20
  4201. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiation therapy
    n1=en:contraindications aspect | n2=en:radiation therapy | rel=r_associated | relid=0 | w=20
  4202. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiation treatment
    n1=en:contraindications aspect | n2=en:radiation treatment | rel=r_associated | relid=0 | w=20
  4203. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radical mastectomy
    n1=en:contraindications aspect | n2=en:radical mastectomy | rel=r_associated | relid=0 | w=20
  4204. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiocontrast agent
    n1=en:contraindications aspect | n2=en:radiocontrast agent | rel=r_associated | relid=0 | w=20
  4205. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiographic magnification
    n1=en:contraindications aspect | n2=en:radiographic magnification | rel=r_associated | relid=0 | w=20
  4206. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiography, abdominal
    n1=en:contraindications aspect | n2=en:radiography, abdominal | rel=r_associated | relid=0 | w=20
  4207. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiography, dental
    n1=en:contraindications aspect | n2=en:radiography, dental | rel=r_associated | relid=0 | w=20
  4208. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiography, dual-energy scanned projection
    n1=en:contraindications aspect | n2=en:radiography, dual-energy scanned projection | rel=r_associated | relid=0 | w=20
  4209. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiography, thoracic
    n1=en:contraindications aspect | n2=en:radiography, thoracic | rel=r_associated | relid=0 | w=20
  4210. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radioimmunoassay
    n1=en:contraindications aspect | n2=en:radioimmunoassay | rel=r_associated | relid=0 | w=20
  4211. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radioisotope
    n1=en:contraindications aspect | n2=en:radioisotope | rel=r_associated | relid=0 | w=20
  4212. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radioisotope renography
    n1=en:contraindications aspect | n2=en:radioisotope renography | rel=r_associated | relid=0 | w=20
  4213. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radioisotope scanning
    n1=en:contraindications aspect | n2=en:radioisotope scanning | rel=r_associated | relid=0 | w=20
  4214. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radioisotope teletherapy
    n1=en:contraindications aspect | n2=en:radioisotope teletherapy | rel=r_associated | relid=0 | w=20
  4215. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radioligand assay
    n1=en:contraindications aspect | n2=en:radioligand assay | rel=r_associated | relid=0 | w=20
  4216. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radionuclide imaging
    n1=en:contraindications aspect | n2=en:radionuclide imaging | rel=r_associated | relid=0 | w=20
  4217. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radioprotective agent
    n1=en:contraindications aspect | n2=en:radioprotective agent | rel=r_associated | relid=0 | w=20
  4218. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiosensitizing agent
    n1=en:contraindications aspect | n2=en:radiosensitizing agent | rel=r_associated | relid=0 | w=20
  4219. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiotherapy
    n1=en:contraindications aspect | n2=en:radiotherapy | rel=r_associated | relid=0 | w=20
  4220. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:radiotherapy planning, computer-assisted
    n1=en:contraindications aspect | n2=en:radiotherapy planning, computer-assisted | rel=r_associated | relid=0 | w=20
  4221. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ramipril
    n1=en:contraindications aspect | n2=en:ramipril | rel=r_associated | relid=0 | w=20
  4222. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:range-finding
    n1=en:contraindications aspect | n2=en:range-finding | rel=r_associated | relid=0 | w=20
  4223. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rap gtp-binding proteins
    n1=en:contraindications aspect | n2=en:rap gtp-binding proteins | rel=r_associated | relid=0 | w=20
  4224. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reactive nitrogen species
    n1=en:contraindications aspect | n2=en:reactive nitrogen species | rel=r_associated | relid=0 | w=20
  4225. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reading glasses
    n1=en:contraindications aspect | n2=en:reading glasses | rel=r_associated | relid=0 | w=20
  4226. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reagent strips
    n1=en:contraindications aspect | n2=en:reagent strips | rel=r_associated | relid=0 | w=20
  4227. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reagins
    n1=en:contraindications aspect | n2=en:reagins | rel=r_associated | relid=0 | w=20
  4228. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:receptor tyrosine-protein kinase erbb-3
    n1=en:contraindications aspect | n2=en:receptor tyrosine-protein kinase erbb-3 | rel=r_associated | relid=0 | w=20
  4229. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:receptor tyrosine-protein kinase erbb-4
    n1=en:contraindications aspect | n2=en:receptor tyrosine-protein kinase erbb-4 | rel=r_associated | relid=0 | w=20
  4230. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:receptor-interacting protein serine-threonine kinases
    n1=en:contraindications aspect | n2=en:receptor-interacting protein serine-threonine kinases | rel=r_associated | relid=0 | w=20
  4231. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:receptor-interacting serine/threonine protein kinase 2
    n1=en:contraindications aspect | n2=en:receptor-interacting serine/threonine protein kinase 2 | rel=r_associated | relid=0 | w=20
  4232. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:receptor-like protein tyrosine phosphatases, class 1
    n1=en:contraindications aspect | n2=en:receptor-like protein tyrosine phosphatases, class 1 | rel=r_associated | relid=0 | w=20
  4233. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:receptor-like protein tyrosine phosphatases, class 2
    n1=en:contraindications aspect | n2=en:receptor-like protein tyrosine phosphatases, class 2 | rel=r_associated | relid=0 | w=20
  4234. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:receptor-like protein tyrosine phosphatases, class 3
    n1=en:contraindications aspect | n2=en:receptor-like protein tyrosine phosphatases, class 3 | rel=r_associated | relid=0 | w=20
  4235. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:receptors, tnf-related apoptosis-inducing ligand
    n1=en:contraindications aspect | n2=en:receptors, tnf-related apoptosis-inducing ligand | rel=r_associated | relid=0 | w=20
  4236. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:recombinant interferon beta-1b
    n1=en:contraindications aspect | n2=en:recombinant interferon beta-1b | rel=r_associated | relid=0 | w=20
  4237. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:recombinant protein
    n1=en:contraindications aspect | n2=en:recombinant protein | rel=r_associated | relid=0 | w=20
  4238. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reflexotherapy
    n1=en:contraindications aspect | n2=en:reflexotherapy | rel=r_associated | relid=0 | w=20
  4239. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:regular insulin
    n1=en:contraindications aspect | n2=en:regular insulin | rel=r_associated | relid=0 | w=20
  4240. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rehydration solutions
    n1=en:contraindications aspect | n2=en:rehydration solutions | rel=r_associated | relid=0 | w=20
  4241. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reimplantation
    n1=en:contraindications aspect | n2=en:reimplantation | rel=r_associated | relid=0 | w=20
  4242. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:relations
    n1=en:contraindications aspect | n2=en:relations | rel=r_associated | relid=0 | w=20
  4243. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:relationships
    n1=en:contraindications aspect | n2=en:relationships | rel=r_associated | relid=0 | w=20
  4244. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:relaxin
    n1=en:contraindications aspect | n2=en:relaxin | rel=r_associated | relid=0 | w=20
  4245. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:repeated surgical procedure
    n1=en:contraindications aspect | n2=en:repeated surgical procedure | rel=r_associated | relid=0 | w=20
  4246. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:repifermin
    n1=en:contraindications aspect | n2=en:repifermin | rel=r_associated | relid=0 | w=20
  4247. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reply to
    n1=en:contraindications aspect | n2=en:reply to | rel=r_associated | relid=0 | w=20
  4248. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reply to somebody
    n1=en:contraindications aspect | n2=en:reply to somebody | rel=r_associated | relid=0 | w=20
  4249. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reproductive techniques, assisted
    n1=en:contraindications aspect | n2=en:reproductive techniques, assisted | rel=r_associated | relid=0 | w=20
  4250. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:resistin
    n1=en:contraindications aspect | n2=en:resistin | rel=r_associated | relid=0 | w=20
  4251. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:respiratory function tests
    n1=en:contraindications aspect | n2=en:respiratory function tests | rel=r_associated | relid=0 | w=20
  4252. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:respiratory protective devices
    n1=en:contraindications aspect | n2=en:respiratory protective devices | rel=r_associated | relid=0 | w=20
  4253. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:respiratory-gated imaging techniques
    n1=en:contraindications aspect | n2=en:respiratory-gated imaging techniques | rel=r_associated | relid=0 | w=20
  4254. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:respond
    n1=en:contraindications aspect | n2=en:respond | rel=r_associated | relid=0 | w=20
  4255. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:respond to somebody
    n1=en:contraindications aspect | n2=en:respond to somebody | rel=r_associated | relid=0 | w=20
  4256. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:restriction endonuclease
    n1=en:contraindications aspect | n2=en:restriction endonuclease | rel=r_associated | relid=0 | w=20
  4257. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinoblastoma-like protein 1
    n1=en:contraindications aspect | n2=en:retinoblastoma-like protein 1 | rel=r_associated | relid=0 | w=20
  4258. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinoic acid agent
    n1=en:contraindications aspect | n2=en:retinoic acid agent | rel=r_associated | relid=0 | w=20
  4259. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinoic acid receptor rxr-alpha
    n1=en:contraindications aspect | n2=en:retinoic acid receptor rxr-alpha | rel=r_associated | relid=0 | w=20
  4260. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinoic acid receptor rxr-beta
    n1=en:contraindications aspect | n2=en:retinoic acid receptor rxr-beta | rel=r_associated | relid=0 | w=20
  4261. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinoic acid receptor rxr-gamma
    n1=en:contraindications aspect | n2=en:retinoic acid receptor rxr-gamma | rel=r_associated | relid=0 | w=20
  4262. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinoid x receptor
    n1=en:contraindications aspect | n2=en:retinoid x receptor | rel=r_associated | relid=0 | w=20
  4263. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinol binding proteins
    n1=en:contraindications aspect | n2=en:retinol binding proteins | rel=r_associated | relid=0 | w=20
  4264. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinol-binding proteins, plasma
    n1=en:contraindications aspect | n2=en:retinol-binding proteins, plasma | rel=r_associated | relid=0 | w=20
  4265. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinoscopes
    n1=en:contraindications aspect | n2=en:retinoscopes | rel=r_associated | relid=0 | w=20
  4266. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retinoscopy
    n1=en:contraindications aspect | n2=en:retinoscopy | rel=r_associated | relid=0 | w=20
  4267. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:retrograde obturation
    n1=en:contraindications aspect | n2=en:retrograde obturation | rel=r_associated | relid=0 | w=20
  4268. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:reverse transcriptase inhibitor
    n1=en:contraindications aspect | n2=en:reverse transcriptase inhibitor | rel=r_associated | relid=0 | w=20
  4269. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rho gtp-binding proteins
    n1=en:contraindications aspect | n2=en:rho gtp-binding proteins | rel=r_associated | relid=0 | w=20
  4270. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rhob protein
    n1=en:contraindications aspect | n2=en:rhob protein | rel=r_associated | relid=0 | w=20
  4271. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rhodamine 123
    n1=en:contraindications aspect | n2=en:rhodamine 123 | rel=r_associated | relid=0 | w=20
  4272. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rhodopsin kinase
    n1=en:contraindications aspect | n2=en:rhodopsin kinase | rel=r_associated | relid=0 | w=20
  4273. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rhodopsins, microbial
    n1=en:contraindications aspect | n2=en:rhodopsins, microbial | rel=r_associated | relid=0 | w=20
  4274. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ribitol
    n1=en:contraindications aspect | n2=en:ribitol | rel=r_associated | relid=0 | w=20
  4275. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:riboadenylate transferase
    n1=en:contraindications aspect | n2=en:riboadenylate transferase | rel=r_associated | relid=0 | w=20
  4276. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ribosomal rna
    n1=en:contraindications aspect | n2=en:ribosomal rna | rel=r_associated | relid=0 | w=20
  4277. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ribosomal RNA
    n1=en:contraindications aspect | n2=en:ribosomal RNA | rel=r_associated | relid=0 | w=20
  4278. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ribosome inactivating proteins, type 2
    n1=en:contraindications aspect | n2=en:ribosome inactivating proteins, type 2 | rel=r_associated | relid=0 | w=20
  4279. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ribulose-bisphosphate carboxylase
    n1=en:contraindications aspect | n2=en:ribulose-bisphosphate carboxylase | rel=r_associated | relid=0 | w=20
  4280. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ribulosephosphates
    n1=en:contraindications aspect | n2=en:ribulosephosphates | rel=r_associated | relid=0 | w=20
  4281. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rifamycin
    n1=en:contraindications aspect | n2=en:rifamycin | rel=r_associated | relid=0 | w=20
  4282. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:risa
    n1=en:contraindications aspect | n2=en:risa | rel=r_associated | relid=0 | w=20
  4283. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rituximab
    n1=en:contraindications aspect | n2=en:rituximab | rel=r_associated | relid=0 | w=20
  4284. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rivaroxaban
    n1=en:contraindications aspect | n2=en:rivaroxaban | rel=r_associated | relid=0 | w=20
  4285. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rivastigmine
    n1=en:contraindications aspect | n2=en:rivastigmine | rel=r_associated | relid=0 | w=20
  4286. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rna cap analogs
    n1=en:contraindications aspect | n2=en:rna cap analogs | rel=r_associated | relid=0 | w=20
  4287. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rna nucleotidyltransferases
    n1=en:contraindications aspect | n2=en:rna nucleotidyltransferases | rel=r_associated | relid=0 | w=20
  4288. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rna polymerase iii
    n1=en:contraindications aspect | n2=en:rna polymerase iii | rel=r_associated | relid=0 | w=20
  4289. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rna probes
    n1=en:contraindications aspect | n2=en:rna probes | rel=r_associated | relid=0 | w=20
  4290. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rna recognition motif (rrm) proteins
    n1=en:contraindications aspect | n2=en:rna recognition motif (rrm) proteins | rel=r_associated | relid=0 | w=20
  4291. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rna-directed rna polymerase
    n1=en:contraindications aspect | n2=en:rna-directed rna polymerase | rel=r_associated | relid=0 | w=20
  4292. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rna, chloroplast
    n1=en:contraindications aspect | n2=en:rna, chloroplast | rel=r_associated | relid=0 | w=20
  4293. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rna, messenger, stored
    n1=en:contraindications aspect | n2=en:rna, messenger, stored | rel=r_associated | relid=0 | w=20
  4294. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rna, ribosomal, self-splicing
    n1=en:contraindications aspect | n2=en:rna, ribosomal, self-splicing | rel=r_associated | relid=0 | w=20
  4295. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:roentgenoscopy
    n1=en:contraindications aspect | n2=en:roentgenoscopy | rel=r_associated | relid=0 | w=20
  4296. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:roentgenotherapy
    n1=en:contraindications aspect | n2=en:roentgenotherapy | rel=r_associated | relid=0 | w=20
  4297. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:roentgentherapy
    n1=en:contraindications aspect | n2=en:roentgentherapy | rel=r_associated | relid=0 | w=20
  4298. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:root canal irrigants
    n1=en:contraindications aspect | n2=en:root canal irrigants | rel=r_associated | relid=0 | w=20
  4299. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:root canal preparation
    n1=en:contraindications aspect | n2=en:root canal preparation | rel=r_associated | relid=0 | w=20
  4300. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:root planing
    n1=en:contraindications aspect | n2=en:root planing | rel=r_associated | relid=0 | w=20
  4301. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:Roux's serum
    n1=en:contraindications aspect | n2=en:Roux's serum | rel=r_associated | relid=0 | w=20
  4302. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rRNA
    n1=en:contraindications aspect | n2=en:rRNA | rel=r_associated | relid=0 | w=20
  4303. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rubella vaccine
    n1=en:contraindications aspect | n2=en:rubella vaccine | rel=r_associated | relid=0 | w=20
  4304. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rubella virus vaccine
    n1=en:contraindications aspect | n2=en:rubella virus vaccine | rel=r_associated | relid=0 | w=20
  4305. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rubidium radioisotopes
    n1=en:contraindications aspect | n2=en:rubidium radioisotopes | rel=r_associated | relid=0 | w=20
  4306. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:rubredoxins
    n1=en:contraindications aspect | n2=en:rubredoxins | rel=r_associated | relid=0 | w=20
  4307. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:runt-related transcription factor 2
    n1=en:contraindications aspect | n2=en:runt-related transcription factor 2 | rel=r_associated | relid=0 | w=20
  4308. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:runt-related transcription factor 3
    n1=en:contraindications aspect | n2=en:runt-related transcription factor 3 | rel=r_associated | relid=0 | w=20
  4309. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:s-adenosylhomocysteine
    n1=en:contraindications aspect | n2=en:s-adenosylhomocysteine | rel=r_associated | relid=0 | w=20
  4310. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:s-nitrosoglutathione
    n1=en:contraindications aspect | n2=en:s-nitrosoglutathione | rel=r_associated | relid=0 | w=20
  4311. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:saccharide
    n1=en:contraindications aspect | n2=en:saccharide | rel=r_associated | relid=0 | w=20
  4312. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:saccharin
    n1=en:contraindications aspect | n2=en:saccharin | rel=r_associated | relid=0 | w=20
  4313. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:saccharinum
    n1=en:contraindications aspect | n2=en:saccharinum | rel=r_associated | relid=0 | w=20
  4314. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sal diurecticum
    n1=en:contraindications aspect | n2=en:sal diurecticum | rel=r_associated | relid=0 | w=20
  4315. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:salicylanilides
    n1=en:contraindications aspect | n2=en:salicylanilides | rel=r_associated | relid=0 | w=20
  4316. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:salpingectomy
    n1=en:contraindications aspect | n2=en:salpingectomy | rel=r_associated | relid=0 | w=20
  4317. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:salt
    n1=en:contraindications aspect | n2=en:salt | rel=r_associated | relid=0 | w=20
  4318. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sanitary products
    n1=en:contraindications aspect | n2=en:sanitary products | rel=r_associated | relid=0 | w=20
  4319. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sanitary protection
    n1=en:contraindications aspect | n2=en:sanitary protection | rel=r_associated | relid=0 | w=20
  4320. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:saponin
    n1=en:contraindications aspect | n2=en:saponin | rel=r_associated | relid=0 | w=20
  4321. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sarin
    n1=en:contraindications aspect | n2=en:sarin | rel=r_associated | relid=0 | w=20
  4322. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sarin gas
    n1=en:contraindications aspect | n2=en:sarin gas | rel=r_associated | relid=0 | w=20
  4323. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:scanning laser polarimetry
    n1=en:contraindications aspect | n2=en:scanning laser polarimetry | rel=r_associated | relid=0 | w=20
  4324. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:schistosomicides
    n1=en:contraindications aspect | n2=en:schistosomicides | rel=r_associated | relid=0 | w=20
  4325. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:scintigraphy
    n1=en:contraindications aspect | n2=en:scintigraphy | rel=r_associated | relid=0 | w=20
  4326. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:scintillography
    n1=en:contraindications aspect | n2=en:scintillography | rel=r_associated | relid=0 | w=20
  4327. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:scintiphotography
    n1=en:contraindications aspect | n2=en:scintiphotography | rel=r_associated | relid=0 | w=20
  4328. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:scintography
    n1=en:contraindications aspect | n2=en:scintography | rel=r_associated | relid=0 | w=20
  4329. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:scleroplasty
    n1=en:contraindications aspect | n2=en:scleroplasty | rel=r_associated | relid=0 | w=20
  4330. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sclerostomy
    n1=en:contraindications aspect | n2=en:sclerostomy | rel=r_associated | relid=0 | w=20
  4331. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:scopoletin
    n1=en:contraindications aspect | n2=en:scopoletin | rel=r_associated | relid=0 | w=20
  4332. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:scotoscopy
    n1=en:contraindications aspect | n2=en:scotoscopy | rel=r_associated | relid=0 | w=20
  4333. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:secologanin tryptamine alkaloids
    n1=en:contraindications aspect | n2=en:secologanin tryptamine alkaloids | rel=r_associated | relid=0 | w=20
  4334. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:second look operation
    n1=en:contraindications aspect | n2=en:second look operation | rel=r_associated | relid=0 | w=20
  4335. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:second-look surgery
    n1=en:contraindications aspect | n2=en:second-look surgery | rel=r_associated | relid=0 | w=20
  4336. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:secondary surgical revision
    n1=en:contraindications aspect | n2=en:secondary surgical revision | rel=r_associated | relid=0 | w=20
  4337. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:secretin
    n1=en:contraindications aspect | n2=en:secretin | rel=r_associated | relid=0 | w=20
  4338. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:secretogranin-2
    n1=en:contraindications aspect | n2=en:secretogranin-2 | rel=r_associated | relid=0 | w=20
  4339. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:secretory immunoglobulin a
    n1=en:contraindications aspect | n2=en:secretory immunoglobulin a | rel=r_associated | relid=0 | w=20
  4340. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sedative and hypnotic
    n1=en:contraindications aspect | n2=en:sedative and hypnotic | rel=r_associated | relid=0 | w=20
  4341. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:segmental mastectomy
    n1=en:contraindications aspect | n2=en:segmental mastectomy | rel=r_associated | relid=0 | w=20
  4342. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:selectin
    n1=en:contraindications aspect | n2=en:selectin | rel=r_associated | relid=0 | w=20
  4343. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:selective estrogen receptor modulator
    n1=en:contraindications aspect | n2=en:selective estrogen receptor modulator | rel=r_associated | relid=0 | w=20
  4344. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:selenious acid
    n1=en:contraindications aspect | n2=en:selenious acid | rel=r_associated | relid=0 | w=20
  4345. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:selenium compound
    n1=en:contraindications aspect | n2=en:selenium compound | rel=r_associated | relid=0 | w=20
  4346. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:selenoprotein w
    n1=en:contraindications aspect | n2=en:selenoprotein w | rel=r_associated | relid=0 | w=20
  4347. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:self care
    n1=en:contraindications aspect | n2=en:self care | rel=r_associated | relid=0 | w=20
  4348. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:semiconductors
    n1=en:contraindications aspect | n2=en:semiconductors | rel=r_associated | relid=0 | w=20
  4349. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:seminal vesicle secretory proteins
    n1=en:contraindications aspect | n2=en:seminal vesicle secretory proteins | rel=r_associated | relid=0 | w=20
  4350. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sensibilatrice
    n1=en:contraindications aspect | n2=en:sensibilatrice | rel=r_associated | relid=0 | w=20
  4351. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sensory aids
    n1=en:contraindications aspect | n2=en:sensory aids | rel=r_associated | relid=0 | w=20
  4352. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sensory system agents
    n1=en:contraindications aspect | n2=en:sensory system agents | rel=r_associated | relid=0 | w=20
  4353. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:septal occluder device
    n1=en:contraindications aspect | n2=en:septal occluder device | rel=r_associated | relid=0 | w=20
  4354. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sequestosome-1 protein
    n1=en:contraindications aspect | n2=en:sequestosome-1 protein | rel=r_associated | relid=0 | w=20
  4355. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serial extraction
    n1=en:contraindications aspect | n2=en:serial extraction | rel=r_associated | relid=0 | w=20
  4356. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sericins
    n1=en:contraindications aspect | n2=en:sericins | rel=r_associated | relid=0 | w=20
  4357. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serine-specific trna
    n1=en:contraindications aspect | n2=en:serine-specific trna | rel=r_associated | relid=0 | w=20
  4358. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serine/threonine protein kinase
    n1=en:contraindications aspect | n2=en:serine/threonine protein kinase | rel=r_associated | relid=0 | w=20
  4359. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serine/threonine-protein kinase a-raf
    n1=en:contraindications aspect | n2=en:serine/threonine-protein kinase a-raf | rel=r_associated | relid=0 | w=20
  4360. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serotonin agents
    n1=en:contraindications aspect | n2=en:serotonin agents | rel=r_associated | relid=0 | w=20
  4361. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serotonin uptake inhibitors
    n1=en:contraindications aspect | n2=en:serotonin uptake inhibitors | rel=r_associated | relid=0 | w=20
  4362. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serpin e2
    n1=en:contraindications aspect | n2=en:serpin e2 | rel=r_associated | relid=0 | w=20
  4363. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serrate-jagged proteins
    n1=en:contraindications aspect | n2=en:serrate-jagged proteins | rel=r_associated | relid=0 | w=20
  4364. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serum albumin, bovine
    n1=en:contraindications aspect | n2=en:serum albumin, bovine | rel=r_associated | relid=0 | w=20
  4365. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serum albumin, radio-iodinated
    n1=en:contraindications aspect | n2=en:serum albumin, radio-iodinated | rel=r_associated | relid=0 | w=20
  4366. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serum amyloid a
    n1=en:contraindications aspect | n2=en:serum amyloid a | rel=r_associated | relid=0 | w=20
  4367. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:serum amyloid p-component
    n1=en:contraindications aspect | n2=en:serum amyloid p-component | rel=r_associated | relid=0 | w=20
  4368. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sesquiterpenes, guaiane
    n1=en:contraindications aspect | n2=en:sesquiterpenes, guaiane | rel=r_associated | relid=0 | w=20
  4369. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:set of cogs
    n1=en:contraindications aspect | n2=en:set of cogs | rel=r_associated | relid=0 | w=20
  4370. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:set of false teeth
    n1=en:contraindications aspect | n2=en:set of false teeth | rel=r_associated | relid=0 | w=20
  4371. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sex reassignment procedures
    n1=en:contraindications aspect | n2=en:sex reassignment procedures | rel=r_associated | relid=0 | w=20
  4372. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sexual intercourse
    n1=en:contraindications aspect | n2=en:sexual intercourse | rel=r_associated | relid=0 | w=20
  4373. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sexual relations
    n1=en:contraindications aspect | n2=en:sexual relations | rel=r_associated | relid=0 | w=20
  4374. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sgot (ast)
    n1=en:contraindications aspect | n2=en:sgot (ast) | rel=r_associated | relid=0 | w=20
  4375. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:shiga toxin 2
    n1=en:contraindications aspect | n2=en:shiga toxin 2 | rel=r_associated | relid=0 | w=20
  4376. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:shiga toxins
    n1=en:contraindications aspect | n2=en:shiga toxins | rel=r_associated | relid=0 | w=20
  4377. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:shikimic acid
    n1=en:contraindications aspect | n2=en:shikimic acid | rel=r_associated | relid=0 | w=20
  4378. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:short-chain specific acyl-coa dehydrogenase, mitochondrial
    n1=en:contraindications aspect | n2=en:short-chain specific acyl-coa dehydrogenase, mitochondrial | rel=r_associated | relid=0 | w=20
  4379. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:shoulder prostheses (device)
    n1=en:contraindications aspect | n2=en:shoulder prostheses (device) | rel=r_associated | relid=0 | w=20
  4380. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sialic acid binding ig-like lectin 1
    n1=en:contraindications aspect | n2=en:sialic acid binding ig-like lectin 1 | rel=r_associated | relid=0 | w=20
  4381. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sialic acids
    n1=en:contraindications aspect | n2=en:sialic acids | rel=r_associated | relid=0 | w=20
  4382. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sialomucins
    n1=en:contraindications aspect | n2=en:sialomucins | rel=r_associated | relid=0 | w=20
  4383. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:signal transducer and activator of transcription 2
    n1=en:contraindications aspect | n2=en:signal transducer and activator of transcription 2 | rel=r_associated | relid=0 | w=20
  4384. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:signal transducer and activator of transcription 3
    n1=en:contraindications aspect | n2=en:signal transducer and activator of transcription 3 | rel=r_associated | relid=0 | w=20
  4385. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:signaling lymphocytic activation molecule associated protein
    n1=en:contraindications aspect | n2=en:signaling lymphocytic activation molecule associated protein | rel=r_associated | relid=0 | w=20
  4386. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sildenafil citrate
    n1=en:contraindications aspect | n2=en:sildenafil citrate | rel=r_associated | relid=0 | w=20
  4387. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:silicate cement
    n1=en:contraindications aspect | n2=en:silicate cement | rel=r_associated | relid=0 | w=20
  4388. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:silicone gels
    n1=en:contraindications aspect | n2=en:silicone gels | rel=r_associated | relid=0 | w=20
  4389. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:silicone oils
    n1=en:contraindications aspect | n2=en:silicone oils | rel=r_associated | relid=0 | w=20
  4390. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:simazine
    n1=en:contraindications aspect | n2=en:simazine | rel=r_associated | relid=0 | w=20
  4391. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:single embryo transfer
    n1=en:contraindications aspect | n2=en:single embryo transfer | rel=r_associated | relid=0 | w=20
  4392. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:single photon emission computed tomography
    n1=en:contraindications aspect | n2=en:single photon emission computed tomography | rel=r_associated | relid=0 | w=20
  4393. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:single-chain variable fragment
    n1=en:contraindications aspect | n2=en:single-chain variable fragment | rel=r_associated | relid=0 | w=20
  4394. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:singlet oxygen
    n1=en:contraindications aspect | n2=en:singlet oxygen | rel=r_associated | relid=0 | w=20
  4395. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sirtuins
    n1=en:contraindications aspect | n2=en:sirtuins | rel=r_associated | relid=0 | w=20
  4396. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sitagliptin phosphate, metformin hydrochloride drug combination
    n1=en:contraindications aspect | n2=en:sitagliptin phosphate, metformin hydrochloride drug combination | rel=r_associated | relid=0 | w=20
  4397. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:skeletal muscle ventricle
    n1=en:contraindications aspect | n2=en:skeletal muscle ventricle | rel=r_associated | relid=0 | w=20
  4398. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:skiascopy
    n1=en:contraindications aspect | n2=en:skiascopy | rel=r_associated | relid=0 | w=20
  4399. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:skin patch dosage form
    n1=en:contraindications aspect | n2=en:skin patch dosage form | rel=r_associated | relid=0 | w=20
  4400. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:skin test
    n1=en:contraindications aspect | n2=en:skin test | rel=r_associated | relid=0 | w=20
  4401. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:skin test end-point titration
    n1=en:contraindications aspect | n2=en:skin test end-point titration | rel=r_associated | relid=0 | w=20
  4402. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:small cytoplasmic ribonucleoproteins
    n1=en:contraindications aspect | n2=en:small cytoplasmic ribonucleoproteins | rel=r_associated | relid=0 | w=20
  4403. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:small nucleolar ribonucleoproteins
    n1=en:contraindications aspect | n2=en:small nucleolar ribonucleoproteins | rel=r_associated | relid=0 | w=20
  4404. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:small nucleolar rna
    n1=en:contraindications aspect | n2=en:small nucleolar rna | rel=r_associated | relid=0 | w=20
  4405. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:small ubiquitin-related modifier 1
    n1=en:contraindications aspect | n2=en:small ubiquitin-related modifier 1 | rel=r_associated | relid=0 | w=20
  4406. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:small ubiquitin-related modifier proteins
    n1=en:contraindications aspect | n2=en:small ubiquitin-related modifier proteins | rel=r_associated | relid=0 | w=20
  4407. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:small-conductance calcium-activated potassium channels
    n1=en:contraindications aspect | n2=en:small-conductance calcium-activated potassium channels | rel=r_associated | relid=0 | w=20
  4408. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:smarcb1 protein
    n1=en:contraindications aspect | n2=en:smarcb1 protein | rel=r_associated | relid=0 | w=20
  4409. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:soapstone
    n1=en:contraindications aspect | n2=en:soapstone | rel=r_associated | relid=0 | w=20
  4410. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium channel
    n1=en:contraindications aspect | n2=en:sodium channel | rel=r_associated | relid=0 | w=20
  4411. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium channel blockers
    n1=en:contraindications aspect | n2=en:sodium channel blockers | rel=r_associated | relid=0 | w=20
  4412. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium glutamate
    n1=en:contraindications aspect | n2=en:sodium glutamate | rel=r_associated | relid=0 | w=20
  4413. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium potassium chloride symporter inhibitors
    n1=en:contraindications aspect | n2=en:sodium potassium chloride symporter inhibitors | rel=r_associated | relid=0 | w=20
  4414. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium radioisotopes
    n1=en:contraindications aspect | n2=en:sodium radioisotopes | rel=r_associated | relid=0 | w=20
  4415. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium selenite
    n1=en:contraindications aspect | n2=en:sodium selenite | rel=r_associated | relid=0 | w=20
  4416. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium-calcium exchanger
    n1=en:contraindications aspect | n2=en:sodium-calcium exchanger | rel=r_associated | relid=0 | w=20
  4417. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium-glucose transporter 1
    n1=en:contraindications aspect | n2=en:sodium-glucose transporter 1 | rel=r_associated | relid=0 | w=20
  4418. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium-glucose transporter 2
    n1=en:contraindications aspect | n2=en:sodium-glucose transporter 2 | rel=r_associated | relid=0 | w=20
  4419. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium-phosphate cotransporter proteins
    n1=en:contraindications aspect | n2=en:sodium-phosphate cotransporter proteins | rel=r_associated | relid=0 | w=20
  4420. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium-phosphate cotransporter proteins, type i
    n1=en:contraindications aspect | n2=en:sodium-phosphate cotransporter proteins, type i | rel=r_associated | relid=0 | w=20
  4421. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sodium-phosphate cotransporter proteins, type iii
    n1=en:contraindications aspect | n2=en:sodium-phosphate cotransporter proteins, type iii | rel=r_associated | relid=0 | w=20
  4422. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:soil pollutants
    n1=en:contraindications aspect | n2=en:soil pollutants | rel=r_associated | relid=0 | w=20
  4423. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:soil pollutants, radioactive
    n1=en:contraindications aspect | n2=en:soil pollutants, radioactive | rel=r_associated | relid=0 | w=20
  4424. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:soluble nsf attachment protein
    n1=en:contraindications aspect | n2=en:soluble nsf attachment protein | rel=r_associated | relid=0 | w=20
  4425. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:solute carrier family 12, member 1
    n1=en:contraindications aspect | n2=en:solute carrier family 12, member 1 | rel=r_associated | relid=0 | w=20
  4426. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:solute carrier family 12, member 2
    n1=en:contraindications aspect | n2=en:solute carrier family 12, member 2 | rel=r_associated | relid=0 | w=20
  4427. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:solute carrier family 2, facilitated glucose transporter member 4
    n1=en:contraindications aspect | n2=en:solute carrier family 2, facilitated glucose transporter member 4 | rel=r_associated | relid=0 | w=20
  4428. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:solute carrier family 22 member 1
    n1=en:contraindications aspect | n2=en:solute carrier family 22 member 1 | rel=r_associated | relid=0 | w=20
  4429. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:solution
    n1=en:contraindications aspect | n2=en:solution | rel=r_associated | relid=0 | w=20
  4430. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:solvent
    n1=en:contraindications aspect | n2=en:solvent | rel=r_associated | relid=0 | w=20
  4431. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:somatostatin
    n1=en:contraindications aspect | n2=en:somatostatin | rel=r_associated | relid=0 | w=20
  4432. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:somatostatin-28
    n1=en:contraindications aspect | n2=en:somatostatin-28 | rel=r_associated | relid=0 | w=20
  4433. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:son of sevenless protein, drosophila
    n1=en:contraindications aspect | n2=en:son of sevenless protein, drosophila | rel=r_associated | relid=0 | w=20
  4434. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sonication
    n1=en:contraindications aspect | n2=en:sonication | rel=r_associated | relid=0 | w=20
  4435. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sorbose
    n1=en:contraindications aspect | n2=en:sorbose | rel=r_associated | relid=0 | w=20
  4436. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sorption detoxification
    n1=en:contraindications aspect | n2=en:sorption detoxification | rel=r_associated | relid=0 | w=20
  4437. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:source code
    n1=en:contraindications aspect | n2=en:source code | rel=r_associated | relid=0 | w=20
  4438. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:source text
    n1=en:contraindications aspect | n2=en:source text | rel=r_associated | relid=0 | w=20
  4439. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:soxc transcription factors
    n1=en:contraindications aspect | n2=en:soxc transcription factors | rel=r_associated | relid=0 | w=20
  4440. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:soxd transcription factors
    n1=en:contraindications aspect | n2=en:soxd transcription factors | rel=r_associated | relid=0 | w=20
  4441. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sp4 transcription factor
    n1=en:contraindications aspect | n2=en:sp4 transcription factor | rel=r_associated | relid=0 | w=20
  4442. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:space maintenance, orthodontic
    n1=en:contraindications aspect | n2=en:space maintenance, orthodontic | rel=r_associated | relid=0 | w=20
  4443. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:space simulation
    n1=en:contraindications aspect | n2=en:space simulation | rel=r_associated | relid=0 | w=20
  4444. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:space suits
    n1=en:contraindications aspect | n2=en:space suits | rel=r_associated | relid=0 | w=20
  4445. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:spanner
    n1=en:contraindications aspect | n2=en:spanner | rel=r_associated | relid=0 | w=20
  4446. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:specs
    n1=en:contraindications aspect | n2=en:specs | rel=r_associated | relid=0 | w=20
  4447. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:spectacles
    n1=en:contraindications aspect | n2=en:spectacles | rel=r_associated | relid=0 | w=20
  4448. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:speech articulation tests
    n1=en:contraindications aspect | n2=en:speech articulation tests | rel=r_associated | relid=0 | w=20
  4449. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:speech discrimination tests
    n1=en:contraindications aspect | n2=en:speech discrimination tests | rel=r_associated | relid=0 | w=20
  4450. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sperm immobilizing agents
    n1=en:contraindications aspect | n2=en:sperm immobilizing agents | rel=r_associated | relid=0 | w=20
  4451. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sperm injections, intracytoplasmic
    n1=en:contraindications aspect | n2=en:sperm injections, intracytoplasmic | rel=r_associated | relid=0 | w=20
  4452. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:spermatogenesis-blocking agents
    n1=en:contraindications aspect | n2=en:spermatogenesis-blocking agents | rel=r_associated | relid=0 | w=20
  4453. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:spermicide
    n1=en:contraindications aspect | n2=en:spermicide | rel=r_associated | relid=0 | w=20
  4454. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sphingosine n-acyltransferase
    n1=en:contraindications aspect | n2=en:sphingosine n-acyltransferase | rel=r_associated | relid=0 | w=20
  4455. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sphygmomanometer
    n1=en:contraindications aspect | n2=en:sphygmomanometer | rel=r_associated | relid=0 | w=20
  4456. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:spike glycoprotein, coronavirus
    n1=en:contraindications aspect | n2=en:spike glycoprotein, coronavirus | rel=r_associated | relid=0 | w=20
  4457. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:spinal fusion (procedure)
    n1=en:contraindications aspect | n2=en:spinal fusion (procedure) | rel=r_associated | relid=0 | w=20
  4458. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:spiral cone-beam computed tomography
    n1=en:contraindications aspect | n2=en:spiral cone-beam computed tomography | rel=r_associated | relid=0 | w=20
  4459. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:spiritual therapy
    n1=en:contraindications aspect | n2=en:spiritual therapy | rel=r_associated | relid=0 | w=20
  4460. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:splenectomy
    n1=en:contraindications aspect | n2=en:splenectomy | rel=r_associated | relid=0 | w=20
  4461. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:stage-specific embryonic antigens
    n1=en:contraindications aspect | n2=en:stage-specific embryonic antigens | rel=r_associated | relid=0 | w=20
  4462. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:staging
    n1=en:contraindications aspect | n2=en:staging | rel=r_associated | relid=0 | w=20
  4463. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:stapes mobilization
    n1=en:contraindications aspect | n2=en:stapes mobilization | rel=r_associated | relid=0 | w=20
  4464. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:staphylococcal toxoid
    n1=en:contraindications aspect | n2=en:staphylococcal toxoid | rel=r_associated | relid=0 | w=20
  4465. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:starch (bacterial glycogen) synthase
    n1=en:contraindications aspect | n2=en:starch (bacterial glycogen) synthase | rel=r_associated | relid=0 | w=20
  4466. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:stat transcription factors
    n1=en:contraindications aspect | n2=en:stat transcription factors | rel=r_associated | relid=0 | w=20
  4467. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:stearates
    n1=en:contraindications aspect | n2=en:stearates | rel=r_associated | relid=0 | w=20
  4468. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:steatite
    n1=en:contraindications aspect | n2=en:steatite | rel=r_associated | relid=0 | w=20
  4469. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:stereotaxic techniques
    n1=en:contraindications aspect | n2=en:stereotaxic techniques | rel=r_associated | relid=0 | w=20
  4470. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sterilization, involuntary
    n1=en:contraindications aspect | n2=en:sterilization, involuntary | rel=r_associated | relid=0 | w=20
  4471. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sternotomy
    n1=en:contraindications aspect | n2=en:sternotomy | rel=r_associated | relid=0 | w=20
  4472. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:steroid 21-monooxygenase
    n1=en:contraindications aspect | n2=en:steroid 21-monooxygenase | rel=r_associated | relid=0 | w=20
  4473. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:steroid compound
    n1=en:contraindications aspect | n2=en:steroid compound | rel=r_associated | relid=0 | w=20
  4474. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:steroid isomerases
    n1=en:contraindications aspect | n2=en:steroid isomerases | rel=r_associated | relid=0 | w=20
  4475. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:steroid synthesis inhibitors
    n1=en:contraindications aspect | n2=en:steroid synthesis inhibitors | rel=r_associated | relid=0 | w=20
  4476. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:steroids, fluorinated
    n1=en:contraindications aspect | n2=en:steroids, fluorinated | rel=r_associated | relid=0 | w=20
  4477. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sterol o-acyltransferase
    n1=en:contraindications aspect | n2=en:sterol o-acyltransferase | rel=r_associated | relid=0 | w=20
  4478. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sterol regulatory element binding proteins
    n1=en:contraindications aspect | n2=en:sterol regulatory element binding proteins | rel=r_associated | relid=0 | w=20
  4479. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sterols
    n1=en:contraindications aspect | n2=en:sterols | rel=r_associated | relid=0 | w=20
  4480. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:steryl-sulfatase
    n1=en:contraindications aspect | n2=en:steryl-sulfatase | rel=r_associated | relid=0 | w=20
  4481. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:stoma
    n1=en:contraindications aspect | n2=en:stoma | rel=r_associated | relid=0 | w=20
  4482. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:streptococcal vaccines
    n1=en:contraindications aspect | n2=en:streptococcal vaccines | rel=r_associated | relid=0 | w=20
  4483. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:streptodornase and streptokinase
    n1=en:contraindications aspect | n2=en:streptodornase and streptokinase | rel=r_associated | relid=0 | w=20
  4484. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:streptogramin b
    n1=en:contraindications aspect | n2=en:streptogramin b | rel=r_associated | relid=0 | w=20
  4485. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:stromal interaction molecule 2
    n1=en:contraindications aspect | n2=en:stromal interaction molecule 2 | rel=r_associated | relid=0 | w=20
  4486. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:stromal interaction molecules
    n1=en:contraindications aspect | n2=en:stromal interaction molecules | rel=r_associated | relid=0 | w=20
  4487. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:stromelysin 2
    n1=en:contraindications aspect | n2=en:stromelysin 2 | rel=r_associated | relid=0 | w=20
  4488. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:subcutaneous infusions
    n1=en:contraindications aspect | n2=en:subcutaneous infusions | rel=r_associated | relid=0 | w=20
  4489. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:subcutaneous mastectomy
    n1=en:contraindications aspect | n2=en:subcutaneous mastectomy | rel=r_associated | relid=0 | w=20
  4490. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:subgingival curettage
    n1=en:contraindications aspect | n2=en:subgingival curettage | rel=r_associated | relid=0 | w=20
  4491. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:subtilisin
    n1=en:contraindications aspect | n2=en:subtilisin | rel=r_associated | relid=0 | w=20
  4492. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:subtilisins
    n1=en:contraindications aspect | n2=en:subtilisins | rel=r_associated | relid=0 | w=20
  4493. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:succinic acid
    n1=en:contraindications aspect | n2=en:succinic acid | rel=r_associated | relid=0 | w=20
  4494. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:succinic anhydrides
    n1=en:contraindications aspect | n2=en:succinic anhydrides | rel=r_associated | relid=0 | w=20
  4495. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sucrose
    n1=en:contraindications aspect | n2=en:sucrose | rel=r_associated | relid=0 | w=20
  4496. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sugar acids
    n1=en:contraindications aspect | n2=en:sugar acids | rel=r_associated | relid=0 | w=20
  4497. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sugar alcohols
    n1=en:contraindications aspect | n2=en:sugar alcohols | rel=r_associated | relid=0 | w=20
  4498. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sugar phosphates
    n1=en:contraindications aspect | n2=en:sugar phosphates | rel=r_associated | relid=0 | w=20
  4499. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sulfates, inorganic
    n1=en:contraindications aspect | n2=en:sulfates, inorganic | rel=r_associated | relid=0 | w=20
  4500. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sulfhydryl compounds
    n1=en:contraindications aspect | n2=en:sulfhydryl compounds | rel=r_associated | relid=0 | w=20
  4501. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sulfhydryl reagents
    n1=en:contraindications aspect | n2=en:sulfhydryl reagents | rel=r_associated | relid=0 | w=20
  4502. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sulfites
    n1=en:contraindications aspect | n2=en:sulfites | rel=r_associated | relid=0 | w=20
  4503. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sulfonylurea compounds
    n1=en:contraindications aspect | n2=en:sulfonylurea compounds | rel=r_associated | relid=0 | w=20
  4504. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sulfuric acids
    n1=en:contraindications aspect | n2=en:sulfuric acids | rel=r_associated | relid=0 | w=20
  4505. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:superficial radiotherapy
    n1=en:contraindications aspect | n2=en:superficial radiotherapy | rel=r_associated | relid=0 | w=20
  4506. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:superoxide dismutase 1
    n1=en:contraindications aspect | n2=en:superoxide dismutase 1 | rel=r_associated | relid=0 | w=20
  4507. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:suppressor of cytokine signaling 1 protein
    n1=en:contraindications aspect | n2=en:suppressor of cytokine signaling 1 protein | rel=r_associated | relid=0 | w=20
  4508. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:suppressor of cytokine signaling 3 protein
    n1=en:contraindications aspect | n2=en:suppressor of cytokine signaling 3 protein | rel=r_associated | relid=0 | w=20
  4509. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:suppressor of cytokine signaling family protein
    n1=en:contraindications aspect | n2=en:suppressor of cytokine signaling family protein | rel=r_associated | relid=0 | w=20
  4510. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:surgery
    n1=en:contraindications aspect | n2=en:surgery | rel=r_associated | relid=0 | w=20
  4511. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:surgical castration
    n1=en:contraindications aspect | n2=en:surgical castration | rel=r_associated | relid=0 | w=20
  4512. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:surgical intervention
    n1=en:contraindications aspect | n2=en:surgical intervention | rel=r_associated | relid=0 | w=20
  4513. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:surgical ocular refractive procedure
    n1=en:contraindications aspect | n2=en:surgical ocular refractive procedure | rel=r_associated | relid=0 | w=20
  4514. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:surgical operation
    n1=en:contraindications aspect | n2=en:surgical operation | rel=r_associated | relid=0 | w=20
  4515. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:surgical portosystemic shunt
    n1=en:contraindications aspect | n2=en:surgical portosystemic shunt | rel=r_associated | relid=0 | w=20
  4516. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:surgical replantation
    n1=en:contraindications aspect | n2=en:surgical replantation | rel=r_associated | relid=0 | w=20
  4517. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:surgical tape
    n1=en:contraindications aspect | n2=en:surgical tape | rel=r_associated | relid=0 | w=20
  4518. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:surgically created structure
    n1=en:contraindications aspect | n2=en:surgically created structure | rel=r_associated | relid=0 | w=20
  4519. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:suspenders
    n1=en:contraindications aspect | n2=en:suspenders | rel=r_associated | relid=0 | w=20
  4520. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:suspension dosage form
    n1=en:contraindications aspect | n2=en:suspension dosage form | rel=r_associated | relid=0 | w=20
  4521. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:suture device component
    n1=en:contraindications aspect | n2=en:suture device component | rel=r_associated | relid=0 | w=20
  4522. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:swan-ganz catheterization
    n1=en:contraindications aspect | n2=en:swan-ganz catheterization | rel=r_associated | relid=0 | w=20
  4523. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:sympathectomy, chemical
    n1=en:contraindications aspect | n2=en:sympathectomy, chemical | rel=r_associated | relid=0 | w=20
  4524. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:synaptotagmin i
    n1=en:contraindications aspect | n2=en:synaptotagmin i | rel=r_associated | relid=0 | w=20
  4525. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:synaptotagmin ii
    n1=en:contraindications aspect | n2=en:synaptotagmin ii | rel=r_associated | relid=0 | w=20
  4526. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:syntaxin 16
    n1=en:contraindications aspect | n2=en:syntaxin 16 | rel=r_associated | relid=0 | w=20
  4527. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:synuclein gamma
    n1=en:contraindications aspect | n2=en:synuclein gamma | rel=r_associated | relid=0 | w=20
  4528. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:synucleins
    n1=en:contraindications aspect | n2=en:synucleins | rel=r_associated | relid=0 | w=20
  4529. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:syringe
    n1=en:contraindications aspect | n2=en:syringe | rel=r_associated | relid=0 | w=20
  4530. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:t-antigen
    n1=en:contraindications aspect | n2=en:t-antigen | rel=r_associated | relid=0 | w=20
  4531. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:t-type calcium channels
    n1=en:contraindications aspect | n2=en:t-type calcium channels | rel=r_associated | relid=0 | w=20
  4532. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:table salt
    n1=en:contraindications aspect | n2=en:table salt | rel=r_associated | relid=0 | w=20
  4533. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:talcum
    n1=en:contraindications aspect | n2=en:talcum | rel=r_associated | relid=0 | w=20
  4534. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:talcum powder
    n1=en:contraindications aspect | n2=en:talcum powder | rel=r_associated | relid=0 | w=20
  4535. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tampons, surgical
    n1=en:contraindications aspect | n2=en:tampons, surgical | rel=r_associated | relid=0 | w=20
  4536. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tankyrases
    n1=en:contraindications aspect | n2=en:tankyrases | rel=r_associated | relid=0 | w=20
  4537. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tar-water
    n1=en:contraindications aspect | n2=en:tar-water | rel=r_associated | relid=0 | w=20
  4538. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:targeted gene repair
    n1=en:contraindications aspect | n2=en:targeted gene repair | rel=r_associated | relid=0 | w=20
  4539. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tat protein
    n1=en:contraindications aspect | n2=en:tat protein | rel=r_associated | relid=0 | w=20
  4540. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tata box binding protein-like proteins
    n1=en:contraindications aspect | n2=en:tata box binding protein-like proteins | rel=r_associated | relid=0 | w=20
  4541. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tata-binding protein associated factors
    n1=en:contraindications aspect | n2=en:tata-binding protein associated factors | rel=r_associated | relid=0 | w=20
  4542. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tau-crystallins
    n1=en:contraindications aspect | n2=en:tau-crystallins | rel=r_associated | relid=0 | w=20
  4543. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:taurochenodeoxycholic acid
    n1=en:contraindications aspect | n2=en:taurochenodeoxycholic acid | rel=r_associated | relid=0 | w=20
  4544. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:taurodeoxycholic acid
    n1=en:contraindications aspect | n2=en:taurodeoxycholic acid | rel=r_associated | relid=0 | w=20
  4545. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:taurolithocholic acid
    n1=en:contraindications aspect | n2=en:taurolithocholic acid | rel=r_associated | relid=0 | w=20
  4546. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:taxoids
    n1=en:contraindications aspect | n2=en:taxoids | rel=r_associated | relid=0 | w=20
  4547. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:technetium
    n1=en:contraindications aspect | n2=en:technetium | rel=r_associated | relid=0 | w=20
  4548. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:teflon
    n1=en:contraindications aspect | n2=en:teflon | rel=r_associated | relid=0 | w=20
  4549. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:Teflon
    n1=en:contraindications aspect | n2=en:Teflon | rel=r_associated | relid=0 | w=20
  4550. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:telemetring
    n1=en:contraindications aspect | n2=en:telemetring | rel=r_associated | relid=0 | w=20
  4551. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:telemetry
    n1=en:contraindications aspect | n2=en:telemetry | rel=r_associated | relid=0 | w=20
  4552. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tenamfetamine
    n1=en:contraindications aspect | n2=en:tenamfetamine | rel=r_associated | relid=0 | w=20
  4553. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:teniposide
    n1=en:contraindications aspect | n2=en:teniposide | rel=r_associated | relid=0 | w=20
  4554. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:terbutaline
    n1=en:contraindications aspect | n2=en:terbutaline | rel=r_associated | relid=0 | w=20
  4555. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ternary complex factors
    n1=en:contraindications aspect | n2=en:ternary complex factors | rel=r_associated | relid=0 | w=20
  4556. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tert-butylhydroperoxide
    n1=en:contraindications aspect | n2=en:tert-butylhydroperoxide | rel=r_associated | relid=0 | w=20
  4557. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:testicular hormones
    n1=en:contraindications aspect | n2=en:testicular hormones | rel=r_associated | relid=0 | w=20
  4558. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:testosterone 5-alpha-reductase
    n1=en:contraindications aspect | n2=en:testosterone 5-alpha-reductase | rel=r_associated | relid=0 | w=20
  4559. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetanus antitoxin
    n1=en:contraindications aspect | n2=en:tetanus antitoxin | rel=r_associated | relid=0 | w=20
  4560. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetanus serum
    n1=en:contraindications aspect | n2=en:tetanus serum | rel=r_associated | relid=0 | w=20
  4561. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetrachlorvinphos
    n1=en:contraindications aspect | n2=en:tetrachlorvinphos | rel=r_associated | relid=0 | w=20
  4562. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetracycline
    n1=en:contraindications aspect | n2=en:tetracycline | rel=r_associated | relid=0 | w=20
  4563. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetraethylammonium compounds
    n1=en:contraindications aspect | n2=en:tetraethylammonium compounds | rel=r_associated | relid=0 | w=20
  4564. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetragastrin
    n1=en:contraindications aspect | n2=en:tetragastrin | rel=r_associated | relid=0 | w=20
  4565. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetralones
    n1=en:contraindications aspect | n2=en:tetralones | rel=r_associated | relid=0 | w=20
  4566. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetramethylphenylenediamine
    n1=en:contraindications aspect | n2=en:tetramethylphenylenediamine | rel=r_associated | relid=0 | w=20
  4567. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetranitromethane
    n1=en:contraindications aspect | n2=en:tetranitromethane | rel=r_associated | relid=0 | w=20
  4568. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetraoxanes
    n1=en:contraindications aspect | n2=en:tetraoxanes | rel=r_associated | relid=0 | w=20
  4569. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetrathionic acid
    n1=en:contraindications aspect | n2=en:tetrathionic acid | rel=r_associated | relid=0 | w=20
  4570. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tetroses
    n1=en:contraindications aspect | n2=en:tetroses | rel=r_associated | relid=0 | w=20
  4571. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tfiid
    n1=en:contraindications aspect | n2=en:tfiid | rel=r_associated | relid=0 | w=20
  4572. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tfiih basal transcription factor complex helicase xpd subunit
    n1=en:contraindications aspect | n2=en:tfiih basal transcription factor complex helicase xpd subunit | rel=r_associated | relid=0 | w=20
  4573. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tgf-beta superfamily proteins
    n1=en:contraindications aspect | n2=en:tgf-beta superfamily proteins | rel=r_associated | relid=0 | w=20
  4574. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:therapeutic corticosteroid
    n1=en:contraindications aspect | n2=en:therapeutic corticosteroid | rel=r_associated | relid=0 | w=20
  4575. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:therapeutic epinephrine
    n1=en:contraindications aspect | n2=en:therapeutic epinephrine | rel=r_associated | relid=0 | w=20
  4576. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:therapeutic estrone
    n1=en:contraindications aspect | n2=en:therapeutic estrone | rel=r_associated | relid=0 | w=20
  4577. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:therapeutic hydrocortisone
    n1=en:contraindications aspect | n2=en:therapeutic hydrocortisone | rel=r_associated | relid=0 | w=20
  4578. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:therapeutic plateletpheresis
    n1=en:contraindications aspect | n2=en:therapeutic plateletpheresis | rel=r_associated | relid=0 | w=20
  4579. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:therapeutic testosterone
    n1=en:contraindications aspect | n2=en:therapeutic testosterone | rel=r_associated | relid=0 | w=20
  4580. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:therapeutic touch
    n1=en:contraindications aspect | n2=en:therapeutic touch | rel=r_associated | relid=0 | w=20
  4581. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:therapies, investigational
    n1=en:contraindications aspect | n2=en:therapies, investigational | rel=r_associated | relid=0 | w=20
  4582. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:therapy, soft tissue
    n1=en:contraindications aspect | n2=en:therapy, soft tissue | rel=r_associated | relid=0 | w=20
  4583. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thermodilution
    n1=en:contraindications aspect | n2=en:thermodilution | rel=r_associated | relid=0 | w=20
  4584. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thermoluminescent dosimetry
    n1=en:contraindications aspect | n2=en:thermoluminescent dosimetry | rel=r_associated | relid=0 | w=20
  4585. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiadiazines
    n1=en:contraindications aspect | n2=en:thiadiazines | rel=r_associated | relid=0 | w=20
  4586. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiamine
    n1=en:contraindications aspect | n2=en:thiamine | rel=r_associated | relid=0 | w=20
  4587. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiamine pyrophosphatase
    n1=en:contraindications aspect | n2=en:thiamine pyrophosphatase | rel=r_associated | relid=0 | w=20
  4588. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thienamycins
    n1=en:contraindications aspect | n2=en:thienamycins | rel=r_associated | relid=0 | w=20
  4589. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiobarbiturates
    n1=en:contraindications aspect | n2=en:thiobarbiturates | rel=r_associated | relid=0 | w=20
  4590. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiobarbituric acid reactive substances
    n1=en:contraindications aspect | n2=en:thiobarbituric acid reactive substances | rel=r_associated | relid=0 | w=20
  4591. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiohydantoins
    n1=en:contraindications aspect | n2=en:thiohydantoins | rel=r_associated | relid=0 | w=20
  4592. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thionins
    n1=en:contraindications aspect | n2=en:thionins | rel=r_associated | relid=0 | w=20
  4593. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thioredoxins
    n1=en:contraindications aspect | n2=en:thioredoxins | rel=r_associated | relid=0 | w=20
  4594. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thioridazine
    n1=en:contraindications aspect | n2=en:thioridazine | rel=r_associated | relid=0 | w=20
  4595. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiosugars
    n1=en:contraindications aspect | n2=en:thiosugars | rel=r_associated | relid=0 | w=20
  4596. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiosulfate sulfurtransferase
    n1=en:contraindications aspect | n2=en:thiosulfate sulfurtransferase | rel=r_associated | relid=0 | w=20
  4597. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiourea
    n1=en:contraindications aspect | n2=en:thiourea | rel=r_associated | relid=0 | w=20
  4598. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thiouridine
    n1=en:contraindications aspect | n2=en:thiouridine | rel=r_associated | relid=0 | w=20
  4599. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thoracic surgical procedure
    n1=en:contraindications aspect | n2=en:thoracic surgical procedure | rel=r_associated | relid=0 | w=20
  4600. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thoracoplasty
    n1=en:contraindications aspect | n2=en:thoracoplasty | rel=r_associated | relid=0 | w=20
  4601. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thoracoscopy
    n1=en:contraindications aspect | n2=en:thoracoscopy | rel=r_associated | relid=0 | w=20
  4602. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:threonine dehydratase
    n1=en:contraindications aspect | n2=en:threonine dehydratase | rel=r_associated | relid=0 | w=20
  4603. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:threonine/tyrosine protein kinase
    n1=en:contraindications aspect | n2=en:threonine/tyrosine protein kinase | rel=r_associated | relid=0 | w=20
  4604. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thrombin time
    n1=en:contraindications aspect | n2=en:thrombin time | rel=r_associated | relid=0 | w=20
  4605. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thrombolytic agent
    n1=en:contraindications aspect | n2=en:thrombolytic agent | rel=r_associated | relid=0 | w=20
  4606. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thromboxane b2
    n1=en:contraindications aspect | n2=en:thromboxane b2 | rel=r_associated | relid=0 | w=20
  4607. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thromboxane-a synthase
    n1=en:contraindications aspect | n2=en:thromboxane-a synthase | rel=r_associated | relid=0 | w=20
  4608. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thymidylate synthase
    n1=en:contraindications aspect | n2=en:thymidylate synthase | rel=r_associated | relid=0 | w=20
  4609. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thymine nucleotides
    n1=en:contraindications aspect | n2=en:thymine nucleotides | rel=r_associated | relid=0 | w=20
  4610. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thymolphthalein
    n1=en:contraindications aspect | n2=en:thymolphthalein | rel=r_associated | relid=0 | w=20
  4611. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:thyrotropin alfa
    n1=en:contraindications aspect | n2=en:thyrotropin alfa | rel=r_associated | relid=0 | w=20
  4612. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ticlopidine
    n1=en:contraindications aspect | n2=en:ticlopidine | rel=r_associated | relid=0 | w=20
  4613. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tiletamine
    n1=en:contraindications aspect | n2=en:tiletamine | rel=r_associated | relid=0 | w=20
  4614. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tin polyphosphates
    n1=en:contraindications aspect | n2=en:tin polyphosphates | rel=r_associated | relid=0 | w=20
  4615. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tin radioisotopes
    n1=en:contraindications aspect | n2=en:tin radioisotopes | rel=r_associated | relid=0 | w=20
  4616. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tissue adhesives
    n1=en:contraindications aspect | n2=en:tissue adhesives | rel=r_associated | relid=0 | w=20
  4617. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tissue conditioning (dental)
    n1=en:contraindications aspect | n2=en:tissue conditioning (dental) | rel=r_associated | relid=0 | w=20
  4618. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tissue expansion devices
    n1=en:contraindications aspect | n2=en:tissue expansion devices | rel=r_associated | relid=0 | w=20
  4619. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tmpo gene product
    n1=en:contraindications aspect | n2=en:tmpo gene product | rel=r_associated | relid=0 | w=20
  4620. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tnf receptor-associated factor 5
    n1=en:contraindications aspect | n2=en:tnf receptor-associated factor 5 | rel=r_associated | relid=0 | w=20
  4621. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:to answer sb back
    n1=en:contraindications aspect | n2=en:to answer sb back | rel=r_associated | relid=0 | w=20
  4622. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:to be the counterpart of
    n1=en:contraindications aspect | n2=en:to be the counterpart of | rel=r_associated | relid=0 | w=20
  4623. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:to correspond to
    n1=en:contraindications aspect | n2=en:to correspond to | rel=r_associated | relid=0 | w=20
  4624. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:to match
    n1=en:contraindications aspect | n2=en:to match | rel=r_associated | relid=0 | w=20
  4625. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:to meet
    n1=en:contraindications aspect | n2=en:to meet | rel=r_associated | relid=0 | w=20
  4626. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:to reply to
    n1=en:contraindications aspect | n2=en:to reply to | rel=r_associated | relid=0 | w=20
  4627. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:to return
    n1=en:contraindications aspect | n2=en:to return | rel=r_associated | relid=0 | w=20
  4628. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tocolysis
    n1=en:contraindications aspect | n2=en:tocolysis | rel=r_associated | relid=0 | w=20
  4629. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:toluene
    n1=en:contraindications aspect | n2=en:toluene | rel=r_associated | relid=0 | w=20
  4630. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:Tomeno's angle
    n1=en:contraindications aspect | n2=en:Tomeno's angle | rel=r_associated | relid=0 | w=20
  4631. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tomography, proton spin
    n1=en:contraindications aspect | n2=en:tomography, proton spin | rel=r_associated | relid=0 | w=20
  4632. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tooth bleaching agents
    n1=en:contraindications aspect | n2=en:tooth bleaching agents | rel=r_associated | relid=0 | w=20
  4633. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tooth preparation, prosthodontic
    n1=en:contraindications aspect | n2=en:tooth preparation, prosthodontic | rel=r_associated | relid=0 | w=20
  4634. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tooth-paste
    n1=en:contraindications aspect | n2=en:tooth-paste | rel=r_associated | relid=0 | w=20
  4635. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tooth, artificial
    n1=en:contraindications aspect | n2=en:tooth, artificial | rel=r_associated | relid=0 | w=20
  4636. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:toothpaste
    n1=en:contraindications aspect | n2=en:toothpaste | rel=r_associated | relid=0 | w=20
  4637. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:topoisomerase i
    n1=en:contraindications aspect | n2=en:topoisomerase i | rel=r_associated | relid=0 | w=20
  4638. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:topoisomerase ii
    n1=en:contraindications aspect | n2=en:topoisomerase ii | rel=r_associated | relid=0 | w=20
  4639. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:topoisomerase inhibitor
    n1=en:contraindications aspect | n2=en:topoisomerase inhibitor | rel=r_associated | relid=0 | w=20
  4640. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:total ankle replacement
    n1=en:contraindications aspect | n2=en:total ankle replacement | rel=r_associated | relid=0 | w=20
  4641. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:total mastectomy
    n1=en:contraindications aspect | n2=en:total mastectomy | rel=r_associated | relid=0 | w=20
  4642. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:toxaphene
    n1=en:contraindications aspect | n2=en:toxaphene | rel=r_associated | relid=0 | w=20
  4643. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trace element
    n1=en:contraindications aspect | n2=en:trace element | rel=r_associated | relid=0 | w=20
  4644. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tracheal intubation
    n1=en:contraindications aspect | n2=en:tracheal intubation | rel=r_associated | relid=0 | w=20
  4645. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tracheostomy
    n1=en:contraindications aspect | n2=en:tracheostomy | rel=r_associated | relid=0 | w=20
  4646. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tranexamic acid
    n1=en:contraindications aspect | n2=en:tranexamic acid | rel=r_associated | relid=0 | w=20
  4647. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transaminase
    n1=en:contraindications aspect | n2=en:transaminase | rel=r_associated | relid=0 | w=20
  4648. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transanal endoscopic microsurgery
    n1=en:contraindications aspect | n2=en:transanal endoscopic microsurgery | rel=r_associated | relid=0 | w=20
  4649. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transcription factor 7-like 1 protein
    n1=en:contraindications aspect | n2=en:transcription factor 7-like 1 protein | rel=r_associated | relid=0 | w=20
  4650. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transcription factor ap-1
    n1=en:contraindications aspect | n2=en:transcription factor ap-1 | rel=r_associated | relid=0 | w=20
  4651. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transcription factor e2f3
    n1=en:contraindications aspect | n2=en:transcription factor e2f3 | rel=r_associated | relid=0 | w=20
  4652. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transcription factor tfiib
    n1=en:contraindications aspect | n2=en:transcription factor tfiib | rel=r_associated | relid=0 | w=20
  4653. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transcriptional activator myb
    n1=en:contraindications aspect | n2=en:transcriptional activator myb | rel=r_associated | relid=0 | w=20
  4654. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transducers
    n1=en:contraindications aspect | n2=en:transducers | rel=r_associated | relid=0 | w=20
  4655. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transesophageal echocardiography
    n1=en:contraindications aspect | n2=en:transesophageal echocardiography | rel=r_associated | relid=0 | w=20
  4656. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transfer factor
    n1=en:contraindications aspect | n2=en:transfer factor | rel=r_associated | relid=0 | w=20
  4657. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transferrins
    n1=en:contraindications aspect | n2=en:transferrins | rel=r_associated | relid=0 | w=20
  4658. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transforming growth factor
    n1=en:contraindications aspect | n2=en:transforming growth factor | rel=r_associated | relid=0 | w=20
  4659. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transforming growth factor alpha
    n1=en:contraindications aspect | n2=en:transforming growth factor alpha | rel=r_associated | relid=0 | w=20
  4660. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transforming growth factor beta 1
    n1=en:contraindications aspect | n2=en:transforming growth factor beta 1 | rel=r_associated | relid=0 | w=20
  4661. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transforming growth factor beta-3
    n1=en:contraindications aspect | n2=en:transforming growth factor beta-3 | rel=r_associated | relid=0 | w=20
  4662. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transforming protein rhoa
    n1=en:contraindications aspect | n2=en:transforming protein rhoa | rel=r_associated | relid=0 | w=20
  4663. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transglutaminase
    n1=en:contraindications aspect | n2=en:transglutaminase | rel=r_associated | relid=0 | w=20
  4664. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transillumination
    n1=en:contraindications aspect | n2=en:transillumination | rel=r_associated | relid=0 | w=20
  4665. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transistors, electronic
    n1=en:contraindications aspect | n2=en:transistors, electronic | rel=r_associated | relid=0 | w=20
  4666. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transjugular intrahepatic portosystemic shunt
    n1=en:contraindications aspect | n2=en:transjugular intrahepatic portosystemic shunt | rel=r_associated | relid=0 | w=20
  4667. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transmyocardial laser revascularization (procedure)
    n1=en:contraindications aspect | n2=en:transmyocardial laser revascularization (procedure) | rel=r_associated | relid=0 | w=20
  4668. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:transplantation
    n1=en:contraindications aspect | n2=en:transplantation | rel=r_associated | relid=0 | w=20
  4669. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trastuzumab
    n1=en:contraindications aspect | n2=en:trastuzumab | rel=r_associated | relid=0 | w=20
  4670. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:treponema immobilization test
    n1=en:contraindications aspect | n2=en:treponema immobilization test | rel=r_associated | relid=0 | w=20
  4671. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tretinoin
    n1=en:contraindications aspect | n2=en:tretinoin | rel=r_associated | relid=0 | w=20
  4672. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:triazene compound
    n1=en:contraindications aspect | n2=en:triazene compound | rel=r_associated | relid=0 | w=20
  4673. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tricarboxylic acids
    n1=en:contraindications aspect | n2=en:tricarboxylic acids | rel=r_associated | relid=0 | w=20
  4674. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trichophytin antigens
    n1=en:contraindications aspect | n2=en:trichophytin antigens | rel=r_associated | relid=0 | w=20
  4675. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trientine
    n1=en:contraindications aspect | n2=en:trientine | rel=r_associated | relid=0 | w=20
  4676. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trifluoperazine
    n1=en:contraindications aspect | n2=en:trifluoperazine | rel=r_associated | relid=0 | w=20
  4677. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:triflupromazine
    n1=en:contraindications aspect | n2=en:triflupromazine | rel=r_associated | relid=0 | w=20
  4678. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:triiodobenzoic acids
    n1=en:contraindications aspect | n2=en:triiodobenzoic acids | rel=r_associated | relid=0 | w=20
  4679. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:triiodothyronine
    n1=en:contraindications aspect | n2=en:triiodothyronine | rel=r_associated | relid=0 | w=20
  4680. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trimeprazine
    n1=en:contraindications aspect | n2=en:trimeprazine | rel=r_associated | relid=0 | w=20
  4681. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trimethyltin compounds
    n1=en:contraindications aspect | n2=en:trimethyltin compounds | rel=r_associated | relid=0 | w=20
  4682. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:triose-phosphate isomerase
    n1=en:contraindications aspect | n2=en:triose-phosphate isomerase | rel=r_associated | relid=0 | w=20
  4683. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:triosephosphate isomerase
    n1=en:contraindications aspect | n2=en:triosephosphate isomerase | rel=r_associated | relid=0 | w=20
  4684. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:triterpenes
    n1=en:contraindications aspect | n2=en:triterpenes | rel=r_associated | relid=0 | w=20
  4685. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:troponin c
    n1=en:contraindications aspect | n2=en:troponin c | rel=r_associated | relid=0 | w=20
  4686. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trpv cation channels
    n1=en:contraindications aspect | n2=en:trpv cation channels | rel=r_associated | relid=0 | w=20
  4687. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trypsin
    n1=en:contraindications aspect | n2=en:trypsin | rel=r_associated | relid=0 | w=20
  4688. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:trypsinogen
    n1=en:contraindications aspect | n2=en:trypsinogen | rel=r_associated | relid=0 | w=20
  4689. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tryptamines
    n1=en:contraindications aspect | n2=en:tryptamines | rel=r_associated | relid=0 | w=20
  4690. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tryptophan synthase
    n1=en:contraindications aspect | n2=en:tryptophan synthase | rel=r_associated | relid=0 | w=20
  4691. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tryptophan-specific trna
    n1=en:contraindications aspect | n2=en:tryptophan-specific trna | rel=r_associated | relid=0 | w=20
  4692. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor necrosis factor decoy receptors
    n1=en:contraindications aspect | n2=en:tumor necrosis factor decoy receptors | rel=r_associated | relid=0 | w=20
  4693. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor necrosis factor ligand superfamily member 11
    n1=en:contraindications aspect | n2=en:tumor necrosis factor ligand superfamily member 11 | rel=r_associated | relid=0 | w=20
  4694. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor necrosis factor ligand superfamily member 6
    n1=en:contraindications aspect | n2=en:tumor necrosis factor ligand superfamily member 6 | rel=r_associated | relid=0 | w=20
  4695. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor necrosis factor receptor superfamily member 11a
    n1=en:contraindications aspect | n2=en:tumor necrosis factor receptor superfamily member 11a | rel=r_associated | relid=0 | w=20
  4696. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor necrosis factor receptor superfamily member 17
    n1=en:contraindications aspect | n2=en:tumor necrosis factor receptor superfamily member 17 | rel=r_associated | relid=0 | w=20
  4697. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor necrosis factor receptor superfamily member 18
    n1=en:contraindications aspect | n2=en:tumor necrosis factor receptor superfamily member 18 | rel=r_associated | relid=0 | w=20
  4698. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor necrosis factor receptor superfamily member 25
    n1=en:contraindications aspect | n2=en:tumor necrosis factor receptor superfamily member 25 | rel=r_associated | relid=0 | w=20
  4699. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor necrosis factor receptor superfamily member 5
    n1=en:contraindications aspect | n2=en:tumor necrosis factor receptor superfamily member 5 | rel=r_associated | relid=0 | w=20
  4700. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor necrosis factor-alpha convertase
    n1=en:contraindications aspect | n2=en:tumor necrosis factor-alpha convertase | rel=r_associated | relid=0 | w=20
  4701. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tumor suppressor arf
    n1=en:contraindications aspect | n2=en:tumor suppressor arf | rel=r_associated | relid=0 | w=20
  4702. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tungsten
    n1=en:contraindications aspect | n2=en:tungsten | rel=r_associated | relid=0 | w=20
  4703. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:two-hybrid system techniques
    n1=en:contraindications aspect | n2=en:two-hybrid system techniques | rel=r_associated | relid=0 | w=20
  4704. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tyk2 kinase
    n1=en:contraindications aspect | n2=en:tyk2 kinase | rel=r_associated | relid=0 | w=20
  4705. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:type ii cgmp-dependent protein kinase, human
    n1=en:contraindications aspect | n2=en:type ii cgmp-dependent protein kinase, human | rel=r_associated | relid=0 | w=20
  4706. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:typhoid-paratyphoid vaccines
    n1=en:contraindications aspect | n2=en:typhoid-paratyphoid vaccines | rel=r_associated | relid=0 | w=20
  4707. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tyrocidine
    n1=en:contraindications aspect | n2=en:tyrocidine | rel=r_associated | relid=0 | w=20
  4708. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:tyrosine-protein phosphatase non-receptor type 13
    n1=en:contraindications aspect | n2=en:tyrosine-protein phosphatase non-receptor type 13 | rel=r_associated | relid=0 | w=20
  4709. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ubiquitin-activating enzymes
    n1=en:contraindications aspect | n2=en:ubiquitin-activating enzymes | rel=r_associated | relid=0 | w=20
  4710. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ubiquitin-conjugating enzymes
    n1=en:contraindications aspect | n2=en:ubiquitin-conjugating enzymes | rel=r_associated | relid=0 | w=20
  4711. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ubiquitin-protein ligase complexes
    n1=en:contraindications aspect | n2=en:ubiquitin-protein ligase complexes | rel=r_associated | relid=0 | w=20
  4712. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ulnar collateral ligament reconstruction
    n1=en:contraindications aspect | n2=en:ulnar collateral ligament reconstruction | rel=r_associated | relid=0 | w=20
  4713. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ultrasonic cardiography
    n1=en:contraindications aspect | n2=en:ultrasonic cardiography | rel=r_associated | relid=0 | w=20
  4714. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ultrasonography
    n1=en:contraindications aspect | n2=en:ultrasonography | rel=r_associated | relid=0 | w=20
  4715. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ultrasonography, mammary
    n1=en:contraindications aspect | n2=en:ultrasonography, mammary | rel=r_associated | relid=0 | w=20
  4716. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ultraviolet therapy
    n1=en:contraindications aspect | n2=en:ultraviolet therapy | rel=r_associated | relid=0 | w=20
  4717. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:unconventional myosin-va
    n1=en:contraindications aspect | n2=en:unconventional myosin-va | rel=r_associated | relid=0 | w=20
  4718. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uncoupling protein 2
    n1=en:contraindications aspect | n2=en:uncoupling protein 2 | rel=r_associated | relid=0 | w=20
  4719. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:undecylenic acids
    n1=en:contraindications aspect | n2=en:undecylenic acids | rel=r_associated | relid=0 | w=20
  4720. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:unnecessary procedures
    n1=en:contraindications aspect | n2=en:unnecessary procedures | rel=r_associated | relid=0 | w=20
  4721. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:upstream stimulatory factor
    n1=en:contraindications aspect | n2=en:upstream stimulatory factor | rel=r_associated | relid=0 | w=20
  4722. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uranyl nitrate
    n1=en:contraindications aspect | n2=en:uranyl nitrate | rel=r_associated | relid=0 | w=20
  4723. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ureohydrolases
    n1=en:contraindications aspect | n2=en:ureohydrolases | rel=r_associated | relid=0 | w=20
  4724. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ureteroscopes
    n1=en:contraindications aspect | n2=en:ureteroscopes | rel=r_associated | relid=0 | w=20
  4725. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ureterostomy
    n1=en:contraindications aspect | n2=en:ureterostomy | rel=r_associated | relid=0 | w=20
  4726. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urethan
    n1=en:contraindications aspect | n2=en:urethan | rel=r_associated | relid=0 | w=20
  4727. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urethane
    n1=en:contraindications aspect | n2=en:urethane | rel=r_associated | relid=0 | w=20
  4728. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uricosuric agent
    n1=en:contraindications aspect | n2=en:uricosuric agent | rel=r_associated | relid=0 | w=20
  4729. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uridine diphosphate
    n1=en:contraindications aspect | n2=en:uridine diphosphate | rel=r_associated | relid=0 | w=20
  4730. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uridine diphosphate glucose
    n1=en:contraindications aspect | n2=en:uridine diphosphate glucose | rel=r_associated | relid=0 | w=20
  4731. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uridine diphosphate n-acetylgalactosamine
    n1=en:contraindications aspect | n2=en:uridine diphosphate n-acetylgalactosamine | rel=r_associated | relid=0 | w=20
  4732. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uridine monophosphate
    n1=en:contraindications aspect | n2=en:uridine monophosphate | rel=r_associated | relid=0 | w=20
  4733. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urobilin
    n1=en:contraindications aspect | n2=en:urobilin | rel=r_associated | relid=0 | w=20
  4734. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urocanic acid
    n1=en:contraindications aspect | n2=en:urocanic acid | rel=r_associated | relid=0 | w=20
  4735. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urocortin
    n1=en:contraindications aspect | n2=en:urocortin | rel=r_associated | relid=0 | w=20
  4736. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urofollitropin
    n1=en:contraindications aspect | n2=en:urofollitropin | rel=r_associated | relid=0 | w=20
  4737. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urogenital surgical procedure
    n1=en:contraindications aspect | n2=en:urogenital surgical procedure | rel=r_associated | relid=0 | w=20
  4738. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urokinase
    n1=en:contraindications aspect | n2=en:urokinase | rel=r_associated | relid=0 | w=20
  4739. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urologic surgical procedure
    n1=en:contraindications aspect | n2=en:urologic surgical procedure | rel=r_associated | relid=0 | w=20
  4740. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:urologic surgical procedures, male
    n1=en:contraindications aspect | n2=en:urologic surgical procedures, male | rel=r_associated | relid=0 | w=20
  4741. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uroplakin ia
    n1=en:contraindications aspect | n2=en:uroplakin ia | rel=r_associated | relid=0 | w=20
  4742. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uroporphyrinogen decarboxylase
    n1=en:contraindications aspect | n2=en:uroporphyrinogen decarboxylase | rel=r_associated | relid=0 | w=20
  4743. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uroporphyrinogens
    n1=en:contraindications aspect | n2=en:uroporphyrinogens | rel=r_associated | relid=0 | w=20
  4744. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ustekinumab
    n1=en:contraindications aspect | n2=en:ustekinumab | rel=r_associated | relid=0 | w=20
  4745. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uterine balloon tamponade
    n1=en:contraindications aspect | n2=en:uterine balloon tamponade | rel=r_associated | relid=0 | w=20
  4746. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:utp-glucose-1-phosphate uridylyltransferase
    n1=en:contraindications aspect | n2=en:utp-glucose-1-phosphate uridylyltransferase | rel=r_associated | relid=0 | w=20
  4747. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:utp-hexose-1-phosphate uridylyltransferase
    n1=en:contraindications aspect | n2=en:utp-hexose-1-phosphate uridylyltransferase | rel=r_associated | relid=0 | w=20
  4748. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:uv light therapy
    n1=en:contraindications aspect | n2=en:uv light therapy | rel=r_associated | relid=0 | w=20
  4749. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vaccine
    n1=en:contraindications aspect | n2=en:vaccine | rel=r_associated | relid=0 | w=20
  4750. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vaccines, acellular
    n1=en:contraindications aspect | n2=en:vaccines, acellular | rel=r_associated | relid=0 | w=20
  4751. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vaccines, marker
    n1=en:contraindications aspect | n2=en:vaccines, marker | rel=r_associated | relid=0 | w=20
  4752. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vaccines, virosome
    n1=en:contraindications aspect | n2=en:vaccines, virosome | rel=r_associated | relid=0 | w=20
  4753. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vaccines, virus-like particle
    n1=en:contraindications aspect | n2=en:vaccines, virus-like particle | rel=r_associated | relid=0 | w=20
  4754. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vacuolar h+-atpase
    n1=en:contraindications aspect | n2=en:vacuolar h+-atpase | rel=r_associated | relid=0 | w=20
  4755. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vacuum aspiration
    n1=en:contraindications aspect | n2=en:vacuum aspiration | rel=r_associated | relid=0 | w=20
  4756. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vagus nerve stimulation
    n1=en:contraindications aspect | n2=en:vagus nerve stimulation | rel=r_associated | relid=0 | w=20
  4757. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:valproic acid
    n1=en:contraindications aspect | n2=en:valproic acid | rel=r_associated | relid=0 | w=20
  4758. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vanadates
    n1=en:contraindications aspect | n2=en:vanadates | rel=r_associated | relid=0 | w=20
  4759. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vancomycin
    n1=en:contraindications aspect | n2=en:vancomycin | rel=r_associated | relid=0 | w=20
  4760. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vascular cell adhesion protein 1
    n1=en:contraindications aspect | n2=en:vascular cell adhesion protein 1 | rel=r_associated | relid=0 | w=20
  4761. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vascular endothelial growth factor receptor-1
    n1=en:contraindications aspect | n2=en:vascular endothelial growth factor receptor-1 | rel=r_associated | relid=0 | w=20
  4762. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vascular endothelial growth factor receptor-2
    n1=en:contraindications aspect | n2=en:vascular endothelial growth factor receptor-2 | rel=r_associated | relid=0 | w=20
  4763. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vascular prosthesis
    n1=en:contraindications aspect | n2=en:vascular prosthesis | rel=r_associated | relid=0 | w=20
  4764. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vasodilating agent
    n1=en:contraindications aspect | n2=en:vasodilating agent | rel=r_associated | relid=0 | w=20
  4765. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vdj recombinases
    n1=en:contraindications aspect | n2=en:vdj recombinases | rel=r_associated | relid=0 | w=20
  4766. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vegetable oil
    n1=en:contraindications aspect | n2=en:vegetable oil | rel=r_associated | relid=0 | w=20
  4767. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:Velpeau's bandage
    n1=en:contraindications aspect | n2=en:Velpeau's bandage | rel=r_associated | relid=0 | w=20
  4768. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:venlafaxine hydrochloride
    n1=en:contraindications aspect | n2=en:venlafaxine hydrochloride | rel=r_associated | relid=0 | w=20
  4769. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:venography
    n1=en:contraindications aspect | n2=en:venography | rel=r_associated | relid=0 | w=20
  4770. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ventricular myosins
    n1=en:contraindications aspect | n2=en:ventricular myosins | rel=r_associated | relid=0 | w=20
  4771. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:ventriculography, first-pass
    n1=en:contraindications aspect | n2=en:ventriculography, first-pass | rel=r_associated | relid=0 | w=20
  4772. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:veratrine
    n1=en:contraindications aspect | n2=en:veratrine | rel=r_associated | relid=0 | w=20
  4773. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:very low density lipoprotein cholesterol
    n1=en:contraindications aspect | n2=en:very low density lipoprotein cholesterol | rel=r_associated | relid=0 | w=20
  4774. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vesicle-associated membrane protein 1
    n1=en:contraindications aspect | n2=en:vesicle-associated membrane protein 1 | rel=r_associated | relid=0 | w=20
  4775. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vesicle-associated membrane protein 3
    n1=en:contraindications aspect | n2=en:vesicle-associated membrane protein 3 | rel=r_associated | relid=0 | w=20
  4776. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vesicular biogenic amine transport proteins
    n1=en:contraindications aspect | n2=en:vesicular biogenic amine transport proteins | rel=r_associated | relid=0 | w=20
  4777. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vesicular glutamate transport protein 1
    n1=en:contraindications aspect | n2=en:vesicular glutamate transport protein 1 | rel=r_associated | relid=0 | w=20
  4778. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vesicular glutamate transport protein 2
    n1=en:contraindications aspect | n2=en:vesicular glutamate transport protein 2 | rel=r_associated | relid=0 | w=20
  4779. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vesicular glutamate transport proteins
    n1=en:contraindications aspect | n2=en:vesicular glutamate transport proteins | rel=r_associated | relid=0 | w=20
  4780. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vesicular inhibitory amino acid transport proteins
    n1=en:contraindications aspect | n2=en:vesicular inhibitory amino acid transport proteins | rel=r_associated | relid=0 | w=20
  4781. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vesicular neurotransmitter transport proteins
    n1=en:contraindications aspect | n2=en:vesicular neurotransmitter transport proteins | rel=r_associated | relid=0 | w=20
  4782. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vestibular function tests
    n1=en:contraindications aspect | n2=en:vestibular function tests | rel=r_associated | relid=0 | w=20
  4783. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:veterinary drugs
    n1=en:contraindications aspect | n2=en:veterinary drugs | rel=r_associated | relid=0 | w=20
  4784. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vinblastine
    n1=en:contraindications aspect | n2=en:vinblastine | rel=r_associated | relid=0 | w=20
  4785. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vinyl chloride
    n1=en:contraindications aspect | n2=en:vinyl chloride | rel=r_associated | relid=0 | w=20
  4786. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:viocid
    n1=en:contraindications aspect | n2=en:viocid | rel=r_associated | relid=0 | w=20
  4787. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:viper venoms
    n1=en:contraindications aspect | n2=en:viper venoms | rel=r_associated | relid=0 | w=20
  4788. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:viral core proteins
    n1=en:contraindications aspect | n2=en:viral core proteins | rel=r_associated | relid=0 | w=20
  4789. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:viral tail proteins
    n1=en:contraindications aspect | n2=en:viral tail proteins | rel=r_associated | relid=0 | w=20
  4790. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:viscoelastic substances
    n1=en:contraindications aspect | n2=en:viscoelastic substances | rel=r_associated | relid=0 | w=20
  4791. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vitallium
    n1=en:contraindications aspect | n2=en:vitallium | rel=r_associated | relid=0 | w=20
  4792. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vitamin a compound
    n1=en:contraindications aspect | n2=en:vitamin a compound | rel=r_associated | relid=0 | w=20
  4793. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vitamin B5
    n1=en:contraindications aspect | n2=en:vitamin B5 | rel=r_associated | relid=0 | w=20
  4794. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vitamin B6
    n1=en:contraindications aspect | n2=en:vitamin B6 | rel=r_associated | relid=0 | w=20
  4795. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vitamin b6
    n1=en:contraindications aspect | n2=en:vitamin b6 | rel=r_associated | relid=0 | w=20
  4796. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vitamin e compound
    n1=en:contraindications aspect | n2=en:vitamin e compound | rel=r_associated | relid=0 | w=20
  4797. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vitellins
    n1=en:contraindications aspect | n2=en:vitellins | rel=r_associated | relid=0 | w=20
  4798. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:vivisection
    n1=en:contraindications aspect | n2=en:vivisection | rel=r_associated | relid=0 | w=20
  4799. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:voltage-dependent anion channel
    n1=en:contraindications aspect | n2=en:voltage-dependent anion channel | rel=r_associated | relid=0 | w=20
  4800. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:voltage-dependent anion channel 1
    n1=en:contraindications aspect | n2=en:voltage-dependent anion channel 1 | rel=r_associated | relid=0 | w=20
  4801. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:voltage-dependent anion channel 2
    n1=en:contraindications aspect | n2=en:voltage-dependent anion channel 2 | rel=r_associated | relid=0 | w=20
  4802. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:voltage-gated sodium channel agonists
    n1=en:contraindications aspect | n2=en:voltage-gated sodium channel agonists | rel=r_associated | relid=0 | w=20
  4803. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:walkers
    n1=en:contraindications aspect | n2=en:walkers | rel=r_associated | relid=0 | w=20
  4804. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:warfarin
    n1=en:contraindications aspect | n2=en:warfarin | rel=r_associated | relid=0 | w=20
  4805. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:water cure
    n1=en:contraindications aspect | n2=en:water cure | rel=r_associated | relid=0 | w=20
  4806. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:water fluoridation
    n1=en:contraindications aspect | n2=en:water fluoridation | rel=r_associated | relid=0 | w=20
  4807. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:water pollutants
    n1=en:contraindications aspect | n2=en:water pollutants | rel=r_associated | relid=0 | w=20
  4808. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:water pollutants, radioactive
    n1=en:contraindications aspect | n2=en:water pollutants, radioactive | rel=r_associated | relid=0 | w=20
  4809. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:whole blood coagulation time
    n1=en:contraindications aspect | n2=en:whole blood coagulation time | rel=r_associated | relid=0 | w=20
  4810. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:whole body scan
    n1=en:contraindications aspect | n2=en:whole body scan | rel=r_associated | relid=0 | w=20
  4811. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:wiring harness
    n1=en:contraindications aspect | n2=en:wiring harness | rel=r_associated | relid=0 | w=20
  4812. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:wiskott-aldrich syndrome protein
    n1=en:contraindications aspect | n2=en:wiskott-aldrich syndrome protein | rel=r_associated | relid=0 | w=20
  4813. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:withanolides
    n1=en:contraindications aspect | n2=en:withanolides | rel=r_associated | relid=0 | w=20
  4814. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:wnt5a protein, human
    n1=en:contraindications aspect | n2=en:wnt5a protein, human | rel=r_associated | relid=0 | w=20
  4815. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:wrench
    n1=en:contraindications aspect | n2=en:wrench | rel=r_associated | relid=0 | w=20
  4816. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:X ray therapy
    n1=en:contraindications aspect | n2=en:X ray therapy | rel=r_associated | relid=0 | w=20
  4817. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:x-linked inhibitor of apoptosis protein
    n1=en:contraindications aspect | n2=en:x-linked inhibitor of apoptosis protein | rel=r_associated | relid=0 | w=20
  4818. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:x-ray therapy
    n1=en:contraindications aspect | n2=en:x-ray therapy | rel=r_associated | relid=0 | w=20
  4819. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:xanthones
    n1=en:contraindications aspect | n2=en:xanthones | rel=r_associated | relid=0 | w=20
  4820. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:xanthopterin
    n1=en:contraindications aspect | n2=en:xanthopterin | rel=r_associated | relid=0 | w=20
  4821. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:xenopus proteins
    n1=en:contraindications aspect | n2=en:xenopus proteins | rel=r_associated | relid=0 | w=20
  4822. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:xeromammography
    n1=en:contraindications aspect | n2=en:xeromammography | rel=r_associated | relid=0 | w=20
  4823. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:xylans
    n1=en:contraindications aspect | n2=en:xylans | rel=r_associated | relid=0 | w=20
  4824. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:xylulose
    n1=en:contraindications aspect | n2=en:xylulose | rel=r_associated | relid=0 | w=20
  4825. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:z-dna
    n1=en:contraindications aspect | n2=en:z-dna | rel=r_associated | relid=0 | w=20
  4826. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zeatin
    n1=en:contraindications aspect | n2=en:zeatin | rel=r_associated | relid=0 | w=20
  4827. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zein
    n1=en:contraindications aspect | n2=en:zein | rel=r_associated | relid=0 | w=20
  4828. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zeolites
    n1=en:contraindications aspect | n2=en:zeolites | rel=r_associated | relid=0 | w=20
  4829. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zeta-globins
    n1=en:contraindications aspect | n2=en:zeta-globins | rel=r_associated | relid=0 | w=20
  4830. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zidovudine
    n1=en:contraindications aspect | n2=en:zidovudine | rel=r_associated | relid=0 | w=20
  4831. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zinc acetate
    n1=en:contraindications aspect | n2=en:zinc acetate | rel=r_associated | relid=0 | w=20
  4832. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zinc isotopes
    n1=en:contraindications aspect | n2=en:zinc isotopes | rel=r_associated | relid=0 | w=20
  4833. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zinc oxide-eugenol cement
    n1=en:contraindications aspect | n2=en:zinc oxide-eugenol cement | rel=r_associated | relid=0 | w=20
  4834. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zinc sulfate
    n1=en:contraindications aspect | n2=en:zinc sulfate | rel=r_associated | relid=0 | w=20
  4835. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zinc sulphate
    n1=en:contraindications aspect | n2=en:zinc sulphate | rel=r_associated | relid=0 | w=20
  4836. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zona pellucida glycoproteins
    n1=en:contraindications aspect | n2=en:zona pellucida glycoproteins | rel=r_associated | relid=0 | w=20
  4837. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> en:zymosan
    n1=en:contraindications aspect | n2=en:zymosan | rel=r_associated | relid=0 | w=20
  4838. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> endonucléase de restriction
    n1=en:contraindications aspect | n2=endonucléase de restriction | rel=r_associated | relid=0 | w=20
  4839. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> endoscopie du duodénum
    n1=en:contraindications aspect | n2=endoscopie du duodénum | rel=r_associated | relid=0 | w=20
  4840. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> endoscopie du tractus digestif
    n1=en:contraindications aspect | n2=endoscopie du tractus digestif | rel=r_associated | relid=0 | w=20
  4841. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> endoscopie gastro-intestinale
    n1=en:contraindications aspect | n2=endoscopie gastro-intestinale | rel=r_associated | relid=0 | w=20
  4842. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> endoscopie gastrointestinale
    n1=en:contraindications aspect | n2=endoscopie gastrointestinale | rel=r_associated | relid=0 | w=20
  4843. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> endostatine
    n1=en:contraindications aspect | n2=endostatine | rel=r_associated | relid=0 | w=20
  4844. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> énoyl-coa hydratase
    n1=en:contraindications aspect | n2=énoyl-coa hydratase | rel=r_associated | relid=0 | w=20
  4845. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> énoyl-CoA hydratase
    n1=en:contraindications aspect | n2=énoyl-CoA hydratase | rel=r_associated | relid=0 | w=20
  4846. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éotaxine
    n1=en:contraindications aspect | n2=éotaxine | rel=r_associated | relid=0 | w=20
  4847. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> épiréguline
    n1=en:contraindications aspect | n2=épiréguline | rel=r_associated | relid=0 | w=20
  4848. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> épisome f
    n1=en:contraindications aspect | n2=épisome f | rel=r_associated | relid=0 | w=20
  4849. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> épisome F
    n1=en:contraindications aspect | n2=épisome F | rel=r_associated | relid=0 | w=20
  4850. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> épitope
    n1=en:contraindications aspect | n2=épitope | rel=r_associated | relid=0 | w=20
  4851. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éponge de gélatine résorbable
    n1=en:contraindications aspect | n2=éponge de gélatine résorbable | rel=r_associated | relid=0 | w=20
  4852. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> épuration extrarénale
    n1=en:contraindications aspect | n2=épuration extrarénale | rel=r_associated | relid=0 | w=20
  4853. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> épuration extrarénale (méthodes d')
    n1=en:contraindications aspect | n2=épuration extrarénale (méthodes d') | rel=r_associated | relid=0 | w=20
  4854. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> équipement dentaire
    n1=en:contraindications aspect | n2=équipement dentaire | rel=r_associated | relid=0 | w=20
  4855. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> équipement dentaire à grande vitesse
    n1=en:contraindications aspect | n2=équipement dentaire à grande vitesse | rel=r_associated | relid=0 | w=20
  4856. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> équipement dentaire pour grandes vitesses
    n1=en:contraindications aspect | n2=équipement dentaire pour grandes vitesses | rel=r_associated | relid=0 | w=20
  4857. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ergométrie
    n1=en:contraindications aspect | n2=ergométrie | rel=r_associated | relid=0 | w=20
  4858. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> érythropoïétine
    n1=en:contraindications aspect | n2=érythropoïétine | rel=r_associated | relid=0 | w=20
  4859. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ésoméprazole
    n1=en:contraindications aspect | n2=ésoméprazole | rel=r_associated | relid=0 | w=20
  4860. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éthanolamine phosphotransférase
    n1=en:contraindications aspect | n2=éthanolamine phosphotransférase | rel=r_associated | relid=0 | w=20
  4861. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éther de glycol
    n1=en:contraindications aspect | n2=éther de glycol | rel=r_associated | relid=0 | w=20
  4862. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éthosuximide
    n1=en:contraindications aspect | n2=éthosuximide | rel=r_associated | relid=0 | w=20
  4863. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Éthylène glycol
    n1=en:contraindications aspect | n2=Éthylène glycol | rel=r_associated | relid=0 | w=20
  4864. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éthylène glycol
    n1=en:contraindications aspect | n2=éthylène glycol | rel=r_associated | relid=0 | w=20
  4865. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éthylène-glycol
    n1=en:contraindications aspect | n2=éthylène-glycol | rel=r_associated | relid=0 | w=20
  4866. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éthylèneglycol
    n1=en:contraindications aspect | n2=éthylèneglycol | rel=r_associated | relid=0 | w=20
  4867. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Eto
    n1=en:contraindications aspect | n2=Eto | rel=r_associated | relid=0 | w=20
  4868. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> étude diagnostique radio-isotopique
    n1=en:contraindications aspect | n2=étude diagnostique radio-isotopique | rel=r_associated | relid=0 | w=20
  4869. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Éviscération de l'orbite
    n1=en:contraindications aspect | n2=Éviscération de l'orbite | rel=r_associated | relid=0 | w=20
  4870. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éviscération de l'orbite
    n1=en:contraindications aspect | n2=éviscération de l'orbite | rel=r_associated | relid=0 | w=20
  4871. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> éviscération orbitaire
    n1=en:contraindications aspect | n2=éviscération orbitaire | rel=r_associated | relid=0 | w=20
  4872. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> examen du fond d'oeil
    n1=en:contraindications aspect | n2=examen du fond d'oeil | rel=r_associated | relid=0 | w=20
  4873. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> examen du fond d'œil
    n1=en:contraindications aspect | n2=examen du fond d'œil | rel=r_associated | relid=0 | w=20
  4874. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> examen radio-isotopique
    n1=en:contraindications aspect | n2=examen radio-isotopique | rel=r_associated | relid=0 | w=20
  4875. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> examen radiologique de l'abdomen
    n1=en:contraindications aspect | n2=examen radiologique de l'abdomen | rel=r_associated | relid=0 | w=20
  4876. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> exentération de l'orbite
    n1=en:contraindications aspect | n2=exentération de l'orbite | rel=r_associated | relid=0 | w=20
  4877. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> exercice thérapeutique
    n1=en:contraindications aspect | n2=exercice thérapeutique | rel=r_associated | relid=0 | w=20
  4878. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> expansion nerveuse
    n1=en:contraindications aspect | n2=expansion nerveuse | rel=r_associated | relid=0 | w=20
  4879. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> extraits placentaires
    n1=en:contraindications aspect | n2=extraits placentaires | rel=r_associated | relid=0 | w=20
  4880. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ézétimibe
    n1=en:contraindications aspect | n2=ézétimibe | rel=r_associated | relid=0 | w=20
  4881. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur de croissance analogue à l'insuline
    n1=en:contraindications aspect | n2=facteur de croissance analogue à l'insuline | rel=r_associated | relid=0 | w=20
  4882. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur de croissance fibroblastique de type 9
    n1=en:contraindications aspect | n2=facteur de croissance fibroblastique de type 9 | rel=r_associated | relid=0 | w=20
  4883. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur de croissance placentaire (PlGF)
    n1=en:contraindications aspect | n2=facteur de croissance placentaire (PlGF) | rel=r_associated | relid=0 | w=20
  4884. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur de croissance transformant
    n1=en:contraindications aspect | n2=facteur de croissance transformant | rel=r_associated | relid=0 | w=20
  4885. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur de fertilité
    n1=en:contraindications aspect | n2=facteur de fertilité | rel=r_associated | relid=0 | w=20
  4886. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur de sexualité
    n1=en:contraindications aspect | n2=facteur de sexualité | rel=r_associated | relid=0 | w=20
  4887. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur de transfert
    n1=en:contraindications aspect | n2=facteur de transfert | rel=r_associated | relid=0 | w=20
  4888. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur de transfert de résistance
    n1=en:contraindications aspect | n2=facteur de transfert de résistance | rel=r_associated | relid=0 | w=20
  4889. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur F
    n1=en:contraindications aspect | n2=facteur F | rel=r_associated | relid=0 | w=20
  4890. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur f
    n1=en:contraindications aspect | n2=facteur f | rel=r_associated | relid=0 | w=20
  4891. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur sexuel
    n1=en:contraindications aspect | n2=facteur sexuel | rel=r_associated | relid=0 | w=20
  4892. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteur sexuel bactérien
    n1=en:contraindications aspect | n2=facteur sexuel bactérien | rel=r_associated | relid=0 | w=20
  4893. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteurs biologiques
    n1=en:contraindications aspect | n2=facteurs biologiques | rel=r_associated | relid=0 | w=20
  4894. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> facteurs de complexes ternaires
    n1=en:contraindications aspect | n2=facteurs de complexes ternaires | rel=r_associated | relid=0 | w=20
  4895. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> faire connaissance
    n1=en:contraindications aspect | n2=faire connaissance | rel=r_associated | relid=0 | w=20
  4896. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> faire connaissance avec
    n1=en:contraindications aspect | n2=faire connaissance avec | rel=r_associated | relid=0 | w=20
  4897. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> faire connaissance avec [qqn]
    n1=en:contraindications aspect | n2=faire connaissance avec [qqn] | rel=r_associated | relid=0 | w=20
  4898. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> faire connaissance avec quelqu'un
    n1=en:contraindications aspect | n2=faire connaissance avec quelqu'un | rel=r_associated | relid=0 | w=20
  4899. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> faire connaissance de
    n1=en:contraindications aspect | n2=faire connaissance de | rel=r_associated | relid=0 | w=20
  4900. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> faire connaissance de [qqn]
    n1=en:contraindications aspect | n2=faire connaissance de [qqn] | rel=r_associated | relid=0 | w=20
  4901. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> faire connaissance de quelqu'un
    n1=en:contraindications aspect | n2=faire connaissance de quelqu'un | rel=r_associated | relid=0 | w=20
  4902. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> faire pendant
    n1=en:contraindications aspect | n2=faire pendant | rel=r_associated | relid=0 | w=20
  4903. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> faire pendant à
    n1=en:contraindications aspect | n2=faire pendant à | rel=r_associated | relid=0 | w=20
  4904. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fausse dent
    n1=en:contraindications aspect | n2=fausse dent | rel=r_associated | relid=0 | w=20
  4905. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Fécondation in vitro
    n1=en:contraindications aspect | n2=Fécondation in vitro | rel=r_associated | relid=0 | w=20
  4906. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fécondation in vitro
    n1=en:contraindications aspect | n2=fécondation in vitro | rel=r_associated | relid=0 | w=20
  4907. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fenamates
    n1=en:contraindications aspect | n2=fenamates | rel=r_associated | relid=0 | w=20
  4908. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fenbendazole
    n1=en:contraindications aspect | n2=fenbendazole | rel=r_associated | relid=0 | w=20
  4909. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fénitrothion
    n1=en:contraindications aspect | n2=fénitrothion | rel=r_associated | relid=0 | w=20
  4910. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fermeture de l'espace orthodontique
    n1=en:contraindications aspect | n2=fermeture de l'espace orthodontique | rel=r_associated | relid=0 | w=20
  4911. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fermeture des espaces orthodontiques
    n1=en:contraindications aspect | n2=fermeture des espaces orthodontiques | rel=r_associated | relid=0 | w=20
  4912. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fermeture espace orthodontique
    n1=en:contraindications aspect | n2=fermeture espace orthodontique | rel=r_associated | relid=0 | w=20
  4913. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fermeture orthodontique d'espace
    n1=en:contraindications aspect | n2=fermeture orthodontique d'espace | rel=r_associated | relid=0 | w=20
  4914. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fermetures de l'espace orthodontique
    n1=en:contraindications aspect | n2=fermetures de l'espace orthodontique | rel=r_associated | relid=0 | w=20
  4915. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> filgrastim
    n1=en:contraindications aspect | n2=filgrastim | rel=r_associated | relid=0 | w=20
  4916. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fils orthodontiques
    n1=en:contraindications aspect | n2=fils orthodontiques | rel=r_associated | relid=0 | w=20
  4917. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> finastéride
    n1=en:contraindications aspect | n2=finastéride | rel=r_associated | relid=0 | w=20
  4918. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fixateurs internes
    n1=en:contraindications aspect | n2=fixateurs internes | rel=r_associated | relid=0 | w=20
  4919. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fixative
    n1=en:contraindications aspect | n2=fixative | rel=r_associated | relid=0 | w=20
  4920. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> flucytosine
    n1=en:contraindications aspect | n2=flucytosine | rel=r_associated | relid=0 | w=20
  4921. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fluoro-5 cytosine
    n1=en:contraindications aspect | n2=fluoro-5 cytosine | rel=r_associated | relid=0 | w=20
  4922. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fluoro-uracile
    n1=en:contraindications aspect | n2=fluoro-uracile | rel=r_associated | relid=0 | w=20
  4923. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fluoroscopie
    n1=en:contraindications aspect | n2=fluoroscopie | rel=r_associated | relid=0 | w=20
  4924. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fluoruration de l'eau
    n1=en:contraindications aspect | n2=fluoruration de l'eau | rel=r_associated | relid=0 | w=20
  4925. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> foetoprotéine
    n1=en:contraindications aspect | n2=foetoprotéine | rel=r_associated | relid=0 | w=20
  4926. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> foetoprotéines
    n1=en:contraindications aspect | n2=foetoprotéines | rel=r_associated | relid=0 | w=20
  4927. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> follitropine
    n1=en:contraindications aspect | n2=follitropine | rel=r_associated | relid=0 | w=20
  4928. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> formaldéhyde
    n1=en:contraindications aspect | n2=formaldéhyde | rel=r_associated | relid=0 | w=20
  4929. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> formamides
    n1=en:contraindications aspect | n2=formamides | rel=r_associated | relid=0 | w=20
  4930. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> formol
    n1=en:contraindications aspect | n2=formol | rel=r_associated | relid=0 | w=20
  4931. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fractionnement des faisceaux rachidiens
    n1=en:contraindications aspect | n2=fractionnement des faisceaux rachidiens | rel=r_associated | relid=0 | w=20
  4932. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fragments des immunoglobulines
    n1=en:contraindications aspect | n2=fragments des immunoglobulines | rel=r_associated | relid=0 | w=20
  4933. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fructose phosphates
    n1=en:contraindications aspect | n2=fructose phosphates | rel=r_associated | relid=0 | w=20
  4934. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fructoses diphosphates
    n1=en:contraindications aspect | n2=fructoses diphosphates | rel=r_associated | relid=0 | w=20
  4935. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fucosidase
    n1=en:contraindications aspect | n2=fucosidase | rel=r_associated | relid=0 | w=20
  4936. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> fundoplication
    n1=en:contraindications aspect | n2=fundoplication | rel=r_associated | relid=0 | w=20
  4937. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gaïac
    n1=en:contraindications aspect | n2=gaïac | rel=r_associated | relid=0 | w=20
  4938. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> galactagogues
    n1=en:contraindications aspect | n2=galactagogues | rel=r_associated | relid=0 | w=20
  4939. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> galactolipides
    n1=en:contraindications aspect | n2=galactolipides | rel=r_associated | relid=0 | w=20
  4940. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> galactose phosphates
    n1=en:contraindications aspect | n2=galactose phosphates | rel=r_associated | relid=0 | w=20
  4941. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gastroscope
    n1=en:contraindications aspect | n2=gastroscope | rel=r_associated | relid=0 | w=20
  4942. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gastroscopie
    n1=en:contraindications aspect | n2=gastroscopie | rel=r_associated | relid=0 | w=20
  4943. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gaz sarin
    n1=en:contraindications aspect | n2=gaz sarin | rel=r_associated | relid=0 | w=20
  4944. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gels au silicone
    n1=en:contraindications aspect | n2=gels au silicone | rel=r_associated | relid=0 | w=20
  4945. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gels de silicone
    n1=en:contraindications aspect | n2=gels de silicone | rel=r_associated | relid=0 | w=20
  4946. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gels silicone
    n1=en:contraindications aspect | n2=gels silicone | rel=r_associated | relid=0 | w=20
  4947. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> génistéine
    n1=en:contraindications aspect | n2=génistéine | rel=r_associated | relid=0 | w=20
  4948. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> géranylgéranyl-diphosphate géranylgéranyltransférase
    n1=en:contraindications aspect | n2=géranylgéranyl-diphosphate géranylgéranyltransférase | rel=r_associated | relid=0 | w=20
  4949. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gingivectomie
    n1=en:contraindications aspect | n2=gingivectomie | rel=r_associated | relid=0 | w=20
  4950. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glicentine
    n1=en:contraindications aspect | n2=glicentine | rel=r_associated | relid=0 | w=20
  4951. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glucide
    n1=en:contraindications aspect | n2=glucide | rel=r_associated | relid=0 | w=20
  4952. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Gluck (technique de)
    n1=en:contraindications aspect | n2=Gluck (technique de) | rel=r_associated | relid=0 | w=20
  4953. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glucocorticoïde
    n1=en:contraindications aspect | n2=glucocorticoïde | rel=r_associated | relid=0 | w=20
  4954. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glucocorticostéroïde
    n1=en:contraindications aspect | n2=glucocorticostéroïde | rel=r_associated | relid=0 | w=20
  4955. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glucosamine
    n1=en:contraindications aspect | n2=glucosamine | rel=r_associated | relid=0 | w=20
  4956. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glucose oxidase
    n1=en:contraindications aspect | n2=glucose oxidase | rel=r_associated | relid=0 | w=20
  4957. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glucosinolate
    n1=en:contraindications aspect | n2=glucosinolate | rel=r_associated | relid=0 | w=20
  4958. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glutamate de sodium
    n1=en:contraindications aspect | n2=glutamate de sodium | rel=r_associated | relid=0 | w=20
  4959. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glutamate décarboxylase
    n1=en:contraindications aspect | n2=glutamate décarboxylase | rel=r_associated | relid=0 | w=20
  4960. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glutamate formimino-transférase
    n1=en:contraindications aspect | n2=glutamate formimino-transférase | rel=r_associated | relid=0 | w=20
  4961. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glutamate formiminotransférase
    n1=en:contraindications aspect | n2=glutamate formiminotransférase | rel=r_associated | relid=0 | w=20
  4962. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glutamate formyltransférase
    n1=en:contraindications aspect | n2=glutamate formyltransférase | rel=r_associated | relid=0 | w=20
  4963. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glutamate monosodique
    n1=en:contraindications aspect | n2=glutamate monosodique | rel=r_associated | relid=0 | w=20
  4964. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Glutamate monosodique
    n1=en:contraindications aspect | n2=Glutamate monosodique | rel=r_associated | relid=0 | w=20
  4965. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glutamyl aminopeptidase
    n1=en:contraindications aspect | n2=glutamyl aminopeptidase | rel=r_associated | relid=0 | w=20
  4966. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glutathion
    n1=en:contraindications aspect | n2=glutathion | rel=r_associated | relid=0 | w=20
  4967. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glutens
    n1=en:contraindications aspect | n2=glutens | rel=r_associated | relid=0 | w=20
  4968. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Glycéraldéhyde
    n1=en:contraindications aspect | n2=Glycéraldéhyde | rel=r_associated | relid=0 | w=20
  4969. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glycéraldéhyde
    n1=en:contraindications aspect | n2=glycéraldéhyde | rel=r_associated | relid=0 | w=20
  4970. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glycogène-phosphorylase
    n1=en:contraindications aspect | n2=glycogène-phosphorylase | rel=r_associated | relid=0 | w=20
  4971. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glycol éthylique
    n1=en:contraindications aspect | n2=glycol éthylique | rel=r_associated | relid=0 | w=20
  4972. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glycol polyéthylénique
    n1=en:contraindications aspect | n2=glycol polyéthylénique | rel=r_associated | relid=0 | w=20
  4973. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glycophorine
    n1=en:contraindications aspect | n2=glycophorine | rel=r_associated | relid=0 | w=20
  4974. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glycosaminoglycane (ou glycosaminoglycanne)
    n1=en:contraindications aspect | n2=glycosaminoglycane (ou glycosaminoglycanne) | rel=r_associated | relid=0 | w=20
  4975. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> glyoxal
    n1=en:contraindications aspect | n2=glyoxal | rel=r_associated | relid=0 | w=20
  4976. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> GMS
    n1=en:contraindications aspect | n2=GMS | rel=r_associated | relid=0 | w=20
  4977. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> GMS
    (glutamate monosodique)
    n1=en:contraindications aspect | n2=GMS
    (glutamate monosodique)
    | rel=r_associated | relid=0 | w=20
  4978. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Gompertz (équation de)
    n1=en:contraindications aspect | n2=Gompertz (équation de) | rel=r_associated | relid=0 | w=20
  4979. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gonadostimuline
    n1=en:contraindications aspect | n2=gonadostimuline | rel=r_associated | relid=0 | w=20
  4980. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gonadotrophine
    n1=en:contraindications aspect | n2=gonadotrophine | rel=r_associated | relid=0 | w=20
  4981. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gonadotrophine ménopausique humaine
    n1=en:contraindications aspect | n2=gonadotrophine ménopausique humaine | rel=r_associated | relid=0 | w=20
  4982. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gonadotropine
    n1=en:contraindications aspect | n2=gonadotropine | rel=r_associated | relid=0 | w=20
  4983. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> goséréline
    n1=en:contraindications aspect | n2=goséréline | rel=r_associated | relid=0 | w=20
  4984. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> graisse alimentaire
    n1=en:contraindications aspect | n2=graisse alimentaire | rel=r_associated | relid=0 | w=20
  4985. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Graisse alimentaire
    n1=en:contraindications aspect | n2=Graisse alimentaire | rel=r_associated | relid=0 | w=20
  4986. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> graisse de machines
    n1=en:contraindications aspect | n2=graisse de machines | rel=r_associated | relid=0 | w=20
  4987. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> granzyme
    n1=en:contraindications aspect | n2=granzyme | rel=r_associated | relid=0 | w=20
  4988. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> greffe cornéenne
    n1=en:contraindications aspect | n2=greffe cornéenne | rel=r_associated | relid=0 | w=20
  4989. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> greffe de cornée
    n1=en:contraindications aspect | n2=greffe de cornée | rel=r_associated | relid=0 | w=20
  4990. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> greffe de la cornée
    n1=en:contraindications aspect | n2=greffe de la cornée | rel=r_associated | relid=0 | w=20
  4991. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> greffe de pancréas
    n1=en:contraindications aspect | n2=greffe de pancréas | rel=r_associated | relid=0 | w=20
  4992. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> greffe osseuse
    n1=en:contraindications aspect | n2=greffe osseuse | rel=r_associated | relid=0 | w=20
  4993. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> groupe sanguin
    n1=en:contraindications aspect | n2=groupe sanguin | rel=r_associated | relid=0 | w=20
  4994. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> guanosine diphosphate fucose
    n1=en:contraindications aspect | n2=guanosine diphosphate fucose | rel=r_associated | relid=0 | w=20
  4995. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> guanosine pentaphosphate
    n1=en:contraindications aspect | n2=guanosine pentaphosphate | rel=r_associated | relid=0 | w=20
  4996. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> guanosine-diphosphate-fucose
    n1=en:contraindications aspect | n2=guanosine-diphosphate-fucose | rel=r_associated | relid=0 | w=20
  4997. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> guanylyl imidodiphosphate
    n1=en:contraindications aspect | n2=guanylyl imidodiphosphate | rel=r_associated | relid=0 | w=20
  4998. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> gymnastique médicale
    n1=en:contraindications aspect | n2=gymnastique médicale | rel=r_associated | relid=0 | w=20
  4999. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> halcinonide
    n1=en:contraindications aspect | n2=halcinonide | rel=r_associated | relid=0 | w=20
  5000. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> halothane
    n1=en:contraindications aspect | n2=halothane | rel=r_associated | relid=0 | w=20
  5001. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hbo2
    n1=en:contraindications aspect | n2=hbo2 | rel=r_associated | relid=0 | w=20
  5002. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> HCTZ
    n1=en:contraindications aspect | n2=HCTZ | rel=r_associated | relid=0 | w=20
  5003. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hélicase
    n1=en:contraindications aspect | n2=hélicase | rel=r_associated | relid=0 | w=20
  5004. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> héliothérapie
    n1=en:contraindications aspect | n2=héliothérapie | rel=r_associated | relid=0 | w=20
  5005. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Hélium
    n1=en:contraindications aspect | n2=Hélium | rel=r_associated | relid=0 | w=20
  5006. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hémagglutinine
    n1=en:contraindications aspect | n2=hémagglutinine | rel=r_associated | relid=0 | w=20
  5007. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hémoglobinomètrie
    n1=en:contraindications aspect | n2=hémoglobinomètrie | rel=r_associated | relid=0 | w=20
  5008. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hémoperfusion
    n1=en:contraindications aspect | n2=hémoperfusion | rel=r_associated | relid=0 | w=20
  5009. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> héparine de bas poids moléculaire
    n1=en:contraindications aspect | n2=héparine de bas poids moléculaire | rel=r_associated | relid=0 | w=20
  5010. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hépatosplénographie
    n1=en:contraindications aspect | n2=hépatosplénographie | rel=r_associated | relid=0 | w=20
  5011. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hepcidine
    n1=en:contraindications aspect | n2=hepcidine | rel=r_associated | relid=0 | w=20
  5012. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> heptanol
    n1=en:contraindications aspect | n2=heptanol | rel=r_associated | relid=0 | w=20
  5013. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hexétidine
    n1=en:contraindications aspect | n2=hexétidine | rel=r_associated | relid=0 | w=20
  5014. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hexylrésorcinol
    n1=en:contraindications aspect | n2=hexylrésorcinol | rel=r_associated | relid=0 | w=20
  5015. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> histidine décarboxylase
    n1=en:contraindications aspect | n2=histidine décarboxylase | rel=r_associated | relid=0 | w=20
  5016. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> histidine-décarboxylase
    n1=en:contraindications aspect | n2=histidine-décarboxylase | rel=r_associated | relid=0 | w=20
  5017. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> histidinol-phosphatase
    n1=en:contraindications aspect | n2=histidinol-phosphatase | rel=r_associated | relid=0 | w=20
  5018. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> HMGCoA
    n1=en:contraindications aspect | n2=HMGCoA | rel=r_associated | relid=0 | w=20
  5019. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hormone de libération de la somatotrophine
    n1=en:contraindications aspect | n2=hormone de libération de la somatotrophine | rel=r_associated | relid=0 | w=20
  5020. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hormone gonadotrope ménopausique humaine
    n1=en:contraindications aspect | n2=hormone gonadotrope ménopausique humaine | rel=r_associated | relid=0 | w=20
  5021. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hormone libératrice de l'hormone de croissance
    n1=en:contraindications aspect | n2=hormone libératrice de l'hormone de croissance | rel=r_associated | relid=0 | w=20
  5022. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hormone mélanostimulante
    n1=en:contraindications aspect | n2=hormone mélanostimulante | rel=r_associated | relid=0 | w=20
  5023. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hormone parathyroïdienne
    n1=en:contraindications aspect | n2=hormone parathyroïdienne | rel=r_associated | relid=0 | w=20
  5024. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> huile de croton
    n1=en:contraindications aspect | n2=huile de croton | rel=r_associated | relid=0 | w=20
  5025. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> huile végétale
    n1=en:contraindications aspect | n2=huile végétale | rel=r_associated | relid=0 | w=20
  5026. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Hyde (prurigo nodulaire de)
    n1=en:contraindications aspect | n2=Hyde (prurigo nodulaire de) | rel=r_associated | relid=0 | w=20
  5027. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydrate de carbone
    n1=en:contraindications aspect | n2=hydrate de carbone | rel=r_associated | relid=0 | w=20
  5028. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydrocarbon
    n1=en:contraindications aspect | n2=hydrocarbon | rel=r_associated | relid=0 | w=20
  5029. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydrocarbure
    n1=en:contraindications aspect | n2=hydrocarbure | rel=r_associated | relid=0 | w=20
  5030. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydrochlorothiazide
    n1=en:contraindications aspect | n2=hydrochlorothiazide | rel=r_associated | relid=0 | w=20
  5031. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydrocortisone
    n1=en:contraindications aspect | n2=hydrocortisone | rel=r_associated | relid=0 | w=20
  5032. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydrocortisones
    n1=en:contraindications aspect | n2=hydrocortisones | rel=r_associated | relid=0 | w=20
  5033. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydroperoxyde tert-butyl
    n1=en:contraindications aspect | n2=hydroperoxyde tert-butyl | rel=r_associated | relid=0 | w=20
  5034. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydroxyde de sodium
    n1=en:contraindications aspect | n2=hydroxyde de sodium | rel=r_associated | relid=0 | w=20
  5035. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydroxyméthylglutaryl-coa synthase
    n1=en:contraindications aspect | n2=hydroxyméthylglutaryl-coa synthase | rel=r_associated | relid=0 | w=20
  5036. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hydroxyméthylglutaryl-CoA synthase
    n1=en:contraindications aspect | n2=hydroxyméthylglutaryl-CoA synthase | rel=r_associated | relid=0 | w=20
  5037. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hypophysectomie chimique
    n1=en:contraindications aspect | n2=hypophysectomie chimique | rel=r_associated | relid=0 | w=20
  5038. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hypotension contrôlée
    n1=en:contraindications aspect | n2=hypotension contrôlée | rel=r_associated | relid=0 | w=20
  5039. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hypoxanthine
    n1=en:contraindications aspect | n2=hypoxanthine | rel=r_associated | relid=0 | w=20
  5040. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hystéroscopie
    n1=en:contraindications aspect | n2=hystéroscopie | rel=r_associated | relid=0 | w=20
  5041. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> hystérotomie
    n1=en:contraindications aspect | n2=hystérotomie | rel=r_associated | relid=0 | w=20
  5042. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> i kappa b
    n1=en:contraindications aspect | n2=i kappa b | rel=r_associated | relid=0 | w=20
  5043. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> IL-18
    n1=en:contraindications aspect | n2=IL-18 | rel=r_associated | relid=0 | w=20
  5044. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Il-18
    n1=en:contraindications aspect | n2=Il-18 | rel=r_associated | relid=0 | w=20
  5045. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> imagerie à résonance magnétique
    n1=en:contraindications aspect | n2=imagerie à résonance magnétique | rel=r_associated | relid=0 | w=20
  5046. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> imagerie de diagnostic
    n1=en:contraindications aspect | n2=imagerie de diagnostic | rel=r_associated | relid=0 | w=20
  5047. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> imagerie de diffusion en IRM
    n1=en:contraindications aspect | n2=imagerie de diffusion en IRM | rel=r_associated | relid=0 | w=20
  5048. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> imagerie de diffusion en irm
    n1=en:contraindications aspect | n2=imagerie de diffusion en irm | rel=r_associated | relid=0 | w=20
  5049. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> imagerie de diffusion par résonance magnétique
    n1=en:contraindications aspect | n2=imagerie de diffusion par résonance magnétique | rel=r_associated | relid=0 | w=20
  5050. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> imagerie diagnostique
    n1=en:contraindications aspect | n2=imagerie diagnostique | rel=r_associated | relid=0 | w=20
  5051. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> imagerie du corps entier
    n1=en:contraindications aspect | n2=imagerie du corps entier | rel=r_associated | relid=0 | w=20
  5052. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> imagerie par résonance magnétique de diffusion
    n1=en:contraindications aspect | n2=imagerie par résonance magnétique de diffusion | rel=r_associated | relid=0 | w=20
  5053. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> immunisation
    n1=en:contraindications aspect | n2=immunisation | rel=r_associated | relid=0 | w=20
  5054. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> immunisation passive
    n1=en:contraindications aspect | n2=immunisation passive | rel=r_associated | relid=0 | w=20
  5055. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> immuno-conglutinines
    n1=en:contraindications aspect | n2=immuno-conglutinines | rel=r_associated | relid=0 | w=20
  5056. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> immunoconglutinines
    n1=en:contraindications aspect | n2=immunoconglutinines | rel=r_associated | relid=0 | w=20
  5057. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> immunoglobuline
    n1=en:contraindications aspect | n2=immunoglobuline | rel=r_associated | relid=0 | w=20
  5058. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> immunoprécipitation
    n1=en:contraindications aspect | n2=immunoprécipitation | rel=r_associated | relid=0 | w=20
  5059. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> immunotoxine
    n1=en:contraindications aspect | n2=immunotoxine | rel=r_associated | relid=0 | w=20
  5060. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> implant mammaire
    n1=en:contraindications aspect | n2=implant mammaire | rel=r_associated | relid=0 | w=20
  5061. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> implantation de prothèse cochléaire
    n1=en:contraindications aspect | n2=implantation de prothèse cochléaire | rel=r_associated | relid=0 | w=20
  5062. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> implants dentaires unitaires
    n1=en:contraindications aspect | n2=implants dentaires unitaires | rel=r_associated | relid=0 | w=20
  5063. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> implants mammaires
    n1=en:contraindications aspect | n2=implants mammaires | rel=r_associated | relid=0 | w=20
  5064. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> indican
    n1=en:contraindications aspect | n2=indican | rel=r_associated | relid=0 | w=20
  5065. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> indigotindisulfonate sodium
    n1=en:contraindications aspect | n2=indigotindisulfonate sodium | rel=r_associated | relid=0 | w=20
  5066. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> indométhacine
    n1=en:contraindications aspect | n2=indométhacine | rel=r_associated | relid=0 | w=20
  5067. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> indoxyle-sulfate de potassium
    n1=en:contraindications aspect | n2=indoxyle-sulfate de potassium | rel=r_associated | relid=0 | w=20
  5068. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inhibiteur d'enzymes
    n1=en:contraindications aspect | n2=inhibiteur d'enzymes | rel=r_associated | relid=0 | w=20
  5069. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inhibiteur de l'aromatase
    n1=en:contraindications aspect | n2=inhibiteur de l'aromatase | rel=r_associated | relid=0 | w=20
  5070. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inhibiteur des canaux calciques
    n1=en:contraindications aspect | n2=inhibiteur des canaux calciques | rel=r_associated | relid=0 | w=20
  5071. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Inhibiteur enzymatique
    n1=en:contraindications aspect | n2=Inhibiteur enzymatique | rel=r_associated | relid=0 | w=20
  5072. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inhibiteur enzymatique
    n1=en:contraindications aspect | n2=inhibiteur enzymatique | rel=r_associated | relid=0 | w=20
  5073. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inhibiteurs de l'aromatase
    n1=en:contraindications aspect | n2=inhibiteurs de l'aromatase | rel=r_associated | relid=0 | w=20
  5074. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inoculation
    n1=en:contraindications aspect | n2=inoculation | rel=r_associated | relid=0 | w=20
  5075. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inosine
    n1=en:contraindications aspect | n2=inosine | rel=r_associated | relid=0 | w=20
  5076. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inosine diphosphate
    n1=en:contraindications aspect | n2=inosine diphosphate | rel=r_associated | relid=0 | w=20
  5077. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inosine triphosphate
    n1=en:contraindications aspect | n2=inosine triphosphate | rel=r_associated | relid=0 | w=20
  5078. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inositol
    n1=en:contraindications aspect | n2=inositol | rel=r_associated | relid=0 | w=20
  5079. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inositol phosphates
    n1=en:contraindications aspect | n2=inositol phosphates | rel=r_associated | relid=0 | w=20
  5080. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> insecticides
    n1=en:contraindications aspect | n2=insecticides | rel=r_associated | relid=0 | w=20
  5081. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> insertion de cathéter
    n1=en:contraindications aspect | n2=insertion de cathéter | rel=r_associated | relid=0 | w=20
  5082. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> insuline glargine
    n1=en:contraindications aspect | n2=insuline glargine | rel=r_associated | relid=0 | w=20
  5083. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> insuline normale
    n1=en:contraindications aspect | n2=insuline normale | rel=r_associated | relid=0 | w=20
  5084. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> insuline ordinaire
    n1=en:contraindications aspect | n2=insuline ordinaire | rel=r_associated | relid=0 | w=20
  5085. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> intention de traitement (analyse en)
    n1=en:contraindications aspect | n2=intention de traitement (analyse en) | rel=r_associated | relid=0 | w=20
  5086. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> interférométrie
    n1=en:contraindications aspect | n2=interférométrie | rel=r_associated | relid=0 | w=20
  5087. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> interferometry
    n1=en:contraindications aspect | n2=interferometry | rel=r_associated | relid=0 | w=20
  5088. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> interféron (traitement par l')
    n1=en:contraindications aspect | n2=interféron (traitement par l') | rel=r_associated | relid=0 | w=20
  5089. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> interleukine 15
    n1=en:contraindications aspect | n2=interleukine 15 | rel=r_associated | relid=0 | w=20
  5090. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> interleukine 18
    n1=en:contraindications aspect | n2=interleukine 18 | rel=r_associated | relid=0 | w=20
  5091. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> interleukine 2
    n1=en:contraindications aspect | n2=interleukine 2 | rel=r_associated | relid=0 | w=20
  5092. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> interleukine 4
    n1=en:contraindications aspect | n2=interleukine 4 | rel=r_associated | relid=0 | w=20
  5093. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> interleukine-18
    n1=en:contraindications aspect | n2=interleukine-18 | rel=r_associated | relid=0 | w=20
  5094. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> intervention chirurgicale
    n1=en:contraindications aspect | n2=intervention chirurgicale | rel=r_associated | relid=0 | w=20
  5095. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> intervention chirurgicale à froid
    n1=en:contraindications aspect | n2=intervention chirurgicale à froid | rel=r_associated | relid=0 | w=20
  5096. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> intervention chirurgicale répétée
    n1=en:contraindications aspect | n2=intervention chirurgicale répétée | rel=r_associated | relid=0 | w=20
  5097. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> intervention thérapeutique
    n1=en:contraindications aspect | n2=intervention thérapeutique | rel=r_associated | relid=0 | w=20
  5098. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> intubation trachéale
    n1=en:contraindications aspect | n2=intubation trachéale | rel=r_associated | relid=0 | w=20
  5099. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> inuline
    n1=en:contraindications aspect | n2=inuline | rel=r_associated | relid=0 | w=20
  5100. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> iodates
    n1=en:contraindications aspect | n2=iodates | rel=r_associated | relid=0 | w=20
  5101. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> iodides
    n1=en:contraindications aspect | n2=iodides | rel=r_associated | relid=0 | w=20
  5102. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> iodine
    n1=en:contraindications aspect | n2=iodine | rel=r_associated | relid=0 | w=20
  5103. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> iodoquinol
    n1=en:contraindications aspect | n2=iodoquinol | rel=r_associated | relid=0 | w=20
  5104. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> iodure de potassium
    n1=en:contraindications aspect | n2=iodure de potassium | rel=r_associated | relid=0 | w=20
  5105. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Iodure de potassium
    n1=en:contraindications aspect | n2=Iodure de potassium | rel=r_associated | relid=0 | w=20
  5106. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> iofétamine
    n1=en:contraindications aspect | n2=iofétamine | rel=r_associated | relid=0 | w=20
  5107. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ionomycine
    n1=en:contraindications aspect | n2=ionomycine | rel=r_associated | relid=0 | w=20
  5108. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> IRM de diffusion
    n1=en:contraindications aspect | n2=IRM de diffusion | rel=r_associated | relid=0 | w=20
  5109. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> irrigation nasale
    n1=en:contraindications aspect | n2=irrigation nasale | rel=r_associated | relid=0 | w=20
  5110. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> isodesmosine
    n1=en:contraindications aspect | n2=isodesmosine | rel=r_associated | relid=0 | w=20
  5111. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> isoflurane
    n1=en:contraindications aspect | n2=isoflurane | rel=r_associated | relid=0 | w=20
  5112. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> isoindoles
    n1=en:contraindications aspect | n2=isoindoles | rel=r_associated | relid=0 | w=20
  5113. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> isomaltose
    n1=en:contraindications aspect | n2=isomaltose | rel=r_associated | relid=0 | w=20
  5114. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> isoniazide
    n1=en:contraindications aspect | n2=isoniazide | rel=r_associated | relid=0 | w=20
  5115. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> isotrétinoïne
    n1=en:contraindications aspect | n2=isotrétinoïne | rel=r_associated | relid=0 | w=20
  5116. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> isozyme
    n1=en:contraindications aspect | n2=isozyme | rel=r_associated | relid=0 | w=20
  5117. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> janus kinase 3
    n1=en:contraindications aspect | n2=janus kinase 3 | rel=r_associated | relid=0 | w=20
  5118. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> KCl
    n1=en:contraindications aspect | n2=KCl | rel=r_associated | relid=0 | w=20
  5119. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> kératoplastie
    n1=en:contraindications aspect | n2=kératoplastie | rel=r_associated | relid=0 | w=20
  5120. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> kinétine
    n1=en:contraindications aspect | n2=kinétine | rel=r_associated | relid=0 | w=20
  5121. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> kystostomie
    n1=en:contraindications aspect | n2=kystostomie | rel=r_associated | relid=0 | w=20
  5122. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> kystotomie
    n1=en:contraindications aspect | n2=kystotomie | rel=r_associated | relid=0 | w=20
  5123. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> L-dopa
    n1=en:contraindications aspect | n2=L-dopa | rel=r_associated | relid=0 | w=20
  5124. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lactase
    n1=en:contraindications aspect | n2=lactase | rel=r_associated | relid=0 | w=20
  5125. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lactotransferrine
    n1=en:contraindications aspect | n2=lactotransferrine | rel=r_associated | relid=0 | w=20
  5126. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> laminectomie
    n1=en:contraindications aspect | n2=laminectomie | rel=r_associated | relid=0 | w=20
  5127. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lamivudine
    n1=en:contraindications aspect | n2=lamivudine | rel=r_associated | relid=0 | w=20
  5128. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> langage de programmation
    n1=en:contraindications aspect | n2=langage de programmation | rel=r_associated | relid=0 | w=20
  5129. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Langage informatique
    n1=en:contraindications aspect | n2=Langage informatique | rel=r_associated | relid=0 | w=20
  5130. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> langage informatique
    n1=en:contraindications aspect | n2=langage informatique | rel=r_associated | relid=0 | w=20
  5131. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> laparoscope
    n1=en:contraindications aspect | n2=laparoscope | rel=r_associated | relid=0 | w=20
  5132. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> laryngoscopie
    n1=en:contraindications aspect | n2=laryngoscopie | rel=r_associated | relid=0 | w=20
  5133. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lavage du nez
    n1=en:contraindications aspect | n2=lavage du nez | rel=r_associated | relid=0 | w=20
  5134. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lavage nasal
    n1=en:contraindications aspect | n2=lavage nasal | rel=r_associated | relid=0 | w=20
  5135. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> laxatif
    n1=en:contraindications aspect | n2=laxatif | rel=r_associated | relid=0 | w=20
  5136. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> laxative
    n1=en:contraindications aspect | n2=laxative | rel=r_associated | relid=0 | w=20
  5137. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Lentilles de contact
    n1=en:contraindications aspect | n2=Lentilles de contact | rel=r_associated | relid=0 | w=20
  5138. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lentilles de contact
    n1=en:contraindications aspect | n2=lentilles de contact | rel=r_associated | relid=0 | w=20
  5139. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> leptine
    n1=en:contraindications aspect | n2=leptine | rel=r_associated | relid=0 | w=20
  5140. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lettre française
    n1=en:contraindications aspect | n2=lettre française | rel=r_associated | relid=0 | w=20
  5141. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> leucine transaminase
    n1=en:contraindications aspect | n2=leucine transaminase | rel=r_associated | relid=0 | w=20
  5142. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Levine-Critchley (syndrome de)
    n1=en:contraindications aspect | n2=Levine-Critchley (syndrome de) | rel=r_associated | relid=0 | w=20
  5143. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lévodopa
    n1=en:contraindications aspect | n2=lévodopa | rel=r_associated | relid=0 | w=20
  5144. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lévofloxacine
    n1=en:contraindications aspect | n2=lévofloxacine | rel=r_associated | relid=0 | w=20
  5145. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lévomépromazine
    n1=en:contraindications aspect | n2=lévomépromazine | rel=r_associated | relid=0 | w=20
  5146. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lier connaissance avec
    n1=en:contraindications aspect | n2=lier connaissance avec | rel=r_associated | relid=0 | w=20
  5147. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lier connaissance avec [qqn]
    n1=en:contraindications aspect | n2=lier connaissance avec [qqn] | rel=r_associated | relid=0 | w=20
  5148. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lier connaissance avec quelqu'un
    n1=en:contraindications aspect | n2=lier connaissance avec quelqu'un | rel=r_associated | relid=0 | w=20
  5149. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lim kinases
    n1=en:contraindications aspect | n2=lim kinases | rel=r_associated | relid=0 | w=20
  5150. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> linuron
    n1=en:contraindications aspect | n2=linuron | rel=r_associated | relid=0 | w=20
  5151. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipase
    n1=en:contraindications aspect | n2=lipase | rel=r_associated | relid=0 | w=20
  5152. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipectomie
    n1=en:contraindications aspect | n2=lipectomie | rel=r_associated | relid=0 | w=20
  5153. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipide alimentaire
    n1=en:contraindications aspect | n2=lipide alimentaire | rel=r_associated | relid=0 | w=20
  5154. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipofuscine
    n1=en:contraindications aspect | n2=lipofuscine | rel=r_associated | relid=0 | w=20
  5155. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipoprotein
    n1=en:contraindications aspect | n2=lipoprotein | rel=r_associated | relid=0 | w=20
  5156. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipoprotein lipase
    n1=en:contraindications aspect | n2=lipoprotein lipase | rel=r_associated | relid=0 | w=20
  5157. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipoprotéine de basse densité
    n1=en:contraindications aspect | n2=lipoprotéine de basse densité | rel=r_associated | relid=0 | w=20
  5158. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipoprotéine de haut poids moléculaire
    n1=en:contraindications aspect | n2=lipoprotéine de haut poids moléculaire | rel=r_associated | relid=0 | w=20
  5159. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipoprotéine de haute densité
    n1=en:contraindications aspect | n2=lipoprotéine de haute densité | rel=r_associated | relid=0 | w=20
  5160. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lipoprotéine-lipase
    n1=en:contraindications aspect | n2=lipoprotéine-lipase | rel=r_associated | relid=0 | w=20
  5161. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> liposome
    n1=en:contraindications aspect | n2=liposome | rel=r_associated | relid=0 | w=20
  5162. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> liposuccion
    n1=en:contraindications aspect | n2=liposuccion | rel=r_associated | relid=0 | w=20
  5163. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> liraglutide
    n1=en:contraindications aspect | n2=liraglutide | rel=r_associated | relid=0 | w=20
  5164. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lisinopril
    n1=en:contraindications aspect | n2=lisinopril | rel=r_associated | relid=0 | w=20
  5165. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lovastatine
    n1=en:contraindications aspect | n2=lovastatine | rel=r_associated | relid=0 | w=20
  5166. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lunettes de vue
    n1=en:contraindications aspect | n2=lunettes de vue | rel=r_associated | relid=0 | w=20
  5167. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lyases intramoléculaires
    n1=en:contraindications aspect | n2=lyases intramoléculaires | rel=r_associated | relid=0 | w=20
  5168. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lymécycline
    n1=en:contraindications aspect | n2=lymécycline | rel=r_associated | relid=0 | w=20
  5169. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lymphangiographie
    n1=en:contraindications aspect | n2=lymphangiographie | rel=r_associated | relid=0 | w=20
  5170. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lynestrénol
    n1=en:contraindications aspect | n2=lynestrénol | rel=r_associated | relid=0 | w=20
  5171. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> lysinoalanine
    n1=en:contraindications aspect | n2=lysinoalanine | rel=r_associated | relid=0 | w=20
  5172. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> magnétocardiographie
    n1=en:contraindications aspect | n2=magnétocardiographie | rel=r_associated | relid=0 | w=20
  5173. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> maintien prothétique
    n1=en:contraindications aspect | n2=maintien prothétique | rel=r_associated | relid=0 | w=20
  5174. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mal parler à
    n1=en:contraindications aspect | n2=mal parler à | rel=r_associated | relid=0 | w=20
  5175. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mammectomie souscutanée
    n1=en:contraindications aspect | n2=mammectomie souscutanée | rel=r_associated | relid=0 | w=20
  5176. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mammographie
    n1=en:contraindications aspect | n2=mammographie | rel=r_associated | relid=0 | w=20
  5177. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mammoplastie
    n1=en:contraindications aspect | n2=mammoplastie | rel=r_associated | relid=0 | w=20
  5178. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> manipulation chiropractique
    n1=en:contraindications aspect | n2=manipulation chiropractique | rel=r_associated | relid=0 | w=20
  5179. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mannomustine
    n1=en:contraindications aspect | n2=mannomustine | rel=r_associated | relid=0 | w=20
  5180. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mannose-6-phosphate isomérase
    n1=en:contraindications aspect | n2=mannose-6-phosphate isomérase | rel=r_associated | relid=0 | w=20
  5181. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> manométrie
    n1=en:contraindications aspect | n2=manométrie | rel=r_associated | relid=0 | w=20
  5182. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> map kinase kinase 5
    n1=en:contraindications aspect | n2=map kinase kinase 5 | rel=r_associated | relid=0 | w=20
  5183. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> map kinase kinase 7
    n1=en:contraindications aspect | n2=map kinase kinase 7 | rel=r_associated | relid=0 | w=20
  5184. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> map kinase kinase kinase 1
    n1=en:contraindications aspect | n2=map kinase kinase kinase 1 | rel=r_associated | relid=0 | w=20
  5185. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> masques laryngés
    n1=en:contraindications aspect | n2=masques laryngés | rel=r_associated | relid=0 | w=20
  5186. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mastectomie élargie
    n1=en:contraindications aspect | n2=mastectomie élargie | rel=r_associated | relid=0 | w=20
  5187. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mastectomie glandulaire
    n1=en:contraindications aspect | n2=mastectomie glandulaire | rel=r_associated | relid=0 | w=20
  5188. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mastectomie sous-cutanée
    n1=en:contraindications aspect | n2=mastectomie sous-cutanée | rel=r_associated | relid=0 | w=20
  5189. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mastectomie totale
    n1=en:contraindications aspect | n2=mastectomie totale | rel=r_associated | relid=0 | w=20
  5190. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mastographie
    n1=en:contraindications aspect | n2=mastographie | rel=r_associated | relid=0 | w=20
  5191. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> matériel contraceptif
    n1=en:contraindications aspect | n2=matériel contraceptif | rel=r_associated | relid=0 | w=20
  5192. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> matériel dentaire
    n1=en:contraindications aspect | n2=matériel dentaire | rel=r_associated | relid=0 | w=20
  5193. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> matériel dentaire à haute vitesse
    n1=en:contraindications aspect | n2=matériel dentaire à haute vitesse | rel=r_associated | relid=0 | w=20
  5194. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> matière grasse alimentaire
    n1=en:contraindications aspect | n2=matière grasse alimentaire | rel=r_associated | relid=0 | w=20
  5195. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Matière grasse alimentaire
    n1=en:contraindications aspect | n2=Matière grasse alimentaire | rel=r_associated | relid=0 | w=20
  5196. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> matière particulaire
    n1=en:contraindications aspect | n2=matière particulaire | rel=r_associated | relid=0 | w=20
  5197. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> matières dangereuses
    n1=en:contraindications aspect | n2=matières dangereuses | rel=r_associated | relid=0 | w=20
  5198. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> matrix metalloproteinase
    n1=en:contraindications aspect | n2=matrix metalloproteinase | rel=r_associated | relid=0 | w=20
  5199. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> médicament anticoagulant
    n1=en:contraindications aspect | n2=médicament anticoagulant | rel=r_associated | relid=0 | w=20
  5200. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> médicament antidiarrhéique
    n1=en:contraindications aspect | n2=médicament antidiarrhéique | rel=r_associated | relid=0 | w=20
  5201. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> médicament laxatif
    n1=en:contraindications aspect | n2=médicament laxatif | rel=r_associated | relid=0 | w=20
  5202. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> médicaments animaux
    n1=en:contraindications aspect | n2=médicaments animaux | rel=r_associated | relid=0 | w=20
  5203. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> médicaments vétérinaires
    n1=en:contraindications aspect | n2=médicaments vétérinaires | rel=r_associated | relid=0 | w=20
  5204. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> méglutol
    n1=en:contraindications aspect | n2=méglutol | rel=r_associated | relid=0 | w=20
  5205. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mélanostimuline
    n1=en:contraindications aspect | n2=mélanostimuline | rel=r_associated | relid=0 | w=20
  5206. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ménadione
    n1=en:contraindications aspect | n2=ménadione | rel=r_associated | relid=0 | w=20
  5207. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mescaline
    n1=en:contraindications aspect | n2=mescaline | rel=r_associated | relid=0 | w=20
  5208. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mesna
    n1=en:contraindications aspect | n2=mesna | rel=r_associated | relid=0 | w=20
  5209. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mesure de la pression artérielle
    n1=en:contraindications aspect | n2=mesure de la pression artérielle | rel=r_associated | relid=0 | w=20
  5210. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mesure de la pression sanguine
    n1=en:contraindications aspect | n2=mesure de la pression sanguine | rel=r_associated | relid=0 | w=20
  5211. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mesure pression sanguine
    n1=en:contraindications aspect | n2=mesure pression sanguine | rel=r_associated | relid=0 | w=20
  5212. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> métalloexopeptidases
    n1=en:contraindications aspect | n2=métalloexopeptidases | rel=r_associated | relid=0 | w=20
  5213. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> métallothionéine
    n1=en:contraindications aspect | n2=métallothionéine | rel=r_associated | relid=0 | w=20
  5214. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> méthadone
    n1=en:contraindications aspect | n2=méthadone | rel=r_associated | relid=0 | w=20
  5215. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> méthoxsalène
    n1=en:contraindications aspect | n2=méthoxsalène | rel=r_associated | relid=0 | w=20
  5216. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> méthylmalonyl-CoA mutase
    n1=en:contraindications aspect | n2=méthylmalonyl-CoA mutase | rel=r_associated | relid=0 | w=20
  5217. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> méthylmalonyl-coa mutase
    n1=en:contraindications aspect | n2=méthylmalonyl-coa mutase | rel=r_associated | relid=0 | w=20
  5218. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> méthylmorphine
    n1=en:contraindications aspect | n2=méthylmorphine | rel=r_associated | relid=0 | w=20
  5219. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> métribolone
    n1=en:contraindications aspect | n2=métribolone | rel=r_associated | relid=0 | w=20
  5220. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> micro-dissection
    n1=en:contraindications aspect | n2=micro-dissection | rel=r_associated | relid=0 | w=20
  5221. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> microdissection
    n1=en:contraindications aspect | n2=microdissection | rel=r_associated | relid=0 | w=20
  5222. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> micromanipulation
    n1=en:contraindications aspect | n2=micromanipulation | rel=r_associated | relid=0 | w=20
  5223. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mimosine
    n1=en:contraindications aspect | n2=mimosine | rel=r_associated | relid=0 | w=20
  5224. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> minocycline
    n1=en:contraindications aspect | n2=minocycline | rel=r_associated | relid=0 | w=20
  5225. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mitobronitol
    n1=en:contraindications aspect | n2=mitobronitol | rel=r_associated | relid=0 | w=20
  5226. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mitogène
    n1=en:contraindications aspect | n2=mitogène | rel=r_associated | relid=0 | w=20
  5227. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mitoguazone
    n1=en:contraindications aspect | n2=mitoguazone | rel=r_associated | relid=0 | w=20
  5228. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mitoguazones
    n1=en:contraindications aspect | n2=mitoguazones | rel=r_associated | relid=0 | w=20
  5229. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> modulateur sélectif des récepteurs ?strogéniques
    n1=en:contraindications aspect | n2=modulateur sélectif des récepteurs ?strogéniques | rel=r_associated | relid=0 | w=20
  5230. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> moment décisif
    n1=en:contraindications aspect | n2=moment décisif | rel=r_associated | relid=0 | w=20
  5231. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> monoclonal antibody
    n1=en:contraindications aspect | n2=monoclonal antibody | rel=r_associated | relid=0 | w=20
  5232. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> monocrotophos
    n1=en:contraindications aspect | n2=monocrotophos | rel=r_associated | relid=0 | w=20
  5233. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> monosaccaride
    n1=en:contraindications aspect | n2=monosaccaride | rel=r_associated | relid=0 | w=20
  5234. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> monosaccharide
    n1=en:contraindications aspect | n2=monosaccharide | rel=r_associated | relid=0 | w=20
  5235. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> monosodium glutamate
    n1=en:contraindications aspect | n2=monosodium glutamate | rel=r_associated | relid=0 | w=20
  5236. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> MSG
    n1=en:contraindications aspect | n2=MSG | rel=r_associated | relid=0 | w=20
  5237. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> murexide
    n1=en:contraindications aspect | n2=murexide | rel=r_associated | relid=0 | w=20
  5238. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mutagène
    n1=en:contraindications aspect | n2=mutagène | rel=r_associated | relid=0 | w=20
  5239. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mycotoxine
    n1=en:contraindications aspect | n2=mycotoxine | rel=r_associated | relid=0 | w=20
  5240. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> mycotoxines
    n1=en:contraindications aspect | n2=mycotoxines | rel=r_associated | relid=0 | w=20
  5241. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> myélographie
    n1=en:contraindications aspect | n2=myélographie | rel=r_associated | relid=0 | w=20
  5242. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> myélotomie
    n1=en:contraindications aspect | n2=myélotomie | rel=r_associated | relid=0 | w=20
  5243. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> myringoplastie
    n1=en:contraindications aspect | n2=myringoplastie | rel=r_associated | relid=0 | w=20
  5244. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nacre
    n1=en:contraindications aspect | n2=nacre | rel=r_associated | relid=0 | w=20
  5245. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nadolol
    n1=en:contraindications aspect | n2=nadolol | rel=r_associated | relid=0 | w=20
  5246. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> NADPH oxidase
    n1=en:contraindications aspect | n2=NADPH oxidase | rel=r_associated | relid=0 | w=20
  5247. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nadph oxydase
    n1=en:contraindications aspect | n2=nadph oxydase | rel=r_associated | relid=0 | w=20
  5248. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nalorphine
    n1=en:contraindications aspect | n2=nalorphine | rel=r_associated | relid=0 | w=20
  5249. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> naproxène
    n1=en:contraindications aspect | n2=naproxène | rel=r_associated | relid=0 | w=20
  5250. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> natalizumab
    n1=en:contraindications aspect | n2=natalizumab | rel=r_associated | relid=0 | w=20
  5251. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nelfinavir
    n1=en:contraindications aspect | n2=nelfinavir | rel=r_associated | relid=0 | w=20
  5252. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> néostigmine
    n1=en:contraindications aspect | n2=néostigmine | rel=r_associated | relid=0 | w=20
  5253. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Néostigmine
    n1=en:contraindications aspect | n2=Néostigmine | rel=r_associated | relid=0 | w=20
  5254. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nestine
    n1=en:contraindications aspect | n2=nestine | rel=r_associated | relid=0 | w=20
  5255. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> neuréguline
    n1=en:contraindications aspect | n2=neuréguline | rel=r_associated | relid=0 | w=20
  5256. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> neuroendoscopes
    n1=en:contraindications aspect | n2=neuroendoscopes | rel=r_associated | relid=0 | w=20
  5257. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> neuropeptide
    n1=en:contraindications aspect | n2=neuropeptide | rel=r_associated | relid=0 | w=20
  5258. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> neurotensine
    n1=en:contraindications aspect | n2=neurotensine | rel=r_associated | relid=0 | w=20
  5259. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> niacinamide
    n1=en:contraindications aspect | n2=niacinamide | rel=r_associated | relid=0 | w=20
  5260. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nicotinamide
    n1=en:contraindications aspect | n2=nicotinamide | rel=r_associated | relid=0 | w=20
  5261. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nicotine
    n1=en:contraindications aspect | n2=nicotine | rel=r_associated | relid=0 | w=20
  5262. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nicotinique
    n1=en:contraindications aspect | n2=nicotinique | rel=r_associated | relid=0 | w=20
  5263. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nisoldipine
    n1=en:contraindications aspect | n2=nisoldipine | rel=r_associated | relid=0 | w=20
  5264. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> norfloxacine
    n1=en:contraindications aspect | n2=norfloxacine | rel=r_associated | relid=0 | w=20
  5265. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> novobiocine
    n1=en:contraindications aspect | n2=novobiocine | rel=r_associated | relid=0 | w=20
  5266. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> NPT
    n1=en:contraindications aspect | n2=NPT | rel=r_associated | relid=0 | w=20
  5267. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> nutrition parentérale totale
    n1=en:contraindications aspect | n2=nutrition parentérale totale | rel=r_associated | relid=0 | w=20
  5268. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oc
    n1=en:contraindications aspect | n2=oc | rel=r_associated | relid=0 | w=20
  5269. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> occludine
    n1=en:contraindications aspect | n2=occludine | rel=r_associated | relid=0 | w=20
  5270. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ocytocinase
    n1=en:contraindications aspect | n2=ocytocinase | rel=r_associated | relid=0 | w=20
  5271. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ocytocine
    n1=en:contraindications aspect | n2=ocytocine | rel=r_associated | relid=0 | w=20
  5272. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oil
    n1=en:contraindications aspect | n2=oil | rel=r_associated | relid=0 | w=20
  5273. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oligo-élément
    n1=en:contraindications aspect | n2=oligo-élément | rel=r_associated | relid=0 | w=20
  5274. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oligoélément
    n1=en:contraindications aspect | n2=oligoélément | rel=r_associated | relid=0 | w=20
  5275. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oligonucléotide
    n1=en:contraindications aspect | n2=oligonucléotide | rel=r_associated | relid=0 | w=20
  5276. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> omalizumab
    n1=en:contraindications aspect | n2=omalizumab | rel=r_associated | relid=0 | w=20
  5277. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> omeprazole
    n1=en:contraindications aspect | n2=omeprazole | rel=r_associated | relid=0 | w=20
  5278. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oméprazole
    n1=en:contraindications aspect | n2=oméprazole | rel=r_associated | relid=0 | w=20
  5279. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> opération chirurgicale
    n1=en:contraindications aspect | n2=opération chirurgicale | rel=r_associated | relid=0 | w=20
  5280. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> opération de bishoff
    n1=en:contraindications aspect | n2=opération de bishoff | rel=r_associated | relid=0 | w=20
  5281. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> opération de Bishoff
    n1=en:contraindications aspect | n2=opération de Bishoff | rel=r_associated | relid=0 | w=20
  5282. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> opération de chirurgie
    n1=en:contraindications aspect | n2=opération de chirurgie | rel=r_associated | relid=0 | w=20
  5283. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> opération de Fontan
    n1=en:contraindications aspect | n2=opération de Fontan | rel=r_associated | relid=0 | w=20
  5284. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ophtalmoscopie
    n1=en:contraindications aspect | n2=ophtalmoscopie | rel=r_associated | relid=0 | w=20
  5285. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ophthalmoscopie
    n1=en:contraindications aspect | n2=ophthalmoscopie | rel=r_associated | relid=0 | w=20
  5286. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> opium
    n1=en:contraindications aspect | n2=opium | rel=r_associated | relid=0 | w=20
  5287. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> orexines
    n1=en:contraindications aspect | n2=orexines | rel=r_associated | relid=0 | w=20
  5288. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ornithine décarboxylase
    n1=en:contraindications aspect | n2=ornithine décarboxylase | rel=r_associated | relid=0 | w=20
  5289. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> orotidine-5'-phosphate décarboxylase
    n1=en:contraindications aspect | n2=orotidine-5'-phosphate décarboxylase | rel=r_associated | relid=0 | w=20
  5290. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oscillométrie
    n1=en:contraindications aspect | n2=oscillométrie | rel=r_associated | relid=0 | w=20
  5291. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ostéopontine
    n1=en:contraindications aspect | n2=ostéopontine | rel=r_associated | relid=0 | w=20
  5292. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxitriptan
    n1=en:contraindications aspect | n2=oxitriptan | rel=r_associated | relid=0 | w=20
  5293. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxyde de magnésium
    n1=en:contraindications aspect | n2=oxyde de magnésium | rel=r_associated | relid=0 | w=20
  5294. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxygénation extracorporelle par membrane artificielle
    n1=en:contraindications aspect | n2=oxygénation extracorporelle par membrane artificielle | rel=r_associated | relid=0 | w=20
  5295. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxygénation extracorporelle sur membrane
    n1=en:contraindications aspect | n2=oxygénation extracorporelle sur membrane | rel=r_associated | relid=0 | w=20
  5296. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxygénation extracorporelle sur oxygénateur à membrane
    n1=en:contraindications aspect | n2=oxygénation extracorporelle sur oxygénateur à membrane | rel=r_associated | relid=0 | w=20
  5297. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxygénation par membrane extra-corporelle
    n1=en:contraindications aspect | n2=oxygénation par membrane extra-corporelle | rel=r_associated | relid=0 | w=20
  5298. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxygénation par membrane extracorporelle
    n1=en:contraindications aspect | n2=oxygénation par membrane extracorporelle | rel=r_associated | relid=0 | w=20
  5299. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxygène singulet
    n1=en:contraindications aspect | n2=oxygène singulet | rel=r_associated | relid=0 | w=20
  5300. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxyhémoglobine
    n1=en:contraindications aspect | n2=oxyhémoglobine | rel=r_associated | relid=0 | w=20
  5301. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxymétholone
    n1=en:contraindications aspect | n2=oxymétholone | rel=r_associated | relid=0 | w=20
  5302. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxyntomoduline
    n1=en:contraindications aspect | n2=oxyntomoduline | rel=r_associated | relid=0 | w=20
  5303. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxyphénbutazone
    n1=en:contraindications aspect | n2=oxyphénbutazone | rel=r_associated | relid=0 | w=20
  5304. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxytétracycline
    n1=en:contraindications aspect | n2=oxytétracycline | rel=r_associated | relid=0 | w=20
  5305. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> oxytocine
    n1=en:contraindications aspect | n2=oxytocine | rel=r_associated | relid=0 | w=20
  5306. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> paire de bretelles
    n1=en:contraindications aspect | n2=paire de bretelles | rel=r_associated | relid=0 | w=20
  5307. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> paire de lunettes
    n1=en:contraindications aspect | n2=paire de lunettes | rel=r_associated | relid=0 | w=20
  5308. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pantéthéine
    n1=en:contraindications aspect | n2=pantéthéine | rel=r_associated | relid=0 | w=20
  5309. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> parabiose
    n1=en:contraindications aspect | n2=parabiose | rel=r_associated | relid=0 | w=20
  5310. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> paraldéhyde
    n1=en:contraindications aspect | n2=paraldéhyde | rel=r_associated | relid=0 | w=20
  5311. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> parathormone
    n1=en:contraindications aspect | n2=parathormone | rel=r_associated | relid=0 | w=20
  5312. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> particules
    n1=en:contraindications aspect | n2=particules | rel=r_associated | relid=0 | w=20
  5313. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pâte dentifrice
    n1=en:contraindications aspect | n2=pâte dentifrice | rel=r_associated | relid=0 | w=20
  5314. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> peau artificielle
    n1=en:contraindications aspect | n2=peau artificielle | rel=r_associated | relid=0 | w=20
  5315. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pénicillamine
    n1=en:contraindications aspect | n2=pénicillamine | rel=r_associated | relid=0 | w=20
  5316. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pentachlorophénol
    n1=en:contraindications aspect | n2=pentachlorophénol | rel=r_associated | relid=0 | w=20
  5317. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pentamidine
    n1=en:contraindications aspect | n2=pentamidine | rel=r_associated | relid=0 | w=20
  5318. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pentoxifylline
    n1=en:contraindications aspect | n2=pentoxifylline | rel=r_associated | relid=0 | w=20
  5319. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> peptides hydrolases
    n1=en:contraindications aspect | n2=peptides hydrolases | rel=r_associated | relid=0 | w=20
  5320. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> peptidyltransférase
    n1=en:contraindications aspect | n2=peptidyltransférase | rel=r_associated | relid=0 | w=20
  5321. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> perchlorates
    n1=en:contraindications aspect | n2=perchlorates | rel=r_associated | relid=0 | w=20
  5322. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> perforine
    n1=en:contraindications aspect | n2=perforine | rel=r_associated | relid=0 | w=20
  5323. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> péricardiectomie
    n1=en:contraindications aspect | n2=péricardiectomie | rel=r_associated | relid=0 | w=20
  5324. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> périndopril
    n1=en:contraindications aspect | n2=périndopril | rel=r_associated | relid=0 | w=20
  5325. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> perphénazine
    n1=en:contraindications aspect | n2=perphénazine | rel=r_associated | relid=0 | w=20
  5326. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pérylène
    n1=en:contraindications aspect | n2=pérylène | rel=r_associated | relid=0 | w=20
  5327. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> PET scan
    n1=en:contraindications aspect | n2=PET scan | rel=r_associated | relid=0 | w=20
  5328. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> péthidine
    n1=en:contraindications aspect | n2=péthidine | rel=r_associated | relid=0 | w=20
  5329. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> péthidine chlorhydrate
    n1=en:contraindications aspect | n2=péthidine chlorhydrate | rel=r_associated | relid=0 | w=20
  5330. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> péthidines
    n1=en:contraindications aspect | n2=péthidines | rel=r_associated | relid=0 | w=20
  5331. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> petites particules cytoplasmiques ribonucléoprotéiques
    n1=en:contraindications aspect | n2=petites particules cytoplasmiques ribonucléoprotéiques | rel=r_associated | relid=0 | w=20
  5332. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phénindione
    n1=en:contraindications aspect | n2=phénindione | rel=r_associated | relid=0 | w=20
  5333. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phénobarbital
    n1=en:contraindications aspect | n2=phénobarbital | rel=r_associated | relid=0 | w=20
  5334. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phénothiazine
    n1=en:contraindications aspect | n2=phénothiazine | rel=r_associated | relid=0 | w=20
  5335. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phénoxy-propanolamines
    n1=en:contraindications aspect | n2=phénoxy-propanolamines | rel=r_associated | relid=0 | w=20
  5336. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phénoxypropanolamines
    n1=en:contraindications aspect | n2=phénoxypropanolamines | rel=r_associated | relid=0 | w=20
  5337. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phlébotomie
    n1=en:contraindications aspect | n2=phlébotomie | rel=r_associated | relid=0 | w=20
  5338. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phonocardiographie
    n1=en:contraindications aspect | n2=phonocardiographie | rel=r_associated | relid=0 | w=20
  5339. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phosphatidyl-inositol
    n1=en:contraindications aspect | n2=phosphatidyl-inositol | rel=r_associated | relid=0 | w=20
  5340. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phosphatidylinositol
    n1=en:contraindications aspect | n2=phosphatidylinositol | rel=r_associated | relid=0 | w=20
  5341. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phosphites
    n1=en:contraindications aspect | n2=phosphites | rel=r_associated | relid=0 | w=20
  5342. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phosphoénolpyruvate carboxylase
    n1=en:contraindications aspect | n2=phosphoénolpyruvate carboxylase | rel=r_associated | relid=0 | w=20
  5343. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phosphofructokinase
    n1=en:contraindications aspect | n2=phosphofructokinase | rel=r_associated | relid=0 | w=20
  5344. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phosphoglycérate mutase
    n1=en:contraindications aspect | n2=phosphoglycérate mutase | rel=r_associated | relid=0 | w=20
  5345. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phosphoglycérides
    n1=en:contraindications aspect | n2=phosphoglycérides | rel=r_associated | relid=0 | w=20
  5346. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phospholipase A1
    n1=en:contraindications aspect | n2=phospholipase A1 | rel=r_associated | relid=0 | w=20
  5347. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phospholipase c delta
    n1=en:contraindications aspect | n2=phospholipase c delta | rel=r_associated | relid=0 | w=20
  5348. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phospholipases a
    n1=en:contraindications aspect | n2=phospholipases a | rel=r_associated | relid=0 | w=20
  5349. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phosphorylases
    n1=en:contraindications aspect | n2=phosphorylases | rel=r_associated | relid=0 | w=20
  5350. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phosvitine
    n1=en:contraindications aspect | n2=phosvitine | rel=r_associated | relid=0 | w=20
  5351. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phycoérythrine
    n1=en:contraindications aspect | n2=phycoérythrine | rel=r_associated | relid=0 | w=20
  5352. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phylloquinone
    n1=en:contraindications aspect | n2=phylloquinone | rel=r_associated | relid=0 | w=20
  5353. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> physiopathique (syndrome)
    n1=en:contraindications aspect | n2=physiopathique (syndrome) | rel=r_associated | relid=0 | w=20
  5354. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> physostigmine
    n1=en:contraindications aspect | n2=physostigmine | rel=r_associated | relid=0 | w=20
  5355. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phytase
    n1=en:contraindications aspect | n2=phytase | rel=r_associated | relid=0 | w=20
  5356. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phytochrome b
    n1=en:contraindications aspect | n2=phytochrome b | rel=r_associated | relid=0 | w=20
  5357. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phytoménadione
    n1=en:contraindications aspect | n2=phytoménadione | rel=r_associated | relid=0 | w=20
  5358. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> phytonadione
    n1=en:contraindications aspect | n2=phytonadione | rel=r_associated | relid=0 | w=20
  5359. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pierre à savon
    n1=en:contraindications aspect | n2=pierre à savon | rel=r_associated | relid=0 | w=20
  5360. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Pierre à savon
    n1=en:contraindications aspect | n2=Pierre à savon | rel=r_associated | relid=0 | w=20
  5361. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pipobroman
    n1=en:contraindications aspect | n2=pipobroman | rel=r_associated | relid=0 | w=20
  5362. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> piroxicam
    n1=en:contraindications aspect | n2=piroxicam | rel=r_associated | relid=0 | w=20
  5363. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> plasmaphérèse
    n1=en:contraindications aspect | n2=plasmaphérèse | rel=r_associated | relid=0 | w=20
  5364. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> plasmide F
    n1=en:contraindications aspect | n2=plasmide F | rel=r_associated | relid=0 | w=20
  5365. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> plasmide f
    n1=en:contraindications aspect | n2=plasmide f | rel=r_associated | relid=0 | w=20
  5366. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> plasminogène (activateur du)
    n1=en:contraindications aspect | n2=plasminogène (activateur du) | rel=r_associated | relid=0 | w=20
  5367. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pléthysmographie
    n1=en:contraindications aspect | n2=pléthysmographie | rel=r_associated | relid=0 | w=20
  5368. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pleuroscopie
    n1=en:contraindications aspect | n2=pleuroscopie | rel=r_associated | relid=0 | w=20
  5369. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> PlGF
    n1=en:contraindications aspect | n2=PlGF | rel=r_associated | relid=0 | w=20
  5370. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> poisons
    n1=en:contraindications aspect | n2=poisons | rel=r_associated | relid=0 | w=20
  5371. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> poly c
    n1=en:contraindications aspect | n2=poly c | rel=r_associated | relid=0 | w=20
  5372. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> poly g
    n1=en:contraindications aspect | n2=poly g | rel=r_associated | relid=0 | w=20
  5373. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> poly t
    n1=en:contraindications aspect | n2=poly t | rel=r_associated | relid=0 | w=20
  5374. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polyesters
    n1=en:contraindications aspect | n2=polyesters | rel=r_associated | relid=0 | w=20
  5375. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polyéthylène glycol
    n1=en:contraindications aspect | n2=polyéthylène glycol | rel=r_associated | relid=0 | w=20
  5376. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polymer
    n1=en:contraindications aspect | n2=polymer | rel=r_associated | relid=0 | w=20
  5377. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polypeptide c de transport d'anions organiques
    n1=en:contraindications aspect | n2=polypeptide c de transport d'anions organiques | rel=r_associated | relid=0 | w=20
  5378. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polypeptide c de transport des anions organiques
    n1=en:contraindications aspect | n2=polypeptide c de transport des anions organiques | rel=r_associated | relid=0 | w=20
  5379. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polypeptide c transporteur des anions organiques
    n1=en:contraindications aspect | n2=polypeptide c transporteur des anions organiques | rel=r_associated | relid=0 | w=20
  5380. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polyphosphates
    n1=en:contraindications aspect | n2=polyphosphates | rel=r_associated | relid=0 | w=20
  5381. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polytétrafluoroéthylène
    n1=en:contraindications aspect | n2=polytétrafluoroéthylène | rel=r_associated | relid=0 | w=20
  5382. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polyvinyles
    n1=en:contraindications aspect | n2=polyvinyles | rel=r_associated | relid=0 | w=20
  5383. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> polyvinyls
    n1=en:contraindications aspect | n2=polyvinyls | rel=r_associated | relid=0 | w=20
  5384. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ponction amniotique
    n1=en:contraindications aspect | n2=ponction amniotique | rel=r_associated | relid=0 | w=20
  5385. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ponction biopsie
    n1=en:contraindications aspect | n2=ponction biopsie | rel=r_associated | relid=0 | w=20
  5386. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> porphyrin
    n1=en:contraindications aspect | n2=porphyrin | rel=r_associated | relid=0 | w=20
  5387. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> porphyrine
    n1=en:contraindications aspect | n2=porphyrine | rel=r_associated | relid=0 | w=20
  5388. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> portographie
    n1=en:contraindications aspect | n2=portographie | rel=r_associated | relid=0 | w=20
  5389. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pose d'implants cochléaires
    n1=en:contraindications aspect | n2=pose d'implants cochléaires | rel=r_associated | relid=0 | w=20
  5390. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> poudrer
    n1=en:contraindications aspect | n2=poudrer | rel=r_associated | relid=0 | w=20
  5391. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prastérone
    n1=en:contraindications aspect | n2=prastérone | rel=r_associated | relid=0 | w=20
  5392. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> premiers secours
    n1=en:contraindications aspect | n2=premiers secours | rel=r_associated | relid=0 | w=20
  5393. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Premiers Secours
    n1=en:contraindications aspect | n2=Premiers Secours | rel=r_associated | relid=0 | w=20
  5394. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> premiers soins
    n1=en:contraindications aspect | n2=premiers soins | rel=r_associated | relid=0 | w=20
  5395. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> préparation d'hydrocortisone
    n1=en:contraindications aspect | n2=préparation d'hydrocortisone | rel=r_associated | relid=0 | w=20
  5396. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> préparation de cortisol
    n1=en:contraindications aspect | n2=préparation de cortisol | rel=r_associated | relid=0 | w=20
  5397. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> préparation du composé f
    n1=en:contraindications aspect | n2=préparation du composé f | rel=r_associated | relid=0 | w=20
  5398. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> préparation du composé F
    n1=en:contraindications aspect | n2=préparation du composé F | rel=r_associated | relid=0 | w=20
  5399. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pression artérielle
    n1=en:contraindications aspect | n2=pression artérielle | rel=r_associated | relid=0 | w=20
  5400. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Pression artérielle
    n1=en:contraindications aspect | n2=Pression artérielle | rel=r_associated | relid=0 | w=20
  5401. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pression du sang
    n1=en:contraindications aspect | n2=pression du sang | rel=r_associated | relid=0 | w=20
  5402. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pristinamycine
    n1=en:contraindications aspect | n2=pristinamycine | rel=r_associated | relid=0 | w=20
  5403. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> PRNA
    n1=en:contraindications aspect | n2=PRNA | rel=r_associated | relid=0 | w=20
  5404. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pro-glucagon
    n1=en:contraindications aspect | n2=pro-glucagon | rel=r_associated | relid=0 | w=20
  5405. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pro-insuline
    n1=en:contraindications aspect | n2=pro-insuline | rel=r_associated | relid=0 | w=20
  5406. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> procarbazine
    n1=en:contraindications aspect | n2=procarbazine | rel=r_associated | relid=0 | w=20
  5407. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> procédure chirurgicale
    n1=en:contraindications aspect | n2=procédure chirurgicale | rel=r_associated | relid=0 | w=20
  5408. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> procédure de Fontan
    n1=en:contraindications aspect | n2=procédure de Fontan | rel=r_associated | relid=0 | w=20
  5409. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> procédure médicale
    n1=en:contraindications aspect | n2=procédure médicale | rel=r_associated | relid=0 | w=20
  5410. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prochlorpérazine
    n1=en:contraindications aspect | n2=prochlorpérazine | rel=r_associated | relid=0 | w=20
  5411. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> produit anesthésiant
    n1=en:contraindications aspect | n2=produit anesthésiant | rel=r_associated | relid=0 | w=20
  5412. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> produit chimique organique
    n1=en:contraindications aspect | n2=produit chimique organique | rel=r_associated | relid=0 | w=20
  5413. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> produit de contraste
    n1=en:contraindications aspect | n2=produit de contraste | rel=r_associated | relid=0 | w=20
  5414. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> produits d'hygiène féminine
    n1=en:contraindications aspect | n2=produits d'hygiène féminine | rel=r_associated | relid=0 | w=20
  5415. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> produits déodorants
    n1=en:contraindications aspect | n2=produits déodorants | rel=r_associated | relid=0 | w=20
  5416. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> produits désodorisants
    n1=en:contraindications aspect | n2=produits désodorisants | rel=r_associated | relid=0 | w=20
  5417. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> proflavine
    n1=en:contraindications aspect | n2=proflavine | rel=r_associated | relid=0 | w=20
  5418. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> progestine
    n1=en:contraindications aspect | n2=progestine | rel=r_associated | relid=0 | w=20
  5419. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> proglucagon
    n1=en:contraindications aspect | n2=proglucagon | rel=r_associated | relid=0 | w=20
  5420. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> proguanil
    n1=en:contraindications aspect | n2=proguanil | rel=r_associated | relid=0 | w=20
  5421. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> proinsuline
    n1=en:contraindications aspect | n2=proinsuline | rel=r_associated | relid=0 | w=20
  5422. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> promazine
    n1=en:contraindications aspect | n2=promazine | rel=r_associated | relid=0 | w=20
  5423. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prométhazine
    n1=en:contraindications aspect | n2=prométhazine | rel=r_associated | relid=0 | w=20
  5424. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prométhazines
    n1=en:contraindications aspect | n2=prométhazines | rel=r_associated | relid=0 | w=20
  5425. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> propanil
    n1=en:contraindications aspect | n2=propanil | rel=r_associated | relid=0 | w=20
  5426. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> proscillaridine
    n1=en:contraindications aspect | n2=proscillaridine | rel=r_associated | relid=0 | w=20
  5427. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prostatectomie
    n1=en:contraindications aspect | n2=prostatectomie | rel=r_associated | relid=0 | w=20
  5428. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protection absorbante incontinence
    n1=en:contraindications aspect | n2=protection absorbante incontinence | rel=r_associated | relid=0 | w=20
  5429. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protection hygiénique
    n1=en:contraindications aspect | n2=protection hygiénique | rel=r_associated | relid=0 | w=20
  5430. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protections absorbantes de l'incontinence
    n1=en:contraindications aspect | n2=protections absorbantes de l'incontinence | rel=r_associated | relid=0 | w=20
  5431. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protections absorbantes pour incontinence
    n1=en:contraindications aspect | n2=protections absorbantes pour incontinence | rel=r_associated | relid=0 | w=20
  5432. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protections absorbantes pour l'incontinence
    n1=en:contraindications aspect | n2=protections absorbantes pour l'incontinence | rel=r_associated | relid=0 | w=20
  5433. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protein
    n1=en:contraindications aspect | n2=protein | rel=r_associated | relid=0 | w=20
  5434. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protein kinase
    n1=en:contraindications aspect | n2=protein kinase | rel=r_associated | relid=0 | w=20
  5435. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> proteine
    n1=en:contraindications aspect | n2=proteine | rel=r_associated | relid=0 | w=20
  5436. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protéine foetale
    n1=en:contraindications aspect | n2=protéine foetale | rel=r_associated | relid=0 | w=20
  5437. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protéine kinase
    n1=en:contraindications aspect | n2=protéine kinase | rel=r_associated | relid=0 | w=20
  5438. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protéine morphogénétique de l'os
    n1=en:contraindications aspect | n2=protéine morphogénétique de l'os | rel=r_associated | relid=0 | w=20
  5439. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protéine morphogénétique osseuse
    n1=en:contraindications aspect | n2=protéine morphogénétique osseuse | rel=r_associated | relid=0 | w=20
  5440. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> proteine myo d
    n1=en:contraindications aspect | n2=proteine myo d | rel=r_associated | relid=0 | w=20
  5441. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protéine-kinase
    n1=en:contraindications aspect | n2=protéine-kinase | rel=r_associated | relid=0 | w=20
  5442. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protéines de foetus
    n1=en:contraindications aspect | n2=protéines de foetus | rel=r_associated | relid=0 | w=20
  5443. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protéines foetales
    n1=en:contraindications aspect | n2=protéines foetales | rel=r_associated | relid=0 | w=20
  5444. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> proteines foetales
    n1=en:contraindications aspect | n2=proteines foetales | rel=r_associated | relid=0 | w=20
  5445. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prothèse de vaisseau sanguin
    n1=en:contraindications aspect | n2=prothèse de vaisseau sanguin | rel=r_associated | relid=0 | w=20
  5446. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prothèse dentaire
    n1=en:contraindications aspect | n2=prothèse dentaire | rel=r_associated | relid=0 | w=20
  5447. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prothèse mammaire
    n1=en:contraindications aspect | n2=prothèse mammaire | rel=r_associated | relid=0 | w=20
  5448. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prothèse mammaire interne
    n1=en:contraindications aspect | n2=prothèse mammaire interne | rel=r_associated | relid=0 | w=20
  5449. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prothèse vasculaire
    n1=en:contraindications aspect | n2=prothèse vasculaire | rel=r_associated | relid=0 | w=20
  5450. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prothèses dentaires
    n1=en:contraindications aspect | n2=prothèses dentaires | rel=r_associated | relid=0 | w=20
  5451. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> prothrombine
    n1=en:contraindications aspect | n2=prothrombine | rel=r_associated | relid=0 | w=20
  5452. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> protide
    n1=en:contraindications aspect | n2=protide | rel=r_associated | relid=0 | w=20
  5453. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pseudo-uridine
    n1=en:contraindications aspect | n2=pseudo-uridine | rel=r_associated | relid=0 | w=20
  5454. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pseudocholinestérase
    n1=en:contraindications aspect | n2=pseudocholinestérase | rel=r_associated | relid=0 | w=20
  5455. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pseudouridine
    n1=en:contraindications aspect | n2=pseudouridine | rel=r_associated | relid=0 | w=20
  5456. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> psychosine
    n1=en:contraindications aspect | n2=psychosine | rel=r_associated | relid=0 | w=20
  5457. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pulpectomie
    n1=en:contraindications aspect | n2=pulpectomie | rel=r_associated | relid=0 | w=20
  5458. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> putrescine
    n1=en:contraindications aspect | n2=putrescine | rel=r_associated | relid=0 | w=20
  5459. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pyrrolidines
    n1=en:contraindications aspect | n2=pyrrolidines | rel=r_associated | relid=0 | w=20
  5460. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> pyruvate oxidase
    n1=en:contraindications aspect | n2=pyruvate oxidase | rel=r_associated | relid=0 | w=20
  5461. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radio-immunoessai
    n1=en:contraindications aspect | n2=radio-immunoessai | rel=r_associated | relid=0 | w=20
  5462. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radio-isotope
    n1=en:contraindications aspect | n2=radio-isotope | rel=r_associated | relid=0 | w=20
  5463. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radiographie abdominale
    n1=en:contraindications aspect | n2=radiographie abdominale | rel=r_associated | relid=0 | w=20
  5464. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radiographie d'abdomen
    n1=en:contraindications aspect | n2=radiographie d'abdomen | rel=r_associated | relid=0 | w=20
  5465. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radiographie de contraste des voies biliaires
    n1=en:contraindications aspect | n2=radiographie de contraste des voies biliaires | rel=r_associated | relid=0 | w=20
  5466. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radiographie de l'abdomen
    n1=en:contraindications aspect | n2=radiographie de l'abdomen | rel=r_associated | relid=0 | w=20
  5467. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radiographie dentaire
    n1=en:contraindications aspect | n2=radiographie dentaire | rel=r_associated | relid=0 | w=20
  5468. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radiographie des dents
    n1=en:contraindications aspect | n2=radiographie des dents | rel=r_associated | relid=0 | w=20
  5469. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radiographies des vaisseaux
    n1=en:contraindications aspect | n2=radiographies des vaisseaux | rel=r_associated | relid=0 | w=20
  5470. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radioisotope
    n1=en:contraindications aspect | n2=radioisotope | rel=r_associated | relid=0 | w=20
  5471. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radioscopie
    n1=en:contraindications aspect | n2=radioscopie | rel=r_associated | relid=0 | w=20
  5472. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radiothérapie
    n1=en:contraindications aspect | n2=radiothérapie | rel=r_associated | relid=0 | w=20
  5473. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> radiothérapie cutanée
    n1=en:contraindications aspect | n2=radiothérapie cutanée | rel=r_associated | relid=0 | w=20
  5474. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ramipril
    n1=en:contraindications aspect | n2=ramipril | rel=r_associated | relid=0 | w=20
  5475. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ranimation
    n1=en:contraindications aspect | n2=ranimation | rel=r_associated | relid=0 | w=20
  5476. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> rapports sexuels
    n1=en:contraindications aspect | n2=rapports sexuels | rel=r_associated | relid=0 | w=20
  5477. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> réanimation cardiaque
    n1=en:contraindications aspect | n2=réanimation cardiaque | rel=r_associated | relid=0 | w=20
  5478. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> reconstruction d'une articulation
    n1=en:contraindications aspect | n2=reconstruction d'une articulation | rel=r_associated | relid=0 | w=20
  5479. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> régime cétogène
    n1=en:contraindications aspect | n2=régime cétogène | rel=r_associated | relid=0 | w=20
  5480. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> réimplantation
    n1=en:contraindications aspect | n2=réimplantation | rel=r_associated | relid=0 | w=20
  5481. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> réimplantation chirurgicale
    n1=en:contraindications aspect | n2=réimplantation chirurgicale | rel=r_associated | relid=0 | w=20
  5482. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> réimplantations
    n1=en:contraindications aspect | n2=réimplantations | rel=r_associated | relid=0 | w=20
  5483. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> réinsertion
    n1=en:contraindications aspect | n2=réinsertion | rel=r_associated | relid=0 | w=20
  5484. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> réintervention
    n1=en:contraindications aspect | n2=réintervention | rel=r_associated | relid=0 | w=20
  5485. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> réinterventions
    n1=en:contraindications aspect | n2=réinterventions | rel=r_associated | relid=0 | w=20
  5486. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> relation sexuelle
    n1=en:contraindications aspect | n2=relation sexuelle | rel=r_associated | relid=0 | w=20
  5487. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> relations
    n1=en:contraindications aspect | n2=relations | rel=r_associated | relid=0 | w=20
  5488. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> relations sexuelles
    n1=en:contraindications aspect | n2=relations sexuelles | rel=r_associated | relid=0 | w=20
  5489. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> relaxine
    n1=en:contraindications aspect | n2=relaxine | rel=r_associated | relid=0 | w=20
  5490. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> remnographie
    n1=en:contraindications aspect | n2=remnographie | rel=r_associated | relid=0 | w=20
  5491. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> répondre à
    n1=en:contraindications aspect | n2=répondre à | rel=r_associated | relid=0 | w=20
  5492. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> répondre à [qqn]
    n1=en:contraindications aspect | n2=répondre à [qqn] | rel=r_associated | relid=0 | w=20
  5493. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> répondre à qn
    n1=en:contraindications aspect | n2=répondre à qn | rel=r_associated | relid=0 | w=20
  5494. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> répondre à quelqu'un
    n1=en:contraindications aspect | n2=répondre à quelqu'un | rel=r_associated | relid=0 | w=20
  5495. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> reprise chirurgicale
    n1=en:contraindications aspect | n2=reprise chirurgicale | rel=r_associated | relid=0 | w=20
  5496. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> reprise opératoire
    n1=en:contraindications aspect | n2=reprise opératoire | rel=r_associated | relid=0 | w=20
  5497. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> résidus de chylomicron
    n1=en:contraindications aspect | n2=résidus de chylomicron | rel=r_associated | relid=0 | w=20
  5498. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> résistine
    n1=en:contraindications aspect | n2=résistine | rel=r_associated | relid=0 | w=20
  5499. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ressuscitation cardiaque
    n1=en:contraindications aspect | n2=ressuscitation cardiaque | rel=r_associated | relid=0 | w=20
  5500. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> restes de chylomicrons
    n1=en:contraindications aspect | n2=restes de chylomicrons | rel=r_associated | relid=0 | w=20
  5501. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> restriction (endonucléase de)
    n1=en:contraindications aspect | n2=restriction (endonucléase de) | rel=r_associated | relid=0 | w=20
  5502. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> rétinoscopie
    n1=en:contraindications aspect | n2=rétinoscopie | rel=r_associated | relid=0 | w=20
  5503. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> révision chirurgicale
    n1=en:contraindications aspect | n2=révision chirurgicale | rel=r_associated | relid=0 | w=20
  5504. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> rhodamine 123
    n1=en:contraindications aspect | n2=rhodamine 123 | rel=r_associated | relid=0 | w=20
  5505. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> rhodopsine kinase
    n1=en:contraindications aspect | n2=rhodopsine kinase | rel=r_associated | relid=0 | w=20
  5506. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> rhodopsine-kinase
    n1=en:contraindications aspect | n2=rhodopsine-kinase | rel=r_associated | relid=0 | w=20
  5507. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ri
    n1=en:contraindications aspect | n2=ri | rel=r_associated | relid=0 | w=20
  5508. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ribitol
    n1=en:contraindications aspect | n2=ribitol | rel=r_associated | relid=0 | w=20
  5509. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ribodésose
    n1=en:contraindications aspect | n2=ribodésose | rel=r_associated | relid=0 | w=20
  5510. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ribonucléase H
    n1=en:contraindications aspect | n2=ribonucléase H | rel=r_associated | relid=0 | w=20
  5511. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> rifamycine
    n1=en:contraindications aspect | n2=rifamycine | rel=r_associated | relid=0 | w=20
  5512. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> rituximab
    n1=en:contraindications aspect | n2=rituximab | rel=r_associated | relid=0 | w=20
  5513. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> rivaroxaban
    n1=en:contraindications aspect | n2=rivaroxaban | rel=r_associated | relid=0 | w=20
  5514. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> rivastigmine
    n1=en:contraindications aspect | n2=rivastigmine | rel=r_associated | relid=0 | w=20
  5515. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ruban adhésif chirurgical
    n1=en:contraindications aspect | n2=ruban adhésif chirurgical | rel=r_associated | relid=0 | w=20
  5516. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ry
    n1=en:contraindications aspect | n2=ry | rel=r_associated | relid=0 | w=20
  5517. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> S-adénosylhomocystéine
    n1=en:contraindications aspect | n2=S-adénosylhomocystéine | rel=r_associated | relid=0 | w=20
  5518. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> saccarine
    n1=en:contraindications aspect | n2=saccarine | rel=r_associated | relid=0 | w=20
  5519. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> saccarose
    n1=en:contraindications aspect | n2=saccarose | rel=r_associated | relid=0 | w=20
  5520. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> saccharine
    n1=en:contraindications aspect | n2=saccharine | rel=r_associated | relid=0 | w=20
  5521. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> saccharose
    n1=en:contraindications aspect | n2=saccharose | rel=r_associated | relid=0 | w=20
  5522. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> salpingectomie
    n1=en:contraindications aspect | n2=salpingectomie | rel=r_associated | relid=0 | w=20
  5523. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> saponine
    n1=en:contraindications aspect | n2=saponine | rel=r_associated | relid=0 | w=20
  5524. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> saponoside
    n1=en:contraindications aspect | n2=saponoside | rel=r_associated | relid=0 | w=20
  5525. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sarin
    n1=en:contraindications aspect | n2=sarin | rel=r_associated | relid=0 | w=20
  5526. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> scan ir
    n1=en:contraindications aspect | n2=scan ir | rel=r_associated | relid=0 | w=20
  5527. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> scanner CT
    n1=en:contraindications aspect | n2=scanner CT | rel=r_associated | relid=0 | w=20
  5528. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> scanner du corps entier
    n1=en:contraindications aspect | n2=scanner du corps entier | rel=r_associated | relid=0 | w=20
  5529. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> scanographe
    n1=en:contraindications aspect | n2=scanographe | rel=r_associated | relid=0 | w=20
  5530. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> scanographie quantitative
    n1=en:contraindications aspect | n2=scanographie quantitative | rel=r_associated | relid=0 | w=20
  5531. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> scellement
    n1=en:contraindications aspect | n2=scellement | rel=r_associated | relid=0 | w=20
  5532. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> scintigraphie
    n1=en:contraindications aspect | n2=scintigraphie | rel=r_associated | relid=0 | w=20
  5533. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> scintillographie
    n1=en:contraindications aspect | n2=scintillographie | rel=r_associated | relid=0 | w=20
  5534. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> scopolétine
    n1=en:contraindications aspect | n2=scopolétine | rel=r_associated | relid=0 | w=20
  5535. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> se joindre
    n1=en:contraindications aspect | n2=se joindre | rel=r_associated | relid=0 | w=20
  5536. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Seckel-like type Majoor-Krakauer (syndrome de)
    n1=en:contraindications aspect | n2=Seckel-like type Majoor-Krakauer (syndrome de) | rel=r_associated | relid=0 | w=20
  5537. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> secourisme
    n1=en:contraindications aspect | n2=secourisme | rel=r_associated | relid=0 | w=20
  5538. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sécrétine
    n1=en:contraindications aspect | n2=sécrétine | rel=r_associated | relid=0 | w=20
  5539. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> section des faisceaux rachidiens
    n1=en:contraindications aspect | n2=section des faisceaux rachidiens | rel=r_associated | relid=0 | w=20
  5540. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> section transversale des faisceaux rachidiens
    n1=en:contraindications aspect | n2=section transversale des faisceaux rachidiens | rel=r_associated | relid=0 | w=20
  5541. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sédation profonde
    n1=en:contraindications aspect | n2=sédation profonde | rel=r_associated | relid=0 | w=20
  5542. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sel d'Epsom
    n1=en:contraindications aspect | n2=sel d'Epsom | rel=r_associated | relid=0 | w=20
  5543. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sel d'epsom
    n1=en:contraindications aspect | n2=sel d'epsom | rel=r_associated | relid=0 | w=20
  5544. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sel de table
    n1=en:contraindications aspect | n2=sel de table | rel=r_associated | relid=0 | w=20
  5545. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sel fin
    n1=en:contraindications aspect | n2=sel fin | rel=r_associated | relid=0 | w=20
  5546. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sélectine
    n1=en:contraindications aspect | n2=sélectine | rel=r_associated | relid=0 | w=20
  5547. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> série des lanthanides
    n1=en:contraindications aspect | n2=série des lanthanides | rel=r_associated | relid=0 | w=20
  5548. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> seringue
    n1=en:contraindications aspect | n2=seringue | rel=r_associated | relid=0 | w=20
  5549. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Sertoli (tumeur calcifiée à grandes cellules de)
    n1=en:contraindications aspect | n2=Sertoli (tumeur calcifiée à grandes cellules de) | rel=r_associated | relid=0 | w=20
  5550. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sérum albumine bovine
    n1=en:contraindications aspect | n2=sérum albumine bovine | rel=r_associated | relid=0 | w=20
  5551. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sérum anti-diphtérique
    n1=en:contraindications aspect | n2=sérum anti-diphtérique | rel=r_associated | relid=0 | w=20
  5552. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sérum antidiphtérique
    n1=en:contraindications aspect | n2=sérum antidiphtérique | rel=r_associated | relid=0 | w=20
  5553. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sérum antilymphocytaire
    n1=en:contraindications aspect | n2=sérum antilymphocytaire | rel=r_associated | relid=0 | w=20
  5554. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sérum antitétanique
    n1=en:contraindications aspect | n2=sérum antitétanique | rel=r_associated | relid=0 | w=20
  5555. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sérumalbumine bovine
    n1=en:contraindications aspect | n2=sérumalbumine bovine | rel=r_associated | relid=0 | w=20
  5556. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> silicate d'aluminium
    n1=en:contraindications aspect | n2=silicate d'aluminium | rel=r_associated | relid=0 | w=20
  5557. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Silicate d'aluminium
    n1=en:contraindications aspect | n2=Silicate d'aluminium | rel=r_associated | relid=0 | w=20
  5558. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> simazine
    n1=en:contraindications aspect | n2=simazine | rel=r_associated | relid=0 | w=20
  5559. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> single photon emission computed tomography
    n1=en:contraindications aspect | n2=single photon emission computed tomography | rel=r_associated | relid=0 | w=20
  5560. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> skiascopie
    n1=en:contraindications aspect | n2=skiascopie | rel=r_associated | relid=0 | w=20
  5561. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> soin dentaire
    n1=en:contraindications aspect | n2=soin dentaire | rel=r_associated | relid=0 | w=20
  5562. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> soins d'urgence
    n1=en:contraindications aspect | n2=soins d'urgence | rel=r_associated | relid=0 | w=20
  5563. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> somatocrinine
    n1=en:contraindications aspect | n2=somatocrinine | rel=r_associated | relid=0 | w=20
  5564. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> somatostatine
    n1=en:contraindications aspect | n2=somatostatine | rel=r_associated | relid=0 | w=20
  5565. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sonication
    n1=en:contraindications aspect | n2=sonication | rel=r_associated | relid=0 | w=20
  5566. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sorbose
    n1=en:contraindications aspect | n2=sorbose | rel=r_associated | relid=0 | w=20
  5567. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> soude caustique
    n1=en:contraindications aspect | n2=soude caustique | rel=r_associated | relid=0 | w=20
  5568. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> spanner
    n1=en:contraindications aspect | n2=spanner | rel=r_associated | relid=0 | w=20
  5569. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sparadrap chirurgical
    n1=en:contraindications aspect | n2=sparadrap chirurgical | rel=r_associated | relid=0 | w=20
  5570. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> spectacles
    n1=en:contraindications aspect | n2=spectacles | rel=r_associated | relid=0 | w=20
  5571. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> spermicide
    n1=en:contraindications aspect | n2=spermicide | rel=r_associated | relid=0 | w=20
  5572. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sphygmomanomètre
    n1=en:contraindications aspect | n2=sphygmomanomètre | rel=r_associated | relid=0 | w=20
  5573. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> splénectomie
    n1=en:contraindications aspect | n2=splénectomie | rel=r_associated | relid=0 | w=20
  5574. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> splénographie
    n1=en:contraindications aspect | n2=splénographie | rel=r_associated | relid=0 | w=20
  5575. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> SRIH
    n1=en:contraindications aspect | n2=SRIH | rel=r_associated | relid=0 | w=20
  5576. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> stadage
    n1=en:contraindications aspect | n2=stadage | rel=r_associated | relid=0 | w=20
  5577. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> staging
    n1=en:contraindications aspect | n2=staging | rel=r_associated | relid=0 | w=20
  5578. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> stéarates
    n1=en:contraindications aspect | n2=stéarates | rel=r_associated | relid=0 | w=20
  5579. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> stéatite
    n1=en:contraindications aspect | n2=stéatite | rel=r_associated | relid=0 | w=20
  5580. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> stérilet
    n1=en:contraindications aspect | n2=stérilet | rel=r_associated | relid=0 | w=20
  5581. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> stérilet intrauterine
    n1=en:contraindications aspect | n2=stérilet intrauterine | rel=r_associated | relid=0 | w=20
  5582. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sternotomie
    n1=en:contraindications aspect | n2=sternotomie | rel=r_associated | relid=0 | w=20
  5583. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> stéroïde isomérases
    n1=en:contraindications aspect | n2=stéroïde isomérases | rel=r_associated | relid=0 | w=20
  5584. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> stérol O-acyltransférase
    n1=en:contraindications aspect | n2=stérol O-acyltransférase | rel=r_associated | relid=0 | w=20
  5585. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> stérols
    n1=en:contraindications aspect | n2=stérols | rel=r_associated | relid=0 | w=20
  5586. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> substance colloïde
    n1=en:contraindications aspect | n2=substance colloïde | rel=r_associated | relid=0 | w=20
  5587. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> substitut du sang
    n1=en:contraindications aspect | n2=substitut du sang | rel=r_associated | relid=0 | w=20
  5588. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> subtilisine
    n1=en:contraindications aspect | n2=subtilisine | rel=r_associated | relid=0 | w=20
  5589. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sucrose
    n1=en:contraindications aspect | n2=sucrose | rel=r_associated | relid=0 | w=20
  5590. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sulfate de magnésie
    n1=en:contraindications aspect | n2=sulfate de magnésie | rel=r_associated | relid=0 | w=20
  5591. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sulfate de magnésium
    n1=en:contraindications aspect | n2=sulfate de magnésium | rel=r_associated | relid=0 | w=20
  5592. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sulfate de zinc
    n1=en:contraindications aspect | n2=sulfate de zinc | rel=r_associated | relid=0 | w=20
  5593. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> sulfites
    n1=en:contraindications aspect | n2=sulfites | rel=r_associated | relid=0 | w=20
  5594. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> surveillance pharmacologique
    n1=en:contraindications aspect | n2=surveillance pharmacologique | rel=r_associated | relid=0 | w=20
  5595. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> syringe
    n1=en:contraindications aspect | n2=syringe | rel=r_associated | relid=0 | w=20
  5596. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> talc
    n1=en:contraindications aspect | n2=talc | rel=r_associated | relid=0 | w=20
  5597. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> talquer quelque chose
    n1=en:contraindications aspect | n2=talquer quelque chose | rel=r_associated | relid=0 | w=20
  5598. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tdm
    n1=en:contraindications aspect | n2=tdm | rel=r_associated | relid=0 | w=20
  5599. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tdm
    (tomodensitométrie)
    n1=en:contraindications aspect | n2=tdm
    (tomodensitométrie)
    | rel=r_associated | relid=0 | w=20
  5600. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> technetium
    n1=en:contraindications aspect | n2=technetium | rel=r_associated | relid=0 | w=20
  5601. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> technétium
    n1=en:contraindications aspect | n2=technétium | rel=r_associated | relid=0 | w=20
  5602. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Téflon
    n1=en:contraindications aspect | n2=Téflon | rel=r_associated | relid=0 | w=20
  5603. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> téflon
    n1=en:contraindications aspect | n2=téflon | rel=r_associated | relid=0 | w=20
  5604. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> télémétrie
    n1=en:contraindications aspect | n2=télémétrie | rel=r_associated | relid=0 | w=20
  5605. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> temps de coagulation du sang entier
    n1=en:contraindications aspect | n2=temps de coagulation du sang entier | rel=r_associated | relid=0 | w=20
  5606. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> temps de prothrombine
    n1=en:contraindications aspect | n2=temps de prothrombine | rel=r_associated | relid=0 | w=20
  5607. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> temps de Quick
    n1=en:contraindications aspect | n2=temps de Quick | rel=r_associated | relid=0 | w=20
  5608. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> temps de quick
    n1=en:contraindications aspect | n2=temps de quick | rel=r_associated | relid=0 | w=20
  5609. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> temps de thrombine
    n1=en:contraindications aspect | n2=temps de thrombine | rel=r_associated | relid=0 | w=20
  5610. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> téniposide
    n1=en:contraindications aspect | n2=téniposide | rel=r_associated | relid=0 | w=20
  5611. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tension artérielle
    n1=en:contraindications aspect | n2=tension artérielle | rel=r_associated | relid=0 | w=20
  5612. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> TEP
    (tomographie par émission de positons)
    n1=en:contraindications aspect | n2=TEP
    (tomographie par émission de positons)
    | rel=r_associated | relid=0 | w=20
  5613. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> terbutaline
    n1=en:contraindications aspect | n2=terbutaline | rel=r_associated | relid=0 | w=20
  5614. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tert-butyl hydroperoxyde
    n1=en:contraindications aspect | n2=tert-butyl hydroperoxyde | rel=r_associated | relid=0 | w=20
  5615. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tests hématologiques
    n1=en:contraindications aspect | n2=tests hématologiques | rel=r_associated | relid=0 | w=20
  5616. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tétracycline
    n1=en:contraindications aspect | n2=tétracycline | rel=r_associated | relid=0 | w=20
  5617. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tétrahydroazoles
    n1=en:contraindications aspect | n2=tétrahydroazoles | rel=r_associated | relid=0 | w=20
  5618. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tétrahydropyrroles
    n1=en:contraindications aspect | n2=tétrahydropyrroles | rel=r_associated | relid=0 | w=20
  5619. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> texte source
    n1=en:contraindications aspect | n2=texte source | rel=r_associated | relid=0 | w=20
  5620. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thérapie à la lumière ultraviolet
    n1=en:contraindications aspect | n2=thérapie à la lumière ultraviolet | rel=r_associated | relid=0 | w=20
  5621. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thérapie d'exercice physique
    n1=en:contraindications aspect | n2=thérapie d'exercice physique | rel=r_associated | relid=0 | w=20
  5622. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thérapie par les exercices physiques
    n1=en:contraindications aspect | n2=thérapie par les exercices physiques | rel=r_associated | relid=0 | w=20
  5623. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thermodilution
    n1=en:contraindications aspect | n2=thermodilution | rel=r_associated | relid=0 | w=20
  5624. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thiadiazines
    n1=en:contraindications aspect | n2=thiadiazines | rel=r_associated | relid=0 | w=20
  5625. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thiamine
    n1=en:contraindications aspect | n2=thiamine | rel=r_associated | relid=0 | w=20
  5626. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thiamine pyrophosphatase
    n1=en:contraindications aspect | n2=thiamine pyrophosphatase | rel=r_associated | relid=0 | w=20
  5627. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thioridazine
    n1=en:contraindications aspect | n2=thioridazine | rel=r_associated | relid=0 | w=20
  5628. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thoracoabdominal (signe)
    n1=en:contraindications aspect | n2=thoracoabdominal (signe) | rel=r_associated | relid=0 | w=20
  5629. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thoracoplastie
    n1=en:contraindications aspect | n2=thoracoplastie | rel=r_associated | relid=0 | w=20
  5630. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thoracoplastie de Sauerbruch-Maurer
    n1=en:contraindications aspect | n2=thoracoplastie de Sauerbruch-Maurer | rel=r_associated | relid=0 | w=20
  5631. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thoracoscopie
    n1=en:contraindications aspect | n2=thoracoscopie | rel=r_associated | relid=0 | w=20
  5632. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thréonine déhydratase
    n1=en:contraindications aspect | n2=thréonine déhydratase | rel=r_associated | relid=0 | w=20
  5633. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thréonine-déshydratase
    n1=en:contraindications aspect | n2=thréonine-déshydratase | rel=r_associated | relid=0 | w=20
  5634. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thrombolytique
    n1=en:contraindications aspect | n2=thrombolytique | rel=r_associated | relid=0 | w=20
  5635. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thrombolytique (médicament)
    n1=en:contraindications aspect | n2=thrombolytique (médicament) | rel=r_associated | relid=0 | w=20
  5636. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thymidylate synthase
    n1=en:contraindications aspect | n2=thymidylate synthase | rel=r_associated | relid=0 | w=20
  5637. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> thyrotropine alfa
    n1=en:contraindications aspect | n2=thyrotropine alfa | rel=r_associated | relid=0 | w=20
  5638. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ticlopidine
    n1=en:contraindications aspect | n2=ticlopidine | rel=r_associated | relid=0 | w=20
  5639. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tilétamine
    n1=en:contraindications aspect | n2=tilétamine | rel=r_associated | relid=0 | w=20
  5640. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tocolyse
    n1=en:contraindications aspect | n2=tocolyse | rel=r_associated | relid=0 | w=20
  5641. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tolène
    n1=en:contraindications aspect | n2=tolène | rel=r_associated | relid=0 | w=20
  5642. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> toluène
    n1=en:contraindications aspect | n2=toluène | rel=r_associated | relid=0 | w=20
  5643. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Tomeno (angle de)
    n1=en:contraindications aspect | n2=Tomeno (angle de) | rel=r_associated | relid=0 | w=20
  5644. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomie
    n1=en:contraindications aspect | n2=tomie | rel=r_associated | relid=0 | w=20
  5645. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomo-échographie
    n1=en:contraindications aspect | n2=tomo-échographie | rel=r_associated | relid=0 | w=20
  5646. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomocaméra
    n1=en:contraindications aspect | n2=tomocaméra | rel=r_associated | relid=0 | w=20
  5647. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomodensimétrie
    n1=en:contraindications aspect | n2=tomodensimétrie | rel=r_associated | relid=0 | w=20
  5648. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Tomodensitométrie
    n1=en:contraindications aspect | n2=Tomodensitométrie | rel=r_associated | relid=0 | w=20
  5649. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> TomoDensitoMétrie
    n1=en:contraindications aspect | n2=TomoDensitoMétrie | rel=r_associated | relid=0 | w=20
  5650. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomodensitométrie
    n1=en:contraindications aspect | n2=tomodensitométrie | rel=r_associated | relid=0 | w=20
  5651. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomodensitométrie avec opacification cisternale
    n1=en:contraindications aspect | n2=tomodensitométrie avec opacification cisternale | rel=r_associated | relid=0 | w=20
  5652. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomodensitométrie cérébrale
    n1=en:contraindications aspect | n2=tomodensitométrie cérébrale | rel=r_associated | relid=0 | w=20
  5653. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomodensitométrie vertébrale
    n1=en:contraindications aspect | n2=tomodensitométrie vertébrale | rel=r_associated | relid=0 | w=20
  5654. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomogramme
    n1=en:contraindications aspect | n2=tomogramme | rel=r_associated | relid=0 | w=20
  5655. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographe
    n1=en:contraindications aspect | n2=tomographe | rel=r_associated | relid=0 | w=20
  5656. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographie à émission de positons
    n1=en:contraindications aspect | n2=tomographie à émission de positons | rel=r_associated | relid=0 | w=20
  5657. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographie à émission de positrons
    n1=en:contraindications aspect | n2=tomographie à émission de positrons | rel=r_associated | relid=0 | w=20
  5658. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographie à émission simple photon
    n1=en:contraindications aspect | n2=tomographie à émission simple photon | rel=r_associated | relid=0 | w=20
  5659. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographie à positons
    n1=en:contraindications aspect | n2=tomographie à positons | rel=r_associated | relid=0 | w=20
  5660. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographie à positrons
    n1=en:contraindications aspect | n2=tomographie à positrons | rel=r_associated | relid=0 | w=20
  5661. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographie assistée par ordinateur
    n1=en:contraindications aspect | n2=tomographie assistée par ordinateur | rel=r_associated | relid=0 | w=20
  5662. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographie axiale calculée par ordinateur
    n1=en:contraindications aspect | n2=tomographie axiale calculée par ordinateur | rel=r_associated | relid=0 | w=20
  5663. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographie par émission de positons
    n1=en:contraindications aspect | n2=tomographie par émission de positons | rel=r_associated | relid=0 | w=20
  5664. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tomographie par émission de positrons
    n1=en:contraindications aspect | n2=tomographie par émission de positrons | rel=r_associated | relid=0 | w=20
  5665. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Topografov (virus)
    n1=en:contraindications aspect | n2=Topografov (virus) | rel=r_associated | relid=0 | w=20
  5666. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> topographie cornéenne
    n1=en:contraindications aspect | n2=topographie cornéenne | rel=r_associated | relid=0 | w=20
  5667. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> toxaphène
    n1=en:contraindications aspect | n2=toxaphène | rel=r_associated | relid=0 | w=20
  5668. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> trachéostomie
    n1=en:contraindications aspect | n2=trachéostomie | rel=r_associated | relid=0 | w=20
  5669. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tractotomie de la moelle épinière
    n1=en:contraindications aspect | n2=tractotomie de la moelle épinière | rel=r_associated | relid=0 | w=20
  5670. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> traitement dentaire
    n1=en:contraindications aspect | n2=traitement dentaire | rel=r_associated | relid=0 | w=20
  5671. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> traitement par l'exercice
    n1=en:contraindications aspect | n2=traitement par l'exercice | rel=r_associated | relid=0 | w=20
  5672. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> traitement par l'exercice physique
    n1=en:contraindications aspect | n2=traitement par l'exercice physique | rel=r_associated | relid=0 | w=20
  5673. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> traitement par les exercices physiques
    n1=en:contraindications aspect | n2=traitement par les exercices physiques | rel=r_associated | relid=0 | w=20
  5674. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> traitement par lumière ultraviolette
    n1=en:contraindications aspect | n2=traitement par lumière ultraviolette | rel=r_associated | relid=0 | w=20
  5675. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> traitement par rayonnements ultraviolets
    n1=en:contraindications aspect | n2=traitement par rayonnements ultraviolets | rel=r_associated | relid=0 | w=20
  5676. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> traitement par ultra-violets
    n1=en:contraindications aspect | n2=traitement par ultra-violets | rel=r_associated | relid=0 | w=20
  5677. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> traitement par ultraviolets
    n1=en:contraindications aspect | n2=traitement par ultraviolets | rel=r_associated | relid=0 | w=20
  5678. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transaminase
    n1=en:contraindications aspect | n2=transaminase | rel=r_associated | relid=0 | w=20
  5679. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transforming growth factor
    n1=en:contraindications aspect | n2=transforming growth factor | rel=r_associated | relid=0 | w=20
  5680. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transfusion de sang
    n1=en:contraindications aspect | n2=transfusion de sang | rel=r_associated | relid=0 | w=20
  5681. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transfusion sanguine
    n1=en:contraindications aspect | n2=transfusion sanguine | rel=r_associated | relid=0 | w=20
  5682. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transfusion sanguine (organisation de la)
    n1=en:contraindications aspect | n2=transfusion sanguine (organisation de la) | rel=r_associated | relid=0 | w=20
  5683. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transglutaminase
    n1=en:contraindications aspect | n2=transglutaminase | rel=r_associated | relid=0 | w=20
  5684. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transillumination
    n1=en:contraindications aspect | n2=transillumination | rel=r_associated | relid=0 | w=20
  5685. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transplantation cornéenne
    n1=en:contraindications aspect | n2=transplantation cornéenne | rel=r_associated | relid=0 | w=20
  5686. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transplantation d'un pancreas
    n1=en:contraindications aspect | n2=transplantation d'un pancreas | rel=r_associated | relid=0 | w=20
  5687. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transplantation de cornée
    n1=en:contraindications aspect | n2=transplantation de cornée | rel=r_associated | relid=0 | w=20
  5688. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transplantation de pancreas
    n1=en:contraindications aspect | n2=transplantation de pancreas | rel=r_associated | relid=0 | w=20
  5689. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transplantation du pancreas
    n1=en:contraindications aspect | n2=transplantation du pancreas | rel=r_associated | relid=0 | w=20
  5690. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transplantation du pancréas
    n1=en:contraindications aspect | n2=transplantation du pancréas | rel=r_associated | relid=0 | w=20
  5691. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transplantations de pancreas
    n1=en:contraindications aspect | n2=transplantations de pancreas | rel=r_associated | relid=0 | w=20
  5692. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> transporteur de la dopamine
    n1=en:contraindications aspect | n2=transporteur de la dopamine | rel=r_associated | relid=0 | w=20
  5693. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> trastuzumab
    n1=en:contraindications aspect | n2=trastuzumab | rel=r_associated | relid=0 | w=20
  5694. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> trétinoïne
    n1=en:contraindications aspect | n2=trétinoïne | rel=r_associated | relid=0 | w=20
  5695. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> trientine
    n1=en:contraindications aspect | n2=trientine | rel=r_associated | relid=0 | w=20
  5696. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> trifluopérazine
    n1=en:contraindications aspect | n2=trifluopérazine | rel=r_associated | relid=0 | w=20
  5697. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> triflupromazine
    n1=en:contraindications aspect | n2=triflupromazine | rel=r_associated | relid=0 | w=20
  5698. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> triiodothyronine
    n1=en:contraindications aspect | n2=triiodothyronine | rel=r_associated | relid=0 | w=20
  5699. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> triméprazine
    n1=en:contraindications aspect | n2=triméprazine | rel=r_associated | relid=0 | w=20
  5700. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> triose-phosphate isomérase
    n1=en:contraindications aspect | n2=triose-phosphate isomérase | rel=r_associated | relid=0 | w=20
  5701. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> triterpènes
    n1=en:contraindications aspect | n2=triterpènes | rel=r_associated | relid=0 | w=20
  5702. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tropo-élastine
    n1=en:contraindications aspect | n2=tropo-élastine | rel=r_associated | relid=0 | w=20
  5703. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tropocollagène
    n1=en:contraindications aspect | n2=tropocollagène | rel=r_associated | relid=0 | w=20
  5704. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> trypsine
    n1=en:contraindications aspect | n2=trypsine | rel=r_associated | relid=0 | w=20
  5705. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> trypsinogène
    n1=en:contraindications aspect | n2=trypsinogène | rel=r_associated | relid=0 | w=20
  5706. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tryptamines
    n1=en:contraindications aspect | n2=tryptamines | rel=r_associated | relid=0 | w=20
  5707. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tungsten
    n1=en:contraindications aspect | n2=tungsten | rel=r_associated | relid=0 | w=20
  5708. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tungstène
    n1=en:contraindications aspect | n2=tungstène | rel=r_associated | relid=0 | w=20
  5709. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> type c phospholipases
    n1=en:contraindications aspect | n2=type c phospholipases | rel=r_associated | relid=0 | w=20
  5710. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> tyrocidine
    n1=en:contraindications aspect | n2=tyrocidine | rel=r_associated | relid=0 | w=20
  5711. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ultrasonographie
    n1=en:contraindications aspect | n2=ultrasonographie | rel=r_associated | relid=0 | w=20
  5712. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> un dentier
    n1=en:contraindications aspect | n2=un dentier | rel=r_associated | relid=0 | w=20
  5713. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> urétérostomie
    n1=en:contraindications aspect | n2=urétérostomie | rel=r_associated | relid=0 | w=20
  5714. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> uréthane
    n1=en:contraindications aspect | n2=uréthane | rel=r_associated | relid=0 | w=20
  5715. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> uridine diphosphate
    n1=en:contraindications aspect | n2=uridine diphosphate | rel=r_associated | relid=0 | w=20
  5716. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> uridine diphosphate glucose
    n1=en:contraindications aspect | n2=uridine diphosphate glucose | rel=r_associated | relid=0 | w=20
  5717. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> uridine-diphosphate
    n1=en:contraindications aspect | n2=uridine-diphosphate | rel=r_associated | relid=0 | w=20
  5718. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> uridine-diphosphate-glucose
    n1=en:contraindications aspect | n2=uridine-diphosphate-glucose | rel=r_associated | relid=0 | w=20
  5719. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> uridine-monophosphate
    n1=en:contraindications aspect | n2=uridine-monophosphate | rel=r_associated | relid=0 | w=20
  5720. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> urobiline
    n1=en:contraindications aspect | n2=urobiline | rel=r_associated | relid=0 | w=20
  5721. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> urocortine
    n1=en:contraindications aspect | n2=urocortine | rel=r_associated | relid=0 | w=20
  5722. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> urokinase
    n1=en:contraindications aspect | n2=urokinase | rel=r_associated | relid=0 | w=20
  5723. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> uroporphyrinogène-décarboxylase
    n1=en:contraindications aspect | n2=uroporphyrinogène-décarboxylase | rel=r_associated | relid=0 | w=20
  5724. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ursine
    n1=en:contraindications aspect | n2=ursine | rel=r_associated | relid=0 | w=20
  5725. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> ustekinumab
    n1=en:contraindications aspect | n2=ustekinumab | rel=r_associated | relid=0 | w=20
  5726. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin à ADN
    n1=en:contraindications aspect | n2=vaccin à ADN | rel=r_associated | relid=0 | w=20
  5727. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin à virus vivant de la rubéole
    n1=en:contraindications aspect | n2=vaccin à virus vivant de la rubéole | rel=r_associated | relid=0 | w=20
  5728. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin ADN
    n1=en:contraindications aspect | n2=vaccin ADN | rel=r_associated | relid=0 | w=20
  5729. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin adn
    n1=en:contraindications aspect | n2=vaccin adn | rel=r_associated | relid=0 | w=20
  5730. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin anti virus de l'herpes simplex
    n1=en:contraindications aspect | n2=vaccin anti virus de l'herpes simplex | rel=r_associated | relid=0 | w=20
  5731. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin anti virus herpes simplex
    n1=en:contraindications aspect | n2=vaccin anti virus herpes simplex | rel=r_associated | relid=0 | w=20
  5732. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin anti-hépatite A
    n1=en:contraindications aspect | n2=vaccin anti-hépatite A | rel=r_associated | relid=0 | w=20
  5733. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin anti-virus herpes simplex
    n1=en:contraindications aspect | n2=vaccin anti-virus herpes simplex | rel=r_associated | relid=0 | w=20
  5734. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin antigrippal
    n1=en:contraindications aspect | n2=vaccin antigrippal | rel=r_associated | relid=0 | w=20
  5735. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin antimicrobien
    n1=en:contraindications aspect | n2=vaccin antimicrobien | rel=r_associated | relid=0 | w=20
  5736. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin antirubéoleux
    n1=en:contraindications aspect | n2=vaccin antirubéoleux | rel=r_associated | relid=0 | w=20
  5737. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin antivirus de l'herpes simplex
    n1=en:contraindications aspect | n2=vaccin antivirus de l'herpes simplex | rel=r_associated | relid=0 | w=20
  5738. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin contre l'hépatite A
    n1=en:contraindications aspect | n2=vaccin contre l'hépatite A | rel=r_associated | relid=0 | w=20
  5739. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin contre l'hépatite a
    n1=en:contraindications aspect | n2=vaccin contre l'hépatite a | rel=r_associated | relid=0 | w=20
  5740. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Vaccin contre l'hépatite A
    n1=en:contraindications aspect | n2=Vaccin contre l'hépatite A | rel=r_associated | relid=0 | w=20
  5741. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin contre la rubéole
    n1=en:contraindications aspect | n2=vaccin contre la rubéole | rel=r_associated | relid=0 | w=20
  5742. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin contre le virus de la rubéole
    n1=en:contraindications aspect | n2=vaccin contre le virus de la rubéole | rel=r_associated | relid=0 | w=20
  5743. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccin microbien
    n1=en:contraindications aspect | n2=vaccin microbien | rel=r_associated | relid=0 | w=20
  5744. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccinal
    n1=en:contraindications aspect | n2=vaccinal | rel=r_associated | relid=0 | w=20
  5745. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccine
    n1=en:contraindications aspect | n2=vaccine | rel=r_associated | relid=0 | w=20
  5746. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccins anti virus herpes simplex
    n1=en:contraindications aspect | n2=vaccins anti virus herpes simplex | rel=r_associated | relid=0 | w=20
  5747. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccins anti-virus de l'herpes simplex
    n1=en:contraindications aspect | n2=vaccins anti-virus de l'herpes simplex | rel=r_associated | relid=0 | w=20
  5748. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccins antivirus de l'herpes simplex
    n1=en:contraindications aspect | n2=vaccins antivirus de l'herpes simplex | rel=r_associated | relid=0 | w=20
  5749. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vaccins contre le virus herpès simplex
    n1=en:contraindications aspect | n2=vaccins contre le virus herpès simplex | rel=r_associated | relid=0 | w=20
  5750. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vanadates
    n1=en:contraindications aspect | n2=vanadates | rel=r_associated | relid=0 | w=20
  5751. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vancomycine
    n1=en:contraindications aspect | n2=vancomycine | rel=r_associated | relid=0 | w=20
  5752. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vasodilatateur
    n1=en:contraindications aspect | n2=vasodilatateur | rel=r_associated | relid=0 | w=20
  5753. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vératrine
    n1=en:contraindications aspect | n2=vératrine | rel=r_associated | relid=0 | w=20
  5754. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vert d'indocyanine
    n1=en:contraindications aspect | n2=vert d'indocyanine | rel=r_associated | relid=0 | w=20
  5755. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vert indocyanine
    n1=en:contraindications aspect | n2=vert indocyanine | rel=r_associated | relid=0 | w=20
  5756. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vinblastine
    n1=en:contraindications aspect | n2=vinblastine | rel=r_associated | relid=0 | w=20
  5757. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> violet de gentiane
    n1=en:contraindications aspect | n2=violet de gentiane | rel=r_associated | relid=0 | w=20
  5758. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vitallium
    n1=en:contraindications aspect | n2=vitallium | rel=r_associated | relid=0 | w=20
  5759. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vitamine B1
    n1=en:contraindications aspect | n2=vitamine B1 | rel=r_associated | relid=0 | w=20
  5760. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vitamine b5
    n1=en:contraindications aspect | n2=vitamine b5 | rel=r_associated | relid=0 | w=20
  5761. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vitamine B5
    n1=en:contraindications aspect | n2=vitamine B5 | rel=r_associated | relid=0 | w=20
  5762. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vitamine b6
    n1=en:contraindications aspect | n2=vitamine b6 | rel=r_associated | relid=0 | w=20
  5763. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Vitamine B6
    n1=en:contraindications aspect | n2=Vitamine B6 | rel=r_associated | relid=0 | w=20
  5764. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vitamine B6
    n1=en:contraindications aspect | n2=vitamine B6 | rel=r_associated | relid=0 | w=20
  5765. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> Vitamine K1
    n1=en:contraindications aspect | n2=Vitamine K1 | rel=r_associated | relid=0 | w=20
  5766. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vitamine k1
    n1=en:contraindications aspect | n2=vitamine k1 | rel=r_associated | relid=0 | w=20
  5767. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vitamine K1
    n1=en:contraindications aspect | n2=vitamine K1 | rel=r_associated | relid=0 | w=20
  5768. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vitellins
    n1=en:contraindications aspect | n2=vitellins | rel=r_associated | relid=0 | w=20
  5769. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> vivisection
    n1=en:contraindications aspect | n2=vivisection | rel=r_associated | relid=0 | w=20
  5770. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> warfarine
    n1=en:contraindications aspect | n2=warfarine | rel=r_associated | relid=0 | w=20
  5771. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> wolframite
    n1=en:contraindications aspect | n2=wolframite | rel=r_associated | relid=0 | w=20
  5772. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> xanthoptérine
    n1=en:contraindications aspect | n2=xanthoptérine | rel=r_associated | relid=0 | w=20
  5773. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> xéromammographie
    n1=en:contraindications aspect | n2=xéromammographie | rel=r_associated | relid=0 | w=20
  5774. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> xylulose
    n1=en:contraindications aspect | n2=xylulose | rel=r_associated | relid=0 | w=20
  5775. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> zéatine
    n1=en:contraindications aspect | n2=zéatine | rel=r_associated | relid=0 | w=20
  5776. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> zéine
    n1=en:contraindications aspect | n2=zéine | rel=r_associated | relid=0 | w=20
  5777. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> zéolites
    n1=en:contraindications aspect | n2=zéolites | rel=r_associated | relid=0 | w=20
  5778. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> zidovudine
    n1=en:contraindications aspect | n2=zidovudine | rel=r_associated | relid=0 | w=20
  5779. en:contraindications aspect -- r_associated #0: 20 / 0.571 -> zymosan
    n1=en:contraindications aspect | n2=zymosan | rel=r_associated | relid=0 | w=20
≈ 7738 relations entrantes

  1. lipoprotein --- r_associated #0: 888.17 --> en:contraindications aspect
    n1=lipoprotein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=888.17
  2. protein --- r_associated #0: 825 --> en:contraindications aspect
    n1=protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=825
  3. protéine --- r_associated #0: 798.95 --> en:contraindications aspect
    n1=protéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=798.95
  4. en:protein --- r_associated #0: 798.67 --> en:contraindications aspect
    n1=en:protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=798.67
  5. lipoproteine --- r_associated #0: 750 --> en:contraindications aspect
    n1=lipoproteine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=750
  6. en:therapeutic procedure --- r_associated #0: 725 --> en:contraindications aspect
    n1=en:therapeutic procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=725
  7. procédure thérapeutique --- r_associated #0: 723 --> en:contraindications aspect
    n1=procédure thérapeutique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=723
  8. traitement médical --- r_associated #0: 716 --> en:contraindications aspect
    n1=traitement médical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=716
  9. en:lipoprotein --- r_associated #0: 671.16 --> en:contraindications aspect
    n1=en:lipoprotein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=671.16
  10. lipoprotéine --- r_associated #0: 656.44 --> en:contraindications aspect
    n1=lipoprotéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=656.44
  11. en:receptors, guanylate cyclase-coupled --- r_associated #0: 535 --> en:contraindications aspect
    n1=en:receptors, guanylate cyclase-coupled | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=535
  12. récepteurs à activité guanylate cyclase --- r_associated #0: 534 --> en:contraindications aspect
    n1=récepteurs à activité guanylate cyclase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=534
  13. en:interleukin --- r_associated #0: 478 --> en:contraindications aspect
    n1=en:interleukin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=478
  14. interleukine --- r_associated #0: 475 --> en:contraindications aspect
    n1=interleukine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=475
  15. en:vaccination --- r_associated #0: 444 --> en:contraindications aspect
    n1=en:vaccination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=444
  16. vaccination --- r_associated #0: 440 --> en:contraindications aspect
    n1=vaccination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=440
  17. cystatine B --- r_associated #0: 419 --> en:contraindications aspect
    n1=cystatine B | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=419
  18. en:cystatin b --- r_associated #0: 415 --> en:contraindications aspect
    n1=en:cystatin b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=415
  19. prostaglandine --- r_associated #0: 413 --> en:contraindications aspect
    n1=prostaglandine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=413
  20. en:prostaglandin --- r_associated #0: 409 --> en:contraindications aspect
    n1=en:prostaglandin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=409
  21. en:sorbitol --- r_associated #0: 401 --> en:contraindications aspect
    n1=en:sorbitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=401
  22. sorbitol --- r_associated #0: 397 --> en:contraindications aspect
    n1=sorbitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=397
  23. en:medical treatment --- r_associated #0: 386 --> en:contraindications aspect
    n1=en:medical treatment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=386
  24. ressuscitation --- r_associated #0: 380 --> en:contraindications aspect
    n1=ressuscitation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=380
  25. en:resuscitation --- r_associated #0: 379 --> en:contraindications aspect
    n1=en:resuscitation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=379
  26. ose --- r_associated #0: 359 --> en:contraindications aspect
    n1=ose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=359
  27. en:monosaccharide --- r_associated #0: 358 --> en:contraindications aspect
    n1=en:monosaccharide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=358
  28. radiographie de contraste des voies biliaires --- r_associated #0: 353 --> en:contraindications aspect
    n1=radiographie de contraste des voies biliaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=353
  29. en:cholangiography --- r_associated #0: 350 --> en:contraindications aspect
    n1=en:cholangiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=350
  30. talc --- r_associated #0: 345 --> en:contraindications aspect
    n1=talc | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=345
  31. cholangiographies --- r_associated #0: 344 --> en:contraindications aspect
    n1=cholangiographies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=344
  32. en:talc --- r_associated #0: 342 --> en:contraindications aspect
    n1=en:talc | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=342
  33. angiocholégraphie --- r_associated #0: 335 --> en:contraindications aspect
    n1=angiocholégraphie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=335
  34. angiocholécystographie --- r_associated #0: 327 --> en:contraindications aspect
    n1=angiocholécystographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=327
  35. Chola --- r_associated #0: 323 --> en:contraindications aspect
    n1=Chola | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=323
  36. déodorants --- r_associated #0: 320 --> en:contraindications aspect
    n1=déodorants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=320
  37. tubuline --- r_associated #0: 319 --> en:contraindications aspect
    n1=tubuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=319
  38. en:tubulin --- r_associated #0: 318 --> en:contraindications aspect
    n1=en:tubulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=318
  39. produits désodorisants --- r_associated #0: 318 --> en:contraindications aspect
    n1=produits désodorisants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=318
  40. cholangiographie --- r_associated #0: 315 --> en:contraindications aspect
    n1=cholangiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=315
  41. en:antineoplastic agent --- r_associated #0: 315 --> en:contraindications aspect
    n1=en:antineoplastic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=315
  42. agent antinéoplasique --- r_associated #0: 313 --> en:contraindications aspect
    n1=agent antinéoplasique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=313
  43. tests hématologiques --- r_associated #0: 312 --> en:contraindications aspect
    n1=tests hématologiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=312
  44. en:hematologic tests --- r_associated #0: 310 --> en:contraindications aspect
    n1=en:hematologic tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=310
  45. agents désodorisants --- r_associated #0: 309 --> en:contraindications aspect
    n1=agents désodorisants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=309
  46. désodorisants --- r_associated #0: 309 --> en:contraindications aspect
    n1=désodorisants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=309
  47. proteine --- r_associated #0: 305 --> en:contraindications aspect
    n1=proteine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=305
  48. produits déodorants --- r_associated #0: 302 --> en:contraindications aspect
    n1=produits déodorants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=302
  49. biligraphie --- r_associated #0: 300 --> en:contraindications aspect
    n1=biligraphie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=300
  50. en:deodorants --- r_associated #0: 300 --> en:contraindications aspect
    n1=en:deodorants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=300
  51. agents déodorants --- r_associated #0: 299 --> en:contraindications aspect
    n1=agents déodorants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=299
  52. cholangio --- r_associated #0: 295 --> en:contraindications aspect
    n1=cholangio | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=295
  53. en:organic chemical --- r_associated #0: 295 --> en:contraindications aspect
    n1=en:organic chemical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=295
  54. mesure de la pa --- r_associated #0: 295 --> en:contraindications aspect
    n1=mesure de la pa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=295
  55. composé chimique organique --- r_associated #0: 293 --> en:contraindications aspect
    n1=composé chimique organique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=293
  56. en:cholangiogram --- r_associated #0: 291 --> en:contraindications aspect
    n1=en:cholangiogram | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=291
  57. produit chimique organique --- r_associated #0: 289 --> en:contraindications aspect
    n1=produit chimique organique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=289
  58. troponine --- r_associated #0: 275 --> en:contraindications aspect
    n1=troponine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=275
  59. en:troponin --- r_associated #0: 272 --> en:contraindications aspect
    n1=en:troponin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=272
  60. en:enzyme --- r_associated #0: 271 --> en:contraindications aspect
    n1=en:enzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=271
  61. enzyme --- r_associated #0: 269 --> en:contraindications aspect
    n1=enzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=269
  62. en:antidiarrheal agent --- r_associated #0: 256 --> en:contraindications aspect
    n1=en:antidiarrheal agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=256
  63. agent antidiarrhéique --- r_associated #0: 255 --> en:contraindications aspect
    n1=agent antidiarrhéique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=255
  64. anti-diarrhéique --- r_associated #0: 255 --> en:contraindications aspect
    n1=anti-diarrhéique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=255
  65. médicament antidiarrhéique --- r_associated #0: 255 --> en:contraindications aspect
    n1=médicament antidiarrhéique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=255
  66. fluorouracile --- r_associated #0: 254 --> en:contraindications aspect
    n1=fluorouracile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=254
  67. en:fluorouracil --- r_associated #0: 251 --> en:contraindications aspect
    n1=en:fluorouracil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=251
  68. insertion de cathéter --- r_associated #0: 251 --> en:contraindications aspect
    n1=insertion de cathéter | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=251
  69. en:antibody --- r_associated #0: 250 --> en:contraindications aspect
    n1=en:antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=250
  70. en:catheterization --- r_associated #0: 250 --> en:contraindications aspect
    n1=en:catheterization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=250
  71. anticorps --- r_associated #0: 246 --> en:contraindications aspect
    n1=anticorps | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=246
  72. péthidines --- r_associated #0: 246 --> en:contraindications aspect
    n1=péthidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=246
  73. chlorhydrate de péthidine --- r_associated #0: 245 --> en:contraindications aspect
    n1=chlorhydrate de péthidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=245
  74. albumine bovine sérique --- r_associated #0: 244 --> en:contraindications aspect
    n1=albumine bovine sérique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=244
  75. en:dna vaccine --- r_associated #0: 244 --> en:contraindications aspect
    n1=en:dna vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=244
  76. chaperon moléculaire --- r_associated #0: 241 --> en:contraindications aspect
    n1=chaperon moléculaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=241
  77. en:DNA vaccine --- r_associated #0: 240 --> en:contraindications aspect
    n1=en:DNA vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=240
  78. en:bovine serum albumin --- r_associated #0: 240 --> en:contraindications aspect
    n1=en:bovine serum albumin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=240
  79. en:dolargan --- r_associated #0: 240 --> en:contraindications aspect
    n1=en:dolargan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=240
  80. en:chaperone --- r_associated #0: 239 --> en:contraindications aspect
    n1=en:chaperone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=239
  81. en:dolantin --- r_associated #0: 239 --> en:contraindications aspect
    n1=en:dolantin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=239
  82. en:haemato fu --- r_associated #0: 239 --> en:contraindications aspect
    n1=en:haemato fu | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=239
  83. en:serum albumin, bovine --- r_associated #0: 238 --> en:contraindications aspect
    n1=en:serum albumin, bovine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=238
  84. en:meperidine --- r_associated #0: 236 --> en:contraindications aspect
    n1=en:meperidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=236
  85. sérum albumine bovine --- r_associated #0: 236 --> en:contraindications aspect
    n1=sérum albumine bovine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=236
  86. en:dolcontral --- r_associated #0: 235 --> en:contraindications aspect
    n1=en:dolcontral | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=235
  87. en:dolosal --- r_associated #0: 235 --> en:contraindications aspect
    n1=en:dolosal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=235
  88. en:dolsin --- r_associated #0: 235 --> en:contraindications aspect
    n1=en:dolsin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=235
  89. en:meperidine hydrochloride --- r_associated #0: 235 --> en:contraindications aspect
    n1=en:meperidine hydrochloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=235
  90. sérumalbumine bovine --- r_associated #0: 235 --> en:contraindications aspect
    n1=sérumalbumine bovine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=235
  91. péthidine --- r_associated #0: 234 --> en:contraindications aspect
    n1=péthidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=234
  92. cathétérisation --- r_associated #0: 232 --> en:contraindications aspect
    n1=cathétérisation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=232
  93. en:operidine epj i --- r_associated #0: 230 --> en:contraindications aspect
    n1=en:operidine epj i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=230
  94. hydrocortisones --- r_associated #0: 230 --> en:contraindications aspect
    n1=hydrocortisones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=230
  95. préparation du composé f --- r_associated #0: 230 --> en:contraindications aspect
    n1=préparation du composé f | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=230
  96. en:lactic acid --- r_associated #0: 228 --> en:contraindications aspect
    n1=en:lactic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=228
  97. en:hydrocortisone --- r_associated #0: 226 --> en:contraindications aspect
    n1=en:hydrocortisone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=226
  98. Acide lactique --- r_associated #0: 225 --> en:contraindications aspect
    n1=Acide lactique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=225
  99. en:dolin --- r_associated #0: 225 --> en:contraindications aspect
    n1=en:dolin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=225
  100. vaccin adn --- r_associated #0: 225 --> en:contraindications aspect
    n1=vaccin adn | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=225
  101. vaccin à ADN --- r_associated #0: 225 --> en:contraindications aspect
    n1=vaccin à ADN | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=225
  102. acide lactique --- r_associated #0: 224 --> en:contraindications aspect
    n1=acide lactique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=224
  103. irm --- r_associated #0: 224 --> en:contraindications aspect
    n1=irm | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=224
  104. albumine de sérum bovin --- r_associated #0: 223 --> en:contraindications aspect
    n1=albumine de sérum bovin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=223
  105. en:magnetic resonance imaging --- r_associated #0: 223 --> en:contraindications aspect
    n1=en:magnetic resonance imaging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=223
  106. albumine sérique bovine --- r_associated #0: 221 --> en:contraindications aspect
    n1=albumine sérique bovine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=221
  107. préparation d'hydrocortisone --- r_associated #0: 220 --> en:contraindications aspect
    n1=préparation d'hydrocortisone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=220
  108. préparation de cortisol --- r_associated #0: 220 --> en:contraindications aspect
    n1=préparation de cortisol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=220
  109. vaccin ADN --- r_associated #0: 220 --> en:contraindications aspect
    n1=vaccin ADN | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=220
  110. bronchogramme de contraste --- r_associated #0: 215 --> en:contraindications aspect
    n1=bronchogramme de contraste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=215
  111. cortisol --- r_associated #0: 215 --> en:contraindications aspect
    n1=cortisol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=215
  112. inoculation --- r_associated #0: 215 --> en:contraindications aspect
    n1=inoculation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=215
  113. xanthoptérine --- r_associated #0: 215 --> en:contraindications aspect
    n1=xanthoptérine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=215
  114. hydrocortisone --- r_associated #0: 214 --> en:contraindications aspect
    n1=hydrocortisone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=214
  115. en:bronchography --- r_associated #0: 213 --> en:contraindications aspect
    n1=en:bronchography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=213
  116. en:catheterization, central venous --- r_associated #0: 213 --> en:contraindications aspect
    n1=en:catheterization, central venous | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=213
  117. en:nonesterified fatty acids --- r_associated #0: 212 --> en:contraindications aspect
    n1=en:nonesterified fatty acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=212
  118. en:xanthopterin --- r_associated #0: 212 --> en:contraindications aspect
    n1=en:xanthopterin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=212
  119. bronchogramme --- r_associated #0: 211 --> en:contraindications aspect
    n1=bronchogramme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=211
  120. acides gras non estérifiés --- r_associated #0: 210 --> en:contraindications aspect
    n1=acides gras non estérifiés | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=210
  121. cathétérisation veineuse centrale --- r_associated #0: 210 --> en:contraindications aspect
    n1=cathétérisation veineuse centrale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=210
  122. en:contrast bronchogram --- r_associated #0: 210 --> en:contraindications aspect
    n1=en:contrast bronchogram | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=210
  123. cathétérisme veineux central --- r_associated #0: 209 --> en:contraindications aspect
    n1=cathétérisme veineux central | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=209
  124. en:endotamponade --- r_associated #0: 207 --> en:contraindications aspect
    n1=en:endotamponade | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=207
  125. intervention thérapeutique --- r_associated #0: 207 --> en:contraindications aspect
    n1=intervention thérapeutique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=207
  126. bronchographie --- r_associated #0: 205 --> en:contraindications aspect
    n1=bronchographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=205
  127. en:scintiphotography --- r_associated #0: 204 --> en:contraindications aspect
    n1=en:scintiphotography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=204
  128. en:steatite --- r_associated #0: 204 --> en:contraindications aspect
    n1=en:steatite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=204
  129. tamponnement interne --- r_associated #0: 203 --> en:contraindications aspect
    n1=tamponnement interne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=203
  130. en:radionuclide imaging --- r_associated #0: 200 --> en:contraindications aspect
    n1=en:radionuclide imaging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=200
  131. imagerie de diffusion en irm --- r_associated #0: 200 --> en:contraindications aspect
    n1=imagerie de diffusion en irm | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=200
  132. imagerie de diffusion par résonance magnétique --- r_associated #0: 200 --> en:contraindications aspect
    n1=imagerie de diffusion par résonance magnétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=200
  133. imagerie par résonance magnétique de diffusion --- r_associated #0: 200 --> en:contraindications aspect
    n1=imagerie par résonance magnétique de diffusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=200
  134. scintigraphie --- r_associated #0: 200 --> en:contraindications aspect
    n1=scintigraphie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=200
  135. série des lanthanides --- r_associated #0: 197 --> en:contraindications aspect
    n1=série des lanthanides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=197
  136. en:diffusion magnetic resonance imaging --- r_associated #0: 196 --> en:contraindications aspect
    n1=en:diffusion magnetic resonance imaging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=196
  137. en:diffusion mri --- r_associated #0: 196 --> en:contraindications aspect
    n1=en:diffusion mri | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=196
  138. acide gras libre --- r_associated #0: 195 --> en:contraindications aspect
    n1=acide gras libre | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=195
  139. agoniste myelo ablatif --- r_associated #0: 195 --> en:contraindications aspect
    n1=agoniste myelo ablatif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=195
  140. antidiarrhéique --- r_associated #0: 195 --> en:contraindications aspect
    n1=antidiarrhéique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=195
  141. en:cortisol --- r_associated #0: 195 --> en:contraindications aspect
    n1=en:cortisol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=195
  142. en:dental high-speed equipment --- r_associated #0: 195 --> en:contraindications aspect
    n1=en:dental high-speed equipment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=195
  143. en:lanthanoid series elements --- r_associated #0: 195 --> en:contraindications aspect
    n1=en:lanthanoid series elements | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=195
  144. en:soapstone --- r_associated #0: 195 --> en:contraindications aspect
    n1=en:soapstone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=195
  145. pierre à savon --- r_associated #0: 195 --> en:contraindications aspect
    n1=pierre à savon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=195
  146. agonistes myelo ablatifs --- r_associated #0: 194 --> en:contraindications aspect
    n1=agonistes myelo ablatifs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=194
  147. bioprothèse --- r_associated #0: 192 --> en:contraindications aspect
    n1=bioprothèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=192
  148. en:veterinary drugs --- r_associated #0: 192 --> en:contraindications aspect
    n1=en:veterinary drugs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=192
  149. matériel dentaire à haute vitesse --- r_associated #0: 192 --> en:contraindications aspect
    n1=matériel dentaire à haute vitesse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=192
  150. équipement dentaire à grande vitesse --- r_associated #0: 192 --> en:contraindications aspect
    n1=équipement dentaire à grande vitesse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=192
  151. en:atosil --- r_associated #0: 190 --> en:contraindications aspect
    n1=en:atosil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=190
  152. en:bioprosthesis device --- r_associated #0: 190 --> en:contraindications aspect
    n1=en:bioprosthesis device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=190
  153. en:isopromethazine --- r_associated #0: 190 --> en:contraindications aspect
    n1=en:isopromethazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=190
  154. prométhazines --- r_associated #0: 190 --> en:contraindications aspect
    n1=prométhazines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=190
  155. médicaments animaux --- r_associated #0: 188 --> en:contraindications aspect
    n1=médicaments animaux | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=188
  156. médicaments vétérinaires --- r_associated #0: 188 --> en:contraindications aspect
    n1=médicaments vétérinaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=188
  157. surveillance pharmacologique --- r_associated #0: 187 --> en:contraindications aspect
    n1=surveillance pharmacologique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=187
  158. alimentation parentérale exclusive --- r_associated #0: 185 --> en:contraindications aspect
    n1=alimentation parentérale exclusive | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=185
  159. alimentation parentérale totale --- r_associated #0: 185 --> en:contraindications aspect
    n1=alimentation parentérale totale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=185
  160. en:carbohydrate --- r_associated #0: 185 --> en:contraindications aspect
    n1=en:carbohydrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=185
  161. en:diprazin --- r_associated #0: 185 --> en:contraindications aspect
    n1=en:diprazin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=185
  162. en:drug monitoring --- r_associated #0: 185 --> en:contraindications aspect
    n1=en:drug monitoring | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=185
  163. en:myeloablative agonist --- r_associated #0: 185 --> en:contraindications aspect
    n1=en:myeloablative agonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=185
  164. en:phensedyl --- r_associated #0: 185 --> en:contraindications aspect
    n1=en:phensedyl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=185
  165. inhibiteur de l'aromatase --- r_associated #0: 185 --> en:contraindications aspect
    n1=inhibiteur de l'aromatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=185
  166. prométhazine --- r_associated #0: 183 --> en:contraindications aspect
    n1=prométhazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=183
  167. en:aromatase inhibitor --- r_associated #0: 182 --> en:contraindications aspect
    n1=en:aromatase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=182
  168. craniométrie --- r_associated #0: 181 --> en:contraindications aspect
    n1=craniométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=181
  169. glucide --- r_associated #0: 181 --> en:contraindications aspect
    n1=glucide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=181
  170. toxaphène --- r_associated #0: 181 --> en:contraindications aspect
    n1=toxaphène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=181
  171. en:craniometry --- r_associated #0: 180 --> en:contraindications aspect
    n1=en:craniometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=180
  172. en:promet --- r_associated #0: 180 --> en:contraindications aspect
    n1=en:promet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=180
  173. en:promethazine --- r_associated #0: 180 --> en:contraindications aspect
    n1=en:promethazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=180
  174. en:pyrethia --- r_associated #0: 180 --> en:contraindications aspect
    n1=en:pyrethia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=180
  175. en:toxaphene --- r_associated #0: 180 --> en:contraindications aspect
    n1=en:toxaphene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=180
  176. nutrition parentérale totale --- r_associated #0: 180 --> en:contraindications aspect
    n1=nutrition parentérale totale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=180
  177. produit anesthésiant --- r_associated #0: 180 --> en:contraindications aspect
    n1=produit anesthésiant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=180
  178. en:anesthetic agent --- r_associated #0: 179 --> en:contraindications aspect
    n1=en:anesthetic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=179
  179. céphalométrie --- r_associated #0: 177 --> en:contraindications aspect
    n1=céphalométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=177
  180. acide oxalique --- r_associated #0: 176 --> en:contraindications aspect
    n1=acide oxalique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=176
  181. en:talcum powder --- r_associated #0: 176 --> en:contraindications aspect
    n1=en:talcum powder | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=176
  182. en:total parenteral nutrition --- r_associated #0: 176 --> en:contraindications aspect
    n1=en:total parenteral nutrition | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=176
  183. en:prothazin --- r_associated #0: 175 --> en:contraindications aspect
    n1=en:prothazin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=175
  184. oxygénation par membrane extracorporelle --- r_associated #0: 174 --> en:contraindications aspect
    n1=oxygénation par membrane extracorporelle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=174
  185. en:oxalic acid --- r_associated #0: 173 --> en:contraindications aspect
    n1=en:oxalic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=173
  186. méthadone --- r_associated #0: 173 --> en:contraindications aspect
    n1=méthadone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=173
  187. oxygénation par membrane extra-corporelle --- r_associated #0: 173 --> en:contraindications aspect
    n1=oxygénation par membrane extra-corporelle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=173
  188. agonistes myélo-ablatifs --- r_associated #0: 170 --> en:contraindications aspect
    n1=agonistes myélo-ablatifs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  189. chordotomie spinale --- r_associated #0: 170 --> en:contraindications aspect
    n1=chordotomie spinale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  190. cordotomie spinale --- r_associated #0: 170 --> en:contraindications aspect
    n1=cordotomie spinale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  191. en:cephalometry --- r_associated #0: 170 --> en:contraindications aspect
    n1=en:cephalometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  192. en:cordotomy --- r_associated #0: 170 --> en:contraindications aspect
    n1=en:cordotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  193. en:extracorporeal membrane oxygenation --- r_associated #0: 170 --> en:contraindications aspect
    n1=en:extracorporeal membrane oxygenation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  194. en:hydrocarbon --- r_associated #0: 170 --> en:contraindications aspect
    n1=en:hydrocarbon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  195. en:methadone --- r_associated #0: 170 --> en:contraindications aspect
    n1=en:methadone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  196. fractionnement des faisceaux rachidiens --- r_associated #0: 170 --> en:contraindications aspect
    n1=fractionnement des faisceaux rachidiens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  197. opération de bishoff --- r_associated #0: 170 --> en:contraindications aspect
    n1=opération de bishoff | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  198. prothèse de vaisseau sanguin --- r_associated #0: 170 --> en:contraindications aspect
    n1=prothèse de vaisseau sanguin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  199. section des faisceaux rachidiens --- r_associated #0: 170 --> en:contraindications aspect
    n1=section des faisceaux rachidiens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  200. section transversale des faisceaux rachidiens --- r_associated #0: 170 --> en:contraindications aspect
    n1=section transversale des faisceaux rachidiens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  201. tractotomie de la moelle épinière --- r_associated #0: 170 --> en:contraindications aspect
    n1=tractotomie de la moelle épinière | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  202. équipement dentaire pour grandes vitesses --- r_associated #0: 170 --> en:contraindications aspect
    n1=équipement dentaire pour grandes vitesses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=170
  203. agonistes myéloablatifs --- r_associated #0: 169 --> en:contraindications aspect
    n1=agonistes myéloablatifs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=169
  204. en:blood vessel prosthesis --- r_associated #0: 169 --> en:contraindications aspect
    n1=en:blood vessel prosthesis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=169
  205. oxygénation extracorporelle sur oxygénateur à membrane --- r_associated #0: 169 --> en:contraindications aspect
    n1=oxygénation extracorporelle sur oxygénateur à membrane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=169
  206. chordotomie --- r_associated #0: 167 --> en:contraindications aspect
    n1=chordotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=167
  207. IRM de diffusion --- r_associated #0: 166 --> en:contraindications aspect
    n1=IRM de diffusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=166
  208. hydrocarbure --- r_associated #0: 166 --> en:contraindications aspect
    n1=hydrocarbure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=166
  209. aedes albopictus --- r_associated #0: 165 --> en:contraindications aspect
    n1=aedes albopictus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=165
  210. en:dental prosthesis --- r_associated #0: 165 --> en:contraindications aspect
    n1=en:dental prosthesis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=165
  211. hydrate de carbone --- r_associated #0: 165 --> en:contraindications aspect
    n1=hydrate de carbone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=165
  212. oxygénation extracorporelle par membrane artificielle --- r_associated #0: 165 --> en:contraindications aspect
    n1=oxygénation extracorporelle par membrane artificielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=165
  213. radiographie abdominale --- r_associated #0: 165 --> en:contraindications aspect
    n1=radiographie abdominale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=165
  214. amputation --- r_associated #0: 164 --> en:contraindications aspect
    n1=amputation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=164
  215. en:aedes albopictus --- r_associated #0: 164 --> en:contraindications aspect
    n1=en:aedes albopictus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=164
  216. Aedes albopictus --- r_associated #0: 162 --> en:contraindications aspect
    n1=Aedes albopictus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=162
  217. prothèse dentaire --- r_associated #0: 161 --> en:contraindications aspect
    n1=prothèse dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=161
  218. Vitamine K1 --- r_associated #0: 160 --> en:contraindications aspect
    n1=Vitamine K1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=160
  219. anesthésique --- r_associated #0: 160 --> en:contraindications aspect
    n1=anesthésique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=160
  220. en:amputation --- r_associated #0: 160 --> en:contraindications aspect
    n1=en:amputation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=160
  221. oxygénation extracorporelle sur membrane --- r_associated #0: 160 --> en:contraindications aspect
    n1=oxygénation extracorporelle sur membrane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=160
  222. scan ir --- r_associated #0: 160 --> en:contraindications aspect
    n1=scan ir | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=160
  223. vitamine K1 --- r_associated #0: 160 --> en:contraindications aspect
    n1=vitamine K1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=160
  224. chlore --- r_associated #0: 159 --> en:contraindications aspect
    n1=chlore | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=159
  225. vitamine k1 --- r_associated #0: 158 --> en:contraindications aspect
    n1=vitamine k1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=158
  226. en:abdominal radiography --- r_associated #0: 157 --> en:contraindications aspect
    n1=en:abdominal radiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=157
  227. en:aequorin --- r_associated #0: 155 --> en:contraindications aspect
    n1=en:aequorin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=155
  228. en:ballistocardiography --- r_associated #0: 155 --> en:contraindications aspect
    n1=en:ballistocardiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=155
  229. en:biological agent --- r_associated #0: 155 --> en:contraindications aspect
    n1=en:biological agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=155
  230. en:chlorine --- r_associated #0: 155 --> en:contraindications aspect
    n1=en:chlorine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=155
  231. myélotomie --- r_associated #0: 155 --> en:contraindications aspect
    n1=myélotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=155
  232. prothèses dentaires --- r_associated #0: 155 --> en:contraindications aspect
    n1=prothèses dentaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=155
  233. étude diagnostique radio-isotopique --- r_associated #0: 155 --> en:contraindications aspect
    n1=étude diagnostique radio-isotopique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=155
  234. agent biologique --- r_associated #0: 154 --> en:contraindications aspect
    n1=agent biologique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=154
  235. en:contrast agent --- r_associated #0: 154 --> en:contraindications aspect
    n1=en:contrast agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=154
  236. électrode --- r_associated #0: 153 --> en:contraindications aspect
    n1=électrode | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=153
  237. balistocardiographie --- r_associated #0: 152 --> en:contraindications aspect
    n1=balistocardiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=152
  238. cordotomie --- r_associated #0: 152 --> en:contraindications aspect
    n1=cordotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=152
  239. radiographie d'abdomen --- r_associated #0: 152 --> en:contraindications aspect
    n1=radiographie d'abdomen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=152
  240. en:conization --- r_associated #0: 150 --> en:contraindications aspect
    n1=en:conization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=150
  241. en:electrode --- r_associated #0: 150 --> en:contraindications aspect
    n1=en:electrode | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=150
  242. examen radio-isotopique --- r_associated #0: 150 --> en:contraindications aspect
    n1=examen radio-isotopique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=150
  243. phytoménadione --- r_associated #0: 150 --> en:contraindications aspect
    n1=phytoménadione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=150
  244. phytonadione --- r_associated #0: 150 --> en:contraindications aspect
    n1=phytonadione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=150
  245. produit de contraste --- r_associated #0: 150 --> en:contraindications aspect
    n1=produit de contraste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=150
  246. radiographie de l'abdomen --- r_associated #0: 150 --> en:contraindications aspect
    n1=radiographie de l'abdomen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=150
  247. réimplantation chirurgicale --- r_associated #0: 150 --> en:contraindications aspect
    n1=réimplantation chirurgicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=150
  248. endoscopie du tractus digestif --- r_associated #0: 149 --> en:contraindications aspect
    n1=endoscopie du tractus digestif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=149
  249. conisation --- r_associated #0: 148 --> en:contraindications aspect
    n1=conisation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=148
  250. en:phytonadione --- r_associated #0: 147 --> en:contraindications aspect
    n1=en:phytonadione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=147
  251. antibody --- r_associated #0: 145 --> en:contraindications aspect
    n1=antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=145
  252. préparation du composé F --- r_associated #0: 145 --> en:contraindications aspect
    n1=préparation du composé F | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=145
  253. Électrode --- r_associated #0: 145 --> en:contraindications aspect
    n1=Électrode | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=145
  254. en:reimplantation --- r_associated #0: 144 --> en:contraindications aspect
    n1=en:reimplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=144
  255. prothèse vasculaire --- r_associated #0: 142 --> en:contraindications aspect
    n1=prothèse vasculaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=142
  256. aminotransférase --- r_associated #0: 141 --> en:contraindications aspect
    n1=aminotransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=141
  257. en:human menopausal gonadotropin --- r_associated #0: 141 --> en:contraindications aspect
    n1=en:human menopausal gonadotropin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=141
  258. facteur de sexualité --- r_associated #0: 141 --> en:contraindications aspect
    n1=facteur de sexualité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=141
  259. glycéraldéhyde --- r_associated #0: 141 --> en:contraindications aspect
    n1=glycéraldéhyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=141
  260. micro-dissection --- r_associated #0: 141 --> en:contraindications aspect
    n1=micro-dissection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=141
  261. acide dicarboxylique --- r_associated #0: 140 --> en:contraindications aspect
    n1=acide dicarboxylique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  262. en:endoscopy, gastrointestinal --- r_associated #0: 140 --> en:contraindications aspect
    n1=en:endoscopy, gastrointestinal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  263. en:gastrointestinal endoscopy --- r_associated #0: 140 --> en:contraindications aspect
    n1=en:gastrointestinal endoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  264. en:microdissection --- r_associated #0: 140 --> en:contraindications aspect
    n1=en:microdissection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  265. en:radiography, abdominal --- r_associated #0: 140 --> en:contraindications aspect
    n1=en:radiography, abdominal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  266. en:talcum --- r_associated #0: 140 --> en:contraindications aspect
    n1=en:talcum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  267. en:zidovudine --- r_associated #0: 140 --> en:contraindications aspect
    n1=en:zidovudine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  268. endoscopie gastro-intestinale --- r_associated #0: 140 --> en:contraindications aspect
    n1=endoscopie gastro-intestinale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  269. endoscopie gastrointestinale --- r_associated #0: 140 --> en:contraindications aspect
    n1=endoscopie gastrointestinale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  270. gonadotrophine ménopausique humaine --- r_associated #0: 140 --> en:contraindications aspect
    n1=gonadotrophine ménopausique humaine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  271. microdissection --- r_associated #0: 140 --> en:contraindications aspect
    n1=microdissection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  272. réimplantations --- r_associated #0: 140 --> en:contraindications aspect
    n1=réimplantations | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  273. rétinoscopie --- r_associated #0: 140 --> en:contraindications aspect
    n1=rétinoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  274. scintillographie --- r_associated #0: 140 --> en:contraindications aspect
    n1=scintillographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=140
  275. Glycéraldéhyde --- r_associated #0: 138 --> en:contraindications aspect
    n1=Glycéraldéhyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=138
  276. en:retinoscopy --- r_associated #0: 138 --> en:contraindications aspect
    n1=en:retinoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=138
  277. angioscopie --- r_associated #0: 137 --> en:contraindications aspect
    n1=angioscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=137
  278. en:dicarboxylic acid --- r_associated #0: 137 --> en:contraindications aspect
    n1=en:dicarboxylic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=137
  279. amino-transférase --- r_associated #0: 136 --> en:contraindications aspect
    n1=amino-transférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=136
  280. débridement --- r_associated #0: 136 --> en:contraindications aspect
    n1=débridement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=136
  281. zidovudine --- r_associated #0: 136 --> en:contraindications aspect
    n1=zidovudine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=136
  282. en:angioscopy --- r_associated #0: 135 --> en:contraindications aspect
    n1=en:angioscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=135
  283. en:debridement --- r_associated #0: 135 --> en:contraindications aspect
    n1=en:debridement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=135
  284. en:glyceraldehyde --- r_associated #0: 135 --> en:contraindications aspect
    n1=en:glyceraldehyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=135
  285. en:surgical replantation --- r_associated #0: 135 --> en:contraindications aspect
    n1=en:surgical replantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=135
  286. en:transaminase --- r_associated #0: 135 --> en:contraindications aspect
    n1=en:transaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=135
  287. prothèse mammaire interne --- r_associated #0: 135 --> en:contraindications aspect
    n1=prothèse mammaire interne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=135
  288. en:cysteic acid --- r_associated #0: 134 --> en:contraindications aspect
    n1=en:cysteic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=134
  289. en:f factor --- r_associated #0: 134 --> en:contraindications aspect
    n1=en:f factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=134
  290. transaminase --- r_associated #0: 133 --> en:contraindications aspect
    n1=transaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=133
  291. acide cystéique --- r_associated #0: 132 --> en:contraindications aspect
    n1=acide cystéique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=132
  292. anticorps monoclonal --- r_associated #0: 132 --> en:contraindications aspect
    n1=anticorps monoclonal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=132
  293. cholécystostomie --- r_associated #0: 132 --> en:contraindications aspect
    n1=cholécystostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=132
  294. facteur f --- r_associated #0: 132 --> en:contraindications aspect
    n1=facteur f | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=132
  295. phylloquinone --- r_associated #0: 132 --> en:contraindications aspect
    n1=phylloquinone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=132
  296. éponge de gélatine résorbable --- r_associated #0: 132 --> en:contraindications aspect
    n1=éponge de gélatine résorbable | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=132
  297. en:absorbable gelatin sponge --- r_associated #0: 131 --> en:contraindications aspect
    n1=en:absorbable gelatin sponge | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=131
  298. en:breast implant --- r_associated #0: 131 --> en:contraindications aspect
    n1=en:breast implant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=131
  299. irrigation nasale --- r_associated #0: 131 --> en:contraindications aspect
    n1=irrigation nasale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=131
  300. prothèse mammaire --- r_associated #0: 131 --> en:contraindications aspect
    n1=prothèse mammaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=131
  301. skiascopie --- r_associated #0: 131 --> en:contraindications aspect
    n1=skiascopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=131
  302. échographie cardiaque --- r_associated #0: 131 --> en:contraindications aspect
    n1=échographie cardiaque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=131
  303. NPT --- r_associated #0: 130 --> en:contraindications aspect
    n1=NPT | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  304. appareil dentaire --- r_associated #0: 130 --> en:contraindications aspect
    n1=appareil dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  305. en:axotomy --- r_associated #0: 130 --> en:contraindications aspect
    n1=en:axotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  306. en:braces --- r_associated #0: 130 --> en:contraindications aspect
    n1=en:braces | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  307. en:breast prosthesis, internal --- r_associated #0: 130 --> en:contraindications aspect
    n1=en:breast prosthesis, internal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  308. en:cholecystostomy --- r_associated #0: 130 --> en:contraindications aspect
    n1=en:cholecystostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  309. en:dental brace --- r_associated #0: 130 --> en:contraindications aspect
    n1=en:dental brace | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  310. en:dentures --- r_associated #0: 130 --> en:contraindications aspect
    n1=en:dentures | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  311. en:false teeth --- r_associated #0: 130 --> en:contraindications aspect
    n1=en:false teeth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  312. en:gelatin sponge, absorbable --- r_associated #0: 130 --> en:contraindications aspect
    n1=en:gelatin sponge, absorbable | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  313. en:monoclonal antibody --- r_associated #0: 130 --> en:contraindications aspect
    n1=en:monoclonal antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  314. implants mammaires --- r_associated #0: 130 --> en:contraindications aspect
    n1=implants mammaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  315. traitement par lumière ultraviolette --- r_associated #0: 130 --> en:contraindications aspect
    n1=traitement par lumière ultraviolette | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=130
  316. en:nasal lavage --- r_associated #0: 128 --> en:contraindications aspect
    n1=en:nasal lavage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=128
  317. amifostine --- r_associated #0: 127 --> en:contraindications aspect
    n1=amifostine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=127
  318. cystostomie --- r_associated #0: 127 --> en:contraindications aspect
    n1=cystostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=127
  319. facteur sexuel --- r_associated #0: 127 --> en:contraindications aspect
    n1=facteur sexuel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=127
  320. traitement par ultraviolets --- r_associated #0: 127 --> en:contraindications aspect
    n1=traitement par ultraviolets | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=127
  321. air comprimé --- r_associated #0: 126 --> en:contraindications aspect
    n1=air comprimé | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=126
  322. axotomie --- r_associated #0: 126 --> en:contraindications aspect
    n1=axotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=126
  323. bronchospirométrie --- r_associated #0: 126 --> en:contraindications aspect
    n1=bronchospirométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=126
  324. capsaïcine --- r_associated #0: 126 --> en:contraindications aspect
    n1=capsaïcine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=126
  325. douche nasale --- r_associated #0: 126 --> en:contraindications aspect
    n1=douche nasale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=126
  326. monosaccharide --- r_associated #0: 126 --> en:contraindications aspect
    n1=monosaccharide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=126
  327. cuti-réaction --- r_associated #0: 125 --> en:contraindications aspect
    n1=cuti-réaction | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=125
  328. en:capsaicin --- r_associated #0: 125 --> en:contraindications aspect
    n1=en:capsaicin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=125
  329. en:echocardiography --- r_associated #0: 125 --> en:contraindications aspect
    n1=en:echocardiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=125
  330. en:immunization --- r_associated #0: 125 --> en:contraindications aspect
    n1=en:immunization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=125
  331. glutamate de sodium --- r_associated #0: 125 --> en:contraindications aspect
    n1=glutamate de sodium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=125
  332. implant mammaire --- r_associated #0: 125 --> en:contraindications aspect
    n1=implant mammaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=125
  333. lavage du nez --- r_associated #0: 125 --> en:contraindications aspect
    n1=lavage du nez | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=125
  334. lavage nasal --- r_associated #0: 125 --> en:contraindications aspect
    n1=lavage nasal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=125
  335. Néostigmine --- r_associated #0: 124 --> en:contraindications aspect
    n1=Néostigmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=124
  336. en:bronchospirometry --- r_associated #0: 124 --> en:contraindications aspect
    n1=en:bronchospirometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=124
  337. en:cystostomy --- r_associated #0: 124 --> en:contraindications aspect
    n1=en:cystostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=124
  338. échocardiographie --- r_associated #0: 124 --> en:contraindications aspect
    n1=échocardiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=124
  339. en:amifostine --- r_associated #0: 123 --> en:contraindications aspect
    n1=en:amifostine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=123
  340. gingivectomie --- r_associated #0: 123 --> en:contraindications aspect
    n1=gingivectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=123
  341. prastérone --- r_associated #0: 123 --> en:contraindications aspect
    n1=prastérone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=123
  342. ticlopidine --- r_associated #0: 123 --> en:contraindications aspect
    n1=ticlopidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=123
  343. en:compressed air --- r_associated #0: 122 --> en:contraindications aspect
    n1=en:compressed air | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=122
  344. en:electric wiring --- r_associated #0: 122 --> en:contraindications aspect
    n1=en:electric wiring | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=122
  345. en:thyrotropin alfa --- r_associated #0: 122 --> en:contraindications aspect
    n1=en:thyrotropin alfa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=122
  346. en:ultraviolet therapy --- r_associated #0: 122 --> en:contraindications aspect
    n1=en:ultraviolet therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=122
  347. facteur sexuel bactérien --- r_associated #0: 122 --> en:contraindications aspect
    n1=facteur sexuel bactérien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=122
  348. GMS
    (glutamate monosodique)
     --- r_associated #0: 121 --> en:contraindications aspect
    n1=GMS
    (glutamate monosodique)
    | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=121
  349. colostomie --- r_associated #0: 121 --> en:contraindications aspect
    n1=colostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=121
  350. en:prasterone --- r_associated #0: 121 --> en:contraindications aspect
    n1=en:prasterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=121
  351. en:skin test --- r_associated #0: 121 --> en:contraindications aspect
    n1=en:skin test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=121
  352. glutamate monosodique --- r_associated #0: 121 --> en:contraindications aspect
    n1=glutamate monosodique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=121
  353. néostigmine --- r_associated #0: 121 --> en:contraindications aspect
    n1=néostigmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=121
  354. thérapie à la lumière ultraviolet --- r_associated #0: 121 --> en:contraindications aspect
    n1=thérapie à la lumière ultraviolet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=121
  355. acte médical --- r_associated #0: 120 --> en:contraindications aspect
    n1=acte médical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=120
  356. dentier --- r_associated #0: 120 --> en:contraindications aspect
    n1=dentier | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=120
  357. en:colostomy --- r_associated #0: 120 --> en:contraindications aspect
    n1=en:colostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=120
  358. en:gingivectomy --- r_associated #0: 120 --> en:contraindications aspect
    n1=en:gingivectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=120
  359. en:monosodium glutamate --- r_associated #0: 120 --> en:contraindications aspect
    n1=en:monosodium glutamate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=120
  360. en:nasal wash --- r_associated #0: 120 --> en:contraindications aspect
    n1=en:nasal wash | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=120
  361. réimplantation --- r_associated #0: 120 --> en:contraindications aspect
    n1=réimplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=120
  362. thyrotropine alfa --- r_associated #0: 120 --> en:contraindications aspect
    n1=thyrotropine alfa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=120
  363. traitement par les exercices physiques --- r_associated #0: 120 --> en:contraindications aspect
    n1=traitement par les exercices physiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=120
  364. cystectomie --- r_associated #0: 119 --> en:contraindications aspect
    n1=cystectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=119
  365. en:ticlopidine --- r_associated #0: 119 --> en:contraindications aspect
    n1=en:ticlopidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=119
  366. traitement par ultra-violets --- r_associated #0: 119 --> en:contraindications aspect
    n1=traitement par ultra-violets | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=119
  367. anæsthésique --- r_associated #0: 118 --> en:contraindications aspect
    n1=anæsthésique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=118
  368. câblage électrique --- r_associated #0: 118 --> en:contraindications aspect
    n1=câblage électrique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=118
  369. polypeptide c de transport d'anions organiques --- r_associated #0: 118 --> en:contraindications aspect
    n1=polypeptide c de transport d'anions organiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=118
  370. pénicillamine --- r_associated #0: 118 --> en:contraindications aspect
    n1=pénicillamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=118
  371. 3TC --- r_associated #0: 117 --> en:contraindications aspect
    n1=3TC | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=117
  372. en:physical therapy exercises --- r_associated #0: 117 --> en:contraindications aspect
    n1=en:physical therapy exercises | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=117
  373. goséréline --- r_associated #0: 117 --> en:contraindications aspect
    n1=goséréline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=117
  374. pulpectomie --- r_associated #0: 117 --> en:contraindications aspect
    n1=pulpectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=117
  375. huile végétale --- r_associated #0: 116 --> en:contraindications aspect
    n1=huile végétale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=116
  376. monosodium glutamate --- r_associated #0: 116 --> en:contraindications aspect
    n1=monosodium glutamate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=116
  377. prostatectomie --- r_associated #0: 116 --> en:contraindications aspect
    n1=prostatectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=116
  378. électronystagmographie --- r_associated #0: 116 --> en:contraindications aspect
    n1=électronystagmographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=116
  379. acarbose --- r_associated #0: 115 --> en:contraindications aspect
    n1=acarbose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  380. en:antineoplastic antibiotic --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:antineoplastic antibiotic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  381. en:computed tomography --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:computed tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  382. en:cystectomy --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:cystectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  383. en:dna intercalating agent --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:dna intercalating agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  384. en:goserelin --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:goserelin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  385. en:neostigmine --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:neostigmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  386. en:organic anion transport polypeptide c --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:organic anion transport polypeptide c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  387. en:penicillamine --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:penicillamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  388. en:prostatectomy --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:prostatectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  389. en:pulpectomy --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:pulpectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  390. en:uv light therapy --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:uv light therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  391. en:vegetable oil --- r_associated #0: 115 --> en:contraindications aspect
    n1=en:vegetable oil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  392. monoclonal antibody --- r_associated #0: 115 --> en:contraindications aspect
    n1=monoclonal antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  393. polypeptide c de transport des anions organiques --- r_associated #0: 115 --> en:contraindications aspect
    n1=polypeptide c de transport des anions organiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  394. polypeptide c transporteur des anions organiques --- r_associated #0: 115 --> en:contraindications aspect
    n1=polypeptide c transporteur des anions organiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  395. portographie --- r_associated #0: 115 --> en:contraindications aspect
    n1=portographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  396. révision chirurgicale --- r_associated #0: 115 --> en:contraindications aspect
    n1=révision chirurgicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=115
  397. berbérine --- r_associated #0: 114 --> en:contraindications aspect
    n1=berbérine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=114
  398. cimétidine --- r_associated #0: 113 --> en:contraindications aspect
    n1=cimétidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=113
  399. en:adrenergic antagonist --- r_associated #0: 113 --> en:contraindications aspect
    n1=en:adrenergic antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=113
  400. en:electronystagmography --- r_associated #0: 113 --> en:contraindications aspect
    n1=en:electronystagmography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=113
  401. en:portography --- r_associated #0: 113 --> en:contraindications aspect
    n1=en:portography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=113
  402. lymphangiographie --- r_associated #0: 113 --> en:contraindications aspect
    n1=lymphangiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=113
  403. ophthalmoscopie --- r_associated #0: 113 --> en:contraindications aspect
    n1=ophthalmoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=113
  404. phénindione --- r_associated #0: 113 --> en:contraindications aspect
    n1=phénindione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=113
  405. thérapie par les exercices physiques --- r_associated #0: 113 --> en:contraindications aspect
    n1=thérapie par les exercices physiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=113
  406. antibiotique antinéoplasique --- r_associated #0: 112 --> en:contraindications aspect
    n1=antibiotique antinéoplasique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=112
  407. diagnostic pré-implantatoire --- r_associated #0: 112 --> en:contraindications aspect
    n1=diagnostic pré-implantatoire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=112
  408. exercice thérapeutique --- r_associated #0: 112 --> en:contraindications aspect
    n1=exercice thérapeutique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=112
  409. facteur de transfert de résistance --- r_associated #0: 112 --> en:contraindications aspect
    n1=facteur de transfert de résistance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=112
  410. myélographie --- r_associated #0: 112 --> en:contraindications aspect
    n1=myélographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=112
  411. agent intercalant --- r_associated #0: 111 --> en:contraindications aspect
    n1=agent intercalant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=111
  412. en:acarbose --- r_associated #0: 111 --> en:contraindications aspect
    n1=en:acarbose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=111
  413. en:cam exercise therapy --- r_associated #0: 111 --> en:contraindications aspect
    n1=en:cam exercise therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=111
  414. fixateurs internes --- r_associated #0: 111 --> en:contraindications aspect
    n1=fixateurs internes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=111
  415. isoniazide --- r_associated #0: 111 --> en:contraindications aspect
    n1=isoniazide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=111
  416. sécrétine --- r_associated #0: 111 --> en:contraindications aspect
    n1=sécrétine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=111
  417. tdm
    (tomodensitométrie)
     --- r_associated #0: 111 --> en:contraindications aspect
    n1=tdm
    (tomodensitométrie)
    | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=111
  418. agent de contraste --- r_associated #0: 110 --> en:contraindications aspect
    n1=agent de contraste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  419. bloquant adrénergique --- r_associated #0: 110 --> en:contraindications aspect
    n1=bloquant adrénergique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  420. en:berberine --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:berberine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  421. en:cimetidine --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:cimetidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  422. en:contrast medium --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:contrast medium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  423. en:inoculation --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:inoculation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  424. en:isoniazid --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:isoniazid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  425. en:myelography --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:myelography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  426. en:ophthalmoscopy --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:ophthalmoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  427. en:phenindione --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:phenindione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  428. en:preimplantation screenings --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:preimplantation screenings | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  429. en:repeated surgical procedure --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:repeated surgical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  430. en:secretin --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:secretin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  431. en:vasodilating agent --- r_associated #0: 110 --> en:contraindications aspect
    n1=en:vasodilating agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  432. gymnastique médicale --- r_associated #0: 110 --> en:contraindications aspect
    n1=gymnastique médicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  433. hormone parathyroïdienne --- r_associated #0: 110 --> en:contraindications aspect
    n1=hormone parathyroïdienne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  434. hydrocarbon --- r_associated #0: 110 --> en:contraindications aspect
    n1=hydrocarbon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  435. ophtalmoscopie --- r_associated #0: 110 --> en:contraindications aspect
    n1=ophtalmoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  436. plasmide f --- r_associated #0: 110 --> en:contraindications aspect
    n1=plasmide f | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  437. tomodensitométrie --- r_associated #0: 110 --> en:contraindications aspect
    n1=tomodensitométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  438. tomographie assistée par ordinateur --- r_associated #0: 110 --> en:contraindications aspect
    n1=tomographie assistée par ordinateur | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=110
  439. en:lymphangiography --- r_associated #0: 109 --> en:contraindications aspect
    n1=en:lymphangiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=109
  440. isotrétinoïne --- r_associated #0: 109 --> en:contraindications aspect
    n1=isotrétinoïne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=109
  441. antagoniste adrénergique --- r_associated #0: 108 --> en:contraindications aspect
    n1=antagoniste adrénergique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=108
  442. carbohydrate --- r_associated #0: 108 --> en:contraindications aspect
    n1=carbohydrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=108
  443. en:internal fixators --- r_associated #0: 108 --> en:contraindications aspect
    n1=en:internal fixators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=108
  444. en:lamivudine --- r_associated #0: 108 --> en:contraindications aspect
    n1=en:lamivudine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=108
  445. en:parathyroid hormone --- r_associated #0: 108 --> en:contraindications aspect
    n1=en:parathyroid hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=108
  446. lamivudine --- r_associated #0: 108 --> en:contraindications aspect
    n1=lamivudine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=108
  447. thioridazine --- r_associated #0: 108 --> en:contraindications aspect
    n1=thioridazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=108
  448. agent vasodilatateur --- r_associated #0: 107 --> en:contraindications aspect
    n1=agent vasodilatateur | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=107
  449. fluoroscopie --- r_associated #0: 107 --> en:contraindications aspect
    n1=fluoroscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=107
  450. manométrie --- r_associated #0: 107 --> en:contraindications aspect
    n1=manométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=107
  451. traitement par l'exercice --- r_associated #0: 107 --> en:contraindications aspect
    n1=traitement par l'exercice | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=107
  452. émétine --- r_associated #0: 107 --> en:contraindications aspect
    n1=émétine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=107
  453. E621 --- r_associated #0: 106 --> en:contraindications aspect
    n1=E621 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=106
  454. anus artificiel --- r_associated #0: 106 --> en:contraindications aspect
    n1=anus artificiel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=106
  455. en:manometry --- r_associated #0: 106 --> en:contraindications aspect
    n1=en:manometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=106
  456. examen du fond d'oeil --- r_associated #0: 106 --> en:contraindications aspect
    n1=examen du fond d'oeil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=106
  457. facteur de fertilité --- r_associated #0: 106 --> en:contraindications aspect
    n1=facteur de fertilité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=106
  458. triterpènes --- r_associated #0: 106 --> en:contraindications aspect
    n1=triterpènes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=106
  459. computed tomography --- r_associated #0: 105 --> en:contraindications aspect
    n1=computed tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  460. en:emetine --- r_associated #0: 105 --> en:contraindications aspect
    n1=en:emetine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  461. en:fluoroscopy --- r_associated #0: 105 --> en:contraindications aspect
    n1=en:fluoroscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  462. en:gastroscopy --- r_associated #0: 105 --> en:contraindications aspect
    n1=en:gastroscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  463. en:isotretinoin --- r_associated #0: 105 --> en:contraindications aspect
    n1=en:isotretinoin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  464. en:preimplantation diagnosis --- r_associated #0: 105 --> en:contraindications aspect
    n1=en:preimplantation diagnosis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  465. en:thioridazine --- r_associated #0: 105 --> en:contraindications aspect
    n1=en:thioridazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  466. en:triterpenes --- r_associated #0: 105 --> en:contraindications aspect
    n1=en:triterpenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  467. imagerie de diffusion en IRM --- r_associated #0: 105 --> en:contraindications aspect
    n1=imagerie de diffusion en IRM | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  468. oméprazole --- r_associated #0: 105 --> en:contraindications aspect
    n1=oméprazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  469. polyéthylène glycol --- r_associated #0: 105 --> en:contraindications aspect
    n1=polyéthylène glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  470. transglutaminase --- r_associated #0: 105 --> en:contraindications aspect
    n1=transglutaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=105
  471. amitriptyline --- r_associated #0: 104 --> en:contraindications aspect
    n1=amitriptyline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=104
  472. angiocardiographie --- r_associated #0: 104 --> en:contraindications aspect
    n1=angiocardiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=104
  473. en:transglutaminase --- r_associated #0: 104 --> en:contraindications aspect
    n1=en:transglutaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=104
  474. gastroscopie --- r_associated #0: 104 --> en:contraindications aspect
    n1=gastroscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=104
  475. mutagène --- r_associated #0: 104 --> en:contraindications aspect
    n1=mutagène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=104
  476. phénobarbital --- r_associated #0: 104 --> en:contraindications aspect
    n1=phénobarbital | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=104
  477. desmostérol --- r_associated #0: 103 --> en:contraindications aspect
    n1=desmostérol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=103
  478. phénothiazine --- r_associated #0: 103 --> en:contraindications aspect
    n1=phénothiazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=103
  479. stéarates --- r_associated #0: 103 --> en:contraindications aspect
    n1=stéarates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=103
  480. thérapie d'exercice physique --- r_associated #0: 103 --> en:contraindications aspect
    n1=thérapie d'exercice physique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=103
  481. cholécystotomie --- r_associated #0: 102 --> en:contraindications aspect
    n1=cholécystotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=102
  482. en:polyethylene glycol --- r_associated #0: 102 --> en:contraindications aspect
    n1=en:polyethylene glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=102
  483. indométhacine --- r_associated #0: 102 --> en:contraindications aspect
    n1=indométhacine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=102
  484. kystostomie --- r_associated #0: 102 --> en:contraindications aspect
    n1=kystostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=102
  485. E406 --- r_associated #0: 101 --> en:contraindications aspect
    n1=E406 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=101
  486. aténolol --- r_associated #0: 101 --> en:contraindications aspect
    n1=aténolol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=101
  487. hélicase --- r_associated #0: 101 --> en:contraindications aspect
    n1=hélicase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=101
  488. intervention chirurgicale répétée --- r_associated #0: 101 --> en:contraindications aspect
    n1=intervention chirurgicale répétée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=101
  489. mesure de la pression artérielle --- r_associated #0: 101 --> en:contraindications aspect
    n1=mesure de la pression artérielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=101
  490. omeprazole --- r_associated #0: 101 --> en:contraindications aspect
    n1=omeprazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=101
  491. procédure chirurgicale --- r_associated #0: 101 --> en:contraindications aspect
    n1=procédure chirurgicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=101
  492. thoracoscopie --- r_associated #0: 101 --> en:contraindications aspect
    n1=thoracoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=101
  493. Acte médical --- r_associated #0: 100 --> en:contraindications aspect
    n1=Acte médical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  494. amitryptyline --- r_associated #0: 100 --> en:contraindications aspect
    n1=amitryptyline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  495. diagnostic préimplantatoire --- r_associated #0: 100 --> en:contraindications aspect
    n1=diagnostic préimplantatoire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  496. détermination de la pression artérielle --- r_associated #0: 100 --> en:contraindications aspect
    n1=détermination de la pression artérielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  497. en:amitriptyline --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:amitriptyline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  498. en:angiocardiography --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:angiocardiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  499. en:atenolol --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:atenolol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  500. en:blood pressure determination --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:blood pressure determination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  501. en:desmosterol --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:desmosterol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  502. en:genistein --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:genistein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  503. en:indomethacin --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:indomethacin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  504. en:medical procedure --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:medical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  505. en:mutagen --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:mutagen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  506. en:omeprazole --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:omeprazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  507. en:phenobarbital --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:phenobarbital | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  508. en:phenothiazine --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:phenothiazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  509. en:stearates --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:stearates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  510. en:thoracoscopy --- r_associated #0: 100 --> en:contraindications aspect
    n1=en:thoracoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  511. lévofloxacine --- r_associated #0: 100 --> en:contraindications aspect
    n1=lévofloxacine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  512. mesure de la pression sanguine --- r_associated #0: 100 --> en:contraindications aspect
    n1=mesure de la pression sanguine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  513. pression artérielle --- r_associated #0: 100 --> en:contraindications aspect
    n1=pression artérielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  514. traitement par l'exercice physique --- r_associated #0: 100 --> en:contraindications aspect
    n1=traitement par l'exercice physique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  515. traitement par rayonnements ultraviolets --- r_associated #0: 100 --> en:contraindications aspect
    n1=traitement par rayonnements ultraviolets | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=100
  516. benzaldéhydes --- r_associated #0: 99 --> en:contraindications aspect
    n1=benzaldéhydes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=99
  517. en:surgical procedure --- r_associated #0: 99 --> en:contraindications aspect
    n1=en:surgical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=99
  518. isoflurane --- r_associated #0: 99 --> en:contraindications aspect
    n1=isoflurane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=99
  519. mammoplastie --- r_associated #0: 99 --> en:contraindications aspect
    n1=mammoplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=99
  520. pentamidine --- r_associated #0: 99 --> en:contraindications aspect
    n1=pentamidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=99
  521. phlébotomie --- r_associated #0: 99 --> en:contraindications aspect
    n1=phlébotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=99
  522. agar --- r_associated #0: 98 --> en:contraindications aspect
    n1=agar | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=98
  523. en:agar --- r_associated #0: 98 --> en:contraindications aspect
    n1=en:agar | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=98
  524. en:phlebotomy --- r_associated #0: 98 --> en:contraindications aspect
    n1=en:phlebotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=98
  525. génistéine --- r_associated #0: 98 --> en:contraindications aspect
    n1=génistéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=98
  526. myringoplastie --- r_associated #0: 98 --> en:contraindications aspect
    n1=myringoplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=98
  527. nadolol --- r_associated #0: 98 --> en:contraindications aspect
    n1=nadolol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=98
  528. sérum antidiphtérique --- r_associated #0: 98 --> en:contraindications aspect
    n1=sérum antidiphtérique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=98
  529. diazinon --- r_associated #0: 97 --> en:contraindications aspect
    n1=diazinon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=97
  530. dobutamine --- r_associated #0: 97 --> en:contraindications aspect
    n1=dobutamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=97
  531. en:dna helicase --- r_associated #0: 97 --> en:contraindications aspect
    n1=en:dna helicase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=97
  532. en:myringoplasty --- r_associated #0: 97 --> en:contraindications aspect
    n1=en:myringoplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=97
  533. en:terbutaline --- r_associated #0: 97 --> en:contraindications aspect
    n1=en:terbutaline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=97
  534. lisinopril --- r_associated #0: 97 --> en:contraindications aspect
    n1=lisinopril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=97
  535. lysinoalanine --- r_associated #0: 97 --> en:contraindications aspect
    n1=lysinoalanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=97
  536. mesure pression sanguine --- r_associated #0: 97 --> en:contraindications aspect
    n1=mesure pression sanguine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=97
  537. protéines de foetus --- r_associated #0: 97 --> en:contraindications aspect
    n1=protéines de foetus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=97
  538. déroulase --- r_associated #0: 96 --> en:contraindications aspect
    n1=déroulase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=96
  539. en:denture --- r_associated #0: 96 --> en:contraindications aspect
    n1=en:denture | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=96
  540. en:iodine --- r_associated #0: 96 --> en:contraindications aspect
    n1=en:iodine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=96
  541. en:levofloxacin --- r_associated #0: 96 --> en:contraindications aspect
    n1=en:levofloxacin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=96
  542. oxyphénbutazone --- r_associated #0: 96 --> en:contraindications aspect
    n1=oxyphénbutazone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=96
  543. porphyrine --- r_associated #0: 96 --> en:contraindications aspect
    n1=porphyrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=96
  544. protéines foetales --- r_associated #0: 96 --> en:contraindications aspect
    n1=protéines foetales | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=96
  545. acitrétine --- r_associated #0: 95 --> en:contraindications aspect
    n1=acitrétine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  546. agar-agar --- r_associated #0: 95 --> en:contraindications aspect
    n1=agar-agar | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  547. azolidines --- r_associated #0: 95 --> en:contraindications aspect
    n1=azolidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  548. cinéangiographie --- r_associated #0: 95 --> en:contraindications aspect
    n1=cinéangiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  549. diclofénac --- r_associated #0: 95 --> en:contraindications aspect
    n1=diclofénac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  550. diénestrol --- r_associated #0: 95 --> en:contraindications aspect
    n1=diénestrol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  551. en:1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  552. en:benzaldehydes --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:benzaldehydes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  553. en:cartography --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:cartography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  554. en:diethylstilbestrol --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:diethylstilbestrol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  555. en:diphtheria antitoxin --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:diphtheria antitoxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  556. en:dobutamine --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:dobutamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  557. en:fundoscopy --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:fundoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  558. en:isoflurane --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:isoflurane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  559. en:laroxyl --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:laroxyl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  560. en:lisinopril --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:lisinopril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  561. en:lysinoalanine --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:lysinoalanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  562. en:mammoplasty --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:mammoplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  563. en:nadolol --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:nadolol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  564. en:pentamidine --- r_associated #0: 95 --> en:contraindications aspect
    n1=en:pentamidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  565. fénitrothion --- r_associated #0: 95 --> en:contraindications aspect
    n1=fénitrothion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  566. imagerie diagnostique --- r_associated #0: 95 --> en:contraindications aspect
    n1=imagerie diagnostique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  567. laminectomie --- r_associated #0: 95 --> en:contraindications aspect
    n1=laminectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  568. ménadione --- r_associated #0: 95 --> en:contraindications aspect
    n1=ménadione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  569. méthoxsalène --- r_associated #0: 95 --> en:contraindications aspect
    n1=méthoxsalène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  570. oligonucléotide --- r_associated #0: 95 --> en:contraindications aspect
    n1=oligonucléotide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  571. pantéthéine --- r_associated #0: 95 --> en:contraindications aspect
    n1=pantéthéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  572. réinterventions --- r_associated #0: 95 --> en:contraindications aspect
    n1=réinterventions | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  573. sérum anti-diphtérique --- r_associated #0: 95 --> en:contraindications aspect
    n1=sérum anti-diphtérique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  574. terbutaline --- r_associated #0: 95 --> en:contraindications aspect
    n1=terbutaline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  575. vasodilatateur --- r_associated #0: 95 --> en:contraindications aspect
    n1=vasodilatateur | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  576. Éviscération de l'orbite --- r_associated #0: 95 --> en:contraindications aspect
    n1=Éviscération de l'orbite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  577. épisome f --- r_associated #0: 95 --> en:contraindications aspect
    n1=épisome f | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=95
  578. 1-méthyl-4-phényl-1,2,3,6-tétrahydropyridine --- r_associated #0: 94 --> en:contraindications aspect
    n1=1-méthyl-4-phényl-1,2,3,6-tétrahydropyridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  579. albumine sérique radioiodée --- r_associated #0: 94 --> en:contraindications aspect
    n1=albumine sérique radioiodée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  580. aortographie --- r_associated #0: 94 --> en:contraindications aspect
    n1=aortographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  581. diéthylstilbestrol --- r_associated #0: 94 --> en:contraindications aspect
    n1=diéthylstilbestrol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  582. en:diagnostic imaging --- r_associated #0: 94 --> en:contraindications aspect
    n1=en:diagnostic imaging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  583. en:fenitrothion --- r_associated #0: 94 --> en:contraindications aspect
    n1=en:fenitrothion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  584. en:laminectomy --- r_associated #0: 94 --> en:contraindications aspect
    n1=en:laminectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  585. en:pantetheine --- r_associated #0: 94 --> en:contraindications aspect
    n1=en:pantetheine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  586. en:porphyrin --- r_associated #0: 94 --> en:contraindications aspect
    n1=en:porphyrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  587. en:whole body scan --- r_associated #0: 94 --> en:contraindications aspect
    n1=en:whole body scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  588. exentération de l'orbite --- r_associated #0: 94 --> en:contraindications aspect
    n1=exentération de l'orbite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  589. iodine --- r_associated #0: 94 --> en:contraindications aspect
    n1=iodine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  590. mimosine --- r_associated #0: 94 --> en:contraindications aspect
    n1=mimosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  591. pyrrolidines --- r_associated #0: 94 --> en:contraindications aspect
    n1=pyrrolidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=94
  592. bêta-amylase --- r_associated #0: 93 --> en:contraindications aspect
    n1=bêta-amylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  593. chloroprène --- r_associated #0: 93 --> en:contraindications aspect
    n1=chloroprène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  594. en:diazinon --- r_associated #0: 93 --> en:contraindications aspect
    n1=en:diazinon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  595. en:menadione --- r_associated #0: 93 --> en:contraindications aspect
    n1=en:menadione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  596. en:methoxsalen --- r_associated #0: 93 --> en:contraindications aspect
    n1=en:methoxsalen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  597. en:oxyphenbutazone --- r_associated #0: 93 --> en:contraindications aspect
    n1=en:oxyphenbutazone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  598. foetoprotéines --- r_associated #0: 93 --> en:contraindications aspect
    n1=foetoprotéines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  599. isodesmosine --- r_associated #0: 93 --> en:contraindications aspect
    n1=isodesmosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  600. manipulation chiropractique --- r_associated #0: 93 --> en:contraindications aspect
    n1=manipulation chiropractique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  601. niacinamide --- r_associated #0: 93 --> en:contraindications aspect
    n1=niacinamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  602. prothrombine --- r_associated #0: 93 --> en:contraindications aspect
    n1=prothrombine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=93
  603. bronchoscopie --- r_associated #0: 92 --> en:contraindications aspect
    n1=bronchoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  604. chlortétracycline --- r_associated #0: 92 --> en:contraindications aspect
    n1=chlortétracycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  605. cyprotérone --- r_associated #0: 92 --> en:contraindications aspect
    n1=cyprotérone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  606. diméthoate --- r_associated #0: 92 --> en:contraindications aspect
    n1=diméthoate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  607. en:acitretin --- r_associated #0: 92 --> en:contraindications aspect
    n1=en:acitretin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  608. en:cineangiography --- r_associated #0: 92 --> en:contraindications aspect
    n1=en:cineangiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  609. en:isodesmosine --- r_associated #0: 92 --> en:contraindications aspect
    n1=en:isodesmosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  610. iofétamine --- r_associated #0: 92 --> en:contraindications aspect
    n1=iofétamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  611. liraglutide --- r_associated #0: 92 --> en:contraindications aspect
    n1=liraglutide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  612. peptidyltransférase --- r_associated #0: 92 --> en:contraindications aspect
    n1=peptidyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  613. ultrasonographie --- r_associated #0: 92 --> en:contraindications aspect
    n1=ultrasonographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=92
  614. en:chlortetracycline --- r_associated #0: 91 --> en:contraindications aspect
    n1=en:chlortetracycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  615. en:diclofenac --- r_associated #0: 91 --> en:contraindications aspect
    n1=en:diclofenac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  616. en:dienestrol --- r_associated #0: 91 --> en:contraindications aspect
    n1=en:dienestrol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  617. en:oligonucleotide --- r_associated #0: 91 --> en:contraindications aspect
    n1=en:oligonucleotide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  618. en:peptidyltransferase --- r_associated #0: 91 --> en:contraindications aspect
    n1=en:peptidyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  619. immunisation --- r_associated #0: 91 --> en:contraindications aspect
    n1=immunisation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  620. perphénazine --- r_associated #0: 91 --> en:contraindications aspect
    n1=perphénazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  621. phycoérythrine --- r_associated #0: 91 --> en:contraindications aspect
    n1=phycoérythrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  622. protéine-kinase --- r_associated #0: 91 --> en:contraindications aspect
    n1=protéine-kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  623. sulfate de zinc --- r_associated #0: 91 --> en:contraindications aspect
    n1=sulfate de zinc | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  624. trifluopérazine --- r_associated #0: 91 --> en:contraindications aspect
    n1=trifluopérazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=91
  625. albumine sérique radio-iodée --- r_associated #0: 90 --> en:contraindications aspect
    n1=albumine sérique radio-iodée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  626. antiperspirants --- r_associated #0: 90 --> en:contraindications aspect
    n1=antiperspirants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  627. déméclocycline --- r_associated #0: 90 --> en:contraindications aspect
    n1=déméclocycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  628. en:antiperspirants --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:antiperspirants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  629. en:aortography --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:aortography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  630. en:beta-amylase --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:beta-amylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  631. en:bronchoscopy --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:bronchoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  632. en:cementoplasty --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:cementoplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  633. en:chiropractic manipulation --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:chiropractic manipulation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  634. en:chloroprene --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:chloroprene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  635. en:cyproterone --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:cyproterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  636. en:dimethoate --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:dimethoate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  637. en:fundoscopic examination --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:fundoscopic examination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  638. en:iofetamine --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:iofetamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  639. en:lactase --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:lactase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  640. en:liraglutide --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:liraglutide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  641. en:mimosine --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:mimosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  642. en:niacinamide --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:niacinamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  643. en:perphenazine --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:perphenazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  644. en:phycoerythrin --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:phycoerythrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  645. en:plant oil --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:plant oil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  646. en:prothrombin --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:prothrombin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  647. en:serum albumin, radio-iodinated --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:serum albumin, radio-iodinated | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  648. en:trifluoperazine --- r_associated #0: 90 --> en:contraindications aspect
    n1=en:trifluoperazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  649. hexylrésorcinol --- r_associated #0: 90 --> en:contraindications aspect
    n1=hexylrésorcinol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  650. inuline --- r_associated #0: 90 --> en:contraindications aspect
    n1=inuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  651. iodoquinol --- r_associated #0: 90 --> en:contraindications aspect
    n1=iodoquinol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  652. lipide alimentaire --- r_associated #0: 90 --> en:contraindications aspect
    n1=lipide alimentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  653. lymécycline --- r_associated #0: 90 --> en:contraindications aspect
    n1=lymécycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  654. naproxène --- r_associated #0: 90 --> en:contraindications aspect
    n1=naproxène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  655. opération de Bishoff --- r_associated #0: 90 --> en:contraindications aspect
    n1=opération de Bishoff | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  656. oxytétracycline --- r_associated #0: 90 --> en:contraindications aspect
    n1=oxytétracycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  657. ribonucléase H --- r_associated #0: 90 --> en:contraindications aspect
    n1=ribonucléase H | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  658. scanner du corps entier --- r_associated #0: 90 --> en:contraindications aspect
    n1=scanner du corps entier | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  659. triose-phosphate isomérase --- r_associated #0: 90 --> en:contraindications aspect
    n1=triose-phosphate isomérase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  660. trypsine --- r_associated #0: 90 --> en:contraindications aspect
    n1=trypsine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  661. tétrahydroazoles --- r_associated #0: 90 --> en:contraindications aspect
    n1=tétrahydroazoles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  662. tétrahydropyrroles --- r_associated #0: 90 --> en:contraindications aspect
    n1=tétrahydropyrroles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=90
  663. acétylcystéine --- r_associated #0: 89 --> en:contraindications aspect
    n1=acétylcystéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  664. anti-transpirants --- r_associated #0: 89 --> en:contraindications aspect
    n1=anti-transpirants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  665. en:11 epicortisol --- r_associated #0: 89 --> en:contraindications aspect
    n1=en:11 epicortisol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  666. en:dietary lipid --- r_associated #0: 89 --> en:contraindications aspect
    n1=en:dietary lipid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  667. en:lymecycline --- r_associated #0: 89 --> en:contraindications aspect
    n1=en:lymecycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  668. en:ribonuclease h --- r_associated #0: 89 --> en:contraindications aspect
    n1=en:ribonuclease h | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  669. en:ultrasonography --- r_associated #0: 89 --> en:contraindications aspect
    n1=en:ultrasonography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  670. en:zinc sulphate --- r_associated #0: 89 --> en:contraindications aspect
    n1=en:zinc sulphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  671. hexétidine --- r_associated #0: 89 --> en:contraindications aspect
    n1=hexétidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  672. lactase --- r_associated #0: 89 --> en:contraindications aspect
    n1=lactase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  673. matière grasse alimentaire --- r_associated #0: 89 --> en:contraindications aspect
    n1=matière grasse alimentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  674. phosphatidylinositol --- r_associated #0: 89 --> en:contraindications aspect
    n1=phosphatidylinositol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  675. pipobroman --- r_associated #0: 89 --> en:contraindications aspect
    n1=pipobroman | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  676. protein kinase --- r_associated #0: 89 --> en:contraindications aspect
    n1=protein kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=89
  677. acétoïne --- r_associated #0: 88 --> en:contraindications aspect
    n1=acétoïne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=88
  678. arthroplastie --- r_associated #0: 88 --> en:contraindications aspect
    n1=arthroplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=88
  679. en:demeclocycline --- r_associated #0: 88 --> en:contraindications aspect
    n1=en:demeclocycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=88
  680. en:hexylresorcinol --- r_associated #0: 88 --> en:contraindications aspect
    n1=en:hexylresorcinol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=88
  681. en:trypsin --- r_associated #0: 88 --> en:contraindications aspect
    n1=en:trypsin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=88
  682. graisse alimentaire --- r_associated #0: 88 --> en:contraindications aspect
    n1=graisse alimentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=88
  683. indigotindisulfonate sodium --- r_associated #0: 88 --> en:contraindications aspect
    n1=indigotindisulfonate sodium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=88
  684. anti-perspirants --- r_associated #0: 87 --> en:contraindications aspect
    n1=anti-perspirants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=87
  685. en:fetal proteins --- r_associated #0: 87 --> en:contraindications aspect
    n1=en:fetal proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=87
  686. en:inulin --- r_associated #0: 87 --> en:contraindications aspect
    n1=en:inulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=87
  687. en:naproxen --- r_associated #0: 87 --> en:contraindications aspect
    n1=en:naproxen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=87
  688. glutathion --- r_associated #0: 87 --> en:contraindications aspect
    n1=glutathion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=87
  689. minocycline --- r_associated #0: 87 --> en:contraindications aspect
    n1=minocycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=87
  690. proteines foetales --- r_associated #0: 87 --> en:contraindications aspect
    n1=proteines foetales | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=87
  691. triflupromazine --- r_associated #0: 87 --> en:contraindications aspect
    n1=triflupromazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=87
  692. acide pyroglutamique --- r_associated #0: 86 --> en:contraindications aspect
    n1=acide pyroglutamique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  693. cimentoplastie --- r_associated #0: 86 --> en:contraindications aspect
    n1=cimentoplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  694. cystotomie --- r_associated #0: 86 --> en:contraindications aspect
    n1=cystotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  695. dacryocystorhinostomie --- r_associated #0: 86 --> en:contraindications aspect
    n1=dacryocystorhinostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  696. en:cystotomy --- r_associated #0: 86 --> en:contraindications aspect
    n1=en:cystotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  697. en:iodoquinol --- r_associated #0: 86 --> en:contraindications aspect
    n1=en:iodoquinol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  698. en:orbit evisceration --- r_associated #0: 86 --> en:contraindications aspect
    n1=en:orbit evisceration | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  699. en:oxytetracycline --- r_associated #0: 86 --> en:contraindications aspect
    n1=en:oxytetracycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  700. en:protein kinase --- r_associated #0: 86 --> en:contraindications aspect
    n1=en:protein kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  701. expansion nerveuse --- r_associated #0: 86 --> en:contraindications aspect
    n1=expansion nerveuse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  702. physostigmine --- r_associated #0: 86 --> en:contraindications aspect
    n1=physostigmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  703. éviscération de l'orbite --- r_associated #0: 86 --> en:contraindications aspect
    n1=éviscération de l'orbite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=86
  704. acide pidolique --- r_associated #0: 85 --> en:contraindications aspect
    n1=acide pidolique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  705. anti-coagulant --- r_associated #0: 85 --> en:contraindications aspect
    n1=anti-coagulant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  706. baclofène --- r_associated #0: 85 --> en:contraindications aspect
    n1=baclofène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  707. chirurgie articulaire reconstructrice --- r_associated #0: 85 --> en:contraindications aspect
    n1=chirurgie articulaire reconstructrice | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  708. chlorine --- r_associated #0: 85 --> en:contraindications aspect
    n1=chlorine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  709. diphenhydramine --- r_associated #0: 85 --> en:contraindications aspect
    n1=diphenhydramine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  710. en:acetoin --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:acetoin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  711. en:acetylcysteine --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:acetylcysteine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  712. en:arthroplasty --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:arthroplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  713. en:bevacizumab --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:bevacizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  714. en:glutathione --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:glutathione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  715. en:hexetidine --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:hexetidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  716. en:indigotindisulfonate sodium --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:indigotindisulfonate sodium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  717. en:keratoplasty --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:keratoplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  718. en:minocycline --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:minocycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  719. en:physostigmine --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:physostigmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  720. en:pipobroman --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:pipobroman | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  721. en:scintigraphy --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:scintigraphy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  722. en:triflupromazine --- r_associated #0: 85 --> en:contraindications aspect
    n1=en:triflupromazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  723. endoscopie du duodénum --- r_associated #0: 85 --> en:contraindications aspect
    n1=endoscopie du duodénum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  724. greffe cornéenne --- r_associated #0: 85 --> en:contraindications aspect
    n1=greffe cornéenne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  725. greffe de la cornée --- r_associated #0: 85 --> en:contraindications aspect
    n1=greffe de la cornée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  726. immunoglobuline --- r_associated #0: 85 --> en:contraindications aspect
    n1=immunoglobuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  727. lipectomie --- r_associated #0: 85 --> en:contraindications aspect
    n1=lipectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  728. lovastatine --- r_associated #0: 85 --> en:contraindications aspect
    n1=lovastatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  729. novobiocine --- r_associated #0: 85 --> en:contraindications aspect
    n1=novobiocine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  730. paraldéhyde --- r_associated #0: 85 --> en:contraindications aspect
    n1=paraldéhyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  731. phosphatidyl-inositol --- r_associated #0: 85 --> en:contraindications aspect
    n1=phosphatidyl-inositol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  732. procarbazine --- r_associated #0: 85 --> en:contraindications aspect
    n1=procarbazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  733. reconstruction d'une articulation --- r_associated #0: 85 --> en:contraindications aspect
    n1=reconstruction d'une articulation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  734. reprise chirurgicale --- r_associated #0: 85 --> en:contraindications aspect
    n1=reprise chirurgicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  735. réintervention --- r_associated #0: 85 --> en:contraindications aspect
    n1=réintervention | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  736. transplantation cornéenne --- r_associated #0: 85 --> en:contraindications aspect
    n1=transplantation cornéenne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  737. uréthane --- r_associated #0: 85 --> en:contraindications aspect
    n1=uréthane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=85
  738. diphénhydramine --- r_associated #0: 84 --> en:contraindications aspect
    n1=diphénhydramine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=84
  739. en:cortifair --- r_associated #0: 84 --> en:contraindications aspect
    n1=en:cortifair | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=84
  740. en:paraldehyde --- r_associated #0: 84 --> en:contraindications aspect
    n1=en:paraldehyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=84
  741. hypoxanthine --- r_associated #0: 84 --> en:contraindications aspect
    n1=hypoxanthine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=84
  742. acridine --- r_associated #0: 83 --> en:contraindications aspect
    n1=acridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  743. cannabinol --- r_associated #0: 83 --> en:contraindications aspect
    n1=cannabinol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  744. dacryocysto-rhinostomie --- r_associated #0: 83 --> en:contraindications aspect
    n1=dacryocysto-rhinostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  745. dextrorphane --- r_associated #0: 83 --> en:contraindications aspect
    n1=dextrorphane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  746. en:anticoagulant agent --- r_associated #0: 83 --> en:contraindications aspect
    n1=en:anticoagulant agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  747. en:dacryocystorhinostomy --- r_associated #0: 83 --> en:contraindications aspect
    n1=en:dacryocystorhinostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  748. en:immunoglobulin --- r_associated #0: 83 --> en:contraindications aspect
    n1=en:immunoglobulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  749. en:novobiocin --- r_associated #0: 83 --> en:contraindications aspect
    n1=en:novobiocin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  750. en:pyrrolidines --- r_associated #0: 83 --> en:contraindications aspect
    n1=en:pyrrolidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  751. en:triosephosphate isomerase --- r_associated #0: 83 --> en:contraindications aspect
    n1=en:triosephosphate isomerase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  752. en:urethane --- r_associated #0: 83 --> en:contraindications aspect
    n1=en:urethane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  753. glyoxal --- r_associated #0: 83 --> en:contraindications aspect
    n1=glyoxal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  754. immunoconglutinines --- r_associated #0: 83 --> en:contraindications aspect
    n1=immunoconglutinines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  755. kystotomie --- r_associated #0: 83 --> en:contraindications aspect
    n1=kystotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  756. linuron --- r_associated #0: 83 --> en:contraindications aspect
    n1=linuron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  757. pentoxifylline --- r_associated #0: 83 --> en:contraindications aspect
    n1=pentoxifylline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  758. salpingectomie --- r_associated #0: 83 --> en:contraindications aspect
    n1=salpingectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=83
  759. allongement du nerf --- r_associated #0: 82 --> en:contraindications aspect
    n1=allongement du nerf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  760. cisplatine --- r_associated #0: 82 --> en:contraindications aspect
    n1=cisplatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  761. en:diphenhydramine --- r_associated #0: 82 --> en:contraindications aspect
    n1=en:diphenhydramine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  762. en:linuron --- r_associated #0: 82 --> en:contraindications aspect
    n1=en:linuron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  763. en:lovastatin --- r_associated #0: 82 --> en:contraindications aspect
    n1=en:lovastatin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  764. en:pidolic acid --- r_associated #0: 82 --> en:contraindications aspect
    n1=en:pidolic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  765. greffe de cornée --- r_associated #0: 82 --> en:contraindications aspect
    n1=greffe de cornée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  766. peptides hydrolases --- r_associated #0: 82 --> en:contraindications aspect
    n1=peptides hydrolases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  767. prochlorpérazine --- r_associated #0: 82 --> en:contraindications aspect
    n1=prochlorpérazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  768. proglucagon --- r_associated #0: 82 --> en:contraindications aspect
    n1=proglucagon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=82
  769. adrénodoxine --- r_associated #0: 81 --> en:contraindications aspect
    n1=adrénodoxine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  770. bevacizumab --- r_associated #0: 81 --> en:contraindications aspect
    n1=bevacizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  771. béthanéchol --- r_associated #0: 81 --> en:contraindications aspect
    n1=béthanéchol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  772. cannabidiol --- r_associated #0: 81 --> en:contraindications aspect
    n1=cannabidiol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  773. cis-diaminedichloroplatine --- r_associated #0: 81 --> en:contraindications aspect
    n1=cis-diaminedichloroplatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  774. en:baclofen --- r_associated #0: 81 --> en:contraindications aspect
    n1=en:baclofen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  775. en:cisplatin --- r_associated #0: 81 --> en:contraindications aspect
    n1=en:cisplatin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  776. en:duodenoscopy --- r_associated #0: 81 --> en:contraindications aspect
    n1=en:duodenoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  777. en:hypoxanthine --- r_associated #0: 81 --> en:contraindications aspect
    n1=en:hypoxanthine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  778. en:lipectomy --- r_associated #0: 81 --> en:contraindications aspect
    n1=en:lipectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  779. en:procarbazine --- r_associated #0: 81 --> en:contraindications aspect
    n1=en:procarbazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  780. mescaline --- r_associated #0: 81 --> en:contraindications aspect
    n1=mescaline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  781. médicament anticoagulant --- r_associated #0: 81 --> en:contraindications aspect
    n1=médicament anticoagulant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  782. protéine kinase --- r_associated #0: 81 --> en:contraindications aspect
    n1=protéine kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=81
  783. antimétabolite --- r_associated #0: 80 --> en:contraindications aspect
    n1=antimétabolite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  784. baclofen --- r_associated #0: 80 --> en:contraindications aspect
    n1=baclofen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  785. duodénoscopie --- r_associated #0: 80 --> en:contraindications aspect
    n1=duodénoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  786. en:CT-scan --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:CT-scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  787. en:acridine --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:acridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  788. en:adrenodoxin --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:adrenodoxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  789. en:axial computerized tomography --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:axial computerized tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  790. en:bethanechol --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:bethanechol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  791. en:cannabidiol --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:cannabidiol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  792. en:cannabinol --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:cannabinol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  793. en:carcinogen --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:carcinogen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  794. en:dextrorphan --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:dextrorphan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  795. en:mapping --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:mapping | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  796. en:mescaline --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:mescaline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  797. en:murexide --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:murexide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  798. en:nerve expansion --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:nerve expansion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  799. en:neuropeptide --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:neuropeptide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  800. en:pentoxifylline --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:pentoxifylline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  801. en:peptides hydrolases --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:peptides hydrolases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  802. en:phosphatidylinositol --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:phosphatidylinositol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  803. en:prochlorperazine --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:prochlorperazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  804. en:punch-biopsy --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:punch-biopsy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  805. en:triose-phosphate isomerase --- r_associated #0: 80 --> en:contraindications aspect
    n1=en:triose-phosphate isomerase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  806. flucytosine --- r_associated #0: 80 --> en:contraindications aspect
    n1=flucytosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  807. lentilles de contact --- r_associated #0: 80 --> en:contraindications aspect
    n1=lentilles de contact | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  808. mycotoxine --- r_associated #0: 80 --> en:contraindications aspect
    n1=mycotoxine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  809. ponction biopsie --- r_associated #0: 80 --> en:contraindications aspect
    n1=ponction biopsie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  810. pristinamycine --- r_associated #0: 80 --> en:contraindications aspect
    n1=pristinamycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  811. pseudouridine --- r_associated #0: 80 --> en:contraindications aspect
    n1=pseudouridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  812. saponine --- r_associated #0: 80 --> en:contraindications aspect
    n1=saponine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=80
  813. anthracènes --- r_associated #0: 79 --> en:contraindications aspect
    n1=anthracènes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  814. curcumine --- r_associated #0: 79 --> en:contraindications aspect
    n1=curcumine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  815. dentifrices --- r_associated #0: 79 --> en:contraindications aspect
    n1=dentifrices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  816. en:glyoxal --- r_associated #0: 79 --> en:contraindications aspect
    n1=en:glyoxal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  817. en:mycotoxin --- r_associated #0: 79 --> en:contraindications aspect
    n1=en:mycotoxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  818. en:pseudouridine --- r_associated #0: 79 --> en:contraindications aspect
    n1=en:pseudouridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  819. en:salpingectomy --- r_associated #0: 79 --> en:contraindications aspect
    n1=en:salpingectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  820. en:saponin --- r_associated #0: 79 --> en:contraindications aspect
    n1=en:saponin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  821. immuno-conglutinines --- r_associated #0: 79 --> en:contraindications aspect
    n1=immuno-conglutinines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  822. lynestrénol --- r_associated #0: 79 --> en:contraindications aspect
    n1=lynestrénol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  823. pro-glucagon --- r_associated #0: 79 --> en:contraindications aspect
    n1=pro-glucagon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  824. périndopril --- r_associated #0: 79 --> en:contraindications aspect
    n1=périndopril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=79
  825. bufoténine --- r_associated #0: 78 --> en:contraindications aspect
    n1=bufoténine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  826. colonoscope --- r_associated #0: 78 --> en:contraindications aspect
    n1=colonoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  827. en:clarithromycin --- r_associated #0: 78 --> en:contraindications aspect
    n1=en:clarithromycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  828. en:compression bandage --- r_associated #0: 78 --> en:contraindications aspect
    n1=en:compression bandage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  829. en:pristinamycin --- r_associated #0: 78 --> en:contraindications aspect
    n1=en:pristinamycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  830. en:therapeutic hydrocortisone --- r_associated #0: 78 --> en:contraindications aspect
    n1=en:therapeutic hydrocortisone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  831. glucosamine --- r_associated #0: 78 --> en:contraindications aspect
    n1=glucosamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  832. murexide --- r_associated #0: 78 --> en:contraindications aspect
    n1=murexide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  833. neuropeptide --- r_associated #0: 78 --> en:contraindications aspect
    n1=neuropeptide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  834. radio-isotope --- r_associated #0: 78 --> en:contraindications aspect
    n1=radio-isotope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  835. syringe --- r_associated #0: 78 --> en:contraindications aspect
    n1=syringe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  836. sélectine --- r_associated #0: 78 --> en:contraindications aspect
    n1=sélectine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=78
  837. carcinogène --- r_associated #0: 77 --> en:contraindications aspect
    n1=carcinogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  838. delavirdine --- r_associated #0: 77 --> en:contraindications aspect
    n1=delavirdine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  839. en:antimetabolite --- r_associated #0: 77 --> en:contraindications aspect
    n1=en:antimetabolite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  840. en:bufotenin --- r_associated #0: 77 --> en:contraindications aspect
    n1=en:bufotenin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  841. en:chymotrypsin --- r_associated #0: 77 --> en:contraindications aspect
    n1=en:chymotrypsin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  842. en:contacts --- r_associated #0: 77 --> en:contraindications aspect
    n1=en:contacts | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  843. en:flucytosine --- r_associated #0: 77 --> en:contraindications aspect
    n1=en:flucytosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  844. en:galactosephosphates --- r_associated #0: 77 --> en:contraindications aspect
    n1=en:galactosephosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  845. en:radioisotope --- r_associated #0: 77 --> en:contraindications aspect
    n1=en:radioisotope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  846. lipofuscine --- r_associated #0: 77 --> en:contraindications aspect
    n1=lipofuscine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  847. radioisotope --- r_associated #0: 77 --> en:contraindications aspect
    n1=radioisotope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  848. éviscération orbitaire --- r_associated #0: 77 --> en:contraindications aspect
    n1=éviscération orbitaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=77
  849. auranofine --- r_associated #0: 76 --> en:contraindications aspect
    n1=auranofine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  850. duodénostomie --- r_associated #0: 76 --> en:contraindications aspect
    n1=duodénostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  851. en:anthracenes --- r_associated #0: 76 --> en:contraindications aspect
    n1=en:anthracenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  852. en:batroxobin --- r_associated #0: 76 --> en:contraindications aspect
    n1=en:batroxobin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  853. en:curcumin --- r_associated #0: 76 --> en:contraindications aspect
    n1=en:curcumin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  854. en:lipofuscin --- r_associated #0: 76 --> en:contraindications aspect
    n1=en:lipofuscin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  855. en:natalizumab --- r_associated #0: 76 --> en:contraindications aspect
    n1=en:natalizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  856. en:needle biopsy --- r_associated #0: 76 --> en:contraindications aspect
    n1=en:needle biopsy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  857. en:perindopril --- r_associated #0: 76 --> en:contraindications aspect
    n1=en:perindopril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  858. en:technetium --- r_associated #0: 76 --> en:contraindications aspect
    n1=en:technetium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  859. galactose phosphates --- r_associated #0: 76 --> en:contraindications aspect
    n1=galactose phosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  860. granzyme --- r_associated #0: 76 --> en:contraindications aspect
    n1=granzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  861. kératoplastie --- r_associated #0: 76 --> en:contraindications aspect
    n1=kératoplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  862. proflavine --- r_associated #0: 76 --> en:contraindications aspect
    n1=proflavine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  863. radioscopie --- r_associated #0: 76 --> en:contraindications aspect
    n1=radioscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  864. technétium --- r_associated #0: 76 --> en:contraindications aspect
    n1=technétium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=76
  865. antitranspirants --- r_associated #0: 75 --> en:contraindications aspect
    n1=antitranspirants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  866. bande Velpeau --- r_associated #0: 75 --> en:contraindications aspect
    n1=bande Velpeau | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  867. batroxobine --- r_associated #0: 75 --> en:contraindications aspect
    n1=batroxobine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  868. bronchoscope --- r_associated #0: 75 --> en:contraindications aspect
    n1=bronchoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  869. canthaxanthine --- r_associated #0: 75 --> en:contraindications aspect
    n1=canthaxanthine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  870. chymotrypsine --- r_associated #0: 75 --> en:contraindications aspect
    n1=chymotrypsine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  871. clarithromycine --- r_associated #0: 75 --> en:contraindications aspect
    n1=clarithromycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  872. dapsone --- r_associated #0: 75 --> en:contraindications aspect
    n1=dapsone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  873. daunorubicine --- r_associated #0: 75 --> en:contraindications aspect
    n1=daunorubicine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  874. en:auranofin --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:auranofin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  875. en:colonoscope --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:colonoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  876. en:computer-assisted tomography --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:computer-assisted tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  877. en:delavirdine --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:delavirdine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  878. en:elastic bandage --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:elastic bandage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  879. en:emtricitabine --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:emtricitabine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  880. en:glucosamine --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:glucosamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  881. en:lynestrenol --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:lynestrenol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  882. en:selectin --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:selectin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  883. en:syringe --- r_associated #0: 75 --> en:contraindications aspect
    n1=en:syringe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  884. monosaccaride --- r_associated #0: 75 --> en:contraindications aspect
    n1=monosaccaride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  885. natalizumab --- r_associated #0: 75 --> en:contraindications aspect
    n1=natalizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  886. saponoside --- r_associated #0: 75 --> en:contraindications aspect
    n1=saponoside | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  887. seringue --- r_associated #0: 75 --> en:contraindications aspect
    n1=seringue | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  888. technetium --- r_associated #0: 75 --> en:contraindications aspect
    n1=technetium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  889. vaccin microbien --- r_associated #0: 75 --> en:contraindications aspect
    n1=vaccin microbien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=75
  890. allongement d'un nerf --- r_associated #0: 74 --> en:contraindications aspect
    n1=allongement d'un nerf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=74
  891. en:defibrillators --- r_associated #0: 74 --> en:contraindications aspect
    n1=en:defibrillators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=74
  892. en:diuron --- r_associated #0: 74 --> en:contraindications aspect
    n1=en:diuron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=74
  893. en:duodenostomy --- r_associated #0: 74 --> en:contraindications aspect
    n1=en:duodenostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=74
  894. en:gallic acid --- r_associated #0: 74 --> en:contraindications aspect
    n1=en:gallic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=74
  895. en:granzyme --- r_associated #0: 74 --> en:contraindications aspect
    n1=en:granzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=74
  896. en:parathormone --- r_associated #0: 74 --> en:contraindications aspect
    n1=en:parathormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=74
  897. en:proglucagon --- r_associated #0: 74 --> en:contraindications aspect
    n1=en:proglucagon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=74
  898. en:vaccine --- r_associated #0: 74 --> en:contraindications aspect
    n1=en:vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=74
  899. capnographie --- r_associated #0: 73 --> en:contraindications aspect
    n1=capnographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=73
  900. emtricitabine --- r_associated #0: 73 --> en:contraindications aspect
    n1=emtricitabine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=73
  901. en:bronchoscope --- r_associated #0: 73 --> en:contraindications aspect
    n1=en:bronchoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=73
  902. en:canthaxanthin --- r_associated #0: 73 --> en:contraindications aspect
    n1=en:canthaxanthin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=73
  903. en:filgrastim --- r_associated #0: 73 --> en:contraindications aspect
    n1=en:filgrastim | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=73
  904. gastroscope --- r_associated #0: 73 --> en:contraindications aspect
    n1=gastroscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=73
  905. inhibiteur enzymatique --- r_associated #0: 73 --> en:contraindications aspect
    n1=inhibiteur enzymatique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=73
  906. arabinose --- r_associated #0: 72 --> en:contraindications aspect
    n1=arabinose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=72
  907. colectomie --- r_associated #0: 72 --> en:contraindications aspect
    n1=colectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=72
  908. cycloleucine --- r_associated #0: 72 --> en:contraindications aspect
    n1=cycloleucine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=72
  909. en:enzyme inhibitor --- r_associated #0: 72 --> en:contraindications aspect
    n1=en:enzyme inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=72
  910. en:gastroscope --- r_associated #0: 72 --> en:contraindications aspect
    n1=en:gastroscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=72
  911. en:proflavine --- r_associated #0: 72 --> en:contraindications aspect
    n1=en:proflavine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=72
  912. en:prothrombin time --- r_associated #0: 72 --> en:contraindications aspect
    n1=en:prothrombin time | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=72
  913. en:rna, ribosomal, self-splicing --- r_associated #0: 72 --> en:contraindications aspect
    n1=en:rna, ribosomal, self-splicing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=72
  914. perforine --- r_associated #0: 72 --> en:contraindications aspect
    n1=perforine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=72
  915. 2-aminopurine --- r_associated #0: 71 --> en:contraindications aspect
    n1=2-aminopurine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  916. E161g --- r_associated #0: 71 --> en:contraindications aspect
    n1=E161g | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  917. E452 --- r_associated #0: 71 --> en:contraindications aspect
    n1=E452 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  918. acide gallique --- r_associated #0: 71 --> en:contraindications aspect
    n1=acide gallique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  919. acide orotique --- r_associated #0: 71 --> en:contraindications aspect
    n1=acide orotique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  920. aurothioglucose --- r_associated #0: 71 --> en:contraindications aspect
    n1=aurothioglucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  921. autoépissage de l'arn ribosomique --- r_associated #0: 71 --> en:contraindications aspect
    n1=autoépissage de l'arn ribosomique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  922. benzidines --- r_associated #0: 71 --> en:contraindications aspect
    n1=benzidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  923. cystéine synthase --- r_associated #0: 71 --> en:contraindications aspect
    n1=cystéine synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  924. en:arabinose --- r_associated #0: 71 --> en:contraindications aspect
    n1=en:arabinose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  925. en:contact lenses --- r_associated #0: 71 --> en:contraindications aspect
    n1=en:contact lenses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  926. en:dapsone --- r_associated #0: 71 --> en:contraindications aspect
    n1=en:dapsone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  927. en:daunorubicin --- r_associated #0: 71 --> en:contraindications aspect
    n1=en:daunorubicin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  928. en:phenoxypropanolamines --- r_associated #0: 71 --> en:contraindications aspect
    n1=en:phenoxypropanolamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  929. mitoguazones --- r_associated #0: 71 --> en:contraindications aspect
    n1=mitoguazones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  930. phénoxy-propanolamines --- r_associated #0: 71 --> en:contraindications aspect
    n1=phénoxy-propanolamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  931. substance colloïde --- r_associated #0: 71 --> en:contraindications aspect
    n1=substance colloïde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  932. temps de Quick --- r_associated #0: 71 --> en:contraindications aspect
    n1=temps de Quick | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  933. temps de prothrombine --- r_associated #0: 71 --> en:contraindications aspect
    n1=temps de prothrombine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=71
  934. E100 --- r_associated #0: 70 --> en:contraindications aspect
    n1=E100 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  935. E100(i) --- r_associated #0: 70 --> en:contraindications aspect
    n1=E100(i) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  936. E1521 --- r_associated #0: 70 --> en:contraindications aspect
    n1=E1521 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  937. E420(i) --- r_associated #0: 70 --> en:contraindications aspect
    n1=E420(i) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  938. diuron --- r_associated #0: 70 --> en:contraindications aspect
    n1=diuron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  939. défibrillateurs --- r_associated #0: 70 --> en:contraindications aspect
    n1=défibrillateurs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  940. en:acquaintance --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:acquaintance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  941. en:acquaintances --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:acquaintances | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  942. en:colectomy --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:colectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  943. en:colloid --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:colloid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  944. en:connections --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:connections | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  945. en:dental polishes --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:dental polishes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  946. en:dentifrices --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:dentifrices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  947. en:hysterotomy --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:hysterotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  948. en:immunoconglutinins --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:immunoconglutinins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  949. en:inositol --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:inositol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  950. en:integrin alpha-4 --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:integrin alpha-4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  951. en:people that you know --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:people that you know | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  952. en:people you know --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:people you know | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  953. en:polyphosphates --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:polyphosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  954. en:quantitative computerized tomography --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:quantitative computerized tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  955. en:relations --- r_associated #0: 70 --> en:contraindications aspect
    n1=en:relations | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  956. filgrastim --- r_associated #0: 70 --> en:contraindications aspect
    n1=filgrastim | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  957. inhibiteur d'enzymes --- r_associated #0: 70 --> en:contraindications aspect
    n1=inhibiteur d'enzymes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  958. médicament laxatif --- r_associated #0: 70 --> en:contraindications aspect
    n1=médicament laxatif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  959. métribolone --- r_associated #0: 70 --> en:contraindications aspect
    n1=métribolone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  960. ornithine décarboxylase --- r_associated #0: 70 --> en:contraindications aspect
    n1=ornithine décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  961. phospholipase A1 --- r_associated #0: 70 --> en:contraindications aspect
    n1=phospholipase A1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  962. phénoxypropanolamines --- r_associated #0: 70 --> en:contraindications aspect
    n1=phénoxypropanolamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  963. propanil --- r_associated #0: 70 --> en:contraindications aspect
    n1=propanil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  964. relations --- r_associated #0: 70 --> en:contraindications aspect
    n1=relations | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  965. saccharine --- r_associated #0: 70 --> en:contraindications aspect
    n1=saccharine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  966. scanographie quantitative --- r_associated #0: 70 --> en:contraindications aspect
    n1=scanographie quantitative | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=70
  967. S-adénosylhomocystéine --- r_associated #0: 69 --> en:contraindications aspect
    n1=S-adénosylhomocystéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  968. acétolactate synthase --- r_associated #0: 69 --> en:contraindications aspect
    n1=acétolactate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  969. colpotomie --- r_associated #0: 69 --> en:contraindications aspect
    n1=colpotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  970. en:capnography --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:capnography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  971. en:cycloleucine --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:cycloleucine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  972. en:cysteine synthase --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:cysteine synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  973. en:dasatinib --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:dasatinib | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  974. en:deep sedation --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:deep sedation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  975. en:dental equipment --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:dental equipment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  976. en:metribolone --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:metribolone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  977. en:mitoguazone --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:mitoguazone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  978. en:ornithine decarboxylase --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:ornithine decarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  979. en:perforin --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:perforin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  980. en:phospholipase a1 --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:phospholipase a1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  981. en:propanil --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:propanil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  982. en:rivaroxaban --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:rivaroxaban | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  983. en:saccharin --- r_associated #0: 69 --> en:contraindications aspect
    n1=en:saccharin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  984. fructose phosphates --- r_associated #0: 69 --> en:contraindications aspect
    n1=fructose phosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  985. inositol --- r_associated #0: 69 --> en:contraindications aspect
    n1=inositol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  986. mannose-6-phosphate isomérase --- r_associated #0: 69 --> en:contraindications aspect
    n1=mannose-6-phosphate isomérase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=69
  987. CT-scan --- r_associated #0: 68 --> en:contraindications aspect
    n1=CT-scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  988. acétate de potassium --- r_associated #0: 68 --> en:contraindications aspect
    n1=acétate de potassium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  989. bisphosphoglycérate mutase --- r_associated #0: 68 --> en:contraindications aspect
    n1=bisphosphoglycérate mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  990. carmustine --- r_associated #0: 68 --> en:contraindications aspect
    n1=carmustine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  991. chlorpyrifos --- r_associated #0: 68 --> en:contraindications aspect
    n1=chlorpyrifos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  992. en:2-aminopurine --- r_associated #0: 68 --> en:contraindications aspect
    n1=en:2-aminopurine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  993. en:aurothioglucose --- r_associated #0: 68 --> en:contraindications aspect
    n1=en:aurothioglucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  994. en:integrin alpha4 --- r_associated #0: 68 --> en:contraindications aspect
    n1=en:integrin alpha4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  995. en:mannose-6-phosphate isomerase --- r_associated #0: 68 --> en:contraindications aspect
    n1=en:mannose-6-phosphate isomerase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  996. hystérotomie --- r_associated #0: 68 --> en:contraindications aspect
    n1=hystérotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  997. phosphoglycérate mutase --- r_associated #0: 68 --> en:contraindications aspect
    n1=phosphoglycérate mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  998. polyphosphates --- r_associated #0: 68 --> en:contraindications aspect
    n1=polyphosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  999. relations sexuelles --- r_associated #0: 68 --> en:contraindications aspect
    n1=relations sexuelles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  1000. stérol O-acyltransférase --- r_associated #0: 68 --> en:contraindications aspect
    n1=stérol O-acyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  1001. toluène --- r_associated #0: 68 --> en:contraindications aspect
    n1=toluène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=68
  1002. aldicarbe --- r_associated #0: 67 --> en:contraindications aspect
    n1=aldicarbe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1003. amorces d'adn --- r_associated #0: 67 --> en:contraindications aspect
    n1=amorces d'adn | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1004. auriculothérapie --- r_associated #0: 67 --> en:contraindications aspect
    n1=auriculothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1005. autoépissage de l'arn ribosomal --- r_associated #0: 67 --> en:contraindications aspect
    n1=autoépissage de l'arn ribosomal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1006. benzilates --- r_associated #0: 67 --> en:contraindications aspect
    n1=benzilates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1007. chlorates --- r_associated #0: 67 --> en:contraindications aspect
    n1=chlorates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1008. en:benzidines --- r_associated #0: 67 --> en:contraindications aspect
    n1=en:benzidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1009. en:bisphosphoglycerate mutase --- r_associated #0: 67 --> en:contraindications aspect
    n1=en:bisphosphoglycerate mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1010. en:carmustine --- r_associated #0: 67 --> en:contraindications aspect
    n1=en:carmustine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1011. en:chlorpyrifos --- r_associated #0: 67 --> en:contraindications aspect
    n1=en:chlorpyrifos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1012. en:colpotomy --- r_associated #0: 67 --> en:contraindications aspect
    n1=en:colpotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1013. en:integrin alpha-v --- r_associated #0: 67 --> en:contraindications aspect
    n1=en:integrin alpha-v | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1014. en:interferometry --- r_associated #0: 67 --> en:contraindications aspect
    n1=en:interferometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1015. en:risa --- r_associated #0: 67 --> en:contraindications aspect
    n1=en:risa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1016. en:sterol o-acyltransferase --- r_associated #0: 67 --> en:contraindications aspect
    n1=en:sterol o-acyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1017. orotidine-5'-phosphate décarboxylase --- r_associated #0: 67 --> en:contraindications aspect
    n1=orotidine-5'-phosphate décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1018. phosphoénolpyruvate carboxylase --- r_associated #0: 67 --> en:contraindications aspect
    n1=phosphoénolpyruvate carboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1019. sédation profonde --- r_associated #0: 67 --> en:contraindications aspect
    n1=sédation profonde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=67
  1020. E270 --- r_associated #0: 66 --> en:contraindications aspect
    n1=E270 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1021. PET scan --- r_associated #0: 66 --> en:contraindications aspect
    n1=PET scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1022. acides gras libres --- r_associated #0: 66 --> en:contraindications aspect
    n1=acides gras libres | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1023. agent laxatif --- r_associated #0: 66 --> en:contraindications aspect
    n1=agent laxatif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1024. auto-épissage de l'arn ribosomique --- r_associated #0: 66 --> en:contraindications aspect
    n1=auto-épissage de l'arn ribosomique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1025. culdoscopie --- r_associated #0: 66 --> en:contraindications aspect
    n1=culdoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1026. cytochrome c1 --- r_associated #0: 66 --> en:contraindications aspect
    n1=cytochrome c1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1027. dasatinib --- r_associated #0: 66 --> en:contraindications aspect
    n1=dasatinib | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1028. diflubenzuron --- r_associated #0: 66 --> en:contraindications aspect
    n1=diflubenzuron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1029. en:acetolactate synthase --- r_associated #0: 66 --> en:contraindications aspect
    n1=en:acetolactate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1030. en:corneal transplant --- r_associated #0: 66 --> en:contraindications aspect
    n1=en:corneal transplant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1031. en:integrin alpha-6 --- r_associated #0: 66 --> en:contraindications aspect
    n1=en:integrin alpha-6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1032. en:methyl-gag --- r_associated #0: 66 --> en:contraindications aspect
    n1=en:methyl-gag | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1033. en:orotidine-5'-phosphate decarboxylase --- r_associated #0: 66 --> en:contraindications aspect
    n1=en:orotidine-5'-phosphate decarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1034. en:potassium acetate --- r_associated #0: 66 --> en:contraindications aspect
    n1=en:potassium acetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1035. en:s-adenosylhomocysteine --- r_associated #0: 66 --> en:contraindications aspect
    n1=en:s-adenosylhomocysteine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1036. halothane --- r_associated #0: 66 --> en:contraindications aspect
    n1=halothane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1037. mitoguazone --- r_associated #0: 66 --> en:contraindications aspect
    n1=mitoguazone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1038. nestine --- r_associated #0: 66 --> en:contraindications aspect
    n1=nestine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1039. parathormone --- r_associated #0: 66 --> en:contraindications aspect
    n1=parathormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1040. thréonine déhydratase --- r_associated #0: 66 --> en:contraindications aspect
    n1=thréonine déhydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1041. tomographie axiale calculée par ordinateur --- r_associated #0: 66 --> en:contraindications aspect
    n1=tomographie axiale calculée par ordinateur | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1042. tomographie à émission de positons --- r_associated #0: 66 --> en:contraindications aspect
    n1=tomographie à émission de positons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=66
  1043. 1-acylglycérol-3-phosphate O-acyltransférase --- r_associated #0: 65 --> en:contraindications aspect
    n1=1-acylglycérol-3-phosphate O-acyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1044. E261 --- r_associated #0: 65 --> en:contraindications aspect
    n1=E261 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1045. adénosylméthionine décarboxylase --- r_associated #0: 65 --> en:contraindications aspect
    n1=adénosylméthionine décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1046. antienzyme --- r_associated #0: 65 --> en:contraindications aspect
    n1=antienzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1047. caprolactame --- r_associated #0: 65 --> en:contraindications aspect
    n1=caprolactame | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1048. diacylglycérol O-acyltransférase --- r_associated #0: 65 --> en:contraindications aspect
    n1=diacylglycérol O-acyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1049. en:CT scanner --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:CT scanner | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1050. en:alginates --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:alginates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1051. en:antistreptolysin --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:antistreptolysin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1052. en:benzilates --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:benzilates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1053. en:chlorates --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:chlorates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1054. en:culdoscopy --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:culdoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1055. en:dna primers --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:dna primers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1056. en:ethanolaminephosphotransferase --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:ethanolaminephosphotransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1057. en:fructosephosphates --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:fructosephosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1058. en:integrin alpha6 --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:integrin alpha6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1059. en:intercourse --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:intercourse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1060. en:laxative --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:laxative | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1061. en:mammography --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:mammography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1062. en:orotic acid --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:orotic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1063. en:polytetrafluoroethylene --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:polytetrafluoroethylene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1064. en:toluene --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:toluene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1065. en:urethan --- r_associated #0: 65 --> en:contraindications aspect
    n1=en:urethan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1066. imagerie du corps entier --- r_associated #0: 65 --> en:contraindications aspect
    n1=imagerie du corps entier | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1067. lunettes de vue --- r_associated #0: 65 --> en:contraindications aspect
    n1=lunettes de vue | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1068. matériel dentaire --- r_associated #0: 65 --> en:contraindications aspect
    n1=matériel dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1069. oscillométrie --- r_associated #0: 65 --> en:contraindications aspect
    n1=oscillométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1070. promazine --- r_associated #0: 65 --> en:contraindications aspect
    n1=promazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1071. rifamycine --- r_associated #0: 65 --> en:contraindications aspect
    n1=rifamycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1072. rivaroxaban --- r_associated #0: 65 --> en:contraindications aspect
    n1=rivaroxaban | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1073. réinsertion --- r_associated #0: 65 --> en:contraindications aspect
    n1=réinsertion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1074. tomographie par émission de positrons --- r_associated #0: 65 --> en:contraindications aspect
    n1=tomographie par émission de positrons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1075. transplantation de cornée --- r_associated #0: 65 --> en:contraindications aspect
    n1=transplantation de cornée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1076. équipement dentaire --- r_associated #0: 65 --> en:contraindications aspect
    n1=équipement dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=65
  1077. CAT-scan --- r_associated #0: 64 --> en:contraindications aspect
    n1=CAT-scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1078. acyltransférase --- r_associated #0: 64 --> en:contraindications aspect
    n1=acyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1079. cryoglobuline --- r_associated #0: 64 --> en:contraindications aspect
    n1=cryoglobuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1080. en:auriculotherapy --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:auriculotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1081. en:citrulline --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:citrulline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1082. en:glycerophospholipids --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:glycerophospholipids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1083. en:integrin alphav --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:integrin alphav | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1084. en:neurotensin --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:neurotensin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1085. en:oscillometry --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:oscillometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1086. en:phosphoenolpyruvate carboxylase --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:phosphoenolpyruvate carboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1087. en:phosphoglycerate mutase --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:phosphoglycerate mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1088. en:promazine --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:promazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1089. en:sal diurecticum --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:sal diurecticum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1090. en:vivisection --- r_associated #0: 64 --> en:contraindications aspect
    n1=en:vivisection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1091. imagerie par résonance magnétique --- r_associated #0: 64 --> en:contraindications aspect
    n1=imagerie par résonance magnétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1092. ramipril --- r_associated #0: 64 --> en:contraindications aspect
    n1=ramipril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1093. transillumination --- r_associated #0: 64 --> en:contraindications aspect
    n1=transillumination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1094. æquorine --- r_associated #0: 64 --> en:contraindications aspect
    n1=æquorine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=64
  1095. adénylate cyclase --- r_associated #0: 63 --> en:contraindications aspect
    n1=adénylate cyclase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1096. arbutine --- r_associated #0: 63 --> en:contraindications aspect
    n1=arbutine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1097. en:1-acylglycerol-3-phosphate o-acyltransferase --- r_associated #0: 63 --> en:contraindications aspect
    n1=en:1-acylglycerol-3-phosphate o-acyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1098. en:3-hydroxyanthranilic acid --- r_associated #0: 63 --> en:contraindications aspect
    n1=en:3-hydroxyanthranilic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1099. en:adenosylmethionine decarboxylase --- r_associated #0: 63 --> en:contraindications aspect
    n1=en:adenosylmethionine decarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1100. en:adenylate cyclase --- r_associated #0: 63 --> en:contraindications aspect
    n1=en:adenylate cyclase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1101. en:aldicarb --- r_associated #0: 63 --> en:contraindications aspect
    n1=en:aldicarb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1102. en:caprolactam --- r_associated #0: 63 --> en:contraindications aspect
    n1=en:caprolactam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1103. en:diflubenzuron --- r_associated #0: 63 --> en:contraindications aspect
    n1=en:diflubenzuron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1104. en:gonadotropin --- r_associated #0: 63 --> en:contraindications aspect
    n1=en:gonadotropin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1105. en:rifamycin --- r_associated #0: 63 --> en:contraindications aspect
    n1=en:rifamycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1106. hydroxyméthylglutaryl-CoA synthase --- r_associated #0: 63 --> en:contraindications aspect
    n1=hydroxyméthylglutaryl-CoA synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1107. interférométrie --- r_associated #0: 63 --> en:contraindications aspect
    n1=interférométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1108. lipoprotein lipase --- r_associated #0: 63 --> en:contraindications aspect
    n1=lipoprotein lipase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1109. mammographie --- r_associated #0: 63 --> en:contraindications aspect
    n1=mammographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1110. oxitriptan --- r_associated #0: 63 --> en:contraindications aspect
    n1=oxitriptan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1111. pyruvate oxidase --- r_associated #0: 63 --> en:contraindications aspect
    n1=pyruvate oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1112. éthanolamine phosphotransférase --- r_associated #0: 63 --> en:contraindications aspect
    n1=éthanolamine phosphotransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=63
  1113. aminophénols --- r_associated #0: 62 --> en:contraindications aspect
    n1=aminophénols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1114. angéiographie --- r_associated #0: 62 --> en:contraindications aspect
    n1=angéiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1115. anti-streptolysine --- r_associated #0: 62 --> en:contraindications aspect
    n1=anti-streptolysine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1116. antistreptolysine --- r_associated #0: 62 --> en:contraindications aspect
    n1=antistreptolysine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1117. diglycérides --- r_associated #0: 62 --> en:contraindications aspect
    n1=diglycérides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1118. en:adenylylcyclase --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:adenylylcyclase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1119. en:codon --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:codon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1120. en:cytochrome c1 --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:cytochrome c1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1121. en:glasses --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:glasses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1122. en:halothane --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:halothane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1123. en:hydroxymethylglutaryl-coa synthase --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:hydroxymethylglutaryl-coa synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1124. en:lipoprotein lipase --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:lipoprotein lipase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1125. en:nestin --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:nestin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1126. en:pethidine hydrochloride --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:pethidine hydrochloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1127. en:threonine dehydratase --- r_associated #0: 62 --> en:contraindications aspect
    n1=en:threonine dehydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1128. gonadotrophine --- r_associated #0: 62 --> en:contraindications aspect
    n1=gonadotrophine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1129. insuline glargine --- r_associated #0: 62 --> en:contraindications aspect
    n1=insuline glargine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1130. interleukine 18 --- r_associated #0: 62 --> en:contraindications aspect
    n1=interleukine 18 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1131. paire de bretelles --- r_associated #0: 62 --> en:contraindications aspect
    n1=paire de bretelles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1132. porphyrin --- r_associated #0: 62 --> en:contraindications aspect
    n1=porphyrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1133. relaxine --- r_associated #0: 62 --> en:contraindications aspect
    n1=relaxine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1134. régime cétogène --- r_associated #0: 62 --> en:contraindications aspect
    n1=régime cétogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1135. télémétrie --- r_associated #0: 62 --> en:contraindications aspect
    n1=télémétrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1136. vivisection --- r_associated #0: 62 --> en:contraindications aspect
    n1=vivisection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=62
  1137. acétaminophène --- r_associated #0: 61 --> en:contraindications aspect
    n1=acétaminophène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1138. alginates --- r_associated #0: 61 --> en:contraindications aspect
    n1=alginates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1139. composés de l'aniline --- r_associated #0: 61 --> en:contraindications aspect
    n1=composés de l'aniline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1140. dérivés de l'aniline --- r_associated #0: 61 --> en:contraindications aspect
    n1=dérivés de l'aniline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1141. désoximétasone --- r_associated #0: 61 --> en:contraindications aspect
    n1=désoximétasone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1142. en:apexification --- r_associated #0: 61 --> en:contraindications aspect
    n1=en:apexification | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1143. en:cochlear implant procedure --- r_associated #0: 61 --> en:contraindications aspect
    n1=en:cochlear implant procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1144. en:cryosurgery --- r_associated #0: 61 --> en:contraindications aspect
    n1=en:cryosurgery | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1145. en:ct scanner --- r_associated #0: 61 --> en:contraindications aspect
    n1=en:ct scanner | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1146. en:diacylglycerol o-acyltransferase --- r_associated #0: 61 --> en:contraindications aspect
    n1=en:diacylglycerol o-acyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1147. en:insulin glargine --- r_associated #0: 61 --> en:contraindications aspect
    n1=en:insulin glargine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1148. en:nisoldipine --- r_associated #0: 61 --> en:contraindications aspect
    n1=en:nisoldipine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1149. fucosidase --- r_associated #0: 61 --> en:contraindications aspect
    n1=fucosidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1150. glucocorticoïde --- r_associated #0: 61 --> en:contraindications aspect
    n1=glucocorticoïde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1151. héliothérapie --- r_associated #0: 61 --> en:contraindications aspect
    n1=héliothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1152. hémagglutinine --- r_associated #0: 61 --> en:contraindications aspect
    n1=hémagglutinine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1153. interferometry --- r_associated #0: 61 --> en:contraindications aspect
    n1=interferometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1154. neurotensine --- r_associated #0: 61 --> en:contraindications aspect
    n1=neurotensine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1155. nicotine --- r_associated #0: 61 --> en:contraindications aspect
    n1=nicotine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1156. phosphoglycérides --- r_associated #0: 61 --> en:contraindications aspect
    n1=phosphoglycérides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1157. protéine morphogénétique osseuse --- r_associated #0: 61 --> en:contraindications aspect
    n1=protéine morphogénétique osseuse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1158. pseudocholinestérase --- r_associated #0: 61 --> en:contraindications aspect
    n1=pseudocholinestérase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1159. tomographie à émission simple photon --- r_associated #0: 61 --> en:contraindications aspect
    n1=tomographie à émission simple photon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1160. transplantation du pancreas --- r_associated #0: 61 --> en:contraindications aspect
    n1=transplantation du pancreas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1161. téflon --- r_associated #0: 61 --> en:contraindications aspect
    n1=téflon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1162. ursine --- r_associated #0: 61 --> en:contraindications aspect
    n1=ursine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1163. échinomycine --- r_associated #0: 61 --> en:contraindications aspect
    n1=échinomycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=61
  1164. Il-18 --- r_associated #0: 60 --> en:contraindications aspect
    n1=Il-18 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1165. L-dopa --- r_associated #0: 60 --> en:contraindications aspect
    n1=L-dopa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1166. acétyl-CoA C-acétyltransférase --- r_associated #0: 60 --> en:contraindications aspect
    n1=acétyl-CoA C-acétyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1167. alvéolectomie --- r_associated #0: 60 --> en:contraindications aspect
    n1=alvéolectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1168. antifongiques --- r_associated #0: 60 --> en:contraindications aspect
    n1=antifongiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1169. citrulline --- r_associated #0: 60 --> en:contraindications aspect
    n1=citrulline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1170. contrepulsion diastolique intra-aortique --- r_associated #0: 60 --> en:contraindications aspect
    n1=contrepulsion diastolique intra-aortique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1171. cryochirurgie --- r_associated #0: 60 --> en:contraindications aspect
    n1=cryochirurgie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1172. digue dentaire --- r_associated #0: 60 --> en:contraindications aspect
    n1=digue dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1173. en:acetaminophen --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:acetaminophen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1174. en:acyltransferase --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:acyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1175. en:aniline compounds --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:aniline compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1176. en:anticodon --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:anticodon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1177. en:bone morphogenetic protein --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:bone morphogenetic protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1178. en:cryoglobulin --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:cryoglobulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1179. en:dental procedure --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:dental procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1180. en:deoxyribose --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:deoxyribose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1181. en:desmoglein 2 --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:desmoglein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1182. en:desoximetasone --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:desoximetasone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1183. en:diglycerides --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:diglycerides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1184. en:dipeptidases --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:dipeptidases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1185. en:dopa --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:dopa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1186. en:echinomycin --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:echinomycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1187. en:enteroproctia --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:enteroproctia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1188. en:false tooth --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:false tooth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1189. en:fundoplication --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:fundoplication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1190. en:glicentin --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:glicentin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1191. en:heliotherapy --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:heliotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1192. en:interleukin-18 --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:interleukin-18 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1193. en:levodopa --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:levodopa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1194. en:nicotine --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:nicotine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1195. en:oxitriptan --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:oxitriptan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1196. en:phosphites --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:phosphites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1197. en:ramipril --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:ramipril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1198. en:relationships --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:relationships | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1199. en:sexual intercourse --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:sexual intercourse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1200. en:sexual relations --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:sexual relations | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1201. en:single photon emission computed tomography --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:single photon emission computed tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1202. en:sodium glutamate --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:sodium glutamate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1203. en:transillumination --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:transillumination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1204. en:warfarin --- r_associated #0: 60 --> en:contraindications aspect
    n1=en:warfarin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1205. examen du fond d'œil --- r_associated #0: 60 --> en:contraindications aspect
    n1=examen du fond d'œil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1206. facteur de croissance fibroblastique de type 9 --- r_associated #0: 60 --> en:contraindications aspect
    n1=facteur de croissance fibroblastique de type 9 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1207. gonadotropine --- r_associated #0: 60 --> en:contraindications aspect
    n1=gonadotropine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1208. interleukine-18 --- r_associated #0: 60 --> en:contraindications aspect
    n1=interleukine-18 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1209. lévodopa --- r_associated #0: 60 --> en:contraindications aspect
    n1=lévodopa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1210. nisoldipine --- r_associated #0: 60 --> en:contraindications aspect
    n1=nisoldipine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1211. paire de lunettes --- r_associated #0: 60 --> en:contraindications aspect
    n1=paire de lunettes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1212. polytétrafluoroéthylène --- r_associated #0: 60 --> en:contraindications aspect
    n1=polytétrafluoroéthylène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1213. radiographies des vaisseaux --- r_associated #0: 60 --> en:contraindications aspect
    n1=radiographies des vaisseaux | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1214. rapports sexuels --- r_associated #0: 60 --> en:contraindications aspect
    n1=rapports sexuels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1215. single photon emission computed tomography --- r_associated #0: 60 --> en:contraindications aspect
    n1=single photon emission computed tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1216. soin dentaire --- r_associated #0: 60 --> en:contraindications aspect
    n1=soin dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1217. transplantation du pancréas --- r_associated #0: 60 --> en:contraindications aspect
    n1=transplantation du pancréas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1218. warfarine --- r_associated #0: 60 --> en:contraindications aspect
    n1=warfarine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1219. éthylène glycol --- r_associated #0: 60 --> en:contraindications aspect
    n1=éthylène glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1220. éthylène-glycol --- r_associated #0: 60 --> en:contraindications aspect
    n1=éthylène-glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=60
  1221. acide 3-hydroxyanthranilique --- r_associated #0: 59 --> en:contraindications aspect
    n1=acide 3-hydroxyanthranilique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1222. amorceurs d'adn --- r_associated #0: 59 --> en:contraindications aspect
    n1=amorceurs d'adn | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1223. anti-fongiques --- r_associated #0: 59 --> en:contraindications aspect
    n1=anti-fongiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1224. anticodon --- r_associated #0: 59 --> en:contraindications aspect
    n1=anticodon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1225. codon --- r_associated #0: 59 --> en:contraindications aspect
    n1=codon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1226. colposcopie --- r_associated #0: 59 --> en:contraindications aspect
    n1=colposcopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1227. contrepulsion diastolique intraaortique --- r_associated #0: 59 --> en:contraindications aspect
    n1=contrepulsion diastolique intraaortique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1228. désoxyribose --- r_associated #0: 59 --> en:contraindications aspect
    n1=désoxyribose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1229. en:aminophenols --- r_associated #0: 59 --> en:contraindications aspect
    n1=en:aminophenols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1230. en:cardiomyoplasty --- r_associated #0: 59 --> en:contraindications aspect
    n1=en:cardiomyoplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1231. en:dental dam --- r_associated #0: 59 --> en:contraindications aspect
    n1=en:dental dam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1232. en:glucocorticoid --- r_associated #0: 59 --> en:contraindications aspect
    n1=en:glucocorticoid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1233. en:mitogen --- r_associated #0: 59 --> en:contraindications aspect
    n1=en:mitogen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1234. en:pyruvate oxidase --- r_associated #0: 59 --> en:contraindications aspect
    n1=en:pyruvate oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1235. en:spectacles --- r_associated #0: 59 --> en:contraindications aspect
    n1=en:spectacles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1236. en:telemetry --- r_associated #0: 59 --> en:contraindications aspect
    n1=en:telemetry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1237. en:zinc sulfate --- r_associated #0: 59 --> en:contraindications aspect
    n1=en:zinc sulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1238. lévomépromazine --- r_associated #0: 59 --> en:contraindications aspect
    n1=lévomépromazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1239. magnétocardiographie --- r_associated #0: 59 --> en:contraindications aspect
    n1=magnétocardiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1240. procédure médicale --- r_associated #0: 59 --> en:contraindications aspect
    n1=procédure médicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1241. protéine morphogénétique de l'os --- r_associated #0: 59 --> en:contraindications aspect
    n1=protéine morphogénétique de l'os | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1242. radiographie dentaire --- r_associated #0: 59 --> en:contraindications aspect
    n1=radiographie dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1243. thoracoplastie --- r_associated #0: 59 --> en:contraindications aspect
    n1=thoracoplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1244. vanadates --- r_associated #0: 59 --> en:contraindications aspect
    n1=vanadates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1245. zéine --- r_associated #0: 59 --> en:contraindications aspect
    n1=zéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=59
  1246. 3,4-dihydroxyphénylalanine --- r_associated #0: 58 --> en:contraindications aspect
    n1=3,4-dihydroxyphénylalanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1247. CVC --- r_associated #0: 58 --> en:contraindications aspect
    n1=CVC | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1248. E508 --- r_associated #0: 58 --> en:contraindications aspect
    n1=E508 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1249. apexification --- r_associated #0: 58 --> en:contraindications aspect
    n1=apexification | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1250. cefotiam --- r_associated #0: 58 --> en:contraindications aspect
    n1=cefotiam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1251. chlorure de potassium --- r_associated #0: 58 --> en:contraindications aspect
    n1=chlorure de potassium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1252. clofazimine --- r_associated #0: 58 --> en:contraindications aspect
    n1=clofazimine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1253. en:carbofuran --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:carbofuran | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1254. en:clofazimine --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:clofazimine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1255. en:colposcope --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:colposcope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1256. en:fucosidase --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:fucosidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1257. en:hemagglutinin --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:hemagglutinin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1258. en:ketogenic diet --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:ketogenic diet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1259. en:omalizumab --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:omalizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1260. en:pseudocholinesterase --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:pseudocholinesterase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1261. en:radiography, dental --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:radiography, dental | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1262. en:relaxin --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:relaxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1263. en:rivastigmine --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:rivastigmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1264. en:silicone gels --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:silicone gels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1265. en:teflon --- r_associated #0: 58 --> en:contraindications aspect
    n1=en:teflon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1266. fundoplication --- r_associated #0: 58 --> en:contraindications aspect
    n1=fundoplication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1267. gels de silicone --- r_associated #0: 58 --> en:contraindications aspect
    n1=gels de silicone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1268. géranylgéranyl-diphosphate géranylgéranyltransférase --- r_associated #0: 58 --> en:contraindications aspect
    n1=géranylgéranyl-diphosphate géranylgéranyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1269. imagerie de diagnostic --- r_associated #0: 58 --> en:contraindications aspect
    n1=imagerie de diagnostic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1270. résistine --- r_associated #0: 58 --> en:contraindications aspect
    n1=résistine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1271. temps de quick --- r_associated #0: 58 --> en:contraindications aspect
    n1=temps de quick | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=58
  1272. alpha-amylase --- r_associated #0: 57 --> en:contraindications aspect
    n1=alpha-amylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1273. aryl sulfotransférase --- r_associated #0: 57 --> en:contraindications aspect
    n1=aryl sulfotransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1274. braces --- r_associated #0: 57 --> en:contraindications aspect
    n1=braces | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1275. cholécystectomie --- r_associated #0: 57 --> en:contraindications aspect
    n1=cholécystectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1276. digoxigénine --- r_associated #0: 57 --> en:contraindications aspect
    n1=digoxigénine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1277. diphénoxylate --- r_associated #0: 57 --> en:contraindications aspect
    n1=diphénoxylate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1278. en:acetyl-coa c-acetyltransferase --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:acetyl-coa c-acetyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1279. en:alveolectomy --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:alveolectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1280. en:arbutin --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:arbutin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1281. en:certolizumab pegol --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:certolizumab pegol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1282. en:dicofol --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:dicofol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1283. en:fibroblast growth factor 9 --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:fibroblast growth factor 9 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1284. en:galactogogues --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:galactogogues | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1285. en:geranylgeranyl-diphosphate geranylgeranyltransferase --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:geranylgeranyl-diphosphate geranylgeranyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1286. en:growth hormone releasing hormone --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:growth hormone releasing hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1287. en:heptanol --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:heptanol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1288. en:pancreas transplantation --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:pancreas transplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1289. en:potassium chloride --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:potassium chloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1290. en:proguanil --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:proguanil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1291. en:veratrine --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:veratrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1292. en:zein --- r_associated #0: 57 --> en:contraindications aspect
    n1=en:zein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1293. formaldéhyde --- r_associated #0: 57 --> en:contraindications aspect
    n1=formaldéhyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1294. gels silicone --- r_associated #0: 57 --> en:contraindications aspect
    n1=gels silicone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1295. insecticides --- r_associated #0: 57 --> en:contraindications aspect
    n1=insecticides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1296. isomaltose --- r_associated #0: 57 --> en:contraindications aspect
    n1=isomaltose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1297. phosphites --- r_associated #0: 57 --> en:contraindications aspect
    n1=phosphites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1298. pose d'implants cochléaires --- r_associated #0: 57 --> en:contraindications aspect
    n1=pose d'implants cochléaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1299. stérols --- r_associated #0: 57 --> en:contraindications aspect
    n1=stérols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1300. tilétamine --- r_associated #0: 57 --> en:contraindications aspect
    n1=tilétamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=57
  1301. ARN ribosomique --- r_associated #0: 56 --> en:contraindications aspect
    n1=ARN ribosomique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1302. Eto --- r_associated #0: 56 --> en:contraindications aspect
    n1=Eto | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1303. acides nicotiniques --- r_associated #0: 56 --> en:contraindications aspect
    n1=acides nicotiniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1304. cardiomyoplastie --- r_associated #0: 56 --> en:contraindications aspect
    n1=cardiomyoplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1305. colloid --- r_associated #0: 56 --> en:contraindications aspect
    n1=colloid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1306. colposcope --- r_associated #0: 56 --> en:contraindications aspect
    n1=colposcope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1307. contraceptif oral --- r_associated #0: 56 --> en:contraindications aspect
    n1=contraceptif oral | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1308. coumaphène --- r_associated #0: 56 --> en:contraindications aspect
    n1=coumaphène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1309. desmogléine II --- r_associated #0: 56 --> en:contraindications aspect
    n1=desmogléine II | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1310. diazométhane --- r_associated #0: 56 --> en:contraindications aspect
    n1=diazométhane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1311. dipeptidases --- r_associated #0: 56 --> en:contraindications aspect
    n1=dipeptidases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1312. dpi --- r_associated #0: 56 --> en:contraindications aspect
    n1=dpi | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1313. en:alpha-amylase --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:alpha-amylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1314. en:arsenates --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:arsenates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1315. en:aryl sulfotransferase --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:aryl sulfotransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1316. en:butanes --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:butanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1317. en:cefotiam --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:cefotiam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1318. en:collagenase --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:collagenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1319. en:colposcopy --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:colposcopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1320. en:ethylene glycol --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:ethylene glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1321. en:liposome --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:liposome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1322. en:opium --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:opium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1323. en:resistin --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:resistin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1324. en:thoracoplasty --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:thoracoplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1325. en:uridine diphosphate --- r_associated #0: 56 --> en:contraindications aspect
    n1=en:uridine diphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1326. fermeture orthodontique d'espace --- r_associated #0: 56 --> en:contraindications aspect
    n1=fermeture orthodontique d'espace | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1327. glicentine --- r_associated #0: 56 --> en:contraindications aspect
    n1=glicentine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1328. heptanol --- r_associated #0: 56 --> en:contraindications aspect
    n1=heptanol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1329. hormone libératrice de l'hormone de croissance --- r_associated #0: 56 --> en:contraindications aspect
    n1=hormone libératrice de l'hormone de croissance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1330. hydrochlorothiazide --- r_associated #0: 56 --> en:contraindications aspect
    n1=hydrochlorothiazide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1331. monocrotophos --- r_associated #0: 56 --> en:contraindications aspect
    n1=monocrotophos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1332. traitement dentaire --- r_associated #0: 56 --> en:contraindications aspect
    n1=traitement dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1333. trétinoïne --- r_associated #0: 56 --> en:contraindications aspect
    n1=trétinoïne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1334. urokinase --- r_associated #0: 56 --> en:contraindications aspect
    n1=urokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1335. vitamine B6 --- r_associated #0: 56 --> en:contraindications aspect
    n1=vitamine B6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1336. éthylèneglycol --- r_associated #0: 56 --> en:contraindications aspect
    n1=éthylèneglycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=56
  1337. Digue dentaire --- r_associated #0: 55 --> en:contraindications aspect
    n1=Digue dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1338. KCl --- r_associated #0: 55 --> en:contraindications aspect
    n1=KCl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1339. arn ribosomique --- r_associated #0: 55 --> en:contraindications aspect
    n1=arn ribosomique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1340. arséniates --- r_associated #0: 55 --> en:contraindications aspect
    n1=arséniates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1341. carbofuran --- r_associated #0: 55 --> en:contraindications aspect
    n1=carbofuran | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1342. dicofol --- r_associated #0: 55 --> en:contraindications aspect
    n1=dicofol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1343. en:atrazine --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:atrazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1344. en:centrifugation --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:centrifugation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1345. en:cholecystectomy --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:cholecystectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1346. en:diazomethane --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:diazomethane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1347. en:digoxigenin --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:digoxigenin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1348. en:diphenoxylate --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:diphenoxylate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1349. en:formaldehyde --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:formaldehyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1350. en:levomepromazine --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:levomepromazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1351. en:magnetocardiography --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:magnetocardiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1352. en:monocrotophos --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:monocrotophos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1353. en:ribosomal RNA --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:ribosomal RNA | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1354. en:sterols --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:sterols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1355. en:tiletamine --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:tiletamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1356. en:transesophageal echocardiography --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:transesophageal echocardiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1357. en:urokinase --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:urokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1358. en:vanadates --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:vanadates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1359. en:vitamin B6 --- r_associated #0: 55 --> en:contraindications aspect
    n1=en:vitamin B6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1360. examen radiologique de l'abdomen --- r_associated #0: 55 --> en:contraindications aspect
    n1=examen radiologique de l'abdomen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1361. galactagogues --- r_associated #0: 55 --> en:contraindications aspect
    n1=galactagogues | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1362. glycol éthylique --- r_associated #0: 55 --> en:contraindications aspect
    n1=glycol éthylique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1363. hormone de libération de la somatotrophine --- r_associated #0: 55 --> en:contraindications aspect
    n1=hormone de libération de la somatotrophine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1364. i kappa b --- r_associated #0: 55 --> en:contraindications aspect
    n1=i kappa b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1365. implantation de prothèse cochléaire --- r_associated #0: 55 --> en:contraindications aspect
    n1=implantation de prothèse cochléaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1366. iodure de potassium --- r_associated #0: 55 --> en:contraindications aspect
    n1=iodure de potassium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1367. mitogène --- r_associated #0: 55 --> en:contraindications aspect
    n1=mitogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1368. oc --- r_associated #0: 55 --> en:contraindications aspect
    n1=oc | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1369. omalizumab --- r_associated #0: 55 --> en:contraindications aspect
    n1=omalizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1370. opération chirurgicale --- r_associated #0: 55 --> en:contraindications aspect
    n1=opération chirurgicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1371. péricardiectomie --- r_associated #0: 55 --> en:contraindications aspect
    n1=péricardiectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1372. radiographie des dents --- r_associated #0: 55 --> en:contraindications aspect
    n1=radiographie des dents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1373. rivastigmine --- r_associated #0: 55 --> en:contraindications aspect
    n1=rivastigmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1374. tomographie à positrons --- r_associated #0: 55 --> en:contraindications aspect
    n1=tomographie à positrons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1375. transplantation d'un pancreas --- r_associated #0: 55 --> en:contraindications aspect
    n1=transplantation d'un pancreas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1376. urocortine --- r_associated #0: 55 --> en:contraindications aspect
    n1=urocortine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1377. zéatine --- r_associated #0: 55 --> en:contraindications aspect
    n1=zéatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1378. Équipement dentaire --- r_associated #0: 55 --> en:contraindications aspect
    n1=Équipement dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1379. Éthylène glycol --- r_associated #0: 55 --> en:contraindications aspect
    n1=Éthylène glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1380. échocardiographie par voie transoesophagienne --- r_associated #0: 55 --> en:contraindications aspect
    n1=échocardiographie par voie transoesophagienne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=55
  1381. anti-parasitaire --- r_associated #0: 54 --> en:contraindications aspect
    n1=anti-parasitaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1382. butanes --- r_associated #0: 54 --> en:contraindications aspect
    n1=butanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1383. centrifugation --- r_associated #0: 54 --> en:contraindications aspect
    n1=centrifugation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1384. certolizumab pegol --- r_associated #0: 54 --> en:contraindications aspect
    n1=certolizumab pegol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1385. collagénase --- r_associated #0: 54 --> en:contraindications aspect
    n1=collagénase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1386. cymarine --- r_associated #0: 54 --> en:contraindications aspect
    n1=cymarine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1387. diathermie --- r_associated #0: 54 --> en:contraindications aspect
    n1=diathermie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1388. en:acrylates --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:acrylates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1389. en:androstanes --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:androstanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1390. en:angiogram --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:angiogram | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1391. en:answer somebody back --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:answer somebody back | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1392. en:antiparasitic agent --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:antiparasitic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1393. en:artificial anus --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:artificial anus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1394. en:chromogranin --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:chromogranin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1395. en:cytochrome a --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:cytochrome a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1396. en:iodates --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:iodates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1397. en:isomaltose --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:isomaltose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1398. en:neuroendoscopes --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:neuroendoscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1399. en:nicotinic acids --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:nicotinic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1400. en:orthodontic space closure --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:orthodontic space closure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1401. en:perchlorates --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:perchlorates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1402. en:phytochrome b --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:phytochrome b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1403. en:potassium iodide --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:potassium iodide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1404. en:rituximab --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:rituximab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1405. en:sulfites --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:sulfites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1406. en:tetracycline --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:tetracycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1407. en:zeatin --- r_associated #0: 54 --> en:contraindications aspect
    n1=en:zeatin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1408. fermeture espace orthodontique --- r_associated #0: 54 --> en:contraindications aspect
    n1=fermeture espace orthodontique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1409. iodides --- r_associated #0: 54 --> en:contraindications aspect
    n1=iodides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1410. liposome --- r_associated #0: 54 --> en:contraindications aspect
    n1=liposome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1411. mesna --- r_associated #0: 54 --> en:contraindications aspect
    n1=mesna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1412. pentachlorophénol --- r_associated #0: 54 --> en:contraindications aspect
    n1=pentachlorophénol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1413. proguanil --- r_associated #0: 54 --> en:contraindications aspect
    n1=proguanil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1414. pérylène --- r_associated #0: 54 --> en:contraindications aspect
    n1=pérylène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1415. rituximab --- r_associated #0: 54 --> en:contraindications aspect
    n1=rituximab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=54
  1416. antigène de Forssman --- r_associated #0: 53 --> en:contraindications aspect
    n1=antigène de Forssman | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1417. cytochromes b --- r_associated #0: 53 --> en:contraindications aspect
    n1=cytochromes b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1418. en:cecostomy --- r_associated #0: 53 --> en:contraindications aspect
    n1=en:cecostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1419. en:chloramines --- r_associated #0: 53 --> en:contraindications aspect
    n1=en:chloramines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1420. en:clopidol --- r_associated #0: 53 --> en:contraindications aspect
    n1=en:clopidol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1421. en:forssman antigen --- r_associated #0: 53 --> en:contraindications aspect
    n1=en:forssman antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1422. en:insecticides --- r_associated #0: 53 --> en:contraindications aspect
    n1=en:insecticides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1423. en:mesna --- r_associated #0: 53 --> en:contraindications aspect
    n1=en:mesna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1424. en:vitamin b6 --- r_associated #0: 53 --> en:contraindications aspect
    n1=en:vitamin b6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1425. iodates --- r_associated #0: 53 --> en:contraindications aspect
    n1=iodates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1426. tungsten --- r_associated #0: 53 --> en:contraindications aspect
    n1=tungsten | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1427. vératrine --- r_associated #0: 53 --> en:contraindications aspect
    n1=vératrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=53
  1428. 2-isopropylmalate synthase --- r_associated #0: 52 --> en:contraindications aspect
    n1=2-isopropylmalate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1429. E954(i) --- r_associated #0: 52 --> en:contraindications aspect
    n1=E954(i) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1430. Hélium --- r_associated #0: 52 --> en:contraindications aspect
    n1=Hélium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1431. condom --- r_associated #0: 52 --> en:contraindications aspect
    n1=condom | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1432. cytochrome a --- r_associated #0: 52 --> en:contraindications aspect
    n1=cytochrome a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1433. en:astringent --- r_associated #0: 52 --> en:contraindications aspect
    n1=en:astringent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1434. en:glucosinolate --- r_associated #0: 52 --> en:contraindications aspect
    n1=en:glucosinolate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1435. en:hydrochlorothiazide --- r_associated #0: 52 --> en:contraindications aspect
    n1=en:hydrochlorothiazide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1436. en:rhodopsin kinase --- r_associated #0: 52 --> en:contraindications aspect
    n1=en:rhodopsin kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1437. en:sonication --- r_associated #0: 52 --> en:contraindications aspect
    n1=en:sonication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1438. en:steroid isomerases --- r_associated #0: 52 --> en:contraindications aspect
    n1=en:steroid isomerases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1439. en:tretinoin --- r_associated #0: 52 --> en:contraindications aspect
    n1=en:tretinoin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1440. formol --- r_associated #0: 52 --> en:contraindications aspect
    n1=formol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1441. gaz sarin --- r_associated #0: 52 --> en:contraindications aspect
    n1=gaz sarin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1442. immunoprécipitation --- r_associated #0: 52 --> en:contraindications aspect
    n1=immunoprécipitation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1443. inosine diphosphate --- r_associated #0: 52 --> en:contraindications aspect
    n1=inosine diphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1444. laryngoscopie --- r_associated #0: 52 --> en:contraindications aspect
    n1=laryngoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1445. leptine --- r_associated #0: 52 --> en:contraindications aspect
    n1=leptine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1446. métalloexopeptidases --- r_associated #0: 52 --> en:contraindications aspect
    n1=métalloexopeptidases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1447. phytochrome b --- r_associated #0: 52 --> en:contraindications aspect
    n1=phytochrome b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1448. ribitol --- r_associated #0: 52 --> en:contraindications aspect
    n1=ribitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1449. spectacles --- r_associated #0: 52 --> en:contraindications aspect
    n1=spectacles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1450. sulfites --- r_associated #0: 52 --> en:contraindications aspect
    n1=sulfites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1451. thréonine-déshydratase --- r_associated #0: 52 --> en:contraindications aspect
    n1=thréonine-déshydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1452. thymidylate synthase --- r_associated #0: 52 --> en:contraindications aspect
    n1=thymidylate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1453. uridine diphosphate --- r_associated #0: 52 --> en:contraindications aspect
    n1=uridine diphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=52
  1454. E240 --- r_associated #0: 51 --> en:contraindications aspect
    n1=E240 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1455. acrylates --- r_associated #0: 51 --> en:contraindications aspect
    n1=acrylates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1456. adjuvant immunologique --- r_associated #0: 51 --> en:contraindications aspect
    n1=adjuvant immunologique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1457. antigène de forssman --- r_associated #0: 51 --> en:contraindications aspect
    n1=antigène de forssman | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1458. astringente --- r_associated #0: 51 --> en:contraindications aspect
    n1=astringente | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1459. atrazine --- r_associated #0: 51 --> en:contraindications aspect
    n1=atrazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1460. bleu de méthylène --- r_associated #0: 51 --> en:contraindications aspect
    n1=bleu de méthylène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1461. bêta-lipoprotéine --- r_associated #0: 51 --> en:contraindications aspect
    n1=bêta-lipoprotéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1462. dentifrice --- r_associated #0: 51 --> en:contraindications aspect
    n1=dentifrice | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1463. en:cadmium compound --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:cadmium compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1464. en:cymarine --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:cymarine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1465. en:cytidine triphosphate --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:cytidine triphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1466. en:diathermy --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:diathermy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1467. en:formalin --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:formalin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1468. en:helium --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:helium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1469. en:i kappa b --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:i kappa b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1470. en:immunoprecipitation --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:immunoprecipitation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1471. en:indocyanine green --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:indocyanine green | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1472. en:iodides --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:iodides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1473. en:laryngoscopy --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:laryngoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1474. en:leptin --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:leptin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1475. en:myod protein --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:myod protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1476. en:nalorphine --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:nalorphine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1477. en:pentachlorophenol --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:pentachlorophenol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1478. en:pericardiectomy --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:pericardiectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1479. en:putrescine --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:putrescine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1480. en:sorbose --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:sorbose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1481. en:sucrose --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:sucrose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1482. en:thymidylate synthase --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:thymidylate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1483. en:urocortin --- r_associated #0: 51 --> en:contraindications aspect
    n1=en:urocortin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1484. fermeture de l'espace orthodontique --- r_associated #0: 51 --> en:contraindications aspect
    n1=fermeture de l'espace orthodontique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1485. perchlorates --- r_associated #0: 51 --> en:contraindications aspect
    n1=perchlorates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1486. rhodopsine-kinase --- r_associated #0: 51 --> en:contraindications aspect
    n1=rhodopsine-kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1487. répondre à [qqn] --- r_associated #0: 51 --> en:contraindications aspect
    n1=répondre à [qqn] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1488. sonication --- r_associated #0: 51 --> en:contraindications aspect
    n1=sonication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1489. tétracycline --- r_associated #0: 51 --> en:contraindications aspect
    n1=tétracycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1490. vaccin antirubéoleux --- r_associated #0: 51 --> en:contraindications aspect
    n1=vaccin antirubéoleux | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1491. vert d'indocyanine --- r_associated #0: 51 --> en:contraindications aspect
    n1=vert d'indocyanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=51
  1492. Anticorps monoclonal --- r_associated #0: 50 --> en:contraindications aspect
    n1=Anticorps monoclonal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1493. GMS --- r_associated #0: 50 --> en:contraindications aspect
    n1=GMS | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1494. Iodure de potassium --- r_associated #0: 50 --> en:contraindications aspect
    n1=Iodure de potassium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1495. Tomeno (angle de) --- r_associated #0: 50 --> en:contraindications aspect
    n1=Tomeno (angle de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1496. Vitamine B6 --- r_associated #0: 50 --> en:contraindications aspect
    n1=Vitamine B6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1497. acide 3-hydroxy-3-méthylglutarique --- r_associated #0: 50 --> en:contraindications aspect
    n1=acide 3-hydroxy-3-méthylglutarique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1498. androstanes --- r_associated #0: 50 --> en:contraindications aspect
    n1=androstanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1499. caecostomie --- r_associated #0: 50 --> en:contraindications aspect
    n1=caecostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1500. chloramines --- r_associated #0: 50 --> en:contraindications aspect
    n1=chloramines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1501. chromogranine --- r_associated #0: 50 --> en:contraindications aspect
    n1=chromogranine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1502. dna polymerase ii --- r_associated #0: 50 --> en:contraindications aspect
    n1=dna polymerase ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1503. en:2-isopropylmalate synthase --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:2-isopropylmalate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1504. en:Forssman antigen --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:Forssman antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1505. en:French letter --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:French letter | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1506. en:a set of false teeth --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:a set of false teeth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1507. en:antidiphtheric serum --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:antidiphtheric serum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1508. en:artificial breast --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:artificial breast | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1509. en:biuret --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:biuret | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1510. en:catalase --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:catalase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1511. en:citric acid --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:citric acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1512. en:cyclobutanes --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:cyclobutanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1513. en:dental plate --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:dental plate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1514. en:inosine diphosphate --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:inosine diphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1515. en:isozyme --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:isozyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1516. en:lithium carbonate --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:lithium carbonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1517. en:mammary prosthesis --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:mammary prosthesis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1518. en:map kinase kinase 5 --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:map kinase kinase 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1519. en:meglutol --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:meglutol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1520. en:nelfinavir --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:nelfinavir | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1521. en:oral contraceptive --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:oral contraceptive | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1522. en:perylene --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:perylene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1523. en:phospholipase A1 --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:phospholipase A1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1524. en:poisons --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:poisons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1525. en:rRNA --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:rRNA | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1526. en:reply to somebody --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:reply to somebody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1527. en:sarin --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:sarin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1528. en:set of false teeth --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:set of false teeth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1529. en:skiascopy --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:skiascopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1530. en:vitamin B5 --- r_associated #0: 50 --> en:contraindications aspect
    n1=en:vitamin B5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1531. fœtoprotéine --- r_associated #0: 50 --> en:contraindications aspect
    n1=fœtoprotéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1532. fausse dent --- r_associated #0: 50 --> en:contraindications aspect
    n1=fausse dent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1533. fermetures de l'espace orthodontique --- r_associated #0: 50 --> en:contraindications aspect
    n1=fermetures de l'espace orthodontique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1534. glucosinolate --- r_associated #0: 50 --> en:contraindications aspect
    n1=glucosinolate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1535. glycol polyéthylénique --- r_associated #0: 50 --> en:contraindications aspect
    n1=glycol polyéthylénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1536. lettre française --- r_associated #0: 50 --> en:contraindications aspect
    n1=lettre française | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1537. neuroendoscopes --- r_associated #0: 50 --> en:contraindications aspect
    n1=neuroendoscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1538. polyvinyles --- r_associated #0: 50 --> en:contraindications aspect
    n1=polyvinyles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1539. polyvinyls --- r_associated #0: 50 --> en:contraindications aspect
    n1=polyvinyls | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1540. putrescine --- r_associated #0: 50 --> en:contraindications aspect
    n1=putrescine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1541. reprise opératoire --- r_associated #0: 50 --> en:contraindications aspect
    n1=reprise opératoire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1542. répondre à qn --- r_associated #0: 50 --> en:contraindications aspect
    n1=répondre à qn | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1543. répondre à quelqu'un --- r_associated #0: 50 --> en:contraindications aspect
    n1=répondre à quelqu'un | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1544. sorbose --- r_associated #0: 50 --> en:contraindications aspect
    n1=sorbose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1545. tolène --- r_associated #0: 50 --> en:contraindications aspect
    n1=tolène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1546. tomographie à positons --- r_associated #0: 50 --> en:contraindications aspect
    n1=tomographie à positons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1547. trientine --- r_associated #0: 50 --> en:contraindications aspect
    n1=trientine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1548. un dentier --- r_associated #0: 50 --> en:contraindications aspect
    n1=un dentier | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1549. vaccin anti virus de l'herpes simplex --- r_associated #0: 50 --> en:contraindications aspect
    n1=vaccin anti virus de l'herpes simplex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1550. vaccin contre le virus de la rubéole --- r_associated #0: 50 --> en:contraindications aspect
    n1=vaccin contre le virus de la rubéole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1551. vitamine b6 --- r_associated #0: 50 --> en:contraindications aspect
    n1=vitamine b6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1552. ézétimibe --- r_associated #0: 50 --> en:contraindications aspect
    n1=ézétimibe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=50
  1553. 5'-nucléotidase --- r_associated #0: 49 --> en:contraindications aspect
    n1=5'-nucléotidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1554. apatites --- r_associated #0: 49 --> en:contraindications aspect
    n1=apatites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1555. biuret --- r_associated #0: 49 --> en:contraindications aspect
    n1=biuret | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1556. catalase --- r_associated #0: 49 --> en:contraindications aspect
    n1=catalase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1557. clopidol --- r_associated #0: 49 --> en:contraindications aspect
    n1=clopidol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1558. cyclobutanes --- r_associated #0: 49 --> en:contraindications aspect
    n1=cyclobutanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1559. cytidine triphosphate --- r_associated #0: 49 --> en:contraindications aspect
    n1=cytidine triphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1560. en:chondro-4-sulfatase --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:chondro-4-sulfatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1561. en:cytochromes b --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:cytochromes b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1562. en:cytochromes d --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:cytochromes d | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1563. en:dna polymerase ii --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:dna polymerase ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1564. en:galactolipids --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:galactolipids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1565. en:lim kinases --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:lim kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1566. en:lipase --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:lipase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1567. en:ribitol --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:ribitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1568. en:tooth-paste --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:tooth-paste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1569. en:tungsten --- r_associated #0: 49 --> en:contraindications aspect
    n1=en:tungsten | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1570. gels au silicone --- r_associated #0: 49 --> en:contraindications aspect
    n1=gels au silicone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1571. histidinol-phosphatase --- r_associated #0: 49 --> en:contraindications aspect
    n1=histidinol-phosphatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1572. inosine --- r_associated #0: 49 --> en:contraindications aspect
    n1=inosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1573. isozyme --- r_associated #0: 49 --> en:contraindications aspect
    n1=isozyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1574. méglutol --- r_associated #0: 49 --> en:contraindications aspect
    n1=méglutol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1575. opium --- r_associated #0: 49 --> en:contraindications aspect
    n1=opium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1576. plasminogène (activateur du) --- r_associated #0: 49 --> en:contraindications aspect
    n1=plasminogène (activateur du) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1577. sucrose --- r_associated #0: 49 --> en:contraindications aspect
    n1=sucrose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1578. tungstène --- r_associated #0: 49 --> en:contraindications aspect
    n1=tungstène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=49
  1579. carbonate lithium --- r_associated #0: 48 --> en:contraindications aspect
    n1=carbonate lithium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1580. composé de cadmium --- r_associated #0: 48 --> en:contraindications aspect
    n1=composé de cadmium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1581. en:apatites --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:apatites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1582. en:cytochrome b6f --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:cytochrome b6f | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1583. en:ezetimibe --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:ezetimibe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1584. en:metalloexopeptidases --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:metalloexopeptidases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1585. en:poly g --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:poly g | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1586. en:polyvinyls --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:polyvinyls | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1587. en:rhodamine 123 --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:rhodamine 123 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1588. en:trientine --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:trientine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1589. en:ustekinumab --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:ustekinumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1590. en:vascular prosthesis --- r_associated #0: 48 --> en:contraindications aspect
    n1=en:vascular prosthesis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1591. matrix metalloproteinase --- r_associated #0: 48 --> en:contraindications aspect
    n1=matrix metalloproteinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1592. proteine myo d --- r_associated #0: 48 --> en:contraindications aspect
    n1=proteine myo d | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1593. stéroïde isomérases --- r_associated #0: 48 --> en:contraindications aspect
    n1=stéroïde isomérases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1594. thrombolytique --- r_associated #0: 48 --> en:contraindications aspect
    n1=thrombolytique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1595. type c phospholipases --- r_associated #0: 48 --> en:contraindications aspect
    n1=type c phospholipases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1596. vaccins contre le virus herpès simplex --- r_associated #0: 48 --> en:contraindications aspect
    n1=vaccins contre le virus herpès simplex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1597. vitamine B5 --- r_associated #0: 48 --> en:contraindications aspect
    n1=vitamine B5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1598. épisome F --- r_associated #0: 48 --> en:contraindications aspect
    n1=épisome F | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=48
  1599. ECC --- r_associated #0: 47 --> en:contraindications aspect
    n1=ECC | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1600. bêtalipoprotéine --- r_associated #0: 47 --> en:contraindications aspect
    n1=bêtalipoprotéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1601. chartographie --- r_associated #0: 47 --> en:contraindications aspect
    n1=chartographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1602. corticostérone --- r_associated #0: 47 --> en:contraindications aspect
    n1=corticostérone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1603. cyclitols --- r_associated #0: 47 --> en:contraindications aspect
    n1=cyclitols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1604. cyclooxygenase 2 --- r_associated #0: 47 --> en:contraindications aspect
    n1=cyclooxygenase 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1605. en:Roux's serum --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:Roux's serum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1606. en:acupuncture, ear --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:acupuncture, ear | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1607. en:adiponectin --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:adiponectin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1608. en:arylsulfonates --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:arylsulfonates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1609. en:condom --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:condom | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1610. en:dicumarol --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:dicumarol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1611. en:dna glycosylase --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:dna glycosylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1612. en:gentian violet --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:gentian violet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1613. en:immunoadjuvant --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:immunoadjuvant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1614. en:inositol phosphates --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:inositol phosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1615. en:nuclear receptor corepressor 1 --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:nuclear receptor corepressor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1616. en:oral contraception --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:oral contraception | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1617. en:plasminogen activator --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:plasminogen activator | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1618. en:respond to somebody --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:respond to somebody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1619. en:scintillography --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:scintillography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1620. en:singlet oxygen --- r_associated #0: 47 --> en:contraindications aspect
    n1=en:singlet oxygen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1621. foetoprotéine --- r_associated #0: 47 --> en:contraindications aspect
    n1=foetoprotéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1622. nalorphine --- r_associated #0: 47 --> en:contraindications aspect
    n1=nalorphine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1623. norfloxacine --- r_associated #0: 47 --> en:contraindications aspect
    n1=norfloxacine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1624. ranimation --- r_associated #0: 47 --> en:contraindications aspect
    n1=ranimation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1625. somatostatine --- r_associated #0: 47 --> en:contraindications aspect
    n1=somatostatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1626. vert indocyanine --- r_associated #0: 47 --> en:contraindications aspect
    n1=vert indocyanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=47
  1627. E330 --- r_associated #0: 46 --> en:contraindications aspect
    n1=E330 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1628. NADPH oxidase --- r_associated #0: 46 --> en:contraindications aspect
    n1=NADPH oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1629. acide pantothénique --- r_associated #0: 46 --> en:contraindications aspect
    n1=acide pantothénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1630. acquaintance --- r_associated #0: 46 --> en:contraindications aspect
    n1=acquaintance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1631. agoniste dopaminergique --- r_associated #0: 46 --> en:contraindications aspect
    n1=agoniste dopaminergique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1632. chondro-4-sulfatase --- r_associated #0: 46 --> en:contraindications aspect
    n1=chondro-4-sulfatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1633. contraception orale --- r_associated #0: 46 --> en:contraindications aspect
    n1=contraception orale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1634. cytochrome b6f --- r_associated #0: 46 --> en:contraindications aspect
    n1=cytochrome b6f | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1635. en:Tomeno's angle --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:Tomeno's angle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1636. en:biguanides --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:biguanides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1637. en:corticosterone --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:corticosterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1638. en:counterpulsation --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:counterpulsation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1639. en:cyclitols --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:cyclitols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1640. en:cyclooxygenase 2 --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:cyclooxygenase 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1641. en:fenbendazole --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:fenbendazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1642. en:glutens --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:glutens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1643. en:histidinol-phosphatase --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:histidinol-phosphatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1644. en:intraocular tamponade --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:intraocular tamponade | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1645. en:janus kinase 3 --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:janus kinase 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1646. en:leucine transaminase --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:leucine transaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1647. en:mannomustine --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:mannomustine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1648. en:matrix metalloproteinase --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:matrix metalloproteinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1649. en:nadph oxidase --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:nadph oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1650. en:norfloxacin --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:norfloxacin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1651. en:nuclear receptor co-repressor 1 --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:nuclear receptor co-repressor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1652. en:oxyhemoglobin --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:oxyhemoglobin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1653. en:phospholipase c delta --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:phospholipase c delta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1654. en:prostaglandine --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:prostaglandine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1655. en:radiation therapy --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:radiation therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1656. en:solution --- r_associated #0: 46 --> en:contraindications aspect
    n1=en:solution | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1657. galactolipides --- r_associated #0: 46 --> en:contraindications aspect
    n1=galactolipides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1658. glucose oxidase --- r_associated #0: 46 --> en:contraindications aspect
    n1=glucose oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1659. map kinase kinase 5 --- r_associated #0: 46 --> en:contraindications aspect
    n1=map kinase kinase 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1660. nelfinavir --- r_associated #0: 46 --> en:contraindications aspect
    n1=nelfinavir | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1661. oxytocine --- r_associated #0: 46 --> en:contraindications aspect
    n1=oxytocine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1662. poisons --- r_associated #0: 46 --> en:contraindications aspect
    n1=poisons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1663. pseudo-uridine --- r_associated #0: 46 --> en:contraindications aspect
    n1=pseudo-uridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1664. radiothérapie --- r_associated #0: 46 --> en:contraindications aspect
    n1=radiothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1665. rhodamine 123 --- r_associated #0: 46 --> en:contraindications aspect
    n1=rhodamine 123 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1666. uridine diphosphate glucose --- r_associated #0: 46 --> en:contraindications aspect
    n1=uridine diphosphate glucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1667. vaccin anti virus herpes simplex --- r_associated #0: 46 --> en:contraindications aspect
    n1=vaccin anti virus herpes simplex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1668. vaccin contre la rubéole --- r_associated #0: 46 --> en:contraindications aspect
    n1=vaccin contre la rubéole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1669. vinblastine --- r_associated #0: 46 --> en:contraindications aspect
    n1=vinblastine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1670. xéromammographie --- r_associated #0: 46 --> en:contraindications aspect
    n1=xéromammographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=46
  1671. Acide gallique --- r_associated #0: 45 --> en:contraindications aspect
    n1=Acide gallique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1672. Adjuvant immunologique --- r_associated #0: 45 --> en:contraindications aspect
    n1=Adjuvant immunologique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1673. Air comprimé --- r_associated #0: 45 --> en:contraindications aspect
    n1=Air comprimé | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1674. Pierre à savon --- r_associated #0: 45 --> en:contraindications aspect
    n1=Pierre à savon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1675. TEP
    (tomographie par émission de positons)
     --- r_associated #0: 45 --> en:contraindications aspect
    n1=TEP
    (tomographie par émission de positons)
    | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1676. acide citrique --- r_associated #0: 45 --> en:contraindications aspect
    n1=acide citrique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1677. activateur du plasminogène --- r_associated #0: 45 --> en:contraindications aspect
    n1=activateur du plasminogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1678. antiparasitaire --- r_associated #0: 45 --> en:contraindications aspect
    n1=antiparasitaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1679. capote anglaise --- r_associated #0: 45 --> en:contraindications aspect
    n1=capote anglaise | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1680. clef --- r_associated #0: 45 --> en:contraindications aspect
    n1=clef | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1681. codéine --- r_associated #0: 45 --> en:contraindications aspect
    n1=codéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1682. codéïne --- r_associated #0: 45 --> en:contraindications aspect
    n1=codéïne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1683. cytochromes de type d --- r_associated #0: 45 --> en:contraindications aspect
    n1=cytochromes de type d | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1684. en:5'-nucleotidase --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:5'-nucleotidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1685. en:codeine --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:codeine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1686. en:deoxyribonucleoproteins --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:deoxyribonucleoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1687. en:digalactolipids --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:digalactolipids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1688. en:dopamine agonist --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:dopamine agonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1689. en:glucose oxidase --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:glucose oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1690. en:inosine --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:inosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1691. en:oil --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:oil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1692. en:orthodontic wires --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:orthodontic wires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1693. en:pantothenic acid --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:pantothenic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1694. en:phospholipases a --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:phospholipases a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1695. en:poly c --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:poly c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1696. en:ribosomal rna --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:ribosomal rna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1697. en:small cytoplasmic ribonucleoproteins --- r_associated #0: 45 --> en:contraindications aspect
    n1=en:small cytoplasmic ribonucleoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1698. fenbendazole --- r_associated #0: 45 --> en:contraindications aspect
    n1=fenbendazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1699. graisse de machines --- r_associated #0: 45 --> en:contraindications aspect
    n1=graisse de machines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1700. greffe de pancréas --- r_associated #0: 45 --> en:contraindications aspect
    n1=greffe de pancréas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1701. hydroxyméthylglutaryl-coa synthase --- r_associated #0: 45 --> en:contraindications aspect
    n1=hydroxyméthylglutaryl-coa synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1702. lim kinases --- r_associated #0: 45 --> en:contraindications aspect
    n1=lim kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1703. lipase --- r_associated #0: 45 --> en:contraindications aspect
    n1=lipase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1704. mannomustine --- r_associated #0: 45 --> en:contraindications aspect
    n1=mannomustine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1705. méthylmorphine --- r_associated #0: 45 --> en:contraindications aspect
    n1=méthylmorphine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1706. oxygène singulet --- r_associated #0: 45 --> en:contraindications aspect
    n1=oxygène singulet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1707. poly g --- r_associated #0: 45 --> en:contraindications aspect
    n1=poly g | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1708. protection absorbante incontinence --- r_associated #0: 45 --> en:contraindications aspect
    n1=protection absorbante incontinence | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1709. ruban adhésif chirurgical --- r_associated #0: 45 --> en:contraindications aspect
    n1=ruban adhésif chirurgical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1710. sarin --- r_associated #0: 45 --> en:contraindications aspect
    n1=sarin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1711. sparadrap chirurgical --- r_associated #0: 45 --> en:contraindications aspect
    n1=sparadrap chirurgical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1712. temps de thrombine --- r_associated #0: 45 --> en:contraindications aspect
    n1=temps de thrombine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1713. transplantation de pancreas --- r_associated #0: 45 --> en:contraindications aspect
    n1=transplantation de pancreas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1714. ustekinumab --- r_associated #0: 45 --> en:contraindications aspect
    n1=ustekinumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1715. vaccin antimicrobien --- r_associated #0: 45 --> en:contraindications aspect
    n1=vaccin antimicrobien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1716. vaccin à virus vivant de la rubéole --- r_associated #0: 45 --> en:contraindications aspect
    n1=vaccin à virus vivant de la rubéole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1717. épuration extrarénale (méthodes d') --- r_associated #0: 45 --> en:contraindications aspect
    n1=épuration extrarénale (méthodes d') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=45
  1718. E261(i) --- r_associated #0: 44 --> en:contraindications aspect
    n1=E261(i) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1719. PlGF --- r_associated #0: 44 --> en:contraindications aspect
    n1=PlGF | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1720. acupuncture auriculaire --- r_associated #0: 44 --> en:contraindications aspect
    n1=acupuncture auriculaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1721. adiponectine --- r_associated #0: 44 --> en:contraindications aspect
    n1=adiponectine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1722. benzaldéhyde --- r_associated #0: 44 --> en:contraindications aspect
    n1=benzaldéhyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1723. biguanides --- r_associated #0: 44 --> en:contraindications aspect
    n1=biguanides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1724. bleu méthylène --- r_associated #0: 44 --> en:contraindications aspect
    n1=bleu méthylène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1725. chlorobenzènes --- r_associated #0: 44 --> en:contraindications aspect
    n1=chlorobenzènes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1726. dicumarol --- r_associated #0: 44 --> en:contraindications aspect
    n1=dicumarol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1727. en:anthranilate synthase --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:anthranilate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1728. en:beam radiation therapy --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:beam radiation therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1729. en:calcium channel blocker --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:calcium channel blocker | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1730. en:dialysis --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:dialysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1731. en:guanosine pentaphosphate --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:guanosine pentaphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1732. en:herpes simplex virus vaccines --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:herpes simplex virus vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1733. en:hypotension, controlled --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:hypotension, controlled | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1734. en:lubricant --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:lubricant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1735. en:magnesium oxide --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:magnesium oxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1736. en:map kinase kinase 7 --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:map kinase kinase 7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1737. en:methylmorphine --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:methylmorphine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1738. en:oxytocin --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:oxytocin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1739. en:polyéthylène glycol --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:polyéthylène glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1740. en:thermodilution --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:thermodilution | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1741. en:thrombolytic agent --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:thrombolytic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1742. en:type c phospholipases --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:type c phospholipases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1743. en:uridine diphosphate glucose --- r_associated #0: 44 --> en:contraindications aspect
    n1=en:uridine diphosphate glucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1744. glutens --- r_associated #0: 44 --> en:contraindications aspect
    n1=glutens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1745. inositol phosphates --- r_associated #0: 44 --> en:contraindications aspect
    n1=inositol phosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1746. modulateur sélectif des récepteurs ?strogéniques --- r_associated #0: 44 --> en:contraindications aspect
    n1=modulateur sélectif des récepteurs ?strogéniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1747. oil --- r_associated #0: 44 --> en:contraindications aspect
    n1=oil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1748. phospholipase c delta --- r_associated #0: 44 --> en:contraindications aspect
    n1=phospholipase c delta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1749. rhodopsine kinase --- r_associated #0: 44 --> en:contraindications aspect
    n1=rhodopsine kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1750. tropo-élastine --- r_associated #0: 44 --> en:contraindications aspect
    n1=tropo-élastine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1751. uridine-monophosphate --- r_associated #0: 44 --> en:contraindications aspect
    n1=uridine-monophosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1752. éotaxine --- r_associated #0: 44 --> en:contraindications aspect
    n1=éotaxine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=44
  1753. AOD et NAOC --- r_associated #0: 43 --> en:contraindications aspect
    n1=AOD et NAOC | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1754. Acide oxalique --- r_associated #0: 43 --> en:contraindications aspect
    n1=Acide oxalique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1755. Adénylate cyclase --- r_associated #0: 43 --> en:contraindications aspect
    n1=Adénylate cyclase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1756. ECLS --- r_associated #0: 43 --> en:contraindications aspect
    n1=ECLS | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1757. anthranilate synthase --- r_associated #0: 43 --> en:contraindications aspect
    n1=anthranilate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1758. appareils de prothèse dentaire --- r_associated #0: 43 --> en:contraindications aspect
    n1=appareils de prothèse dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1759. aryl sulfonates --- r_associated #0: 43 --> en:contraindications aspect
    n1=aryl sulfonates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1760. dna glycosylase --- r_associated #0: 43 --> en:contraindications aspect
    n1=dna glycosylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1761. en:adenovirus vaccine --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:adenovirus vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1762. en:amino acid transport system l --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:amino acid transport system l | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1763. en:athletic tape --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:athletic tape | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1764. en:cd30 ligand --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:cd30 ligand | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1765. en:chloride channel agonists --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:chloride channel agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1766. en:contra-indication --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:contra-indication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1767. en:convulsive therapy --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:convulsive therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1768. en:cyclooxygenase inhibitor --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:cyclooxygenase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1769. en:cystine depleting agents --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:cystine depleting agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1770. en:endo-1,3-(4)-beta-d-glucanase --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:endo-1,3-(4)-beta-d-glucanase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1771. en:exoskeleton device --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:exoskeleton device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1772. en:facial transplantation --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:facial transplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1773. en:fanft --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:fanft | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1774. en:finasteride --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:finasteride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1775. en:fixative --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:fixative | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1776. en:folate transporter 1 --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:folate transporter 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1777. en:frankincense --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:frankincense | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1778. en:gaba transporter --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:gaba transporter | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1779. en:gtp phosphohydrolase activators --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:gtp phosphohydrolase activators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1780. en:haemophilus vaccines --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:haemophilus vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1781. en:homoserine o-succinyltransferase --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:homoserine o-succinyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1782. en:leucomycins --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:leucomycins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1783. en:microtubule associated protein --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:microtubule associated protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1784. en:nadp transhydrogenase, b-specific --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:nadp transhydrogenase, b-specific | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1785. en:nuclear factor-i --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:nuclear factor-i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1786. en:orthodontic retainer (physical object) --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:orthodontic retainer (physical object) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1787. en:poly (adp-ribose) polymerase inhibitor --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:poly (adp-ribose) polymerase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1788. en:prescription drugs --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:prescription drugs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1789. en:s-nitroso-n-acetylpenicillamine --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:s-nitroso-n-acetylpenicillamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1790. en:sarin gas --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:sarin gas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1791. en:shiga toxin 2 --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:shiga toxin 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1792. en:smad2 protein --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:smad2 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1793. en:sodium channel --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:sodium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1794. en:somatostatin --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:somatostatin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1795. en:thrombin time --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:thrombin time | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1796. en:vernamycin b --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:vernamycin b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1797. en:vinyl chloride --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:vinyl chloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1798. en:walkers --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:walkers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1799. en:xeromammography --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:xeromammography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1800. en:xylulose --- r_associated #0: 43 --> en:contraindications aspect
    n1=en:xylulose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1801. fluoro-uracile --- r_associated #0: 43 --> en:contraindications aspect
    n1=fluoro-uracile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1802. guanosine pentaphosphate --- r_associated #0: 43 --> en:contraindications aspect
    n1=guanosine pentaphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1803. guanylyl imidodiphosphate --- r_associated #0: 43 --> en:contraindications aspect
    n1=guanylyl imidodiphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1804. hormone mélanostimulante --- r_associated #0: 43 --> en:contraindications aspect
    n1=hormone mélanostimulante | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1805. inhibiteur des canaux calciques --- r_associated #0: 43 --> en:contraindications aspect
    n1=inhibiteur des canaux calciques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1806. janus kinase 3 --- r_associated #0: 43 --> en:contraindications aspect
    n1=janus kinase 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1807. ostéopontine --- r_associated #0: 43 --> en:contraindications aspect
    n1=ostéopontine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1808. protections absorbantes pour incontinence --- r_associated #0: 43 --> en:contraindications aspect
    n1=protections absorbantes pour incontinence | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1809. ressuscitation cardiaque --- r_associated #0: 43 --> en:contraindications aspect
    n1=ressuscitation cardiaque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1810. résidus de chylomicron --- r_associated #0: 43 --> en:contraindications aspect
    n1=résidus de chylomicron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1811. tropocollagène --- r_associated #0: 43 --> en:contraindications aspect
    n1=tropocollagène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1812. violet de gentiane --- r_associated #0: 43 --> en:contraindications aspect
    n1=violet de gentiane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=43
  1813. Matière grasse alimentaire --- r_associated #0: 42 --> en:contraindications aspect
    n1=Matière grasse alimentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1814. acide lysergique --- r_associated #0: 42 --> en:contraindications aspect
    n1=acide lysergique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1815. bretelles --- r_associated #0: 42 --> en:contraindications aspect
    n1=bretelles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1816. diurétique osmotique --- r_associated #0: 42 --> en:contraindications aspect
    n1=diurétique osmotique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1817. en:6-aminonicotinamide --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:6-aminonicotinamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1818. en:NADPH oxidase --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:NADPH oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1819. en:angiography --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:angiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1820. en:anti-intermediary body --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:anti-intermediary body | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1821. en:apc5 subunit, anaphase-promoting complex-cyclosome --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:apc5 subunit, anaphase-promoting complex-cyclosome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1822. en:arterial pressure --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:arterial pressure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1823. en:atp synthetase complexes --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:atp synthetase complexes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1824. en:bacterial vaccine --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:bacterial vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1825. en:bacteriochlorophylls --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:bacteriochlorophylls | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1826. en:benzaldehyde --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:benzaldehyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1827. en:cardiac resuscitation --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:cardiac resuscitation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1828. en:cd98 antigen --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:cd98 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1829. en:chlorobenzenes --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:chlorobenzenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1830. en:cytochromes c' --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:cytochromes c' | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1831. en:dentifrice --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:dentifrice | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1832. en:dibenzazepines --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:dibenzazepines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1833. en:dothiepin --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:dothiepin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1834. en:dpi --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:dpi | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1835. en:duodenofibrescopy --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:duodenofibrescopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1836. en:ectodysplasin a2 receptor --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:ectodysplasin a2 receptor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1837. en:equilenin --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:equilenin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1838. en:glycogen phosphorylase, liver form --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:glycogen phosphorylase, liver form | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1839. en:guanosine diphosphate fucose --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:guanosine diphosphate fucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1840. en:halcinonide --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:halcinonide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1841. en:hepatocyte nuclear factor 6 --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:hepatocyte nuclear factor 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1842. en:hydroxycholesterols --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:hydroxycholesterols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1843. en:incontinence pads --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:incontinence pads | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1844. en:insulin-like growth factor-binding protein 2 --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:insulin-like growth factor-binding protein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1845. en:lysergic acid --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:lysergic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1846. en:magnetic resonance cholangiopancreatography --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:magnetic resonance cholangiopancreatography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1847. en:maltose-binding proteins --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:maltose-binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1848. en:methionine synthase --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:methionine synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1849. en:mitomycin antineoplastic antibiotic --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:mitomycin antineoplastic antibiotic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1850. en:mitosis modulators --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:mitosis modulators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1851. en:molteno implants --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:molteno implants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1852. en:mosquito nets --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:mosquito nets | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1853. en:osteopontin --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:osteopontin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1854. en:oxygenated hemoglobin --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:oxygenated hemoglobin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1855. en:phenylphosphonothioic acid, 2-ethyl 2-(4-nitrophenyl) ester --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:phenylphosphonothioic acid, 2-ethyl 2-(4-nitrophenyl) ester | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1856. en:placental growth factor --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:placental growth factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1857. en:presenilins --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:presenilins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1858. en:receptor, epha1 --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:receptor, epha1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1859. en:retinol-binding proteins, plasma --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:retinol-binding proteins, plasma | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1860. en:rna, messenger, stored --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:rna, messenger, stored | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1861. en:selective estrogen receptor modulator --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:selective estrogen receptor modulator | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1862. en:smad1 protein --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:smad1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1863. en:soxf transcription factors --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:soxf transcription factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1864. en:sulfenic acids --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:sulfenic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1865. en:surgical tape --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:surgical tape | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1866. en:thiocholine --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:thiocholine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1867. en:transcriptional activator myb --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:transcriptional activator myb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1868. en:triiodothyronine --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:triiodothyronine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1869. en:uridine monophosphate --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:uridine monophosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1870. en:vinblastine --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:vinblastine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1871. en:viocid --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:viocid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1872. en:vitellins --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:vitellins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1873. en:zymosan --- r_associated #0: 42 --> en:contraindications aspect
    n1=en:zymosan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1874. guanosine diphosphate fucose --- r_associated #0: 42 --> en:contraindications aspect
    n1=guanosine diphosphate fucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1875. hypophysectomie chimique --- r_associated #0: 42 --> en:contraindications aspect
    n1=hypophysectomie chimique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1876. leucine transaminase --- r_associated #0: 42 --> en:contraindications aspect
    n1=leucine transaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1877. map kinase kinase kinase 1 --- r_associated #0: 42 --> en:contraindications aspect
    n1=map kinase kinase kinase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1878. nadph oxydase --- r_associated #0: 42 --> en:contraindications aspect
    n1=nadph oxydase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1879. petites particules cytoplasmiques ribonucléoprotéiques --- r_associated #0: 42 --> en:contraindications aspect
    n1=petites particules cytoplasmiques ribonucléoprotéiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1880. phospholipases a --- r_associated #0: 42 --> en:contraindications aspect
    n1=phospholipases a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1881. ponction amniotique --- r_associated #0: 42 --> en:contraindications aspect
    n1=ponction amniotique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1882. restes de chylomicrons --- r_associated #0: 42 --> en:contraindications aspect
    n1=restes de chylomicrons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1883. restriction (endonucléase de) --- r_associated #0: 42 --> en:contraindications aspect
    n1=restriction (endonucléase de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1884. saccharose --- r_associated #0: 42 --> en:contraindications aspect
    n1=saccharose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1885. sérum antitétanique --- r_associated #0: 42 --> en:contraindications aspect
    n1=sérum antitétanique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1886. tension artérielle --- r_associated #0: 42 --> en:contraindications aspect
    n1=tension artérielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1887. tert-butyl hydroperoxyde --- r_associated #0: 42 --> en:contraindications aspect
    n1=tert-butyl hydroperoxyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1888. thoracoplastie de Sauerbruch-Maurer --- r_associated #0: 42 --> en:contraindications aspect
    n1=thoracoplastie de Sauerbruch-Maurer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1889. thrombolytique (médicament) --- r_associated #0: 42 --> en:contraindications aspect
    n1=thrombolytique (médicament) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1890. urétérostomie --- r_associated #0: 42 --> en:contraindications aspect
    n1=urétérostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1891. vaccin antivirus de l'herpes simplex --- r_associated #0: 42 --> en:contraindications aspect
    n1=vaccin antivirus de l'herpes simplex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=42
  1892. 5 FU --- r_associated #0: 41 --> en:contraindications aspect
    n1=5 FU | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1893. PRNA --- r_associated #0: 41 --> en:contraindications aspect
    n1=PRNA | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1894. acide tranexamique --- r_associated #0: 41 --> en:contraindications aspect
    n1=acide tranexamique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1895. antibiotique antineoplasique --- r_associated #0: 41 --> en:contraindications aspect
    n1=antibiotique antineoplasique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1896. bronchographies --- r_associated #0: 41 --> en:contraindications aspect
    n1=bronchographies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1897. cémentation --- r_associated #0: 41 --> en:contraindications aspect
    n1=cémentation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1898. dentures --- r_associated #0: 41 --> en:contraindications aspect
    n1=dentures | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1899. désoxyribonucléoprotéines --- r_associated #0: 41 --> en:contraindications aspect
    n1=désoxyribonucléoprotéines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1900. en:anti-immune substance --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:anti-immune substance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1901. en:biflavonoids --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:biflavonoids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1902. en:cadherin related proteins --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:cadherin related proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1903. en:chylomicron remnants --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:chylomicron remnants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1904. en:cloacin --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:cloacin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1905. en:endocrine-gland-derived vascular endothelial growth factor --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:endocrine-gland-derived vascular endothelial growth factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1906. en:enema administration --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:enema administration | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1907. en:eotaxin --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:eotaxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1908. en:glycosylphosphatidylinositol diacylglycerol-lyase --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:glycosylphosphatidylinositol diacylglycerol-lyase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1909. en:gravity suits --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:gravity suits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1910. en:hematocrit measurement --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:hematocrit measurement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1911. en:hypophysectomy, chemical --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:hypophysectomy, chemical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1912. en:indicators and reagents --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:indicators and reagents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1913. en:interleukin-4 --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:interleukin-4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1914. en:iodoacetic acid --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:iodoacetic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1915. en:methylene blue --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:methylene blue | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1916. en:mucin-3 --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:mucin-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1917. en:nitrate reductases --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:nitrate reductases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1918. en:nitrosomethylurethane --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:nitrosomethylurethane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1919. en:nm23 nucleoside diphosphate kinases --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:nm23 nucleoside diphosphate kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1920. en:operative treatment --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:operative treatment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1921. en:osmotic diuretic --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:osmotic diuretic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1922. en:pol gene products, human immunodeficiency virus --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:pol gene products, human immunodeficiency virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1923. en:prodigiosin --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:prodigiosin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1924. en:protoveratrines --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:protoveratrines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1925. en:pulsed radiofrequency treatment --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:pulsed radiofrequency treatment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1926. en:radiotherapy --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:radiotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1927. en:retinoscopes --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:retinoscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1928. en:roentgenotherapy --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:roentgenotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1929. en:roentgentherapy --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:roentgentherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1930. en:signaling lymphocytic activation molecule associated protein --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:signaling lymphocytic activation molecule associated protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1931. en:sirtuin 3 --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:sirtuin 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1932. en:tetraisopropylpyrophosphamide --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:tetraisopropylpyrophosphamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1933. en:trpv cation channels --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:trpv cation channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1934. en:tyk2 kinase --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:tyk2 kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1935. en:ureterostomy --- r_associated #0: 41 --> en:contraindications aspect
    n1=en:ureterostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1936. facteur de croissance placentaire (PlGF) --- r_associated #0: 41 --> en:contraindications aspect
    n1=facteur de croissance placentaire (PlGF) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1937. fermeture des espaces orthodontiques --- r_associated #0: 41 --> en:contraindications aspect
    n1=fermeture des espaces orthodontiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1938. fils orthodontiques --- r_associated #0: 41 --> en:contraindications aspect
    n1=fils orthodontiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1939. finastéride --- r_associated #0: 41 --> en:contraindications aspect
    n1=finastéride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1940. fixative --- r_associated #0: 41 --> en:contraindications aspect
    n1=fixative | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1941. fluoruration de l'eau --- r_associated #0: 41 --> en:contraindications aspect
    n1=fluoruration de l'eau | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1942. glutamyl aminopeptidase --- r_associated #0: 41 --> en:contraindications aspect
    n1=glutamyl aminopeptidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1943. hormone mélano-stimulante --- r_associated #0: 41 --> en:contraindications aspect
    n1=hormone mélano-stimulante | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1944. hypotension contrôlée --- r_associated #0: 41 --> en:contraindications aspect
    n1=hypotension contrôlée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1945. héparine de bas poids moléculaire --- r_associated #0: 41 --> en:contraindications aspect
    n1=héparine de bas poids moléculaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1946. lyases intramoléculaires --- r_associated #0: 41 --> en:contraindications aspect
    n1=lyases intramoléculaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1947. map kinase kinase 7 --- r_associated #0: 41 --> en:contraindications aspect
    n1=map kinase kinase 7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1948. oxyde de magnésium --- r_associated #0: 41 --> en:contraindications aspect
    n1=oxyde de magnésium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1949. poly c --- r_associated #0: 41 --> en:contraindications aspect
    n1=poly c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1950. radiothérapie cutanée --- r_associated #0: 41 --> en:contraindications aspect
    n1=radiothérapie cutanée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1951. ri --- r_associated #0: 41 --> en:contraindications aspect
    n1=ri | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1952. ribodésose --- r_associated #0: 41 --> en:contraindications aspect
    n1=ribodésose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1953. stadage --- r_associated #0: 41 --> en:contraindications aspect
    n1=stadage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1954. stérilet --- r_associated #0: 41 --> en:contraindications aspect
    n1=stérilet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1955. tdm --- r_associated #0: 41 --> en:contraindications aspect
    n1=tdm | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1956. thermodilution --- r_associated #0: 41 --> en:contraindications aspect
    n1=thermodilution | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1957. thiamine --- r_associated #0: 41 --> en:contraindications aspect
    n1=thiamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1958. tocolyse --- r_associated #0: 41 --> en:contraindications aspect
    n1=tocolyse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1959. tomie --- r_associated #0: 41 --> en:contraindications aspect
    n1=tomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1960. tomo-échographie --- r_associated #0: 41 --> en:contraindications aspect
    n1=tomo-échographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1961. tomographie par émission de positons --- r_associated #0: 41 --> en:contraindications aspect
    n1=tomographie par émission de positons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1962. topographie cornéenne --- r_associated #0: 41 --> en:contraindications aspect
    n1=topographie cornéenne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1963. uridine-diphosphate --- r_associated #0: 41 --> en:contraindications aspect
    n1=uridine-diphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1964. uridine-diphosphate-glucose --- r_associated #0: 41 --> en:contraindications aspect
    n1=uridine-diphosphate-glucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1965. urobiline --- r_associated #0: 41 --> en:contraindications aspect
    n1=urobiline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=41
  1966. DIU
    (dispositif intra-utérin)
     --- r_associated #0: 40 --> en:contraindications aspect
    n1=DIU
    (dispositif intra-utérin)
    | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1967. E391 --- r_associated #0: 40 --> en:contraindications aspect
    n1=E391 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1968. acide phytique --- r_associated #0: 40 --> en:contraindications aspect
    n1=acide phytique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1969. acétate de glatiramère --- r_associated #0: 40 --> en:contraindications aspect
    n1=acétate de glatiramère | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1970. bas de contention --- r_associated #0: 40 --> en:contraindications aspect
    n1=bas de contention | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1971. contre-indication --- r_associated #0: 40 --> en:contraindications aspect
    n1=contre-indication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1972. contrindication --- r_associated #0: 40 --> en:contraindications aspect
    n1=contrindication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1973. cow-pox --- r_associated #0: 40 --> en:contraindications aspect
    n1=cow-pox | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1974. cowpox --- r_associated #0: 40 --> en:contraindications aspect
    n1=cowpox | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1975. en:Epsom salt --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:Epsom salt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1976. en:Teflon --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:Teflon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1977. en:androstenes --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:androstenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1978. en:answer --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:answer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1979. en:antacid preparation --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:antacid preparation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1980. en:apolipoproteins --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:apolipoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1981. en:blood substitute --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:blood substitute | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1982. en:calcium channel inhibitor --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:calcium channel inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1983. en:caspases, initiator --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:caspases, initiator | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1984. en:cathepsin w --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:cathepsin w | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1985. en:cation transport proteins --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:cation transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1986. en:continuous sphygmomanometers --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:continuous sphygmomanometers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1987. en:corneal topography --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:corneal topography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1988. en:corticotropin-like intermediate lobe peptide --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:corticotropin-like intermediate lobe peptide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1989. en:cowpox --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:cowpox | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1990. en:cytochalasin d --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:cytochalasin d | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1991. en:dianhydrogalactitol --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:dianhydrogalactitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1992. en:dibenzofurans --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:dibenzofurans | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1993. en:digoxigénine --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:digoxigénine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1994. en:ets domain-containing protein elk-1 --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:ets domain-containing protein elk-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1995. en:fluorescent treponemal antibody-absorption test --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:fluorescent treponemal antibody-absorption test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1996. en:free fatty acid --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:free fatty acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1997. en:free flap --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:free flap | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1998. en:group ia phospholipases a2 --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:group ia phospholipases a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  1999. en:guanylyl imidodiphosphate --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:guanylyl imidodiphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2000. en:high-intensity focused ultrasound ablation --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:high-intensity focused ultrasound ablation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2001. en:histamine h3 antagonists --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:histamine h3 antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2002. en:imatinib mesylate --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:imatinib mesylate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2003. en:interleukin-1 receptor-associated kinases --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:interleukin-1 receptor-associated kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2004. en:intrauterine device --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:intrauterine device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2005. en:ionomycin --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:ionomycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2006. en:janus kinase family --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:janus kinase family | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2007. en:low molecular weight heparin --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:low molecular weight heparin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2008. en:magnesium sulfate --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:magnesium sulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2009. en:magnesium sulphate --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:magnesium sulphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2010. en:methylmalonyl-coa mutase --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:methylmalonyl-coa mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2011. en:perilipin 2 --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:perilipin 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2012. en:pheromones, human --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:pheromones, human | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2013. en:physalaemin --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:physalaemin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2014. en:prdx3 peroxidase --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:prdx3 peroxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2015. en:respond --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:respond | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2016. en:salivary alpha-amylases --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:salivary alpha-amylases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2017. en:sodium channel blockers --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:sodium channel blockers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2018. en:spanner --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:spanner | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2019. en:specs --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:specs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2020. en:staging --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:staging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2021. en:surgery --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:surgery | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2022. en:surgical operation --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:surgical operation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2023. en:tetanus antitoxin --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:tetanus antitoxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2024. en:thiamine pyrophosphatase --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:thiamine pyrophosphatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2025. en:thienamycins --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:thienamycins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2026. en:thiorphan --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:thiorphan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2027. en:toothpaste --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:toothpaste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2028. en:tranexamic acid --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:tranexamic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2029. en:transducers --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:transducers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2030. en:tropocollagen --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:tropocollagen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2031. en:tropoelastin --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:tropoelastin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2032. en:vitallium --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:vitallium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2033. en:water fluoridation --- r_associated #0: 40 --> en:contraindications aspect
    n1=en:water fluoridation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2034. fructoses diphosphates --- r_associated #0: 40 --> en:contraindications aspect
    n1=fructoses diphosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2035. gonadostimuline --- r_associated #0: 40 --> en:contraindications aspect
    n1=gonadostimuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2036. immuno-précipitation --- r_associated #0: 40 --> en:contraindications aspect
    n1=immuno-précipitation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2037. intervention chirurgicale --- r_associated #0: 40 --> en:contraindications aspect
    n1=intervention chirurgicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2038. ionomycine --- r_associated #0: 40 --> en:contraindications aspect
    n1=ionomycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2039. liposuccion --- r_associated #0: 40 --> en:contraindications aspect
    n1=liposuccion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2040. mastectomie glandulaire --- r_associated #0: 40 --> en:contraindications aspect
    n1=mastectomie glandulaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2041. méthylmalonyl-CoA mutase --- r_associated #0: 40 --> en:contraindications aspect
    n1=méthylmalonyl-CoA mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2042. méthylmalonyl-coa mutase --- r_associated #0: 40 --> en:contraindications aspect
    n1=méthylmalonyl-coa mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2043. neuréguline --- r_associated #0: 40 --> en:contraindications aspect
    n1=neuréguline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2044. plasmaphérèse --- r_associated #0: 40 --> en:contraindications aspect
    n1=plasmaphérèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2045. péthidine chlorhydrate --- r_associated #0: 40 --> en:contraindications aspect
    n1=péthidine chlorhydrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2046. répondre à --- r_associated #0: 40 --> en:contraindications aspect
    n1=répondre à | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2047. saccarine --- r_associated #0: 40 --> en:contraindications aspect
    n1=saccarine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2048. sel d'Epsom --- r_associated #0: 40 --> en:contraindications aspect
    n1=sel d'Epsom | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2049. spanner --- r_associated #0: 40 --> en:contraindications aspect
    n1=spanner | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2050. sternotomie --- r_associated #0: 40 --> en:contraindications aspect
    n1=sternotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2051. stéatite --- r_associated #0: 40 --> en:contraindications aspect
    n1=stéatite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2052. substitut du sang --- r_associated #0: 40 --> en:contraindications aspect
    n1=substitut du sang | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2053. triiodothyronine --- r_associated #0: 40 --> en:contraindications aspect
    n1=triiodothyronine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2054. vaccine --- r_associated #0: 40 --> en:contraindications aspect
    n1=vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2055. xylulose --- r_associated #0: 40 --> en:contraindications aspect
    n1=xylulose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2056. échodoppler cardiaque --- r_associated #0: 40 --> en:contraindications aspect
    n1=échodoppler cardiaque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2057. énoyl-coa hydratase --- r_associated #0: 40 --> en:contraindications aspect
    n1=énoyl-coa hydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=40
  2058. E553(iii) --- r_associated #0: 39 --> en:contraindications aspect
    n1=E553(iii) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2059. Graisse alimentaire --- r_associated #0: 39 --> en:contraindications aspect
    n1=Graisse alimentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2060. IL-18 --- r_associated #0: 39 --> en:contraindications aspect
    n1=IL-18 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2061. adonitol --- r_associated #0: 39 --> en:contraindications aspect
    n1=adonitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2062. bandage compressif --- r_associated #0: 39 --> en:contraindications aspect
    n1=bandage compressif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2063. cadres de marche --- r_associated #0: 39 --> en:contraindications aspect
    n1=cadres de marche | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2064. cytochromes c' --- r_associated #0: 39 --> en:contraindications aspect
    n1=cytochromes c' | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2065. détersion --- r_associated #0: 39 --> en:contraindications aspect
    n1=détersion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2066. en:17-hydroxycorticosterone --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:17-hydroxycorticosterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2067. en:4-nitrophenylphosphatase --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:4-nitrophenylphosphatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2068. en:adenosine diphosphate sugars --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:adenosine diphosphate sugars | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2069. en:adenovirus e4 protein --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:adenovirus e4 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2070. en:ammotherapy --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:ammotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2071. en:amniocentesis --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:amniocentesis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2072. en:capsulorhexis --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:capsulorhexis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2073. en:complement c3-c5 convertases, classical pathway --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:complement c3-c5 convertases, classical pathway | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2074. en:crocidolite asbestos --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:crocidolite asbestos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2075. en:cross circulation --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:cross circulation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2076. en:cyclic amp-dependent protein kinase riibeta subunit --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:cyclic amp-dependent protein kinase riibeta subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2077. en:cyclin-a1 --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:cyclin-a1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2078. en:dactinomycin --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:dactinomycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2079. en:enoyl-coa hydratase --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:enoyl-coa hydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2080. en:enzyme reactivators --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:enzyme reactivators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2081. en:fat substitutes --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:fat substitutes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2082. en:glucocorticoid receptor-interacting protein 1 --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:glucocorticoid receptor-interacting protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2083. en:glutamyl aminopeptidase --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:glutamyl aminopeptidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2084. en:human menopausal gonadotrophin --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:human menopausal gonadotrophin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2085. en:immune body --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:immune body | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2086. en:intrauterine devices, medicated --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:intrauterine devices, medicated | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2087. en:liposoma --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:liposoma | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2088. en:mercury --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:mercury | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2089. en:mitogen-activated protein kinase p38 --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:mitogen-activated protein kinase p38 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2090. en:pair of spectacles --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:pair of spectacles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2091. en:pemoline --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:pemoline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2092. en:phytomenadione --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:phytomenadione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2093. en:preservative excipient --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:preservative excipient | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2094. en:rad51 recombinase --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:rad51 recombinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2095. en:restriction endonuclease --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:restriction endonuclease | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2096. en:smad proteins, inhibitory --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:smad proteins, inhibitory | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2097. en:sternotomy --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:sternotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2098. en:subcutaneous mastectomy --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:subcutaneous mastectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2099. en:sulfuric acids --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:sulfuric acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2100. en:superficial radiotherapy --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:superficial radiotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2101. en:suspenders --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:suspenders | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2102. en:thenoyltrifluoroacetone --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:thenoyltrifluoroacetone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2103. en:urobilin --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:urobilin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2104. en:uroplakins --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:uroplakins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2105. en:vesicular biogenic amine transport proteins --- r_associated #0: 39 --> en:contraindications aspect
    n1=en:vesicular biogenic amine transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2106. glycosaminoglycane (ou glycosaminoglycanne) --- r_associated #0: 39 --> en:contraindications aspect
    n1=glycosaminoglycane (ou glycosaminoglycanne) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2107. hydroperoxyde tert-butyl --- r_associated #0: 39 --> en:contraindications aspect
    n1=hydroperoxyde tert-butyl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2108. implants dentaires unitaires --- r_associated #0: 39 --> en:contraindications aspect
    n1=implants dentaires unitaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2109. lipoprotéine-lipase --- r_associated #0: 39 --> en:contraindications aspect
    n1=lipoprotéine-lipase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2110. mastectomie élargie --- r_associated #0: 39 --> en:contraindications aspect
    n1=mastectomie élargie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2111. scanner CT --- r_associated #0: 39 --> en:contraindications aspect
    n1=scanner CT | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2112. splénographie --- r_associated #0: 39 --> en:contraindications aspect
    n1=splénographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2113. transfusion sanguine (organisation de la) --- r_associated #0: 39 --> en:contraindications aspect
    n1=transfusion sanguine (organisation de la) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2114. vitamine B1 --- r_associated #0: 39 --> en:contraindications aspect
    n1=vitamine B1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2115. zymosan --- r_associated #0: 39 --> en:contraindications aspect
    n1=zymosan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2116. énoyl-CoA hydratase --- r_associated #0: 39 --> en:contraindications aspect
    n1=énoyl-CoA hydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=39
  2117. apolipoprotéines --- r_associated #0: 38 --> en:contraindications aspect
    n1=apolipoprotéines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2118. en:5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2119. en:adenosine a3 receptor antagonists --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:adenosine a3 receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2120. en:alpha-chlorohydrin --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:alpha-chlorohydrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2121. en:atmosphere exposure chambers --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:atmosphere exposure chambers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2122. en:atp phosphoribosyltransferase --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:atp phosphoribosyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2123. en:cardioangiography --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:cardioangiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2124. en:carfecillin --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:carfecillin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2125. en:compound q --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:compound q | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2126. en:crêpe bandage --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:crêpe bandage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2127. en:cutaneous radiotherapy --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:cutaneous radiotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2128. en:cyclic s-oxides --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:cyclic s-oxides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2129. en:cytochrome reductases --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:cytochrome reductases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2130. en:dental pins --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:dental pins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2131. en:dystrophin-associated protein complex --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:dystrophin-associated protein complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2132. en:efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2133. en:epsom salt --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:epsom salt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2134. en:gi2-alpha protein --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:gi2-alpha protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2135. en:hexamethylphosphoramide --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:hexamethylphosphoramide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2136. en:hla-dr beta ag --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:hla-dr beta ag | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2137. en:hydroxypropiophenone --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:hydroxypropiophenone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2138. en:hypophysectomy --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:hypophysectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2139. en:interleukin-2 receptor beta --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:interleukin-2 receptor beta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2140. en:iodamide --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:iodamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2141. en:map kinase kinase kinase 1 --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:map kinase kinase kinase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2142. en:monocyte chemoattractant protein-2 --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:monocyte chemoattractant protein-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2143. en:neuroimaging --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:neuroimaging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2144. en:nucleic acid heteroduplexes --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:nucleic acid heteroduplexes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2145. en:omega-conotoxins --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:omega-conotoxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2146. en:oncogene protein p65(gag-jun) --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:oncogene protein p65(gag-jun) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2147. en:peptidyl-prolyl cis-trans isomerase nima-interacting 4 --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:peptidyl-prolyl cis-trans isomerase nima-interacting 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2148. en:pethidin --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:pethidin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2149. en:phonocardiography --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:phonocardiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2150. en:photodynamic therapy --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:photodynamic therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2151. en:platelet endothelial cell adhesion molecule --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:platelet endothelial cell adhesion molecule | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2152. en:prostaglandin g/h synthase 1 --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:prostaglandin g/h synthase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2153. en:prostatic secretory proteins --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:prostatic secretory proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2154. en:protective clothing --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:protective clothing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2155. en:receptor-like protein tyrosine phosphatases, class 7 --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:receptor-like protein tyrosine phosphatases, class 7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2156. en:ribonucleoprotein, u2 small nuclear --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:ribonucleoprotein, u2 small nuclear | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2157. en:roentgenoscopy --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:roentgenoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2158. en:secondary surgical revision --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:secondary surgical revision | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2159. en:sensibilatrice --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:sensibilatrice | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2160. en:sialic acid binding ig-like lectin 1 --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:sialic acid binding ig-like lectin 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2161. en:sodium potassium chloride symporter inhibitors --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:sodium potassium chloride symporter inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2162. en:sodium selenite --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:sodium selenite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2163. en:soxb1 transcription factors --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:soxb1 transcription factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2164. en:syntaxin 1 --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:syntaxin 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2165. en:thyroid function tests --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:thyroid function tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2166. en:tin radioisotopes --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:tin radioisotopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2167. en:tocolysis --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:tocolysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2168. en:tremorine --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:tremorine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2169. en:trifluoroethanol --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:trifluoroethanol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2170. en:tumor necrosis factor receptor superfamily member 18 --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:tumor necrosis factor receptor superfamily member 18 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2171. en:urologic surgical procedures, male --- r_associated #0: 38 --> en:contraindications aspect
    n1=en:urologic surgical procedures, male | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2172. facteur F --- r_associated #0: 38 --> en:contraindications aspect
    n1=facteur F | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2173. glycophorine --- r_associated #0: 38 --> en:contraindications aspect
    n1=glycophorine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2174. halcinonide --- r_associated #0: 38 --> en:contraindications aspect
    n1=halcinonide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2175. hbo2 --- r_associated #0: 38 --> en:contraindications aspect
    n1=hbo2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2176. huile de croton --- r_associated #0: 38 --> en:contraindications aspect
    n1=huile de croton | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2177. mastographie --- r_associated #0: 38 --> en:contraindications aspect
    n1=mastographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2178. vaccin anti-virus herpes simplex --- r_associated #0: 38 --> en:contraindications aspect
    n1=vaccin anti-virus herpes simplex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2179. vaccins antivirus de l'herpes simplex --- r_associated #0: 38 --> en:contraindications aspect
    n1=vaccins antivirus de l'herpes simplex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2180. vitallium --- r_associated #0: 38 --> en:contraindications aspect
    n1=vitallium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2181. vitellins --- r_associated #0: 38 --> en:contraindications aspect
    n1=vitellins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2182. épuration extrarénale --- r_associated #0: 38 --> en:contraindications aspect
    n1=épuration extrarénale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=38
  2183. ADN bactérien --- r_associated #0: 37 --> en:contraindications aspect
    n1=ADN bactérien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2184. Pression artérielle --- r_associated #0: 37 --> en:contraindications aspect
    n1=Pression artérielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2185. antigène --- r_associated #0: 37 --> en:contraindications aspect
    n1=antigène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2186. diéthylstilboestrol --- r_associated #0: 37 --> en:contraindications aspect
    n1=diéthylstilboestrol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2187. en:adenine nucleotide translocator 1 --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:adenine nucleotide translocator 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2188. en:alcian blue --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:alcian blue | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2189. en:antiviral agent --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:antiviral agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2190. en:benzopyrene hydroxylase --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:benzopyrene hydroxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2191. en:calcimimetic agents --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:calcimimetic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2192. en:chloramphenicol o-acetyltransferase --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:chloramphenicol o-acetyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2193. en:compression stockings --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:compression stockings | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2194. en:cytochrome p450 cyp11b1, mitochondrial --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:cytochrome p450 cyp11b1, mitochondrial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2195. en:dental implants, single-tooth --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:dental implants, single-tooth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2196. en:electric power supplies --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:electric power supplies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2197. en:electronic nose --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:electronic nose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2198. en:embolization therapy --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:embolization therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2199. en:fatty alcohols --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:fatty alcohols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2200. en:folate receptor beta --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:folate receptor beta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2201. en:fructosediphosphates --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:fructosediphosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2202. en:g2/mitotic-specific cyclin-b2 --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:g2/mitotic-specific cyclin-b2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2203. en:general hair removal - epilation --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:general hair removal - epilation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2204. en:genetic vectors --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:genetic vectors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2205. en:influenza virus vaccine --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:influenza virus vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2206. en:intramolecular lyases --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:intramolecular lyases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2207. en:keratin-16 --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:keratin-16 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2208. en:keto acids --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:keto acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2209. en:mannosyl-glycoprotein endo-beta-n-acetylglucosaminidase --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:mannosyl-glycoprotein endo-beta-n-acetylglucosaminidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2210. en:methyl methanesulfonate --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:methyl methanesulfonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2211. en:neuregulin --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:neuregulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2212. en:paired box protein pax-7 --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:paired box protein pax-7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2213. en:plasmapheresis --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:plasmapheresis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2214. en:polychlorinated dibenzodioxins --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:polychlorinated dibenzodioxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2215. en:polyubiquitin --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:polyubiquitin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2216. en:protein tyrosine kinase pyk2 --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:protein tyrosine kinase pyk2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2217. en:pyronine --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:pyronine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2218. en:radiation treatment --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:radiation treatment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2219. en:retinoid x receptor --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:retinoid x receptor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2220. en:ribosomal protein s6 kinases, 90-kda --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:ribosomal protein s6 kinases, 90-kda | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2221. en:tyrocidine --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:tyrocidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2222. en:vesicle-associated membrane protein 2 --- r_associated #0: 37 --> en:contraindications aspect
    n1=en:vesicle-associated membrane protein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2223. glycogène-phosphorylase --- r_associated #0: 37 --> en:contraindications aspect
    n1=glycogène-phosphorylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2224. interleukine 2 --- r_associated #0: 37 --> en:contraindications aspect
    n1=interleukine 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2225. lipoprotéine de basse densité --- r_associated #0: 37 --> en:contraindications aspect
    n1=lipoprotéine de basse densité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2226. mammectomie souscutanée --- r_associated #0: 37 --> en:contraindications aspect
    n1=mammectomie souscutanée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2227. orexines --- r_associated #0: 37 --> en:contraindications aspect
    n1=orexines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2228. physiopathique (syndrome) --- r_associated #0: 37 --> en:contraindications aspect
    n1=physiopathique (syndrome) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2229. réanimation cardiaque --- r_associated #0: 37 --> en:contraindications aspect
    n1=réanimation cardiaque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2230. tomocaméra --- r_associated #0: 37 --> en:contraindications aspect
    n1=tomocaméra | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2231. vaccin anti-hépatite A --- r_associated #0: 37 --> en:contraindications aspect
    n1=vaccin anti-hépatite A | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=37
  2232. CT --- r_associated #0: 36 --> en:contraindications aspect
    n1=CT | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2233. CT scan --- r_associated #0: 36 --> en:contraindications aspect
    n1=CT scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2234. Fécondation in vitro --- r_associated #0: 36 --> en:contraindications aspect
    n1=Fécondation in vitro | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2235. albumine de sérum de boeuf --- r_associated #0: 36 --> en:contraindications aspect
    n1=albumine de sérum de boeuf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2236. embolisation thérapeutique --- r_associated #0: 36 --> en:contraindications aspect
    n1=embolisation thérapeutique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2237. en:actin-related protein 2-3 complex --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:actin-related protein 2-3 complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2238. en:actin-related protein 3 --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:actin-related protein 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2239. en:apoptotic protease-activating factor 1 --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:apoptotic protease-activating factor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2240. en:chimerin proteins --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:chimerin proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2241. en:claudins --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:claudins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2242. en:continent urinary reservoir --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:continent urinary reservoir | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2243. en:culture media, serum-free --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:culture media, serum-free | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2244. en:cytidine monophosphate n-acetylneuraminic acid --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:cytidine monophosphate n-acetylneuraminic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2245. en:demecolcine --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:demecolcine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2246. en:dental amalgam --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:dental amalgam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2247. en:dental care for children --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:dental care for children | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2248. en:diapers, adult --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:diapers, adult | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2249. en:diterpenes, abietane --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:diterpenes, abietane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2250. en:doppler echocardiography --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:doppler echocardiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2251. en:droxidopa --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:droxidopa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2252. en:egg proteins, dietary --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:egg proteins, dietary | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2253. en:epsilon-globins --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:epsilon-globins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2254. en:ergometry --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:ergometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2255. en:eukaryotic initiation factor-4a --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:eukaryotic initiation factor-4a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2256. en:fanconi anemia group d2 protein --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:fanconi anemia group d2 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2257. en:flowmeters --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:flowmeters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2258. en:gamma chemokine --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:gamma chemokine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2259. en:gelatinases --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:gelatinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2260. en:glatiramer acetate --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:glatiramer acetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2261. en:glial cell line-derived neurotrophic factors --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:glial cell line-derived neurotrophic factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2262. en:glycogen phosphorylase --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:glycogen phosphorylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2263. en:hip replacement arthroplasty (procedure) --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:hip replacement arthroplasty (procedure) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2264. en:interferon-stimulated gene factor 3, alpha subunit --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:interferon-stimulated gene factor 3, alpha subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2265. en:interleukin-2 --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:interleukin-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2266. en:isopréniques --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:isopréniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2267. en:kv channel-interacting proteins --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:kv channel-interacting proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2268. en:lung transplantation --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:lung transplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2269. en:macrophage-1 antigen --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:macrophage-1 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2270. en:mandibular prosthesis --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:mandibular prosthesis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2271. en:melanocyte stimulating hormone --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:melanocyte stimulating hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2272. en:nod1 signaling adaptor protein --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:nod1 signaling adaptor protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2273. en:oxo-acid-lyases --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:oxo-acid-lyases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2274. en:perilipin-5 --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:perilipin-5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2275. en:phenylthiazolylthiourea --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:phenylthiazolylthiourea | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2276. en:phosphatidylinositol-3,4,5-trisphosphate 5-phosphatases --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:phosphatidylinositol-3,4,5-trisphosphate 5-phosphatases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2277. en:phytic acid --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:phytic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2278. en:positron emission tomography --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:positron emission tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2279. en:pyrroloiminoquinones --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:pyrroloiminoquinones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2280. en:radiation dosimetry --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:radiation dosimetry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2281. en:radioimmunoassay --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:radioimmunoassay | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2282. en:radiotherapy planning, computer-assisted --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:radiotherapy planning, computer-assisted | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2283. en:rubella virus vaccine --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:rubella virus vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2284. en:shal potassium channels --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:shal potassium channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2285. en:tert-butylhydroperoxide --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:tert-butylhydroperoxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2286. en:thiamine --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:thiamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2287. en:tomography, proton spin --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:tomography, proton spin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2288. en:tyrosine-protein phosphatase non-receptor type 13 --- r_associated #0: 36 --> en:contraindications aspect
    n1=en:tyrosine-protein phosphatase non-receptor type 13 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2289. ergométrie --- r_associated #0: 36 --> en:contraindications aspect
    n1=ergométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2290. gaïac --- r_associated #0: 36 --> en:contraindications aspect
    n1=gaïac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2291. glucocorticostéroïde --- r_associated #0: 36 --> en:contraindications aspect
    n1=glucocorticostéroïde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2292. hémoglobinomètrie --- r_associated #0: 36 --> en:contraindications aspect
    n1=hémoglobinomètrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2293. occludine --- r_associated #0: 36 --> en:contraindications aspect
    n1=occludine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2294. oligo-élément --- r_associated #0: 36 --> en:contraindications aspect
    n1=oligo-élément | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2295. opération de Fontan --- r_associated #0: 36 --> en:contraindications aspect
    n1=opération de Fontan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2296. plasmide F --- r_associated #0: 36 --> en:contraindications aspect
    n1=plasmide F | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2297. premiers soins --- r_associated #0: 36 --> en:contraindications aspect
    n1=premiers soins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2298. produits d'hygiène féminine --- r_associated #0: 36 --> en:contraindications aspect
    n1=produits d'hygiène féminine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2299. radio-immunoessai --- r_associated #0: 36 --> en:contraindications aspect
    n1=radio-immunoessai | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2300. sphygmomanomètre --- r_associated #0: 36 --> en:contraindications aspect
    n1=sphygmomanomètre | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2301. sérum antilymphocytaire --- r_associated #0: 36 --> en:contraindications aspect
    n1=sérum antilymphocytaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2302. tomodensimétrie --- r_associated #0: 36 --> en:contraindications aspect
    n1=tomodensimétrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2303. vaccins anti virus herpes simplex --- r_associated #0: 36 --> en:contraindications aspect
    n1=vaccins anti virus herpes simplex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2304. vaccins anti-virus de l'herpes simplex --- r_associated #0: 36 --> en:contraindications aspect
    n1=vaccins anti-virus de l'herpes simplex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=36
  2305. Agglutinine --- r_associated #0: 35 --> en:contraindications aspect
    n1=Agglutinine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2306. Hyde (prurigo nodulaire de) --- r_associated #0: 35 --> en:contraindications aspect
    n1=Hyde (prurigo nodulaire de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2307. Inhibiteur enzymatique --- r_associated #0: 35 --> en:contraindications aspect
    n1=Inhibiteur enzymatique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2308. MSG --- r_associated #0: 35 --> en:contraindications aspect
    n1=MSG | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2309. Téflon --- r_associated #0: 35 --> en:contraindications aspect
    n1=Téflon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2310. acide pyruvique --- r_associated #0: 35 --> en:contraindications aspect
    n1=acide pyruvique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2311. acénocoumarol --- r_associated #0: 35 --> en:contraindications aspect
    n1=acénocoumarol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2312. agglutinine --- r_associated #0: 35 --> en:contraindications aspect
    n1=agglutinine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2313. angiostatine --- r_associated #0: 35 --> en:contraindications aspect
    n1=angiostatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2314. antihormone --- r_associated #0: 35 --> en:contraindications aspect
    n1=antihormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2315. asparaginase --- r_associated #0: 35 --> en:contraindications aspect
    n1=asparaginase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2316. bande adhésive élastique ace --- r_associated #0: 35 --> en:contraindications aspect
    n1=bande adhésive élastique ace | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2317. bas de compression --- r_associated #0: 35 --> en:contraindications aspect
    n1=bas de compression | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2318. bioprothèses --- r_associated #0: 35 --> en:contraindications aspect
    n1=bioprothèses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2319. biphosphonate --- r_associated #0: 35 --> en:contraindications aspect
    n1=biphosphonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2320. caspase 10 --- r_associated #0: 35 --> en:contraindications aspect
    n1=caspase 10 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2321. cetuximab --- r_associated #0: 35 --> en:contraindications aspect
    n1=cetuximab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2322. cholécystographie --- r_associated #0: 35 --> en:contraindications aspect
    n1=cholécystographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2323. clé à fourches --- r_associated #0: 35 --> en:contraindications aspect
    n1=clé à fourches | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2324. cure thermale --- r_associated #0: 35 --> en:contraindications aspect
    n1=cure thermale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2325. diphosphonate --- r_associated #0: 35 --> en:contraindications aspect
    n1=diphosphonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2326. disopyramide --- r_associated #0: 35 --> en:contraindications aspect
    n1=disopyramide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2327. dopa-décarboxylase --- r_associated #0: 35 --> en:contraindications aspect
    n1=dopa-décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2328. dopathérapie --- r_associated #0: 35 --> en:contraindications aspect
    n1=dopathérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2329. doppler transcrânien --- r_associated #0: 35 --> en:contraindications aspect
    n1=doppler transcrânien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2330. en:1-(5-isoquinolinesulfonyl)-2-methylpiperazine --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:1-(5-isoquinolinesulfonyl)-2-methylpiperazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2331. en:1-acylglycerophosphocholine o-acyltransferase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:1-acylglycerophosphocholine o-acyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2332. en:1-carboxyglutamic acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:1-carboxyglutamic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2333. en:11-beta-hydroxysteroid dehydrogenase type 2 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:11-beta-hydroxysteroid dehydrogenase type 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2334. en:12-hydroxy-5,8,10,14-eicosatetraenoic acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:12-hydroxy-5,8,10,14-eicosatetraenoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2335. en:20-methylcholanthrene --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:20-methylcholanthrene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2336. en:24,25-dihydroxycholecalciferol --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:24,25-dihydroxycholecalciferol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2337. en:2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2338. en:3-iodotyrosine --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:3-iodotyrosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2339. en:4-butyrolactone --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:4-butyrolactone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2340. en:7-alkoxycoumarin o-dealkylase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:7-alkoxycoumarin o-dealkylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2341. en:abortifacient agents --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:abortifacient agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2342. en:abortifacient agents, steroidal --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:abortifacient agents, steroidal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2343. en:acenocoumarol --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:acenocoumarol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2344. en:acetyldigitoxins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:acetyldigitoxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2345. en:acetylgalactosamine --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:acetylgalactosamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2346. en:acridine orange --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:acridine orange | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2347. en:activin receptors, type i --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:activin receptors, type i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2348. en:acyl-carrier protein s-malonyltransferase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:acyl-carrier protein s-malonyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2349. en:adamts proteins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:adamts proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2350. en:adamts7 protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:adamts7 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2351. en:adenylyl cyclase inhibitors --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:adenylyl cyclase inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2352. en:aflatoxin m1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:aflatoxin m1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2353. en:agglutinin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:agglutinin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2354. en:alamethicin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:alamethicin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2355. en:aldose-ketose isomerases --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:aldose-ketose isomerases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2356. en:alpha-n-acetylgalactosaminidase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:alpha-n-acetylgalactosaminidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2357. en:alveolar ridge augmentation --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:alveolar ridge augmentation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2358. en:aminocaproic acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:aminocaproic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2359. en:androstatrienes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:androstatrienes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2360. en:anesthesia, inhalation --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:anesthesia, inhalation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2361. en:anesthetics, intravenous --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:anesthetics, intravenous | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2362. en:angioplasty, balloon, laser-assisted --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:angioplasty, balloon, laser-assisted | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2363. en:angiopoietin-1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:angiopoietin-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2364. en:angiostatin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:angiostatin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2365. en:anti-inflammatory agents --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:anti-inflammatory agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2366. en:antihormone --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:antihormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2367. en:antinematodal agents --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:antinematodal agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2368. en:apoferritins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:apoferritins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2369. en:aquaporin 6 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:aquaporin 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2370. en:armin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:armin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2371. en:arthroscopes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:arthroscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2372. en:artificial organs --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:artificial organs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2373. en:artificial saliva --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:artificial saliva | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2374. en:artificial skin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:artificial skin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2375. en:asparaginase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:asparaginase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2376. en:aspartokinase homoserine dehydrogenase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:aspartokinase homoserine dehydrogenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2377. en:atrial myosins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:atrial myosins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2378. en:aurintricarboxylic acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:aurintricarboxylic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2379. en:autophagy-related protein 7 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:autophagy-related protein 7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2380. en:autophagy-related protein-1 homolog --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:autophagy-related protein-1 homolog | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2381. en:azetines --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:azetines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2382. en:bacteriochlorophyll a --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:bacteriochlorophyll a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2383. en:benzbromarone --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:benzbromarone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2384. en:benzophenones --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:benzophenones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2385. en:benzyl viologen --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:benzyl viologen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2386. en:beta karyopherins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:beta karyopherins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2387. en:beta-naphthoflavone --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:beta-naphthoflavone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2388. en:betaxanthins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:betaxanthins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2389. en:bioelectric energy sources --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:bioelectric energy sources | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2390. en:biological dressings --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:biological dressings | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2391. en:biphosphonate --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:biphosphonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2392. en:bispecific antibody --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:bispecific antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2393. en:blood pressure --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:blood pressure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2394. en:blood transfusion --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:blood transfusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2395. en:bloodletting --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:bloodletting | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2396. en:bone graft --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:bone graft | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2397. en:brinolase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:brinolase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2398. en:bromodeoxycytidine --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:bromodeoxycytidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2399. en:bromotrichloromethane --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:bromotrichloromethane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2400. en:calcium-activated potassium channel --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:calcium-activated potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2401. en:cannabinoid receptor antagonists --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cannabinoid receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2402. en:carbamoyl-phosphate synthase (glutamine-hydrolyzing) --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:carbamoyl-phosphate synthase (glutamine-hydrolyzing) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2403. en:carbon-nitrogen lyases --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:carbon-nitrogen lyases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2404. en:carbonate dehydratase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:carbonate dehydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2405. en:carboquone --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:carboquone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2406. en:cardiac catheters --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cardiac catheters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2407. en:cariogenic agents --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cariogenic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2408. en:caspase-10 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:caspase-10 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2409. en:caspase-3 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:caspase-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2410. en:catechol 2,3-dioxygenase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:catechol 2,3-dioxygenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2411. en:cathepsin f --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cathepsin f | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2412. en:cd1 glycoprotein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cd1 glycoprotein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2413. en:cd15 antigen --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cd15 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2414. en:cd44 antigen --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cd44 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2415. en:cd8 antigens --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cd8 antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2416. en:central nervous system agents --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:central nervous system agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2417. en:cephalosporinase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cephalosporinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2418. en:cephamycins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cephamycins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2419. en:cetuximab --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cetuximab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2420. en:chaperonin containing tcp-1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:chaperonin containing tcp-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2421. en:chemokine cxcl13 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:chemokine cxcl13 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2422. en:cholecystography --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cholecystography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2423. en:cholestadienols --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cholestadienols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2424. en:cholestenone 5 alpha-reductase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cholestenone 5 alpha-reductase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2425. en:cholestenones --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cholestenones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2426. en:class iii phosphatidylinositol 3-kinases --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:class iii phosphatidylinositol 3-kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2427. en:collection of blood specimen for laboratory procedure --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:collection of blood specimen for laboratory procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2428. en:colonic pouches --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:colonic pouches | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2429. en:complement 3b inactivators --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:complement 3b inactivators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2430. en:complement c5 convertase, classical pathway --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:complement c5 convertase, classical pathway | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2431. en:complement c5a, des-arginine --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:complement c5a, des-arginine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2432. en:complement component c1r --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:complement component c1r | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2433. en:cone-beam computed tomography --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cone-beam computed tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2434. en:conjugate vaccine --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:conjugate vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2435. en:contraceptive devices, female --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:contraceptive devices, female | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2436. en:counterindication --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:counterindication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2437. en:croton oil --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:croton oil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2438. en:cryoanesthesia --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cryoanesthesia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2439. en:cucumber mosaic virus satellite --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cucumber mosaic virus satellite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2440. en:curing lights, dental --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:curing lights, dental | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2441. en:cyanoketone --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cyanoketone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2442. en:cyclic amp-dependent protein kinase type ii --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cyclic amp-dependent protein kinase type ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2443. en:cyclic nucleotide phosphodiesterases, type 5 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cyclic nucleotide phosphodiesterases, type 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2444. en:cyclin b1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cyclin b1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2445. en:cyclin-dependent kinase inhibitor p57 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cyclin-dependent kinase inhibitor p57 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2446. en:cyclodecanes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cyclodecanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2447. en:cyclohexanecarboxylic acids --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cyclohexanecarboxylic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2448. en:cystaphos --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cystaphos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2449. en:cytochrome p450 family 24 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cytochrome p450 family 24 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2450. en:cytoskeletal protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:cytoskeletal protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2451. en:dalfampridine --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dalfampridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2452. en:dental alloys --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dental alloys | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2453. en:dental atraumatic restorative treatment --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dental atraumatic restorative treatment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2454. en:dental caries activity tests --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dental caries activity tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2455. en:dental enamel proteins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dental enamel proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2456. en:dental instruments --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dental instruments | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2457. en:dental models --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dental models | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2458. en:dental pulp test --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dental pulp test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2459. en:dental restoration repair --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dental restoration repair | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2460. en:denture, partial, temporary --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:denture, partial, temporary | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2461. en:desmoglein 1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:desmoglein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2462. en:dextran sulfate --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dextran sulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2463. en:dialysis fluid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dialysis fluid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2464. en:diet, protein-restricted --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:diet, protein-restricted | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2465. en:dihydroxycholecalciferols --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dihydroxycholecalciferols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2466. en:dimethyl sulfoxide --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dimethyl sulfoxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2467. en:diphosphotransferases --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:diphosphotransferases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2468. en:disopyramide --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:disopyramide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2469. en:diynes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:diynes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2470. en:dna photolyase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dna photolyase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2471. en:dna probes, hla --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dna probes, hla | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2472. en:dna, bacterial --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dna, bacterial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2473. en:dopamine antagonist --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dopamine antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2474. en:dry powder inhaler (device) --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dry powder inhaler (device) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2475. en:dydrogesterone --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:dydrogesterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2476. en:ebola vaccines --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ebola vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2477. en:echocardiography, three-dimensional --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:echocardiography, three-dimensional | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2478. en:electrical equipment and supplies --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:electrical equipment and supplies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2479. en:emodin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:emodin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2480. en:enclomiphene --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:enclomiphene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2481. en:ephrin-b1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ephrin-b1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2482. en:epimestrol --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:epimestrol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2483. en:epiregulin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:epiregulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2484. en:epitope --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:epitope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2485. en:equilin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:equilin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2486. en:estrogenic steroids, alkylated --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:estrogenic steroids, alkylated | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2487. en:ethinyl estradiol --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ethinyl estradiol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2488. en:eukaryotic translation initiation factor 5 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:eukaryotic translation initiation factor 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2489. en:examination tables --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:examination tables | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2490. en:eye protective devices --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:eye protective devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2491. en:fanconi anemia group e protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:fanconi anemia group e protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2492. en:feminine hygiene products --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:feminine hygiene products | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2493. en:ferrichrome --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ferrichrome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2494. en:fetal tissue transplantation --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:fetal tissue transplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2495. en:fgfr4 protein, human --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:fgfr4 protein, human | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2496. en:first aid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:first aid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2497. en:fluorine radioisotopes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:fluorine radioisotopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2498. en:fosinopril --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:fosinopril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2499. en:fructokinases --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:fructokinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2500. en:fura-2 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:fura-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2501. en:galactosylgalactosylglucosylceramidase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:galactosylgalactosylglucosylceramidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2502. en:gamma-glutamyl transpeptidase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:gamma-glutamyl transpeptidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2503. en:gamma-glutamylcysteine synthetase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:gamma-glutamylcysteine synthetase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2504. en:gastrin-releasing peptide --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:gastrin-releasing peptide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2505. en:germine acetates --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:germine acetates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2506. en:gibberellins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:gibberellins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2507. en:glucan 1,4-alpha-glucosidase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:glucan 1,4-alpha-glucosidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2508. en:glucose dehydrogenases --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:glucose dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2509. en:glucosephosphates --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:glucosephosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2510. en:glutamate decarboxylase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:glutamate decarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2511. en:glutamate formiminotransferase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:glutamate formiminotransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2512. en:glycodelin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:glycodelin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2513. en:glycogen (starch) synthase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:glycogen (starch) synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2514. en:glycosaminoglycan --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:glycosaminoglycan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2515. en:gold sodium thiomalate --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:gold sodium thiomalate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2516. en:graft enhancement, immunologic --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:graft enhancement, immunologic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2517. en:grape seed extract --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:grape seed extract | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2518. en:group i phospholipases a2 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:group i phospholipases a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2519. en:gtp phosphohydrolase-linked elongation factors --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:gtp phosphohydrolase-linked elongation factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2520. en:gtp-binding protein gamma subunits --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:gtp-binding protein gamma subunits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2521. en:hand assisted laparoscopy --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hand assisted laparoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2522. en:heart bypass, left --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:heart bypass, left | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2523. en:hemagglutinin glycoproteins, influenza virus --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hemagglutinin glycoproteins, influenza virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2524. en:hemoglobinometry --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hemoglobinometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2525. en:hemostatic agent --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hemostatic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2526. en:heparin cofactor 2 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:heparin cofactor 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2527. en:hip joint implantable prostheses (device) --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hip joint implantable prostheses (device) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2528. en:hla-b38 antigen --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hla-b38 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2529. en:hla-b39 antigen --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hla-b39 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2530. en:hormone antagonist --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hormone antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2531. en:hyalectins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hyalectins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2532. en:hydrobromic acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hydrobromic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2533. en:hydrotherapy --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hydrotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2534. en:hydroxyacetylaminofluorene --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hydroxyacetylaminofluorene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2535. en:hydroxydopamines --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hydroxydopamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2536. en:hysteroscopy --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:hysteroscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2537. en:iduronic acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:iduronic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2538. en:ikaros transcription factor --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ikaros transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2539. en:immunodominant epitopes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:immunodominant epitopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2540. en:in vitro fertilization --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:in vitro fertilization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2541. en:indolizidines --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:indolizidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2542. en:induction of labor --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:induction of labor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2543. en:inhibitor of differentiation protein 1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:inhibitor of differentiation protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2544. en:injections, jet --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:injections, jet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2545. en:inlay casting wax --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:inlay casting wax | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2546. en:insemination, artificial, homologous --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:insemination, artificial, homologous | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2547. en:insulin, regular --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:insulin, regular | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2548. en:insulin-like growth factor-binding protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:insulin-like growth factor-binding protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2549. en:interleukin-1 alpha --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:interleukin-1 alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2550. en:intra-aortic balloon pumping --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:intra-aortic balloon pumping | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2551. en:intramolecular oxidoreductases --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:intramolecular oxidoreductases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2552. en:iodohippuric acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:iodohippuric acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2553. en:isopropyl thiogalactoside --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:isopropyl thiogalactoside | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2554. en:jejunostomy --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:jejunostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2555. en:karaya gum --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:karaya gum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2556. en:kassinin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:kassinin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2557. en:kcnq2 potassium channel --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:kcnq2 potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2558. en:keratin-15 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:keratin-15 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2559. en:ketoglutaric acids --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ketoglutaric acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2560. en:kininogen, low-molecular-weight protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:kininogen, low-molecular-weight protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2561. en:kynurenine 3-monooxygenase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:kynurenine 3-monooxygenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2562. en:lanosterol 14 alpha-demethylase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:lanosterol 14 alpha-demethylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2563. en:large neutral amino acids transporter small subunit 1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:large neutral amino acids transporter small subunit 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2564. en:laryngeal masks --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:laryngeal masks | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2565. en:laurates --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:laurates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2566. en:ldl cholesterol lipoproteins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ldl cholesterol lipoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2567. en:linolenic acids --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:linolenic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2568. en:lithium compounds --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:lithium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2569. en:liver glycogen --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:liver glycogen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2570. en:luminescent proteins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:luminescent proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2571. en:lupus coagulation inhibitor --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:lupus coagulation inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2572. en:lurasidone hydrochloride --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:lurasidone hydrochloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2573. en:magainins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:magainins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2574. en:mandibular advancement --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:mandibular advancement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2575. en:mechanism of action qualifier --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:mechanism of action qualifier | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2576. en:medigoxin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:medigoxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2577. en:megacins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:megacins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2578. en:methiothepin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:methiothepin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2579. en:methyl green --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:methyl green | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2580. en:methyldimethylaminoazobenzene --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:methyldimethylaminoazobenzene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2581. en:milk acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:milk acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2582. en:mitogen-activated protein kinase 13 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:mitogen-activated protein kinase 13 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2583. en:mixed function oxidase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:mixed function oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2584. en:mnss blood-group system --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:mnss blood-group system | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2585. en:molybdoferredoxin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:molybdoferredoxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2586. en:msh release-inhibiting hormone --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:msh release-inhibiting hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2587. en:n-formylmethionine --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:n-formylmethionine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2588. en:negative-pressure ventilators --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:negative-pressure ventilators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2589. en:neuromuscular depolarizing agents --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:neuromuscular depolarizing agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2590. en:neutrophil collagenase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:neutrophil collagenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2591. en:nicotinic antagonist --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:nicotinic antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2592. en:nitroanisole o-demethylase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:nitroanisole o-demethylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2593. en:nitrovin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:nitrovin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2594. en:nodal protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:nodal protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2595. en:nuclear receptor subfamily 4 group a member 1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:nuclear receptor subfamily 4 group a member 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2596. en:nuclear receptor subfamily 4, group a, member 2 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:nuclear receptor subfamily 4, group a, member 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2597. en:nucleoside-phosphate kinase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:nucleoside-phosphate kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2598. en:nutritive sweeteners --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:nutritive sweeteners | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2599. en:o antigens --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:o antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2600. en:occludin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:occludin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2601. en:occlusive dressings --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:occlusive dressings | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2602. en:omega-conotoxin gvia --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:omega-conotoxin gvia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2603. en:oncogene proteins v-abl --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:oncogene proteins v-abl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2604. en:oncogene proteins v-erba --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:oncogene proteins v-erba | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2605. en:optical coherence tomography --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:optical coherence tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2606. en:organ preservation --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:organ preservation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2607. en:orthopedic procedures --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:orthopedic procedures | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2608. en:parenteral nutrition, home total --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:parenteral nutrition, home total | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2609. en:peroxisomal multifunctional protein-2 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:peroxisomal multifunctional protein-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2610. en:petrosal sinus sampling --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:petrosal sinus sampling | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2611. en:pharmaceutical excipient --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:pharmaceutical excipient | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2612. en:phenylisopropyladenosine --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:phenylisopropyladenosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2613. en:phorbol 12,13-dibutyrate --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:phorbol 12,13-dibutyrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2614. en:phospholipase a2 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:phospholipase a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2615. en:phosphoribosylaminoimidazolecarboxamide formyltransferase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:phosphoribosylaminoimidazolecarboxamide formyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2616. en:phosphoribosylglycinamide formyltransferase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:phosphoribosylglycinamide formyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2617. en:phototropins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:phototropins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2618. en:physical conditioning, animal --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:physical conditioning, animal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2619. en:phytase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:phytase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2620. en:piroxicam --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:piroxicam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2621. en:pituitary irradiation --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:pituitary irradiation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2622. en:pituitary-adrenal function tests --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:pituitary-adrenal function tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2623. en:plakophilins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:plakophilins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2624. en:plastic surgery, neck --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:plastic surgery, neck | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2625. en:pokeweed mitogen --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:pokeweed mitogen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2626. en:polyglycolic acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:polyglycolic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2627. en:pregnancy-associated alpha 2-macroglobulins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:pregnancy-associated alpha 2-macroglobulins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2628. en:progestin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:progestin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2629. en:prokaryotic initiation factors --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:prokaryotic initiation factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2630. en:protein inhibitors of activated stat --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:protein inhibitors of activated stat | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2631. en:protein replacement therapy --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:protein replacement therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2632. en:protein tyrosine kinase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:protein tyrosine kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2633. en:proto-oncogene int-1 related protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:proto-oncogene int-1 related protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2634. en:psyllium husk --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:psyllium husk | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2635. en:pyocins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:pyocins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2636. en:pyrrolidinones --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:pyrrolidinones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2637. en:pyruvic acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:pyruvic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2638. en:qb-snare proteins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:qb-snare proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2639. en:qigong --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:qigong | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2640. en:rab3 gtp-binding proteins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:rab3 gtp-binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2641. en:radical mastectomy --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:radical mastectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2642. en:radioligand assay --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:radioligand assay | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2643. en:receptor tyrosine-protein kinase erbb-3 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:receptor tyrosine-protein kinase erbb-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2644. en:receptor, epha4 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:receptor, epha4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2645. en:receptor-like protein tyrosine phosphatases, class 1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:receptor-like protein tyrosine phosphatases, class 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2646. en:regular insulin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:regular insulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2647. en:retrograde obturation --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:retrograde obturation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2648. en:rna probes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:rna probes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2649. en:rna, transfer, met --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:rna, transfer, met | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2650. en:scanning laser polarimetry --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:scanning laser polarimetry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2651. en:schistosomicides --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:schistosomicides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2652. en:seminal vesicle secretory proteins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:seminal vesicle secretory proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2653. en:sensory aids --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:sensory aids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2654. en:sesquiterpenes, guaiane --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:sesquiterpenes, guaiane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2655. en:sh2 domain-containing protein tyrosine phosphatases --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:sh2 domain-containing protein tyrosine phosphatases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2656. en:shikimic acid --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:shikimic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2657. en:sildenafil citrate --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:sildenafil citrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2658. en:smad proteins, receptor-regulated --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:smad proteins, receptor-regulated | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2659. en:smad3 protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:smad3 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2660. en:sodium-hydrogen antiporter --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:sodium-hydrogen antiporter | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2661. en:solute carrier family 22 member 1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:solute carrier family 22 member 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2662. en:space maintenance, orthodontic --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:space maintenance, orthodontic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2663. en:sphincterotomy, endoscopic --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:sphincterotomy, endoscopic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2664. en:sterol 12-alpha-hydroxylase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:sterol 12-alpha-hydroxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2665. en:sterol regulatory element binding protein 2 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:sterol regulatory element binding protein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2666. en:subgingival curettage --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:subgingival curettage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2667. en:suppressor of cytokine signaling 1 protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:suppressor of cytokine signaling 1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2668. en:survival of motor neuron 2 protein --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:survival of motor neuron 2 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2669. en:synucleins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:synucleins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2670. en:t-type calcium channels --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:t-type calcium channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2671. en:tata box binding protein-like proteins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:tata box binding protein-like proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2672. en:tata-binding protein associated factors --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:tata-binding protein associated factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2673. en:tau-crystallins --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:tau-crystallins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2674. en:tetraphenylborate --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:tetraphenylborate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2675. en:tetroses --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:tetroses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2676. en:thapsigargin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:thapsigargin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2677. en:therapeutic touch --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:therapeutic touch | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2678. en:tin polyphosphates --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:tin polyphosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2679. en:topoisomerase iv --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:topoisomerase iv | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2680. en:transcranial doppler ultrasonography --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:transcranial doppler ultrasonography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2681. en:transcription factor pit-1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:transcription factor pit-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2682. en:transfer factor --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:transfer factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2683. en:transplantation --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:transplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2684. en:triethyltin compounds --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:triethyltin compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2685. en:trypsinogen --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:trypsinogen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2686. en:tryptamines --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:tryptamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2687. en:tumor necrosis factor decoy receptors --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:tumor necrosis factor decoy receptors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2688. en:tumor necrosis factor-alpha convertase --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:tumor necrosis factor-alpha convertase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2689. en:ubiquitin-conjugating enzymes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ubiquitin-conjugating enzymes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2690. en:ubiquitin-protein ligase complexes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ubiquitin-protein ligase complexes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2691. en:undecylenic acids --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:undecylenic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2692. en:unnecessary procedures --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:unnecessary procedures | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2693. en:upstream stimulatory factor --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:upstream stimulatory factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2694. en:ureteroscopes --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:ureteroscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2695. en:urologic surgical procedure --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:urologic surgical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2696. en:vaccines, acellular --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:vaccines, acellular | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2697. en:vancomycin --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:vancomycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2698. en:vitamin a compound --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:vitamin a compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2699. en:voltage-dependent anion channel --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:voltage-dependent anion channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2700. en:voltage-dependent anion channel 1 --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:voltage-dependent anion channel 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2701. en:voltage-gated potassium channel --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:voltage-gated potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2702. en:water pollutants, radioactive --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:water pollutants, radioactive | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2703. en:zeolites --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:zeolites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2704. en:zinc acetate --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:zinc acetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2705. en:zinc oxide-eugenol cement --- r_associated #0: 35 --> en:contraindications aspect
    n1=en:zinc oxide-eugenol cement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2706. facteur de croissance transformant --- r_associated #0: 35 --> en:contraindications aspect
    n1=facteur de croissance transformant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2707. glutamate décarboxylase --- r_associated #0: 35 --> en:contraindications aspect
    n1=glutamate décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2708. glutamate formimino-transférase --- r_associated #0: 35 --> en:contraindications aspect
    n1=glutamate formimino-transférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2709. glutamate formiminotransférase --- r_associated #0: 35 --> en:contraindications aspect
    n1=glutamate formiminotransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2710. glutamate formyltransférase --- r_associated #0: 35 --> en:contraindications aspect
    n1=glutamate formyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2711. greffe osseuse --- r_associated #0: 35 --> en:contraindications aspect
    n1=greffe osseuse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2712. hystéroscopie --- r_associated #0: 35 --> en:contraindications aspect
    n1=hystéroscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2713. hétérogreffe valvulaire --- r_associated #0: 35 --> en:contraindications aspect
    n1=hétérogreffe valvulaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2714. insuline normale --- r_associated #0: 35 --> en:contraindications aspect
    n1=insuline normale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2715. insuline ordinaire --- r_associated #0: 35 --> en:contraindications aspect
    n1=insuline ordinaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2716. interféron (traitement par l') --- r_associated #0: 35 --> en:contraindications aspect
    n1=interféron (traitement par l') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2717. masques laryngés --- r_associated #0: 35 --> en:contraindications aspect
    n1=masques laryngés | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2718. oligoélément --- r_associated #0: 35 --> en:contraindications aspect
    n1=oligoélément | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2719. phytase --- r_associated #0: 35 --> en:contraindications aspect
    n1=phytase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2720. piroxicam --- r_associated #0: 35 --> en:contraindications aspect
    n1=piroxicam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2721. progestine --- r_associated #0: 35 --> en:contraindications aspect
    n1=progestine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2722. protéine du cytosquelette --- r_associated #0: 35 --> en:contraindications aspect
    n1=protéine du cytosquelette | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2723. protéine foetale --- r_associated #0: 35 --> en:contraindications aspect
    n1=protéine foetale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2724. secourisme --- r_associated #0: 35 --> en:contraindications aspect
    n1=secourisme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2725. soude caustique --- r_associated #0: 35 --> en:contraindications aspect
    n1=soude caustique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2726. staging --- r_associated #0: 35 --> en:contraindications aspect
    n1=staging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2727. sulfate de magnésium --- r_associated #0: 35 --> en:contraindications aspect
    n1=sulfate de magnésium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2728. thiamine pyrophosphatase --- r_associated #0: 35 --> en:contraindications aspect
    n1=thiamine pyrophosphatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2729. trypsinogène --- r_associated #0: 35 --> en:contraindications aspect
    n1=trypsinogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2730. tryptamines --- r_associated #0: 35 --> en:contraindications aspect
    n1=tryptamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2731. tyrocidine --- r_associated #0: 35 --> en:contraindications aspect
    n1=tyrocidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2732. vancomycine --- r_associated #0: 35 --> en:contraindications aspect
    n1=vancomycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2733. zéolites --- r_associated #0: 35 --> en:contraindications aspect
    n1=zéolites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2734. épiréguline --- r_associated #0: 35 --> en:contraindications aspect
    n1=épiréguline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2735. épitope --- r_associated #0: 35 --> en:contraindications aspect
    n1=épitope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=35
  2736. Lentilles de contact --- r_associated #0: 34 --> en:contraindications aspect
    n1=Lentilles de contact | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2737. acides phénylpyruviques --- r_associated #0: 34 --> en:contraindications aspect
    n1=acides phénylpyruviques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2738. agent antiviral --- r_associated #0: 34 --> en:contraindications aspect
    n1=agent antiviral | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2739. agents cariogènes --- r_associated #0: 34 --> en:contraindications aspect
    n1=agents cariogènes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2740. anaphylatoxines --- r_associated #0: 34 --> en:contraindications aspect
    n1=anaphylatoxines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2741. bagues --- r_associated #0: 34 --> en:contraindications aspect
    n1=bagues | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2742. bed --- r_associated #0: 34 --> en:contraindications aspect
    n1=bed | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2743. busulfan --- r_associated #0: 34 --> en:contraindications aspect
    n1=busulfan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2744. catgut --- r_associated #0: 34 --> en:contraindications aspect
    n1=catgut | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2745. clef à fourches --- r_associated #0: 34 --> en:contraindications aspect
    n1=clef à fourches | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2746. dioxanes --- r_associated #0: 34 --> en:contraindications aspect
    n1=dioxanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2747. diphosphoglycérate-mutase --- r_associated #0: 34 --> en:contraindications aspect
    n1=diphosphoglycérate-mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2748. dispositif intra-utérin --- r_associated #0: 34 --> en:contraindications aspect
    n1=dispositif intra-utérin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2749. en:15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2750. en:17-hydroxysteroid dehydrogenases --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:17-hydroxysteroid dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2751. en:2,3-diphosphoglycerate --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:2,3-diphosphoglycerate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2752. en:2-5a synthetase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:2-5a synthetase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2753. en:3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-isomer --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-isomer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2754. en:3-deazauridine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:3-deazauridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2755. en:3-methoxy-4-hydroxyphenylethanol --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:3-methoxy-4-hydroxyphenylethanol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2756. en:4,4-methylenebis,2-chloroaniline --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:4,4-methylenebis,2-chloroaniline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2757. en:8-azaguanine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:8-azaguanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2758. en:X ray therapy --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:X ray therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2759. en:absorbent pads --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:absorbent pads | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2760. en:acoustic impedance tests --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:acoustic impedance tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2761. en:adaptor protein complex delta subunits --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:adaptor protein complex delta subunits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2762. en:adenosine a3 receptor agonists --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:adenosine a3 receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2763. en:adenosine-5'-(n-ethylcarboxamide) --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:adenosine-5'-(n-ethylcarboxamide) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2764. en:adenovirus e1 proteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:adenovirus e1 proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2765. en:adp-ribosylation factor 1 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:adp-ribosylation factor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2766. en:agonists --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2767. en:allografting --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:allografting | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2768. en:alum compounds --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:alum compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2769. en:ambergris --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ambergris | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2770. en:amidine-lyases --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:amidine-lyases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2771. en:aminoethylphosphonic acid --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:aminoethylphosphonic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2772. en:aminohippuric acid --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:aminohippuric acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2773. en:aminopyrine n-demethylase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:aminopyrine n-demethylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2774. en:analgesia, obstetrical --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:analgesia, obstetrical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2775. en:androstane-3,17-diol --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:androstane-3,17-diol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2776. en:angiocholegraphy --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:angiocholegraphy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2777. en:angiopoietin-1 receptor --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:angiopoietin-1 receptor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2778. en:angioscopes --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:angioscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2779. en:anti-obesity agents --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:anti-obesity agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2780. en:antibodies, archaeal --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:antibodies, archaeal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2781. en:antidepressive agents, second-generation --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:antidepressive agents, second-generation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2782. en:antifungal agent --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:antifungal agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2783. en:antilymphocyte serum --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:antilymphocyte serum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2784. en:antipain --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:antipain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2785. en:antiphospholipid antibody --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:antiphospholipid antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2786. en:antithrombin proteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:antithrombin proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2787. en:aphidicolin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:aphidicolin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2788. en:apolipoprotein e4 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:apolipoprotein e4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2789. en:argininosuccinic acid --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:argininosuccinic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2790. en:arthrogram --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:arthrogram | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2791. en:asbestos, serpentine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:asbestos, serpentine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2792. en:atp binding cassette transporter, sub-family g, member 8 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:atp binding cassette transporter, sub-family g, member 8 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2793. en:atropine derivatives --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:atropine derivatives | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2794. en:axonemal dyneins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:axonemal dyneins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2795. en:bcr/abl1 fusion protein --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:bcr/abl1 fusion protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2796. en:bed --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:bed | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2797. en:benzyl alcohols --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:benzyl alcohols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2798. en:beta-2-microglobulin protein --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:beta-2-microglobulin protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2799. en:beta-adrenergic antagonist --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:beta-adrenergic antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2800. en:beta-adrenergic receptor kinase 2 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:beta-adrenergic receptor kinase 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2801. en:bilobalides --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:bilobalides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2802. en:bioartificial organs --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:bioartificial organs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2803. en:bleaching agents --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:bleaching agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2804. en:bone morphogenetic protein 4 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:bone morphogenetic protein 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2805. en:bortezomib --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:bortezomib | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2806. en:busulfan --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:busulfan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2807. en:butirosin sulfate --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:butirosin sulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2808. en:ca19-9 antigen --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ca19-9 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2809. en:cadmium chloride --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cadmium chloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2810. en:calcium citrate --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:calcium citrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2811. en:cane, includes canes of all materials, adjustable or fixed, with tip --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cane, includes canes of all materials, adjustable or fixed, with tip | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2812. en:capecitabine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:capecitabine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2813. en:capillary tubing --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:capillary tubing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2814. en:capsule endoscope --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:capsule endoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2815. en:carcinoembryonic antigen --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:carcinoembryonic antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2816. en:cardiac myosins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cardiac myosins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2817. en:cardiac resynchronization therapy --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cardiac resynchronization therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2818. en:catgut --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:catgut | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2819. en:cations, monovalent --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cations, monovalent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2820. en:cdc28 protein kinase, s cerevisiae --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cdc28 protein kinase, s cerevisiae | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2821. en:celf1 protein --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:celf1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2822. en:chaperonin 10 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:chaperonin 10 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2823. en:chelating agent --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:chelating agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2824. en:chemokine cxcl2 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:chemokine cxcl2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2825. en:chemoradiotherapy, adjuvant --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:chemoradiotherapy, adjuvant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2826. en:chlorodiphenyl (54% chlorine) --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:chlorodiphenyl (54% chlorine) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2827. en:choline o-acetyltransferase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:choline o-acetyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2828. en:choline-phosphate cytidylyltransferase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:choline-phosphate cytidylyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2829. en:chondroitin lyases --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:chondroitin lyases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2830. en:collagen type vii --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:collagen type vii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2831. en:complement c3 convertase, classical pathway --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:complement c3 convertase, classical pathway | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2832. en:complement c3d --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:complement c3d | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2833. en:complement c5 convertase, alternative pathway --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:complement c5 convertase, alternative pathway | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2834. en:complete upper denture --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:complete upper denture | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2835. en:contactin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:contactin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2836. en:cosmetic --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cosmetic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2837. en:crown lengthening --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:crown lengthening | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2838. en:cyclic amp response element modulator --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cyclic amp response element modulator | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2839. en:cyclic imp --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cyclic imp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2840. en:cyclic p-oxides --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cyclic p-oxides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2841. en:cytochrome p-450 cyp1a2 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cytochrome p-450 cyp1a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2842. en:cytochrome p-450 cyp1a2 inducers --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cytochrome p-450 cyp1a2 inducers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2843. en:cytochromes a3 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:cytochromes a3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2844. en:delayed rectifier potassium channel --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:delayed rectifier potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2845. en:denture, partial, immediate --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:denture, partial, immediate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2846. en:deoxyribonuclease hpaii --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:deoxyribonuclease hpaii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2847. en:diamond --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:diamond | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2848. en:dibenzothiazepines --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dibenzothiazepines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2849. en:dietary phosphorus --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dietary phosphorus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2850. en:dimethoxyphenylethylamine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dimethoxyphenylethylamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2851. en:dimethylphenylpiperazinium iodide --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dimethylphenylpiperazinium iodide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2852. en:dimyristoyl lecithin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dimyristoyl lecithin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2853. en:dinitrogenase reductase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dinitrogenase reductase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2854. en:dioxanes --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dioxanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2855. en:dithioerythritol --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dithioerythritol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2856. en:dna restriction-modification enzymes --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dna restriction-modification enzymes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2857. en:dna, superhelical --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dna, superhelical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2858. en:dna-(apurinic or apyrimidinic site) lyase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:dna-(apurinic or apyrimidinic site) lyase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2859. en:drug eluting stent --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:drug eluting stent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2860. en:e2f1 transcription factor --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:e2f1 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2861. en:e2f7 transcription factor --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:e2f7 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2862. en:ectodysplasin a receptor --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ectodysplasin a receptor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2863. en:elav-like protein 2 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:elav-like protein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2864. en:eledoisin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:eledoisin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2865. en:ellipticines --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ellipticines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2866. en:endoscopes, gastrointestinal --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:endoscopes, gastrointestinal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2867. en:enhancer of zeste homolog 2 protein --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:enhancer of zeste homolog 2 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2868. en:env gene products, human immunodeficiency virus --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:env gene products, human immunodeficiency virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2869. en:ephrin type-b receptor 1 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ephrin type-b receptor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2870. en:ephrin-a3 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ephrin-a3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2871. en:estetrol --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:estetrol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2872. en:estrogen receptor antagonists --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:estrogen receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2873. en:extracorporeal photopheresis --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:extracorporeal photopheresis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2874. en:extraoral traction appliances --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:extraoral traction appliances | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2875. en:ezetimibe/simvastatin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ezetimibe/simvastatin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2876. en:fanconi anemia complementation group l protein --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:fanconi anemia complementation group l protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2877. en:fatty acid transport proteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:fatty acid transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2878. en:felypressin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:felypressin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2879. en:fertilins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:fertilins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2880. en:flavor excipient --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:flavor excipient | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2881. en:fluorodeoxyuridylate --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:fluorodeoxyuridylate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2882. en:formocresols --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:formocresols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2883. en:fractalkine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:fractalkine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2884. en:ga-binding protein transcription factor --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ga-binding protein transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2885. en:galanin-like peptide --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:galanin-like peptide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2886. en:gamma-glutamylcyclotransferase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:gamma-glutamylcyclotransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2887. en:gammagraphy --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:gammagraphy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2888. en:gentisates --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:gentisates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2889. en:ginkgolides --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ginkgolides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2890. en:glucid --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:glucid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2891. en:glycogen phosphorylase, brain form --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:glycogen phosphorylase, brain form | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2892. en:glycophorin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:glycophorin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2893. en:growth differentiation factor 2 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:growth differentiation factor 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2894. en:gtp pyrophosphokinase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:gtp pyrophosphokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2895. en:guaiac --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:guaiac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2896. en:guanine deaminase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:guanine deaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2897. en:guided tissue regeneration, periodontal --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:guided tissue regeneration, periodontal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2898. en:hazardous substances --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hazardous substances | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2899. en:heat shock protein 90 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:heat shock protein 90 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2900. en:hemoperfusion --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hemoperfusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2901. en:hepatitis A vaccine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hepatitis A vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2902. en:hepatitis a vaccine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hepatitis a vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2903. en:hepes --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hepes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2904. en:heptachlor epoxide --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:heptachlor epoxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2905. en:hexobendine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hexobendine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2906. en:hexosediphosphates --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hexosediphosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2907. en:heymann nephritis antigenic complex --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:heymann nephritis antigenic complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2908. en:high affinity nerve growth factor receptor --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:high affinity nerve growth factor receptor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2909. en:high mobility group protein hmg-y --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:high mobility group protein hmg-y | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2910. en:histamine agents --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:histamine agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2911. en:histidine kinase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:histidine kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2912. en:hla-b14 antigen --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hla-b14 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2913. en:hla-b18 antigen --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hla-b18 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2914. en:hla-b44 antigen --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hla-b44 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2915. en:hla-dp alpha-chains --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hla-dp alpha-chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2916. en:holothurin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:holothurin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2917. en:host-derived cellular factors --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:host-derived cellular factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2918. en:hsp30 heat-shock proteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hsp30 heat-shock proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2919. en:hydro-lyases --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hydro-lyases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2920. en:hygromycin b --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hygromycin b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2921. en:hypoxia-inducible factor-proline dioxygenases --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:hypoxia-inducible factor-proline dioxygenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2922. en:id2 protein --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:id2 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2923. en:ileostomy --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ileostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2924. en:immediate dental implant loading --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:immediate dental implant loading | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2925. en:immunoenzyme procedure --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:immunoenzyme procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2926. en:immunoglobulin fragments --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:immunoglobulin fragments | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2927. en:immunology test --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:immunology test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2928. en:intrapartum cardiotocography --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:intrapartum cardiotocography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2929. en:inward rectifier potassium channel --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:inward rectifier potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2930. en:iodopyridones --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:iodopyridones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2931. en:iron carbonyl compounds --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:iron carbonyl compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2932. en:jejunoileal bypass --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:jejunoileal bypass | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2933. en:jnk mitogen-activated protein kinases --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:jnk mitogen-activated protein kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2934. en:keratectomy, subepithelial, laser-assisted --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:keratectomy, subepithelial, laser-assisted | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2935. en:keratin, type i cytoskeletal 17 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:keratin, type i cytoskeletal 17 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2936. en:kv1.6 potassium channel --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:kv1.6 potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2937. en:lactase-phlorizin hydrolase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:lactase-phlorizin hydrolase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2938. en:laser lithotripsy --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:laser lithotripsy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2939. en:linagliptin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:linagliptin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2940. en:maf transcription factors, large --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:maf transcription factors, large | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2941. en:malaria vaccines --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:malaria vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2942. en:manipulation of spine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:manipulation of spine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2943. en:mechanical ventilator --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:mechanical ventilator | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2944. en:meclofenoxate --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:meclofenoxate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2945. en:medicine chests --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:medicine chests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2946. en:membrane-type 1 matrix metalloproteinase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:membrane-type 1 matrix metalloproteinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2947. en:menstruation-inducing agents --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:menstruation-inducing agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2948. en:mesterolone --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:mesterolone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2949. en:methacycline --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:methacycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2950. en:methyl n-butyl ketone --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:methyl n-butyl ketone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2951. en:methylhistidines --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:methylhistidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2952. en:methylthiouracil --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:methylthiouracil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2953. en:methyltyrosines --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:methyltyrosines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2954. en:mi-2 nucleosome remodeling and deacetylase complex --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:mi-2 nucleosome remodeling and deacetylase complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2955. en:microdialysis --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:microdialysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2956. en:minor lymphocyte stimulatory antigens --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:minor lymphocyte stimulatory antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2957. en:mustard compounds --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:mustard compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2958. en:mutant chimeric proteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:mutant chimeric proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2959. en:myeloid differentiation factor 88 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:myeloid differentiation factor 88 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2960. en:n-acetylhexosaminyltransferases --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:n-acetylhexosaminyltransferases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2961. en:n-chimaerin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:n-chimaerin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2962. en:n-substituted glycines --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:n-substituted glycines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2963. en:nacre --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nacre | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2964. en:nadh tetrazolium reductase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nadh tetrazolium reductase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2965. en:naphthaleneacetic acids --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:naphthaleneacetic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2966. en:naphthylvinylpyridine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:naphthylvinylpyridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2967. en:nebramycin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nebramycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2968. en:neuromuscular nondepolarizing agents --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:neuromuscular nondepolarizing agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2969. en:neuroprostanes --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:neuroprostanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2970. en:neurosurgical procedure --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:neurosurgical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2971. en:nima-interacting peptidylprolyl isomerase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nima-interacting peptidylprolyl isomerase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2972. en:nitric oxide synthetase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nitric oxide synthetase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2973. en:norandrostanes --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:norandrostanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2974. en:nordefrin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nordefrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2975. en:norepinephrine, dl- --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:norepinephrine, dl- | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2976. en:nucleobase, nucleoside, nucleotide, and nucleic acid transport proteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nucleobase, nucleoside, nucleotide, and nucleic acid transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2977. en:nucleoplasmins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nucleoplasmins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2978. en:nutrition, cholesterol --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nutrition, cholesterol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2979. en:nutritional therapy --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:nutritional therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2980. en:octanols --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:octanols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2981. en:oncogene protein v-akt --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:oncogene protein v-akt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2982. en:oncogene protein v-crk --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:oncogene protein v-crk | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2983. en:oncostatin-m --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:oncostatin-m | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2984. en:ophthalmodynamometry --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ophthalmodynamometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2985. en:orexins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:orexins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2986. en:organic anion transport protein 1 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:organic anion transport protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2987. en:orthodontic appliances --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:orthodontic appliances | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2988. en:orthotic devices --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:orthotic devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2989. en:ovarian function tests --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ovarian function tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2990. en:oxazocines --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:oxazocines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2991. en:oxazolone --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:oxazolone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2992. en:oxyntomodulin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:oxyntomodulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2993. en:pain assessment --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:pain assessment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2994. en:palatal obturators --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:palatal obturators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2995. en:parasympatholytics --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:parasympatholytics | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2996. en:parathyroid hormone-related protein --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:parathyroid hormone-related protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2997. en:pentacyclic triterpenes --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:pentacyclic triterpenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2998. en:pentoxyl --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:pentoxyl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  2999. en:percutaneous transluminal coronary angioplasty --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:percutaneous transluminal coronary angioplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3000. en:period circadian proteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:period circadian proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3001. en:permanent dental restoration --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:permanent dental restoration | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3002. en:phosphotransferases (nitrogenous group acceptor) --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:phosphotransferases (nitrogenous group acceptor) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3003. en:picloram --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:picloram | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3004. en:pimelic acids --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:pimelic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3005. en:plethysmography, whole body --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:plethysmography, whole body | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3006. en:poly(adp-ribose) polymerases --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:poly(adp-ribose) polymerases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3007. en:polyisoprenyl phosphate oligosaccharides --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:polyisoprenyl phosphate oligosaccharides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3008. en:posterior cruciate ligament reconstruction --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:posterior cruciate ligament reconstruction | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3009. en:potassium channels, tandem pore domain --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:potassium channels, tandem pore domain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3010. en:pregnancy-specific beta 1-glycoproteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:pregnancy-specific beta 1-glycoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3011. en:prescription glasses --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:prescription glasses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3012. en:procaterol --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:procaterol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3013. en:promethium --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:promethium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3014. en:prostaglandins a --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:prostaglandins a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3015. en:proteasome inhibitor --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:proteasome inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3016. en:protein tyrosine phosphatase, non-receptor type 1 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:protein tyrosine phosphatase, non-receptor type 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3017. en:protein tyrosine phosphatase, non-receptor type 12 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:protein tyrosine phosphatase, non-receptor type 12 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3018. en:protein tyrosine phosphatase, non-receptor type 6 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:protein tyrosine phosphatase, non-receptor type 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3019. en:proto-oncogene proteins b-raf --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:proto-oncogene proteins b-raf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3020. en:protochlorophyllide --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:protochlorophyllide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3021. en:proton ionophores --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:proton ionophores | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3022. en:psychosine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:psychosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3023. en:purinergic p2 receptor agonists --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:purinergic p2 receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3024. en:q beta replicase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:q beta replicase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3025. en:quillaja saponins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:quillaja saponins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3026. en:receptor-interacting protein serine-threonine kinases --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:receptor-interacting protein serine-threonine kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3027. en:retinoblastoma-binding protein 7 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:retinoblastoma-binding protein 7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3028. en:retinoic acid receptor rxr-alpha --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:retinoic acid receptor rxr-alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3029. en:rhodopsins, microbial --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:rhodopsins, microbial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3030. en:rna, ribosomal, 5.8s --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:rna, ribosomal, 5.8s | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3031. en:ronidazole --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:ronidazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3032. en:root canal preparation --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:root canal preparation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3033. en:root planing --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:root planing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3034. en:rubidium radioisotopes --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:rubidium radioisotopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3035. en:selenious acid --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:selenious acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3036. en:serrate-jagged proteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:serrate-jagged proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3037. en:serum amyloid p-component --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:serum amyloid p-component | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3038. en:short-chain specific acyl-coa dehydrogenase, mitochondrial --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:short-chain specific acyl-coa dehydrogenase, mitochondrial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3039. en:sigmoidoscope --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:sigmoidoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3040. en:sitagliptin phosphate, metformin hydrochloride drug combination --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:sitagliptin phosphate, metformin hydrochloride drug combination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3041. en:skin patch dosage form --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:skin patch dosage form | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3042. en:smooth muscle myosins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:smooth muscle myosins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3043. en:sodium-glucose transporter 1 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:sodium-glucose transporter 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3044. en:sodium-glucose transporter 2 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:sodium-glucose transporter 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3045. en:solute carrier family 12, member 1 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:solute carrier family 12, member 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3046. en:soxd transcription factors --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:soxd transcription factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3047. en:sp2 transcription factor --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:sp2 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3048. en:space simulation --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:space simulation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3049. en:speech discrimination tests --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:speech discrimination tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3050. en:sphygmomanometer --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:sphygmomanometer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3051. en:stereotaxic techniques --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:stereotaxic techniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3052. en:sterilization, involuntary --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:sterilization, involuntary | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3053. en:steroids, fluorinated --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:steroids, fluorinated | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3054. en:stoma --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:stoma | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3055. en:strophanthidin --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:strophanthidin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3056. en:subcutaneous infusions --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:subcutaneous infusions | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3057. en:sugar phosphates --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:sugar phosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3058. en:suppressor factors, immunologic --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:suppressor factors, immunologic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3059. en:suppressor of cytokine signaling 3 protein --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:suppressor of cytokine signaling 3 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3060. en:swan-ganz catheterization --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:swan-ganz catheterization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3061. en:sympathectomy, chemical --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:sympathectomy, chemical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3062. en:telemetring --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:telemetring | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3063. en:tetranitromethane --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:tetranitromethane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3064. en:tfiid --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:tfiid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3065. en:therapy, soft tissue --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:therapy, soft tissue | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3066. en:thioredoxin h --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:thioredoxin h | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3067. en:thiouridine --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:thiouridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3068. en:thoracoscope --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:thoracoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3069. en:threonine/tyrosine protein kinase --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:threonine/tyrosine protein kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3070. en:tissue conditioning (dental) --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:tissue conditioning (dental) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3071. en:tnf receptor-associated factor 1 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:tnf receptor-associated factor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3072. en:tnf receptor-associated factor 5 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:tnf receptor-associated factor 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3073. en:tosylphenylalanyl chloromethyl ketone --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:tosylphenylalanyl chloromethyl ketone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3074. en:transcription factor 7-like 1 protein --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:transcription factor 7-like 1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3075. en:transcription factor brn-3c --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:transcription factor brn-3c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3076. en:transcription factor mafk --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:transcription factor mafk | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3077. en:tumor necrosis factor ligand superfamily member 6 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:tumor necrosis factor ligand superfamily member 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3078. en:twist transcription factor --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:twist transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3079. en:two-hybrid system techniques --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:two-hybrid system techniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3080. en:uranyl nitrate --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:uranyl nitrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3081. en:uroplakin ia --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:uroplakin ia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3082. en:vacuum aspiration --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:vacuum aspiration | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3083. en:vascular endothelial growth factor receptor-1 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:vascular endothelial growth factor receptor-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3084. en:vesicular glutamate transport protein 2 --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:vesicular glutamate transport protein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3085. en:viral core proteins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:viral core proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3086. en:zeta-globins --- r_associated #0: 34 --> en:contraindications aspect
    n1=en:zeta-globins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3087. hémoperfusion --- r_associated #0: 34 --> en:contraindications aspect
    n1=hémoperfusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3088. interleukine 4 --- r_associated #0: 34 --> en:contraindications aspect
    n1=interleukine 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3089. mycotoxines --- r_associated #0: 34 --> en:contraindications aspect
    n1=mycotoxines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3090. ocytocine --- r_associated #0: 34 --> en:contraindications aspect
    n1=ocytocine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3091. oxyntomoduline --- r_associated #0: 34 --> en:contraindications aspect
    n1=oxyntomoduline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3092. particules --- r_associated #0: 34 --> en:contraindications aspect
    n1=particules | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3093. procédure de Fontan --- r_associated #0: 34 --> en:contraindications aspect
    n1=procédure de Fontan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3094. psychosine --- r_associated #0: 34 --> en:contraindications aspect
    n1=psychosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3095. vaccin contre l'hépatite A --- r_associated #0: 34 --> en:contraindications aspect
    n1=vaccin contre l'hépatite A | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3096. vaccin contre l'hépatite a --- r_associated #0: 34 --> en:contraindications aspect
    n1=vaccin contre l'hépatite a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=34
  3097. en:anti-immune body --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:anti-immune body | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3098. en:antigen --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3099. en:dopa decarboxylase --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:dopa decarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3100. en:extracorporeal life support --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:extracorporeal life support | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3101. en:intra uterine device --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:intra uterine device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3102. en:isodesmosin --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:isodesmosin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3103. en:low density lipoprotein --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:low density lipoprotein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3104. en:lye --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:lye | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3105. en:particulate matter --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:particulate matter | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3106. en:phenylpyruvic acids --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:phenylpyruvic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3107. en:ultrasonic cardiography --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:ultrasonic cardiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3108. en:whole blood coagulation time --- r_associated #0: 33 --> en:contraindications aspect
    n1=en:whole blood coagulation time | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3109. hormone gonadotrope ménopausique humaine --- r_associated #0: 33 --> en:contraindications aspect
    n1=hormone gonadotrope ménopausique humaine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3110. immunotoxine --- r_associated #0: 33 --> en:contraindications aspect
    n1=immunotoxine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3111. inhibiteurs de l'aromatase --- r_associated #0: 33 --> en:contraindications aspect
    n1=inhibiteurs de l'aromatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3112. maintien prothétique --- r_associated #0: 33 --> en:contraindications aspect
    n1=maintien prothétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3113. matériel contraceptif --- r_associated #0: 33 --> en:contraindications aspect
    n1=matériel contraceptif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3114. parabiose --- r_associated #0: 33 --> en:contraindications aspect
    n1=parabiose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3115. tomodensitométrie vertébrale --- r_associated #0: 33 --> en:contraindications aspect
    n1=tomodensitométrie vertébrale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3116. veinographie --- r_associated #0: 33 --> en:contraindications aspect
    n1=veinographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=33
  3117. Glutamate monosodique --- r_associated #0: 32 --> en:contraindications aspect
    n1=Glutamate monosodique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3118. abatacept --- r_associated #0: 32 --> en:contraindications aspect
    n1=abatacept | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3119. acide abscissique --- r_associated #0: 32 --> en:contraindications aspect
    n1=acide abscissique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3120. acide kainique --- r_associated #0: 32 --> en:contraindications aspect
    n1=acide kainique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3121. angiogramme --- r_associated #0: 32 --> en:contraindications aspect
    n1=angiogramme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3122. apoprotéines --- r_associated #0: 32 --> en:contraindications aspect
    n1=apoprotéines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3123. arylsulfatases --- r_associated #0: 32 --> en:contraindications aspect
    n1=arylsulfatases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3124. cervicectomie --- r_associated #0: 32 --> en:contraindications aspect
    n1=cervicectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3125. diamanté --- r_associated #0: 32 --> en:contraindications aspect
    n1=diamanté | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3126. dolichol monophosphate mannose --- r_associated #0: 32 --> en:contraindications aspect
    n1=dolichol monophosphate mannose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3127. en diamant --- r_associated #0: 32 --> en:contraindications aspect
    n1=en diamant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3128. en:1-propanol --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:1-propanol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3129. en:19-iodocholesterol --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:19-iodocholesterol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3130. en:2,4,5-trichlorophenoxyacetic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:2,4,5-trichlorophenoxyacetic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3131. en:2,4-dichlorophenoxyacetic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:2,4-dichlorophenoxyacetic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3132. en:2,4-dinitrophenol --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:2,4-dinitrophenol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3133. en:2-hydroxy-5-nitrobenzyl bromide --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:2-hydroxy-5-nitrobenzyl bromide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3134. en:2-hydroxypropanoic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:2-hydroxypropanoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3135. en:3-hydroxyacyl coa dehydrogenases --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:3-hydroxyacyl coa dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3136. en:3-mercaptopropionic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:3-mercaptopropionic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3137. en:5'-nucléotidase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:5'-nucléotidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3138. en:IVF --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:IVF | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3139. en:abatacept --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:abatacept | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3140. en:abiraterone acetate --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:abiraterone acetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3141. en:abscisic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:abscisic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3142. en:absorbable implants --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:absorbable implants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3143. en:acetic anhydrides --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:acetic anhydrides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3144. en:actinoscopy --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:actinoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3145. en:adenosine a1 receptor antagonists --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:adenosine a1 receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3146. en:advanced cardiac life support --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:advanced cardiac life support | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3147. en:agmatine --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:agmatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3148. en:alpha karyopherins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:alpha karyopherins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3149. en:alpha-amanitin --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:alpha-amanitin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3150. en:alpha-cyclodextrins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:alpha-cyclodextrins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3151. en:amino acid transport system a --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:amino acid transport system a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3152. en:amino acids, dicarboxylic --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:amino acids, dicarboxylic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3153. en:aminooxyacetic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:aminooxyacetic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3154. en:aminosalicylic acids --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:aminosalicylic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3155. en:angiocholecystography --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:angiocholecystography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3156. en:aniline mustard --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:aniline mustard | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3157. en:anti-retroviral agents --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:anti-retroviral agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3158. en:antihypertensive agent --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:antihypertensive agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3159. en:antineutrophil cytoplasmic antibody --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:antineutrophil cytoplasmic antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3160. en:antinuclear antibody --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:antinuclear antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3161. en:antitetanic serum --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:antitetanic serum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3162. en:antithyroid agent --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:antithyroid agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3163. en:apoproteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:apoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3164. en:arabinofuranosyluracil --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:arabinofuranosyluracil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3165. en:arecoline --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:arecoline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3166. en:arsenazo iii --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:arsenazo iii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3167. en:arsenite transporting atpases --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:arsenite transporting atpases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3168. en:arylsulfatases --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:arylsulfatases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3169. en:ataxin-3 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:ataxin-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3170. en:atorvastatin calcium --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:atorvastatin calcium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3171. en:atp-citrate synthase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:atp-citrate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3172. en:b-dna --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:b-dna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3173. en:baculoviral iap repeat-containing protein 1 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:baculoviral iap repeat-containing protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3174. en:barium radioisotopes --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:barium radioisotopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3175. en:beta-hexosaminidase beta chain --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:beta-hexosaminidase beta chain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3176. en:beta-lipotropin --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:beta-lipotropin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3177. en:beta-n-acetyl-galactosaminidase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:beta-n-acetyl-galactosaminidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3178. en:blood coagulation factor inhibitors --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:blood coagulation factor inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3179. en:blood grouping and crossmatching --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:blood grouping and crossmatching | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3180. en:brain-computer interfaces --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:brain-computer interfaces | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3181. en:brocresine --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:brocresine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3182. en:bucrylate --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:bucrylate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3183. en:bungarotoxins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:bungarotoxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3184. en:calmodulin-dependent protein kinase ii --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:calmodulin-dependent protein kinase ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3185. en:calnexin --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:calnexin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3186. en:casein kinase idelta --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:casein kinase idelta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3187. en:catheterization, peripheral --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:catheterization, peripheral | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3188. en:cathode ray tubes --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cathode ray tubes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3189. en:ccaat-enhancer-binding protein-delta --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:ccaat-enhancer-binding protein-delta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3190. en:cdx2 transcription factor --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cdx2 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3191. en:cecropins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cecropins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3192. en:cell surface antigen --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cell surface antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3193. en:cerebrospinal fluid shunts procedure --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cerebrospinal fluid shunts procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3194. en:cervicectomy --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cervicectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3195. en:cgmp phosphodiesterase inhibitor --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cgmp phosphodiesterase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3196. en:chlormadinone acetate --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:chlormadinone acetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3197. en:chlorophyll binding proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:chlorophyll binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3198. en:chloroplast thioredoxins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:chloroplast thioredoxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3199. en:chloroquinolinols --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:chloroquinolinols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3200. en:cholestanones --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cholestanones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3201. en:cholinergic antagonists --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cholinergic antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3202. en:collagen type xviii --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:collagen type xviii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3203. en:complement c3a --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:complement c3a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3204. en:complement component c1 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:complement component c1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3205. en:complement component c8 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:complement component c8 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3206. en:complement factor h, human --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:complement factor h, human | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3207. en:consciousness monitors --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:consciousness monitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3208. en:contact lens solutions --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:contact lens solutions | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3209. en:contact lenses, extended-wear --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:contact lenses, extended-wear | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3210. en:contraceptive devices, male --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:contraceptive devices, male | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3211. en:convulsants --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:convulsants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3212. en:copper-containing intrauterine device [epc] --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:copper-containing intrauterine device [epc] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3213. en:core binding factor alpha subunits --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:core binding factor alpha subunits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3214. en:corneal pachymetry --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:corneal pachymetry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3215. en:crape bandage --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:crape bandage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3216. en:cross-linking reagents --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cross-linking reagents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3217. en:cyclin d2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cyclin d2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3218. en:cytidine diphosphate diglycerides --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cytidine diphosphate diglycerides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3219. en:cytochrome p450 11b2, mitochondrial --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cytochrome p450 11b2, mitochondrial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3220. en:cytochromes c6 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:cytochromes c6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3221. en:d-alanine transaminase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:d-alanine transaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3222. en:deafferentation --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:deafferentation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3223. en:dental implant --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dental implant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3224. en:dental implant-abutment design --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dental implant-abutment design | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3225. en:dental veneer application --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dental veneer application | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3226. en:denture identification marking --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:denture identification marking | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3227. en:deoxycholic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:deoxycholic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3228. en:deoxyepinephrine --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:deoxyepinephrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3229. en:deoxyribonuclease iv (phage t4-induced) --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:deoxyribonuclease iv (phage t4-induced) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3230. en:desmocollins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:desmocollins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3231. en:desoxycorticosterone acetate --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:desoxycorticosterone acetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3232. en:diaminopimelic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:diaminopimelic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3233. en:dimethyl suberimidate --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dimethyl suberimidate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3234. en:dioxin compound --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dioxin compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3235. en:disulfides --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:disulfides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3236. en:dna (cytosine-5-)-methyltransferase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dna (cytosine-5-)-methyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3237. en:dna, kinetoplast --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dna, kinetoplast | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3238. en:dna-directed rna polymerase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dna-directed rna polymerase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3239. en:dolichol monophosphate mannose --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dolichol monophosphate mannose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3240. en:drug residues --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:drug residues | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3241. en:dutasteride --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:dutasteride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3242. en:e-z scrub --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:e-z scrub | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3243. en:e2f5 transcription factor --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:e2f5 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3244. en:ecdysteroids --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:ecdysteroids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3245. en:echocardiography, four-dimensional --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:echocardiography, four-dimensional | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3246. en:ectodysplasin a protein --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:ectodysplasin a protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3247. en:edar-associated death domain protein --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:edar-associated death domain protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3248. en:eif2b --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:eif2b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3249. en:electroconvulsive shock --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:electroconvulsive shock | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3250. en:electron transport chain complex proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:electron transport chain complex proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3251. en:emergency medical tags --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:emergency medical tags | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3252. en:emtricitabine, rilpivirine, tenofovir drug combination --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:emtricitabine, rilpivirine, tenofovir drug combination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3253. en:enamel microabrasion --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:enamel microabrasion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3254. en:enprostil --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:enprostil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3255. en:equilibrative nucleoside transporter 2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:equilibrative nucleoside transporter 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3256. en:estranes --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:estranes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3257. en:excitatory amino acid transporter 1 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:excitatory amino acid transporter 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3258. en:fatty acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:fatty acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3259. en:fatty acid-binding protein 7 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:fatty acid-binding protein 7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3260. en:fetuin-b --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:fetuin-b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3261. en:fibrinogens, abnormal --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:fibrinogens, abnormal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3262. en:fragile x mental retardation protein 1 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:fragile x mental retardation protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3263. en:furylfuramide --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:furylfuramide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3264. en:fusaric acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:fusaric acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3265. en:fusion proteins, gag-onc --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:fusion proteins, gag-onc | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3266. en:gaba-a receptor agonists --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:gaba-a receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3267. en:gaba-b receptor agonists --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:gaba-b receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3268. en:galactose dehydrogenases --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:galactose dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3269. en:gamma-lipotropin --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:gamma-lipotropin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3270. en:gene products, rex --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:gene products, rex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3271. en:gene products, vif --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:gene products, vif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3272. en:genetic complementation test --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:genetic complementation test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3273. en:glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3274. en:glycoside hydrolase inhibitors --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:glycoside hydrolase inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3275. en:glyoxylates --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:glyoxylates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3276. en:glypican --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:glypican | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3277. en:gold compounds --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:gold compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3278. en:gold isotopes --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:gold isotopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3279. en:group ii phospholipases a2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:group ii phospholipases a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3280. en:group iii phospholipases a2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:group iii phospholipases a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3281. en:group v phospholipases a2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:group v phospholipases a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3282. en:growth differentiation factor 1 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:growth differentiation factor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3283. en:growth differentiation factor 6 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:growth differentiation factor 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3284. en:gtp-binding protein alpha subunits, gq-g11 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:gtp-binding protein alpha subunits, gq-g11 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3285. en:guanylthiourea --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:guanylthiourea | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3286. en:heat shock protein 70 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:heat shock protein 70 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3287. en:hemagglutination inhibition assay --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hemagglutination inhibition assay | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3288. en:heparan sulfate proteoglycan --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:heparan sulfate proteoglycan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3289. en:heterotrimeric g protein --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:heterotrimeric g protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3290. en:hexosyltransferase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hexosyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3291. en:high-frequency jet ventilation --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:high-frequency jet ventilation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3292. en:histamine-2 receptor antagonist --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:histamine-2 receptor antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3293. en:hla class i histocompatibility antigen, a-24 alpha chain --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hla class i histocompatibility antigen, a-24 alpha chain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3294. en:hla-b13 antigen --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hla-b13 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3295. en:hla-b35 antigen --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hla-b35 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3296. en:hla-dq alpha-chains --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hla-dq alpha-chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3297. en:hla-dr6 antigen --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hla-dr6 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3298. en:hmgb family protein --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hmgb family protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3299. en:hsp110 heat-shock proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hsp110 heat-shock proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3300. en:hsp20 heat-shock proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:hsp20 heat-shock proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3301. en:immunosorbents --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:immunosorbents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3302. en:incubators, infant --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:incubators, infant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3303. en:inosine monophosphate dehydrogenase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:inosine monophosphate dehydrogenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3304. en:insecticide-treated bednets --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:insecticide-treated bednets | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3305. en:insulin-like growth factor-binding protein 5 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:insulin-like growth factor-binding protein 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3306. en:interleukin-23 subunit p19 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:interleukin-23 subunit p19 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3307. en:intervertebral disc chemolysis --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:intervertebral disc chemolysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3308. en:iodocyanopindolol --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:iodocyanopindolol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3309. en:isocoumarins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:isocoumarins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3310. en:juvenile hormones --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:juvenile hormones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3311. en:kainic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:kainic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3312. en:kcnq3 potassium channel --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:kcnq3 potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3313. en:keratin, type i cytoskeletal 19 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:keratin, type i cytoskeletal 19 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3314. en:keratin, type ii cytoskeletal 7 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:keratin, type ii cytoskeletal 7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3315. en:keratin-2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:keratin-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3316. en:kinetin --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:kinetin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3317. en:kininogens --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:kininogens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3318. en:lacryglobin --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:lacryglobin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3319. en:lactate dehydrogenases --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:lactate dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3320. en:lamin b --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:lamin b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3321. en:latent tgf-beta binding proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:latent tgf-beta binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3322. en:levopropoxyphene --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:levopropoxyphene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3323. en:light-curing of dental adhesives --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:light-curing of dental adhesives | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3324. en:lipocalin-2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:lipocalin-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3325. en:menstrual hygiene products --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:menstrual hygiene products | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3326. en:merozoite surface protein 1 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:merozoite surface protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3327. en:metallochaperones --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:metallochaperones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3328. en:methoxydimethyltryptamines --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:methoxydimethyltryptamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3329. en:microbubbles --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:microbubbles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3330. en:middle ear ventilation --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:middle ear ventilation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3331. en:mri-based angiogram --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:mri-based angiogram | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3332. en:mucin-2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:mucin-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3333. en:mucin-6 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:mucin-6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3334. en:n,n-dimethylformamide --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:n,n-dimethylformamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3335. en:n-nitrosopyrrolidine --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:n-nitrosopyrrolidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3336. en:neoplasm grading --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:neoplasm grading | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3337. en:neurokinin a --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:neurokinin a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3338. en:neuromuscular blocking agents --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:neuromuscular blocking agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3339. en:neuronal tract-tracers --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:neuronal tract-tracers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3340. en:nicotinyl alcohol --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:nicotinyl alcohol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3341. en:nitracrine --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:nitracrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3342. en:nitroquinolines --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:nitroquinolines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3343. en:norethandrolone --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:norethandrolone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3344. en:norpregnatrienes --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:norpregnatrienes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3345. en:nuclear cap-binding protein complex --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:nuclear cap-binding protein complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3346. en:nuclear factor erythroid 2-related factor 2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:nuclear factor erythroid 2-related factor 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3347. en:nucleoside diphosphate kinase d --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:nucleoside diphosphate kinase d | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3348. en:nucleosome assembly protein 1 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:nucleosome assembly protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3349. en:ophthalmic solution --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:ophthalmic solution | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3350. en:oral surgery --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:oral surgery | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3351. en:oxamic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:oxamic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3352. en:oxotremorine --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:oxotremorine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3353. en:oxyclozanide --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:oxyclozanide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3354. en:oxygenators, membrane --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:oxygenators, membrane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3355. en:oxyphenisatin acetate --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:oxyphenisatin acetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3356. en:parabiosis --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:parabiosis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3357. en:parachloroamphetamine --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:parachloroamphetamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3358. en:peanut agglutinin --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:peanut agglutinin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3359. en:pentetic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:pentetic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3360. en:peridural injection --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:peridural injection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3361. en:phakic intraocular lenses --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:phakic intraocular lenses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3362. en:pharmacokinetic aspects --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:pharmacokinetic aspects | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3363. en:phenoxyacetates --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:phenoxyacetates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3364. en:phenylmethylsulfonyl fluoride --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:phenylmethylsulfonyl fluoride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3365. en:phex phosphate regulating neutral endopeptidase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:phex phosphate regulating neutral endopeptidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3366. en:phleomycins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:phleomycins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3367. en:phosphoinositide phosphatases --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:phosphoinositide phosphatases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3368. en:phospholipase a2 enzyme family --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:phospholipase a2 enzyme family | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3369. en:phytochelatins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:phytochelatins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3370. en:picoline compound --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:picoline compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3371. en:picolinic acids --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:picolinic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3372. en:piezosurgery --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:piezosurgery | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3373. en:platelet glycoprotein gpib-ix complex --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:platelet glycoprotein gpib-ix complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3374. en:polydioxanone --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:polydioxanone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3375. en:polyglactin 910 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:polyglactin 910 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3376. en:prajmaline --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:prajmaline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3377. en:prenalterol --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:prenalterol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3378. en:primary care nursing --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:primary care nursing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3379. en:prostaglandin h2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:prostaglandin h2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3380. en:prosthesis retention --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:prosthesis retention | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3381. en:protein tyrosine phosphatase, non-receptor type 3 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:protein tyrosine phosphatase, non-receptor type 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3382. en:proto-oncogene proteins c-pim-1 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:proto-oncogene proteins c-pim-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3383. en:pulse radiolysis --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:pulse radiolysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3384. en:purine nucleotides --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:purine nucleotides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3385. en:purinergic p2x receptor agonists --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:purinergic p2x receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3386. en:purinergic p2y receptor antagonists --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:purinergic p2y receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3387. en:pyrvinium compounds --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:pyrvinium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3388. en:quinolinic acids --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:quinolinic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3389. en:rab5 gtp-binding proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:rab5 gtp-binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3390. en:rap gtp-binding proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:rap gtp-binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3391. en:rap guanine nucleotide exchange factor 1 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:rap guanine nucleotide exchange factor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3392. en:reagent strips --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:reagent strips | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3393. en:receptor-like protein tyrosine phosphatases, class 2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:receptor-like protein tyrosine phosphatases, class 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3394. en:retinoic acid receptor rxr-beta --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:retinoic acid receptor rxr-beta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3395. en:retinoic acid receptor rxr-gamma --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:retinoic acid receptor rxr-gamma | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3396. en:rev gene products, human immunodeficiency virus --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:rev gene products, human immunodeficiency virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3397. en:reverse transcriptase inhibitor --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:reverse transcriptase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3398. en:rna precursors --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:rna precursors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3399. en:rna, chloroplast --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:rna, chloroplast | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3400. en:root canal irrigants --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:root canal irrigants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3401. en:secretory phospholipase a2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:secretory phospholipase a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3402. en:selenium compound --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:selenium compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3403. en:semiconductors --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:semiconductors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3404. en:sequestosome-1 protein --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:sequestosome-1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3405. en:serotonin 5-ht4 receptor agonists --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:serotonin 5-ht4 receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3406. en:shaker superfamily of potassium channels --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:shaker superfamily of potassium channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3407. en:shoulder prostheses (device) --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:shoulder prostheses (device) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3408. en:sialic acids --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:sialic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3409. en:signal transducer and activator of transcription 3 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:signal transducer and activator of transcription 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3410. en:smad8 protein --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:smad8 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3411. en:sodium radioisotopes --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:sodium radioisotopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3412. en:soxb2 transcription factors --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:soxb2 transcription factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3413. en:sparsomycin --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:sparsomycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3414. en:sphincterotomy, transhepatic --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:sphincterotomy, transhepatic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3415. en:spike glycoprotein, coronavirus --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:spike glycoprotein, coronavirus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3416. en:spinal fusion (procedure) --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:spinal fusion (procedure) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3417. en:stat1 protein --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:stat1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3418. en:stat5 transcription factor --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:stat5 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3419. en:steroid compound --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:steroid compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3420. en:succinic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:succinic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3421. en:sugar acids --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:sugar acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3422. en:sulfonylurea compounds --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:sulfonylurea compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3423. en:suloctidil --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:suloctidil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3424. en:sydnones --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:sydnones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3425. en:telomeric repeat binding protein 2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:telomeric repeat binding protein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3426. en:thiadiazines --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:thiadiazines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3427. en:thioredoxins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:thioredoxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3428. en:thromboxane b2 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:thromboxane b2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3429. en:tolloid-like metalloproteinases --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:tolloid-like metalloproteinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3430. en:tooth preparation, prosthodontic --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:tooth preparation, prosthodontic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3431. en:tooth, artificial --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:tooth, artificial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3432. en:topoisomerase inhibitor --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:topoisomerase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3433. en:trace element --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:trace element | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3434. en:trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3435. en:transcription factor e2f3 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:transcription factor e2f3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3436. en:transcription factor gata-4 --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:transcription factor gata-4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3437. en:transforming protein rhoa --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:transforming protein rhoa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3438. en:tricarboxylic acids --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:tricarboxylic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3439. en:triethylenephosphoramide --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:triethylenephosphoramide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3440. en:triiodobenzoic acids --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:triiodobenzoic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3441. en:trpm cation channels --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:trpm cation channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3442. en:tryptophan synthase --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:tryptophan synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3443. en:ubiquitin-activating enzymes --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:ubiquitin-activating enzymes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3444. en:ultrasonography, doppler, duplex --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:ultrasonography, doppler, duplex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3445. en:uridine diphosphate n-acetylgalactosamine --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:uridine diphosphate n-acetylgalactosamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3446. en:urocanic acid --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:urocanic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3447. en:uterine balloon tamponade --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:uterine balloon tamponade | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3448. en:uteroglobin --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:uteroglobin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3449. en:vesicular glutamate transport proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:vesicular glutamate transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3450. en:vesicular inhibitory amino acid transport proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:vesicular inhibitory amino acid transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3451. en:vesicular neurotransmitter transport proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:vesicular neurotransmitter transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3452. en:viral tail proteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:viral tail proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3453. en:visual field study --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:visual field study | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3454. en:withanolides --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:withanolides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3455. en:wnt3a protein --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:wnt3a protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3456. en:x-linked inhibitor of apoptosis protein --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:x-linked inhibitor of apoptosis protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3457. en:x-ray microtomography --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:x-ray microtomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3458. en:zona pellucida glycoproteins --- r_associated #0: 32 --> en:contraindications aspect
    n1=en:zona pellucida glycoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3459. extraits placentaires --- r_associated #0: 32 --> en:contraindications aspect
    n1=extraits placentaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3460. facteur de croissance analogue à l'insuline --- r_associated #0: 32 --> en:contraindications aspect
    n1=facteur de croissance analogue à l'insuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3461. fécondation in vitro --- r_associated #0: 32 --> en:contraindications aspect
    n1=fécondation in vitro | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3462. guanosine-diphosphate-fucose --- r_associated #0: 32 --> en:contraindications aspect
    n1=guanosine-diphosphate-fucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3463. hepcidine --- r_associated #0: 32 --> en:contraindications aspect
    n1=hepcidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3464. nicotinamide --- r_associated #0: 32 --> en:contraindications aspect
    n1=nicotinamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3465. opération de chirurgie --- r_associated #0: 32 --> en:contraindications aspect
    n1=opération de chirurgie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3466. saccarose --- r_associated #0: 32 --> en:contraindications aspect
    n1=saccarose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3467. soins d'urgence --- r_associated #0: 32 --> en:contraindications aspect
    n1=soins d'urgence | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3468. talquer quelque chose --- r_associated #0: 32 --> en:contraindications aspect
    n1=talquer quelque chose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3469. trachéostomie --- r_associated #0: 32 --> en:contraindications aspect
    n1=trachéostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=32
  3470. ARN ribosomal --- r_associated #0: 31 --> en:contraindications aspect
    n1=ARN ribosomal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3471. Ac --- r_associated #0: 31 --> en:contraindications aspect
    n1=Ac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3472. Teflon --- r_associated #0: 31 --> en:contraindications aspect
    n1=Teflon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3473. Tomodensitométrie --- r_associated #0: 31 --> en:contraindications aspect
    n1=Tomodensitométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3474. acide tranéxamique --- r_associated #0: 31 --> en:contraindications aspect
    n1=acide tranéxamique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3475. acides muramiques --- r_associated #0: 31 --> en:contraindications aspect
    n1=acides muramiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3476. agonistes myelo-ablatifs --- r_associated #0: 31 --> en:contraindications aspect
    n1=agonistes myelo-ablatifs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3477. alanine racémase --- r_associated #0: 31 --> en:contraindications aspect
    n1=alanine racémase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3478. arn ribosomal --- r_associated #0: 31 --> en:contraindications aspect
    n1=arn ribosomal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3479. composés d'ammonium quaternaire --- r_associated #0: 31 --> en:contraindications aspect
    n1=composés d'ammonium quaternaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3480. couches pour adulte incontinent --- r_associated #0: 31 --> en:contraindications aspect
    n1=couches pour adulte incontinent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3481. couches pour incontinents --- r_associated #0: 31 --> en:contraindications aspect
    n1=couches pour incontinents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3482. cryoanesthésie --- r_associated #0: 31 --> en:contraindications aspect
    n1=cryoanesthésie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3483. cyclophosphamide --- r_associated #0: 31 --> en:contraindications aspect
    n1=cyclophosphamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3484. cétirizine --- r_associated #0: 31 --> en:contraindications aspect
    n1=cétirizine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3485. dermoscopie --- r_associated #0: 31 --> en:contraindications aspect
    n1=dermoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3486. dinoprostone --- r_associated #0: 31 --> en:contraindications aspect
    n1=dinoprostone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3487. diquat --- r_associated #0: 31 --> en:contraindications aspect
    n1=diquat | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3488. en:1,4-alpha-glucan branching enzyme --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:1,4-alpha-glucan branching enzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3489. en:1-methyl-3-isobutylxanthine --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:1-methyl-3-isobutylxanthine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3490. en:1-naphthylamine --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:1-naphthylamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3491. en:1-octanol --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:1-octanol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3492. en:14-alpha demethylase inhibitors --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:14-alpha demethylase inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3493. en:17-ketosteroids --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:17-ketosteroids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3494. en:18-hydroxycorticosterone --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:18-hydroxycorticosterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3495. en:2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1h-3-benzazepine --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1h-3-benzazepine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3496. en:25-hydroxyvitamin d 2 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:25-hydroxyvitamin d 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3497. en:3,3-dichlorobenzidine --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:3,3-dichlorobenzidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3498. en:3,4-dihydroxyphenylacetic acid --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:3,4-dihydroxyphenylacetic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3499. en:3-hydroxysteroid dehydrogenases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:3-hydroxysteroid dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3500. en:4-aminobenzoic acid --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:4-aminobenzoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3501. en:actinoid series elements --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:actinoid series elements | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3502. en:activin receptors, type ii --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:activin receptors, type ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3503. en:adamts13 protein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:adamts13 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3504. en:adamts9 protein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:adamts9 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3505. en:adjuvant --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:adjuvant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3506. en:adp/atp translocase 2 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:adp/atp translocase 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3507. en:adp/atp translocase 3 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:adp/atp translocase 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3508. en:air filters --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:air filters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3509. en:alanine racemase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:alanine racemase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3510. en:allyl compounds --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:allyl compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3511. en:allylisopropylacetamide --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:allylisopropylacetamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3512. en:alpha-2-hs-glycoprotein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:alpha-2-hs-glycoprotein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3513. en:amino acid transport system y+l --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:amino acid transport system y+l | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3514. en:amino alcohols --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:amino alcohols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3515. en:ammonia-lyases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ammonia-lyases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3516. en:anaphylatoxins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:anaphylatoxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3517. en:anti-ulcer agent --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:anti-ulcer agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3518. en:antigens, neoplasm --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:antigens, neoplasm | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3519. en:apicoectomy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:apicoectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3520. en:aspects of adverse effects --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:aspects of adverse effects | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3521. en:aurodox --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:aurodox | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3522. en:autophagy-related protein 5 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:autophagy-related protein 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3523. en:autovaccines --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:autovaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3524. en:b3 antigen --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:b3 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3525. en:bacterial proton-translocating atpases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:bacterial proton-translocating atpases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3526. en:balloon angioplasty --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:balloon angioplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3527. en:bathing --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:bathing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3528. en:bcl2 antagonist of cell death --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:bcl2 antagonist of cell death | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3529. en:behind-the-counter drugs --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:behind-the-counter drugs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3530. en:benzo(a)pyrene-7,8-diol 9,10-epoxide --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:benzo(a)pyrene-7,8-diol 9,10-epoxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3531. en:beta-aminoethyl isothiourea --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:beta-aminoethyl isothiourea | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3532. en:beta-crystallins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:beta-crystallins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3533. en:betacyanins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:betacyanins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3534. en:bicyclo compounds --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:bicyclo compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3535. en:biogenic monoamines --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:biogenic monoamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3536. en:biological factors --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:biological factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3537. en:biological therapy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:biological therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3538. en:bioresonance therapy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:bioresonance therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3539. en:butyrylthiocholine --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:butyrylthiocholine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3540. en:calretinin --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:calretinin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3541. en:carbohydrate epimerases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:carbohydrate epimerases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3542. en:carbonic anhydrase iii --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:carbonic anhydrase iii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3543. en:carboxymethylcellulose sodium --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:carboxymethylcellulose sodium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3544. en:cardiac-gated imaging techniques --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cardiac-gated imaging techniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3545. en:caveolin 2 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:caveolin 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3546. en:cd3 complex --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cd3 complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3547. en:cetirizine --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cetirizine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3548. en:chemosterilants --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:chemosterilants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3549. en:chlorobenzoates --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:chlorobenzoates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3550. en:choledochostomy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:choledochostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3551. en:cholenes --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cholenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3552. en:chondroitinases and chondroitin lyases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:chondroitinases and chondroitin lyases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3553. en:cialit --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cialit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3554. en:ciliary neurotrophic factor --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ciliary neurotrophic factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3555. en:class ib phosphatidylinositol 3-kinase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:class ib phosphatidylinositol 3-kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3556. en:claudin 4 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:claudin 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3557. en:clinical alarms --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:clinical alarms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3558. en:clinical chemistry tests --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:clinical chemistry tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3559. en:coagulation study --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:coagulation study | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3560. en:coated materials, biocompatible --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:coated materials, biocompatible | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3561. en:cofilin-1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cofilin-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3562. en:collagen type viii --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:collagen type viii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3563. en:collapse therapy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:collapse therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3564. en:complement c3b --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:complement c3b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3565. en:complement c3c --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:complement c3c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3566. en:complement c4-a --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:complement c4-a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3567. en:complement c5a --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:complement c5a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3568. en:complement component c7 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:complement component c7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3569. en:contactin 1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:contactin 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3570. en:contactin 2 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:contactin 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3571. en:contraceptive device --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:contraceptive device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3572. en:counter-argument --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:counter-argument | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3573. en:crotonates --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:crotonates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3574. en:cryogels --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cryogels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3575. en:cycasin --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cycasin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3576. en:cyclic amp-dependent protein kinase rialpha subunit --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cyclic amp-dependent protein kinase rialpha subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3577. en:cyclic amp-dependent transcription factor atf-1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cyclic amp-dependent transcription factor atf-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3578. en:cyclic nucleotide phosphodiesterases, type 2 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cyclic nucleotide phosphodiesterases, type 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3579. en:cyclin g1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cyclin g1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3580. en:cyclopenthiazide --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cyclopenthiazide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3581. en:cyclophosphamide --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cyclophosphamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3582. en:cystathionine beta-synthase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cystathionine beta-synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3583. en:cytochrome p-450 cyp1a1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cytochrome p-450 cyp1a1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3584. en:cytochrome p450 family 3 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cytochrome p450 family 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3585. en:cytochrome p450 family 46 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cytochrome p450 family 46 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3586. en:cytochromes c2 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:cytochromes c2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3587. en:dental articulators --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:dental articulators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3588. en:dental pulp devitalization --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:dental pulp devitalization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3589. en:dentin desensitizing agents --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:dentin desensitizing agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3590. en:denture liners --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:denture liners | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3591. en:denture, complete --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:denture, complete | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3592. en:dermoscopy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:dermoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3593. en:detergent --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:detergent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3594. en:dichlororibofuranosylbenzimidazole --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:dichlororibofuranosylbenzimidazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3595. en:dinoprostone --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:dinoprostone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3596. en:dioxolanes --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:dioxolanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3597. en:diquat --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:diquat | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3598. en:dopamine d2 receptor antagonists --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:dopamine d2 receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3599. en:drug delivery system --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:drug delivery system | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3600. en:duffy blood group system --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:duffy blood group system | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3601. en:electric cardioversion --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:electric cardioversion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3602. en:enbucrilate --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:enbucrilate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3603. en:endostatin --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:endostatin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3604. en:endothelin receptor type a antagonist --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:endothelin receptor type a antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3605. en:enoyl-coa hydratase 2 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:enoyl-coa hydratase 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3606. en:eosinophil granule proteins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:eosinophil granule proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3607. en:ephrins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ephrins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3608. en:epigen --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:epigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3609. en:epstein-barr virus nuclear antigens --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:epstein-barr virus nuclear antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3610. en:equilibrative nucleoside transport proteins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:equilibrative nucleoside transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3611. en:equol --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:equol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3612. en:ergothioneine --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ergothioneine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3613. en:estradiol dehydrogenases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:estradiol dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3614. en:eszopiclone --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:eszopiclone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3615. en:ether-a-go-go potassium channels --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ether-a-go-go potassium channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3616. en:everolimus --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:everolimus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3617. en:excitatory amino acid transporter 3 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:excitatory amino acid transporter 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3618. en:female condoms --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:female condoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3619. en:fiber optic cables --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:fiber optic cables | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3620. en:fibric acids --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:fibric acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3621. en:fluorescein-5-isothiocyanate --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:fluorescein-5-isothiocyanate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3622. en:fontan procedure --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:fontan procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3623. en:free radical scavengers --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:free radical scavengers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3624. en:furagin --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:furagin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3625. en:gamma-cyclodextrins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:gamma-cyclodextrins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3626. en:gastric balloon --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:gastric balloon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3627. en:gata3 transcription factor --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:gata3 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3628. en:glaucoma drainage implants --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:glaucoma drainage implants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3629. en:glucaric acid --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:glucaric acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3630. en:glucosephosphate isomerase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:glucosephosphate isomerase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3631. en:glucuronide --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:glucuronide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3632. en:halorhodopsins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:halorhodopsins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3633. en:hepatitis b virus hbsag surface protein antigen --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:hepatitis b virus hbsag surface protein antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3634. en:heptoses --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:heptoses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3635. en:heterogeneous-nuclear ribonucleoprotein d --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:heterogeneous-nuclear ribonucleoprotein d | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3636. en:hippocalcin --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:hippocalcin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3637. en:histamine-1 receptor antagonist --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:histamine-1 receptor antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3638. en:histidine decarboxylase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:histidine decarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3639. en:hiv reverse transcriptase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:hiv reverse transcriptase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3640. en:hla-dq beta-chains --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:hla-dq beta-chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3641. en:home childbirth --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:home childbirth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3642. en:hsp72 heat-shock proteins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:hsp72 heat-shock proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3643. en:htlv-i antigens --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:htlv-i antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3644. en:htlv-ii antibodies --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:htlv-ii antibodies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3645. en:hydroxyethylrutoside --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:hydroxyethylrutoside | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3646. en:hydroxytryptophol --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:hydroxytryptophol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3647. en:hypolipidemic agents --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:hypolipidemic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3648. en:hypoxia-inducible factor-1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:hypoxia-inducible factor-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3649. en:immunoglobulin delta-chains --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:immunoglobulin delta-chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3650. en:immunotoxin --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:immunotoxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3651. en:inducible t-cell co-stimulator ligand --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:inducible t-cell co-stimulator ligand | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3652. en:infusions, intralesional --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:infusions, intralesional | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3653. en:insulin-like growth factor --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:insulin-like growth factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3654. en:insulin-like growth factor-binding protein 4 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:insulin-like growth factor-binding protein 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3655. en:integrin beta4 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:integrin beta4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3656. en:interleukin-15 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:interleukin-15 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3657. en:intradermal tests --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:intradermal tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3658. en:isoindoles --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:isoindoles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3659. en:kcnq1 potassium channel --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:kcnq1 potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3660. en:keratin, type ii cytoskeletal 5 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:keratin, type ii cytoskeletal 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3661. en:kv1.1 potassium channel --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:kv1.1 potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3662. en:lab-on-a-chip devices --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:lab-on-a-chip devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3663. en:lactams, macrocyclic --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:lactams, macrocyclic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3664. en:large-conductance calcium-activated potassium channel beta subunits --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:large-conductance calcium-activated potassium channel beta subunits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3665. en:latex fixation tests --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:latex fixation tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3666. en:lipoprotein hdl3 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:lipoprotein hdl3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3667. en:liver, artificial --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:liver, artificial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3668. en:local anesthesia procedure --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:local anesthesia procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3669. en:maintenance chemotherapy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:maintenance chemotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3670. en:masoprocol --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:masoprocol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3671. en:maximal respiratory pressures --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:maximal respiratory pressures | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3672. en:measure of the blood pressure --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:measure of the blood pressure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3673. en:medazepam --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:medazepam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3674. en:mediastinoscope --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:mediastinoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3675. en:melanocortins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:melanocortins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3676. en:meptazinol --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:meptazinol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3677. en:methallibure --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:methallibure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3678. en:mhc class ii protein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:mhc class ii protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3679. en:micromanipulation --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:micromanipulation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3680. en:micronutrients --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:micronutrients | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3681. en:mitogen-activated protein kinase 10 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:mitogen-activated protein kinase 10 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3682. en:monitoring, ambulatory --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:monitoring, ambulatory | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3683. en:muramic acids --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:muramic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3684. en:myogenic regulatory factor 5 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:myogenic regulatory factor 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3685. en:n-acetylglucosaminyltransferases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:n-acetylglucosaminyltransferases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3686. en:n-acylsphingosine galactosyltransferase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:n-acylsphingosine galactosyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3687. en:n-nitrosodimethylamine --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:n-nitrosodimethylamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3688. en:n-terminal acetyltransferase a --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:n-terminal acetyltransferase a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3689. en:nadroparin calcium --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nadroparin calcium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3690. en:nef gene products, human immunodeficiency virus --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nef gene products, human immunodeficiency virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3691. en:nf-e2 transcription factor --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nf-e2 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3692. en:nf-kappa b p52 subunit --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nf-kappa b p52 subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3693. en:ng-nitroarginine methyl ester --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ng-nitroarginine methyl ester | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3694. en:niceritrol --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:niceritrol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3695. en:nicotinic agonist --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nicotinic agonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3696. en:nitromifene --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nitromifene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3697. en:nod2 signaling adaptor protein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nod2 signaling adaptor protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3698. en:nonmuscle myosin type iib --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nonmuscle myosin type iib | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3699. en:nuclear receptor subfamily 1 group d member 1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nuclear receptor subfamily 1 group d member 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3700. en:nucleotide deaminases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:nucleotide deaminases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3701. en:o-acetyl-adp-ribose --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:o-acetyl-adp-ribose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3702. en:octamer transcription factor-6 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:octamer transcription factor-6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3703. en:operating tables --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:operating tables | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3704. en:ophthalmologic surgical procedure --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ophthalmologic surgical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3705. en:organic anion transporters, atp-dependent --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:organic anion transporters, atp-dependent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3706. en:palivizumab --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:palivizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3707. en:pax9 transcription factor --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:pax9 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3708. en:peptide hydrolases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:peptide hydrolases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3709. en:peptide synthase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:peptide synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3710. en:peritoneal dialysis, continuous ambulatory --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:peritoneal dialysis, continuous ambulatory | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3711. en:pheophytins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:pheophytins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3712. en:phosphate-binding proteins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:phosphate-binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3713. en:phosphatidylinositol 4,5-bisphosphate --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:phosphatidylinositol 4,5-bisphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3714. en:phosphofructokinase-1, liver type --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:phosphofructokinase-1, liver type | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3715. en:phosphotransferases (paired acceptors) --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:phosphotransferases (paired acceptors) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3716. en:photobioreactors --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:photobioreactors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3717. en:phycobiliproteins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:phycobiliproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3718. en:picryl chloride --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:picryl chloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3719. en:pituitary hormone release inhibiting hormones --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:pituitary hormone release inhibiting hormones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3720. en:poloxamer --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:poloxamer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3721. en:poly adenosine diphosphate ribose --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:poly adenosine diphosphate ribose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3722. en:poly t --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:poly t | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3723. en:poly(a)-binding protein i --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:poly(a)-binding protein i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3724. en:polyamine compound --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:polyamine compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3725. en:polyanetholesulfonate --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:polyanetholesulfonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3726. en:polyesters --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:polyesters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3727. en:polyglutamic acid --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:polyglutamic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3728. en:polyisoprenyl phosphate monosaccharides --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:polyisoprenyl phosphate monosaccharides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3729. en:polymer --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:polymer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3730. en:pre-implantation diagnosis --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:pre-implantation diagnosis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3731. en:pregabalin --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:pregabalin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3732. en:prions --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:prions | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3733. en:prodigiozan --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:prodigiozan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3734. en:prokaryotic initiation factor-1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:prokaryotic initiation factor-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3735. en:prostaglandin d2 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:prostaglandin d2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3736. en:prostaglandins e, synthetic --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:prostaglandins e, synthetic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3737. en:prostaglandins g --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:prostaglandins g | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3738. en:protein s100-a9 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:protein s100-a9 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3739. en:protein tyrosine phosphatase, non-receptor type 11 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:protein tyrosine phosphatase, non-receptor type 11 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3740. en:protein-tyrosine phosphatase lyp --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:protein-tyrosine phosphatase lyp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3741. en:proto-oncogene proteins c-raf --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:proto-oncogene proteins c-raf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3742. en:pteroylpolyglutamic acids --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:pteroylpolyglutamic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3743. en:puromycin aminonucleoside --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:puromycin aminonucleoside | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3744. en:pyridostigmine bromide --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:pyridostigmine bromide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3745. en:qc-snare proteins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:qc-snare proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3746. en:quaternary ammonium compounds --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:quaternary ammonium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3747. en:quinolizidines --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:quinolizidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3748. en:radiosensitizing agent --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:radiosensitizing agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3749. en:reactive nitrogen species --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:reactive nitrogen species | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3750. en:receptor tyrosine kinase-like orphan receptors --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:receptor tyrosine kinase-like orphan receptors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3751. en:receptor, trkb --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:receptor, trkb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3752. en:retinoblastoma binding protein 1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:retinoblastoma binding protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3753. en:retinoblastoma-like protein 1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:retinoblastoma-like protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3754. en:ribonucleoprotein, u5 small nuclear --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ribonucleoprotein, u5 small nuclear | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3755. en:ribosome inactivating proteins, type 1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ribosome inactivating proteins, type 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3756. en:rna, archaeal --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:rna, archaeal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3757. en:rotarod performance test --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:rotarod performance test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3758. en:s-nitrosoglutathione --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:s-nitrosoglutathione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3759. en:sclerostomy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:sclerostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3760. en:semaphorin-3a --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:semaphorin-3a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3761. en:single embryo transfer --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:single embryo transfer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3762. en:small ubiquitin-related modifier 1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:small ubiquitin-related modifier 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3763. en:sodium cholate --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:sodium cholate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3764. en:sodium-phosphate cotransporter proteins, type i --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:sodium-phosphate cotransporter proteins, type i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3765. en:soluble nsf attachment protein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:soluble nsf attachment protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3766. en:sp transcription factors --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:sp transcription factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3767. en:sp4 transcription factor --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:sp4 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3768. en:space suits --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:space suits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3769. en:spiritual therapy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:spiritual therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3770. en:steroid synthesis inhibitors --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:steroid synthesis inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3771. en:stromal interaction molecules --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:stromal interaction molecules | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3772. en:succinic anhydrides --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:succinic anhydrides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3773. en:succinyldiaminopimelate aminotransferase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:succinyldiaminopimelate aminotransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3774. en:sulfates, inorganic --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:sulfates, inorganic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3775. en:survival of motor neuron 1 protein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:survival of motor neuron 1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3776. en:syndecan-4 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:syndecan-4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3777. en:t-cell protein tyrosine phosphatase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:t-cell protein tyrosine phosphatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3778. en:tankyrases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:tankyrases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3779. en:tar-water --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:tar-water | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3780. en:technetium tc 99m diethyl-iminodiacetic acid --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:technetium tc 99m diethyl-iminodiacetic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3781. en:tetrachlorvinphos --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:tetrachlorvinphos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3782. en:tetraethylammonium compounds --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:tetraethylammonium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3783. en:tetrahydropapaveroline --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:tetrahydropapaveroline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3784. en:therapeutic testosterone --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:therapeutic testosterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3785. en:thiobarbiturates --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:thiobarbiturates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3786. en:thiohydantoins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:thiohydantoins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3787. en:thiomalates --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:thiomalates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3788. en:thionins --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:thionins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3789. en:thiosugars --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:thiosugars | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3790. en:thiosulfate sulfurtransferase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:thiosulfate sulfurtransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3791. en:thromboxane-a synthase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:thromboxane-a synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3792. en:total mastectomy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:total mastectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3793. en:tracheal intubation --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:tracheal intubation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3794. en:tracheostomy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:tracheostomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3795. en:transcription factor brn-3a --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:transcription factor brn-3a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3796. en:transcription factor tfiiia --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:transcription factor tfiiia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3797. en:transforming growth factor beta 1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:transforming growth factor beta 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3798. en:transistors, electronic --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:transistors, electronic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3799. en:transposon resolvases --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:transposon resolvases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3800. en:tryptophan-specific trna --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:tryptophan-specific trna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3801. en:tumor necrosis factor ligand superfamily member 14 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:tumor necrosis factor ligand superfamily member 14 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3802. en:type ii cgmp-dependent protein kinase, human --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:type ii cgmp-dependent protein kinase, human | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3803. en:ultrasonography, interventional --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:ultrasonography, interventional | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3804. en:urofollitropin --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:urofollitropin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3805. en:utp-glucose-1-phosphate uridylyltransferase --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:utp-glucose-1-phosphate uridylyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3806. en:v-set domain-containing t-cell activation inhibitor 1 --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:v-set domain-containing t-cell activation inhibitor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3807. en:v-src protein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:v-src protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3808. en:vaccines, virosome --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:vaccines, virosome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3809. en:vagus nerve stimulation --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:vagus nerve stimulation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3810. en:valproic acid --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:valproic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3811. en:viscoelastic substances --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:viscoelastic substances | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3812. en:vitamin e compound --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:vitamin e compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3813. en:von hippel-lindau tumor suppressor protein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:von hippel-lindau tumor suppressor protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3814. en:wiskott-aldrich syndrome protein --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:wiskott-aldrich syndrome protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3815. en:x-ray therapy --- r_associated #0: 31 --> en:contraindications aspect
    n1=en:x-ray therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3816. endonucléase de restriction --- r_associated #0: 31 --> en:contraindications aspect
    n1=endonucléase de restriction | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3817. endostatine --- r_associated #0: 31 --> en:contraindications aspect
    n1=endostatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3818. facteur de transfert --- r_associated #0: 31 --> en:contraindications aspect
    n1=facteur de transfert | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3819. facteurs biologiques --- r_associated #0: 31 --> en:contraindications aspect
    n1=facteurs biologiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3820. histidine décarboxylase --- r_associated #0: 31 --> en:contraindications aspect
    n1=histidine décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3821. histidine-décarboxylase --- r_associated #0: 31 --> en:contraindications aspect
    n1=histidine-décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3822. interleukine 15 --- r_associated #0: 31 --> en:contraindications aspect
    n1=interleukine 15 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3823. intervention chirurgicale à froid --- r_associated #0: 31 --> en:contraindications aspect
    n1=intervention chirurgicale à froid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3824. intubation trachéale --- r_associated #0: 31 --> en:contraindications aspect
    n1=intubation trachéale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3825. isoindoles --- r_associated #0: 31 --> en:contraindications aspect
    n1=isoindoles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3826. kinétine --- r_associated #0: 31 --> en:contraindications aspect
    n1=kinétine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3827. lipoprotéine de haute densité --- r_associated #0: 31 --> en:contraindications aspect
    n1=lipoprotéine de haute densité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3828. mastectomie sous-cutanée --- r_associated #0: 31 --> en:contraindications aspect
    n1=mastectomie sous-cutanée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3829. mastectomie totale --- r_associated #0: 31 --> en:contraindications aspect
    n1=mastectomie totale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3830. micromanipulation --- r_associated #0: 31 --> en:contraindications aspect
    n1=micromanipulation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3831. peau artificielle --- r_associated #0: 31 --> en:contraindications aspect
    n1=peau artificielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3832. phonocardiographie --- r_associated #0: 31 --> en:contraindications aspect
    n1=phonocardiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3833. pleuroscopie --- r_associated #0: 31 --> en:contraindications aspect
    n1=pleuroscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3834. poly t --- r_associated #0: 31 --> en:contraindications aspect
    n1=poly t | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3835. polyesters --- r_associated #0: 31 --> en:contraindications aspect
    n1=polyesters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3836. polymer --- r_associated #0: 31 --> en:contraindications aspect
    n1=polymer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3837. protections absorbantes de l'incontinence --- r_associated #0: 31 --> en:contraindications aspect
    n1=protections absorbantes de l'incontinence | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3838. protections absorbantes pour l'incontinence --- r_associated #0: 31 --> en:contraindications aspect
    n1=protections absorbantes pour l'incontinence | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3839. remnographie --- r_associated #0: 31 --> en:contraindications aspect
    n1=remnographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3840. scanographe --- r_associated #0: 31 --> en:contraindications aspect
    n1=scanographe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3841. scellement --- r_associated #0: 31 --> en:contraindications aspect
    n1=scellement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3842. silicate d'aluminium --- r_associated #0: 31 --> en:contraindications aspect
    n1=silicate d'aluminium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3843. stérilet intrauterine --- r_associated #0: 31 --> en:contraindications aspect
    n1=stérilet intrauterine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3844. temps de coagulation du sang entier --- r_associated #0: 31 --> en:contraindications aspect
    n1=temps de coagulation du sang entier | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3845. tomodensitométrie cérébrale --- r_associated #0: 31 --> en:contraindications aspect
    n1=tomodensitométrie cérébrale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3846. tomographe --- r_associated #0: 31 --> en:contraindications aspect
    n1=tomographe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3847. transplantations de pancreas --- r_associated #0: 31 --> en:contraindications aspect
    n1=transplantations de pancreas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=31
  3848. Gluck (technique de) --- r_associated #0: 30 --> en:contraindications aspect
    n1=Gluck (technique de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3849. Gompertz (équation de) --- r_associated #0: 30 --> en:contraindications aspect
    n1=Gompertz (équation de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3850. Groupe sanguin --- r_associated #0: 30 --> en:contraindications aspect
    n1=Groupe sanguin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3851. HMGCoA --- r_associated #0: 30 --> en:contraindications aspect
    n1=HMGCoA | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3852. Hydroxyméthylglutaryl-CoA synthase --- r_associated #0: 30 --> en:contraindications aspect
    n1=Hydroxyméthylglutaryl-CoA synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3853. Langage informatique --- r_associated #0: 30 --> en:contraindications aspect
    n1=Langage informatique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3854. Premiers Secours --- r_associated #0: 30 --> en:contraindications aspect
    n1=Premiers Secours | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3855. Sertoli (tumeur calcifiée à grandes cellules de) --- r_associated #0: 30 --> en:contraindications aspect
    n1=Sertoli (tumeur calcifiée à grandes cellules de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3856. Silicate d'aluminium --- r_associated #0: 30 --> en:contraindications aspect
    n1=Silicate d'aluminium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3857. acide aspartique --- r_associated #0: 30 --> en:contraindications aspect
    n1=acide aspartique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3858. acide nucléique peptidique --- r_associated #0: 30 --> en:contraindications aspect
    n1=acide nucléique peptidique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3859. acides glutiminiques --- r_associated #0: 30 --> en:contraindications aspect
    n1=acides glutiminiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3860. aller ensemble --- r_associated #0: 30 --> en:contraindications aspect
    n1=aller ensemble | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3861. anticoagulant --- r_associated #0: 30 --> en:contraindications aspect
    n1=anticoagulant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3862. anticoagulant (médicament) --- r_associated #0: 30 --> en:contraindications aspect
    n1=anticoagulant (médicament) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3863. anticoagulants oraux directs --- r_associated #0: 30 --> en:contraindications aspect
    n1=anticoagulants oraux directs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3864. antifongique --- r_associated #0: 30 --> en:contraindications aspect
    n1=antifongique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3865. aquaporine de type 4 --- r_associated #0: 30 --> en:contraindications aspect
    n1=aquaporine de type 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3866. bain de dialyse --- r_associated #0: 30 --> en:contraindications aspect
    n1=bain de dialyse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3867. bande élastique --- r_associated #0: 30 --> en:contraindications aspect
    n1=bande élastique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3868. bandelettes réactives --- r_associated #0: 30 --> en:contraindications aspect
    n1=bandelettes réactives | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3869. cadhérine --- r_associated #0: 30 --> en:contraindications aspect
    n1=cadhérine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3870. caoutchouc naturel --- r_associated #0: 30 --> en:contraindications aspect
    n1=caoutchouc naturel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3871. carbachol --- r_associated #0: 30 --> en:contraindications aspect
    n1=carbachol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3872. caspase 14 --- r_associated #0: 30 --> en:contraindications aspect
    n1=caspase 14 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3873. chaîne légère d'immunoglobuline --- r_associated #0: 30 --> en:contraindications aspect
    n1=chaîne légère d'immunoglobuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3874. chimique organique --- r_associated #0: 30 --> en:contraindications aspect
    n1=chimique organique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3875. chlorfenvinphos --- r_associated #0: 30 --> en:contraindications aspect
    n1=chlorfenvinphos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3876. clef ouverte --- r_associated #0: 30 --> en:contraindications aspect
    n1=clef ouverte | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3877. clef à fourche --- r_associated #0: 30 --> en:contraindications aspect
    n1=clef à fourche | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3878. clé ouverte --- r_associated #0: 30 --> en:contraindications aspect
    n1=clé ouverte | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3879. clé à fourche --- r_associated #0: 30 --> en:contraindications aspect
    n1=clé à fourche | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3880. cobalamine --- r_associated #0: 30 --> en:contraindications aspect
    n1=cobalamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3881. colloïdal --- r_associated #0: 30 --> en:contraindications aspect
    n1=colloïdal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3882. disulfoton --- r_associated #0: 30 --> en:contraindications aspect
    n1=disulfoton | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3883. duodénojéjunal (angle) --- r_associated #0: 30 --> en:contraindications aspect
    n1=duodénojéjunal (angle) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3884. défécographie --- r_associated #0: 30 --> en:contraindications aspect
    n1=défécographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3885. en:1,25-dihydroxyvitamin d(3) 24-hydroxylase, mitochondrial --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:1,25-dihydroxyvitamin d(3) 24-hydroxylase, mitochondrial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3886. en:1-naphthylisothiocyanate --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:1-naphthylisothiocyanate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3887. en:11-beta-hydroxysteroid dehydrogenase type 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:11-beta-hydroxysteroid dehydrogenase type 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3888. en:2,3-diketogulonic acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:2,3-diketogulonic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3889. en:2-methyl-4-chlorophenoxyacetic acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:2-methyl-4-chlorophenoxyacetic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3890. en:2-naphthylamine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:2-naphthylamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3891. en:25-hydroxyvitamin d-1 alpha-hydroxylase, mitochondrial --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:25-hydroxyvitamin d-1 alpha-hydroxylase, mitochondrial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3892. en:2s albumins, plant --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:2s albumins, plant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3893. en:4,5-dihydro-1-(3-(trifluoromethyl)phenyl)-1h-pyrazol-3-amine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:4,5-dihydro-1-(3-(trifluoromethyl)phenyl)-1h-pyrazol-3-amine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3894. en:4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3895. en:4-chloro-7-nitrobenzofurazan --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:4-chloro-7-nitrobenzofurazan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3896. en:5,6-dihydroxytryptamine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:5,6-dihydroxytryptamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3897. en:5,8,11,14-eicosatetraynoic acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:5,8,11,14-eicosatetraynoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3898. en:8-bromo cyclic adenosine monophosphate --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:8-bromo cyclic adenosine monophosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3899. en:L-dopa --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:L-dopa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3900. en:PET scan --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:PET scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3901. en:abdominal wound closure techniques --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:abdominal wound closure techniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3902. en:acetylesterase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:acetylesterase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3903. en:acetylthiocholine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:acetylthiocholine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3904. en:actin-related protein 2 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:actin-related protein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3905. en:activating transcription factor 2 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:activating transcription factor 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3906. en:actuarial analysis --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:actuarial analysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3907. en:adamts4 protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:adamts4 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3908. en:adaptor protein complex alpha subunits --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:adaptor protein complex alpha subunits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3909. en:adenosine a2 receptor antagonists --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:adenosine a2 receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3910. en:adenosine deaminase inhibitor --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:adenosine deaminase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3911. en:adenosine diphosphate glucose --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:adenosine diphosphate glucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3912. en:adrenal cortex function tests --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:adrenal cortex function tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3913. en:adrenergic alpha-1 receptor antagonists --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:adrenergic alpha-1 receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3914. en:adrenergic beta-3 receptor antagonists --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:adrenergic beta-3 receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3915. en:agamous protein, arabidopsis --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:agamous protein, arabidopsis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3916. en:air bags --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:air bags | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3917. en:airway management --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:airway management | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3918. en:alanine aminotransferase 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:alanine aminotransferase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3919. en:alfaxalone alfadolone mixture --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:alfaxalone alfadolone mixture | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3920. en:alpha-hypophamine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:alpha-hypophamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3921. en:aluminum hydroxide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:aluminum hydroxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3922. en:alveoloplasty --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:alveoloplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3923. en:amido black --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:amido black | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3924. en:amino acid transport system x-ag --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:amino acid transport system x-ag | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3925. en:amino-transferase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:amino-transferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3926. en:ampholyte mixtures --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ampholyte mixtures | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3927. en:ampyrone --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ampyrone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3928. en:analgesic agent --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:analgesic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3929. en:anesthesia, closed-circuit --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:anesthesia, closed-circuit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3930. en:angiotensin-2 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:angiotensin-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3931. en:anisoles --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:anisoles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3932. en:anonymous testing --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:anonymous testing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3933. en:answer sb back --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:answer sb back | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3934. en:antibiotics, antitubercular --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:antibiotics, antitubercular | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3935. en:antifreeze proteins, type iii --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:antifreeze proteins, type iii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3936. en:antimutagenic agents --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:antimutagenic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3937. en:apolipoprotein B-100 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:apolipoprotein B-100 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3938. en:apoptosis regulator bax --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:apoptosis regulator bax | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3939. en:aquaporin 4 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:aquaporin 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3940. en:aroclors --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:aroclors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3941. en:arterial tension --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:arterial tension | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3942. en:arthroplasty of the knee --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:arthroplasty of the knee | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3943. en:artificial teeth --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:artificial teeth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3944. en:aspartic acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:aspartic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3945. en:atp binding cassette transporter, sub-family g, member 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:atp binding cassette transporter, sub-family g, member 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3946. en:auditory brain stem implants --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:auditory brain stem implants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3947. en:autoanalysis procedure --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:autoanalysis procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3948. en:auxilins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:auxilins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3949. en:bacterial secretion systems --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:bacterial secretion systems | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3950. en:be a counterpart to something --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:be a counterpart to something | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3951. en:be the counterpart of --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:be the counterpart of | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3952. en:benzoxepins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:benzoxepins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3953. en:benzoylarginine-2-naphthylamide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:benzoylarginine-2-naphthylamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3954. en:beta-alanine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:beta-alanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3955. en:beta-crystallin a chain --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:beta-crystallin a chain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3956. en:biolistics --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:biolistics | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3957. en:blood glucose self-monitoring --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:blood glucose self-monitoring | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3958. en:blood volume determination --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:blood volume determination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3959. en:body surface potential mapping --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:body surface potential mapping | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3960. en:bone substitutes --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:bone substitutes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3961. en:breast self-examination --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:breast self-examination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3962. en:bromosuccinimide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:bromosuccinimide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3963. en:burr hole procedure --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:burr hole procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3964. en:ca(2+) mg(2+)-atpase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ca(2+) mg(2+)-atpase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3965. en:cadherin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cadherin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3966. en:calcium isotopes --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:calcium isotopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3967. en:carbachol --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:carbachol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3968. en:carbamoyl phosphate synthetase i activators --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:carbamoyl phosphate synthetase i activators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3969. en:carbonate ion --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:carbonate ion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3970. en:carcinogenicity test --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:carcinogenicity test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3971. en:casein kinase 2 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:casein kinase 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3972. en:caspase 14 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:caspase 14 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3973. en:cation exchange resins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cation exchange resins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3974. en:ccaat enhancer binding protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ccaat enhancer binding protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3975. en:cd137 antigen --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cd137 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3976. en:cd151 antigen --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cd151 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3977. en:celf proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:celf proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3978. en:cementation --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cementation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3979. en:chitin synthase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:chitin synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3980. en:chlorfenvinphos --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:chlorfenvinphos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3981. en:chloroplast dna --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:chloroplast dna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3982. en:cholates --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cholates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3983. en:chromium compounds --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:chromium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3984. en:chromosmon --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:chromosmon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3985. en:citrate (si)-synthase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:citrate (si)-synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3986. en:class i phosphatidylinositol 3-kinases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:class i phosphatidylinositol 3-kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3987. en:class ii phosphatidylinositol 3-kinases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:class ii phosphatidylinositol 3-kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3988. en:clofenapate --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:clofenapate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3989. en:cobalamin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cobalamin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3990. en:cobamides --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cobamides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3991. en:code --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:code | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3992. en:collagen iv --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:collagen iv | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3993. en:complement c1 inactivator proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:complement c1 inactivator proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3994. en:complement c3 convertase, alternative pathway --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:complement c3 convertase, alternative pathway | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3995. en:complement c5b --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:complement c5b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3996. en:complement component 9 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:complement component 9 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3997. en:computer language --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:computer language | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3998. en:contraceptives, postcoital, synthetic --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:contraceptives, postcoital, synthetic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  3999. en:contraindication --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:contraindication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4000. en:correspond to --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:correspond to | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4001. en:corrinoids --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:corrinoids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4002. en:coup transcription factor i --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:coup transcription factor i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4003. en:creatine kinase, mitochondrial form --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:creatine kinase, mitochondrial form | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4004. en:crown compounds --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:crown compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4005. en:crystalline silica quartz --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:crystalline silica quartz | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4006. en:cyclic amp-dependent transcription factor atf-3 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cyclic amp-dependent transcription factor atf-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4007. en:cytochrome p-450 cyp3a inducers --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cytochrome p-450 cyp3a inducers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4008. en:cytochrome p-450 enzyme inhibitors --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cytochrome p-450 enzyme inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4009. en:cytosolic phospholipase a2 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:cytosolic phospholipase a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4010. en:decamethonium compounds --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:decamethonium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4011. en:defecography --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:defecography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4012. en:dental cavity lining --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dental cavity lining | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4013. en:dental clasps --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dental clasps | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4014. en:dental scaling --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dental scaling | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4015. en:dental soldering --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dental soldering | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4016. en:denture bases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:denture bases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4017. en:deoxyuracil nucleotides --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:deoxyuracil nucleotides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4018. en:deoxyuridine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:deoxyuridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4019. en:device removal --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:device removal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4020. en:dibenz(b,f)(1,4)oxazepine-10(11h)-carboxylic acid, 8-chloro-, 2-acetylhydrazide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dibenz(b,f)(1,4)oxazepine-10(11h)-carboxylic acid, 8-chloro-, 2-acetylhydrazide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4021. en:dibenzofurans, polychlorinated --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dibenzofurans, polychlorinated | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4022. en:dihydroalprenolol --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dihydroalprenolol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4023. en:dihydromorphine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dihydromorphine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4024. en:dimaprit --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dimaprit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4025. en:dimethylbenzanthracene --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dimethylbenzanthracene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4026. en:diphenylcarbazide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:diphenylcarbazide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4027. en:dishevelled proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dishevelled proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4028. en:disulfoton --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:disulfoton | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4029. en:dithionitrobenzoic acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dithionitrobenzoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4030. en:dna topoisomerases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dna topoisomerases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4031. en:dna-directed dna polymerase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dna-directed dna polymerase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4032. en:dual specificity protein phosphatase 6 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dual specificity protein phosphatase 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4033. en:duodenoscopes --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:duodenoscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4034. en:dye --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dye | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4035. en:dystroglycans --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:dystroglycans | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4036. en:ear protective devices --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ear protective devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4037. en:early termination of clinical trials --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:early termination of clinical trials | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4038. en:echocardiography, doppler, color --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:echocardiography, doppler, color | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4039. en:electron transport complex i --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:electron transport complex i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4040. en:electronarcosis --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:electronarcosis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4041. en:enkephalin, d-penicillamine (2,5)- --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:enkephalin, d-penicillamine (2,5)- | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4042. en:enteric coated tablet dosage form --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:enteric coated tablet dosage form | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4043. en:ephrin type-a receptor 8 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ephrin type-a receptor 8 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4044. en:ephrin-b3 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ephrin-b3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4045. en:epitopes, b-lymphocyte --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:epitopes, b-lymphocyte | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4046. en:epoetin alfa --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:epoetin alfa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4047. en:equipment and supplies --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:equipment and supplies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4048. en:esomeprazole --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:esomeprazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4049. en:estrus detection --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:estrus detection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4050. en:ethan-1,2-diol --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ethan-1,2-diol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4051. en:ethanediol --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ethanediol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4052. en:ethosuximide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ethosuximide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4053. en:ethylenebis(dithiocarbamates) --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ethylenebis(dithiocarbamates) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4054. en:ethylmaleimide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ethylmaleimide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4055. en:ethylmercuric chloride --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ethylmercuric chloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4056. en:excitatory amino acid antagonists --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:excitatory amino acid antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4057. en:fanconi anemia group a protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:fanconi anemia group a protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4058. en:fanconi anemia group c protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:fanconi anemia group c protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4059. en:fatty acid synthesis inhibitors --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:fatty acid synthesis inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4060. en:fenamates --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:fenamates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4061. en:fertility agents, female --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:fertility agents, female | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4062. en:fibroblast growth factor receptor 3 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:fibroblast growth factor receptor 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4063. en:fork wrench --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:fork wrench | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4064. en:form a pair with something --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:form a pair with something | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4065. en:formamides --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:formamides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4066. en:fracture fixation, intramedullary --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:fracture fixation, intramedullary | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4067. en:fructose-1,6-bisphosphatase 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:fructose-1,6-bisphosphatase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4068. en:gamma-crystallins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:gamma-crystallins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4069. en:gas --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:gas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4070. en:gdp --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:gdp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4071. en:get acquainted with somebody --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:get acquainted with somebody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4072. en:get to know somebody --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:get to know somebody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4073. en:glucose-1-phosphate adenylyltransferase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:glucose-1-phosphate adenylyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4074. en:glut-1 protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:glut-1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4075. en:glutamate dehydrogenase (nadp+) --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:glutamate dehydrogenase (nadp+) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4076. en:glutamate plasma membrane transport proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:glutamate plasma membrane transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4077. en:glutaral --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:glutaral | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4078. en:glycogen synthase kinase 3 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:glycogen synthase kinase 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4079. en:go well together --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:go well together | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4080. en:go with something --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:go with something | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4081. en:growth/differentiation factor 3 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:growth/differentiation factor 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4082. en:gtp-binding protein alpha subunits, gi-go --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:gtp-binding protein alpha subunits, gi-go | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4083. en:guiac --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:guiac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4084. en:h-y antigen --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:h-y antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4085. en:heart auscultation --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:heart auscultation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4086. en:hemoglobin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hemoglobin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4087. en:hemoglobin subunit delta --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hemoglobin subunit delta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4088. en:hepatitis b e antigens --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hepatitis b e antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4089. en:hepcidin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hepcidin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4090. en:hirudin therapy --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hirudin therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4091. en:hla-a11 antigen --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hla-a11 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4092. en:hla-b51 antigen --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hla-b51 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4093. en:hla-dq antigen --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hla-dq antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4094. en:homoarginine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:homoarginine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4095. en:hydroxymethyl and formyl transferases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hydroxymethyl and formyl transferases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4096. en:hypodicarbonous acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hypodicarbonous acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4097. en:hypoxia-inducible factor 1-alpha --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:hypoxia-inducible factor 1-alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4098. en:ilizarov technique --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ilizarov technique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4099. en:immunoglobulin light chain --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:immunoglobulin light chain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4100. en:implantable pump --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:implantable pump | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4101. en:induction of neuromuscular blockade --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:induction of neuromuscular blockade | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4102. en:inflammasomes --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:inflammasomes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4103. en:inosine triphosphate --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:inosine triphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4104. en:insulin, ultralente --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:insulin, ultralente | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4105. en:insulin-like growth factor-binding protein 6 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:insulin-like growth factor-binding protein 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4106. en:intercalating agent --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:intercalating agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4107. en:intraocular lens implant device --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:intraocular lens implant device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4108. en:iron compounds, organic --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:iron compounds, organic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4109. en:iron dextran complex --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:iron dextran complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4110. en:isocitrates --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:isocitrates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4111. en:jagged-1 protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:jagged-1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4112. en:jumonji domain-containing histone demethylases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:jumonji domain-containing histone demethylases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4113. en:katp channels --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:katp channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4114. en:kcnq potassium channels --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:kcnq potassium channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4115. en:keratin, type i cytoskeletal 20 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:keratin, type i cytoskeletal 20 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4116. en:keratin-6 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:keratin-6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4117. en:keratomileusis, laser in situ --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:keratomileusis, laser in situ | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4118. en:key moment --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:key moment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4119. en:kidd blood-group system --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:kidd blood-group system | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4120. en:lactotransferrin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:lactotransferrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4121. en:laparoscope --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:laparoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4122. en:left-right determination factors --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:left-right determination factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4123. en:leu-enkephalin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:leu-enkephalin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4124. en:levulinic acids --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:levulinic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4125. en:luteolin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:luteolin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4126. en:lymphotoxin alpha1, beta2 heterotrimer --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:lymphotoxin alpha1, beta2 heterotrimer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4127. en:lysine 6-aminotransferase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:lysine 6-aminotransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4128. en:macrophage-activating factors --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:macrophage-activating factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4129. en:make a counterpart to something --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:make a counterpart to something | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4130. en:make a pair with something --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:make a pair with something | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4131. en:make somebody 's acquaintance --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:make somebody 's acquaintance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4132. en:make somebody's acquaintance --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:make somebody's acquaintance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4133. en:mammaglobin-a --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mammaglobin-a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4134. en:mammiplasty --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mammiplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4135. en:mandibular reconstruction --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mandibular reconstruction | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4136. en:mannich bases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mannich bases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4137. en:maping --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:maping | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4138. en:marek disease vaccines --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:marek disease vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4139. en:mast/stem cell growth factor receptor kit --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mast/stem cell growth factor receptor kit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4140. en:match --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:match | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4141. en:matrix bands --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:matrix bands | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4142. en:maxillofacial prosthesis implantation --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:maxillofacial prosthesis implantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4143. en:medical marijuana --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:medical marijuana | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4144. en:meet --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:meet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4145. en:methacholine compounds --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:methacholine compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4146. en:methionine adenosyltransferase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:methionine adenosyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4147. en:methylmannosides --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:methylmannosides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4148. en:methylnitrosourea --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:methylnitrosourea | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4149. en:methylthionine chloride --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:methylthionine chloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4150. en:mevalonic acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mevalonic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4151. en:microinjections --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:microinjections | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4152. en:mitochondrial trifunctional protein, alpha subunit --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mitochondrial trifunctional protein, alpha subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4153. en:mitogen-activated protein kinase 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mitogen-activated protein kinase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4154. en:mitogen-activated protein kinase 6 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mitogen-activated protein kinase 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4155. en:mollusk venoms --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mollusk venoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4156. en:mouth off to [sb] --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:mouth off to [sb] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4157. en:muellerian-inhibiting factor --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:muellerian-inhibiting factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4158. en:muramoylpentapeptide carboxypeptidase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:muramoylpentapeptide carboxypeptidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4159. en:myosin iv --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:myosin iv | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4160. en:myosin subfragments --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:myosin subfragments | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4161. en:myosin type i --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:myosin type i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4162. en:n-glycosyl hydrolases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:n-glycosyl hydrolases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4163. en:nadp transhydrogenase, ab-specific --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:nadp transhydrogenase, ab-specific | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4164. en:nanog homeobox protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:nanog homeobox protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4165. en:natural rubber --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:natural rubber | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4166. en:nav1.2 voltage-gated sodium channel --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:nav1.2 voltage-gated sodium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4167. en:neuronal calcium-sensor proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:neuronal calcium-sensor proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4168. en:nf-e2-related factor 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:nf-e2-related factor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4169. en:nonheme iron proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:nonheme iron proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4170. en:nuchal translucency screen --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:nuchal translucency screen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4171. en:o-aminoazotoluene --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:o-aminoazotoluene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4172. en:olfactometry --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:olfactometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4173. en:oligosaccharides, branched-chain --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:oligosaccharides, branched-chain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4174. en:open end wrench --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:open end wrench | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4175. en:open-end wrench --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:open-end wrench | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4176. en:open-ended spanner --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:open-ended spanner | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4177. en:organic anion transporters, sodium-dependent --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:organic anion transporters, sodium-dependent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4178. en:organogold compounds --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:organogold compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4179. en:organosilicon compounds --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:organosilicon compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4180. en:organothiophosphonates --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:organothiophosphonates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4181. en:over the counter product --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:over the counter product | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4182. en:oxepins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:oxepins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4183. en:oxymetholone --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:oxymetholone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4184. en:oxytocic hormone --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:oxytocic hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4185. en:p-hydroxynorephedrine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:p-hydroxynorephedrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4186. en:p-methoxy-n-methylphenethylamine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:p-methoxy-n-methylphenethylamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4187. en:pactamycin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:pactamycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4188. en:paracetamol --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:paracetamol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4189. en:parathyroïd hormone --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:parathyroïd hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4190. en:pepsinogen c --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:pepsinogen c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4191. en:peptidomimetics --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:peptidomimetics | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4192. en:peroxisome proliferators --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:peroxisome proliferators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4193. en:peroxynitrous acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:peroxynitrous acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4194. en:phosphoamino acids --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:phosphoamino acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4195. en:phosphofructokinase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:phosphofructokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4196. en:phospholipase a2, group x protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:phospholipase a2, group x protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4197. en:pitocin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:pitocin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4198. en:pituitary hormone-releasing hormones --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:pituitary hormone-releasing hormones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4199. en:pivotal moment --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:pivotal moment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4200. en:placental extracts --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:placental extracts | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4201. en:plasma serine protease inhibitor --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:plasma serine protease inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4202. en:platelet transfusion --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:platelet transfusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4203. en:polychlorinated biphenyl --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:polychlorinated biphenyl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4204. en:polygeline --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:polygeline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4205. en:polyisoprenyl phosphate sugars --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:polyisoprenyl phosphate sugars | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4206. en:polyribonucleotides --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:polyribonucleotides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4207. en:proinsulin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:proinsulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4208. en:proline-specific trna --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:proline-specific trna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4209. en:promedol --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:promedol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4210. en:propanediol dehydratase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:propanediol dehydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4211. en:propylbenzilylcholine mustard --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:propylbenzilylcholine mustard | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4212. en:proscillaridin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:proscillaridin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4213. en:prostaglandin-e synthases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:prostaglandin-e synthases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4214. en:prostaglandins h --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:prostaglandins h | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4215. en:protein footprinting --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:protein footprinting | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4216. en:protein kinase c beta type --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:protein kinase c beta type | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4217. en:protein kinase c-epsilon --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:protein kinase c-epsilon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4218. en:proteinase inhibitory proteins, secretory --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:proteinase inhibitory proteins, secretory | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4219. en:purine nucleosides --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:purine nucleosides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4220. en:put powder on something --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:put powder on something | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4221. en:put talc on something --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:put talc on something | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4222. en:pyrroline carboxylate reductases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:pyrroline carboxylate reductases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4223. en:pyruvaldehyde --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:pyruvaldehyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4224. en:pyruvate dehydrogenase (lipoamide)-phosphatase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:pyruvate dehydrogenase (lipoamide)-phosphatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4225. en:quinuclidinyl benzilate --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:quinuclidinyl benzilate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4226. en:rab1 gtp-binding proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:rab1 gtp-binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4227. en:rab4 gtp-binding proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:rab4 gtp-binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4228. en:radiocontrast agent --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:radiocontrast agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4229. en:radiography, dual-energy scanned projection --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:radiography, dual-energy scanned projection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4230. en:radiography, thoracic --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:radiography, thoracic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4231. en:reading glasses --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:reading glasses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4232. en:receptor, epha7 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:receptor, epha7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4233. en:receptor, tie-1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:receptor, tie-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4234. en:receptor-like protein tyrosine phosphatases, class 5 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:receptor-like protein tyrosine phosphatases, class 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4235. en:receptors, tnf-related apoptosis-inducing ligand --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:receptors, tnf-related apoptosis-inducing ligand | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4236. en:recombinant fusion proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:recombinant fusion proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4237. en:reply to --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:reply to | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4238. en:retinoblastoma-like protein p130 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:retinoblastoma-like protein p130 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4239. en:rho gtp-binding proteins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:rho gtp-binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4240. en:rhob protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:rhob protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4241. en:ribonucleoprotein, u7 small nuclear --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ribonucleoprotein, u7 small nuclear | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4242. en:rna, small cytoplasmic --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:rna, small cytoplasmic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4243. en:rna, spliced leader --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:rna, spliced leader | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4244. en:rubella vaccine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:rubella vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4245. en:saccharide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:saccharide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4246. en:salmine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:salmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4247. en:salt --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:salt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4248. en:sanitary products --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sanitary products | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4249. en:sanitary protection --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sanitary protection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4250. en:scotoscopy --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:scotoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4251. en:second look operation --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:second look operation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4252. en:secretory immunoglobulin a --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:secretory immunoglobulin a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4253. en:sedative and hypnotic --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sedative and hypnotic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4254. en:septal occluder device --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:septal occluder device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4255. en:serine/threonine protein kinase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:serine/threonine protein kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4256. en:sgot (ast) --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sgot (ast) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4257. en:shiga toxins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:shiga toxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4258. en:silicate cement --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:silicate cement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4259. en:simazine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:simazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4260. en:sin3 histone deacetylase and corepressor complex --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sin3 histone deacetylase and corepressor complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4261. en:single-chain variable fragment --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:single-chain variable fragment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4262. en:sirtuin 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sirtuin 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4263. en:skeletal muscle ventricle --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:skeletal muscle ventricle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4264. en:smad6 protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:smad6 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4265. en:smarcb1 protein --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:smarcb1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4266. en:sodium-phosphate cotransporter proteins, type iic --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sodium-phosphate cotransporter proteins, type iic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4267. en:sodium-potassium-chloride symporters --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sodium-potassium-chloride symporters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4268. en:soil pollutants, radioactive --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:soil pollutants, radioactive | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4269. en:solute carrier family 12, member 3 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:solute carrier family 12, member 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4270. en:source code --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:source code | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4271. en:source text --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:source text | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4272. en:soxc transcription factors --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:soxc transcription factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4273. en:sperm injections, intracytoplasmic --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sperm injections, intracytoplasmic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4274. en:spermicide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:spermicide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4275. en:sphingosine n-acyltransferase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:sphingosine n-acyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4276. en:splenectomy --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:splenectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4277. en:stat6 transcription factor --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:stat6 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4278. en:streptothricins --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:streptothricins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4279. en:superoxide dismutase 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:superoxide dismutase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4280. en:surgical intervention --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:surgical intervention | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4281. en:tacrolimus binding protein 1a --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tacrolimus binding protein 1a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4282. en:teniposide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:teniposide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4283. en:teprotide --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:teprotide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4284. en:tetanus serum --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tetanus serum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4285. en:therapeutic estrone --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:therapeutic estrone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4286. en:thermoluminescent dosimetry --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:thermoluminescent dosimetry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4287. en:thiobarbituric acid reactive substances --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:thiobarbituric acid reactive substances | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4288. en:thioredoxin reductase 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:thioredoxin reductase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4289. en:thioredoxin reductase 2 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:thioredoxin reductase 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4290. en:thiouracil --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:thiouracil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4291. en:tissue expansion devices --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tissue expansion devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4292. en:tissue inhibitor of metalloproteinase-3 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tissue inhibitor of metalloproteinase-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4293. en:tmpo gene product --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tmpo gene product | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4294. en:tnf receptor-associated factor 2 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tnf receptor-associated factor 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4295. en:to answer sb back --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:to answer sb back | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4296. en:to be the counterpart of --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:to be the counterpart of | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4297. en:to correspond to --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:to correspond to | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4298. en:to match --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:to match | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4299. en:to meet --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:to meet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4300. en:to reply to --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:to reply to | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4301. en:tosyllysine chloromethyl ketone --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tosyllysine chloromethyl ketone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4302. en:transcription factor brn-3 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:transcription factor brn-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4303. en:trastuzumab --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:trastuzumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4304. en:trimedoxime --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:trimedoxime | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4305. en:troponin c --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:troponin c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4306. en:tumor necrosis factor ligand superfamily member 11 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tumor necrosis factor ligand superfamily member 11 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4307. en:tumor necrosis factor receptor superfamily member 5 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tumor necrosis factor receptor superfamily member 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4308. en:tumor suppressor arf --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:tumor suppressor arf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4309. en:typhoid-paratyphoid vaccines --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:typhoid-paratyphoid vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4310. en:ureohydrolases --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:ureohydrolases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4311. en:uricosuric agent --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:uricosuric agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4312. en:uridine diphosphate n-acetylmuramic acid --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:uridine diphosphate n-acetylmuramic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4313. en:uroplakin ib --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:uroplakin ib | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4314. en:utp-hexose-1-phosphate uridylyltransferase --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:utp-hexose-1-phosphate uridylyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4315. en:vaccines, marker --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:vaccines, marker | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4316. en:valinomycin --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:valinomycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4317. en:vascular cell adhesion protein 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:vascular cell adhesion protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4318. en:vascular endothelial growth factor receptor-2 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:vascular endothelial growth factor receptor-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4319. en:veratridine --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:veratridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4320. en:vesicular glutamate transport protein 1 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:vesicular glutamate transport protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4321. en:vif gene products, human immunodeficiency virus --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:vif gene products, human immunodeficiency virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4322. en:viper venoms --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:viper venoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4323. en:voltage-dependent anion channel 2 --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:voltage-dependent anion channel 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4324. en:water cure --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:water cure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4325. en:wrench --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:wrench | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4326. en:xylans --- r_associated #0: 30 --> en:contraindications aspect
    n1=en:xylans | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4327. faire connaissance --- r_associated #0: 30 --> en:contraindications aspect
    n1=faire connaissance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4328. faire connaissance avec --- r_associated #0: 30 --> en:contraindications aspect
    n1=faire connaissance avec | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4329. faire connaissance avec [qqn] --- r_associated #0: 30 --> en:contraindications aspect
    n1=faire connaissance avec [qqn] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4330. faire connaissance avec qn --- r_associated #0: 30 --> en:contraindications aspect
    n1=faire connaissance avec qn | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4331. faire connaissance avec quelqu'un --- r_associated #0: 30 --> en:contraindications aspect
    n1=faire connaissance avec quelqu'un | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4332. faire connaissance de --- r_associated #0: 30 --> en:contraindications aspect
    n1=faire connaissance de | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4333. faire connaissance de [qqn] --- r_associated #0: 30 --> en:contraindications aspect
    n1=faire connaissance de [qqn] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4334. faire connaissance de quelqu'un --- r_associated #0: 30 --> en:contraindications aspect
    n1=faire connaissance de quelqu'un | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4335. faire pendant à --- r_associated #0: 30 --> en:contraindications aspect
    n1=faire pendant à | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4336. fenamates --- r_associated #0: 30 --> en:contraindications aspect
    n1=fenamates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4337. formamides --- r_associated #0: 30 --> en:contraindications aspect
    n1=formamides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4338. fragments des immunoglobulines --- r_associated #0: 30 --> en:contraindications aspect
    n1=fragments des immunoglobulines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4339. hépatosplénographie --- r_associated #0: 30 --> en:contraindications aspect
    n1=hépatosplénographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4340. indolequinones --- r_associated #0: 30 --> en:contraindications aspect
    n1=indolequinones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4341. inosine triphosphate --- r_associated #0: 30 --> en:contraindications aspect
    n1=inosine triphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4342. lactotransferrine --- r_associated #0: 30 --> en:contraindications aspect
    n1=lactotransferrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4343. langage informatique --- r_associated #0: 30 --> en:contraindications aspect
    n1=langage informatique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4344. laparoscope --- r_associated #0: 30 --> en:contraindications aspect
    n1=laparoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4345. lier connaissance avec --- r_associated #0: 30 --> en:contraindications aspect
    n1=lier connaissance avec | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4346. lier connaissance avec [qqn] --- r_associated #0: 30 --> en:contraindications aspect
    n1=lier connaissance avec [qqn] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4347. lier connaissance avec quelqu'un --- r_associated #0: 30 --> en:contraindications aspect
    n1=lier connaissance avec quelqu'un | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4348. mam --- r_associated #0: 30 --> en:contraindications aspect
    n1=mam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4349. oxymétholone --- r_associated #0: 30 --> en:contraindications aspect
    n1=oxymétholone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4350. phosphofructokinase --- r_associated #0: 30 --> en:contraindications aspect
    n1=phosphofructokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4351. poudrer --- r_associated #0: 30 --> en:contraindications aspect
    n1=poudrer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4352. premiers secours --- r_associated #0: 30 --> en:contraindications aspect
    n1=premiers secours | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4353. pro-insuline --- r_associated #0: 30 --> en:contraindications aspect
    n1=pro-insuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4354. proinsuline --- r_associated #0: 30 --> en:contraindications aspect
    n1=proinsuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4355. proscillaridine --- r_associated #0: 30 --> en:contraindications aspect
    n1=proscillaridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4356. protection hygiénique --- r_associated #0: 30 --> en:contraindications aspect
    n1=protection hygiénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4357. scanner
    (Nom)
     --- r_associated #0: 30 --> en:contraindications aspect
    n1=scanner
    (Nom)
    | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4358. se joindre --- r_associated #0: 30 --> en:contraindications aspect
    n1=se joindre | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4359. sel fin --- r_associated #0: 30 --> en:contraindications aspect
    n1=sel fin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4360. simazine --- r_associated #0: 30 --> en:contraindications aspect
    n1=simazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4361. somatocrinine --- r_associated #0: 30 --> en:contraindications aspect
    n1=somatocrinine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4362. spermicide --- r_associated #0: 30 --> en:contraindications aspect
    n1=spermicide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4363. splénectomie --- r_associated #0: 30 --> en:contraindications aspect
    n1=splénectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4364. sulfate de magnésie --- r_associated #0: 30 --> en:contraindications aspect
    n1=sulfate de magnésie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4365. texte source --- r_associated #0: 30 --> en:contraindications aspect
    n1=texte source | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4366. thoracoabdominal (signe) --- r_associated #0: 30 --> en:contraindications aspect
    n1=thoracoabdominal (signe) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4367. tomographie à émission de positrons --- r_associated #0: 30 --> en:contraindications aspect
    n1=tomographie à émission de positrons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4368. transfusion de sang --- r_associated #0: 30 --> en:contraindications aspect
    n1=transfusion de sang | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4369. transfusion sanguine --- r_associated #0: 30 --> en:contraindications aspect
    n1=transfusion sanguine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4370. trastuzumab --- r_associated #0: 30 --> en:contraindications aspect
    n1=trastuzumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4371. téniposide --- r_associated #0: 30 --> en:contraindications aspect
    n1=téniposide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4372. vaccinal --- r_associated #0: 30 --> en:contraindications aspect
    n1=vaccinal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4373. vitamine b5 --- r_associated #0: 30 --> en:contraindications aspect
    n1=vitamine b5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4374. électronarcose --- r_associated #0: 30 --> en:contraindications aspect
    n1=électronarcose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4375. éther de glycol --- r_associated #0: 30 --> en:contraindications aspect
    n1=éther de glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4376. éthosuximide --- r_associated #0: 30 --> en:contraindications aspect
    n1=éthosuximide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=30
  4377. SRIH --- r_associated #0: 29 --> en:contraindications aspect
    n1=SRIH | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4378. acide ophtalmique --- r_associated #0: 29 --> en:contraindications aspect
    n1=acide ophtalmique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4379. acide shikimique --- r_associated #0: 29 --> en:contraindications aspect
    n1=acide shikimique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4380. agonistes purinergiques --- r_associated #0: 29 --> en:contraindications aspect
    n1=agonistes purinergiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4381. amniocentèse --- r_associated #0: 29 --> en:contraindications aspect
    n1=amniocentèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4382. analyse en intention de traiter --- r_associated #0: 29 --> en:contraindications aspect
    n1=analyse en intention de traiter | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4383. auscultation cardiaque --- r_associated #0: 29 --> en:contraindications aspect
    n1=auscultation cardiaque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4384. cancérigène --- r_associated #0: 29 --> en:contraindications aspect
    n1=cancérigène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4385. carbonate de lithium --- r_associated #0: 29 --> en:contraindications aspect
    n1=carbonate de lithium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4386. cartographie isotopique --- r_associated #0: 29 --> en:contraindications aspect
    n1=cartographie isotopique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4387. cholangiopancréatographie rétrograde endoscopique --- r_associated #0: 29 --> en:contraindications aspect
    n1=cholangiopancréatographie rétrograde endoscopique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4388. chélateur --- r_associated #0: 29 --> en:contraindications aspect
    n1=chélateur | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4389. cimentation --- r_associated #0: 29 --> en:contraindications aspect
    n1=cimentation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4390. contre-argument --- r_associated #0: 29 --> en:contraindications aspect
    n1=contre-argument | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4391. cytochrome a et a3 --- r_associated #0: 29 --> en:contraindications aspect
    n1=cytochrome a et a3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4392. digitoxine --- r_associated #0: 29 --> en:contraindications aspect
    n1=digitoxine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4393. désoxyribonucléase --- r_associated #0: 29 --> en:contraindications aspect
    n1=désoxyribonucléase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4394. en:1-methyl-4-phenylpyridinium --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:1-methyl-4-phenylpyridinium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4395. en:2',3'-cyclic-nucleotide phosphodiesterases --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:2',3'-cyclic-nucleotide phosphodiesterases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4396. en:2-acetolactate mutase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:2-acetolactate mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4397. en:3,3'-diaminobenzidine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:3,3'-diaminobenzidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4398. en:3-hydroxybutyric acid --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:3-hydroxybutyric acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4399. en:3-o-methylglucose --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:3-o-methylglucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4400. en:4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4401. en:4-dimensional computed tomography --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:4-dimensional computed tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4402. en:4-hydroxybenzoate 3-monooxygenase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:4-hydroxybenzoate 3-monooxygenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4403. en:4-hydroxyphenylpyruvate dioxygenase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:4-hydroxyphenylpyruvate dioxygenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4404. en:5-hydroxyindoleacetic acid --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:5-hydroxyindoleacetic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4405. en:5-methoxytryptamine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:5-methoxytryptamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4406. en:6-ketoprostaglandin f1 alpha --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:6-ketoprostaglandin f1 alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4407. en:aberrometry --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:aberrometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4408. en:acid of milk --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:acid of milk | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4409. en:acrylic resins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:acrylic resins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4410. en:acupuncture therapy --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:acupuncture therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4411. en:adam10 protein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:adam10 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4412. en:adamts1 protein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:adamts1 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4413. en:adamts5 protein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:adamts5 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4414. en:adrenergic alpha-1 receptor agonists --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:adrenergic alpha-1 receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4415. en:adrenergic beta-3 receptor agonists --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:adrenergic beta-3 receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4416. en:advanced glycation end product --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:advanced glycation end product | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4417. en:aerosol propellants --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:aerosol propellants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4418. en:agglutination tests --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:agglutination tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4419. en:alpha-adrenergic antagonist --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:alpha-adrenergic antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4420. en:aluminum compounds --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:aluminum compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4421. en:alveolar bone grafting --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:alveolar bone grafting | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4422. en:ambulatory surgical procedure --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ambulatory surgical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4423. en:amino acid isomerases --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:amino acid isomerases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4424. en:amino acid n-acetyltransferase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:amino acid n-acetyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4425. en:anacardic acids --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:anacardic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4426. en:angiotensin amide --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:angiotensin amide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4427. en:anti-allergic agents --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:anti-allergic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4428. en:anti-asthmatic agent --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:anti-asthmatic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4429. en:antianxiety agent --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antianxiety agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4430. en:anticardiolipin antibody --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:anticardiolipin antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4431. en:antifoaming agents --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antifoaming agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4432. en:antifreeze proteins, type i --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antifreeze proteins, type i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4433. en:antifreeze proteins, type iv --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antifreeze proteins, type iv | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4434. en:antigen ki-67 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antigen ki-67 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4435. en:antigens, cd79 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antigens, cd79 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4436. en:antigens, cd98 heavy chain --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antigens, cd98 heavy chain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4437. en:antigens, ly --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antigens, ly | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4438. en:antihyperkalemic agents --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antihyperkalemic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4439. en:antimuscarinic agent --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:antimuscarinic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4440. en:apolipoprotein C-I --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:apolipoprotein C-I | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4441. en:apolipoprotein b-100 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:apolipoprotein b-100 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4442. en:apolipoprotein b-48 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:apolipoprotein b-48 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4443. en:aspartate aminotransferase, mitochondrial --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:aspartate aminotransferase, mitochondrial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4444. en:atazanavir sulfate --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:atazanavir sulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4445. en:atpase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:atpase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4446. en:balsams --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:balsams | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4447. en:bcl-x protein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:bcl-x protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4448. en:bendamustine hydrochloride --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:bendamustine hydrochloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4449. en:benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4450. en:benzylamine oxidase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:benzylamine oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4451. en:bephenium compounds --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:bephenium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4452. en:berberine alkaloids --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:berberine alkaloids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4453. en:beta chemokine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:beta chemokine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4454. en:biomimetic materials --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:biomimetic materials | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4455. en:blade implantation --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:blade implantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4456. en:bone-patellar tendon-bone grafting --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:bone-patellar tendon-bone grafting | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4457. en:brassinosteroids --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:brassinosteroids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4458. en:bromobenzoates --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:bromobenzoates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4459. en:burimamide --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:burimamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4460. en:c-c motif chemokine 3 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:c-c motif chemokine 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4461. en:calcium channels, q-type --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:calcium channels, q-type | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4462. en:calcium channels, r-type --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:calcium channels, r-type | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4463. en:caproates --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:caproates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4464. en:carbapenems --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:carbapenems | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4465. en:carbenoxolone --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:carbenoxolone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4466. en:carotid endarterectomy --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:carotid endarterectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4467. en:casein kinase ialpha --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:casein kinase ialpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4468. en:caspase inhibitor --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:caspase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4469. en:caspases, effector --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:caspases, effector | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4470. en:casts, surgical --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:casts, surgical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4471. en:cd70 antigen --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cd70 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4472. en:cdc2-cdc28 kinases --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cdc2-cdc28 kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4473. en:cdc25 phosphatases --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cdc25 phosphatases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4474. en:cerebral computerized tomography --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cerebral computerized tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4475. en:chemokine ccl20 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:chemokine ccl20 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4476. en:chemokine ccl4 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:chemokine ccl4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4477. en:chenodiol --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:chenodiol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4478. en:chloromercuribenzoates --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:chloromercuribenzoates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4479. en:cholestadienes --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cholestadienes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4480. en:cholesterol esters --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cholesterol esters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4481. en:cholinesterase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cholinesterase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4482. en:cleavage and polyadenylation specificity factor --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cleavage and polyadenylation specificity factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4483. en:cnidarian venoms --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cnidarian venoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4484. en:co-repressor proteins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:co-repressor proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4485. en:coformycin --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:coformycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4486. en:complement c5 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:complement c5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4487. en:contraceptives, oral, synthetic --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:contraceptives, oral, synthetic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4488. en:contraceptives, postcoital, hormonal --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:contraceptives, postcoital, hormonal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4489. en:contrast media --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:contrast media | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4490. en:creation of peritoneovascular shunt --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:creation of peritoneovascular shunt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4491. en:crowns --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:crowns | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4492. en:cryptoxanthins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cryptoxanthins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4493. en:cyclin i --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cyclin i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4494. en:cyclin t --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cyclin t | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4495. en:cyclin-a2 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cyclin-a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4496. en:cyclopropanes --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cyclopropanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4497. en:cytochrome p450 cyp2c9 enzyme --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cytochrome p450 cyp2c9 enzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4498. en:cytosolic phospholipase a2 group iv --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:cytosolic phospholipase a2 group iv | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4499. en:d-ala(2),mephe(4),met(0)-ol-enkephalin --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:d-ala(2),mephe(4),met(0)-ol-enkephalin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4500. en:dead box protein 20 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:dead box protein 20 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4501. en:deae-dextran --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:deae-dextran | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4502. en:decanoates --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:decanoates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4503. en:decoquinate --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:decoquinate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4504. en:decortication --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:decortication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4505. en:decoy receptor 3 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:decoy receptor 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4506. en:denosumab --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:denosumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4507. en:denture retention --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:denture retention | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4508. en:denture, partial --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:denture, partial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4509. en:dibenzylchlorethamine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:dibenzylchlorethamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4510. en:dibromothymoquinone --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:dibromothymoquinone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4511. en:dicyclohexylcarbodiimide --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:dicyclohexylcarbodiimide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4512. en:dietary sodium --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:dietary sodium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4513. en:digitoxin --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:digitoxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4514. en:dihydroxydihydrobenzopyrenes --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:dihydroxydihydrobenzopyrenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4515. en:dipeptidyl-peptidases and tripeptidyl-peptidases --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:dipeptidyl-peptidases and tripeptidyl-peptidases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4516. en:diphenylacetic acids --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:diphenylacetic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4517. en:dithizone --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:dithizone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4518. en:drugs, chinese herbal --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:drugs, chinese herbal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4519. en:dulanermin --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:dulanermin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4520. en:elav-like protein 1 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:elav-like protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4521. en:elective surgical procedure --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:elective surgical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4522. en:electrosurgery --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:electrosurgery | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4523. en:emergency care --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:emergency care | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4524. en:endpoint determination --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:endpoint determination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4525. en:epoxide compound --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:epoxide compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4526. en:ethylene glycols --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ethylene glycols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4527. en:etilefrine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:etilefrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4528. en:eyeglasses --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:eyeglasses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4529. en:farnesyl-diphosphate farnesyltransferase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:farnesyl-diphosphate farnesyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4530. en:farnesyltranstransferase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:farnesyltranstransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4531. en:fat emulsion --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:fat emulsion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4532. en:fat-restricted diet --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:fat-restricted diet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4533. en:ferrous compounds --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ferrous compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4534. en:ferrozine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ferrozine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4535. en:fetal globulins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:fetal globulins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4536. en:filaricides --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:filaricides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4537. en:film dosimetry --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:film dosimetry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4538. en:fluorescamine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:fluorescamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4539. en:fluoro-uracile --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:fluoro-uracile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4540. en:fos oncoprotein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:fos oncoprotein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4541. en:fracture fixation, internal --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:fracture fixation, internal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4542. en:glucose solution, hypertonic --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:glucose solution, hypertonic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4543. en:glucose transporter type 2 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:glucose transporter type 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4544. en:glycine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:glycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4545. en:gonadostimulin --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:gonadostimulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4546. en:granulocyte colony-stimulating factor --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:granulocyte colony-stimulating factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4547. en:green fluorescent proteins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:green fluorescent proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4548. en:group ii chaperonins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:group ii chaperonins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4549. en:growth differentiation factor 5 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:growth differentiation factor 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4550. en:gtp --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:gtp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4551. en:gtp-binding protein alpha subunits, g12-g13 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:gtp-binding protein alpha subunits, g12-g13 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4552. en:guanine nucleotide dissociation inhibitors --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:guanine nucleotide dissociation inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4553. en:halogenated diphenyl ethers --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:halogenated diphenyl ethers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4554. en:hemodialysis solutions --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hemodialysis solutions | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4555. en:hemostasis, endoscopic --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hemostasis, endoscopic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4556. en:hepatitis b vaccines --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hepatitis b vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4557. en:hepatocyte nuclear factor 1-alpha --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hepatocyte nuclear factor 1-alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4558. en:hepatocyte nuclear factor 4 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hepatocyte nuclear factor 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4559. en:heptavalent pneumococcal conjugate vaccine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:heptavalent pneumococcal conjugate vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4560. en:herpes simplex virus protein vmw65 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:herpes simplex virus protein vmw65 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4561. en:high density lipoprotein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:high density lipoprotein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4562. en:high density lipoprotein cholesterol --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:high density lipoprotein cholesterol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4563. en:hla-b40 antigen, human --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hla-b40 antigen, human | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4564. en:hla-drb5 antigen --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hla-drb5 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4565. en:hmga family protein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hmga family protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4566. en:human glandular kallikrein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:human glandular kallikrein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4567. en:human immunodeficiency virus proteins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:human immunodeficiency virus proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4568. en:human rho(d) immune globulin --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:human rho(d) immune globulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4569. en:hydroxy acids --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hydroxy acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4570. en:hydroxysteroid dehydrogenases --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hydroxysteroid dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4571. en:hydroxytestosterones --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hydroxytestosterones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4572. en:hyperpolarization-activated cyclic nucleotide-gated channels --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:hyperpolarization-activated cyclic nucleotide-gated channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4573. en:immunoglobulin alpha-chains --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:immunoglobulin alpha-chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4574. en:immunophenotyping --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:immunophenotyping | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4575. en:in vitro fertilisation --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:in vitro fertilisation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4576. en:induced hypotension --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:induced hypotension | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4577. en:infusions, spinal --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:infusions, spinal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4578. en:insulin-like growth factor-binding protein 3 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:insulin-like growth factor-binding protein 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4579. en:intention to treat analysis --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:intention to treat analysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4580. en:interleukin-12 subunit p40 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:interleukin-12 subunit p40 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4581. en:intraocular lens implantation procedure --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:intraocular lens implantation procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4582. en:intravenous infusion --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:intravenous infusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4583. en:ischemic preconditioning, myocardial --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ischemic preconditioning, myocardial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4584. en:isochores --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:isochores | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4585. en:isothiuronium --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:isothiuronium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4586. en:junctional adhesion molecule c --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:junctional adhesion molecule c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4587. en:keratin-14 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:keratin-14 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4588. en:keratins, hair-specific --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:keratins, hair-specific | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4589. en:kinetocardiography --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:kinetocardiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4590. en:l-ascorbate oxidase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:l-ascorbate oxidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4591. en:l-tyrosine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:l-tyrosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4592. en:large-conductance calcium-activated potassium channel alpha subunits --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:large-conductance calcium-activated potassium channel alpha subunits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4593. en:leukocyte surface antigen cd47 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:leukocyte surface antigen cd47 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4594. en:leukotriene d4 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:leukotriene d4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4595. en:lipid regulating agents --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:lipid regulating agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4596. en:lipoproteins, hdl2 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:lipoproteins, hdl2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4597. en:liposuction --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:liposuction | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4598. en:luciferases, renilla --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:luciferases, renilla | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4599. en:lymphocyte transfusion --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:lymphocyte transfusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4600. en:lymphotoxin-alpha --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:lymphotoxin-alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4601. en:lysosome-associated membrane glycoprotein 1 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:lysosome-associated membrane glycoprotein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4602. en:mafg transcription factor --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:mafg transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4603. en:marine toxins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:marine toxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4604. en:mean platelet volume measurement --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:mean platelet volume measurement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4605. en:measles/mumps/rubella vaccine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:measles/mumps/rubella vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4606. en:mercaptoethylamines --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:mercaptoethylamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4607. en:mercuribenzoates --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:mercuribenzoates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4608. en:metalloids --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:metalloids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4609. en:methylglucosides --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:methylglucosides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4610. en:methylhydrazines --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:methylhydrazines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4611. en:methylprednisolone hemisuccinate --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:methylprednisolone hemisuccinate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4612. en:microcystins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:microcystins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4613. en:milk proteins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:milk proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4614. en:minichromosome maintenance complex component 5 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:minichromosome maintenance complex component 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4615. en:mitobronitol --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:mitobronitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4616. en:mitogen-activated protein kinase 3 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:mitogen-activated protein kinase 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4617. en:monomeric clathrin assembly proteins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:monomeric clathrin assembly proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4618. en:multi-ingredient cold, flu, and allergy medications --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:multi-ingredient cold, flu, and allergy medications | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4619. en:muzolimine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:muzolimine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4620. en:myristates --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:myristates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4621. en:n-nitrosodiethylamine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:n-nitrosodiethylamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4622. en:natriuretic agents --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:natriuretic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4623. en:neuroprotective agent --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:neuroprotective agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4624. en:nf-e2 transcription factor, p45 subunit --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:nf-e2 transcription factor, p45 subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4625. en:nf-kappa b p65 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:nf-kappa b p65 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4626. en:nialamide --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:nialamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4627. en:nitric oxide synthase type i --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:nitric oxide synthase type i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4628. en:nitroblue tetrazolium --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:nitroblue tetrazolium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4629. en:nitrophenylgalactosides --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:nitrophenylgalactosides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4630. en:norgestrienone --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:norgestrienone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4631. en:noxae --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:noxae | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4632. en:nucleic acid precursors --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:nucleic acid precursors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4633. en:o-chlorobenzylidenemalonitrile --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:o-chlorobenzylidenemalonitrile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4634. en:obidoxime chloride --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:obidoxime chloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4635. en:oncogene protein v-cbl --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:oncogene protein v-cbl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4636. en:opiate antagonist --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:opiate antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4637. en:ossicular replacement prosthesis --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ossicular replacement prosthesis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4638. en:oxathiins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:oxathiins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4639. en:oxidants, photochemical --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:oxidants, photochemical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4640. en:oxidoreductases, n-demethylating --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:oxidoreductases, n-demethylating | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4641. en:p-fluorophenylalanine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:p-fluorophenylalanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4642. en:p120 gtpase activating protein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:p120 gtpase activating protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4643. en:panoramic radiography --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:panoramic radiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4644. en:peripherins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:peripherins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4645. en:peroxisomal bifunctional enzyme --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:peroxisomal bifunctional enzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4646. en:phenetidine --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:phenetidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4647. en:phenylglyoxal --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:phenylglyoxal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4648. en:phosphatidylinositol 3 kinase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:phosphatidylinositol 3 kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4649. en:phosphoadenosine phosphosulfate --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:phosphoadenosine phosphosulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4650. en:phosphoramide mustards --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:phosphoramide mustards | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4651. en:phosphorylases --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:phosphorylases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4652. en:physical conditioning, human --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:physical conditioning, human | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4653. en:pituitary function tests --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:pituitary function tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4654. en:platelet-derived growth factor receptor beta --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:platelet-derived growth factor receptor beta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4655. en:platelet-derived growth factor subunit b --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:platelet-derived growth factor subunit b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4656. en:plethysmography --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:plethysmography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4657. en:polyubiquitin-c --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:polyubiquitin-c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4658. en:proadifen --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:proadifen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4659. en:proline-directed protein kinases --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:proline-directed protein kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4660. en:protein tyrosine phosphatase, non-receptor type 4 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:protein tyrosine phosphatase, non-receptor type 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4661. en:protein-arginine n-methyltransferase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:protein-arginine n-methyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4662. en:proto-oncogene proteins c-hck --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:proto-oncogene proteins c-hck | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4663. en:punctal plugs --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:punctal plugs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4664. en:purinergic agonists --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:purinergic agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4665. en:purinergic antagonists --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:purinergic antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4666. en:purinergic p2y receptor agonists --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:purinergic p2y receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4667. en:pyrazolones --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:pyrazolones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4668. en:pyridoxic acid --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:pyridoxic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4669. en:quinolinic acid --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:quinolinic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4670. en:rad52 dna repair and recombination protein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:rad52 dna repair and recombination protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4671. en:radiographic magnification --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:radiographic magnification | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4672. en:radioisotope scanning --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:radioisotope scanning | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4673. en:radioprotective agent --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:radioprotective agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4674. en:rafoxanide --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:rafoxanide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4675. en:rehydration solutions --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:rehydration solutions | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4676. en:respiratory protective devices --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:respiratory protective devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4677. en:ribonucleoprotein, u1 small nuclear --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ribonucleoprotein, u1 small nuclear | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4678. en:rna polymerase iii --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:rna polymerase iii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4679. en:runt-related transcription factor 2 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:runt-related transcription factor 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4680. en:runt-related transcription factor 3 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:runt-related transcription factor 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4681. en:rutamycin --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:rutamycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4682. en:sarcoglycans --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:sarcoglycans | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4683. en:second-look surgery --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:second-look surgery | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4684. en:sensory system agents --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:sensory system agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4685. en:serotonin agents --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:serotonin agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4686. en:serpin e2 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:serpin e2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4687. en:set of cogs --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:set of cogs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4688. en:silicone oils --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:silicone oils | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4689. en:sirtuin 2 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:sirtuin 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4690. en:sirtuins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:sirtuins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4691. en:site-specific dna-methyltransferase (cytosine-n4-specific) --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:site-specific dna-methyltransferase (cytosine-n4-specific) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4692. en:small ubiquitin-related modifier proteins --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:small ubiquitin-related modifier proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4693. en:sodium ionophores --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:sodium ionophores | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4694. en:son of sevenless protein, drosophila --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:son of sevenless protein, drosophila | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4695. en:speech articulation tests --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:speech articulation tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4696. en:stapes mobilization --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:stapes mobilization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4697. en:stat transcription factors --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:stat transcription factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4698. en:steroid 16-alpha-hydroxylase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:steroid 16-alpha-hydroxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4699. en:stromal interaction molecule 2 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:stromal interaction molecule 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4700. en:stromelysin 2 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:stromelysin 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4701. en:subtilisin --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:subtilisin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4702. en:sulfhydryl reagents --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:sulfhydryl reagents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4703. en:table salt --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:table salt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4704. en:taurochenodeoxycholic acid --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:taurochenodeoxycholic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4705. en:taurolithocholic acid --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:taurolithocholic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4706. en:technetium tc-99m pyrophosphate --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:technetium tc-99m pyrophosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4707. en:telomeric repeat binding protein 1 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:telomeric repeat binding protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4708. en:testicular hormones --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:testicular hormones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4709. en:tetragastrin --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:tetragastrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4710. en:tetralones --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:tetralones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4711. en:tetraoxanes --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:tetraoxanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4712. en:thermosomes --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:thermosomes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4713. en:tooth bleaching agents --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:tooth bleaching agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4714. en:tpr/met fusion protein --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:tpr/met fusion protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4715. en:transcription factor tfiib --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:transcription factor tfiib | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4716. en:transforming growth factor beta-3 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:transforming growth factor beta-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4717. en:triacetoneamine-n-oxyl --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:triacetoneamine-n-oxyl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4718. en:triazene compound --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:triazene compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4719. en:trichophytin antigens --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:trichophytin antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4720. en:trpc cation channels --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:trpc cation channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4721. en:tumor necrosis factor ligand superfamily member 4 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:tumor necrosis factor ligand superfamily member 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4722. en:tyrosine phenol-lyase --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:tyrosine phenol-lyase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4723. en:ulnar collateral ligament reconstruction --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ulnar collateral ligament reconstruction | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4724. en:ultrasonography, doppler, pulsed --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ultrasonography, doppler, pulsed | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4725. en:ultrasonography, mammary --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:ultrasonography, mammary | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4726. en:uroplakin ii --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:uroplakin ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4727. en:uroporphyrinogens --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:uroporphyrinogens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4728. en:venlafaxine hydrochloride --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:venlafaxine hydrochloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4729. en:vesicle-associated membrane protein 3 --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:vesicle-associated membrane protein 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4730. en:wheat germ agglutinin-horseradish peroxidase conjugate --- r_associated #0: 29 --> en:contraindications aspect
    n1=en:wheat germ agglutinin-horseradish peroxidase conjugate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4731. fluoro-5 cytosine --- r_associated #0: 29 --> en:contraindications aspect
    n1=fluoro-5 cytosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4732. imagerie à résonance magnétique --- r_associated #0: 29 --> en:contraindications aspect
    n1=imagerie à résonance magnétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4733. intention de traitement (analyse en) --- r_associated #0: 29 --> en:contraindications aspect
    n1=intention de traitement (analyse en) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4734. laxatif --- r_associated #0: 29 --> en:contraindications aspect
    n1=laxatif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4735. mal parler à --- r_associated #0: 29 --> en:contraindications aspect
    n1=mal parler à | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4736. matière particulaire --- r_associated #0: 29 --> en:contraindications aspect
    n1=matière particulaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4737. matières dangereuses --- r_associated #0: 29 --> en:contraindications aspect
    n1=matières dangereuses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4738. mitobronitol --- r_associated #0: 29 --> en:contraindications aspect
    n1=mitobronitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4739. moment décisif --- r_associated #0: 29 --> en:contraindications aspect
    n1=moment décisif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4740. phosphorylases --- r_associated #0: 29 --> en:contraindications aspect
    n1=phosphorylases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4741. pléthysmographie --- r_associated #0: 29 --> en:contraindications aspect
    n1=pléthysmographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4742. sel d'epsom --- r_associated #0: 29 --> en:contraindications aspect
    n1=sel d'epsom | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4743. subtilisine --- r_associated #0: 29 --> en:contraindications aspect
    n1=subtilisine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4744. thiadiazines --- r_associated #0: 29 --> en:contraindications aspect
    n1=thiadiazines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4745. vaccin antigrippal --- r_associated #0: 29 --> en:contraindications aspect
    n1=vaccin antigrippal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4746. wolframite --- r_associated #0: 29 --> en:contraindications aspect
    n1=wolframite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=29
  4747. BKNV --- r_associated #0: 28 --> en:contraindications aspect
    n1=BKNV | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4748. DOBV --- r_associated #0: 28 --> en:contraindications aspect
    n1=DOBV | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4749. Levine-Critchley (syndrome de) --- r_associated #0: 28 --> en:contraindications aspect
    n1=Levine-Critchley (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4750. Lunettes de vue --- r_associated #0: 28 --> en:contraindications aspect
    n1=Lunettes de vue | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4751. Seckel-like type Majoor-Krakauer (syndrome de) --- r_associated #0: 28 --> en:contraindications aspect
    n1=Seckel-like type Majoor-Krakauer (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4752. TomoDensitoMétrie --- r_associated #0: 28 --> en:contraindications aspect
    n1=TomoDensitoMétrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4753. acide iduronique --- r_associated #0: 28 --> en:contraindications aspect
    n1=acide iduronique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4754. acide ribonucléique --- r_associated #0: 28 --> en:contraindications aspect
    n1=acide ribonucléique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4755. acide succinique --- r_associated #0: 28 --> en:contraindications aspect
    n1=acide succinique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4756. carbapénèmes --- r_associated #0: 28 --> en:contraindications aspect
    n1=carbapénèmes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4757. chirurgie bucco-dentaire et maxillaire --- r_associated #0: 28 --> en:contraindications aspect
    n1=chirurgie bucco-dentaire et maxillaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4758. cuti --- r_associated #0: 28 --> en:contraindications aspect
    n1=cuti | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4759. cystathionine bêta-synthase --- r_associated #0: 28 --> en:contraindications aspect
    n1=cystathionine bêta-synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4760. cystoscope --- r_associated #0: 28 --> en:contraindications aspect
    n1=cystoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4761. diamond --- r_associated #0: 28 --> en:contraindications aspect
    n1=diamond | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4762. dihydroergocornine --- r_associated #0: 28 --> en:contraindications aspect
    n1=dihydroergocornine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4763. disopyramide n. m --- r_associated #0: 28 --> en:contraindications aspect
    n1=disopyramide n. m | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4764. en:1-sarcosine-8-isoleucine angiotensin ii --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:1-sarcosine-8-isoleucine angiotensin ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4765. en:11-hydroxycorticosteroids --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:11-hydroxycorticosteroids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4766. en:16,16-dimethylprostaglandin e2 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:16,16-dimethylprostaglandin e2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4767. en:18-hydroxydesoxycorticosterone --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:18-hydroxydesoxycorticosterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4768. en:2,6-dichloroindophenol --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:2,6-dichloroindophenol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4769. en:2-amino-5-phosphonovalerate --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:2-amino-5-phosphonovalerate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4770. en:20-hydroxysteroid dehydrogenases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:20-hydroxysteroid dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4771. en:3-oxoacyl-(acyl-carrier-protein) synthase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:3-oxoacyl-(acyl-carrier-protein) synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4772. en:4-chloromercuribenzenesulfonate --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:4-chloromercuribenzenesulfonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4773. en:4-hydroxyaminoquinoline-1-oxide --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:4-hydroxyaminoquinoline-1-oxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4774. en:4-nitroquinoline-1-oxide --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:4-nitroquinoline-1-oxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4775. en:5-lipoxygenase-activating protein inhibitors --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:5-lipoxygenase-activating protein inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4776. en:IUD --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:IUD | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4777. en:Mercury --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:Mercury | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4778. en:NMR imaging --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:NMR imaging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4779. en:acetoxyacetylaminofluorene --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:acetoxyacetylaminofluorene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4780. en:acids, carbocyclic --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:acids, carbocyclic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4781. en:adaptor protein complex sigma subunits --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:adaptor protein complex sigma subunits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4782. en:adenovirus e3 proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:adenovirus e3 proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4783. en:algestone --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:algestone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4784. en:alkylating agent --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:alkylating agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4785. en:alpha-adrenergic agonist --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:alpha-adrenergic agonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4786. en:alpha-naphthyl acetate esterase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:alpha-naphthyl acetate esterase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4787. en:aluminum silicate --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:aluminum silicate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4788. en:amino acid transport systems, acidic --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:amino acid transport systems, acidic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4789. en:amino acids, branched-chain --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:amino acids, branched-chain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4790. en:aminobiphenyl compounds --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:aminobiphenyl compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4791. en:aminorex --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:aminorex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4792. en:angiotensin ii type 1 receptor blockers --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:angiotensin ii type 1 receptor blockers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4793. en:ant venoms --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ant venoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4794. en:antifibrinolytic agents --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:antifibrinolytic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4795. en:antigens, cd1d --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:antigens, cd1d | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4796. en:apc2 subunit, anaphase-promoting complex-cyclosome --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:apc2 subunit, anaphase-promoting complex-cyclosome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4797. en:aphrodisiacs --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:aphrodisiacs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4798. en:apolipoprotein c-i --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:apolipoprotein c-i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4799. en:apolipoprotein e2 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:apolipoprotein e2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4800. en:arabinofuranosylcytosine triphosphate --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:arabinofuranosylcytosine triphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4801. en:arachidonate lipoxygenases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:arachidonate lipoxygenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4802. en:aspartate carbamoyltransferase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:aspartate carbamoyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4803. en:aspartic acid endopeptidases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:aspartic acid endopeptidases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4804. en:atomoxetine hydrochloride --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:atomoxetine hydrochloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4805. en:aurkc protein, human --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:aurkc protein, human | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4806. en:autonomic denervation --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:autonomic denervation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4807. en:azulenes --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:azulenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4808. en:bedding and linens --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:bedding and linens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4809. en:benzophenoneidum --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:benzophenoneidum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4810. en:betacellulin --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:betacellulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4811. en:bone plates --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:bone plates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4812. en:bone screws --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:bone screws | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4813. en:bornanes --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:bornanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4814. en:bronchoalveolar lavage --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:bronchoalveolar lavage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4815. en:calcium ionophores --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:calcium ionophores | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4816. en:calcium-calmodulin-dependent protein kinase type 1 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:calcium-calmodulin-dependent protein kinase type 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4817. en:calcium-calmodulin-dependent protein kinase type 4 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:calcium-calmodulin-dependent protein kinase type 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4818. en:canrenone --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:canrenone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4819. en:carbachol chloride --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:carbachol chloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4820. en:carbon-oxygen lyases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:carbon-oxygen lyases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4821. en:carboxyl and carbamoyl transferases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:carboxyl and carbamoyl transferases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4822. en:cardiac catheterization --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cardiac catheterization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4823. en:cardiac resynchronization therapy devices --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cardiac resynchronization therapy devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4824. en:casein kinase i --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:casein kinase i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4825. en:ccaat/enhancer binding protein beta --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ccaat/enhancer binding protein beta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4826. en:cell adhesion molecules, neuron-glia --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cell adhesion molecules, neuron-glia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4827. en:cellulases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cellulases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4828. en:central venous access catheter --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:central venous access catheter | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4829. en:chemotherapeutic perfusion --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:chemotherapeutic perfusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4830. en:child restraint systems --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:child restraint systems | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4831. en:chloroplast proton-translocating atpases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:chloroplast proton-translocating atpases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4832. en:cholestanes --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cholestanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4833. en:chromium radioisotopes --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:chromium radioisotopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4834. en:citraconic anhydrides --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:citraconic anhydrides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4835. en:clathrin light chains --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:clathrin light chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4836. en:cobra venoms --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cobra venoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4837. en:collagen type ix --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:collagen type ix | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4838. en:collagen type xi --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:collagen type xi | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4839. en:colony stimulating factor --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:colony stimulating factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4840. en:complement c4-b --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:complement c4-b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4841. en:computer aided tomography --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:computer aided tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4842. en:cone opsins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cone opsins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4843. en:coproporphyrinogens --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:coproporphyrinogens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4844. en:core binding factor beta subunit --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:core binding factor beta subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4845. en:cortactin --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cortactin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4846. en:creatine kinase, mm form --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:creatine kinase, mm form | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4847. en:cxc chemokine ip-10 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cxc chemokine ip-10 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4848. en:cyclic adp-ribose --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cyclic adp-ribose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4849. en:cyclic amp response element-binding protein a --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cyclic amp response element-binding protein a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4850. en:cyclic amp-dependent protein kinase riialpha subunit --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cyclic amp-dependent protein kinase riialpha subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4851. en:cyclin g2 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cyclin g2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4852. en:cyclin-dependent kinase 4 inhibitor c --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cyclin-dependent kinase 4 inhibitor c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4853. en:cyclophilin a --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cyclophilin a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4854. en:cystoscope --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cystoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4855. en:cytochrome b6 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cytochrome b6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4856. en:cytochromes a1 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:cytochromes a1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4857. en:d-aspartic acid --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:d-aspartic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4858. en:delta chemokine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:delta chemokine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4859. en:dental high-speed technique --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dental high-speed technique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4860. en:dental inlays --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dental inlays | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4861. en:denture, partial, fixed, resin-bonded --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:denture, partial, fixed, resin-bonded | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4862. en:deoxyribonuclease --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:deoxyribonuclease | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4863. en:deoxyribonuclease bamhi --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:deoxyribonuclease bamhi | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4864. en:deoxyribonuclease ecori --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:deoxyribonuclease ecori | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4865. en:deoxyribonuclease hindiii --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:deoxyribonuclease hindiii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4866. en:dermcidins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dermcidins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4867. en:diabetic diet --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:diabetic diet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4868. en:dicarboxylate-binding protein --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dicarboxylate-binding protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4869. en:dichotic listening tests --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dichotic listening tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4870. en:dietary calcium --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dietary calcium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4871. en:diglycine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:diglycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4872. en:dihydroergocornine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dihydroergocornine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4873. en:dimethyl adipimidate --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dimethyl adipimidate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4874. en:dimethyldithiocarbamate --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dimethyldithiocarbamate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4875. en:diosgenin --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:diosgenin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4876. en:dioxins and dioxin-like compounds --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dioxins and dioxin-like compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4877. en:disinfectant --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:disinfectant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4878. en:dissection --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dissection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4879. en:dna mutational analysis --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dna mutational analysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4880. en:dna nucleotidyltransferases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dna nucleotidyltransferases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4881. en:dopamine transporter --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dopamine transporter | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4882. en:dopaminergic agents --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dopaminergic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4883. en:dynamin i --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dynamin i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4884. en:dynamin iii --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:dynamin iii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4885. en:e1a-associated p300 protein --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:e1a-associated p300 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4886. en:elav-like protein 4 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:elav-like protein 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4887. en:electronic amplifiers --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:electronic amplifiers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4888. en:emtricitabine, tenofovir disoproxil fumarate drug combination --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:emtricitabine, tenofovir disoproxil fumarate drug combination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4889. en:endoscopic retrograde cholangiopancreatography --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:endoscopic retrograde cholangiopancreatography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4890. en:enviomycin --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:enviomycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4891. en:eosinophil major basic protein --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:eosinophil major basic protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4892. en:epha3 receptor --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:epha3 receptor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4893. en:epha5 receptor --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:epha5 receptor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4894. en:esophagoscopes --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:esophagoscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4895. en:ethinyl estradiol-norgestrel combination --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ethinyl estradiol-norgestrel combination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4896. en:ethylketocyclazocine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ethylketocyclazocine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4897. en:ethylmorphine-n-demethylase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ethylmorphine-n-demethylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4898. en:ethylnitrosourea --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ethylnitrosourea | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4899. en:eukaryotic translation initiation factor 4e --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:eukaryotic translation initiation factor 4e | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4900. en:eukaryotic translation initiation factor 4f --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:eukaryotic translation initiation factor 4f | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4901. en:excitatory amino acid agents --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:excitatory amino acid agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4902. en:extracellular matrix protein --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:extracellular matrix protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4903. en:extraction of tooth --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:extraction of tooth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4904. en:factor va --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:factor va | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4905. en:fenclonine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:fenclonine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4906. en:fluorescence angiography --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:fluorescence angiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4907. en:functional neuroimaging --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:functional neuroimaging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4908. en:g/t mismatch-specific thymine dna glycosylase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:g/t mismatch-specific thymine dna glycosylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4909. en:g1/s-specific cyclin-d3 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:g1/s-specific cyclin-d3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4910. en:gaba agonists --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:gaba agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4911. en:gamma-tocopherol --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:gamma-tocopherol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4912. en:gestonorone caproate --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:gestonorone caproate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4913. en:glia maturation factor --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:glia maturation factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4914. en:glutathione s-transferase pi --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:glutathione s-transferase pi | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4915. en:glycine decarboxylase complex h-protein --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:glycine decarboxylase complex h-protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4916. en:glycochenodeoxycholic acid --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:glycochenodeoxycholic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4917. en:guanosine tetraphosphate --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:guanosine tetraphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4918. en:h-2 antigens --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:h-2 antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4919. en:heimlich maneuver --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:heimlich maneuver | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4920. en:herpesvirus vaccines --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:herpesvirus vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4921. en:heterogeneous nuclear ribonucleoprotein m --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:heterogeneous nuclear ribonucleoprotein m | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4922. en:hirudins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hirudins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4923. en:hiv antibody --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hiv antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4924. en:hiv integrase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hiv integrase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4925. en:hla class i histocompatibility antigen, alpha chain g --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hla class i histocompatibility antigen, alpha chain g | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4926. en:hla-a1 antigen --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hla-a1 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4927. en:hla-dr5 antigen --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hla-dr5 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4928. en:hn protein --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hn protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4929. en:hydroxycholecalciferols --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hydroxycholecalciferols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4930. en:hydroxymercuribenzoates --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hydroxymercuribenzoates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4931. en:hydroxymethylglutaryl-coa reductases, nad-dependent --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hydroxymethylglutaryl-coa reductases, nad-dependent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4932. en:hypoglycins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:hypoglycins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4933. en:immunosorbent techniques --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:immunosorbent techniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4934. en:indoleamine 2,3-dioxygenase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:indoleamine 2,3-dioxygenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4935. en:injections, intraventricular --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:injections, intraventricular | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4936. en:insect repellents --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:insect repellents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4937. en:iodoacetates --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:iodoacetates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4938. en:isonicotinic acids --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:isonicotinic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4939. en:kv1.3 potassium channel --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:kv1.3 potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4940. en:kv1.4 potassium channel --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:kv1.4 potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4941. en:kv1.5 potassium channel --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:kv1.5 potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4942. en:kyphoplasty --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:kyphoplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4943. en:l-serine dehydratase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:l-serine dehydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4944. en:l-type calcium channels --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:l-type calcium channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4945. en:levallorphan --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:levallorphan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4946. en:ligand-gated ion channels --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ligand-gated ion channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4947. en:lipid droplet associated proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:lipid droplet associated proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4948. en:lutheran blood-group system --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:lutheran blood-group system | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4949. en:lymphocyte function-associated antigen 3 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:lymphocyte function-associated antigen 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4950. en:lymphotoxin beta --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:lymphotoxin beta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4951. en:lysophosphatidylcholines --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:lysophosphatidylcholines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4952. en:macular pigment --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:macular pigment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4953. en:measurement of blood pressure --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:measurement of blood pressure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4954. en:mediator of rna polymerase ii transcription subunit 1 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:mediator of rna polymerase ii transcription subunit 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4955. en:medical pins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:medical pins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4956. en:microscopy, fluorescence, multiphoton --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:microscopy, fluorescence, multiphoton | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4957. en:mikamycin --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:mikamycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4958. en:minichromosome maintenance complex component 6 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:minichromosome maintenance complex component 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4959. en:mitochondrial proton-translocating atpases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:mitochondrial proton-translocating atpases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4960. en:mitochondrial trifunctional protein, beta subunit --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:mitochondrial trifunctional protein, beta subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4961. en:mitogen-activated protein kinase 14 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:mitogen-activated protein kinase 14 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4962. en:monoamine oxidase inhibitor --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:monoamine oxidase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4963. en:monocarboxylic acid transporters --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:monocarboxylic acid transporters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4964. en:multidetector computed tomography --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:multidetector computed tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4965. en:muscle denervation procedure --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:muscle denervation procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4966. en:n-acetylgalactosaminyltransferases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:n-acetylgalactosaminyltransferases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4967. en:n-butyl-n-(4-hydroxybutyl)nitrosamine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:n-butyl-n-(4-hydroxybutyl)nitrosamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4968. en:n-methyl-n-nitro-n-nitrosoguanidine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:n-methyl-n-nitro-n-nitrosoguanidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4969. en:nafenopin --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:nafenopin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4970. en:nasal decongestants --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:nasal decongestants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4971. en:natriuretic peptide, c-type --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:natriuretic peptide, c-type | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4972. en:neoplasm proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:neoplasm proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4973. en:neuraminic acids --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:neuraminic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4974. en:neurophysiological monitoring --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:neurophysiological monitoring | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4975. en:neutron capture therapy --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:neutron capture therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4976. en:nonsuppressible insulin-like activity --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:nonsuppressible insulin-like activity | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4977. en:norwood procedures --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:norwood procedures | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4978. en:nuclear receptor corepressor 2 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:nuclear receptor corepressor 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4979. en:nuclear receptor subfamily 2, group c, member 1 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:nuclear receptor subfamily 2, group c, member 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4980. en:nuclear respiratory factor 1 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:nuclear respiratory factor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4981. en:nucleobase transport proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:nucleobase transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4982. en:octamer transcription factor-2 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:octamer transcription factor-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4983. en:ointment dosage form --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ointment dosage form | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4984. en:oligodeoxyribonucleotides, antisense --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:oligodeoxyribonucleotides, antisense | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4985. en:oligonucleotide probes --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:oligonucleotide probes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4986. en:oncogene proteins v-erbb --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:oncogene proteins v-erbb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4987. en:operative blood salvage (procedure) --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:operative blood salvage (procedure) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4988. en:oxytocinase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:oxytocinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4989. en:pair of specs --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:pair of specs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4990. en:palmitoyl coenzyme a --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:palmitoyl coenzyme a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4991. en:pancreatic alpha-amylases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:pancreatic alpha-amylases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4992. en:papillomavirus e7 proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:papillomavirus e7 proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4993. en:parasite egg count --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:parasite egg count | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4994. en:peptide elongation factor g --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:peptide elongation factor g | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4995. en:perazine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:perazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4996. en:perilipin-4 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:perilipin-4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4997. en:peroxisome proliferator-activated receptor gamma --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:peroxisome proliferator-activated receptor gamma | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4998. en:phosphatidylinositol 3-kinases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:phosphatidylinositol 3-kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  4999. en:photogrammetry --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:photogrammetry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5000. en:phycobilins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:phycobilins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5001. en:pituitary adenylate cyclase activating polypeptide --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:pituitary adenylate cyclase activating polypeptide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5002. en:plasminogen activator inhibitor --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:plasminogen activator inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5003. en:pol1 transcription initiation complex proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:pol1 transcription initiation complex proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5004. en:poly da-dt --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:poly da-dt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5005. en:porphyrosine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:porphyrosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5006. en:potassium ionophores --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:potassium ionophores | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5007. en:potassium-hydrogen antiporters --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:potassium-hydrogen antiporters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5008. en:pregnant mare serum gonadotropin --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:pregnant mare serum gonadotropin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5009. en:pregnenolone carbonitrile --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:pregnenolone carbonitrile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5010. en:protein kinase c-delta --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:protein kinase c-delta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5011. en:proto-oncogene protein c-ets-1 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:proto-oncogene protein c-ets-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5012. en:proto-oncogene proteins c-fes --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:proto-oncogene proteins c-fes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5013. en:proto-oncogene proteins c-maf --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:proto-oncogene proteins c-maf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5014. en:psychotropic agent --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:psychotropic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5015. en:q-snare proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:q-snare proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5016. en:rab2 gtp-binding protein --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:rab2 gtp-binding protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5017. en:range-finding --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:range-finding | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5018. en:rap1 gtp-binding proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:rap1 gtp-binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5019. en:receptor-interacting serine/threonine protein kinase 2 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:receptor-interacting serine/threonine protein kinase 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5020. en:receptor-like protein tyrosine phosphatases, class 8 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:receptor-like protein tyrosine phosphatases, class 8 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5021. en:reproductive techniques, assisted --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:reproductive techniques, assisted | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5022. en:respiratory-gated imaging techniques --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:respiratory-gated imaging techniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5023. en:retinoic acid agent --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:retinoic acid agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5024. en:rhodanine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:rhodanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5025. en:ribulose-bisphosphate carboxylase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ribulose-bisphosphate carboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5026. en:rna polymerase sigma 54 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:rna polymerase sigma 54 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5027. en:rubredoxins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:rubredoxins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5028. en:self care --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:self care | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5029. en:serine-specific trna --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:serine-specific trna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5030. en:serine-type d-ala-d-ala carboxypeptidase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:serine-type d-ala-d-ala carboxypeptidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5031. en:single-strand specific dna and rna endonucleases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:single-strand specific dna and rna endonucleases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5032. en:sodium chloride symporters --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:sodium chloride symporters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5033. en:sodium-phosphate cotransporter proteins, type ii --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:sodium-phosphate cotransporter proteins, type ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5034. en:sodium-phosphate cotransporter proteins, type iii --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:sodium-phosphate cotransporter proteins, type iii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5035. en:solute carrier family 2, facilitated glucose transporter member 4 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:solute carrier family 2, facilitated glucose transporter member 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5036. en:stage-specific embryonic antigens --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:stage-specific embryonic antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5037. en:starch phosphorylase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:starch phosphorylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5038. en:steroid 21-monooxygenase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:steroid 21-monooxygenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5039. en:sterol regulatory element binding proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:sterol regulatory element binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5040. en:steryl-sulfatase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:steryl-sulfatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5041. en:streptogramin group b --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:streptogramin group b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5042. en:sulfur-sulfur bond isomerases --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:sulfur-sulfur bond isomerases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5043. en:suppressor of cytokine signaling family protein --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:suppressor of cytokine signaling family protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5044. en:surgical portosystemic shunt --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:surgical portosystemic shunt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5045. en:suspension dosage form --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:suspension dosage form | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5046. en:synaptotagmin ii --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:synaptotagmin ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5047. en:syntaxin 16 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:syntaxin 16 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5048. en:targeted gene repair --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:targeted gene repair | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5049. en:tat protein --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:tat protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5050. en:taxoids --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:taxoids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5051. en:testosterone 5-alpha-reductase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:testosterone 5-alpha-reductase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5052. en:tetrathionic acid --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:tetrathionic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5053. en:therapeutic epinephrine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:therapeutic epinephrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5054. en:therapies, investigational --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:therapies, investigational | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5055. en:thiourea --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:thiourea | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5056. en:thoracic surgical procedure --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:thoracic surgical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5057. en:thymine nucleotides --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:thymine nucleotides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5058. en:to return --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:to return | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5059. en:topoisomerase i --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:topoisomerase i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5060. en:total ankle replacement --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:total ankle replacement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5061. en:transanal endoscopic microsurgery --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:transanal endoscopic microsurgery | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5062. en:transferrins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:transferrins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5063. en:trimethyltin compounds --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:trimethyltin compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5064. en:triparanol --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:triparanol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5065. en:tumor necrosis factor receptor superfamily member 17 --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:tumor necrosis factor receptor superfamily member 17 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5066. en:ultrasonography, doppler, color --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ultrasonography, doppler, color | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5067. en:urogenital surgical procedure --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:urogenital surgical procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5068. en:vacuolar h+-atpase --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:vacuolar h+-atpase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5069. en:venography --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:venography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5070. en:ventricular myosins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:ventricular myosins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5071. en:vestibular function tests --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:vestibular function tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5072. en:viral fusion proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:viral fusion proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5073. en:wiskott-aldrich syndrome protein, neuronal --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:wiskott-aldrich syndrome protein, neuronal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5074. en:wt1 proteins --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:wt1 proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5075. en:xanthones --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:xanthones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5076. en:zeta carotene --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:zeta carotene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5077. en:zoxazolamine --- r_associated #0: 28 --> en:contraindications aspect
    n1=en:zoxazolamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5078. indoxyle-sulfate de potassium --- r_associated #0: 28 --> en:contraindications aspect
    n1=indoxyle-sulfate de potassium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5079. lipoprotéine de haut poids moléculaire --- r_associated #0: 28 --> en:contraindications aspect
    n1=lipoprotéine de haut poids moléculaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5080. nacre --- r_associated #0: 28 --> en:contraindications aspect
    n1=nacre | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5081. nicotinique --- r_associated #0: 28 --> en:contraindications aspect
    n1=nicotinique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5082. ocytocinase --- r_associated #0: 28 --> en:contraindications aspect
    n1=ocytocinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5083. talquer [qch] --- r_associated #0: 28 --> en:contraindications aspect
    n1=talquer [qch] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5084. tomodensitométrie avec opacification cisternale --- r_associated #0: 28 --> en:contraindications aspect
    n1=tomodensitométrie avec opacification cisternale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5085. transporteur de la dopamine --- r_associated #0: 28 --> en:contraindications aspect
    n1=transporteur de la dopamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=28
  5086. 5 fluoro-uracile --- r_associated #0: 27 --> en:contraindications aspect
    n1=5 fluoro-uracile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5087. Acide citrique --- r_associated #0: 27 --> en:contraindications aspect
    n1=Acide citrique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5088. Chlorure de potassium --- r_associated #0: 27 --> en:contraindications aspect
    n1=Chlorure de potassium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5089. acide kaïnique --- r_associated #0: 27 --> en:contraindications aspect
    n1=acide kaïnique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5090. acide okadaïque --- r_associated #0: 27 --> en:contraindications aspect
    n1=acide okadaïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5091. antagoniste des morphiniques --- r_associated #0: 27 --> en:contraindications aspect
    n1=antagoniste des morphiniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5092. bactériocine --- r_associated #0: 27 --> en:contraindications aspect
    n1=bactériocine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5093. biopsie --- r_associated #0: 27 --> en:contraindications aspect
    n1=biopsie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5094. chalcone --- r_associated #0: 27 --> en:contraindications aspect
    n1=chalcone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5095. cholangiopancréatographie rétrograde --- r_associated #0: 27 --> en:contraindications aspect
    n1=cholangiopancréatographie rétrograde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5096. connexions --- r_associated #0: 27 --> en:contraindications aspect
    n1=connexions | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5097. dactinomycine --- r_associated #0: 27 --> en:contraindications aspect
    n1=dactinomycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5098. dithionite --- r_associated #0: 27 --> en:contraindications aspect
    n1=dithionite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5099. en:1,2-dipalmitoylphosphatidylcholine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:1,2-dipalmitoylphosphatidylcholine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5100. en:2-chloroadenosine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:2-chloroadenosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5101. en:3',5'-cyclic-nucleotide phosphodiesterase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:3',5'-cyclic-nucleotide phosphodiesterase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5102. en:8-hydroxy-2-(di-n-propylamino)tetralin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:8-hydroxy-2-(di-n-propylamino)tetralin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5103. en:85 kda calcium-independent phospholipase a2 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:85 kda calcium-independent phospholipase a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5104. en:French rubber --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:French rubber | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5105. en:Velpeau's bandage --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:Velpeau's bandage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5106. en:abo blood group --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:abo blood group | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5107. en:actihaemyl --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:actihaemyl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5108. en:activating transcription factor 4 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:activating transcription factor 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5109. en:acylneuraminate cytidylyltransferase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:acylneuraminate cytidylyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5110. en:adenosine a1 receptor agonists --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:adenosine a1 receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5111. en:adenosine phosphosulfate --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:adenosine phosphosulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5112. en:alkylmercury compounds --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:alkylmercury compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5113. en:allylestrenol --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:allylestrenol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5114. en:alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5115. en:alpha-crystallins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:alpha-crystallins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5116. en:aminoglycoside antibiotic --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:aminoglycoside antibiotic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5117. en:analgesics, short-acting --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:analgesics, short-acting | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5118. en:androgen receptor antagonists --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:androgen receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5119. en:aneugens --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:aneugens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5120. en:angiogenesis inducing agents --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:angiogenesis inducing agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5121. en:angiotensin receptor antagonists --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:angiotensin receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5122. en:annexin a1 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:annexin a1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5123. en:annexin a3 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:annexin a3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5124. en:antibodies, monoclonal, murine-derived --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:antibodies, monoclonal, murine-derived | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5125. en:antienzyme --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:antienzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5126. en:antigens, cd98 light chains --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:antigens, cd98 light chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5127. en:antirheumatic agents --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:antirheumatic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5128. en:antitreponemal agents --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:antitreponemal agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5129. en:aprindine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:aprindine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5130. en:apurinic acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:apurinic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5131. en:arabinonucleosides --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:arabinonucleosides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5132. en:aromatherapy and essential oils --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:aromatherapy and essential oils | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5133. en:aromatic-l-amino-acid decarboxylases --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:aromatic-l-amino-acid decarboxylases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5134. en:artemisinins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:artemisinins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5135. en:arteriovenous shunt procedure --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:arteriovenous shunt procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5136. en:arthroplasty, replacement, finger --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:arthroplasty, replacement, finger | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5137. en:arylsulfonic acids --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:arylsulfonic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5138. en:asparagine-specific trna --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:asparagine-specific trna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5139. en:aspartate aminotransferase, cytoplasmic --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:aspartate aminotransferase, cytoplasmic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5140. en:aspartyl peptidase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:aspartyl peptidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5141. en:atp binding cassette transporter, sub-family g, member 2 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:atp binding cassette transporter, sub-family g, member 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5142. en:atp binding cassette transporter, sub-family g, member 5 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:atp binding cassette transporter, sub-family g, member 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5143. en:atp-dependent endopeptidases --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:atp-dependent endopeptidases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5144. en:azetidinecarboxylic acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:azetidinecarboxylic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5145. en:bacteriocin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:bacteriocin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5146. en:balloon valvuloplasty --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:balloon valvuloplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5147. en:benzoxazines --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:benzoxazines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5148. en:benzoylarginine nitroanilide --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:benzoylarginine nitroanilide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5149. en:benzoylcholine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:benzoylcholine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5150. en:beta-transducin repeat-containing proteins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:beta-transducin repeat-containing proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5151. en:bh3-interacting domain death agonist --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:bh3-interacting domain death agonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5152. en:biogenic amines --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:biogenic amines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5153. en:biopsy --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:biopsy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5154. en:blood patch, epidural --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:blood patch, epidural | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5155. en:botulinum toxin type a --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:botulinum toxin type a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5156. en:breast cancer type 1 susceptibility protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:breast cancer type 1 susceptibility protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5157. en:bretylol --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:bretylol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5158. en:bromouracil --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:bromouracil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5159. en:buformin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:buformin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5160. en:butaclamol --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:butaclamol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5161. en:butoxamine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:butoxamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5162. en:c-x-c motif chemokine 6 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:c-x-c motif chemokine 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5163. en:caffeic acids --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:caffeic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5164. en:canrenoic acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:canrenoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5165. en:carbon-nitrogen ligases with glutamine as amide-n-donor --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:carbon-nitrogen ligases with glutamine as amide-n-donor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5166. en:cardiotonic agent --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cardiotonic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5167. en:catechol 1,2-dioxygenase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:catechol 1,2-dioxygenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5168. en:cd40 ligand --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cd40 ligand | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5169. en:cermet cements --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cermet cements | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5170. en:cervical length measurement --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cervical length measurement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5171. en:chalcone --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:chalcone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5172. en:chemoembolization, therapeutic --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:chemoembolization, therapeutic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5173. en:chloromercurinitrophenols --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:chloromercurinitrophenols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5174. en:chondroitinsulfatases --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:chondroitinsulfatases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5175. en:circulatory arrest, deep hypothermia induced --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:circulatory arrest, deep hypothermia induced | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5176. en:cisplatinum --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cisplatinum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5177. en:class ia phosphatidylinositol 3-kinase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:class ia phosphatidylinositol 3-kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5178. en:cloprostenol --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cloprostenol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5179. en:coatomer protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:coatomer protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5180. en:cobicistat --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cobicistat | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5181. en:cochlear implants --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cochlear implants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5182. en:coitus --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:coitus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5183. en:complement c2a --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:complement c2a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5184. en:complement c3-c5 convertases --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:complement c3-c5 convertases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5185. en:computed tomography colonography --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:computed tomography colonography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5186. en:conserved helix-loop-helix ubiquitous kinase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:conserved helix-loop-helix ubiquitous kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5187. en:contact lenses, hydrophilic --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:contact lenses, hydrophilic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5188. en:contraceptives, oral, hormonal --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:contraceptives, oral, hormonal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5189. en:coup transcription factor 2 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:coup transcription factor 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5190. en:creb-binding protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:creb-binding protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5191. en:cryoprotective agent --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cryoprotective agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5192. en:cuprizone --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cuprizone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5193. en:cyclic amp-dependent protein kinase ribeta subunit --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cyclic amp-dependent protein kinase ribeta subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5194. en:cyclin g --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cyclin g | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5195. en:cyclin-dependent kinase 1 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cyclin-dependent kinase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5196. en:cyclin-dependent kinase 6 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cyclin-dependent kinase 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5197. en:cytochalasin b --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cytochalasin b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5198. en:cytochrome p-450 cyp2b6 inhibitors --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cytochrome p-450 cyp2b6 inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5199. en:cytochrome p-450 cyp2d6 inducers --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cytochrome p-450 cyp2d6 inducers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5200. en:cytochrome p450 family 19 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cytochrome p450 family 19 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5201. en:cytochrome p450 family 6 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cytochrome p450 family 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5202. en:cytokeratin 8 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:cytokeratin 8 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5203. en:dalteparin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dalteparin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5204. en:deae-cellulose --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:deae-cellulose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5205. en:dehydrocholesterols --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dehydrocholesterols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5206. en:dental devices, home care --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dental devices, home care | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5207. en:dental endosseous implant insertion --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dental endosseous implant insertion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5208. en:dental etching --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dental etching | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5209. en:dental implantation, subperiosteal --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dental implantation, subperiosteal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5210. en:denture precision attachment device --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:denture precision attachment device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5211. en:diagnostic equipment --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:diagnostic equipment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5212. en:dibenzocycloheptenes --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dibenzocycloheptenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5213. en:digital subtraction angiography --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:digital subtraction angiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5214. en:dioctyl sulfosuccinic acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dioctyl sulfosuccinic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5215. en:diprenorphine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:diprenorphine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5216. en:dithionite --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dithionite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5217. en:dna nucleotidylexotransferase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dna nucleotidylexotransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5218. en:dnab helicases --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dnab helicases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5219. en:dodecenoyl-coa delta-isomerase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dodecenoyl-coa delta-isomerase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5220. en:dopamine and camp-regulated phosphoprotein 32 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dopamine and camp-regulated phosphoprotein 32 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5221. en:dual specificity mitogen-activated protein kinase kinase 4 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dual specificity mitogen-activated protein kinase kinase 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5222. en:dual specificity phosphatase 1 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dual specificity phosphatase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5223. en:dye dilution technique --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:dye dilution technique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5224. en:eicosapentaenoic acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:eicosapentaenoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5225. en:elastography --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:elastography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5226. en:elav-like protein 3 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:elav-like protein 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5227. en:elbow prostheses (device) --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:elbow prostheses (device) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5228. en:electroacupuncture therapy --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:electroacupuncture therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5229. en:embolic protection devices --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:embolic protection devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5230. en:enalaprilat --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:enalaprilat | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5231. en:endothelin-1 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:endothelin-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5232. en:enkephalin, leucine-2-alanine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:enkephalin, leucine-2-alanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5233. en:equipment and supplies, hospital --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:equipment and supplies, hospital | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5234. en:ergocalciferols --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ergocalciferols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5235. en:essential amino acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:essential amino acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5236. en:ethisterone --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ethisterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5237. en:fab fragment --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:fab fragment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5238. en:factor xiiia --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:factor xiiia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5239. en:feprazone --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:feprazone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5240. en:ferrocyanides --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ferrocyanides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5241. en:fertility agents, male --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:fertility agents, male | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5242. en:ficoll --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ficoll | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5243. en:fiducial marker --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:fiducial marker | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5244. en:fimbriae proteins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:fimbriae proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5245. en:fluorenes --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:fluorenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5246. en:follitropin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:follitropin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5247. en:forkhead transcription factors --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:forkhead transcription factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5248. en:formoterol fumarate --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:formoterol fumarate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5249. en:fracture fixation --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:fracture fixation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5250. en:g(m2) activator protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:g(m2) activator protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5251. en:gaba-b receptor antagonists --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:gaba-b receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5252. en:galectin 2 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:galectin 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5253. en:gamma-globins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:gamma-globins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5254. en:gene knock-in techniques --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:gene knock-in techniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5255. en:general anesthesia procedure --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:general anesthesia procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5256. en:gingival retraction techniques --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:gingival retraction techniques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5257. en:gloves, surgical --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:gloves, surgical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5258. en:glycerylphosphorylcholine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:glycerylphosphorylcholine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5259. en:guanosine 5'-o-(3-thiotriphosphate) --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:guanosine 5'-o-(3-thiotriphosphate) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5260. en:hematoporphyrin photoradiation --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:hematoporphyrin photoradiation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5261. en:heptanoates --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:heptanoates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5262. en:histamine n-methyltransferase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:histamine n-methyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5263. en:histone deacetylase 1 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:histone deacetylase 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5264. en:histone demethylases --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:histone demethylases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5265. en:hiv envelope protein gp41 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:hiv envelope protein gp41 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5266. en:hla-b15 antigen --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:hla-b15 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5267. en:hla-dp beta-chains --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:hla-dp beta-chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5268. en:hla-drb1 antigen --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:hla-drb1 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5269. en:hpv dna probes --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:hpv dna probes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5270. en:hsc70 heat-shock proteins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:hsc70 heat-shock proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5271. en:hypothermia, induced --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:hypothermia, induced | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5272. en:immunoglobin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:immunoglobin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5273. en:indican --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:indican | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5274. en:indolequinones --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:indolequinones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5275. en:infant diaper --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:infant diaper | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5276. en:inhalation spacers --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:inhalation spacers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5277. en:interpleural analgesia --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:interpleural analgesia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5278. en:intrauterine cordocentesis --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:intrauterine cordocentesis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5279. en:intubation procedure --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:intubation procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5280. en:ion-selective electrodes --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ion-selective electrodes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5281. en:ionic liquids --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ionic liquids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5282. en:keratoscopy --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:keratoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5283. en:kv1.2 potassium channel --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:kv1.2 potassium channel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5284. en:leukotriene c4 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:leukotriene c4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5285. en:lipid a --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:lipid a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5286. en:liposuccion --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:liposuccion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5287. en:lipotropic agents --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:lipotropic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5288. en:liver filtrate factor --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:liver filtrate factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5289. en:lorajmine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:lorajmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5290. en:lumicolchicines --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:lumicolchicines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5291. en:lymphotoxin beta receptor --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:lymphotoxin beta receptor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5292. en:maff transcription factor --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:maff transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5293. en:matrix metalloproteinase-16 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:matrix metalloproteinase-16 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5294. en:metalloproteinase inhibitor 2 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:metalloproteinase inhibitor 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5295. en:metallothionein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:metallothionein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5296. en:methiocarb --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:methiocarb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5297. en:methyl benzene --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:methyl benzene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5298. en:methylazoxymethanol acetate --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:methylazoxymethanol acetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5299. en:methylphenazonium methosulfate --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:methylphenazonium methosulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5300. en:microscopy, interference --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:microscopy, interference | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5301. en:microtubule proteins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:microtubule proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5302. en:mind-body therapies --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:mind-body therapies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5303. en:mitogen-activated protein kinase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:mitogen-activated protein kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5304. en:monoclonal ab --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:monoclonal ab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5305. en:natural childbirth assistance --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:natural childbirth assistance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5306. en:neurocalcin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:neurocalcin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5307. en:nf-kappa b p50 subunit --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:nf-kappa b p50 subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5308. en:nicotinamide phosphoribosyltransferase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:nicotinamide phosphoribosyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5309. en:nitric oxide synthase type ii --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:nitric oxide synthase type ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5310. en:nitrogen mustard compound --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:nitrogen mustard compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5311. en:nitrohydroxyiodophenylacetate --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:nitrohydroxyiodophenylacetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5312. en:nonrandomized clinical trial --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:nonrandomized clinical trial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5313. en:norpregnenes --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:norpregnenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5314. en:nuclear factor 45 protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:nuclear factor 45 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5315. en:nuclear localization signal --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:nuclear localization signal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5316. en:nucleoside q --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:nucleoside q | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5317. en:oligomycins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:oligomycins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5318. en:one-stage prothrombin time test --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:one-stage prothrombin time test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5319. en:ornithine decarboxylase inhibitor --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ornithine decarboxylase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5320. en:oxygen radical --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:oxygen radical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5321. en:p-azobenzenearsonate --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:p-azobenzenearsonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5322. en:p-chloromercuribenzoic acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:p-chloromercuribenzoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5323. en:p21 ras protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:p21 ras protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5324. en:paliperidone palmitate --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:paliperidone palmitate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5325. en:parathyrin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:parathyrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5326. en:parenteral nutrition solutions --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:parenteral nutrition solutions | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5327. en:penicillin g benzathine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:penicillin g benzathine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5328. en:periodontal splints --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:periodontal splints | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5329. en:peroxiredoxin 6 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:peroxiredoxin 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5330. en:pertussis toxin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:pertussis toxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5331. en:pharmaceutic aids --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:pharmaceutic aids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5332. en:phenylthiohydantoin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:phenylthiohydantoin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5333. en:phosphotungstic acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:phosphotungstic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5334. en:photoaffinity labels --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:photoaffinity labels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5335. en:plant viral movement proteins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:plant viral movement proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5336. en:plasma skin regeneration --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:plasma skin regeneration | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5337. en:poloxalene --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:poloxalene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5338. en:polycomb-group protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:polycomb-group protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5339. en:polyribonucleotide nucleotidyltransferase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:polyribonucleotide nucleotidyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5340. en:potassium citrate --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:potassium citrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5341. en:potassium magnesium aspartate --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:potassium magnesium aspartate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5342. en:propanolamines --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:propanolamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5343. en:propidium --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:propidium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5344. en:protease nexins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:protease nexins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5345. en:proton-phosphate symporters --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:proton-phosphate symporters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5346. en:prpsc proteins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:prpsc proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5347. en:pyridinium compounds --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:pyridinium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5348. en:rab3a gtp-binding protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:rab3a gtp-binding protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5349. en:radioisotope renography --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:radioisotope renography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5350. en:radioisotope teletherapy --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:radioisotope teletherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5351. en:receptor, epha2 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:receptor, epha2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5352. en:receptor, ephb5 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:receptor, ephb5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5353. en:recombinant interferon beta-1b --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:recombinant interferon beta-1b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5354. en:riboadenylate transferase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:riboadenylate transferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5355. en:ribosomal protein s6 kinases, 70-kda --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ribosomal protein s6 kinases, 70-kda | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5356. en:rna nucleotidyltransferases --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:rna nucleotidyltransferases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5357. en:scopoletin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:scopoletin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5358. en:secologanin tryptamine alkaloids --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:secologanin tryptamine alkaloids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5359. en:secretogranin-2 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:secretogranin-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5360. en:serine/threonine-protein kinase a-raf --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:serine/threonine-protein kinase a-raf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5361. en:signal transducer and activator of transcription 2 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:signal transducer and activator of transcription 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5362. en:skeletal muscle myosins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:skeletal muscle myosins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5363. en:small nucleolar ribonucleoproteins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:small nucleolar ribonucleoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5364. en:sodium-calcium exchanger --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:sodium-calcium exchanger | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5365. en:sorption detoxification --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:sorption detoxification | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5366. en:soxe transcription factors --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:soxe transcription factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5367. en:spermatogenesis-blocking agents --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:spermatogenesis-blocking agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5368. en:starch (bacterial glycogen) synthase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:starch (bacterial glycogen) synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5369. en:sterol regulatory element-binding protein 1 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:sterol regulatory element-binding protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5370. en:stilbamidines --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:stilbamidines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5371. en:stimulants, historical --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:stimulants, historical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5372. en:streptogramin group a --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:streptogramin group a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5373. en:surgical castration --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:surgical castration | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5374. en:surgical ocular refractive procedure --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:surgical ocular refractive procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5375. en:surgically created structure --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:surgically created structure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5376. en:suture device component --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:suture device component | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5377. en:syndecan-3 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:syndecan-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5378. en:t-antigen --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:t-antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5379. en:tampons, surgical --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:tampons, surgical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5380. en:taurodeoxycholic acid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:taurodeoxycholic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5381. en:technetium tc-99m mertiatide --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:technetium tc-99m mertiatide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5382. en:tenamfetamine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:tenamfetamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5383. en:ternary complex factors --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ternary complex factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5384. en:therapeutic corticosteroid --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:therapeutic corticosteroid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5385. en:threonine-specific trna --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:threonine-specific trna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5386. en:topoisomerase ii --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:topoisomerase ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5387. en:toyocamycin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:toyocamycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5388. en:transcription factor brn-3b --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:transcription factor brn-3b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5389. en:transforming growth factor alpha --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:transforming growth factor alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5390. en:transmyocardial laser revascularization (procedure) --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:transmyocardial laser revascularization (procedure) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5391. en:triaziquone --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:triaziquone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5392. en:trichodermin --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:trichodermin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5393. en:trihalomethanes --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:trihalomethanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5394. en:trimeprazine --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:trimeprazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5395. en:trpp cation channels --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:trpp cation channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5396. en:trypsin inhibitor, bowman-birk soybean --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:trypsin inhibitor, bowman-birk soybean | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5397. en:trypsin inhibitor, kunitz soybean --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:trypsin inhibitor, kunitz soybean | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5398. en:tumor necrosis factor receptor superfamily member 11a --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:tumor necrosis factor receptor superfamily member 11a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5399. en:unconventional myosin-va --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:unconventional myosin-va | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5400. en:uroplakin iii --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:uroplakin iii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5401. en:uroporphyrinogen decarboxylase --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:uroporphyrinogen decarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5402. en:vaccines, virus-like particle --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:vaccines, virus-like particle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5403. en:vdj recombinases --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:vdj recombinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5404. en:ventriculography, first-pass --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:ventriculography, first-pass | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5405. en:venturicidins --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:venturicidins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5406. en:vesicle-associated membrane protein 1 --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:vesicle-associated membrane protein 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5407. en:wnt3 protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:wnt3 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5408. en:wnt4 protein --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:wnt4 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5409. en:wnt5a protein, human --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:wnt5a protein, human | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5410. en:zinc isotopes --- r_associated #0: 27 --> en:contraindications aspect
    n1=en:zinc isotopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5411. facteurs de complexes ternaires --- r_associated #0: 27 --> en:contraindications aspect
    n1=facteurs de complexes ternaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5412. faire pendant --- r_associated #0: 27 --> en:contraindications aspect
    n1=faire pendant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5413. follitropine --- r_associated #0: 27 --> en:contraindications aspect
    n1=follitropine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5414. groupe sanguin --- r_associated #0: 27 --> en:contraindications aspect
    n1=groupe sanguin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5415. indican --- r_associated #0: 27 --> en:contraindications aspect
    n1=indican | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5416. lier connaissance avec qn --- r_associated #0: 27 --> en:contraindications aspect
    n1=lier connaissance avec qn | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5417. métallothionéine --- r_associated #0: 27 --> en:contraindications aspect
    n1=métallothionéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5418. protide --- r_associated #0: 27 --> en:contraindications aspect
    n1=protide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5419. relation sexuelle --- r_associated #0: 27 --> en:contraindications aspect
    n1=relation sexuelle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5420. scopolétine --- r_associated #0: 27 --> en:contraindications aspect
    n1=scopolétine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5421. tomogramme --- r_associated #0: 27 --> en:contraindications aspect
    n1=tomogramme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5422. triméprazine --- r_associated #0: 27 --> en:contraindications aspect
    n1=triméprazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5423. uroporphyrinogène-décarboxylase --- r_associated #0: 27 --> en:contraindications aspect
    n1=uroporphyrinogène-décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5424. ésoméprazole --- r_associated #0: 27 --> en:contraindications aspect
    n1=ésoméprazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  5425. Batken (virus) --- r_associated #0: 26 --> en:contraindications aspect
    n1=Batken (virus) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5426. HCTZ --- r_associated #0: 26 --> en:contraindications aspect
    n1=HCTZ | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5427. Topografov (virus) --- r_associated #0: 26 --> en:contraindications aspect
    n1=Topografov (virus) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5428. Vaccin contre l'hépatite A --- r_associated #0: 26 --> en:contraindications aspect
    n1=Vaccin contre l'hépatite A | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5429. acide glucarique --- r_associated #0: 26 --> en:contraindications aspect
    n1=acide glucarique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5430. adénylate-cyclase --- r_associated #0: 26 --> en:contraindications aspect
    n1=adénylate-cyclase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5431. alcoylant --- r_associated #0: 26 --> en:contraindications aspect
    n1=alcoylant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5432. antigènes plaquettaires humains --- r_associated #0: 26 --> en:contraindications aspect
    n1=antigènes plaquettaires humains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5433. baumes --- r_associated #0: 26 --> en:contraindications aspect
    n1=baumes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5434. cancer colloïde --- r_associated #0: 26 --> en:contraindications aspect
    n1=cancer colloïde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5435. capsaïsine --- r_associated #0: 26 --> en:contraindications aspect
    n1=capsaïsine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5436. capécitabine --- r_associated #0: 26 --> en:contraindications aspect
    n1=capécitabine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5437. chlordécone --- r_associated #0: 26 --> en:contraindications aspect
    n1=chlordécone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5438. chloroéthène --- r_associated #0: 26 --> en:contraindications aspect
    n1=chloroéthène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5439. chlorure de magnésium --- r_associated #0: 26 --> en:contraindications aspect
    n1=chlorure de magnésium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5440. cytochromes b5 --- r_associated #0: 26 --> en:contraindications aspect
    n1=cytochromes b5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5441. céphalosporinase --- r_associated #0: 26 --> en:contraindications aspect
    n1=céphalosporinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5442. de mercure --- r_associated #0: 26 --> en:contraindications aspect
    n1=de mercure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5443. dextrométhorphane --- r_associated #0: 26 --> en:contraindications aspect
    n1=dextrométhorphane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5444. dichlorodiphényldichloroéthane --- r_associated #0: 26 --> en:contraindications aspect
    n1=dichlorodiphényldichloroéthane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5445. en:1,2-dimethylhydrazine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:1,2-dimethylhydrazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5446. en:17-hydroxycorticosteroids --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:17-hydroxycorticosteroids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5447. en:2,2'-dipyridyl --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:2,2'-dipyridyl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5448. en:2-acetylaminofluorene --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:2-acetylaminofluorene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5449. en:2-hydroxyphenethylamine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:2-hydroxyphenethylamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5450. en:3',5'-cyclic-gmp phosphodiesterases --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:3',5'-cyclic-gmp phosphodiesterases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5451. en:4-hydroxycoumarins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:4-hydroxycoumarins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5452. en:4-quinolones --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:4-quinolones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5453. en:5,7-dihydroxytryptamine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:5,7-dihydroxytryptamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5454. en:5-alpha-dihydroprogesterone --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:5-alpha-dihydroprogesterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5455. en:5-ht3 receptor antagonist --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:5-ht3 receptor antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5456. en:F agent --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:F agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5457. en:F episome --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:F episome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5458. en:MRI --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:MRI | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5459. en:acetaldehyde dehydrogenase inhibitors --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:acetaldehyde dehydrogenase inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5460. en:acid etching, dental --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:acid etching, dental | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5461. en:aconitic acid --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:aconitic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5462. en:actin depolymerizing factors --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:actin depolymerizing factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5463. en:activator appliances --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:activator appliances | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5464. en:adam12 protein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:adam12 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5465. en:adaptor proteins, vesicular transport --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:adaptor proteins, vesicular transport | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5466. en:adenylate cyclase toxin --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:adenylate cyclase toxin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5467. en:adipates --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:adipates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5468. en:adosterol --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:adosterol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5469. en:adp-ribosyl cyclase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:adp-ribosyl cyclase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5470. en:alpha chemokine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:alpha chemokine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5471. en:alpha-aminoadipic acid --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:alpha-aminoadipic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5472. en:alpha-crystallin a chain --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:alpha-crystallin a chain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5473. en:amino acid transport system y+ --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:amino acid transport system y+ | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5474. en:amino acids, diamino --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:amino acids, diamino | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5475. en:anesthesia, caudal --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:anesthesia, caudal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5476. en:anesthesia, dental --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:anesthesia, dental | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5477. en:angiotensin ii type 2 receptor blockers --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:angiotensin ii type 2 receptor blockers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5478. en:annexin a7 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:annexin a7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5479. en:anticestodal agents --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:anticestodal agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5480. en:antienzyme. --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:antienzyme. | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5481. en:antigens, differentiation, t-lymphocyte --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:antigens, differentiation, t-lymphocyte | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5482. en:arac transcription factor --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:arac transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5483. en:arginine specific trna --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:arginine specific trna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5484. en:arthrodesis --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:arthrodesis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5485. en:aurovertins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:aurovertins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5486. en:axin protein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:axin protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5487. en:b-cell lymphoma 6 protein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:b-cell lymphoma 6 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5488. en:balloon embolectomy --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:balloon embolectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5489. en:benzyl compounds --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:benzyl compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5490. en:benzylammonium compounds --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:benzylammonium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5491. en:beta-adrenergic agonist --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:beta-adrenergic agonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5492. en:beta-alanine-pyruvate aminotransferase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:beta-alanine-pyruvate aminotransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5493. en:beta-hexosaminidase alpha chain --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:beta-hexosaminidase alpha chain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5494. en:beta-synuclein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:beta-synuclein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5495. en:bioassay --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:bioassay | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5496. en:bis(chloromethyl) ether --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:bis(chloromethyl) ether | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5497. en:blood preservation --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:blood preservation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5498. en:bone wires --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:bone wires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5499. en:borohydrides --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:borohydrides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5500. en:breast cancer type 2 susceptibility protein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:breast cancer type 2 susceptibility protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5501. en:bromelains --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:bromelains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5502. en:butyrate response factor 1 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:butyrate response factor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5503. en:calcium-independent phospholipase a2 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:calcium-independent phospholipase a2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5504. en:calorimetry, indirect --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:calorimetry, indirect | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5505. en:carbonic anhydrase ix --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:carbonic anhydrase ix | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5506. en:carbonyl cyanide m-chlorophenyl hydrazone --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:carbonyl cyanide m-chlorophenyl hydrazone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5507. en:carbonyl cyanide p-trifluoromethoxyphenylhydrazone --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:carbonyl cyanide p-trifluoromethoxyphenylhydrazone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5508. en:cardanolides --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cardanolides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5509. en:cardiopulmonary bypass --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cardiopulmonary bypass | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5510. en:casein kinase iepsilon --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:casein kinase iepsilon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5511. en:caspase-9 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:caspase-9 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5512. en:cathepsin l1 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cathepsin l1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5513. en:cationic amino acid transporter 1 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cationic amino acid transporter 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5514. en:cd82 antigen --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cd82 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5515. en:cdc42 gtp-binding protein, saccharomyces cerevisiae --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cdc42 gtp-binding protein, saccharomyces cerevisiae | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5516. en:cell extracts --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cell extracts | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5517. en:cephacetrile --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cephacetrile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5518. en:cerebrospinal fluid proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cerebrospinal fluid proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5519. en:chlordecone --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:chlordecone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5520. en:chloroplast proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:chloroplast proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5521. en:chondroitin abc lyase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:chondroitin abc lyase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5522. en:cinacalcet hydrochloride --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cinacalcet hydrochloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5523. en:clathrin heavy chains --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:clathrin heavy chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5524. en:codon, terminator --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:codon, terminator | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5525. en:color perception tests --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:color perception tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5526. en:communication aids for disabled --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:communication aids for disabled | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5527. en:complement c2b --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:complement c2b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5528. en:complement c3-c5 convertases, alternative pathway --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:complement c3-c5 convertases, alternative pathway | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5529. en:complement component c1s --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:complement component c1s | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5530. en:concanavalin a --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:concanavalin a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5531. en:controlled substance --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:controlled substance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5532. en:coumaric acids --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:coumaric acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5533. en:cyclic amp-dependent protein kinase type i --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cyclic amp-dependent protein kinase type i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5534. en:cyclin-dependent kinase 8 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cyclin-dependent kinase 8 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5535. en:cyclin-h --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cyclin-h | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5536. en:cysteine-rich protein 61 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cysteine-rich protein 61 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5537. en:cytochrome p-450 cyp2d6 inhibitors --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cytochrome p-450 cyp2d6 inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5538. en:cytochrome p-450 cyp2e1 inhibitors --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cytochrome p-450 cyp2e1 inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5539. en:cytochromes b5 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cytochromes b5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5540. en:cytologic test --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:cytologic test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5541. en:darbepoetin alfa --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:darbepoetin alfa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5542. en:dehydroascorbatase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dehydroascorbatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5543. en:dehydroepiandrosterone sulfate --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dehydroepiandrosterone sulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5544. en:dental abutments --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dental abutments | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5545. en:dental implantation, endosseous, endodontic --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dental implantation, endosseous, endodontic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5546. en:dental impression materials --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dental impression materials | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5547. en:dental prosthesis, implant-supported --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dental prosthesis, implant-supported | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5548. en:denture, complete, immediate --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:denture, complete, immediate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5549. en:denture, partial, fixed --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:denture, partial, fixed | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5550. en:deoxyribonuclease (pyrimidine dimer) --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:deoxyribonuclease (pyrimidine dimer) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5551. en:destrin --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:destrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5552. en:dextromethorphan --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dextromethorphan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5553. en:diagnostic techniques, surgical --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:diagnostic techniques, surgical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5554. en:dibutyryl cyclic gmp --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dibutyryl cyclic gmp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5555. en:dicarbethoxydihydrocollidine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dicarbethoxydihydrocollidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5556. en:dichlorodiphenyldichloroethane --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dichlorodiphenyldichloroethane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5557. en:diethyl pyrocarbonate --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:diethyl pyrocarbonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5558. en:dihydroxytryptamines --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dihydroxytryptamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5559. en:diminazene --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:diminazene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5560. en:dna, ribosomal spacer --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:dna, ribosomal spacer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5561. en:drug substitution --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:drug substitution | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5562. en:echocardiography, doppler, pulsed --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:echocardiography, doppler, pulsed | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5563. en:echocardiography, transesophageal --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:echocardiography, transesophageal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5564. en:egf family of proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:egf family of proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5565. en:eicosanoic acids --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:eicosanoic acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5566. en:ellagic acid --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ellagic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5567. en:elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate drug combination --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate drug combination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5568. en:emetic --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:emetic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5569. en:endothelin-3 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:endothelin-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5570. en:enterosorption --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:enterosorption | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5571. en:epsilon-crystallins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:epsilon-crystallins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5572. en:ethamoxytriphetol --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ethamoxytriphetol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5573. en:ethenoadenosine triphosphate --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ethenoadenosine triphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5574. en:ether --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ether | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5575. en:exopeptidase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:exopeptidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5576. en:external fixation devices --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:external fixation devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5577. en:f2-isoprostanes --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:f2-isoprostanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5578. en:fanconi anemia complementation group g protein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:fanconi anemia complementation group g protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5579. en:fibrillins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:fibrillins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5580. en:fibrin foam --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:fibrin foam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5581. en:fingolimod hydrochloride --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:fingolimod hydrochloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5582. en:first-aid --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:first-aid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5583. en:flufenamic acid --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:flufenamic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5584. en:foot orthoses --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:foot orthoses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5585. en:gaba agents --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:gaba agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5586. en:gaba-a receptor antagonists --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:gaba-a receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5587. en:galectin-1 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:galectin-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5588. en:gata1 transcription factor --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:gata1 transcription factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5589. en:gated blood-pool imaging --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:gated blood-pool imaging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5590. en:glial cell line-derived neurotrophic factor --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:glial cell line-derived neurotrophic factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5591. en:glutamic acid-specific trna --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:glutamic acid-specific trna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5592. en:glycerophosphoinositol inositolphosphodiesterase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:glycerophosphoinositol inositolphosphodiesterase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5593. en:glycine agents --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:glycine agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5594. en:glycine n-methyltransferase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:glycine n-methyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5595. en:glycogen debranching enzyme system --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:glycogen debranching enzyme system | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5596. en:group i chaperonins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:group i chaperonins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5597. en:gtp cyclohydrolase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:gtp cyclohydrolase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5598. en:guanine nucleotide-binding protein g(s) subunit alpha isoforms xlas --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:guanine nucleotide-binding protein g(s) subunit alpha isoforms xlas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5599. en:heliation --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:heliation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5600. en:hematometachysis --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hematometachysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5601. en:hemoglobin subunits --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hemoglobin subunits | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5602. en:hemolytic agents --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hemolytic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5603. en:heterogeneous-nuclear ribonucleoprotein group c --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:heterogeneous-nuclear ribonucleoprotein group c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5604. en:heterogeneous-nuclear ribonucleoprotein l --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:heterogeneous-nuclear ribonucleoprotein l | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5605. en:hiv envelope protein gp120 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hiv envelope protein gp120 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5606. en:hiv protease inhibitor --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hiv protease inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5607. en:hla-a3 antigen --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hla-a3 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5608. en:hla-c antigens --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hla-c antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5609. en:hla-dr1 antigen --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hla-dr1 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5610. en:hmg-coa reductase inhibitor --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hmg-coa reductase inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5611. en:human platelet antigens --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:human platelet antigens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5612. en:hydrocarbons, alicyclic --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hydrocarbons, alicyclic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5613. en:hydroxyphenylazouracil --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hydroxyphenylazouracil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5614. en:hypnosis, dental --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hypnosis, dental | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5615. en:hypoglycemic agents --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hypoglycemic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5616. en:hypoxanthines --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hypoxanthines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5617. en:hysteroscopes --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:hysteroscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5618. en:i blood-group system --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:i blood-group system | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5619. en:imidoesters --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:imidoesters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5620. en:implantable neurostimulators --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:implantable neurostimulators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5621. en:interferon treatment --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:interferon treatment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5622. en:kaempferols --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:kaempferols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5623. en:keratin 18 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:keratin 18 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5624. en:keratin-13 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:keratin-13 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5625. en:ketocholesterols --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ketocholesterols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5626. en:kitasamycin --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:kitasamycin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5627. en:kynuramine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:kynuramine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5628. en:lactosylceramides --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:lactosylceramides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5629. en:laparoscopic cholecystectomy --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:laparoscopic cholecystectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5630. en:leptophos --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:leptophos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5631. en:leucogenenol --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:leucogenenol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5632. en:leukocidins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:leukocidins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5633. en:lewis blood-group system --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:lewis blood-group system | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5634. en:lisdexamfetamine dimesylate --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:lisdexamfetamine dimesylate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5635. en:machine-teeth --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:machine-teeth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5636. en:maf transcription factors, small --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:maf transcription factors, small | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5637. en:magnesium chloride --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:magnesium chloride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5638. en:magnetic resonance imaging, interventional --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:magnetic resonance imaging, interventional | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5639. en:matrix metalloproteinase 20 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:matrix metalloproteinase 20 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5640. en:medication --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:medication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5641. en:mesoporphyrins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:mesoporphyrins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5642. en:methylhistamines --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:methylhistamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5643. en:metiamide --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:metiamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5644. en:micronucleus tests --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:micronucleus tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5645. en:moclobemide --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:moclobemide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5646. en:moire topography --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:moire topography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5647. en:mucin-5ac --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:mucin-5ac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5648. en:multimodality therapy --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:multimodality therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5649. en:muscle strength dynamometer --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:muscle strength dynamometer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5650. en:mycophenolic acid --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:mycophenolic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5651. en:myelin p2 protein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:myelin p2 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5652. en:myocardial depressant factor --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:myocardial depressant factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5653. en:myocardial revascularization --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:myocardial revascularization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5654. en:myosin light chain kinase, smooth muscle --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:myosin light chain kinase, smooth muscle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5655. en:n-formylmethionine leucyl-phenylalanine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:n-formylmethionine leucyl-phenylalanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5656. en:nafoxidine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:nafoxidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5657. en:naphthacenes --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:naphthacenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5658. en:nicotinamide-nucleotide adenylyltransferase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:nicotinamide-nucleotide adenylyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5659. en:nlr proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:nlr proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5660. en:non-histone chromosomal protein hmg-17 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:non-histone chromosomal protein hmg-17 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5661. en:non-steroidal estrogen --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:non-steroidal estrogen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5662. en:norepinephrine plasma membrane transport proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:norepinephrine plasma membrane transport proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5663. en:nuclear magnetic resonance imaging --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:nuclear magnetic resonance imaging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5664. en:octamer transcription factor otf-1 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:octamer transcription factor otf-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5665. en:odontometry --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:odontometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5666. en:oligo-1,6-glucosidase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:oligo-1,6-glucosidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5667. en:orexin receptor antagonists --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:orexin receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5668. en:organic ester --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:organic ester | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5669. en:osmium tetroxide --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:osmium tetroxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5670. en:ovulation prediction --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ovulation prediction | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5671. en:oxazepines --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:oxazepines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5672. en:pancreas, artificial --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:pancreas, artificial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5673. en:parasympathectomy --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:parasympathectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5674. en:parenteral infusion procedure --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:parenteral infusion procedure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5675. en:parietal cell vagotomy --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:parietal cell vagotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5676. en:passive immunization --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:passive immunization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5677. en:peptide-n4-(n-acetyl-beta-glucosaminyl)asparagine amidase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:peptide-n4-(n-acetyl-beta-glucosaminyl)asparagine amidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5678. en:phosphatidylcholine-sterol o-acyltransferase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:phosphatidylcholine-sterol o-acyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5679. en:phosphodiesterase 4 inhibitors --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:phosphodiesterase 4 inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5680. en:phosphoprotein phosphatase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:phosphoprotein phosphatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5681. en:phosphorous acids --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:phosphorous acids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5682. en:phosvitin --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:phosvitin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5683. en:phthalazines --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:phthalazines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5684. en:platinum compound --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:platinum compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5685. en:plethysmography, impedance --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:plethysmography, impedance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5686. en:pneumoperitoneum, artificial --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:pneumoperitoneum, artificial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5687. en:poisoning aspects --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:poisoning aspects | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5688. en:polycyclic aromatic hydrocarbons --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:polycyclic aromatic hydrocarbons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5689. en:polyvinylpyridine n-oxide --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:polyvinylpyridine n-oxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5690. en:ppar-beta --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ppar-beta | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5691. en:pralidoxime compounds --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:pralidoxime compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5692. en:pregnenes --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:pregnenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5693. en:prion proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:prion proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5694. en:prostaglandin antagonists --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:prostaglandin antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5695. en:prostaglandin endoperoxides, synthetic --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:prostaglandin endoperoxides, synthetic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5696. en:protease inhibitor --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:protease inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5697. en:protein d-aspartate-l-isoaspartate methyltransferase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:protein d-aspartate-l-isoaspartate methyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5698. en:prp 27-30 protein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:prp 27-30 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5699. en:prpc proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:prpc proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5700. en:pseudorabies vaccines --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:pseudorabies vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5701. en:pulmonary surfactant-associated protein a --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:pulmonary surfactant-associated protein a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5702. en:pulmonary surfactant-associated protein d --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:pulmonary surfactant-associated protein d | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5703. en:pupilloscopy --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:pupilloscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5704. en:purinergic p1 receptor agonists --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:purinergic p1 receptor agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5705. en:purinergic p2x receptor antagonists --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:purinergic p2x receptor antagonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5706. en:putrescin --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:putrescin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5707. en:pyruvate dehydrogenase complex --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:pyruvate dehydrogenase complex | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5708. en:ras gtpase-activating proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ras gtpase-activating proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5709. en:ras-related c3 botulinum toxin substrate 1 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ras-related c3 botulinum toxin substrate 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5710. en:reagins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:reagins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5711. en:receptor tyrosine-protein kinase erbb-4 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:receptor tyrosine-protein kinase erbb-4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5712. en:receptor, epha6 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:receptor, epha6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5713. en:receptor, ephb3 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:receptor, ephb3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5714. en:receptor-like protein tyrosine phosphatases, class 3 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:receptor-like protein tyrosine phosphatases, class 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5715. en:recombinant protein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:recombinant protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5716. en:reflexotherapy --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:reflexotherapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5717. en:repifermin --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:repifermin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5718. en:respiratory function tests --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:respiratory function tests | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5719. en:retinoblastoma-binding protein 2 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:retinoblastoma-binding protein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5720. en:retinol binding proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:retinol binding proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5721. en:ribonuclease h, human immunodeficiency virus --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ribonuclease h, human immunodeficiency virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5722. en:ribonucleoprotein, u4-u6 small nuclear --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ribonucleoprotein, u4-u6 small nuclear | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5723. en:ribosome inactivating proteins, type 2 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ribosome inactivating proteins, type 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5724. en:ribulosephosphates --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:ribulosephosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5725. en:rioprostil --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:rioprostil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5726. en:rna cap analogs --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:rna cap analogs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5727. en:rna recognition motif (rrm) proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:rna recognition motif (rrm) proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5728. en:rna-directed rna polymerase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:rna-directed rna polymerase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5729. en:runt-related transcription factor 1 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:runt-related transcription factor 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5730. en:saccharinum --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:saccharinum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5731. en:saccharopine dehydrogenases --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:saccharopine dehydrogenases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5732. en:salicylanilides --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:salicylanilides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5733. en:sarcoplasmic reticulum calcium-transporting atpases --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sarcoplasmic reticulum calcium-transporting atpases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5734. en:scintography --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:scintography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5735. en:scleroplasty --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:scleroplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5736. en:segmental mastectomy --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:segmental mastectomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5737. en:selenoprotein w --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:selenoprotein w | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5738. en:serial extraction --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:serial extraction | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5739. en:sericins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sericins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5740. en:serotonin uptake inhibitors --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:serotonin uptake inhibitors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5741. en:serum amyloid a --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:serum amyloid a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5742. en:sex reassignment procedures --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sex reassignment procedures | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5743. en:sialomucins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sialomucins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5744. en:skin test end-point titration --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:skin test end-point titration | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5745. en:skp cullin f-box protein ligases --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:skp cullin f-box protein ligases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5746. en:smad5 protein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:smad5 protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5747. en:small nucleolar rna --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:small nucleolar rna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5748. en:small-conductance calcium-activated potassium channels --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:small-conductance calcium-activated potassium channels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5749. en:sodium hydroxide --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sodium hydroxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5750. en:sodium-coupled vitamin c transporters --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sodium-coupled vitamin c transporters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5751. en:sodium-phosphate cotransporter proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sodium-phosphate cotransporter proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5752. en:sodium-phosphate cotransporter proteins, type iia --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sodium-phosphate cotransporter proteins, type iia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5753. en:soil pollutants --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:soil pollutants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5754. en:solute carrier family 12, member 2 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:solute carrier family 12, member 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5755. en:solvent --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:solvent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5756. en:somatostatin-28 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:somatostatin-28 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5757. en:sperm immobilizing agents --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sperm immobilizing agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5758. en:spiperone --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:spiperone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5759. en:spiral cone-beam computed tomography --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:spiral cone-beam computed tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5760. en:staphylococcal toxoid --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:staphylococcal toxoid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5761. en:streptococcal vaccines --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:streptococcal vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5762. en:streptodornase and streptokinase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:streptodornase and streptokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5763. en:streptogramin b --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:streptogramin b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5764. en:streptovaricin --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:streptovaricin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5765. en:subtilisins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:subtilisins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5766. en:sugar alcohols --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sugar alcohols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5767. en:sulfadimethoxine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sulfadimethoxine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5768. en:sulfhydryl compounds --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:sulfhydryl compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5769. en:synaptosomal-associated protein 25 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:synaptosomal-associated protein 25 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5770. en:synaptotagmin i --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:synaptotagmin i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5771. en:synuclein gamma --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:synuclein gamma | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5772. en:tetramethylphenylenediamine --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:tetramethylphenylenediamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5773. en:tfiih basal transcription factor complex helicase xpd subunit --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:tfiih basal transcription factor complex helicase xpd subunit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5774. en:tgf-beta superfamily proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:tgf-beta superfamily proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5775. en:therapeutic plateletpheresis --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:therapeutic plateletpheresis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5776. en:therapeutic use - qualifier --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:therapeutic use - qualifier | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5777. en:thymolphthalein --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:thymolphthalein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5778. en:tissue adhesives --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:tissue adhesives | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5779. en:transcription factor ap-1 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:transcription factor ap-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5780. en:transforming growth factor --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:transforming growth factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5781. en:transjugular intrahepatic portosystemic shunt --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:transjugular intrahepatic portosystemic shunt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5782. en:treponema immobilization test --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:treponema immobilization test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5783. en:trinitrobenzenesulfonic acid --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:trinitrobenzenesulfonic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5784. en:tumor necrosis factor receptor superfamily member 25 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:tumor necrosis factor receptor superfamily member 25 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5785. en:uncoupling protein 2 --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:uncoupling protein 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5786. en:valine dehydrogenase (nadp+) --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:valine dehydrogenase (nadp+) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5787. en:very low density lipoprotein cholesterol --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:very low density lipoprotein cholesterol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5788. en:voltage-gated sodium channel agonists --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:voltage-gated sodium channel agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5789. en:water pollutants --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:water pollutants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5790. en:wiring harness --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:wiring harness | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5791. en:xenopus proteins --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:xenopus proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5792. en:z-dna --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:z-dna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5793. en:zap-70 kinase --- r_associated #0: 26 --> en:contraindications aspect
    n1=en:zap-70 kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5794. hydroxyde de sodium --- r_associated #0: 26 --> en:contraindications aspect
    n1=hydroxyde de sodium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5795. immunisation passive --- r_associated #0: 26 --> en:contraindications aspect
    n1=immunisation passive | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5796. laxative --- r_associated #0: 26 --> en:contraindications aspect
    n1=laxative | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5797. mélanostimuline --- r_associated #0: 26 --> en:contraindications aspect
    n1=mélanostimuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5798. oxyhémoglobine --- r_associated #0: 26 --> en:contraindications aspect
    n1=oxyhémoglobine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5799. phosvitine --- r_associated #0: 26 --> en:contraindications aspect
    n1=phosvitine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5800. pression du sang --- r_associated #0: 26 --> en:contraindications aspect
    n1=pression du sang | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5801. préparation pharmaceutique --- r_associated #0: 26 --> en:contraindications aspect
    n1=préparation pharmaceutique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5802. pâte dentifrice --- r_associated #0: 26 --> en:contraindications aspect
    n1=pâte dentifrice | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5803. rupt --- r_associated #0: 26 --> en:contraindications aspect
    n1=rupt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5804. ry --- r_associated #0: 26 --> en:contraindications aspect
    n1=ry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5805. sel de table --- r_associated #0: 26 --> en:contraindications aspect
    n1=sel de table | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5806. transforming growth factor --- r_associated #0: 26 --> en:contraindications aspect
    n1=transforming growth factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5807. érythropoïétine --- r_associated #0: 26 --> en:contraindications aspect
    n1=érythropoïétine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=26
  5808. 1-fœtoprotéine --- r_associated #0: 25 --> en:contraindications aspect
    n1=1-fœtoprotéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5809. 1-foetoprotéine --- r_associated #0: 25 --> en:contraindications aspect
    n1=1-foetoprotéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5810. BSQV --- r_associated #0: 25 --> en:contraindications aspect
    n1=BSQV | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5811. Centrifugation --- r_associated #0: 25 --> en:contraindications aspect
    n1=Centrifugation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5812. Dieck (méthode de) --- r_associated #0: 25 --> en:contraindications aspect
    n1=Dieck (méthode de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5813. E553b --- r_associated #0: 25 --> en:contraindications aspect
    n1=E553b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5814. NaOH --- r_associated #0: 25 --> en:contraindications aspect
    n1=NaOH | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5815. Phytochrome B --- r_associated #0: 25 --> en:contraindications aspect
    n1=Phytochrome B | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5816. TOPV --- r_associated #0: 25 --> en:contraindications aspect
    n1=TOPV | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5817. acide orotidylique --- r_associated #0: 25 --> en:contraindications aspect
    n1=acide orotidylique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5818. acte chirurgical --- r_associated #0: 25 --> en:contraindications aspect
    n1=acte chirurgical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5819. balistique biologique --- r_associated #0: 25 --> en:contraindications aspect
    n1=balistique biologique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5820. cœlioscopie vaginale --- r_associated #0: 25 --> en:contraindications aspect
    n1=cœlioscopie vaginale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5821. calnexine --- r_associated #0: 25 --> en:contraindications aspect
    n1=calnexine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5822. capsulorhexis --- r_associated #0: 25 --> en:contraindications aspect
    n1=capsulorhexis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5823. cefotiam hexétil --- r_associated #0: 25 --> en:contraindications aspect
    n1=cefotiam hexétil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5824. chirurgie thoracique vidéo-assistée --- r_associated #0: 25 --> en:contraindications aspect
    n1=chirurgie thoracique vidéo-assistée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5825. coelioscopie vaginale --- r_associated #0: 25 --> en:contraindications aspect
    n1=coelioscopie vaginale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5826. dianhydro-galactitol --- r_associated #0: 25 --> en:contraindications aspect
    n1=dianhydro-galactitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5827. en:1,2-Ethanediol --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:1,2-Ethanediol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5828. en:6-phosphofructokinase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:6-phosphofructokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5829. en:Aedes albopictus --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:Aedes albopictus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5830. en:CT --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:CT | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5831. en:X-ray therapy --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:X-ray therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5832. en:a-dna --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:a-dna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5833. en:acidic glycosphingolipids --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:acidic glycosphingolipids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5834. en:activated-leukocyte cell adhesion molecule --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:activated-leukocyte cell adhesion molecule | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5835. en:alcohol deterrents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:alcohol deterrents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5836. en:alcohol oxidoreductases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:alcohol oxidoreductases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5837. en:alpha-macroglobulins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:alpha-macroglobulins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5838. en:aluminum --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:aluminum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5839. en:aminomethyltransferase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:aminomethyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5840. en:angiogenesis modulating agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:angiogenesis modulating agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5841. en:anti-hiv agent --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:anti-hiv agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5842. en:antidermatitis vitamin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:antidermatitis vitamin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5843. en:antimanic agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:antimanic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5844. en:antineoplastic agents, hormonal --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:antineoplastic agents, hormonal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5845. en:antineoplastic alkylating agent --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:antineoplastic alkylating agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5846. en:antiporter --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:antiporter | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5847. en:antitubercular agent --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:antitubercular agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5848. en:aquaglyceroporins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:aquaglyceroporins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5849. en:arylamine n-acetyltransferase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:arylamine n-acetyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5850. en:azabicyclo compounds --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:azabicyclo compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5851. en:beta 2-glycoprotein i --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:beta 2-glycoprotein i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5852. en:beta endorphin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:beta endorphin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5853. en:beta-globins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:beta-globins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5854. en:beta-mannosidase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:beta-mannosidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5855. en:beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5856. en:biogenic polyamines --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:biogenic polyamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5857. en:biphasic insulins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:biphasic insulins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5858. en:bone cements --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:bone cements | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5859. en:bretylium tosylate --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:bretylium tosylate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5860. en:ca(2+)-transporting atpase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:ca(2+)-transporting atpase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5861. en:calcium channel agonists --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:calcium channel agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5862. en:calcium compounds, inorganic --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:calcium compounds, inorganic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5863. en:calcium pyrophosphate --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:calcium pyrophosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5864. en:camphor 5-monooxygenase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:camphor 5-monooxygenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5865. en:carbenicillin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:carbenicillin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5866. en:carbonic anhydrase i --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:carbonic anhydrase i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5867. en:carbonic anhydrase ii --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:carbonic anhydrase ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5868. en:carboxypeptidase b2 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:carboxypeptidase b2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5869. en:cariostatic agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cariostatic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5870. en:casp8 and fadd-like apoptosis regulating protein --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:casp8 and fadd-like apoptosis regulating protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5871. en:caustics --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:caustics | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5872. en:caveolin-1 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:caveolin-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5873. en:cell adhesion molecule --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cell adhesion molecule | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5874. en:cell wall skeleton --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cell wall skeleton | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5875. en:cellulose, oxidized --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cellulose, oxidized | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5876. en:chloride-bicarbonate antiporters --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:chloride-bicarbonate antiporters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5877. en:chlorophyll --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:chlorophyll | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5878. en:choline kinase alpha --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:choline kinase alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5879. en:chondroitin sulfate proteoglycans --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:chondroitin sulfate proteoglycans | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5880. en:cme-carbodiimide --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cme-carbodiimide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5881. en:collagen type v --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:collagen type v | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5882. en:collagen type xii --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:collagen type xii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5883. en:collagen type xiii --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:collagen type xiii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5884. en:complement c3 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:complement c3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5885. en:complement factor b --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:complement factor b | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5886. en:contraceptive agents, female --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:contraceptive agents, female | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5887. en:contraceptive agents, male --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:contraceptive agents, male | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5888. en:crotalid venoms --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:crotalid venoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5889. en:ct scan --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:ct scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5890. en:cyclic nucleotide phosphodiesterases, type 1 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cyclic nucleotide phosphodiesterases, type 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5891. en:cyclic nucleotide phosphodiesterases, type 3 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cyclic nucleotide phosphodiesterases, type 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5892. en:cyclic nucleotide phosphodiesterases, type 4 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cyclic nucleotide phosphodiesterases, type 4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5893. en:cyclin c --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cyclin c | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5894. en:cyclin e --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cyclin e | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5895. en:cytochrome b group --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cytochrome b group | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5896. en:cytostatic agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:cytostatic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5897. en:dead-box rna helicases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dead-box rna helicases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5898. en:defoliants, chemical --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:defoliants, chemical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5899. en:dental porcelain --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dental porcelain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5900. en:dentin-bonding agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dentin-bonding agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5901. en:dessicated thyroid extract --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dessicated thyroid extract | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5902. en:dibenzothiepins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dibenzothiepins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5903. en:dihydrostreptomycin sulfate --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dihydrostreptomycin sulfate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5904. en:dimethindene --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dimethindene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5905. en:dna probes --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dna probes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5906. en:dna, c-form --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dna, c-form | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5907. en:dna, helminth --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dna, helminth | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5908. en:dna-cytosine methylases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dna-cytosine methylases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5909. en:dual-specificity phosphatases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:dual-specificity phosphatases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5910. en:elapid venoms --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:elapid venoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5911. en:endothelin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:endothelin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5912. en:environmental carcinogen --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:environmental carcinogen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5913. en:ergoloid mesylates, usp --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:ergoloid mesylates, usp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5914. en:erythrityl tetranitrate --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:erythrityl tetranitrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5915. en:erythromycin estolate --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:erythromycin estolate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5916. en:erythromycin ethylsuccinate --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:erythromycin ethylsuccinate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5917. en:ethamsylate --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:ethamsylate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5918. en:ethyl biscoumacetate --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:ethyl biscoumacetate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5919. en:ethyl methanesulfonate --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:ethyl methanesulfonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5920. en:ethylene chlorohydrin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:ethylene chlorohydrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5921. en:flap endonucleases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:flap endonucleases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5922. en:florigen --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:florigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5923. en:fungal vaccines --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:fungal vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5924. en:g-protein-coupled receptor kinase 5 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:g-protein-coupled receptor kinase 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5925. en:gamma-glutamyl hydrolase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:gamma-glutamyl hydrolase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5926. en:get to know sb --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:get to know sb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5927. en:glucosamine-phosphate n-acetyltransferase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:glucosamine-phosphate n-acetyltransferase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5928. en:glutethimide --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:glutethimide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5929. en:gout suppressants --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:gout suppressants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5930. en:group iii histone deacetylases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:group iii histone deacetylases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5931. en:hemagglutinins, viral --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:hemagglutinins, viral | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5932. en:hematologic agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:hematologic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5933. en:hemoglobin subunit alpha --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:hemoglobin subunit alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5934. en:histamine agonists --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:histamine agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5935. en:histone deacetylase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:histone deacetylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5936. en:hydroxymethylbilane synthase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:hydroxymethylbilane synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5937. en:indans --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:indans | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5938. en:insulin receptor substrate proteins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:insulin receptor substrate proteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5939. en:integrin alphaxbeta2 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:integrin alphaxbeta2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5940. en:integrin beta chains --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:integrin beta chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5941. en:iridoid glycosides --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:iridoid glycosides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5942. en:keratin i --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:keratin i | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5943. en:keratins, type ii --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:keratins, type ii | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5944. en:lactose factors --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:lactose factors | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5945. en:linoleoyl-coa desaturase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:linoleoyl-coa desaturase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5946. en:lipid bilayers --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:lipid bilayers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5947. en:lipid hydroperoxide --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:lipid hydroperoxide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5948. en:lipoprotein lipase activators --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:lipoprotein lipase activators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5949. en:low molecular-weight heparin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:low molecular-weight heparin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5950. en:luciferases, firefly --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:luciferases, firefly | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5951. en:luteolytic agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:luteolytic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5952. en:lysergic (acid) --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:lysergic (acid) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5953. en:macrocyclic compounds --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:macrocyclic compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5954. en:malathion --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:malathion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5955. en:mannose-binding lectins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:mannose-binding lectins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5956. en:mannosephosphates --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:mannosephosphates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5957. en:map kinase kinase kinase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:map kinase kinase kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5958. en:matrix metalloproteinases, membrane-associated --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:matrix metalloproteinases, membrane-associated | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5959. en:matrix metalloproteinases, secreted --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:matrix metalloproteinases, secreted | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5960. en:meet sb --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:meet sb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5961. en:meet somebody --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:meet somebody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5962. en:melanostimulating hormone --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:melanostimulating hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5963. en:membrane glycoproteins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:membrane glycoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5964. en:mephenesin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:mephenesin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5965. en:methyl parathion --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:methyl parathion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5966. en:metyrosine --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:metyrosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5967. en:minoxidil --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:minoxidil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5968. en:mitogen-activated protein kinase phosphatases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:mitogen-activated protein kinase phosphatases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5969. en:monoacylglycerol lipases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:monoacylglycerol lipases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5970. en:monocrotaline --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:monocrotaline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5971. en:mouth off at [sb] --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:mouth off at [sb] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5972. en:muc-1 antigen --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:muc-1 antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5973. en:multiphasic screening --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:multiphasic screening | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5974. en:multiprotein complexes --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:multiprotein complexes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5975. en:muscarinic agonists --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:muscarinic agonists | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5976. en:neural cell adhesion molecules --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:neural cell adhesion molecules | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5977. en:neutral glycosphingolipids --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:neutral glycosphingolipids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5978. en:nikethamide --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:nikethamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5979. en:nodal signaling ligands --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:nodal signaling ligands | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5980. en:nonsteroidal anti-androgens --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:nonsteroidal anti-androgens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5981. en:nootropic agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:nootropic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5982. en:nuclear receptor coactivators --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:nuclear receptor coactivators | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5983. en:nylidrin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:nylidrin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5984. en:oncogene proteins, fusion --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:oncogene proteins, fusion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5985. en:optical devices --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:optical devices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5986. en:oxyphenonium --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:oxyphenonium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5987. en:parainfluenza vaccines --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:parainfluenza vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5988. en:parvalbumins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:parvalbumins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5989. en:pentetrazol --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:pentetrazol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5990. en:peptide fragments --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:peptide fragments | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5991. en:peptoids --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:peptoids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5992. en:pharmaceutical vehicles --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:pharmaceutical vehicles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5993. en:phenylalanine hydroxylase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:phenylalanine hydroxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5994. en:phosphoric triester hydrolases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:phosphoric triester hydrolases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5995. en:physical examination --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:physical examination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5996. en:pindolol --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:pindolol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5997. en:pituitary gonadotropins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:pituitary gonadotropins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5998. en:plant exudates --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:plant exudates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  5999. en:plant lectins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:plant lectins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6000. en:plant nectar --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:plant nectar | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6001. en:plant tumor-inducing plasmids --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:plant tumor-inducing plasmids | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6002. en:plasma gases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:plasma gases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6003. en:plasma substitutes --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:plasma substitutes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6004. en:platelet membrane glycoproteins --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:platelet membrane glycoproteins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6005. en:poly au --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:poly au | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6006. en:polychloroterphenyl compounds --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:polychloroterphenyl compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6007. en:position emission transaxial tomography --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:position emission transaxial tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6008. en:positon emission tomography --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:positon emission tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6009. en:potassium channel blockers --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:potassium channel blockers | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6010. en:probucol --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:probucol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6011. en:proline dehydrogenase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:proline dehydrogenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6012. en:propyliodone --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:propyliodone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6013. en:protein methyltransferases --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:protein methyltransferases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6014. en:proton-translocating pyrophosphatase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:proton-translocating pyrophosphatase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6015. en:protozoan vaccines --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:protozoan vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6016. en:purinergic agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:purinergic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6017. en:pyrimidine nucleotides --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:pyrimidine nucleotides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6018. en:pyrogen --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:pyrogen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6019. en:radiopharmaceutical compound --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:radiopharmaceutical compound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6020. en:razoxane --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:razoxane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6021. en:remedial gymnastics --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:remedial gymnastics | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6022. en:renal agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:renal agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6023. en:reproductive control agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:reproductive control agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6024. en:resin cements --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:resin cements | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6025. en:respond to --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:respond to | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6026. en:reviving --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:reviving | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6027. en:rickettsial vaccines --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:rickettsial vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6028. en:rna caps --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:rna caps | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6029. en:rna isoforms --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:rna isoforms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6030. en:rna, algal --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:rna, algal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6031. en:root canal filling materials --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:root canal filling materials | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6032. en:saccharinol --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:saccharinol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6033. en:scorpion venoms --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:scorpion venoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6034. en:seed-oil --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:seed-oil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6035. en:serum globulin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:serum globulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6036. en:shigella vaccines --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:shigella vaccines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6037. en:simethicone --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:simethicone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6038. en:spider venoms --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:spider venoms | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6039. en:splenography --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:splenography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6040. en:sterigmatocystin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sterigmatocystin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6041. en:stomachoscopy --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:stomachoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6042. en:streptogramin a --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:streptogramin a | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6043. en:stromelysin-3 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:stromelysin-3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6044. en:sulbactam --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sulbactam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6045. en:sulfachlorpyridazine --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sulfachlorpyridazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6046. en:sulfamethazine --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sulfamethazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6047. en:sulfamethizole --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sulfamethizole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6048. en:sulfamoxole --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sulfamoxole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6049. en:sulfaquinoxaline --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sulfaquinoxaline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6050. en:sulfinpyrazone --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sulfinpyrazone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6051. en:sulfisomidine --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sulfisomidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6052. en:sulfisoxazole --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:sulfisoxazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6053. en:support stocking --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:support stocking | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6054. en:symporters --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:symporters | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6055. en:technetium tc-99m exametazime --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:technetium tc-99m exametazime | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6056. en:thiotepa --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:thiotepa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6057. en:thrombospondin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:thrombospondin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6058. en:ticrynafen --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:ticrynafen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6059. en:tilorone --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tilorone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6060. en:tin --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6061. en:tin fluorides --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tin fluorides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6062. en:to get to know sb --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:to get to know sb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6063. en:to meet sb --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:to meet sb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6064. en:tocolytic agents --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tocolytic agents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6065. en:tomo-echography --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tomo-echography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6066. en:tomocamera --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tomocamera | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6067. en:tomodensitometry --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tomodensitometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6068. en:topoisomerase-i inhibitor --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:topoisomerase-i inhibitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6069. en:toremifene --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:toremifene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6070. en:tosyl compounds --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tosyl compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6071. en:trifluridine --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:trifluridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6072. en:trioxsalen --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:trioxsalen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6073. en:tryptophan 2,3-dioxygenase --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tryptophan 2,3-dioxygenase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6074. en:tumor necrosis factor family protein --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:tumor necrosis factor family protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6075. en:uranium compounds --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:uranium compounds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6076. en:vaccines, contraceptive --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:vaccines, contraceptive | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6077. en:vaccines, edible --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:vaccines, edible | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6078. en:vaccines, synthetic --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:vaccines, synthetic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6079. en:variant surface glycoproteins, trypanosoma --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:variant surface glycoproteins, trypanosoma | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6080. en:vitamin K1 --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:vitamin K1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6081. en:xanthenes --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:xanthenes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6082. en:zeranol --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:zeranol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6083. en:zinc compounds, inorganic --- r_associated #0: 25 --> en:contraindications aspect
    n1=en:zinc compounds, inorganic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6084. gammagraphie --- r_associated #0: 25 --> en:contraindications aspect
    n1=gammagraphie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6085. hydrate de sodium --- r_associated #0: 25 --> en:contraindications aspect
    n1=hydrate de sodium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6086. hydrocarboné --- r_associated #0: 25 --> en:contraindications aspect
    n1=hydrocarboné | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6087. indole-quinones --- r_associated #0: 25 --> en:contraindications aspect
    n1=indole-quinones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6088. phlébographie --- r_associated #0: 25 --> en:contraindications aspect
    n1=phlébographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6089. pyrrolo-iminoquinones --- r_associated #0: 25 --> en:contraindications aspect
    n1=pyrrolo-iminoquinones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6090. pyrroloiminoquinones --- r_associated #0: 25 --> en:contraindications aspect
    n1=pyrroloiminoquinones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6091. uridine monophosphate --- r_associated #0: 25 --> en:contraindications aspect
    n1=uridine monophosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6092. émétisante --- r_associated #0: 25 --> en:contraindications aspect
    n1=émétisante | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=25
  6093. Splendore-Hoeppli (corps astéroïdes de) --- r_associated #0: 24 --> en:contraindications aspect
    n1=Splendore-Hoeppli (corps astéroïdes de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6094. Vitamine B5 --- r_associated #0: 24 --> en:contraindications aspect
    n1=Vitamine B5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6095. acide bromhydrique --- r_associated #0: 24 --> en:contraindications aspect
    n1=acide bromhydrique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6096. acide obéticholique --- r_associated #0: 24 --> en:contraindications aspect
    n1=acide obéticholique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6097. acide octadécanoïque --- r_associated #0: 24 --> en:contraindications aspect
    n1=acide octadécanoïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6098. acide oléique --- r_associated #0: 24 --> en:contraindications aspect
    n1=acide oléique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6099. anticoïncidence --- r_associated #0: 24 --> en:contraindications aspect
    n1=anticoïncidence | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6100. arthrogramme --- r_associated #0: 24 --> en:contraindications aspect
    n1=arthrogramme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6101. binocles --- r_associated #0: 24 --> en:contraindications aspect
    n1=binocles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6102. canal sodique --- r_associated #0: 24 --> en:contraindications aspect
    n1=canal sodique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6103. cardioangiographie --- r_associated #0: 24 --> en:contraindications aspect
    n1=cardioangiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6104. en:PTH --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:PTH | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6105. en:alpha -amylase --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:alpha -amylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6106. en:antiachromotrichia factor --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:antiachromotrichia factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6107. en:caustic soda --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:caustic soda | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6108. en:diuretics, osmotic --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:diuretics, osmotic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6109. en:immunizing --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:immunizing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6110. en:metachysis --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:metachysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6111. en:monoethylene glycol --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:monoethylene glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6112. en:pet scan --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:pet scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6113. en:positron-emission tomography --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:positron-emission tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6114. en:solar therapy --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:solar therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6115. en:spinal computerized tomography --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:spinal computerized tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6116. en:tomography unit --- r_associated #0: 24 --> en:contraindications aspect
    n1=en:tomography unit | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6117. glycosaminoglycane --- r_associated #0: 24 --> en:contraindications aspect
    n1=glycosaminoglycane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6118. gouttes ophtalmiques --- r_associated #0: 24 --> en:contraindications aspect
    n1=gouttes ophtalmiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6119. gélose --- r_associated #0: 24 --> en:contraindications aspect
    n1=gélose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6120. indométacine --- r_associated #0: 24 --> en:contraindications aspect
    n1=indométacine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6121. lipide A --- r_associated #0: 24 --> en:contraindications aspect
    n1=lipide A | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6122. lipoprotéine de faible poids moléculaire --- r_associated #0: 24 --> en:contraindications aspect
    n1=lipoprotéine de faible poids moléculaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6123. manipulations vertébrales --- r_associated #0: 24 --> en:contraindications aspect
    n1=manipulations vertébrales | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6124. prométhéum --- r_associated #0: 24 --> en:contraindications aspect
    n1=prométhéum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6125. toxines fongiques --- r_associated #0: 24 --> en:contraindications aspect
    n1=toxines fongiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6126. traitement aux rayons --- r_associated #0: 24 --> en:contraindications aspect
    n1=traitement aux rayons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=24
  6127. ARN r --- r_associated #0: 23 --> en:contraindications aspect
    n1=ARN r | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6128. ARNr (ou rRNA) --- r_associated #0: 23 --> en:contraindications aspect
    n1=ARNr (ou rRNA) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6129. Spectacles --- r_associated #0: 23 --> en:contraindications aspect
    n1=Spectacles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6130. ZTV --- r_associated #0: 23 --> en:contraindications aspect
    n1=ZTV | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6131. acide valproïque --- r_associated #0: 23 --> en:contraindications aspect
    n1=acide valproïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6132. acétylgalactosamine --- r_associated #0: 23 --> en:contraindications aspect
    n1=acétylgalactosamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6133. arthrodèse --- r_associated #0: 23 --> en:contraindications aspect
    n1=arthrodèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6134. ballistocardiographie --- r_associated #0: 23 --> en:contraindications aspect
    n1=ballistocardiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6135. clé à molette --- r_associated #0: 23 --> en:contraindications aspect
    n1=clé à molette | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6136. coagulation du col utérin --- r_associated #0: 23 --> en:contraindications aspect
    n1=coagulation du col utérin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6137. désafférentation --- r_associated #0: 23 --> en:contraindications aspect
    n1=désafférentation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6138. en:1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6139. en:CAT scan --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:CAT scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6140. en:PGD --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:PGD | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6141. en:PGID --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:PGID | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6142. en:aneurin --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:aneurin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6143. en:antitetanus serum --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:antitetanus serum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6144. en:bacterial DNA --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:bacterial DNA | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6145. en:cobalamine --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:cobalamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6146. en:dopaminergic agent --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:dopaminergic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6147. en:helicase --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:helicase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6148. en:mapmaking --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:mapmaking | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6149. en:ophtalmoscopy --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:ophtalmoscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6150. en:physiopathic syndrome --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:physiopathic syndrome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6151. en:preimplantation genetic diagnosis --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:preimplantation genetic diagnosis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6152. en:pyroglutamic acid --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:pyroglutamic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6153. en:retinoskiascopy --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:retinoskiascopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6154. en:solar treatment --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:solar treatment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6155. en:surgical action --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:surgical action | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6156. en:tomogram --- r_associated #0: 23 --> en:contraindications aspect
    n1=en:tomogram | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6157. nadroparine calcique --- r_associated #0: 23 --> en:contraindications aspect
    n1=nadroparine calcique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6158. partie de jambes en l'air --- r_associated #0: 23 --> en:contraindications aspect
    n1=partie de jambes en l'air | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6159. plaquettes grises (syndrome des) --- r_associated #0: 23 --> en:contraindications aspect
    n1=plaquettes grises (syndrome des) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6160. progestérone --- r_associated #0: 23 --> en:contraindications aspect
    n1=progestérone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6161. sorbier (tache en feuille de) --- r_associated #0: 23 --> en:contraindications aspect
    n1=sorbier (tache en feuille de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6162. tomodensitomètre --- r_associated #0: 23 --> en:contraindications aspect
    n1=tomodensitomètre | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6163. urines à odeur de houblon (maladie des) --- r_associated #0: 23 --> en:contraindications aspect
    n1=urines à odeur de houblon (maladie des) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6164. élastographie --- r_associated #0: 23 --> en:contraindications aspect
    n1=élastographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6165. éthinyl oestradiol --- r_associated #0: 23 --> en:contraindications aspect
    n1=éthinyl oestradiol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=23
  6166. Diu --- r_associated #0: 22 --> en:contraindications aspect
    n1=Diu | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6167. IL-15 --- r_associated #0: 22 --> en:contraindications aspect
    n1=IL-15 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6168. acide éicosapentaénoïque --- r_associated #0: 22 --> en:contraindications aspect
    n1=acide éicosapentaénoïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6169. acétate de chlormadinone --- r_associated #0: 22 --> en:contraindications aspect
    n1=acétate de chlormadinone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6170. alkylant --- r_associated #0: 22 --> en:contraindications aspect
    n1=alkylant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6171. anticorps antinucléaire --- r_associated #0: 22 --> en:contraindications aspect
    n1=anticorps antinucléaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6172. astringent --- r_associated #0: 22 --> en:contraindications aspect
    n1=astringent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6173. calrétinine --- r_associated #0: 22 --> en:contraindications aspect
    n1=calrétinine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6174. cancérogène --- r_associated #0: 22 --> en:contraindications aspect
    n1=cancérogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6175. cycline B/cdk1 --- r_associated #0: 22 --> en:contraindications aspect
    n1=cycline B/cdk1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6176. dopa --- r_associated #0: 22 --> en:contraindications aspect
    n1=dopa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6177. dressant la carte --- r_associated #0: 22 --> en:contraindications aspect
    n1=dressant la carte | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6178. en:GDP --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:GDP | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6179. en:adonitol --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:adonitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6180. en:agar agar --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:agar agar | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6181. en:baby powder --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:baby powder | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6182. en:busulphan --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:busulphan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6183. en:cholecystotomy --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:cholecystotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6184. en:corneal graft --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:corneal graft | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6185. en:corneal transplantation --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:corneal transplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6186. en:elastic hosiery --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:elastic hosiery | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6187. en:intrauterine contraceptive device --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:intrauterine contraceptive device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6188. en:melanocytic stimulating hormone --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:melanocytic stimulating hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6189. en:melanostimulating hormones --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:melanostimulating hormones | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6190. en:phytic acid. --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:phytic acid. | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6191. en:radioisotopic scanning --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:radioisotopic scanning | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6192. en:sex factor --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:sex factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6193. en:shadow test --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:shadow test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6194. en:sunray treatment --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:sunray treatment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6195. en:to respond to --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:to respond to | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6196. en:tooth brace --- r_associated #0: 22 --> en:contraindications aspect
    n1=en:tooth brace | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6197. exopeptidase --- r_associated #0: 22 --> en:contraindications aspect
    n1=exopeptidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6198. isotonique (exercice) --- r_associated #0: 22 --> en:contraindications aspect
    n1=isotonique (exercice) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6199. opération de la taille --- r_associated #0: 22 --> en:contraindications aspect
    n1=opération de la taille | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6200. oxyhémoglobinée (saturation) --- r_associated #0: 22 --> en:contraindications aspect
    n1=oxyhémoglobinée (saturation) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6201. point de montage --- r_associated #0: 22 --> en:contraindications aspect
    n1=point de montage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6202. s. PAB --- r_associated #0: 22 --> en:contraindications aspect
    n1=s. PAB | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6203. salpingotomie --- r_associated #0: 22 --> en:contraindications aspect
    n1=salpingotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6204. transducteurs --- r_associated #0: 22 --> en:contraindications aspect
    n1=transducteurs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6205. union sexuelle --- r_associated #0: 22 --> en:contraindications aspect
    n1=union sexuelle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6206. vêtement de protection --- r_associated #0: 22 --> en:contraindications aspect
    n1=vêtement de protection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=22
  6207. Arg-Gly-Asp --- r_associated #0: 21 --> en:contraindications aspect
    n1=Arg-Gly-Asp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6208. CARV --- r_associated #0: 21 --> en:contraindications aspect
    n1=CARV | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6209. DIU --- r_associated #0: 21 --> en:contraindications aspect
    n1=DIU | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6210. acide aconitique --- r_associated #0: 21 --> en:contraindications aspect
    n1=acide aconitique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6211. acide argininosuccinique --- r_associated #0: 21 --> en:contraindications aspect
    n1=acide argininosuccinique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6212. acide mévalonique --- r_associated #0: 21 --> en:contraindications aspect
    n1=acide mévalonique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6213. acide oléique marqué --- r_associated #0: 21 --> en:contraindications aspect
    n1=acide oléique marqué | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6214. acide quinolinique --- r_associated #0: 21 --> en:contraindications aspect
    n1=acide quinolinique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6215. acide urocanique --- r_associated #0: 21 --> en:contraindications aspect
    n1=acide urocanique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6216. agent neuroprotecteur --- r_associated #0: 21 --> en:contraindications aspect
    n1=agent neuroprotecteur | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6217. antagoniste des opiacés --- r_associated #0: 21 --> en:contraindications aspect
    n1=antagoniste des opiacés | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6218. auto-examen des seins --- r_associated #0: 21 --> en:contraindications aspect
    n1=auto-examen des seins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6219. bésicles --- r_associated #0: 21 --> en:contraindications aspect
    n1=bésicles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6220. cathétérisme --- r_associated #0: 21 --> en:contraindications aspect
    n1=cathétérisme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6221. chlorure de vinyle --- r_associated #0: 21 --> en:contraindications aspect
    n1=chlorure de vinyle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6222. coloscope --- r_associated #0: 21 --> en:contraindications aspect
    n1=coloscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6223. convulsivothérapie --- r_associated #0: 21 --> en:contraindications aspect
    n1=convulsivothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6224. cotransporteur sodium-glucose type 2 --- r_associated #0: 21 --> en:contraindications aspect
    n1=cotransporteur sodium-glucose type 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6225. cytidine-triphosphate --- r_associated #0: 21 --> en:contraindications aspect
    n1=cytidine-triphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6226. en:adrenoreceptor antagonist --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:adrenoreceptor antagonist | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6227. en:answer [sb] back --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:answer [sb] back | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6228. en:computerized tomographic cisternography --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:computerized tomographic cisternography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6229. en:iceberg sign --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:iceberg sign | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6230. en:intra-uterine device --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:intra-uterine device | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6231. en:kepone --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:kepone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6232. en:large cell calcifying Sertoli's tumour --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:large cell calcifying Sertoli's tumour | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6233. en:monkey wrench --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:monkey wrench | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6234. en:nicotinamide --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:nicotinamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6235. en:pair of glasses --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:pair of glasses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6236. en:phospholipase A2 --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:phospholipase A2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6237. en:pleuroscopy --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:pleuroscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6238. en:powder [sth] --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:powder [sth] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6239. en:powder [sth] with [sth] --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:powder [sth] with [sth] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6240. en:rubber dam --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:rubber dam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6241. en:saccaharin --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:saccaharin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6242. en:sexual union --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:sexual union | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6243. en:somatotropin release-inhibiting factor --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:somatotropin release-inhibiting factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6244. en:support stockings --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:support stockings | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6245. en:to answer --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:to answer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6246. en:transcranial doppler ultrasound --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:transcranial doppler ultrasound | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6247. en:ureterostomosis --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:ureterostomosis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6248. en:wolfram --- r_associated #0: 21 --> en:contraindications aspect
    n1=en:wolfram | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6249. fibroduodénoscopie --- r_associated #0: 21 --> en:contraindications aspect
    n1=fibroduodénoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6250. globulines de foetus --- r_associated #0: 21 --> en:contraindications aspect
    n1=globulines de foetus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6251. gonadotrophine de femmes ménopausées --- r_associated #0: 21 --> en:contraindications aspect
    n1=gonadotrophine de femmes ménopausées | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6252. hormone de libération de l'hormone de croissance --- r_associated #0: 21 --> en:contraindications aspect
    n1=hormone de libération de l'hormone de croissance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6253. iléostomie --- r_associated #0: 21 --> en:contraindications aspect
    n1=iléostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6254. implant dentaire --- r_associated #0: 21 --> en:contraindications aspect
    n1=implant dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6255. intervention de Fontan --- r_associated #0: 21 --> en:contraindications aspect
    n1=intervention de Fontan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6256. lipoprotéine de faible densité --- r_associated #0: 21 --> en:contraindications aspect
    n1=lipoprotéine de faible densité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6257. lymphographie --- r_associated #0: 21 --> en:contraindications aspect
    n1=lymphographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6258. phospholipase a1 --- r_associated #0: 21 --> en:contraindications aspect
    n1=phospholipase a1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6259. photogrammétrie --- r_associated #0: 21 --> en:contraindications aspect
    n1=photogrammétrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6260. qi gong --- r_associated #0: 21 --> en:contraindications aspect
    n1=qi gong | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6261. réflexothérapie --- r_associated #0: 21 --> en:contraindications aspect
    n1=réflexothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6262. variole de la vache --- r_associated #0: 21 --> en:contraindications aspect
    n1=variole de la vache | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=21
  6263. Acétaminophène --- r_associated #0: 20 --> en:contraindications aspect
    n1=Acétaminophène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6264. Iléostomie --- r_associated #0: 20 --> en:contraindications aspect
    n1=Iléostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6265. Imagerie par Résonance Magnétique --- r_associated #0: 20 --> en:contraindications aspect
    n1=Imagerie par Résonance Magnétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6266. Relations sexuelles --- r_associated #0: 20 --> en:contraindications aspect
    n1=Relations sexuelles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6267. Rifamycine --- r_associated #0: 20 --> en:contraindications aspect
    n1=Rifamycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6268. Rivaroxaban --- r_associated #0: 20 --> en:contraindications aspect
    n1=Rivaroxaban | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6269. Réimplantation --- r_associated #0: 20 --> en:contraindications aspect
    n1=Réimplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6270. Saccharine --- r_associated #0: 20 --> en:contraindications aspect
    n1=Saccharine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6271. Saccharose --- r_associated #0: 20 --> en:contraindications aspect
    n1=Saccharose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6272. Saponine --- r_associated #0: 20 --> en:contraindications aspect
    n1=Saponine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6273. Scintigraphie --- r_associated #0: 20 --> en:contraindications aspect
    n1=Scintigraphie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6274. Secourisme --- r_associated #0: 20 --> en:contraindications aspect
    n1=Secourisme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6275. Simazine --- r_associated #0: 20 --> en:contraindications aspect
    n1=Simazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6276. Somatostatine --- r_associated #0: 20 --> en:contraindications aspect
    n1=Somatostatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6277. Splénectomie --- r_associated #0: 20 --> en:contraindications aspect
    n1=Splénectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6278. Sternotomie --- r_associated #0: 20 --> en:contraindications aspect
    n1=Sternotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6279. Stéatite --- r_associated #0: 20 --> en:contraindications aspect
    n1=Stéatite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6280. Stérilet --- r_associated #0: 20 --> en:contraindications aspect
    n1=Stérilet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6281. Sulfites --- r_associated #0: 20 --> en:contraindications aspect
    n1=Sulfites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6282. Sécrétine --- r_associated #0: 20 --> en:contraindications aspect
    n1=Sécrétine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6283. Talc --- r_associated #0: 20 --> en:contraindications aspect
    n1=Talc | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6284. Thiamine --- r_associated #0: 20 --> en:contraindications aspect
    n1=Thiamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6285. Thioridazine --- r_associated #0: 20 --> en:contraindications aspect
    n1=Thioridazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6286. Thoracoscopie --- r_associated #0: 20 --> en:contraindications aspect
    n1=Thoracoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6287. Transglutaminase --- r_associated #0: 20 --> en:contraindications aspect
    n1=Transglutaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6288. Trastuzumab --- r_associated #0: 20 --> en:contraindications aspect
    n1=Trastuzumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6289. anticorps anti-nucléaire --- r_associated #0: 20 --> en:contraindications aspect
    n1=anticorps anti-nucléaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6290. arn --- r_associated #0: 20 --> en:contraindications aspect
    n1=arn | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6291. cholecystographie --- r_associated #0: 20 --> en:contraindications aspect
    n1=cholecystographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6292. dianhydrogalactitol --- r_associated #0: 20 --> en:contraindications aspect
    n1=dianhydrogalactitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6293. en:carcinogenic --- r_associated #0: 20 --> en:contraindications aspect
    n1=en:carcinogenic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6294. pseudocholinéstérase --- r_associated #0: 20 --> en:contraindications aspect
    n1=pseudocholinéstérase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6295. Éthylène-glycol --- r_associated #0: 20 --> en:contraindications aspect
    n1=Éthylène-glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=20
  6296. paracétamol --- r_associated #0: 16 --> en:contraindications aspect
    n1=paracétamol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=16
  6297. Acide RiboNucléique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Acide RiboNucléique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6298. Acide aspartique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Acide aspartique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6299. Acide bromhydrique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Acide bromhydrique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6300. Acide mévalonique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Acide mévalonique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6301. Acide pantothénique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Acide pantothénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6302. Acide phytique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Acide phytique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6303. Acide ribonucléique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Acide ribonucléique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6304. Acide urocanique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Acide urocanique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6305. Adson (opération d') --- r_associated #0: 15 --> en:contraindications aspect
    n1=Adson (opération d') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6306. Agent biologique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Agent biologique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6307. Angelucci (syndrome d') --- r_associated #0: 15 --> en:contraindications aspect
    n1=Angelucci (syndrome d') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6308. Anti-coagulant --- r_associated #0: 15 --> en:contraindications aspect
    n1=Anti-coagulant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6309. Anton-Babinski (syndrome d') --- r_associated #0: 15 --> en:contraindications aspect
    n1=Anton-Babinski (syndrome d') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6310. Arabinose --- r_associated #0: 15 --> en:contraindications aspect
    n1=Arabinose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6311. Aténolol --- r_associated #0: 15 --> en:contraindications aspect
    n1=Aténolol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6312. Auger (effet) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Auger (effet) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6313. Bagues --- r_associated #0: 15 --> en:contraindications aspect
    n1=Bagues | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6314. Beurmann et Gougerot (maladie de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Beurmann et Gougerot (maladie de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6315. Biglieri (syndrome de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Biglieri (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6316. Bleu de méthylène --- r_associated #0: 15 --> en:contraindications aspect
    n1=Bleu de méthylène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6317. Buerger (maladie de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Buerger (maladie de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6318. Bussuquara (virus) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Bussuquara (virus) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6319. CPEF --- r_associated #0: 15 --> en:contraindications aspect
    n1=CPEF | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6320. Canal sodique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Canal sodique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6321. Cancérigène --- r_associated #0: 15 --> en:contraindications aspect
    n1=Cancérigène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6322. Caraparu (virus) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Caraparu (virus) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6323. Carlens (sonde de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Carlens (sonde de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6324. Castleman (pseudotumeur de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Castleman (pseudotumeur de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6325. Clara (cellule de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Clara (cellule de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6326. Clé à molette --- r_associated #0: 15 --> en:contraindications aspect
    n1=Clé à molette | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6327. Coats (syndrome de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Coats (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6328. Cobalamine --- r_associated #0: 15 --> en:contraindications aspect
    n1=Cobalamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6329. Cole-Rauschkolb-Toomey (syndrome de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Cole-Rauschkolb-Toomey (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6330. Contraception orale --- r_associated #0: 15 --> en:contraindications aspect
    n1=Contraception orale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6331. Contre-indication --- r_associated #0: 15 --> en:contraindications aspect
    n1=Contre-indication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6332. Cowper (glande de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Cowper (glande de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6333. Cruveilhier-Baumgarten (syndrome de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Cruveilhier-Baumgarten (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6334. Curcumine --- r_associated #0: 15 --> en:contraindications aspect
    n1=Curcumine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6335. Cuti --- r_associated #0: 15 --> en:contraindications aspect
    n1=Cuti | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6336. Cystectomie --- r_associated #0: 15 --> en:contraindications aspect
    n1=Cystectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6337. Danon (maladie de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Danon (maladie de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6338. Debré-Fibiger (syndrome de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Debré-Fibiger (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6339. Delalande (méthode de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Delalande (méthode de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6340. Dentifrice --- r_associated #0: 15 --> en:contraindications aspect
    n1=Dentifrice | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6341. Desmons (syndrome de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Desmons (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6342. DiGeorge (syndrome de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=DiGeorge (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6343. Diagnostic préimplantatoire --- r_associated #0: 15 --> en:contraindications aspect
    n1=Diagnostic préimplantatoire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6344. Diazinon --- r_associated #0: 15 --> en:contraindications aspect
    n1=Diazinon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6345. Diclofénac --- r_associated #0: 15 --> en:contraindications aspect
    n1=Diclofénac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6346. Dobrava (virus) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Dobrava (virus) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6347. Doppler transcrânien --- r_associated #0: 15 --> en:contraindications aspect
    n1=Doppler transcrânien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6348. Désoxyribonucléase --- r_associated #0: 15 --> en:contraindications aspect
    n1=Désoxyribonucléase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6349. E511 --- r_associated #0: 15 --> en:contraindications aspect
    n1=E511 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6350. E518 --- r_associated #0: 15 --> en:contraindications aspect
    n1=E518 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6351. E559 --- r_associated #0: 15 --> en:contraindications aspect
    n1=E559 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6352. Enzyme --- r_associated #0: 15 --> en:contraindications aspect
    n1=Enzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6353. Facteurs biologiques --- r_associated #0: 15 --> en:contraindications aspect
    n1=Facteurs biologiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6354. Fechtner (syndrome de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Fechtner (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6355. Flourens (lois de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Flourens (lois de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6356. Forgue (signes de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Forgue (signes de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6357. Formaldéhyde --- r_associated #0: 15 --> en:contraindications aspect
    n1=Formaldéhyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6358. Fuchs (syndrome de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Fuchs (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6359. Gley (glandes de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=Gley (glandes de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6360. Greffe de pancréas --- r_associated #0: 15 --> en:contraindications aspect
    n1=Greffe de pancréas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6361. Guanosine-DiPhosphate-fucose --- r_associated #0: 15 --> en:contraindications aspect
    n1=Guanosine-DiPhosphate-fucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6362. Hydrate de carbone --- r_associated #0: 15 --> en:contraindications aspect
    n1=Hydrate de carbone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6363. Imagerie par résonance magnétique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Imagerie par résonance magnétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6364. Imagerie à résonance magnétique --- r_associated #0: 15 --> en:contraindications aspect
    n1=Imagerie à résonance magnétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6365. Immunisation --- r_associated #0: 15 --> en:contraindications aspect
    n1=Immunisation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6366. Implant dentaire --- r_associated #0: 15 --> en:contraindications aspect
    n1=Implant dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6367. Implant mammaire --- r_associated #0: 15 --> en:contraindications aspect
    n1=Implant mammaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6368. Interférométrie --- r_associated #0: 15 --> en:contraindications aspect
    n1=Interférométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6369. Lipoprotéine de basse densité --- r_associated #0: 15 --> en:contraindications aspect
    n1=Lipoprotéine de basse densité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6370. Lipoprotéine de haute densité --- r_associated #0: 15 --> en:contraindications aspect
    n1=Lipoprotéine de haute densité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6371. Mycotoxines --- r_associated #0: 15 --> en:contraindications aspect
    n1=Mycotoxines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6372. Médicament anticoagulant --- r_associated #0: 15 --> en:contraindications aspect
    n1=Médicament anticoagulant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6373. Neuropeptide --- r_associated #0: 15 --> en:contraindications aspect
    n1=Neuropeptide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6374. Neurotensine --- r_associated #0: 15 --> en:contraindications aspect
    n1=Neurotensine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6375. Oligo-élément --- r_associated #0: 15 --> en:contraindications aspect
    n1=Oligo-élément | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6376. Ophtalmoscopie --- r_associated #0: 15 --> en:contraindications aspect
    n1=Ophtalmoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6377. Oxyde de magnésium --- r_associated #0: 15 --> en:contraindications aspect
    n1=Oxyde de magnésium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6378. PROTEIN --- r_associated #0: 15 --> en:contraindications aspect
    n1=PROTEIN | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6379. Procédure médicale --- r_associated #0: 15 --> en:contraindications aspect
    n1=Procédure médicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6380. Proguanil --- r_associated #0: 15 --> en:contraindications aspect
    n1=Proguanil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6381. Prostaglandine --- r_associated #0: 15 --> en:contraindications aspect
    n1=Prostaglandine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6382. Prothèse dentaire --- r_associated #0: 15 --> en:contraindications aspect
    n1=Prothèse dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6383. Protéine --- r_associated #0: 15 --> en:contraindications aspect
    n1=Protéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6384. Q qui a été remplace par WR --- r_associated #0: 15 --> en:contraindications aspect
    n1=Q qui a été remplace par WR | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6385. Radiographie dentaire --- r_associated #0: 15 --> en:contraindications aspect
    n1=Radiographie dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6386. Radioisotope --- r_associated #0: 15 --> en:contraindications aspect
    n1=Radioisotope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6387. Rapports sexuels --- r_associated #0: 15 --> en:contraindications aspect
    n1=Rapports sexuels | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6388. Ribitol --- r_associated #0: 15 --> en:contraindications aspect
    n1=Ribitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6389. Régime cétogène --- r_associated #0: 15 --> en:contraindications aspect
    n1=Régime cétogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6390. Sarin --- r_associated #0: 15 --> en:contraindications aspect
    n1=Sarin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6391. Sphygmomanomètre --- r_associated #0: 15 --> en:contraindications aspect
    n1=Sphygmomanomètre | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6392. Stérols --- r_associated #0: 15 --> en:contraindications aspect
    n1=Stérols | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6393. Sulfate de zinc --- r_associated #0: 15 --> en:contraindications aspect
    n1=Sulfate de zinc | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6394. Tomographie par émission de positons --- r_associated #0: 15 --> en:contraindications aspect
    n1=Tomographie par émission de positons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6395. Tomographie par émission de positrons --- r_associated #0: 15 --> en:contraindications aspect
    n1=Tomographie par émission de positrons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6396. Traitement médical --- r_associated #0: 15 --> en:contraindications aspect
    n1=Traitement médical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6397. Transfusion sanguine --- r_associated #0: 15 --> en:contraindications aspect
    n1=Transfusion sanguine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6398. Tungstène --- r_associated #0: 15 --> en:contraindications aspect
    n1=Tungstène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6399. Uridine-DiPhosphate-Glucose --- r_associated #0: 15 --> en:contraindications aspect
    n1=Uridine-DiPhosphate-Glucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6400. Vaccin antigrippal --- r_associated #0: 15 --> en:contraindications aspect
    n1=Vaccin antigrippal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6401. Violet de gentiane --- r_associated #0: 15 --> en:contraindications aspect
    n1=Violet de gentiane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6402. acide palmitique-acide oléique (rapport) --- r_associated #0: 15 --> en:contraindications aspect
    n1=acide palmitique-acide oléique (rapport) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6403. actinoscopie --- r_associated #0: 15 --> en:contraindications aspect
    n1=actinoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6404. adn bactérien --- r_associated #0: 15 --> en:contraindications aspect
    n1=adn bactérien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6405. adolescent (répercussions psychiques d'un handicap somatique majeur chez l') --- r_associated #0: 15 --> en:contraindications aspect
    n1=adolescent (répercussions psychiques d'un handicap somatique majeur chez l') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6406. adrénaline (collyre à l') --- r_associated #0: 15 --> en:contraindications aspect
    n1=adrénaline (collyre à l') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6407. angl. WISC --- r_associated #0: 15 --> en:contraindications aspect
    n1=angl. WISC | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6408. anti-corps --- r_associated #0: 15 --> en:contraindications aspect
    n1=anti-corps | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6409. anti-hormone --- r_associated #0: 15 --> en:contraindications aspect
    n1=anti-hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6410. antigen --- r_associated #0: 15 --> en:contraindications aspect
    n1=antigen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6411. antireflux urinaire endoscopique (technique) --- r_associated #0: 15 --> en:contraindications aspect
    n1=antireflux urinaire endoscopique (technique) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6412. auto-surveillance du glucose sanguin --- r_associated #0: 15 --> en:contraindications aspect
    n1=auto-surveillance du glucose sanguin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6413. axis (malformations de l') --- r_associated #0: 15 --> en:contraindications aspect
    n1=axis (malformations de l') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6414. bas champ (magnétique) --- r_associated #0: 15 --> en:contraindications aspect
    n1=bas champ (magnétique) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6415. bilieuse hémoglobinurique (fièvre) --- r_associated #0: 15 --> en:contraindications aspect
    n1=bilieuse hémoglobinurique (fièvre) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6416. bêta adrénergique (médicament) --- r_associated #0: 15 --> en:contraindications aspect
    n1=bêta adrénergique (médicament) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6417. bêta-MSH --- r_associated #0: 15 --> en:contraindications aspect
    n1=bêta-MSH | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6418. bêta-hydroxy-acyl-CoA-déshydrogénase des acides gras à longue chaîne (déficit en) --- r_associated #0: 15 --> en:contraindications aspect
    n1=bêta-hydroxy-acyl-CoA-déshydrogénase des acides gras à longue chaîne (déficit en) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6419. bêta-hydroxybutyryl-CoA-déshydrogénase --- r_associated #0: 15 --> en:contraindications aspect
    n1=bêta-hydroxybutyryl-CoA-déshydrogénase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6420. bêta-hydroxylé-CoA-déshydrogénase --- r_associated #0: 15 --> en:contraindications aspect
    n1=bêta-hydroxylé-CoA-déshydrogénase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6421. bêta-hydroxyvaléryl-CoA-carboxylase --- r_associated #0: 15 --> en:contraindications aspect
    n1=bêta-hydroxyvaléryl-CoA-carboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6422. bêta-lactoglobuline --- r_associated #0: 15 --> en:contraindications aspect
    n1=bêta-lactoglobuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6423. ciseaux (marche en) --- r_associated #0: 15 --> en:contraindications aspect
    n1=ciseaux (marche en) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6424. cyclope (oeil) --- r_associated #0: 15 --> en:contraindications aspect
    n1=cyclope (oeil) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6425. dacryocystite (ostéopoïkilose et) --- r_associated #0: 15 --> en:contraindications aspect
    n1=dacryocystite (ostéopoïkilose et) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6426. diabétiques (ostéo-arthropathies) --- r_associated #0: 15 --> en:contraindications aspect
    n1=diabétiques (ostéo-arthropathies) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6427. en:electrical wiring --- r_associated #0: 15 --> en:contraindications aspect
    n1=en:electrical wiring | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6428. en:informatics language --- r_associated #0: 15 --> en:contraindications aspect
    n1=en:informatics language | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6429. en:medicament --- r_associated #0: 15 --> en:contraindications aspect
    n1=en:medicament | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6430. en:medicinal product --- r_associated #0: 15 --> en:contraindications aspect
    n1=en:medicinal product | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6431. en:okadaic acid --- r_associated #0: 15 --> en:contraindications aspect
    n1=en:okadaic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6432. en:programming language --- r_associated #0: 15 --> en:contraindications aspect
    n1=en:programming language | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6433. en:tablet --- r_associated #0: 15 --> en:contraindications aspect
    n1=en:tablet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6434. eto --- r_associated #0: 15 --> en:contraindications aspect
    n1=eto | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6435. examen de médecine nucléaire --- r_associated #0: 15 --> en:contraindications aspect
    n1=examen de médecine nucléaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6436. examen du fond d'oeil --- r_associated #0: 15 --> en:contraindications aspect
    n1=examen du fond d'oeil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6437. examens diagnostiques généraux en médecine nucléaire --- r_associated #0: 15 --> en:contraindications aspect
    n1=examens diagnostiques généraux en médecine nucléaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6438. facteur de croissance du nerf --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de croissance du nerf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6439. facteur de grandissement ophtalmologique --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de grandissement ophtalmologique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6440. facteur de perméabilité vasculaire --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de perméabilité vasculaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6441. facteur de pondération d'irradiation pour les tissus --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de pondération d'irradiation pour les tissus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6442. facteur de pondération pour les rayonnements --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de pondération pour les rayonnements | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6443. facteur de pondération pour les tissus --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de pondération pour les tissus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6444. facteur de qualité --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de qualité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6445. facteur de régulation de l'interféron 6 --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de régulation de l'interféron 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6446. facteur de réplication --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de réplication | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6447. facteur de résistance --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de résistance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6448. facteur de survie --- r_associated #0: 15 --> en:contraindications aspect
    n1=facteur de survie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6449. fluorescence induite par la tétracycline (test de) --- r_associated #0: 15 --> en:contraindications aspect
    n1=fluorescence induite par la tétracycline (test de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6450. fulminans (purpura) --- r_associated #0: 15 --> en:contraindications aspect
    n1=fulminans (purpura) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6451. gammagraphies --- r_associated #0: 15 --> en:contraindications aspect
    n1=gammagraphies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6452. gayac --- r_associated #0: 15 --> en:contraindications aspect
    n1=gayac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6453. glucagonome (syndrome du) --- r_associated #0: 15 --> en:contraindications aspect
    n1=glucagonome (syndrome du) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6454. gluten (intolérance au) --- r_associated #0: 15 --> en:contraindications aspect
    n1=gluten (intolérance au) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6455. glycuronique (acide) --- r_associated #0: 15 --> en:contraindications aspect
    n1=glycuronique (acide) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6456. halo (signe du) --- r_associated #0: 15 --> en:contraindications aspect
    n1=halo (signe du) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6457. hystérie (histoire de l') --- r_associated #0: 15 --> en:contraindications aspect
    n1=hystérie (histoire de l') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6458. hélicopode (démarche) --- r_associated #0: 15 --> en:contraindications aspect
    n1=hélicopode (démarche) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6459. interleukines 18 --- r_associated #0: 15 --> en:contraindications aspect
    n1=interleukines 18 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6460. kepone --- r_associated #0: 15 --> en:contraindications aspect
    n1=kepone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6461. maintien de prothèse --- r_associated #0: 15 --> en:contraindications aspect
    n1=maintien de prothèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6462. medicament --- r_associated #0: 15 --> en:contraindications aspect
    n1=medicament | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6463. médicament --- r_associated #0: 15 --> en:contraindications aspect
    n1=médicament | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6464. obéir à --- r_associated #0: 15 --> en:contraindications aspect
    n1=obéir à | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6465. oxygène dans l'organisme (transport de l') --- r_associated #0: 15 --> en:contraindications aspect
    n1=oxygène dans l'organisme (transport de l') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6466. progéroïde de de Barsy (syndrome) --- r_associated #0: 15 --> en:contraindications aspect
    n1=progéroïde de de Barsy (syndrome) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6467. scintigraphies --- r_associated #0: 15 --> en:contraindications aspect
    n1=scintigraphies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6468. scintillographies --- r_associated #0: 15 --> en:contraindications aspect
    n1=scintillographies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6469. tri-iodothyronine --- r_associated #0: 15 --> en:contraindications aspect
    n1=tri-iodothyronine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6470. uridinediphosphate --- r_associated #0: 15 --> en:contraindications aspect
    n1=uridinediphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6471. échoDoppler cardiaque --- r_associated #0: 15 --> en:contraindications aspect
    n1=échoDoppler cardiaque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=15
  6472. acide osmique --- r_associated #0: 11 --> en:contraindications aspect
    n1=acide osmique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6473. acide para-aminobenzoïque --- r_associated #0: 11 --> en:contraindications aspect
    n1=acide para-aminobenzoïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6474. acide saccharique --- r_associated #0: 11 --> en:contraindications aspect
    n1=acide saccharique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6475. circulation croisée --- r_associated #0: 11 --> en:contraindications aspect
    n1=circulation croisée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6476. diméthyldithiocarbamate --- r_associated #0: 11 --> en:contraindications aspect
    n1=diméthyldithiocarbamate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6477. iso-indoles --- r_associated #0: 11 --> en:contraindications aspect
    n1=iso-indoles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6478. kératoscopie --- r_associated #0: 11 --> en:contraindications aspect
    n1=kératoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6479. mélanotropine --- r_associated #0: 11 --> en:contraindications aspect
    n1=mélanotropine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6480. saccharide --- r_associated #0: 11 --> en:contraindications aspect
    n1=saccharide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6481. test cutané --- r_associated #0: 11 --> en:contraindications aspect
    n1=test cutané | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6482. uréthanne --- r_associated #0: 11 --> en:contraindications aspect
    n1=uréthanne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6483. vaccinothérapie --- r_associated #0: 11 --> en:contraindications aspect
    n1=vaccinothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6484. violet cristallisé --- r_associated #0: 11 --> en:contraindications aspect
    n1=violet cristallisé | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=11
  6485. 252Cf --- r_associated #0: 10 --> en:contraindications aspect
    n1=252Cf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6486. 5 HIA --- r_associated #0: 10 --> en:contraindications aspect
    n1=5 HIA | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6487. 5'-aminolévulinate synthase --- r_associated #0: 10 --> en:contraindications aspect
    n1=5'-aminolévulinate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6488. 5-alpha-réductase --- r_associated #0: 10 --> en:contraindications aspect
    n1=5-alpha-réductase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6489. 5FC --- r_associated #0: 10 --> en:contraindications aspect
    n1=5FC | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6490. ARN
    (acide ribonucléique)
     --- r_associated #0: 10 --> en:contraindications aspect
    n1=ARN
    (acide ribonucléique)
    | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6491. Acide 3-hydroxyanthranilique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acide 3-hydroxyanthranilique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6492. Acide abscissique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acide abscissique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6493. Acide aconitique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acide aconitique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6494. Acide dicarboxylique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acide dicarboxylique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6495. Acide lysergique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acide lysergique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6496. Acide orotique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acide orotique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6497. Acide pyruvique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acide pyruvique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6498. Acridine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6499. Acyltransférase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6500. Acétate de potassium --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acétate de potassium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6501. Acétoïne --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acétoïne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6502. Acétylcystéine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Acétylcystéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6503. Adiponectine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Adiponectine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6504. Ag
    (antigène)
     --- r_associated #0: 10 --> en:contraindications aspect
    n1=Ag
    (antigène)
    | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6505. Agar-agar --- r_associated #0: 10 --> en:contraindications aspect
    n1=Agar-agar | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6506. AminoTransférase --- r_associated #0: 10 --> en:contraindications aspect
    n1=AminoTransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6507. Amitriptyline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Amitriptyline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6508. Amniocentèse --- r_associated #0: 10 --> en:contraindications aspect
    n1=Amniocentèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6509. Anti-parasitaire --- r_associated #0: 10 --> en:contraindications aspect
    n1=Anti-parasitaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6510. Antibody --- r_associated #0: 10 --> en:contraindications aspect
    n1=Antibody | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6511. Anticodon --- r_associated #0: 10 --> en:contraindications aspect
    n1=Anticodon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6512. Anticorps --- r_associated #0: 10 --> en:contraindications aspect
    n1=Anticorps | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6513. Antifongiques --- r_associated #0: 10 --> en:contraindications aspect
    n1=Antifongiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6514. Antimétabolite --- r_associated #0: 10 --> en:contraindications aspect
    n1=Antimétabolite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6515. Apolipoprotéines --- r_associated #0: 10 --> en:contraindications aspect
    n1=Apolipoprotéines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6516. Asparaginase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Asparaginase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6517. Atrazine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Atrazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6518. Auriculothérapie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Auriculothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6519. Baclofène --- r_associated #0: 10 --> en:contraindications aspect
    n1=Baclofène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6520. Bactériocine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Bactériocine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6521. Bas de compression --- r_associated #0: 10 --> en:contraindications aspect
    n1=Bas de compression | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6522. Baumes --- r_associated #0: 10 --> en:contraindications aspect
    n1=Baumes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6523. Benzaldéhyde --- r_associated #0: 10 --> en:contraindications aspect
    n1=Benzaldéhyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6524. Biopsie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Biopsie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6525. Biuret --- r_associated #0: 10 --> en:contraindications aspect
    n1=Biuret | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6526. Bufoténine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Bufoténine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6527. Busulfan --- r_associated #0: 10 --> en:contraindications aspect
    n1=Busulfan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6528. Cannabidiol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cannabidiol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6529. Canthaxanthine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Canthaxanthine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6530. Caoutchouc naturel --- r_associated #0: 10 --> en:contraindications aspect
    n1=Caoutchouc naturel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6531. Capsaïcine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Capsaïcine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6532. Capécitabine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Capécitabine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6533. Carbofuran --- r_associated #0: 10 --> en:contraindications aspect
    n1=Carbofuran | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6534. Carbohydrate --- r_associated #0: 10 --> en:contraindications aspect
    n1=Carbohydrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6535. Carmustine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Carmustine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6536. Cartographie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cartographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6537. Catalase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Catalase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6538. Catgut --- r_associated #0: 10 --> en:contraindications aspect
    n1=Catgut | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6539. Cathétérisme --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cathétérisme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6540. Chalcone --- r_associated #0: 10 --> en:contraindications aspect
    n1=Chalcone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6541. Chlorates --- r_associated #0: 10 --> en:contraindications aspect
    n1=Chlorates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6542. Chlordécone --- r_associated #0: 10 --> en:contraindications aspect
    n1=Chlordécone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6543. Chlorfenvinphos --- r_associated #0: 10 --> en:contraindications aspect
    n1=Chlorfenvinphos | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6544. Chlorine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Chlorine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6545. Chlortétracycline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Chlortétracycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6546. Chlorure de magnésium --- r_associated #0: 10 --> en:contraindications aspect
    n1=Chlorure de magnésium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6547. Chymotrypsine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Chymotrypsine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6548. Cimétidine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cimétidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6549. Cisplatine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cisplatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6550. Clarithromycine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Clarithromycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6551. Codon --- r_associated #0: 10 --> en:contraindications aspect
    n1=Codon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6552. Codéine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Codéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6553. Collagénase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Collagénase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6554. Collins (liquide de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Collins (liquide de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6555. Colloïdal --- r_associated #0: 10 --> en:contraindications aspect
    n1=Colloïdal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6556. Colostomie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Colostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6557. Colposcopie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Colposcopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6558. Contre-argument --- r_associated #0: 10 --> en:contraindications aspect
    n1=Contre-argument | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6559. Corticostérone --- r_associated #0: 10 --> en:contraindications aspect
    n1=Corticostérone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6560. Cortisol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cortisol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6561. Craniométrie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Craniométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6562. Cure thermale --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cure thermale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6563. Cyclophosphamide --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cyclophosphamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6564. Cytidine triphosphate --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cytidine triphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6565. Cytochrome c1 --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cytochrome c1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6566. Câblage électrique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Câblage électrique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6567. Cétirizine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Cétirizine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6568. DES (syndrome du) --- r_associated #0: 10 --> en:contraindications aspect
    n1=DES (syndrome du) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6569. DOPA-décarboxylase --- r_associated #0: 10 --> en:contraindications aspect
    n1=DOPA-décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6570. DPi --- r_associated #0: 10 --> en:contraindications aspect
    n1=DPi | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6571. Dapsone --- r_associated #0: 10 --> en:contraindications aspect
    n1=Dapsone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6572. Dasatinib --- r_associated #0: 10 --> en:contraindications aspect
    n1=Dasatinib | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6573. Daunorubicine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Daunorubicine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6574. Desmostérol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Desmostérol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6575. Dextrométhorphane --- r_associated #0: 10 --> en:contraindications aspect
    n1=Dextrométhorphane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6576. Diamond --- r_associated #0: 10 --> en:contraindications aspect
    n1=Diamond | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6577. Dichlorodiphényldichloroéthane --- r_associated #0: 10 --> en:contraindications aspect
    n1=Dichlorodiphényldichloroéthane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6578. Diflubenzuron --- r_associated #0: 10 --> en:contraindications aspect
    n1=Diflubenzuron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6579. Digitoxine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Digitoxine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6580. Diméthoate --- r_associated #0: 10 --> en:contraindications aspect
    n1=Diméthoate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6581. Diphenhydramine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Diphenhydramine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6582. Diphénhydramine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Diphénhydramine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6583. Diquat --- r_associated #0: 10 --> en:contraindications aspect
    n1=Diquat | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6584. Diuron --- r_associated #0: 10 --> en:contraindications aspect
    n1=Diuron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6585. Diéthylstilbestrol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Diéthylstilbestrol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6586. Dobutamine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Dobutamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6587. Doose (syndrome de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Doose (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6588. Dopa-décarboxylase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Dopa-décarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6589. Désoxyribose --- r_associated #0: 10 --> en:contraindications aspect
    n1=Désoxyribose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6590. Détersion --- r_associated #0: 10 --> en:contraindications aspect
    n1=Détersion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6591. Ecklin (maladie d') --- r_associated #0: 10 --> en:contraindications aspect
    n1=Ecklin (maladie d') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6592. Fluoroscopie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Fluoroscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6593. Fluorouracile --- r_associated #0: 10 --> en:contraindications aspect
    n1=Fluorouracile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6594. Formol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Formol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6595. Fénitrothion --- r_associated #0: 10 --> en:contraindications aspect
    n1=Fénitrothion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6596. GTP --- r_associated #0: 10 --> en:contraindications aspect
    n1=GTP | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6597. Gammagraphie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Gammagraphie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6598. Gardénal --- r_associated #0: 10 --> en:contraindications aspect
    n1=Gardénal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6599. Gaïac --- r_associated #0: 10 --> en:contraindications aspect
    n1=Gaïac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6600. Geller et Scholler (test de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Geller et Scholler (test de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6601. Glucide --- r_associated #0: 10 --> en:contraindications aspect
    n1=Glucide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6602. Glucocorticostéroïde --- r_associated #0: 10 --> en:contraindications aspect
    n1=Glucocorticostéroïde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6603. Glucocorticoïde --- r_associated #0: 10 --> en:contraindications aspect
    n1=Glucocorticoïde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6604. Glucosamine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Glucosamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6605. Glutathion --- r_associated #0: 10 --> en:contraindications aspect
    n1=Glutathion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6606. Glycosaminoglycane --- r_associated #0: 10 --> en:contraindications aspect
    n1=Glycosaminoglycane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6607. Gonadostimuline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Gonadostimuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6608. Gonadotrophine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Gonadotrophine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6609. Granzyme --- r_associated #0: 10 --> en:contraindications aspect
    n1=Granzyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6610. Greffe cornéenne --- r_associated #0: 10 --> en:contraindications aspect
    n1=Greffe cornéenne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6611. HbO 2 --- r_associated #0: 10 --> en:contraindications aspect
    n1=HbO 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6612. Hepcidine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Hepcidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6613. His (faisceau de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=His (faisceau de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6614. Hormone de libération de l'hormone de croissance --- r_associated #0: 10 --> en:contraindications aspect
    n1=Hormone de libération de l'hormone de croissance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6615. Hydrocarbure --- r_associated #0: 10 --> en:contraindications aspect
    n1=Hydrocarbure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6616. Hydrocortisone --- r_associated #0: 10 --> en:contraindications aspect
    n1=Hydrocortisone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6617. Hypoxanthine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Hypoxanthine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6618. Hystéroscopie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Hystéroscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6619. Hélicase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Hélicase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6620. Héliothérapie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Héliothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6621. Hühner (test de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Hühner (test de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6622. IL-2 --- r_associated #0: 10 --> en:contraindications aspect
    n1=IL-2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6623. Il-4 --- r_associated #0: 10 --> en:contraindications aspect
    n1=Il-4 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6624. Imagerie diagnostique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Imagerie diagnostique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6625. Immunoglobuline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Immunoglobuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6626. Immunoprécipitation --- r_associated #0: 10 --> en:contraindications aspect
    n1=Immunoprécipitation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6627. Implants mammaires --- r_associated #0: 10 --> en:contraindications aspect
    n1=Implants mammaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6628. Indiana (neuropathie amyloïde familiale de type) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Indiana (neuropathie amyloïde familiale de type) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6629. Indométacine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Indométacine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6630. Inoculation --- r_associated #0: 10 --> en:contraindications aspect
    n1=Inoculation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6631. Inosine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Inosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6632. Inosine diphosphate --- r_associated #0: 10 --> en:contraindications aspect
    n1=Inosine diphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6633. Inosine triphosphate --- r_associated #0: 10 --> en:contraindications aspect
    n1=Inosine triphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6634. Inositol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Inositol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6635. Insecticides --- r_associated #0: 10 --> en:contraindications aspect
    n1=Insecticides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6636. Interferometry --- r_associated #0: 10 --> en:contraindications aspect
    n1=Interferometry | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6637. Interleukine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Interleukine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6638. Intervention chirurgicale --- r_associated #0: 10 --> en:contraindications aspect
    n1=Intervention chirurgicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6639. Intubation trachéale --- r_associated #0: 10 --> en:contraindications aspect
    n1=Intubation trachéale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6640. Inuline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Inuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6641. Iodates --- r_associated #0: 10 --> en:contraindications aspect
    n1=Iodates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6642. Iodine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Iodine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6643. Irm --- r_associated #0: 10 --> en:contraindications aspect
    n1=Irm | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6644. Isomaltose --- r_associated #0: 10 --> en:contraindications aspect
    n1=Isomaltose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6645. Isoniazide --- r_associated #0: 10 --> en:contraindications aspect
    n1=Isoniazide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6646. Isotrétinoïne --- r_associated #0: 10 --> en:contraindications aspect
    n1=Isotrétinoïne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6647. Isozyme --- r_associated #0: 10 --> en:contraindications aspect
    n1=Isozyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6648. Kinétine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Kinétine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6649. LPL ou LPLase --- r_associated #0: 10 --> en:contraindications aspect
    n1=LPL ou LPLase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6650. Lactase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lactase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6651. Lamivudine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lamivudine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6652. Langage de Programmation --- r_associated #0: 10 --> en:contraindications aspect
    n1=Langage de Programmation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6653. Leptine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Leptine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6654. Linton-Nachlas (sonde de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Linton-Nachlas (sonde de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6655. Linuron --- r_associated #0: 10 --> en:contraindications aspect
    n1=Linuron | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6656. Lipase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lipase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6657. Lipide A --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lipide A | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6658. Lipoprotéine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lipoprotéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6659. Liposome --- r_associated #0: 10 --> en:contraindications aspect
    n1=Liposome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6660. Liposuccion --- r_associated #0: 10 --> en:contraindications aspect
    n1=Liposuccion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6661. Lisfranc (fracture de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lisfranc (fracture de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6662. Lisinopril --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lisinopril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6663. Louis-Bar (syndrome de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Louis-Bar (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6664. Lovastatine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lovastatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6665. Lymécycline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lymécycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6666. Lynch (syndrome de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lynch (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6667. Lévofloxacine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lévofloxacine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6668. Lévomépromazine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Lévomépromazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6669. MERRF (syndrome) --- r_associated #0: 10 --> en:contraindications aspect
    n1=MERRF (syndrome) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6670. MSH angl. pour Melanocyte Stimulating Hormone --- r_associated #0: 10 --> en:contraindications aspect
    n1=MSH angl. pour Melanocyte Stimulating Hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6671. Mammoplastie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Mammoplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6672. Manométrie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Manométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6673. Masson (technique d'argentation) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Masson (technique d'argentation) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6674. Mescaline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Mescaline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6675. Mesure de la pression artérielle --- r_associated #0: 10 --> en:contraindications aspect
    n1=Mesure de la pression artérielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6676. Metenier (signe de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Metenier (signe de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6677. Minkowski-Chauffard (maladie de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Minkowski-Chauffard (maladie de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6678. Minocycline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Minocycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6679. Murexide --- r_associated #0: 10 --> en:contraindications aspect
    n1=Murexide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6680. Musto (coloration de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Musto (coloration de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6681. Mutagène --- r_associated #0: 10 --> en:contraindications aspect
    n1=Mutagène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6682. Mycotoxine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Mycotoxine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6683. Myélographie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Myélographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6684. Médicament --- r_associated #0: 10 --> en:contraindications aspect
    n1=Médicament | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6685. Médicaments vétérinaires --- r_associated #0: 10 --> en:contraindications aspect
    n1=Médicaments vétérinaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6686. MélanoStimuline --- r_associated #0: 10 --> en:contraindications aspect
    n1=MélanoStimuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6687. Ménadione --- r_associated #0: 10 --> en:contraindications aspect
    n1=Ménadione | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6688. Métallothionéine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Métallothionéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6689. Méthadone --- r_associated #0: 10 --> en:contraindications aspect
    n1=Méthadone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6690. Métras (sonde de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Métras (sonde de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6691. NAD+ --- r_associated #0: 10 --> en:contraindications aspect
    n1=NAD+ | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6692. NADPH oxydase --- r_associated #0: 10 --> en:contraindications aspect
    n1=NADPH oxydase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6693. NANA. --- r_associated #0: 10 --> en:contraindications aspect
    n1=NANA. | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6694. Nakano (maladie de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Nakano (maladie de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6695. Naproxène --- r_associated #0: 10 --> en:contraindications aspect
    n1=Naproxène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6696. Natalizumab --- r_associated #0: 10 --> en:contraindications aspect
    n1=Natalizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6697. Neuréguline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Neuréguline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6698. Nicotinamide --- r_associated #0: 10 --> en:contraindications aspect
    n1=Nicotinamide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6699. Nisoldipine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Nisoldipine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6700. Norfloxacine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Norfloxacine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6701. Nélaton (ligne de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Nélaton (ligne de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6702. OC --- r_associated #0: 10 --> en:contraindications aspect
    n1=OC | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6703. Oc --- r_associated #0: 10 --> en:contraindications aspect
    n1=Oc | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6704. Ocytocine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Ocytocine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6705. Oil --- r_associated #0: 10 --> en:contraindications aspect
    n1=Oil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6706. Oligonucléotide --- r_associated #0: 10 --> en:contraindications aspect
    n1=Oligonucléotide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6707. Oligoélément --- r_associated #0: 10 --> en:contraindications aspect
    n1=Oligoélément | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6708. Omalizumab --- r_associated #0: 10 --> en:contraindications aspect
    n1=Omalizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6709. Oméprazole --- r_associated #0: 10 --> en:contraindications aspect
    n1=Oméprazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6710. Opération chirurgicale --- r_associated #0: 10 --> en:contraindications aspect
    n1=Opération chirurgicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6711. Oxygène singulet --- r_associated #0: 10 --> en:contraindications aspect
    n1=Oxygène singulet | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6712. Oxyhémoglobine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Oxyhémoglobine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6713. Oxytocine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Oxytocine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6714. Oxytétracycline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Oxytétracycline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6715. PET-scan --- r_associated #0: 10 --> en:contraindications aspect
    n1=PET-scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6716. POAN --- r_associated #0: 10 --> en:contraindications aspect
    n1=POAN | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6717. Paraldéhyde --- r_associated #0: 10 --> en:contraindications aspect
    n1=Paraldéhyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6718. Parathormone --- r_associated #0: 10 --> en:contraindications aspect
    n1=Parathormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6719. Particules --- r_associated #0: 10 --> en:contraindications aspect
    n1=Particules | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6720. Pearson (maladie de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Pearson (maladie de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6721. Pentachlorophénol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Pentachlorophénol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6722. Pentamidine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Pentamidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6723. Pentoxifylline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Pentoxifylline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6724. Peptidyltransférase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Peptidyltransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6725. Perforine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Perforine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6726. Perphénazine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Perphénazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6727. Petges-Jacobi (poïkilodermie généralisée de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Petges-Jacobi (poïkilodermie généralisée de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6728. Phosphatidylinositol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phosphatidylinositol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6729. Phosphofructokinase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phosphofructokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6730. Phosphoglycérate mutase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phosphoglycérate mutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6731. Phosphoénolpyruvate carboxylase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phosphoénolpyruvate carboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6732. Photogrammétrie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Photogrammétrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6733. Phtirius inguinalis (ou pubis ) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phtirius inguinalis (ou pubis ) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6734. Phycoérythrine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phycoérythrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6735. Phylloquinone --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phylloquinone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6736. Physostigmine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Physostigmine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6737. Phytase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phytase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6738. Phénobarbital --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phénobarbital | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6739. Phénothiazine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Phénothiazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6740. Piroxicam --- r_associated #0: 10 --> en:contraindications aspect
    n1=Piroxicam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6741. Plasmaphérèse --- r_associated #0: 10 --> en:contraindications aspect
    n1=Plasmaphérèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6742. Polytétrafluoroéthylène --- r_associated #0: 10 --> en:contraindications aspect
    n1=Polytétrafluoroéthylène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6743. Polyéthylène glycol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Polyéthylène glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6744. Poncet-Spiegler (tumeur de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Poncet-Spiegler (tumeur de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6745. Porphyrine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Porphyrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6746. Procarbazine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Procarbazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6747. Produit de contraste --- r_associated #0: 10 --> en:contraindications aspect
    n1=Produit de contraste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6748. Progestérone --- r_associated #0: 10 --> en:contraindications aspect
    n1=Progestérone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6749. Promazine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Promazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6750. Prométhazine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Prométhazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6751. Prométhéum --- r_associated #0: 10 --> en:contraindications aspect
    n1=Prométhéum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6752. Prostatectomie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Prostatectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6753. Protein --- r_associated #0: 10 --> en:contraindications aspect
    n1=Protein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6754. Prothrombine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Prothrombine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6755. Prothèses dentaires --- r_associated #0: 10 --> en:contraindications aspect
    n1=Prothèses dentaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6756. Protée (syndrome de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Protée (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6757. Protéine kinase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Protéine kinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6758. Pseudouridine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Pseudouridine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6759. Pulpectomie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Pulpectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6760. Putrescine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Putrescine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6761. Pénicillamine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Pénicillamine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6762. Périndopril --- r_associated #0: 10 --> en:contraindications aspect
    n1=Périndopril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6763. Péthidine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Péthidine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6764. Qi gong --- r_associated #0: 10 --> en:contraindications aspect
    n1=Qi gong | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6765. RY --- r_associated #0: 10 --> en:contraindications aspect
    n1=RY | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6766. Radiothérapie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Radiothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6767. Ramipril --- r_associated #0: 10 --> en:contraindications aspect
    n1=Ramipril | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6768. Relation sexuelle --- r_associated #0: 10 --> en:contraindications aspect
    n1=Relation sexuelle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6769. Relations --- r_associated #0: 10 --> en:contraindications aspect
    n1=Relations | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6770. Riazi-Palmer (canule de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Riazi-Palmer (canule de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6771. Ritter-Lyell (syndrome de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Ritter-Lyell (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6772. Rivalta (réaction de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Rivalta (réaction de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6773. Salleras-Záraté (syndrome de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Salleras-Záraté (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6774. Schweninger-Buzzi (atrophie maculeuse de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Schweninger-Buzzi (atrophie maculeuse de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6775. Sel de table --- r_associated #0: 10 --> en:contraindications aspect
    n1=Sel de table | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6776. Seldinger (technique de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Seldinger (technique de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6777. Soins d'urgence --- r_associated #0: 10 --> en:contraindications aspect
    n1=Soins d'urgence | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6778. Sorbitol --- r_associated #0: 10 --> en:contraindications aspect
    n1=Sorbitol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6779. Sorbose --- r_associated #0: 10 --> en:contraindications aspect
    n1=Sorbose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6780. Soude caustique --- r_associated #0: 10 --> en:contraindications aspect
    n1=Soude caustique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6781. Spanner --- r_associated #0: 10 --> en:contraindications aspect
    n1=Spanner | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6782. St. Abbs's Head (virus) --- r_associated #0: 10 --> en:contraindications aspect
    n1=St. Abbs's Head (virus) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6783. Staging --- r_associated #0: 10 --> en:contraindications aspect
    n1=Staging | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6784. Sucquet-Hoyer (canal de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Sucquet-Hoyer (canal de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6785. Sucrose --- r_associated #0: 10 --> en:contraindications aspect
    n1=Sucrose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6786. Sulfate de magnésium --- r_associated #0: 10 --> en:contraindications aspect
    n1=Sulfate de magnésium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6787. TDM
    (tomodensitométrie)
     --- r_associated #0: 10 --> en:contraindications aspect
    n1=TDM
    (tomodensitométrie)
    | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6788. TEP-scan --- r_associated #0: 10 --> en:contraindications aspect
    n1=TEP-scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6789. Tamm et Horsfall (mucoprotéine de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Tamm et Horsfall (mucoprotéine de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6790. Technétium --- r_associated #0: 10 --> en:contraindications aspect
    n1=Technétium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6791. Temps de Quick --- r_associated #0: 10 --> en:contraindications aspect
    n1=Temps de Quick | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6792. Temps de prothrombine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Temps de prothrombine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6793. Tension artérielle --- r_associated #0: 10 --> en:contraindications aspect
    n1=Tension artérielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6794. Thymidylate synthase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Thymidylate synthase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6795. Thévenard (syndrome de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Thévenard (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6796. Tomie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Tomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6797. Trachéostomie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Trachéostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6798. Transaminase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Transaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6799. Trendelenburg (signe de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Trendelenburg (signe de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6800. Trientine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Trientine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6801. Trifluopérazine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Trifluopérazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6802. Triflupromazine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Triflupromazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6803. Triiodothyronine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Triiodothyronine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6804. Triose-phosphate isomérase --- r_associated #0: 10 --> en:contraindications aspect
    n1=Triose-phosphate isomérase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6805. Troponine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Troponine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6806. Trypsine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Trypsine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6807. Tryptamines --- r_associated #0: 10 --> en:contraindications aspect
    n1=Tryptamines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6808. Trétinoïne --- r_associated #0: 10 --> en:contraindications aspect
    n1=Trétinoïne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6809. Tubuline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Tubuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6810. Tungsten --- r_associated #0: 10 --> en:contraindications aspect
    n1=Tungsten | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6811. Télémétrie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Télémétrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6812. Uridine diphosphate --- r_associated #0: 10 --> en:contraindications aspect
    n1=Uridine diphosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6813. Uridine diphosphate glucose --- r_associated #0: 10 --> en:contraindications aspect
    n1=Uridine diphosphate glucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6814. Uridine monophosphate --- r_associated #0: 10 --> en:contraindications aspect
    n1=Uridine monophosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6815. Uridine-DiPhosphate --- r_associated #0: 10 --> en:contraindications aspect
    n1=Uridine-DiPhosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6816. Uridine-DiPhosphate-glucose --- r_associated #0: 10 --> en:contraindications aspect
    n1=Uridine-DiPhosphate-glucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6817. Urobiline --- r_associated #0: 10 --> en:contraindications aspect
    n1=Urobiline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6818. Uréthane --- r_associated #0: 10 --> en:contraindications aspect
    n1=Uréthane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6819. Vaccin contre la rubéole --- r_associated #0: 10 --> en:contraindications aspect
    n1=Vaccin contre la rubéole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6820. Vaccin à ADN --- r_associated #0: 10 --> en:contraindications aspect
    n1=Vaccin à ADN | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6821. Vaccination --- r_associated #0: 10 --> en:contraindications aspect
    n1=Vaccination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6822. Vinblastine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Vinblastine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6823. Vitallium --- r_associated #0: 10 --> en:contraindications aspect
    n1=Vitallium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6824. Vitamine B1 --- r_associated #0: 10 --> en:contraindications aspect
    n1=Vitamine B1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6825. Vivisection --- r_associated #0: 10 --> en:contraindications aspect
    n1=Vivisection | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6826. Ward (triangle de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Ward (triangle de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6827. Warfarine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Warfarine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6828. Wolframite --- r_associated #0: 10 --> en:contraindications aspect
    n1=Wolframite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6829. Xylulose --- r_associated #0: 10 --> en:contraindications aspect
    n1=Xylulose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6830. ZBTB20 gene --- r_associated #0: 10 --> en:contraindications aspect
    n1=ZBTB20 gene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6831. Zaliv Terpeniya (virus) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Zaliv Terpeniya (virus) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6832. Zebrina --- r_associated #0: 10 --> en:contraindications aspect
    n1=Zebrina | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6833. Zeek (angéite allergique de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=Zeek (angéite allergique de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6834. Zéatine --- r_associated #0: 10 --> en:contraindications aspect
    n1=Zéatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6835. ac --- r_associated #0: 10 --> en:contraindications aspect
    n1=ac | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6836. accointances --- r_associated #0: 10 --> en:contraindications aspect
    n1=accointances | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6837. acide orthophosphorique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide orthophosphorique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6838. acide oxaloacétique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide oxaloacétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6839. acide oxalosuccinique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide oxalosuccinique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6840. acide oxalurique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide oxalurique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6841. acide oxolinique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide oxolinique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6842. acide p-aminobenzoïque --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide p-aminobenzoïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6843. acide phocénique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phocénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6844. acide phosphatidique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phosphatidique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6845. acide phospho-2-glycérique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phospho-2-glycérique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6846. acide phospho-3-glycérique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phospho-3-glycérique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6847. acide phosphogluconique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phosphogluconique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6848. acide phosphomévalonique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phosphomévalonique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6849. acide phosphonique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phosphonique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6850. acide phosphorique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phosphorique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6851. acide phosphoénolpyruvique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phosphoénolpyruvique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6852. acide physétérique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide physétérique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6853. acide phytanique --- r_associated #0: 10 --> en:contraindications aspect
    n1=acide phytanique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6854. adjuvante --- r_associated #0: 10 --> en:contraindications aspect
    n1=adjuvante | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6855. agonistes du récepteur A1 de l'adénosine --- r_associated #0: 10 --> en:contraindications aspect
    n1=agonistes du récepteur A1 de l'adénosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6856. agonistes du récepteur A3 de l'adénosine --- r_associated #0: 10 --> en:contraindications aspect
    n1=agonistes du récepteur A3 de l'adénosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6857. agonistes du récepteur alpha-1 adrénergique --- r_associated #0: 10 --> en:contraindications aspect
    n1=agonistes du récepteur alpha-1 adrénergique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6858. agonistes du récepteur bêta-3 adrénergique --- r_associated #0: 10 --> en:contraindications aspect
    n1=agonistes du récepteur bêta-3 adrénergique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6859. aller bien ensemble --- r_associated #0: 10 --> en:contraindications aspect
    n1=aller bien ensemble | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6860. alpha-MSH --- r_associated #0: 10 --> en:contraindications aspect
    n1=alpha-MSH | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6861. alvéoloplastie --- r_associated #0: 10 --> en:contraindications aspect
    n1=alvéoloplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6862. angl. GR-RH --- r_associated #0: 10 --> en:contraindications aspect
    n1=angl. GR-RH | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6863. angl. MSH --- r_associated #0: 10 --> en:contraindications aspect
    n1=angl. MSH | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6864. angl. NGF --- r_associated #0: 10 --> en:contraindications aspect
    n1=angl. NGF | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6865. angl. NSE --- r_associated #0: 10 --> en:contraindications aspect
    n1=angl. NSE | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6866. angl. WR --- r_associated #0: 10 --> en:contraindications aspect
    n1=angl. WR | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6867. angl. wt --- r_associated #0: 10 --> en:contraindications aspect
    n1=angl. wt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6868. angl.wt --- r_associated #0: 10 --> en:contraindications aspect
    n1=angl.wt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6869. antagonistes du récepteur A1 de l'adénosine --- r_associated #0: 10 --> en:contraindications aspect
    n1=antagonistes du récepteur A1 de l'adénosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6870. antagonistes du récepteur A2 de l'adénosine --- r_associated #0: 10 --> en:contraindications aspect
    n1=antagonistes du récepteur A2 de l'adénosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6871. antagonistes du récepteur A3 de l'adénosine --- r_associated #0: 10 --> en:contraindications aspect
    n1=antagonistes du récepteur A3 de l'adénosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6872. antagonistes du récepteur alpha-1 adrénergique --- r_associated #0: 10 --> en:contraindications aspect
    n1=antagonistes du récepteur alpha-1 adrénergique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6873. antagonistes du récepteur bêta-3 adrénergique --- r_associated #0: 10 --> en:contraindications aspect
    n1=antagonistes du récepteur bêta-3 adrénergique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6874. antagonistes du récepteur de l'angiotensine --- r_associated #0: 10 --> en:contraindications aspect
    n1=antagonistes du récepteur de l'angiotensine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6875. anticoagulant circulant --- r_associated #0: 10 --> en:contraindications aspect
    n1=anticoagulant circulant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6876. anticoagulant circulant de type lupique --- r_associated #0: 10 --> en:contraindications aspect
    n1=anticoagulant circulant de type lupique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6877. anticomplémentaire --- r_associated #0: 10 --> en:contraindications aspect
    n1=anticomplémentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6878. anticorps irrégulier --- r_associated #0: 10 --> en:contraindications aspect
    n1=anticorps irrégulier | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6879. antihémophilique B (facteur) --- r_associated #0: 10 --> en:contraindications aspect
    n1=antihémophilique B (facteur) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6880. apolipoprotéine B-100 (déficit familial en) --- r_associated #0: 10 --> en:contraindications aspect
    n1=apolipoprotéine B-100 (déficit familial en) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6881. apolipoprotéine C-I --- r_associated #0: 10 --> en:contraindications aspect
    n1=apolipoprotéine C-I | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6882. aux premiers secours --- r_associated #0: 10 --> en:contraindications aspect
    n1=aux premiers secours | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6883. battement du coeur f?tal --- r_associated #0: 10 --> en:contraindications aspect
    n1=battement du coeur f?tal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6884. bloqueurs du récepteur de type 1 de l'angiotensine II --- r_associated #0: 10 --> en:contraindications aspect
    n1=bloqueurs du récepteur de type 1 de l'angiotensine II | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6885. bloqueurs du récepteur de type 2 de l'angiotensine II --- r_associated #0: 10 --> en:contraindications aspect
    n1=bloqueurs du récepteur de type 2 de l'angiotensine II | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6886. bortezomib --- r_associated #0: 10 --> en:contraindications aspect
    n1=bortezomib | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6887. butyryl-coenzyme A-déshydrogénase --- r_associated #0: 10 --> en:contraindications aspect
    n1=butyryl-coenzyme A-déshydrogénase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6888. bêta-hydroxy-butyrate-déshydrogénase --- r_associated #0: 10 --> en:contraindications aspect
    n1=bêta-hydroxy-butyrate-déshydrogénase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6889. bêta-hydroxy-bêta-méthyl-glutaryl-coenzyme A --- r_associated #0: 10 --> en:contraindications aspect
    n1=bêta-hydroxy-bêta-méthyl-glutaryl-coenzyme A | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6890. bêta-hydroxy-bêta?méthylglutaryl-CoA-réductase --- r_associated #0: 10 --> en:contraindications aspect
    n1=bêta-hydroxy-bêta?méthylglutaryl-CoA-réductase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6891. c?lioscopie vaginale --- r_associated #0: 10 --> en:contraindications aspect
    n1=c?lioscopie vaginale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6892. caraté --- r_associated #0: 10 --> en:contraindications aspect
    n1=caraté | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6893. carbamoyl-phosphate --- r_associated #0: 10 --> en:contraindications aspect
    n1=carbamoyl-phosphate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6894. carbenoxolone --- r_associated #0: 10 --> en:contraindications aspect
    n1=carbenoxolone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6895. carbénicilline --- r_associated #0: 10 --> en:contraindications aspect
    n1=carbénicilline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6896. chlorophylle --- r_associated #0: 10 --> en:contraindications aspect
    n1=chlorophylle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6897. clef à molette --- r_associated #0: 10 --> en:contraindications aspect
    n1=clef à molette | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6898. computer-assisted tomography --- r_associated #0: 10 --> en:contraindications aspect
    n1=computer-assisted tomography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6899. crève-coeur --- r_associated #0: 10 --> en:contraindications aspect
    n1=crève-coeur | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6900. de premiers secours --- r_associated #0: 10 --> en:contraindications aspect
    n1=de premiers secours | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6901. de secourisme --- r_associated #0: 10 --> en:contraindications aspect
    n1=de secourisme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6902. des premiers secours --- r_associated #0: 10 --> en:contraindications aspect
    n1=des premiers secours | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6903. diencéphale --- r_associated #0: 10 --> en:contraindications aspect
    n1=diencéphale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6904. diméthylsulfoxyde --- r_associated #0: 10 --> en:contraindications aspect
    n1=diméthylsulfoxyde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6905. diphosphoglycérate mutase (déficit en) --- r_associated #0: 10 --> en:contraindications aspect
    n1=diphosphoglycérate mutase (déficit en) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6906. dosage radio-immunologique --- r_associated #0: 10 --> en:contraindications aspect
    n1=dosage radio-immunologique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6907. duodénopylorectomie --- r_associated #0: 10 --> en:contraindications aspect
    n1=duodénopylorectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6908. duodénoraphie --- r_associated #0: 10 --> en:contraindications aspect
    n1=duodénoraphie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6909. déchirement --- r_associated #0: 10 --> en:contraindications aspect
    n1=déchirement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6910. en:5-fluorocytosine --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:5-fluorocytosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6911. en:ATPase --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:ATPase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6912. en:Auger's effect --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Auger's effect | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6913. en:CT scan --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:CT scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6914. en:Carlens' tube --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Carlens' tube | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6915. en:Clara's cell --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Clara's cell | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6916. en:Cowper 's gland --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Cowper 's gland | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6917. en:DOPA --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:DOPA | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6918. en:DOPA decarboxylase --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:DOPA decarboxylase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6919. en:DPI --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:DPI | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6920. en:Delalande's method --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Delalande's method | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6921. en:Dobrava virus --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Dobrava virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6922. en:FSH --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:FSH | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6923. en:Flourens'laws --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Flourens'laws | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6924. en:Forgue's signes --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Forgue's signes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6925. en:Gley's glands --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Gley's glands | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6926. en:Gluck's technique --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Gluck's technique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6927. en:MSG --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:MSG | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6928. en:PET-scan --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:PET-scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6929. en:Splendore-Hoeppli's asteroid bodies --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Splendore-Hoeppli's asteroid bodies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6930. en:TEP --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:TEP | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6931. en:TEP-scan --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:TEP-scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6932. en:Topografov virus --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:Topografov virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6933. en:acquaintanceship --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:acquaintanceship | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6934. en:adjustable spanner --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:adjustable spanner | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6935. en:adjustable wrench --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:adjustable wrench | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6936. en:aluminium silicate --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:aluminium silicate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6937. en:angiofollicular hyperplasia --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:angiofollicular hyperplasia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6938. en:angiofollicular lymph node hyperplasia --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:angiofollicular lymph node hyperplasia | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6939. en:anticoagulant --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:anticoagulant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6940. en:anticoïncidence --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:anticoïncidence | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6941. en:antistreptolysine --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:antistreptolysine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6942. en:arginine --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:arginine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6943. en:ash leaf spot --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:ash leaf spot | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6944. en:axis malformations --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:axis malformations | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6945. en:bedecked with diamonds --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:bedecked with diamonds | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6946. en:bilieuse hemoglobinurique fever --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:bilieuse hemoglobinurique fever | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6947. en:biligraphy --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:biligraphy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6948. en:bit of nooky --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:bit of nooky | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6949. en:blood pressure monitor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:blood pressure monitor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6950. en:body oxygen transport --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:body oxygen transport | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6951. en:bonk --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:bonk | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6952. en:boob job --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:boob job | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6953. en:bushings --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:bushings | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6954. en:busulphan. --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:busulphan. | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6955. en:cancer-causing --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:cancer-causing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6956. en:carbon hydrate --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:carbon hydrate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6957. en:carnal knowledge --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:carnal knowledge | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6958. en:cat scan --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:cat scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6959. en:catheterism --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:catheterism | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6960. en:cervical cauterization --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:cervical cauterization | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6961. en:chromatotropic hormone --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:chromatotropic hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6962. en:clef --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:clef | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6963. en:coeliac disease --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:coeliac disease | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6964. en:congenital hydroxybutyric aciduria --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:congenital hydroxybutyric aciduria | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6965. en:cow-pox --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:cow-pox | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6966. en:cuivre --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:cuivre | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6967. en:cyclinB/Cdkl --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:cyclinB/Cdkl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6968. en:cyclops eye --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:cyclops eye | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6969. en:desafferentation --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:desafferentation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6970. en:diabetic osteoarthropathies --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:diabetic osteoarthropathies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6971. en:diamond-encrusted --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:diamond-encrusted | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6972. en:diamond-studded --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:diamond-studded | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6973. en:dietary mineral --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:dietary mineral | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6974. en:diffusion weighted images (DWI) --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:diffusion weighted images (DWI) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6975. en:do as somebody says --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:do as somebody says | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6976. en:do as somebody tells you --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:do as somebody tells you | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6977. en:do what somebody says --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:do what somebody says | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6978. en:duodénojéjunal angle --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:duodénojéjunal angle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6979. en:embedding --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:embedding | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6980. en:epinephrine collyrium --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:epinephrine collyrium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6981. en:erythropoietin --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:erythropoietin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6982. en:extrarenal dialysis --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:extrarenal dialysis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6983. en:eye drops --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:eye drops | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6984. en:field [sth] --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:field [sth] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6985. en:flu jab --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:flu jab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6986. en:gamma globulin --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:gamma globulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6987. en:gamma radiography --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:gamma radiography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6988. en:gelose --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:gelose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6989. en:get acquainted --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:get acquainted | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6990. en:glucagonoma syndrome --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:glucagonoma syndrome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6991. en:gluten intolerance --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:gluten intolerance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6992. en:grey platelet syndrome --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:grey platelet syndrome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6993. en:grippal vaccine --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:grippal vaccine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6994. en:growth hormone inhibiting factor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:growth hormone inhibiting factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6995. en:growth hormone-releasing hormone --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:growth hormone-releasing hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6996. en:grwoth hormone releasing factor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:grwoth hormone releasing factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6997. en:haematopoietin --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:haematopoietin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6998. en:halo sign --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:halo sign | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  6999. en:halothane. --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:halothane. | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7000. en:hemoferrum --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:hemoferrum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7001. en:high-density lipoprotein --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:high-density lipoprotein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7002. en:how's your father --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:how's your father | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7003. en:hydrocarbon containing --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:hydrocarbon containing | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7004. en:hysteria history --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:hysteria history | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7005. en:immune globulin --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:immune globulin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7006. en:in vitro fertilization (IVF) --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:in vitro fertilization (IVF) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7007. en:intercal at ing agent --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:intercal at ing agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7008. en:interferon regulatory factor 6 --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:interferon regulatory factor 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7009. en:intermedin --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:intermedin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7010. en:isopréniques. --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:isopréniques. | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7011. en:isotonic exercise --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:isotonic exercise | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7012. en:les légumineuses et les oléagineuses --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:les légumineuses et les oléagineuses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7013. en:lymphangioadenography --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:lymphangioadenography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7014. en:lymphogram --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:lymphogram | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7015. en:magnetic resonance imaging (MRI) --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:magnetic resonance imaging (MRI) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7016. en:magnification factor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:magnification factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7017. en:mammaplasty --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:mammaplasty | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7018. en:medicine --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:medicine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7019. en:melanin stimulating hormone --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:melanin stimulating hormone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7020. en:mescalin --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:mescalin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7021. en:necrolytic migratory erythema --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:necrolytic migratory erythema | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7022. en:nerve growth factor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:nerve growth factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7023. en:obeticholic acid --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:obeticholic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7024. en:octadecanoic acid --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:octadecanoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7025. en:operation --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:operation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7026. en:ophthalmic acid --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:ophthalmic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7027. en:orotidylic acid --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:orotidylic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7028. en:oxygen-hemoglobin --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:oxygen-hemoglobin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7029. en:palmitic acid-oleic acid ratio --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:palmitic acid-oleic acid ratio | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7030. en:paralytic gait --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:paralytic gait | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7031. en:peptide nucleic acid --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:peptide nucleic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7032. en:phenobarbitone --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:phenobarbitone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7033. en:phlebography --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:phlebography | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7034. en:pill --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:pill | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7035. en:progesterone --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:progesterone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7036. en:proteid --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:proteid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7037. en:protide --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:protide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7038. en:qi gong --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:qi gong | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7039. en:radiation weighting factor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:radiation weighting factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7040. en:radiolabelled oleic acid --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:radiolabelled oleic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7041. en:radioscopy --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:radioscopy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7042. en:re-establishment --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:re-establishment | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7043. en:reactions to severe somatic handicap among adolescents --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:reactions to severe somatic handicap among adolescents | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7044. en:removal of the spleen --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:removal of the spleen | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7045. en:resettling --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:resettling | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7046. en:resistance factor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:resistance factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7047. en:retro-alveolar X-ray method --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:retro-alveolar X-ray method | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7048. en:return [sth] --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:return [sth] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7049. en:ribose nucleoprotein --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:ribose nucleoprotein | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7050. en:rings --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:rings | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7051. en:rumpy-pumpy --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:rumpy-pumpy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7052. en:salpingotomy --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:salpingotomy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7053. en:scanographie --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:scanographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7054. en:scissors gait --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:scissors gait | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7055. en:sex act --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:sex act | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7056. en:somatocrinin --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:somatocrinin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7057. en:somatostatine --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:somatostatine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7058. en:somatotropin release inhibiting factor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:somatotropin release inhibiting factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7059. en:strike up an acquaintance with sb --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:strike up an acquaintance with sb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7060. en:sucrosum --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:sucrosum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7061. en:sunlight therapy --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:sunlight therapy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7062. en:survival factor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:survival factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7063. en:tetracyclin-induced fluorescence test --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:tetracyclin-induced fluorescence test | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7064. en:to strike up an acquaintance with sb --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:to strike up an acquaintance with sb | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7065. en:tomodensitométrie --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:tomodensitométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7066. en:transforming growth factor (TGF) --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:transforming growth factor (TGF) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7067. en:type of endotracheal tube with two lumens --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:type of endotracheal tube with two lumens | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7068. en:urinary endoscopic anti-reflux technique --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:urinary endoscopic anti-reflux technique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7069. en:vaccinal --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:vaccinal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7070. en:valvular heterografting --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:valvular heterografting | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7071. en:vascular permeability factor --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:vascular permeability factor | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7072. en:vitamin B1 --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:vitamin B1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7073. en:vitamin k1 --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:vitamin k1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7074. en:wisteria --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:wisteria | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7075. en:yes --- r_associated #0: 10 --> en:contraindications aspect
    n1=en:yes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7076. endoscopie trachéobronchique (anesthésie pour) --- r_associated #0: 10 --> en:contraindications aspect
    n1=endoscopie trachéobronchique (anesthésie pour) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7077. fixante --- r_associated #0: 10 --> en:contraindications aspect
    n1=fixante | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7078. fond d'oeil (examen du) --- r_associated #0: 10 --> en:contraindications aspect
    n1=fond d'oeil (examen du) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7079. fragments d'ig --- r_associated #0: 10 --> en:contraindications aspect
    n1=fragments d'ig | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7080. fécondation in vitro avec transfert d'embryon --- r_associated #0: 10 --> en:contraindications aspect
    n1=fécondation in vitro avec transfert d'embryon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7081. gardénal --- r_associated #0: 10 --> en:contraindications aspect
    n1=gardénal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7082. gas --- r_associated #0: 10 --> en:contraindications aspect
    n1=gas | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7083. gel lubrifiant --- r_associated #0: 10 --> en:contraindications aspect
    n1=gel lubrifiant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7084. gluco --- r_associated #0: 10 --> en:contraindications aspect
    n1=gluco | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7085. glucocérébrosidase --- r_associated #0: 10 --> en:contraindications aspect
    n1=glucocérébrosidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7086. glucocérébroside --- r_associated #0: 10 --> en:contraindications aspect
    n1=glucocérébroside | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7087. glycosaminoglycanne --- r_associated #0: 10 --> en:contraindications aspect
    n1=glycosaminoglycanne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7088. glycosidase --- r_associated #0: 10 --> en:contraindications aspect
    n1=glycosidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7089. gomme de karaya --- r_associated #0: 10 --> en:contraindications aspect
    n1=gomme de karaya | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7090. gomphose --- r_associated #0: 10 --> en:contraindications aspect
    n1=gomphose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7091. gonadal --- r_associated #0: 10 --> en:contraindications aspect
    n1=gonadal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7092. gonade --- r_associated #0: 10 --> en:contraindications aspect
    n1=gonade | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7093. gonadique --- r_associated #0: 10 --> en:contraindications aspect
    n1=gonadique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7094. gonadoblastome --- r_associated #0: 10 --> en:contraindications aspect
    n1=gonadoblastome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7095. gonadocrinine --- r_associated #0: 10 --> en:contraindications aspect
    n1=gonadocrinine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7096. gonadolibérine --- r_associated #0: 10 --> en:contraindications aspect
    n1=gonadolibérine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7097. gonadoréline --- r_associated #0: 10 --> en:contraindications aspect
    n1=gonadoréline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7098. hormone mélanotrope --- r_associated #0: 10 --> en:contraindications aspect
    n1=hormone mélanotrope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7099. hormones de libération des hormones hypophysaires --- r_associated #0: 10 --> en:contraindications aspect
    n1=hormones de libération des hormones hypophysaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7100. hormones inhibitrices de la libération des hormones hypophysaires --- r_associated #0: 10 --> en:contraindications aspect
    n1=hormones inhibitrices de la libération des hormones hypophysaires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7101. hormones mélanotropes --- r_associated #0: 10 --> en:contraindications aspect
    n1=hormones mélanotropes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7102. hydramnios aigu --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydramnios aigu | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7103. hydramnios chronique --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydramnios chronique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7104. hydranencéphalie --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydranencéphalie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7105. hydrargirose --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydrargirose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7106. hydrargyrisme --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydrargyrisme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7107. hydratase --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydratase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7108. hydratation cutanée --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydratation cutanée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7109. hydrencéphalie --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydrencéphalie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7110. hydrencéphalocèle --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydrencéphalocèle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7111. hydrine --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7112. hydroa --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydroa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7113. hydroa aestivalis --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydroa aestivalis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7114. hydroa vacciniforme de Bazin --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydroa vacciniforme de Bazin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7115. hydroadénome --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydroadénome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7116. hydrocalice --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydrocalice | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7117. hydrothérapie --- r_associated #0: 10 --> en:contraindications aspect
    n1=hydrothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7118. hémoglobine modifiée (solution d') --- r_associated #0: 10 --> en:contraindications aspect
    n1=hémoglobine modifiée (solution d') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7119. iRM --- r_associated #0: 10 --> en:contraindications aspect
    n1=iRM | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7120. immunisant --- r_associated #0: 10 --> en:contraindications aspect
    n1=immunisant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7121. immunisante --- r_associated #0: 10 --> en:contraindications aspect
    n1=immunisante | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7122. immunoglobine --- r_associated #0: 10 --> en:contraindications aspect
    n1=immunoglobine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7123. inhibiteurs des facteurs de coagulation sanguine --- r_associated #0: 10 --> en:contraindications aspect
    n1=inhibiteurs des facteurs de coagulation sanguine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7124. innominé (tronc) --- r_associated #0: 10 --> en:contraindications aspect
    n1=innominé (tronc) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7125. interferon regulatory factor 6 --- r_associated #0: 10 --> en:contraindications aspect
    n1=interferon regulatory factor 6 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7126. interférons et sclérose en plaques --- r_associated #0: 10 --> en:contraindications aspect
    n1=interférons et sclérose en plaques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7127. interhésion --- r_associated #0: 10 --> en:contraindications aspect
    n1=interhésion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7128. isocyanates (allergie professionnelle aux) --- r_associated #0: 10 --> en:contraindications aspect
    n1=isocyanates (allergie professionnelle aux) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7129. isolement et obscurité (retentissement psychique) --- r_associated #0: 10 --> en:contraindications aspect
    n1=isolement et obscurité (retentissement psychique) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7130. isométrie (règle d') --- r_associated #0: 10 --> en:contraindications aspect
    n1=isométrie (règle d') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7131. itp --- r_associated #0: 10 --> en:contraindications aspect
    n1=itp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7132. kcl --- r_associated #0: 10 --> en:contraindications aspect
    n1=kcl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7133. l-dopa --- r_associated #0: 10 --> en:contraindications aspect
    n1=l-dopa | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7134. laminaire (flux) --- r_associated #0: 10 --> en:contraindications aspect
    n1=laminaire (flux) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7135. laroxyl --- r_associated #0: 10 --> en:contraindications aspect
    n1=laroxyl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7136. les premiers soins --- r_associated #0: 10 --> en:contraindications aspect
    n1=les premiers soins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7137. lipodystrophies (manifestations rénales des) --- r_associated #0: 10 --> en:contraindications aspect
    n1=lipodystrophies (manifestations rénales des) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7138. match --- r_associated #0: 10 --> en:contraindications aspect
    n1=match | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7139. menace de trou maculaire (syndrome de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=menace de trou maculaire (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7140. mesure (appareil de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=mesure (appareil de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7141. mesure tensionnelle --- r_associated #0: 10 --> en:contraindications aspect
    n1=mesure tensionnelle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7142. minoxidil --- r_associated #0: 10 --> en:contraindications aspect
    n1=minoxidil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7143. mononucléosique (syndrome) --- r_associated #0: 10 --> en:contraindications aspect
    n1=mononucléosique (syndrome) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7144. monoéthylène glycol --- r_associated #0: 10 --> en:contraindications aspect
    n1=monoéthylène glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7145. mot de réponse --- r_associated #0: 10 --> en:contraindications aspect
    n1=mot de réponse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7146. mycotique (anévrisme) --- r_associated #0: 10 --> en:contraindications aspect
    n1=mycotique (anévrisme) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7147. myriapode venimeux (morsure de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=myriapode venimeux (morsure de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7148. myéline (gaine de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=myéline (gaine de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7149. médicaments --- r_associated #0: 10 --> en:contraindications aspect
    n1=médicaments | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7150. méphénésine --- r_associated #0: 10 --> en:contraindications aspect
    n1=méphénésine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7151. neuro-endoscopes --- r_associated #0: 10 --> en:contraindications aspect
    n1=neuro-endoscopes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7152. omentum (petit) --- r_associated #0: 10 --> en:contraindications aspect
    n1=omentum (petit) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7153. opération de Zárate --- r_associated #0: 10 --> en:contraindications aspect
    n1=opération de Zárate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7154. oxygénothérapie hyperbare --- r_associated #0: 10 --> en:contraindications aspect
    n1=oxygénothérapie hyperbare | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7155. oxygénothérapie normobare --- r_associated #0: 10 --> en:contraindications aspect
    n1=oxygénothérapie normobare | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7156. parasympathique (système nerveux autonome) --- r_associated #0: 10 --> en:contraindications aspect
    n1=parasympathique (système nerveux autonome) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7157. parathyrine --- r_associated #0: 10 --> en:contraindications aspect
    n1=parathyrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7158. pentétrazol --- r_associated #0: 10 --> en:contraindications aspect
    n1=pentétrazol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7159. perforé antérieur (espace) --- r_associated #0: 10 --> en:contraindications aspect
    n1=perforé antérieur (espace) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7160. phlébotomes (fièvre à ) --- r_associated #0: 10 --> en:contraindications aspect
    n1=phlébotomes (fièvre à ) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7161. phospholipase A2 --- r_associated #0: 10 --> en:contraindications aspect
    n1=phospholipase A2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7162. phosphosérine aminotransférase (déficit en) --- r_associated #0: 10 --> en:contraindications aspect
    n1=phosphosérine aminotransférase (déficit en) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7163. physiothérapie --- r_associated #0: 10 --> en:contraindications aspect
    n1=physiothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7164. physique médicale --- r_associated #0: 10 --> en:contraindications aspect
    n1=physique médicale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7165. physométrie --- r_associated #0: 10 --> en:contraindications aspect
    n1=physométrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7166. phénacétine (néphrotoxicité de la) --- r_associated #0: 10 --> en:contraindications aspect
    n1=phénacétine (néphrotoxicité de la) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7167. pitocine --- r_associated #0: 10 --> en:contraindications aspect
    n1=pitocine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7168. plasmo-acanthome --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmo-acanthome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7169. plasmoblaste --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmoblaste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7170. plasmocytaire --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmocytaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7171. plasmocyte --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmocyte | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7172. plasmocytome --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmocytome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7173. plasmocytome cutané --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmocytome cutané | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7174. plasmocytome de Unna --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmocytome de Unna | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7175. plasmocytome solitaire --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmocytome solitaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7176. plasmocytosis circumorificialis --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmocytosis circumorificialis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7177. plasmode --- r_associated #0: 10 --> en:contraindications aspect
    n1=plasmode | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7178. plérocercoïde (larve) --- r_associated #0: 10 --> en:contraindications aspect
    n1=plérocercoïde (larve) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7179. porphyries (neuropathies des) --- r_associated #0: 10 --> en:contraindications aspect
    n1=porphyries (neuropathies des) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7180. ppp --- r_associated #0: 10 --> en:contraindications aspect
    n1=ppp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7181. première espèce (risque de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=première espèce (risque de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7182. propionyl-CoA-carboxylase (déficit) --- r_associated #0: 10 --> en:contraindications aspect
    n1=propionyl-CoA-carboxylase (déficit) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7183. prospective (étude) --- r_associated #0: 10 --> en:contraindications aspect
    n1=prospective (étude) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7184. prostate (tumeur neuroendocrines de la) --- r_associated #0: 10 --> en:contraindications aspect
    n1=prostate (tumeur neuroendocrines de la) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7185. protecteurs respiratoires --- r_associated #0: 10 --> en:contraindications aspect
    n1=protecteurs respiratoires | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7186. protidique --- r_associated #0: 10 --> en:contraindications aspect
    n1=protidique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7187. protéine trifonctionnelle mitochondriale (déficit en) --- r_associated #0: 10 --> en:contraindications aspect
    n1=protéine trifonctionnelle mitochondriale (déficit en) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7188. pseudo-isochromatique (planche) --- r_associated #0: 10 --> en:contraindications aspect
    n1=pseudo-isochromatique (planche) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7189. pseudobulbaire (syndrome) --- r_associated #0: 10 --> en:contraindications aspect
    n1=pseudobulbaire (syndrome) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7190. raccords à la voie --- r_associated #0: 10 --> en:contraindications aspect
    n1=raccords à la voie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7191. raccrochage --- r_associated #0: 10 --> en:contraindications aspect
    n1=raccrochage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7192. radiculocordonal postérieur (syndrome) --- r_associated #0: 10 --> en:contraindications aspect
    n1=radiculocordonal postérieur (syndrome) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7193. radiothérapie (et insuffisance rénale) --- r_associated #0: 10 --> en:contraindications aspect
    n1=radiothérapie (et insuffisance rénale) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7194. radiothérapie superficielle --- r_associated #0: 10 --> en:contraindications aspect
    n1=radiothérapie superficielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7195. radiothérapie x --- r_associated #0: 10 --> en:contraindications aspect
    n1=radiothérapie x | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7196. ranimant --- r_associated #0: 10 --> en:contraindications aspect
    n1=ranimant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7197. reggie (1 et 2) --- r_associated #0: 10 --> en:contraindications aspect
    n1=reggie (1 et 2) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7198. relaxation (training autogène de Schultz) --- r_associated #0: 10 --> en:contraindications aspect
    n1=relaxation (training autogène de Schultz) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7199. remaniements chromosomiques (nomenclature des) --- r_associated #0: 10 --> en:contraindications aspect
    n1=remaniements chromosomiques (nomenclature des) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7200. reprenant --- r_associated #0: 10 --> en:contraindications aspect
    n1=reprenant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7201. réanimation (complications neurologiques de la) --- r_associated #0: 10 --> en:contraindications aspect
    n1=réanimation (complications neurologiques de la) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7202. récepteur de l'angiopoïétine-1 --- r_associated #0: 10 --> en:contraindications aspect
    n1=récepteur de l'angiopoïétine-1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7203. s-adénosylhomocystéine --- r_associated #0: 10 --> en:contraindications aspect
    n1=s-adénosylhomocystéine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7204. saccaride --- r_associated #0: 10 --> en:contraindications aspect
    n1=saccaride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7205. satellite virus mosaïque concombre --- r_associated #0: 10 --> en:contraindications aspect
    n1=satellite virus mosaïque concombre | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7206. service biomédical --- r_associated #0: 10 --> en:contraindications aspect
    n1=service biomédical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7207. ski nautique (position du) --- r_associated #0: 10 --> en:contraindications aspect
    n1=ski nautique (position du) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7208. soin d'hydrothérapie --- r_associated #0: 10 --> en:contraindications aspect
    n1=soin d'hydrothérapie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7209. somatosensitive (crise) --- r_associated #0: 10 --> en:contraindications aspect
    n1=somatosensitive (crise) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7210. spécification --- r_associated #0: 10 --> en:contraindications aspect
    n1=spécification | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7211. spécifications --- r_associated #0: 10 --> en:contraindications aspect
    n1=spécifications | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7212. sternocléiodohyoïdien (muscle) --- r_associated #0: 10 --> en:contraindications aspect
    n1=sternocléiodohyoïdien (muscle) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7213. styptic --- r_associated #0: 10 --> en:contraindications aspect
    n1=styptic | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7214. stéréoscopique (vision) --- r_associated #0: 10 --> en:contraindications aspect
    n1=stéréoscopique (vision) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7215. substitution absolue (méthodes de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=substitution absolue (méthodes de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7216. sulbactam --- r_associated #0: 10 --> en:contraindications aspect
    n1=sulbactam | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7217. sulfaméthizol --- r_associated #0: 10 --> en:contraindications aspect
    n1=sulfaméthizol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7218. syndrome de Torg --- r_associated #0: 10 --> en:contraindications aspect
    n1=syndrome de Torg | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7219. syndrome de Toriello-Carey --- r_associated #0: 10 --> en:contraindications aspect
    n1=syndrome de Toriello-Carey | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7220. syndrome de Tornwaldt --- r_associated #0: 10 --> en:contraindications aspect
    n1=syndrome de Tornwaldt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7221. syndrome de Torre-Muir --- r_associated #0: 10 --> en:contraindications aspect
    n1=syndrome de Torre-Muir | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7222. sérum anti-ophidien --- r_associated #0: 10 --> en:contraindications aspect
    n1=sérum anti-ophidien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7223. sérum-albumine --- r_associated #0: 10 --> en:contraindications aspect
    n1=sérum-albumine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7224. sérum-globuline --- r_associated #0: 10 --> en:contraindications aspect
    n1=sérum-globuline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7225. thermoconduction (analyseur par) --- r_associated #0: 10 --> en:contraindications aspect
    n1=thermoconduction (analyseur par) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7226. thrombospondine --- r_associated #0: 10 --> en:contraindications aspect
    n1=thrombospondine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7227. torr --- r_associated #0: 10 --> en:contraindications aspect
    n1=torr | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7228. torsade de pointes --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsade de pointes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7229. torsion --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7230. torsion axiale d'un utérus myomateux --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion axiale d'un utérus myomateux | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7231. torsion axiale de l'utérus gravide --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion axiale de l'utérus gravide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7232. torsion d'annexe --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion d'annexe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7233. torsion d'hydatide --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion d'hydatide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7234. torsion d'un léiomyome utérin --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion d'un léiomyome utérin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7235. torsion de kyste de l'ovaire --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion de kyste de l'ovaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7236. torsion de testicule --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion de testicule | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7237. torsion du cordon ombilical --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion du cordon ombilical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7238. torsion du cordon spermatique --- r_associated #0: 10 --> en:contraindications aspect
    n1=torsion du cordon spermatique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7239. transaldolase (déficit en) --- r_associated #0: 10 --> en:contraindications aspect
    n1=transaldolase (déficit en) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7240. transfusion de sang (infection transmise par la) --- r_associated #0: 10 --> en:contraindications aspect
    n1=transfusion de sang (infection transmise par la) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7241. transgastrique --- r_associated #0: 10 --> en:contraindications aspect
    n1=transgastrique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7242. transgenèse --- r_associated #0: 10 --> en:contraindications aspect
    n1=transgenèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7243. transgénique --- r_associated #0: 10 --> en:contraindications aspect
    n1=transgénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7244. transgénique (animal) --- r_associated #0: 10 --> en:contraindications aspect
    n1=transgénique (animal) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7245. triiodo-thyronine --- r_associated #0: 10 --> en:contraindications aspect
    n1=triiodo-thyronine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7246. triiodé hydrosoluble (produit de contraste) --- r_associated #0: 10 --> en:contraindications aspect
    n1=triiodé hydrosoluble (produit de contraste) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7247. tumeur calcifiée à grandes cellules de Sertoli --- r_associated #0: 10 --> en:contraindications aspect
    n1=tumeur calcifiée à grandes cellules de Sertoli | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7248. télémesure --- r_associated #0: 10 --> en:contraindications aspect
    n1=télémesure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7249. tétraoxanes --- r_associated #0: 10 --> en:contraindications aspect
    n1=tétraoxanes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7250. ultrasoniques (investigations en pathologie vasculaire cérébrale) --- r_associated #0: 10 --> en:contraindications aspect
    n1=ultrasoniques (investigations en pathologie vasculaire cérébrale) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7251. vaccin antirubéolique --- r_associated #0: 10 --> en:contraindications aspect
    n1=vaccin antirubéolique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7252. vaccin rubéole --- r_associated #0: 10 --> en:contraindications aspect
    n1=vaccin rubéole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7253. vaccin rubéolique --- r_associated #0: 10 --> en:contraindications aspect
    n1=vaccin rubéolique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7254. van't Hoff-Arrhenius (loi de) --- r_associated #0: 10 --> en:contraindications aspect
    n1=van't Hoff-Arrhenius (loi de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7255. vitamine b1 --- r_associated #0: 10 --> en:contraindications aspect
    n1=vitamine b1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7256. wt --- r_associated #0: 10 --> en:contraindications aspect
    n1=wt | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7257. xylose (test au) --- r_associated #0: 10 --> en:contraindications aspect
    n1=xylose (test au) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7258. zanamivir --- r_associated #0: 10 --> en:contraindications aspect
    n1=zanamivir | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7259. zéaralénone --- r_associated #0: 10 --> en:contraindications aspect
    n1=zéaralénone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7260. zébrage chromosomique --- r_associated #0: 10 --> en:contraindications aspect
    n1=zébrage chromosomique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7261. Échocardiographie --- r_associated #0: 10 --> en:contraindications aspect
    n1=Échocardiographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7262. Échographie cardiaque --- r_associated #0: 10 --> en:contraindications aspect
    n1=Échographie cardiaque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7263. Électronarcose --- r_associated #0: 10 --> en:contraindications aspect
    n1=Électronarcose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7264. Épitope --- r_associated #0: 10 --> en:contraindications aspect
    n1=Épitope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7265. Épuration extrarénale --- r_associated #0: 10 --> en:contraindications aspect
    n1=Épuration extrarénale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7266. Ézétimibe --- r_associated #0: 10 --> en:contraindications aspect
    n1=Ézétimibe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7267. écho planar (imagerie par) --- r_associated #0: 10 --> en:contraindications aspect
    n1=écho planar (imagerie par) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7268. électrochirurgie --- r_associated #0: 10 --> en:contraindications aspect
    n1=électrochirurgie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7269. électrochoc (incidents et accidents de l') --- r_associated #0: 10 --> en:contraindications aspect
    n1=électrochoc (incidents et accidents de l') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7270. éosinophilie-myalgie (syndrome) --- r_associated #0: 10 --> en:contraindications aspect
    n1=éosinophilie-myalgie (syndrome) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7271. équateur de l'oeil --- r_associated #0: 10 --> en:contraindications aspect
    n1=équateur de l'oeil | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7272. équateur du cristallin --- r_associated #0: 10 --> en:contraindications aspect
    n1=équateur du cristallin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7273. équation colorée métamérique --- r_associated #0: 10 --> en:contraindications aspect
    n1=équation colorée métamérique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7274. équationnel --- r_associated #0: 10 --> en:contraindications aspect
    n1=équationnel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7275. équilibre acido-basique --- r_associated #0: 10 --> en:contraindications aspect
    n1=équilibre acido-basique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7276. équilibre acidobasique --- r_associated #0: 10 --> en:contraindications aspect
    n1=équilibre acidobasique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7277. équilibre glomérulotubulaire --- r_associated #0: 10 --> en:contraindications aspect
    n1=équilibre glomérulotubulaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7278. équilibre génique --- r_associated #0: 10 --> en:contraindications aspect
    n1=équilibre génique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7279. équilibre électronique --- r_associated #0: 10 --> en:contraindications aspect
    n1=équilibre électronique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7280. éthique (d'un essai randomisé) --- r_associated #0: 10 --> en:contraindications aspect
    n1=éthique (d'un essai randomisé) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7281. éthylène (oxyde d') --- r_associated #0: 10 --> en:contraindications aspect
    n1=éthylène (oxyde d') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7282. évitement (conduite d') --- r_associated #0: 10 --> en:contraindications aspect
    n1=évitement (conduite d') | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=10
  7283. angio-IRM --- r_associated #0: 6 --> en:contraindications aspect
    n1=angio-IRM | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=6
  7284. chlorique --- r_associated #0: 6 --> en:contraindications aspect
    n1=chlorique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=6
  7285. hystéroscope --- r_associated #0: 6 --> en:contraindications aspect
    n1=hystéroscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=6
  7286. splénoportographie --- r_associated #0: 6 --> en:contraindications aspect
    n1=splénoportographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=6
  7287. Abatacept --- r_associated #0: 5 --> en:contraindications aspect
    n1=Abatacept | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7288. Acide octadécanoïque --- r_associated #0: 5 --> en:contraindications aspect
    n1=Acide octadécanoïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7289. Acide oléique --- r_associated #0: 5 --> en:contraindications aspect
    n1=Acide oléique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7290. Acide osmique --- r_associated #0: 5 --> en:contraindications aspect
    n1=Acide osmique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7291. Acide shikimique --- r_associated #0: 5 --> en:contraindications aspect
    n1=Acide shikimique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7292. Acide valproïque --- r_associated #0: 5 --> en:contraindications aspect
    n1=Acide valproïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7293. Acquaintance --- r_associated #0: 5 --> en:contraindications aspect
    n1=Acquaintance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7294. Aedes --- r_associated #0: 5 --> en:contraindications aspect
    n1=Aedes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7295. Aedes aegypti --- r_associated #0: 5 --> en:contraindications aspect
    n1=Aedes aegypti | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7296. Agent de contraste --- r_associated #0: 5 --> en:contraindications aspect
    n1=Agent de contraste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7297. Aminotransférase --- r_associated #0: 5 --> en:contraindications aspect
    n1=Aminotransférase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7298. Anticorps antinucléaire --- r_associated #0: 5 --> en:contraindications aspect
    n1=Anticorps antinucléaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7299. Apatites --- r_associated #0: 5 --> en:contraindications aspect
    n1=Apatites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7300. Appareil dentaire --- r_associated #0: 5 --> en:contraindications aspect
    n1=Appareil dentaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7301. Arbutine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Arbutine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7302. Arthroplastie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Arthroplastie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7303. Auranofine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Auranofine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7304. Aurothioglucose --- r_associated #0: 5 --> en:contraindications aspect
    n1=Aurothioglucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7305. BVT --- r_associated #0: 5 --> en:contraindications aspect
    n1=BVT | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7306. Berbérine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Berbérine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7307. Bevacizumab --- r_associated #0: 5 --> en:contraindications aspect
    n1=Bevacizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7308. Bronchoscopie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Bronchoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7309. CRX gene --- r_associated #0: 5 --> en:contraindications aspect
    n1=CRX gene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7310. CRYBB2 gene --- r_associated #0: 5 --> en:contraindications aspect
    n1=CRYBB2 gene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7311. CWV --- r_associated #0: 5 --> en:contraindications aspect
    n1=CWV | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7312. Cadhérine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Cadhérine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7313. Caprolactame --- r_associated #0: 5 --> en:contraindications aspect
    n1=Caprolactame | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7314. Catacamas virus --- r_associated #0: 5 --> en:contraindications aspect
    n1=Catacamas virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7315. Certolizumab pegol --- r_associated #0: 5 --> en:contraindications aspect
    n1=Certolizumab pegol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7316. Cholécystectomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Cholécystectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7317. Cockett (syndrome de) --- r_associated #0: 5 --> en:contraindications aspect
    n1=Cockett (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7318. Colectomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Colectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7319. Colonoscope --- r_associated #0: 5 --> en:contraindications aspect
    n1=Colonoscope | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7320. Cystotomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Cystotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7321. Delavirdine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Delavirdine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7322. Dentifrices --- r_associated #0: 5 --> en:contraindications aspect
    n1=Dentifrices | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7323. Dientamoeba fragilis --- r_associated #0: 5 --> en:contraindications aspect
    n1=Dientamoeba fragilis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7324. Débridement --- r_associated #0: 5 --> en:contraindications aspect
    n1=Débridement | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7325. Emtricitabine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Emtricitabine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7326. FLT3 gene --- r_associated #0: 5 --> en:contraindications aspect
    n1=FLT3 gene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7327. FLT4 gene --- r_associated #0: 5 --> en:contraindications aspect
    n1=FLT4 gene | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7328. Facteur de croissance transformant --- r_associated #0: 5 --> en:contraindications aspect
    n1=Facteur de croissance transformant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7329. Facteur de qualité --- r_associated #0: 5 --> en:contraindications aspect
    n1=Facteur de qualité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7330. Faire connaissance --- r_associated #0: 5 --> en:contraindications aspect
    n1=Faire connaissance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7331. Finastéride --- r_associated #0: 5 --> en:contraindications aspect
    n1=Finastéride | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7332. Gastroscopie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Gastroscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7333. Gingivectomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Gingivectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7334. Glucosinolate --- r_associated #0: 5 --> en:contraindications aspect
    n1=Glucosinolate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7335. Hejduk (opération de) --- r_associated #0: 5 --> en:contraindications aspect
    n1=Hejduk (opération de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7336. Hormone parathyroïdienne --- r_associated #0: 5 --> en:contraindications aspect
    n1=Hormone parathyroïdienne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7337. Hydroxyde de sodium --- r_associated #0: 5 --> en:contraindications aspect
    n1=Hydroxyde de sodium | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7338. Immunisation passive --- r_associated #0: 5 --> en:contraindications aspect
    n1=Immunisation passive | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7339. Langage de programmation --- r_associated #0: 5 --> en:contraindications aspect
    n1=Langage de programmation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7340. Laryngoscopie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Laryngoscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7341. Liraglutide --- r_associated #0: 5 --> en:contraindications aspect
    n1=Liraglutide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7342. Membre 11 de la superfamille des ligands du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=Membre 11 de la superfamille des ligands du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7343. Membre 11a de la superfamille des récepteurs du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=Membre 11a de la superfamille des récepteurs du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7344. Membre 14 de la superfamille des ligands du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=Membre 14 de la superfamille des ligands du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7345. Membre 17 de la superfamille des récepteurs du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=Membre 17 de la superfamille des récepteurs du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7346. Membre 18 de la superfamille des récepteurs du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=Membre 18 de la superfamille des récepteurs du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7347. Membre 4 de la superfamille des ligands du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=Membre 4 de la superfamille des ligands du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7348. Membre 6 de la superfamille des ligands du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=Membre 6 de la superfamille des ligands du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7349. Nelfinavir --- r_associated #0: 5 --> en:contraindications aspect
    n1=Nelfinavir | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7350. Nicolau et B?lu? (syndrome de) --- r_associated #0: 5 --> en:contraindications aspect
    n1=Nicolau et B?lu? (syndrome de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7351. Occludine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Occludine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7352. Ostéopontine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Ostéopontine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7353. PI 3-kinases --- r_associated #0: 5 --> en:contraindications aspect
    n1=PI 3-kinases | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7354. Pet-scan --- r_associated #0: 5 --> en:contraindications aspect
    n1=Pet-scan | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7355. Phlébotomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Phlébotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7356. Point de montage --- r_associated #0: 5 --> en:contraindications aspect
    n1=Point de montage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7357. Pristinamycine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Pristinamycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7358. Protéine de la famille du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=Protéine de la famille du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7359. Rang (lésion de) --- r_associated #0: 5 --> en:contraindications aspect
    n1=Rang (lésion de) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7360. Rituximab --- r_associated #0: 5 --> en:contraindications aspect
    n1=Rituximab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7361. Réanimation cardiaque --- r_associated #0: 5 --> en:contraindications aspect
    n1=Réanimation cardiaque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7362. Récepteurs leurres du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=Récepteurs leurres du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7363. Répondre à --- r_associated #0: 5 --> en:contraindications aspect
    n1=Répondre à | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7364. SPMS --- r_associated #0: 5 --> en:contraindications aspect
    n1=SPMS | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7365. Serum Glutamic-Oxaloacetic-Transaminase --- r_associated #0: 5 --> en:contraindications aspect
    n1=Serum Glutamic-Oxaloacetic-Transaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7366. Serum Glutamic-Pyruvic-Transaminase --- r_associated #0: 5 --> en:contraindications aspect
    n1=Serum Glutamic-Pyruvic-Transaminase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7367. SpO 2 --- r_associated #0: 5 --> en:contraindications aspect
    n1=SpO 2 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7368. Sélectine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Sélectine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7369. Tocolyse --- r_associated #0: 5 --> en:contraindications aspect
    n1=Tocolyse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7370. Vanadates --- r_associated #0: 5 --> en:contraindications aspect
    n1=Vanadates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7371. Vancomycine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Vancomycine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7372. Zidovudine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Zidovudine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7373. Zéolites --- r_associated #0: 5 --> en:contraindications aspect
    n1=Zéolites | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7374. acide Para-AminoBenzoïque --- r_associated #0: 5 --> en:contraindications aspect
    n1=acide Para-AminoBenzoïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7375. acide palmitoléique --- r_associated #0: 5 --> en:contraindications aspect
    n1=acide palmitoléique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7376. acide pantoïque --- r_associated #0: 5 --> en:contraindications aspect
    n1=acide pantoïque | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7377. adomen pendulum --- r_associated #0: 5 --> en:contraindications aspect
    n1=adomen pendulum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7378. adrénochrome --- r_associated #0: 5 --> en:contraindications aspect
    n1=adrénochrome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7379. adsorbant --- r_associated #0: 5 --> en:contraindications aspect
    n1=adsorbant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7380. adventicectomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=adventicectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7381. adynamie --- r_associated #0: 5 --> en:contraindications aspect
    n1=adynamie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7382. adynamie épisodique héréditaire avec ou sans myotonie --- r_associated #0: 5 --> en:contraindications aspect
    n1=adynamie épisodique héréditaire avec ou sans myotonie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7383. adynamie épisodique héréditaire de Gamstorp --- r_associated #0: 5 --> en:contraindications aspect
    n1=adynamie épisodique héréditaire de Gamstorp | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7384. angine de Vincent --- r_associated #0: 5 --> en:contraindications aspect
    n1=angine de Vincent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7385. angine pustuleuse --- r_associated #0: 5 --> en:contraindications aspect
    n1=angine pustuleuse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7386. angio-endothéliomatose maligne --- r_associated #0: 5 --> en:contraindications aspect
    n1=angio-endothéliomatose maligne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7387. angio-endothéliomatose proliférante systématisée de Tappeiner et Pfleger --- r_associated #0: 5 --> en:contraindications aspect
    n1=angio-endothéliomatose proliférante systématisée de Tappeiner et Pfleger | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7388. angio-endothéliome malin --- r_associated #0: 5 --> en:contraindications aspect
    n1=angio-endothéliome malin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7389. angio-endothéliosarcome infantile --- r_associated #0: 5 --> en:contraindications aspect
    n1=angio-endothéliosarcome infantile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7390. angio-ostéohypertrophie --- r_associated #0: 5 --> en:contraindications aspect
    n1=angio-ostéohypertrophie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7391. angioalgie --- r_associated #0: 5 --> en:contraindications aspect
    n1=angioalgie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7392. angioblaste --- r_associated #0: 5 --> en:contraindications aspect
    n1=angioblaste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7393. angioblastes --- r_associated #0: 5 --> en:contraindications aspect
    n1=angioblastes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7394. angiocardiocinétique --- r_associated #0: 5 --> en:contraindications aspect
    n1=angiocardiocinétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7395. angiocardiogramme --- r_associated #0: 5 --> en:contraindications aspect
    n1=angiocardiogramme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7396. angl. EDRF --- r_associated #0: 5 --> en:contraindications aspect
    n1=angl. EDRF | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7397. angl. ef-g poir elongation factor-protein G --- r_associated #0: 5 --> en:contraindications aspect
    n1=angl. ef-g poir elongation factor-protein G | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7398. antigène 3 associé à la fonction lymphocytaire --- r_associated #0: 5 --> en:contraindications aspect
    n1=antigène 3 associé à la fonction lymphocytaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7399. antigènes stimulateurs mineurs des lymphocytes --- r_associated #0: 5 --> en:contraindications aspect
    n1=antigènes stimulateurs mineurs des lymphocytes | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7400. antirepliement en IRM --- r_associated #0: 5 --> en:contraindications aspect
    n1=antirepliement en IRM | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7401. antirépresseur --- r_associated #0: 5 --> en:contraindications aspect
    n1=antirépresseur | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7402. antistreptohyaluronidase --- r_associated #0: 5 --> en:contraindications aspect
    n1=antistreptohyaluronidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7403. antistreptokinase --- r_associated #0: 5 --> en:contraindications aspect
    n1=antistreptokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7404. antre mastoïdien --- r_associated #0: 5 --> en:contraindications aspect
    n1=antre mastoïdien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7405. antre pylorique --- r_associated #0: 5 --> en:contraindications aspect
    n1=antre pylorique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7406. antre pétreux --- r_associated #0: 5 --> en:contraindications aspect
    n1=antre pétreux | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7407. antre tympanique --- r_associated #0: 5 --> en:contraindications aspect
    n1=antre tympanique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7408. antrectomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=antrectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7409. antrite --- r_associated #0: 5 --> en:contraindications aspect
    n1=antrite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7410. antro-atticotomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=antro-atticotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7411. antroscopie --- r_associated #0: 5 --> en:contraindications aspect
    n1=antroscopie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7412. antrotomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=antrotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7413. anucléé --- r_associated #0: 5 --> en:contraindications aspect
    n1=anucléé | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7414. anulus --- r_associated #0: 5 --> en:contraindications aspect
    n1=anulus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7415. anurie --- r_associated #0: 5 --> en:contraindications aspect
    n1=anurie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7416. anurie gravidique --- r_associated #0: 5 --> en:contraindications aspect
    n1=anurie gravidique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7417. augmentation de l'être humain --- r_associated #0: 5 --> en:contraindications aspect
    n1=augmentation de l'être humain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7418. augnathe --- r_associated #0: 5 --> en:contraindications aspect
    n1=augnathe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7419. axis [C II] --- r_associated #0: 5 --> en:contraindications aspect
    n1=axis [C II] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7420. axonopathie --- r_associated #0: 5 --> en:contraindications aspect
    n1=axonopathie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7421. axonème --- r_associated #0: 5 --> en:contraindications aspect
    n1=axonème | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7422. axostyle --- r_associated #0: 5 --> en:contraindications aspect
    n1=axostyle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7423. axoïdien --- r_associated #0: 5 --> en:contraindications aspect
    n1=axoïdien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7424. bilifuscine --- r_associated #0: 5 --> en:contraindications aspect
    n1=bilifuscine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7425. biligénèse --- r_associated #0: 5 --> en:contraindications aspect
    n1=biligénèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7426. butanol --- r_associated #0: 5 --> en:contraindications aspect
    n1=butanol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7427. butanol extractible iodine --- r_associated #0: 5 --> en:contraindications aspect
    n1=butanol extractible iodine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7428. butoconazole --- r_associated #0: 5 --> en:contraindications aspect
    n1=butoconazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7429. butyrobétaïne --- r_associated #0: 5 --> en:contraindications aspect
    n1=butyrobétaïne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7430. butyrophénone --- r_associated #0: 5 --> en:contraindications aspect
    n1=butyrophénone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7431. butyryl-coenzyme A --- r_associated #0: 5 --> en:contraindications aspect
    n1=butyryl-coenzyme A | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7432. butée de hanche --- r_associated #0: 5 --> en:contraindications aspect
    n1=butée de hanche | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7433. butée de l'épaule --- r_associated #0: 5 --> en:contraindications aspect
    n1=butée de l'épaule | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7434. butée osseuse --- r_associated #0: 5 --> en:contraindications aspect
    n1=butée osseuse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7435. bâton galénique --- r_associated #0: 5 --> en:contraindications aspect
    n1=bâton galénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7436. bâtonnet rétinien --- r_associated #0: 5 --> en:contraindications aspect
    n1=bâtonnet rétinien | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7437. carbamates --- r_associated #0: 5 --> en:contraindications aspect
    n1=carbamates | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7438. carbamazépine --- r_associated #0: 5 --> en:contraindications aspect
    n1=carbamazépine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7439. carbaminohémoglobine --- r_associated #0: 5 --> en:contraindications aspect
    n1=carbaminohémoglobine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7440. carbaryl --- r_associated #0: 5 --> en:contraindications aspect
    n1=carbaryl | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7441. carbhémoglobine --- r_associated #0: 5 --> en:contraindications aspect
    n1=carbhémoglobine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7442. carboligase --- r_associated #0: 5 --> en:contraindications aspect
    n1=carboligase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7443. carbonarcose --- r_associated #0: 5 --> en:contraindications aspect
    n1=carbonarcose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7444. carbonate --- r_associated #0: 5 --> en:contraindications aspect
    n1=carbonate | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7445. carnet de santé --- r_associated #0: 5 --> en:contraindications aspect
    n1=carnet de santé | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7446. carnet de soins --- r_associated #0: 5 --> en:contraindications aspect
    n1=carnet de soins | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7447. catabolite --- r_associated #0: 5 --> en:contraindications aspect
    n1=catabolite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7448. catacalcine --- r_associated #0: 5 --> en:contraindications aspect
    n1=catacalcine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7449. catadidyme --- r_associated #0: 5 --> en:contraindications aspect
    n1=catadidyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7450. centreur lumineux --- r_associated #0: 5 --> en:contraindications aspect
    n1=centreur lumineux | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7451. chola --- r_associated #0: 5 --> en:contraindications aspect
    n1=chola | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7452. clarification hépatocytaire --- r_associated #0: 5 --> en:contraindications aspect
    n1=clarification hépatocytaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7453. colectasie --- r_associated #0: 5 --> en:contraindications aspect
    n1=colectasie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7454. convertase du facteur de nécrose tumorale alpha --- r_associated #0: 5 --> en:contraindications aspect
    n1=convertase du facteur de nécrose tumorale alpha | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7455. cordotomies --- r_associated #0: 5 --> en:contraindications aspect
    n1=cordotomies | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7456. cowperite --- r_associated #0: 5 --> en:contraindications aspect
    n1=cowperite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7457. cowpox virus --- r_associated #0: 5 --> en:contraindications aspect
    n1=cowpox virus | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7458. cryo-ablation --- r_associated #0: 5 --> en:contraindications aspect
    n1=cryo-ablation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7459. cryo-analgésie --- r_associated #0: 5 --> en:contraindications aspect
    n1=cryo-analgésie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7460. cryo-anesthésie --- r_associated #0: 5 --> en:contraindications aspect
    n1=cryo-anesthésie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7461. cryo-extraction du cristallin --- r_associated #0: 5 --> en:contraindications aspect
    n1=cryo-extraction du cristallin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7462. cyclopeptide --- r_associated #0: 5 --> en:contraindications aspect
    n1=cyclopeptide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7463. cyclophiline --- r_associated #0: 5 --> en:contraindications aspect
    n1=cyclophiline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7464. cyclophorie --- r_associated #0: 5 --> en:contraindications aspect
    n1=cyclophorie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7465. dacryocystite aigüe du nouveau-né --- r_associated #0: 5 --> en:contraindications aspect
    n1=dacryocystite aigüe du nouveau-né | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7466. dacryocystotomographie --- r_associated #0: 5 --> en:contraindications aspect
    n1=dacryocystotomographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7467. danse de Saint Guy --- r_associated #0: 5 --> en:contraindications aspect
    n1=danse de Saint Guy | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7468. danse des hiles --- r_associated #0: 5 --> en:contraindications aspect
    n1=danse des hiles | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7469. dantrolène --- r_associated #0: 5 --> en:contraindications aspect
    n1=dantrolène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7470. dapaglifozine --- r_associated #0: 5 --> en:contraindications aspect
    n1=dapaglifozine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7471. delangine --- r_associated #0: 5 --> en:contraindications aspect
    n1=delangine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7472. desmoplakine --- r_associated #0: 5 --> en:contraindications aspect
    n1=desmoplakine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7473. desmoplasie --- r_associated #0: 5 --> en:contraindications aspect
    n1=desmoplasie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7474. desmoplastique --- r_associated #0: 5 --> en:contraindications aspect
    n1=desmoplastique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7475. desmopressine --- r_associated #0: 5 --> en:contraindications aspect
    n1=desmopressine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7476. desmosine --- r_associated #0: 5 --> en:contraindications aspect
    n1=desmosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7477. diagnostic anténatal en dermatologie --- r_associated #0: 5 --> en:contraindications aspect
    n1=diagnostic anténatal en dermatologie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7478. diagnostic biologique de la grossesse --- r_associated #0: 5 --> en:contraindications aspect
    n1=diagnostic biologique de la grossesse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7479. diagnostic de la fibromyalgie --- r_associated #0: 5 --> en:contraindications aspect
    n1=diagnostic de la fibromyalgie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7480. diagnostic génétique --- r_associated #0: 5 --> en:contraindications aspect
    n1=diagnostic génétique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7481. diagnostic génétique postnatal --- r_associated #0: 5 --> en:contraindications aspect
    n1=diagnostic génétique postnatal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7482. diagnostic génétique préconceptionnel --- r_associated #0: 5 --> en:contraindications aspect
    n1=diagnostic génétique préconceptionnel | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7483. diagnostic génétique prénatal --- r_associated #0: 5 --> en:contraindications aspect
    n1=diagnostic génétique prénatal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7484. diagnostic immunologique de la grossesse --- r_associated #0: 5 --> en:contraindications aspect
    n1=diagnostic immunologique de la grossesse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7485. dieldrine --- r_associated #0: 5 --> en:contraindications aspect
    n1=dieldrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7486. digestibilité --- r_associated #0: 5 --> en:contraindications aspect
    n1=digestibilité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7487. digestion chlorhydropeptique --- r_associated #0: 5 --> en:contraindications aspect
    n1=digestion chlorhydropeptique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7488. digestion des glucides --- r_associated #0: 5 --> en:contraindications aspect
    n1=digestion des glucides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7489. digestion des lipides --- r_associated #0: 5 --> en:contraindications aspect
    n1=digestion des lipides | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7490. digestion des protéines --- r_associated #0: 5 --> en:contraindications aspect
    n1=digestion des protéines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7491. digestion entérocytaire --- r_associated #0: 5 --> en:contraindications aspect
    n1=digestion entérocytaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7492. digestion intraluminale --- r_associated #0: 5 --> en:contraindications aspect
    n1=digestion intraluminale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7493. digitaline --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitaline | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7494. digitalisation de l'avant-bras --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitalisation de l'avant-bras | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7495. digitalose --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitalose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7496. digitations hippocampiques --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitations hippocampiques | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7497. digitiforme --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitiforme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7498. digitonine --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitonine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7499. digitonoside --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitonoside | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7500. digitopulpite squameuse --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitopulpite squameuse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7501. digitoxigénine --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitoxigénine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7502. digitoxose --- r_associated #0: 5 --> en:contraindications aspect
    n1=digitoxose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7503. diéthyl-éther --- r_associated #0: 5 --> en:contraindications aspect
    n1=diéthyl-éther | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7504. diéthylcarbamazine --- r_associated #0: 5 --> en:contraindications aspect
    n1=diéthylcarbamazine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7505. duodénojéjunostomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=duodénojéjunostomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7506. duodénopancréatectomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=duodénopancréatectomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7507. duodénostomie transgastrique --- r_associated #0: 5 --> en:contraindications aspect
    n1=duodénostomie transgastrique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7508. duodénotomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=duodénotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7509. duodénum --- r_associated #0: 5 --> en:contraindications aspect
    n1=duodénum | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7510. déficit en bêta-hydroxy-acyl-CoA-déshydrogénase des acides gras à longue chaîne --- r_associated #0: 5 --> en:contraindications aspect
    n1=déficit en bêta-hydroxy-acyl-CoA-déshydrogénase des acides gras à longue chaîne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7511. délamination --- r_associated #0: 5 --> en:contraindications aspect
    n1=délamination | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7512. dépistage multiphasique --- r_associated #0: 5 --> en:contraindications aspect
    n1=dépistage multiphasique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7513. désolidarisation de la tête foetale --- r_associated #0: 5 --> en:contraindications aspect
    n1=désolidarisation de la tête foetale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7514. désordre congénital de la glycosylation type 1 --- r_associated #0: 5 --> en:contraindications aspect
    n1=désordre congénital de la glycosylation type 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7515. désorientation calicielle --- r_associated #0: 5 --> en:contraindications aspect
    n1=désorientation calicielle | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7516. désorientation temporospatiale --- r_associated #0: 5 --> en:contraindications aspect
    n1=désorientation temporospatiale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7517. désose --- r_associated #0: 5 --> en:contraindications aspect
    n1=désose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7518. désoxycorticostérone --- r_associated #0: 5 --> en:contraindications aspect
    n1=désoxycorticostérone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7519. désoxycortisone --- r_associated #0: 5 --> en:contraindications aspect
    n1=désoxycortisone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7520. désoxyglucose --- r_associated #0: 5 --> en:contraindications aspect
    n1=désoxyglucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7521. désoxyhexose --- r_associated #0: 5 --> en:contraindications aspect
    n1=désoxyhexose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7522. désoxyhémoglobine --- r_associated #0: 5 --> en:contraindications aspect
    n1=désoxyhémoglobine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7523. désoxylapachol --- r_associated #0: 5 --> en:contraindications aspect
    n1=désoxylapachol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7524. echelle d?intelligence de Wechsler-Bellevue adaptée aux enfants --- r_associated #0: 5 --> en:contraindications aspect
    n1=echelle d?intelligence de Wechsler-Bellevue adaptée aux enfants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7525. en protéines --- r_associated #0: 5 --> en:contraindications aspect
    n1=en protéines | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7526. en:(9Z)-octadecenoic acid --- r_associated #0: 5 --> en:contraindications aspect
    n1=en:(9Z)-octadecenoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7527. en:address [sth] --- r_associated #0: 5 --> en:contraindications aspect
    n1=en:address [sth] | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7528. en:carcinogenic agent --- r_associated #0: 5 --> en:contraindications aspect
    n1=en:carcinogenic agent | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7529. en:cis-9-octadecenoic acid --- r_associated #0: 5 --> en:contraindications aspect
    n1=en:cis-9-octadecenoic acid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7530. en:lorgnette --- r_associated #0: 5 --> en:contraindications aspect
    n1=en:lorgnette | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7531. en:resistance plasmid --- r_associated #0: 5 --> en:contraindications aspect
    n1=en:resistance plasmid | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7532. flubendazole --- r_associated #0: 5 --> en:contraindications aspect
    n1=flubendazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7533. fluconazole --- r_associated #0: 5 --> en:contraindications aspect
    n1=fluconazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7534. fluctuation du rythme cardiaque foetal --- r_associated #0: 5 --> en:contraindications aspect
    n1=fluctuation du rythme cardiaque foetal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7535. fluctuation quantique --- r_associated #0: 5 --> en:contraindications aspect
    n1=fluctuation quantique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7536. fluoro --- r_associated #0: 5 --> en:contraindications aspect
    n1=fluoro | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7537. formation réticulée spinale --- r_associated #0: 5 --> en:contraindications aspect
    n1=formation réticulée spinale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7538. formation vestigiale --- r_associated #0: 5 --> en:contraindications aspect
    n1=formation vestigiale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7539. forme d'involution --- r_associated #0: 5 --> en:contraindications aspect
    n1=forme d'involution | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7540. forme galénique --- r_associated #0: 5 --> en:contraindications aspect
    n1=forme galénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7541. forme médicamenteuse --- r_associated #0: 5 --> en:contraindications aspect
    n1=forme médicamenteuse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7542. forme pharmaceutique --- r_associated #0: 5 --> en:contraindications aspect
    n1=forme pharmaceutique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7543. forme réplicative des phages --- r_associated #0: 5 --> en:contraindications aspect
    n1=forme réplicative des phages | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7544. forme épimastigote --- r_associated #0: 5 --> en:contraindications aspect
    n1=forme épimastigote | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7545. fuchsine --- r_associated #0: 5 --> en:contraindications aspect
    n1=fuchsine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7546. fucose --- r_associated #0: 5 --> en:contraindications aspect
    n1=fucose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7547. fumarase --- r_associated #0: 5 --> en:contraindications aspect
    n1=fumarase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7548. fumarylacétoacétase --- r_associated #0: 5 --> en:contraindications aspect
    n1=fumarylacétoacétase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7549. fumarylacétoacétate hydrolase --- r_associated #0: 5 --> en:contraindications aspect
    n1=fumarylacétoacétate hydrolase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7550. fumée toxique --- r_associated #0: 5 --> en:contraindications aspect
    n1=fumée toxique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7551. fécondabilité --- r_associated #0: 5 --> en:contraindications aspect
    n1=fécondabilité | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7552. fécondance --- r_associated #0: 5 --> en:contraindications aspect
    n1=fécondance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7553. fécondation --- r_associated #0: 5 --> en:contraindications aspect
    n1=fécondation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7554. fécondation assistée --- r_associated #0: 5 --> en:contraindications aspect
    n1=fécondation assistée | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7555. gliadine --- r_associated #0: 5 --> en:contraindications aspect
    n1=gliadine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7556. glucane --- r_associated #0: 5 --> en:contraindications aspect
    n1=glucane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7557. glucidase --- r_associated #0: 5 --> en:contraindications aspect
    n1=glucidase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7558. glucoformateur --- r_associated #0: 5 --> en:contraindications aspect
    n1=glucoformateur | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7559. glucogénèse --- r_associated #0: 5 --> en:contraindications aspect
    n1=glucogénèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7560. glucokinase --- r_associated #0: 5 --> en:contraindications aspect
    n1=glucokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7561. gluconokinase --- r_associated #0: 5 --> en:contraindications aspect
    n1=gluconokinase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7562. glucophosphomutase --- r_associated #0: 5 --> en:contraindications aspect
    n1=glucophosphomutase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7563. glutine --- r_associated #0: 5 --> en:contraindications aspect
    n1=glutine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7564. gluténine --- r_associated #0: 5 --> en:contraindications aspect
    n1=gluténine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7565. gly --- r_associated #0: 5 --> en:contraindications aspect
    n1=gly | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7566. glycanne --- r_associated #0: 5 --> en:contraindications aspect
    n1=glycanne | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7567. glycation --- r_associated #0: 5 --> en:contraindications aspect
    n1=glycation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7568. glycuronurie --- r_associated #0: 5 --> en:contraindications aspect
    n1=glycuronurie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7569. glycémie --- r_associated #0: 5 --> en:contraindications aspect
    n1=glycémie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7570. glymphatique --- r_associated #0: 5 --> en:contraindications aspect
    n1=glymphatique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7571. halophile --- r_associated #0: 5 --> en:contraindications aspect
    n1=halophile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7572. halopéridol --- r_associated #0: 5 --> en:contraindications aspect
    n1=halopéridol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7573. hydramnios --- r_associated #0: 5 --> en:contraindications aspect
    n1=hydramnios | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7574. hydrargyrie --- r_associated #0: 5 --> en:contraindications aspect
    n1=hydrargyrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7575. hystéro-épilepsie --- r_associated #0: 5 --> en:contraindications aspect
    n1=hystéro-épilepsie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7576. hystérosalpingographie --- r_associated #0: 5 --> en:contraindications aspect
    n1=hystérosalpingographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7577. hystéroscope de contact --- r_associated #0: 5 --> en:contraindications aspect
    n1=hystéroscope de contact | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7578. héliodermie --- r_associated #0: 5 --> en:contraindications aspect
    n1=héliodermie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7579. héliopathie --- r_associated #0: 5 --> en:contraindications aspect
    n1=héliopathie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7580. héliophile --- r_associated #0: 5 --> en:contraindications aspect
    n1=héliophile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7581. héliophobie --- r_associated #0: 5 --> en:contraindications aspect
    n1=héliophobie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7582. interaction en épidémiologie --- r_associated #0: 5 --> en:contraindications aspect
    n1=interaction en épidémiologie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7583. interaction entre communicants --- r_associated #0: 5 --> en:contraindications aspect
    n1=interaction entre communicants | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7584. interaction nucléocytoplasmique --- r_associated #0: 5 --> en:contraindications aspect
    n1=interaction nucléocytoplasmique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7585. interféron alpha-2b pégylé --- r_associated #0: 5 --> en:contraindications aspect
    n1=interféron alpha-2b pégylé | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7586. interleukine 1 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 1 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7587. interleukine 10 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 10 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7588. interleukine 11 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 11 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7589. interleukine 12 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 12 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7590. interleukine 13 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 13 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7591. interleukine 14 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 14 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7592. interleukine 16 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 16 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7593. interleukine 3 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 3 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7594. interleukine 5 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 5 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7595. interleukine 7 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 7 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7596. interleukine 8 --- r_associated #0: 5 --> en:contraindications aspect
    n1=interleukine 8 | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7597. isotransplantation --- r_associated #0: 5 --> en:contraindications aspect
    n1=isotransplantation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7598. isotype --- r_associated #0: 5 --> en:contraindications aspect
    n1=isotype | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7599. isovaléryl-coenzyme A déshydrogénase --- r_associated #0: 5 --> en:contraindications aspect
    n1=isovaléryl-coenzyme A déshydrogénase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7600. isoxanthoptérine --- r_associated #0: 5 --> en:contraindications aspect
    n1=isoxanthoptérine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7601. lévocardie --- r_associated #0: 5 --> en:contraindications aspect
    n1=lévocardie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7602. lévocardiogramme --- r_associated #0: 5 --> en:contraindications aspect
    n1=lévocardiogramme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7603. maladie de Beurmann et Gougerot --- r_associated #0: 5 --> en:contraindications aspect
    n1=maladie de Beurmann et Gougerot | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7604. maladie de Buerger --- r_associated #0: 5 --> en:contraindications aspect
    n1=maladie de Buerger | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7605. maladie de Danon --- r_associated #0: 5 --> en:contraindications aspect
    n1=maladie de Danon | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7606. mamelon (adénomatose érosive du) --- r_associated #0: 5 --> en:contraindications aspect
    n1=mamelon (adénomatose érosive du) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7607. membre 25 de la superfamille des récepteurs du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=membre 25 de la superfamille des récepteurs du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7608. membre 5 de la superfamille des récepteurs du facteur de nécrose tumorale --- r_associated #0: 5 --> en:contraindications aspect
    n1=membre 5 de la superfamille des récepteurs du facteur de nécrose tumorale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7609. méthode radio-immunologique --- r_associated #0: 5 --> en:contraindications aspect
    n1=méthode radio-immunologique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7610. opération d'Adson --- r_associated #0: 5 --> en:contraindications aspect
    n1=opération d'Adson | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7611. oreillons (virus des) --- r_associated #0: 5 --> en:contraindications aspect
    n1=oreillons (virus des) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7612. organisant --- r_associated #0: 5 --> en:contraindications aspect
    n1=organisant | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7613. oxymyoglobine --- r_associated #0: 5 --> en:contraindications aspect
    n1=oxymyoglobine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7614. oxyologie --- r_associated #0: 5 --> en:contraindications aspect
    n1=oxyologie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7615. oxyphile --- r_associated #0: 5 --> en:contraindications aspect
    n1=oxyphile | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7616. oxyphorique --- r_associated #0: 5 --> en:contraindications aspect
    n1=oxyphorique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7617. oxyquinoléine --- r_associated #0: 5 --> en:contraindications aspect
    n1=oxyquinoléine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7618. oxystérol --- r_associated #0: 5 --> en:contraindications aspect
    n1=oxystérol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7619. oxytalane --- r_associated #0: 5 --> en:contraindications aspect
    n1=oxytalane | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7620. oxyurose --- r_associated #0: 5 --> en:contraindications aspect
    n1=oxyurose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7621. ozone --- r_associated #0: 5 --> en:contraindications aspect
    n1=ozone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7622. ozène --- r_associated #0: 5 --> en:contraindications aspect
    n1=ozène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7623. pI --- r_associated #0: 5 --> en:contraindications aspect
    n1=pI | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7624. para (groupe) --- r_associated #0: 5 --> en:contraindications aspect
    n1=para (groupe) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7625. phlébite septique (ou suppurée) --- r_associated #0: 5 --> en:contraindications aspect
    n1=phlébite septique (ou suppurée) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7626. phytine --- r_associated #0: 5 --> en:contraindications aspect
    n1=phytine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7627. phytocénose --- r_associated #0: 5 --> en:contraindications aspect
    n1=phytocénose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7628. phytodermatose --- r_associated #0: 5 --> en:contraindications aspect
    n1=phytodermatose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7629. phytohémagglutinine --- r_associated #0: 5 --> en:contraindications aspect
    n1=phytohémagglutinine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7630. phytol --- r_associated #0: 5 --> en:contraindications aspect
    n1=phytol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7631. phytooestrogène --- r_associated #0: 5 --> en:contraindications aspect
    n1=phytooestrogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7632. phytophotodermatose --- r_associated #0: 5 --> en:contraindications aspect
    n1=phytophotodermatose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7633. phytosphingosine --- r_associated #0: 5 --> en:contraindications aspect
    n1=phytosphingosine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7634. phytostérol --- r_associated #0: 5 --> en:contraindications aspect
    n1=phytostérol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7635. phæohyphomycoses --- r_associated #0: 5 --> en:contraindications aspect
    n1=phæohyphomycoses | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7636. phæomélanine --- r_associated #0: 5 --> en:contraindications aspect
    n1=phæomélanine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7637. phæomélanosome --- r_associated #0: 5 --> en:contraindications aspect
    n1=phæomélanosome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7638. plasma sanguin --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasma sanguin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7639. plasma séminal --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasma séminal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7640. plasmal --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7641. plasmalemme --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmalemme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7642. plasmalogène --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmalogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7643. plasmapexine I --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmapexine I | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7644. plasmide --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7645. plasmide amplifiable --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmide amplifiable | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7646. plasmide auto-amplifiable --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmide auto-amplifiable | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7647. plasmide auto-transférable --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmide auto-transférable | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7648. plasmide auto-transmissible --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmide auto-transmissible | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7649. plasmide chimère --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmide chimère | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7650. plasmide conjugatif --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmide conjugatif | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7651. plasmide de résistance --- r_associated #0: 5 --> en:contraindications aspect
    n1=plasmide de résistance | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7652. progéroïde --- r_associated #0: 5 --> en:contraindications aspect
    n1=progéroïde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7653. protéine suppresseur de tumeur de von Hippel-Lindau --- r_associated #0: 5 --> en:contraindications aspect
    n1=protéine suppresseur de tumeur de von Hippel-Lindau | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7654. pseudo-cholinestérase --- r_associated #0: 5 --> en:contraindications aspect
    n1=pseudo-cholinestérase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7655. secnidazole --- r_associated #0: 5 --> en:contraindications aspect
    n1=secnidazole | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7656. second messager --- r_associated #0: 5 --> en:contraindications aspect
    n1=second messager | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7657. second signal --- r_associated #0: 5 --> en:contraindications aspect
    n1=second signal | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7658. secouriste --- r_associated #0: 5 --> en:contraindications aspect
    n1=secouriste | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7659. secret d'attribution --- r_associated #0: 5 --> en:contraindications aspect
    n1=secret d'attribution | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7660. secret professionnel en psychiatrie --- r_associated #0: 5 --> en:contraindications aspect
    n1=secret professionnel en psychiatrie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7661. secret professionnel médical --- r_associated #0: 5 --> en:contraindications aspect
    n1=secret professionnel médical | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7662. somatique (complaisance) --- r_associated #0: 5 --> en:contraindications aspect
    n1=somatique (complaisance) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7663. sorbitol-déshydrogénase --- r_associated #0: 5 --> en:contraindications aspect
    n1=sorbitol-déshydrogénase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7664. splicéosome --- r_associated #0: 5 --> en:contraindications aspect
    n1=splicéosome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7665. split brain --- r_associated #0: 5 --> en:contraindications aspect
    n1=split brain | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7666. splénique --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7667. splénite --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénite | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7668. splénium du corps calleux --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénium du corps calleux | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7669. splénius --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénius | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7670. splénoclésis --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénoclésis | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7671. splénogramme --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénogramme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7672. splénopexie --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénopexie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7673. splénoportographie de retour --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénoportographie de retour | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7674. splénorrhaphie --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénorrhaphie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7675. splénosclérose --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénosclérose | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7676. splénose péritonéale --- r_associated #0: 5 --> en:contraindications aspect
    n1=splénose péritonéale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7677. suppresseur de tumeur arf --- r_associated #0: 5 --> en:contraindications aspect
    n1=suppresseur de tumeur arf | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7678. syndrome d'Angelucci --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome d'Angelucci | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7679. syndrome d'Anton-Babinski --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome d'Anton-Babinski | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7680. syndrome de Biglieri --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Biglieri | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7681. syndrome de Butler-Albright --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Butler-Albright | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7682. syndrome de Coats --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Coats | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7683. syndrome de Cole-Rauschkolb-Toomey --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Cole-Rauschkolb-Toomey | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7684. syndrome de Cruveilhier-Baumgarten --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Cruveilhier-Baumgarten | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7685. syndrome de Debré-Fibiger --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Debré-Fibiger | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7686. syndrome de Desmons --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Desmons | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7687. syndrome de DiGeorge --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de DiGeorge | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7688. syndrome de Fechtner --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Fechtner | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7689. syndrome de Fuchs --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Fuchs | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7690. syndrome de Levine-Critchley --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Levine-Critchley | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7691. syndrome de Seckel-like type Majoor-Krakauer --- r_associated #0: 5 --> en:contraindications aspect
    n1=syndrome de Seckel-like type Majoor-Krakauer | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7692. sécostéroïde --- r_associated #0: 5 --> en:contraindications aspect
    n1=sécostéroïde | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7693. sécrétase --- r_associated #0: 5 --> en:contraindications aspect
    n1=sécrétase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7694. sécrétion exocrine --- r_associated #0: 5 --> en:contraindications aspect
    n1=sécrétion exocrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7695. sécrétion externe --- r_associated #0: 5 --> en:contraindications aspect
    n1=sécrétion externe | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7696. sécrétion gastrique acide --- r_associated #0: 5 --> en:contraindications aspect
    n1=sécrétion gastrique acide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7697. sécrétion gastrique peptique --- r_associated #0: 5 --> en:contraindications aspect
    n1=sécrétion gastrique peptique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7698. sécrétion holocrine --- r_associated #0: 5 --> en:contraindications aspect
    n1=sécrétion holocrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7699. sérum antivenimeux --- r_associated #0: 5 --> en:contraindications aspect
    n1=sérum antivenimeux | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7700. sérum sanguin --- r_associated #0: 5 --> en:contraindications aspect
    n1=sérum sanguin | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7701. thoracobrachial --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracobrachial | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7702. thoracodyme --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracodyme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7703. thoracogénique --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracogénique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7704. thoracométrie ultrasonique --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracométrie ultrasonique | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7705. thoracopage --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracopage | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7706. thoracophréno-laparotomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracophréno-laparotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7707. thoracophrénotomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracophrénotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7708. thoracoplastie d'Andrews --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracoplastie d'Andrews | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7709. thoracoplastie de Schede --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracoplastie de Schede | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7710. thoracoplastie ostéoplastique de Björk --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracoplastie ostéoplastique de Björk | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7711. thoracotomie --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracotomie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7712. thoracotomie antérieure --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracotomie antérieure | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7713. thoracotomie antérolatérale --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracotomie antérolatérale | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7714. thoracotomie axillaire --- r_associated #0: 5 --> en:contraindications aspect
    n1=thoracotomie axillaire | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7715. transplantation cardiaque (complications neurologiques de la) --- r_associated #0: 5 --> en:contraindications aspect
    n1=transplantation cardiaque (complications neurologiques de la) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7716. urinifère --- r_associated #0: 5 --> en:contraindications aspect
    n1=urinifère | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7717. urinome --- r_associated #0: 5 --> en:contraindications aspect
    n1=urinome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7718. urobilinogène --- r_associated #0: 5 --> en:contraindications aspect
    n1=urobilinogène | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7719. urobilinogènémie --- r_associated #0: 5 --> en:contraindications aspect
    n1=urobilinogènémie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7720. urobilinogénurie --- r_associated #0: 5 --> en:contraindications aspect
    n1=urobilinogénurie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7721. urobilinémie --- r_associated #0: 5 --> en:contraindications aspect
    n1=urobilinémie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7722. urocanase --- r_associated #0: 5 --> en:contraindications aspect
    n1=urocanase | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7723. urochrome --- r_associated #0: 5 --> en:contraindications aspect
    n1=urochrome | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7724. urogastrone --- r_associated #0: 5 --> en:contraindications aspect
    n1=urogastrone | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7725. urogenèse --- r_associated #0: 5 --> en:contraindications aspect
    n1=urogenèse | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7726. urogramme --- r_associated #0: 5 --> en:contraindications aspect
    n1=urogramme | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7727. urographie --- r_associated #0: 5 --> en:contraindications aspect
    n1=urographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7728. urogénital --- r_associated #0: 5 --> en:contraindications aspect
    n1=urogénital | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7729. uroérythrine --- r_associated #0: 5 --> en:contraindications aspect
    n1=uroérythrine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7730. villeuse de la vessie (maladie) --- r_associated #0: 5 --> en:contraindications aspect
    n1=villeuse de la vessie (maladie) | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7731. Élastographie --- r_associated #0: 5 --> en:contraindications aspect
    n1=Élastographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7732. Érythropoïétine --- r_associated #0: 5 --> en:contraindications aspect
    n1=Érythropoïétine | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7733. Éther de glycol --- r_associated #0: 5 --> en:contraindications aspect
    n1=Éther de glycol | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7734. Éthosuximide --- r_associated #0: 5 --> en:contraindications aspect
    n1=Éthosuximide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7735. équation de Gompertz --- r_associated #0: 5 --> en:contraindications aspect
    n1=équation de Gompertz | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5
  7736. coucherie --- r_associated #0: -25 --> en:contraindications aspect
    n1=coucherie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=-25
  7737. langage de programmation --- r_associated #0: -30 --> en:contraindications aspect
    n1=langage de programmation | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=-30
  7738. cartographie --- r_associated #0: -98 --> en:contraindications aspect
    n1=cartographie | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=-98
Le service Rézo permet d'énumérer les relations existant pour un terme. Ce service est interrogeable par programme.
Projet JeuxDeMots - url: http://www.jeuxdemots.org
contact: mathieu.lafourcade@lirmm.fr